"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2014/0145634 A1,095-760-949-601-135,2014-05-29,2014,US 201213686379 A,2012-11-27,US 201213686379 A,2012-11-27,CIRCUIT AND METHOD FOR GENERATING A REFERENCE VOLTAGE FOR A POWER CONVERTER,"Circuits and methods for generating a reference voltage for a power converter control are disclosed herein. The power converter control providing a signal on an output for aligning the voltage and current on a power line so that they are in phase. An embodiment of a circuit includes a voltage detector that detects the voltage on the power line. A signal generator generates a wave that is in phase with voltage on the power line, the wave being generated independent of the voltage on the power line. The output of the signal generator is the reference voltage.",TEXAS INSTRUMENTS INC,SULLIVAN TIMOTHY ROY;;COHEN ISAAC,TEXAS INSTRUMENTS INCORPORATED (2012-11-26),https://lens.org/095-760-949-601-135,Patent Application,yes,2,5,2,2,0,H02M1/4225;;H05B45/14;;Y02B70/10;;H05B45/3725;;H02M1/4225;;H05B45/14;;Y02B70/10;;H05B45/3725,H02M7/217;;H05B44/00,315/201;;363/89,0,0,,,,DISCONTINUED
2,CN,A,CN 103840653 A,115-251-141-458-098,2014-06-04,2014,CN 201310617747 A,2013-11-27,US 201213686379 A,2012-11-27,CIRCUIT AND METHOD FOR GENERATING REFERENCE VOLTAGE FOR POWER CONVERTER,"Circuits and methods for generating a reference voltage for a power converter control (116) are disclosed herein. The power converter control (116) providing a signal on an output (130) for aligning the voltage and current on a power line (115) so that they are in phase. An embodiment of a circuit includes a voltage detector (160) that detects the voltage on the power line (115). A signal generator (162, 168) generates a wave that is in phase with voltage on the power line (115), the wave being generated independent of the voltage on the power line (115). The output of the signal generator (162, 168) is the reference voltage.",TEXAS INSTRUMENTS INC,SULLIVAN TIMOTHY ROY;;COHEN ISAAC,,https://lens.org/115-251-141-458-098,Patent Application,no,3,1,2,2,0,H02M1/4225;;H05B45/14;;Y02B70/10;;H05B45/3725;;H02M1/4225;;H05B45/14;;Y02B70/10;;H05B45/3725,H02M1/42;;H02M3/155;;H05B37/02;;H05B44/00,,0,0,,,,DISCONTINUED
3,CN,A,CN 117015968 A,130-695-216-903-610,2023-11-07,2023,CN 202280019006 A,2022-01-27,US 202117198813 A;;US 2022/0014143 W,2021-03-11,Learning B-frame coding using P-frame coding system,"Techniques are described herein for processing video data, such as bidirectional coding by performing learning using a unidirectional coding system and interpolated reference frames. For example, processing may include obtaining a first reference frame and a second reference frame. The processing may include generating a third reference frame at least in part by performing interpolation between the first reference frame and the second reference frame. The processing may include, for example, performing unidirectional inter prediction on an input frame based on a third reference frame by estimating motion between the input frame and the third reference frame, and generating a deformed frame at least in part by deforming one or more pixels of the third reference frame based on the estimated motion. The processing may include generating a reconstructed frame representing the input frame based on the deformed frame and the prediction residual, the reconstructed frame including a bidirectional prediction frame.",QUALCOMM INC,PRYZA RAKESH;;COHEN TIMOTHY S,,https://lens.org/130-695-216-903-610,Patent Application,no,0,0,9,9,0,H04N19/117;;H04N19/172;;H04N19/139;;H04N19/577;;H04N19/82;;H04N19/577;;H04N19/587;;H04N19/573;;H04N19/105;;H04N19/172;;H04N19/139;;G06N3/0455;;G06N3/0464;;H04N19/59;;G06N3/063;;G06N3/088;;G06N3/045,H04N19/117,,0,0,,,,PENDING
4,EP,A1,EP 2757479 A1,193-412-767-785-975,2014-07-23,2014,EP 14151725 A,2014-01-20,US 201361755442 P,2013-01-22,Management of and region selection for writes to non-volatile memory,"Management of and region selection for writes to non-volatile memory of an SSD improves performance, reliability, unit cost, and/or development cost of an SSD. A controller receives and determines characteristics of writes (e.g. by analyzing the write data (708), the write data source (700), and/or by receiving a hint (709)) and selects a region based on the determined characteristics and properties of regions of non-volatile memory. For example, a controller receives writes determined to be read-only data and selects regions of non-volatile memory containing cells that are likely to have write failures. By placing read-only data in write failure prone regions, the likelihood of an error is reduced, thus improving reliability. As another example, a controller receives writes hinted to be uncompressible and selects regions of non-volatile memory containing uncompressible data.
",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,,https://lens.org/193-412-767-785-975,Patent Application,yes,4,9,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F12/02;;G06F3/06,,0,0,,,,DISCONTINUED
5,JP,A,JP 2014167790 A,022-810-576-031-890,2014-09-11,2014,JP 2014008182 A,2014-01-21,US 201361755442 P,2013-01-22,MANAGEMENT OF AND REGION SELECTION FOR WRITES TO NON-VOLATILE MEMORY,"PROBLEM TO BE SOLVED: To provide management of and region selection for writes to non-volatile memory of an SSD, which improves performance, reliability, unit cost, and/or development cost of the SSD.SOLUTION: A controller receives writes and determines characteristics of writes (e.g., by analyzing write data and/or a write data source, and/or by receiving a hint) and selects a region based on the determined characteristics and properties of regions of non-volatile memory. For example, a controller receives writes determined to be read-only data and selects regions of non-volatile memory containing cells that are likely to have write failures. By placing read-only data in write failure prone regions, the likelihood of an error is reduced, thus improving reliability. As another example, a controller receives writes hinted to be uncompressible and selects regions of non-volatile memory containing uncompressible data.",LSI CORP,EARL T COHEN;;TIMOTHY LAWRENCE CANEPA,,https://lens.org/022-810-576-031-890,Patent Application,no,9,4,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F12/16;;G06F3/06;;G06F3/08,,0,0,,,,INACTIVE
6,US,B2,US 8949517 B2,019-427-009-066-210,2015-02-03,2015,US 201213988019 A,2012-10-04,US 201213988019 A;;US 201161543707 P;;US 2012/0058583 W,2011-10-05,Self-journaling and hierarchical consistency for non-volatile storage,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-03-21),https://lens.org/019-427-009-066-210,Granted Patent,yes,13,55,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/00;;G06F11/07;;G06F12/02;;G11C16/02;;G11C16/06,711/103,5,0,,,"International Search Report and the Written Opinion in the parent PCT/US12/58583, 10 pages.;;CN Office Action (10 pgs. English translation and 7 pgs. CN original) of Mar. 10, 2014 of CN national entry of parent PCT/US12/58583, 17 pgs. total;;CN Search Report (2 pgs. English translation and 2 pgs. CN original) of Feb. 28, 2014 of CN national entry of parent PCT/US12/58583, 4 pgs. total.;;KR Notice (3 pgs. English translation and 4 pgs. KR original) of Jun. 27, 2014 of KR national entry of parent PCT/US12/58583, 7 pgs. total.;;Aug. 25, 2014 List of References Used in Art Rejections in Cases Related to, 1 pg.",INACTIVE
7,US,A1,US 2014/0082261 A1,032-990-060-881-097,2014-03-20,2014,US 201213988019 A,2012-10-04,US 201213988019 A;;US 201161543707 P;;US 2012/0058583 W,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-03-21),https://lens.org/032-990-060-881-097,Patent Application,yes,4,76,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/02,711/103,0,0,,,,INACTIVE
8,WO,A1,WO 2016/106317 A1,092-613-670-429-025,2016-06-30,2016,US 2015/0067376 W,2015-12-22,US 201414580876 A,2014-12-23,CONVERTIBLE GARMENT AND METHOD OF CONVERTING SAME,"A convertible garment and a method of converting a convertible garment is disclosed. A convertible garment includes a piece of fabric possessing a periphery, and a plurality of fasteners disposed on the piece of fabric along the periphery at substantially regular intervals. One of the plurality of fasteners is configured to fasten to each of the other fasteners to form armholes. The convertible garment is configured to adopt a first configuration in which the fasteners are not fastened to one another so that the convertible garment is wearable as a scarf. The convertible garment is configured to adopt a second configuration in which one of the plurality of fasteners is fastened to each of the other fasteners so that the convertible garment is wearable as a vest.",G III APPAREL GROUP LTD,JAMES TIMOTHY;;VOLOSHINA MARINA;;COHEN SHANA,,https://lens.org/092-613-670-429-025,Patent Application,yes,2,1,3,3,0,A41D23/00;;A41D23/00;;A41D15/00;;A41D15/00,A41D15/04,,3,0,,,"VIVI DESIGNS INC (VIVI);: ""Multi-Way Sweater Scarf"", 6 December 2013 (2013-12-06), pages 1 - 7, Retrieved from the Internet <URL:http://www.vividesigninc.com/includes/62900Brochure.pdf> [retrieved on 20160209];;BLOGSPOT: ""Creating Bits of Envy"", vol. 8, no. 20, 2 February 2014 (2014-02-02), pages 22 - 26, Retrieved from the Internet <URL:www.creatingbitsofenvy.blogspto.com?>;;COUPONING 101);: ""Frugal Fashion - Wear your scarf as a Vest"", 29 April 2013 (2013-04-29), Retrieved from the Internet <URL:http://www.couponing101.com/frugal-fashion-wear-your-scarl-as-a-vest> [retrieved on 20160209]",PENDING
9,US,A1,US 2020/0081660 A1,083-673-555-492-115,2020-03-12,2020,US 201916684027 A,2019-11-14,US 201916684027 A;;US 201715661079 A;;US 201313936010 A;;US 2012/0049905 W;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,"Methods, systems, and computer-readable storage media for a storage device to, upon receiving a command from a computing host, determine whether or not the command includes location information targeting a particular portion of a NVM of the storage device, the location information having been retrieved by the computing host from a shadow map and included with the command. Upon determining that the command includes location information, the command is processed by the storage device using the included location information. Upon determining that the command does not include location information, the storage device determines the particular portion of the NVM targeted by the command based on a map stored in a memory of the storage device before processing the command.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/083-673-555-492-115,Patent Application,yes,0,5,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F3/06;;G06F12/00,,0,0,,,,ACTIVE
10,KR,A,KR 20140094468 A,148-110-934-749-272,2014-07-30,2014,KR 20140007211 A,2014-01-21,US 201361755442 P,2013-01-22,MANAGEMENT OF AND REGION SELECTION FOR WRITES TO NON-VOLATILE MEMORY,"The management of a region selection of writes in a nonvolatile memory of SSD improves the performance, reliability, costs, and/or development costs of the SSD. A controller (for example, by analyzing write data and a write data source or receiving a hint) receives and determines the features of the writes and selects a region based on the determined features and properties of the nonvolatile memory. The reliability is improved by reducing the possibility of errors by arranging read-only data on write failure prone regions. For another example, the controller receives writes hinted to be incompressible and selects the regions of the nonvolatile memory including the incompressible data.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,,https://lens.org/148-110-934-749-272,Patent Application,no,6,4,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F12/00,,0,0,,,,ACTIVE
11,US,A1,US 2013/0297894 A1,179-867-994-139-07X,2013-11-07,2013,US 201313936010 A,2013-07-05,US 201313936010 A;;US 2012/0049905 W;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,"An I/O device is coupled to a computing host. In some embodiments, the device is enabled to utilize memory of the computing host not directly coupled to the device to store information such as a shadow copy of a map of the device and/or state of the device. Storage of the shadow copy of the map enables one or both of the device and the computing host to utilize the shadow copy of the map, such as to decrease read latency. Storage of the state enables the device to save volatile state that would otherwise be lost when the device enters a low-power state. In some embodiments, the device implements one or more non-standard modifiers of standard commands. The non-standard modifiers modify the execution of the standard commands, providing features not present in a host protocol having only the standard commands.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-07-09),https://lens.org/179-867-994-139-07X,Patent Application,yes,3,124,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F12/00,711/154,0,0,,,,DISCONTINUED
12,US,B2,US 10061727 B2,196-367-674-080-57X,2018-08-28,2018,US 201615245852 A,2016-08-24,US 201615245852 A;;US 201414209028 A;;US 201361786073 P,2013-03-14,Enhanced queue management,"A paired queue apparatus and method comprising request and response queues wherein queue head and tail pointer update values are communicated through an enhanced pointer word data format providing pointer indicator information and optional auxiliary information in a single transfer, wherein auxiliary information provides additional system communication without consuming additional bandwidth. Auxiliary information is optionally contained in a response data entry written to a response queue or in a request entry written to a request queue.",SEAGATE TECHNOLOGY LLC,CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/196-367-674-080-57X,Granted Patent,yes,1,3,4,4,0,G06F13/362;;G06F13/362;;G06F3/0611;;G06F3/0659;;G06F3/0688;;G06F13/1642;;G06F13/1642;;G06F13/364;;G06F13/4282;;G06F13/4282,G06F13/36;;G06F3/06;;G06F13/00;;G06F13/16;;G06F13/362;;G06F13/364;;G06F13/42,,0,0,,,,ACTIVE
13,US,B2,US 10025735 B2,071-932-347-939-240,2018-07-17,2018,US 201414161290 A,2014-01-22,US 201414161290 A;;US 201361758770 P,2013-01-31,Decoupled locking DMA architecture,"A decoupled Direct Memory Access (DMA) architecture includes at least two DMA controllers, and optionally at least one of the DMA controllers is operable to assert a lock signal operable to selectively inhibit write access to at least a portion of one system data storage element. The DMA controllers are optionally operable to communicate pending task information and to reschedule pending tasks of at least one the DMA controllers. Optionally data is transferred from at least a first one of the DMA controllers to one or more function units, and processed data from the function units is provided to at least a second one of the DMA controllers. Optionally the DMA controllers and one or more memory elements accessible to the DMA controllers are implemented as part of an I/O device.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-01-21),https://lens.org/071-932-347-939-240,Granted Patent,yes,4,0,2,2,0,G06F13/28;;G06F13/28,G06F13/28,,0,0,,,,ACTIVE
14,US,B2,US 9395924 B2,092-792-102-771-742,2016-07-19,2016,US 201414158827 A,2014-01-19,US 201414158827 A;;US 201361755442 P,2013-01-22,Management of and region selection for writes to non-volatile memory,"Management of and region selection for writes to non-volatile memory of an SSD improves performance, reliability, unit cost, and/or development cost of an SSD. A controller receives and determines characteristics of writes (e.g. by analyzing the write data, the write data source, and/or by receiving a hint) and selects a region based on the determined characteristics and properties of regions of non-volatile memory. For example, a controller receives writes determined to be read-only data and selects regions of non-volatile memory containing cells that are likely to have write failures. By placing read-only data in write failure prone regions, the likelihood of an error is reduced, thus improving reliability. As another example, a controller receives writes hinted to be uncompressible and selects regions of non-volatile memory containing uncompressible data.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-01-14),https://lens.org/092-792-102-771-742,Granted Patent,yes,73,3,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F3/06;;G06F12/02,,25,0,,,"'Using the Appropriate Wear Leveling to Extend Product Lifespan' Presented by: Bill Roman, Datalight Software Architect, Aug. 2009.;;'Error Analysis and Retention-Aware Error Management for NAND Flash Memory' by Yu Cai et al., Intel Technology Journal, vol. 17, Issue 1, 2013.;;'The Inconvenient Truths of NAND Flash Memory' by Jim Cooke, Micron Technology, Inc., Aug. 2007.;;European Search Report in related case 14151725.0, 6 pages.;;Office Action of the Intellectual Property Office ROC (Taiwan) Patent Application No. 101128817 including Search Report, Jul. 14, 2014, 17 pages.;;European Search Report in EP 14151725.0, 6 pages.;;International Search Report and the Writien Opinion for PCT/US12/58583, 10 pages.;;CN Office Action (10 pp. English translation and 7 pp. CN original) of Mar. 10, 2014 of CN national entry of PCT/US12/58583, 17 pp. total.;;CN Search Report (2 pp. English translation and 2 pp. CN original) of Feb. 28, 2014 of CN national entry of PCT/US12/58583, 4 pp. total.;;KR Notice (3 pp. English translation and 4 pp. KR original) of Jun. 27, 2014 of KR national entry of PCT/US12/58583, 7 pp. total.;;International Search Report for PCT/US2012/034601, 3 pages.;;Written Opinion for PCT/US2012/034601, 4 pages.;;Agrawal et al, ""Design Tradeoffs for SSD Performance,"" Proceedings of the 2008 USENIX Annual Technical Conference, Jun. 2008, 14 pages.;;Mehling, Herman, ""Solid State Drives Get Faster with TRIM,"" Jan. 27, 2010 (retrieved from http://www.enterprisestorageforum.com/technology/features/article.php/38611 81 /Solid-State-Drives-Get-Faster-with-TRIM. htm and converted to pdf format Apr. 7, 2014), 4 pages.;;Layton, Jeffrey, ""Anatomy of SSDs,"" Linux Magazine, Oct. 27, 2009 (Retrieved from http://www.linux-mag.com/id/7590/2 and converted to pdf format Apr. 7, 2014), 4 pages.;;Shimpi, Anand Lal, ""The Impact of Spare Area on SandForce, More Capacity at No Performance Loss?"" May 3, 2010 (retrieved from http://www.anandtech.com/show/3690/the-impact-of-spare-area-on-sandforce-more-capacity-at-no-performance-loss and converted to pdf format Apr. 7, 2014), 14 pages.;;Frankie et al, ""SSD Trim Commands Considerably Improve Overprovisioning,"" Proceedings Flash Memory Summit 2011, Aug. 2011, 19 pages.;;Smith, Kent, ""Garbage Collection: Understanding Foreground vs. Background GC and Other Related Elements,"" Proceedings Flash Memory Summit 2011, Aug. 2011, 9 pages.;;Smith, Kent, ""Understanding SSD Over Provisioning,"" Proceedings Flash Memory Summit 2012, Aug. 2012, 16 pages.;;""SSDs-Write Amplification, Trim and GC,"" Mar. 2010 (retrieved from http://www.oczenterprise.com/whitepapers/ssds-writeamplification-trim-and-gc.pdf, using Internet Archive Wayback Machine Mar. 28, 2014), 3 pages.;;""Write Amplification,"" Wikipedia (retrieved from http://en.wikipedia.org/wiki/Write-amplification and converted to pdf format Apr. 7, 2014), 14 pages.;;Dec. 4, 2014 List of References Used in Art Rejections in Cases, 2 p.;;Office Action of the State Intellectual Property Office of the People's Republic of China Patent Application No. 2012800314652 including Search Report, May 4, 2014, 14 pages.;;International Search Report for PCT/US2012/049905, 4 pages.;;The Written Opinion for PCT/US2012/049905, 5 pages.",ACTIVE
15,US,B2,US 9189385 B2,100-281-903-559-307,2015-11-17,2015,US 201213652301 A,2012-10-15,US 31637310 P;;US 201113053175 A;;US 201161543707 P;;US 201213652301 A,2010-03-22,Scalable data structures for control and management of non-volatile storage,"Scalable control/management data structures enable optimizing performance and/or attempting to achieve a particular performance target of an SSD in accordance with host interfacing, number of NVM devices, NVM characteristics and size, and NVM aging and performance decline. Pre-scaled data structures are included in SSD controller firmware loadable at system initialization. Static data structure configurations enable load-once-operate-for-product-lifetime operation for consumer applications. Dynamic configurations provide sequences of data structures pre-scaled to optimize operation as NVM ages and performance declines. Pre-configured adjustments in data structure size included in consecutive configurations periodically replace earlier configurations at least one time during product lifetime, producing a periodic rescaling of data structure size to track changes in aging NVM. Optionally, sizes of some data structures are decreased as NVM usage increases, enabling an increase in translation layer mapping structure sizes, reducing accesses to translation tables in NVM, and reducing write amplification.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-10-15),https://lens.org/100-281-903-559-307,Granted Patent,yes,9,22,4,21,0,G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/0292;;G06F12/00;;Y02D10/00;;G06F12/0292;;G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/00;;Y02D10/00;;G06F3/0619;;G06F3/0634;;G06F3/0655,G06F12/00;;G06F3/06;;G06F12/02,,1,0,,,"Shin et al, ""FTL Design Exploration in Reconfigurable High-Performance SSD for Server Applications"", ICS'09 Jun. 8-12, 2009, ACM 978-1-60558-498-0/09/06, pp. 338-349.",ACTIVE
16,KR,A,KR 20130132662 A,123-885-967-820-289,2013-12-04,2013,KR 20137029137 A,2012-10-04,US 201161543707 P;;US 2012/0058583 W,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/123-885-967-820-289,Patent Application,no,0,1,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,,,0,0,,,,ACTIVE
17,US,A1,US 2016/0070496 A1,162-810-587-917-028,2016-03-10,2016,US 201514942475 A,2015-11-16,US 31637310 P;;US 201113053175 A;;US 201161543707 P;;US 201213652301 A,2010-03-22,Scalable Data Structures for Control and Management of Non-Volatile Storage,"Method and apparatus for managing data in a Non-Volatile Memory (NVD). In some embodiments, management information is stored in a buffer memory using a Solid-State Disk (SSD) controller circuit, the management information comprising a map data structure that associates storage addresses of a host device to physical addresses of the NVD. A location in the management information is determined responsive to a selected host storage address and a programmable parameter by arithmetically dividing in accordance with a divisor specified at least in part by the programmable parameter. The location in the management information is used to direct a transfer of user data by the SSD control circuit between the host device and the NVM.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/162-810-587-917-028,Patent Application,yes,0,45,4,21,0,G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/0292;;G06F12/00;;Y02D10/00;;G06F12/0292;;G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/00;;Y02D10/00;;G06F3/0619;;G06F3/0634;;G06F3/0655,G06F3/06,,0,0,,,,ACTIVE
18,US,S,US D0767160 S,194-429-761-756-652,2016-09-20,2016,US 201529544425 F,2015-11-03,US 201529544425 F,2015-11-03,Culture dish,,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/194-429-761-756-652,Design Right,no,0,5,1,1,0,,,2402;;D24/226,0,0,,,,ACTIVE
19,US,B2,US 10936251 B2,133-410-936-728-053,2021-03-02,2021,US 201916684027 A,2019-11-14,US 201916684027 A;;US 201715661079 A;;US 201313936010 A;;US 2012/0049905 W;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P,2011-08-09,I/O device and computing host interoperation,"Methods, systems, and computer-readable storage media for a storage device to, upon receiving a command from a computing host, determine whether or not the command includes location information targeting a particular portion of a NVM of the storage device, the location information having been retrieved by the computing host from a shadow map and included with the command. Upon determining that the command includes location information, the command is processed by the storage device using the included location information. Upon determining that the command does not include location information, the storage device determines the particular portion of the NVM targeted by the command based on a map stored in a memory of the storage device before processing the command.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/133-410-936-728-053,Granted Patent,yes,70,0,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F3/06;;G06F12/00;;G06F12/1027,,25,0,,,"“SSDs—Write Amplification, Trim and GC,” Mar. 2010 (retrieved from http://www.oczenterprise.com/whitepapers/ssds-writeamplification-trim-and-gc.pdf, using Internet Archive Wayback Machine Mar. 28, 2014), 3 pgs.;;“Write Amplification,” Wikipedia (retrieved from http://en.wikipedia.org/wiki/Write_amplification and converted to pdf format Apr. 7, 2014), 14 pgs.;;Cohen, Earl T.; International Search Report and Written Opinion for PCT/US2012/058583, filed Oct. 4, 2012, dated Feb. 25, 2013, 8 pgs.;;Cohen, Earl T.; International Search Report and Written Opinion for PCT/US2012/049905, filed Aug. 8, 2012, dated Jan. 3, 2013, 9 pgs.;;Simionescu, Horia; Notice of Allowance for Korean Patent Application No. 10-2013-0022004, filed Feb. 28, 2013, dated Mar. 28, 2019, 3 pgs.;;Agrawal et al, “Design Tradeoffs for SSD Performance,” Proceedings of the 2008 USENIX Annual Technical Conference, Jun. 2008, 14 pgs.;;Chinese Office Action for serial No. 201280049511.1, filed Aug. 8, 2012, dated Nov. 4, 2014, 18 pgs.;;Cohen, Earl T.; Office Action for Taiwanese Application No. 101128817, filed Aug. 9, 2012, dated Sep. 19, 2016, 6 pgs.;;Cohen, et al; International Preliminary Report on Patentability for PCT/US2012/049905, filed Aug. 8, 2012, dated Feb. 11, 2014, 6 pgs.;;Frankie et al, “SSD Trim Commands Considerably Improve Overprovisioning,” Proceedings Flash Memory Summit 2011, Aug. 2011, 19 pgs.;;IEEE, “band” definition, IEEE Standard Dictionary of Electrical and Electronics Terms, Nov. 3, 1998, p. 80, IEE, Inc. New York, NY, 3 sheets total (1 sheet of content, 2 sheets of title pages).;;Layton, Jeffrey, “Anatomy of SSD's,” Linux Magazine, Oct. 27, 2009 (Retrieved from http://www.linux-mag.com/id/7590/2 and converted to pdf format Apr. 7, 2014), 4 pgs.;;LSI Corporation; Extended European Search Report for serial No. 14151725.0, dated Apr. 22, 2014, 6 pgs.;;LSI Corporation; International Search Report and Written Opinion for PCT/US2012/034601, filed Apr. 22, 2012, dated Nov. 30, 2012, 7 pgs.;;LSI Corporation; Office Action for Chinese patent application No. 201280009888.4, filed Oct. 4, 2012, dated Mar. 10, 2014, 17 pgs.;;LSI Corporation; Office Action for Korean Patent Application No. 10-2013-7029137, dated Jun. 27, 2014, 7 pgs.;;LSI Corporation; Office Action for Taiwan Patent Application No. 101114992, dated Jun. 27, 2014, 8 pgs.;;LSI Corporation; Office Action for Taiwan Patent Application No. 101128817, dated Jul. 14, 2014, 17 pgs.;;LSI Corporation; Office Action for Taiwan Patent Application No. 101137008, dated Jul. 31, 2014, 10 pgs.;;LSI Corporation; Search Report for Chinese Patent Application No. 201280009888.4, filed Oct. 4, 2012, dated Feb. 28, 2014, 4 pgs.;;Mehling, Herman, “Solid State Drives Get Faster with TRIM,” Jan. 27, 2010 (retrieved from http://www.enterprisestorageforum.com/technology/features/article.php/3861181/Solid-State-Drives-Get-Faster-with-TRIM.htm and converted to pdf format Apr. 7, 2014), 4 pgs.;;Office Action of the State Intellectural Property Office of the People's Republic of China Patent Application No. 2012800314652 including Search Report, May 4, 2014, 14 pgs.;;Shimpi, Anand Lal, “The Impact of Spare Area on SandForce, More Capacity at no Performance Loss?” May 3, 2010 (retrieved from http://www.anandtech.com/show/3690/the-impact-of-spare-area-on-sandforce-more-capacity-at-no-performance-loss and converted to pdf, 14 pgs.;;Smith, Kent, “Garbage Collection: Understanding Foreground vs. Background GC and Other Related Elements,” Proceedings Flash Memory Summit 2011, Aug. 2011, 9 pgs.;;Smith, Kent, “Understanding SSD Over Provisioning,” Proceedings Flash Memory Summit 2012, Aug. 2012, 16 pgs.",ACTIVE
20,US,A1,US 2014/0281083 A1,065-865-474-882-078,2014-09-18,2014,US 201414209028 A,2014-03-13,US 201414209028 A;;US 201361786073 P,2013-03-14,ENHANCED QUEUE MANAGEMENT,"A paired queue apparatus and method comprising request and response queues wherein queue head and tail pointer update values are communicated through an enhanced pointer word data format providing pointer indicator information and optional auxiliary information in a single transfer, wherein auxiliary information provides additional system communication without consuming additional bandwidth. Auxiliary information is optionally contained in a response data entry written to a response queue or in a request entry written to a request queue.",LSI CORP,CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-03-13),https://lens.org/065-865-474-882-078,Patent Application,yes,15,26,4,4,0,G06F13/362;;G06F13/362;;G06F3/0611;;G06F3/0659;;G06F3/0688;;G06F13/1642;;G06F13/1642;;G06F13/364;;G06F13/4282;;G06F13/4282,G06F13/364,710/112,0,0,,,,ACTIVE
21,CN,A,CN 103942010 A,040-060-513-779-511,2014-07-23,2014,CN 201410030730 A,2014-01-22,US 201361755442 P,2013-01-22,Management of and region selection for writes to non-volatile memory,"Management of and region selection for writes to non-volatile memory of an SSD improves performance, reliability, unit cost, and/or development cost of an SSD. A controller receives and determines characteristics of writes (e.g. by analyzing the write data, the write data source, and/or by receiving a hint) and selects a region based on the determined characteristics and properties of regions of non-volatile memory. For example, a controller receives writes determined to be read-only data and selects regions of non-volatile memory containing cells that are likely to have write failures. By placing read-only data in write failure prone regions, the likelihood of an error is reduced, thus improving reliability. As another example, a controller receives writes hinted to be uncompressible and selects regions of non-volatile memory containing uncompressible data.",LSI CORP,EARL T COHEN;;TIMOTHY LAWRENCE CANEPA,,https://lens.org/040-060-513-779-511,Patent Application,no,8,21,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F3/06,,0,0,,,,INACTIVE
22,US,A1,US 2014/0176748 A1,044-852-600-372-905,2014-06-26,2014,US 201213721688 A,2012-12-20,US 201213721688 A,2012-12-20,METHOD FOR PROMPTING PHOTOGRAPHS OF EVENTS,"A computer-implemented method, computer program product, and computing system is provided for interacting with images having similar content. In an embodiment, a method may include identifying one or more event attributes associated with an ongoing event. The method may also include determining one or more statistical characteristics associated with the one or more of the event attributes. The method may further include generating a prompt to an event participant to take a photograph during the ongoing event based on, at least in part, the one or more statistical characteristics.",GOOGLE INC,COHEN DAVE;;ST CLAIR TIMOTHY SEPKOSKI,GOOGLE LLC (2012-12-18),https://lens.org/044-852-600-372-905,Patent Application,yes,4,10,4,4,0,H04N23/661;;H04N23/64;;H04N23/64;;H04N23/661,H04N5/232,348/222.1,0,0,,,,ACTIVE
23,US,B2,US 9851910 B2,065-362-639-283-897,2017-12-26,2017,US 201514942475 A,2015-11-16,US 31637310 P;;US 201113053175 A;;US 201161543707 P;;US 201213652301 A,2010-03-22,Scalable data structures for control and management of non-volatile storage,"Method and apparatus for managing data in a Non-Volatile Memory (NVD). In some embodiments, management information is stored in a buffer memory using a Solid-State Disk (SSD) controller circuit, the management information comprising a map data structure that associates storage addresses of a host device to physical addresses of the NVD. A location in the management information is determined responsive to a selected host storage address and a programmable parameter by arithmetically dividing in accordance with a divisor specified at least in part by the programmable parameter. The location in the management information is used to direct a transfer of user data by the SSD control circuit between the host device and the NVM.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/065-362-639-283-897,Granted Patent,yes,9,5,4,21,0,G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/0292;;G06F12/00;;Y02D10/00;;G06F12/0292;;G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/00;;Y02D10/00;;G06F3/0619;;G06F3/0634;;G06F3/0655,G06F12/00;;G06F3/06;;G06F12/02,,1,0,,,"Shin, et al., “FTL Design Exploration in Reconfigurable High-Performance SSD for Server Applications,” ICS 2009, Jun. 8-12, 2009, ACM 978-1-60558-498-0/09/06, pp. 338-349.",ACTIVE
24,EP,A1,EP 2764516 A1,196-992-244-077-841,2014-08-13,2014,EP 12838511 A,2012-10-04,US 201161543707 P;;US 2012/0058583 W,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/196-992-244-077-841,Patent Application,yes,0,0,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G11C16/02;;G06F12/00;;G11C16/06,,0,0,,,,DISCONTINUED
25,US,A1,US 2014/0215103 A1,134-236-873-929-741,2014-07-31,2014,US 201414161290 A,2014-01-22,US 201414161290 A;;US 201361758770 P,2013-01-31,DECOUPLED LOCKING DMA ARCHITECTURE,"A decoupled Direct Memory Access (DMA) architecture includes at least two DMA controllers, and optionally at least one of the DMA controllers is operable to assert a lock signal operable to selectively inhibit write access to at least a portion of one system data storage element. The DMA controllers are optionally operable to communicate pending task information and to reschedule pending tasks of at least one the DMA controllers. Optionally data is transferred from at least a first one of the DMA controllers to one or more function units, and processed data from the function units is provided to at least a second one of the DMA controllers. Optionally the DMA controllers and one or more memory elements accessible to the DMA controllers are implemented as part of an I/O device.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-01-21),https://lens.org/134-236-873-929-741,Patent Application,yes,4,26,2,2,0,G06F13/28;;G06F13/28,G06F13/28,710/23,0,0,,,,ACTIVE
26,US,B2,US 9436634 B2,005-178-113-826-870,2016-09-06,2016,US 201414209028 A,2014-03-13,US 201414209028 A;;US 201361786073 P,2013-03-14,Enhanced queue management,"A paired queue apparatus and method comprising request and response queues wherein queue head and tail pointer update values are communicated through an enhanced pointer word data format providing pointer indicator information and optional auxiliary information in a single transfer, wherein auxiliary information provides additional system communication without consuming additional bandwidth. Auxiliary information is optionally contained in a response data entry written to a response queue or in a request entry written to a request queue.",SEAGATE TECHNOLOGY LLC,CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-03-13),https://lens.org/005-178-113-826-870,Granted Patent,yes,15,11,4,4,0,G06F13/362;;G06F13/362;;G06F3/0611;;G06F3/0659;;G06F3/0688;;G06F13/1642;;G06F13/1642;;G06F13/364;;G06F13/4282;;G06F13/4282,G06F13/36;;G06F13/00;;G06F13/364,,0,0,,,,ACTIVE
27,US,B2,US 9066009 B2,008-518-235-321-261,2015-06-23,2015,US 201213721688 A,2012-12-20,US 201213721688 A,2012-12-20,Method for prompting photographs of events,"A computer-implemented method, computer program product, and computing system is provided for interacting with images having similar content. In an embodiment, a method may include identifying one or more event attributes associated with an ongoing event. The method may also include determining one or more statistical characteristics associated with the one or more of the event attributes. The method may further include generating a prompt to an event participant to take a photograph during the ongoing event based on, at least in part, the one or more statistical characteristics.",GOOGLE INC,COHEN DAVE;;ST CLAIR TIMOTHY SEPKOSKI,GOOGLE LLC (2012-12-18),https://lens.org/008-518-235-321-261,Granted Patent,yes,15,0,4,4,0,H04N23/661;;H04N23/64;;H04N23/64;;H04N23/661,H04N5/232;;H04N5/225,,1,0,,,"International Search Report and Written Opinion mailed Dec. 9, 2014 in related application No. PCT/US13/76754.",ACTIVE
28,WO,A3,WO 2014/100517 A3,146-757-831-451-574,2015-02-19,2015,US 2013/0076754 W,2013-12-19,US 201213721688 A,2012-12-20,METHOD FOR PROMPTING PHOTOGRAPHS OF EVENTS,"A computer-implemented method, computer program product, and computing system is provided for interacting with images having similar content. In an embodiment, a method may include identifying one or more event attributes associated with an ongoing event. The method may also include determining one or more statistical characteristics associated with the one or more of the event attributes. The method may further include generating a prompt to an event participant to take a photograph during the ongoing event based on, at least in part, the one or more statistical characteristics.",GOOGLE INC,COHEN DAVE;;ST CLAIR TIMOTHY SEPKOSKI,,https://lens.org/146-757-831-451-574,Search Report,yes,6,0,4,4,0,H04N23/661;;H04N23/64;;H04N23/64;;H04N23/661,H04N5/228;;H04N5/232,,0,0,,,,PENDING
29,EP,A4,EP 2764516 A4,164-789-858-630-918,2015-07-08,2015,EP 12838511 A,2012-10-04,US 201161543707 P;;US 2012/0058583 W,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/164-789-858-630-918,Search Report,no,1,0,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G11C16/02;;G06F12/00;;G11C16/06,,0,0,,,,DISCONTINUED
30,US,A1,US 2016/0174621 A1,042-368-568-025-008,2016-06-23,2016,US 201414580876 A,2014-12-23,US 201414580876 A,2014-12-23,CONVERTIBLE GARMENT AND METHOD OF CONVERTING SAME,"A convertible garment and a method of converting a convertible garment is disclosed. A convertible garment includes a piece of fabric possessing a periphery, and a plurality of fasteners disposed on the piece of fabric along the periphery at substantially regular intervals. One of the plurality of fasteners is configured to fasten to each of the other fasteners to form armholes. The convertible garment is configured to adopt a first configuration in which the fasteners are not fastened to one another so that the convertible garment is wearable as a scarf. The convertible garment is configured to adopt a second configuration in which one of the plurality of fasteners is fastened to each of the other fasteners so that the convertible garment is wearable as a vest.",G III APPAREL GROUP LTD,JAMES TIMOTHY;;VOLOSHINA MARINA;;COHEN SHANA,G-III APPAREL GROUP LTD (2014-12-23),https://lens.org/042-368-568-025-008,Patent Application,yes,52,5,3,3,0,A41D23/00;;A41D23/00;;A41D15/00;;A41D15/00,A41D1/04;;A41D23/00,,0,0,,,,INACTIVE
31,WO,A1,WO 2013/052562 A1,059-211-852-155-207,2013-04-11,2013,US 2012/0058583 W,2012-10-04,US 201161543707 P,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/059-211-852-155-207,Patent Application,yes,5,11,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/00;;G11C16/02;;G11C16/06,,0,0,,,,PENDING
32,US,A1,US 2017/0161191 A1,099-334-336-394-78X,2017-06-08,2017,US 201514611258 A,2015-02-01,US 201514611258 A;;US 201313988019 A;;US 2012/0058583 W;;US 201161543707 P,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/099-334-336-394-78X,Patent Application,yes,0,10,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/0815,,0,0,,,,ACTIVE
33,US,S,US D0767163 S,133-205-172-735-890,2016-09-20,2016,US 201529544434 F,2015-11-03,US 201529544434 F,2015-11-03,Culture dish,,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/133-205-172-735-890,Design Right,no,0,7,1,1,0,,,2402;;D24/226,0,0,,,,ACTIVE
34,TW,A,TW 201324150 A,138-830-274-239-877,2013-06-16,2013,TW 101137008 A,2012-10-05,US 201161543707 P,2011-10-05,Self-journaling and hierarchical consistency for non-volatile storage,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,,https://lens.org/138-830-274-239-877,Patent of Addition,no,0,11,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/08;;G06F12/14,,0,0,,,,INACTIVE
35,TW,B,TW I516931 B,048-843-321-002-769,2016-01-11,2016,TW 101137008 A,2012-10-05,US 201161543707 P,2011-10-05,Self-journaling and hierarchical consistency for non-volatile storage,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,,https://lens.org/048-843-321-002-769,Granted Patent,no,0,6,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,,,0,0,,,,INACTIVE
36,US,A1,US 2017/0322751 A1,081-589-442-246-714,2017-11-09,2017,US 201715661079 A,2017-07-27,US 201715661079 A;;US 201313936010 A;;US 2012/0049905 W;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,"Methods, systems and computer-readable storage media for receiving, via an external interface of a storage device, a command from a computing host, the command including at least one non-standard command modifier, executing the command according to a particular non-standard command modifier, storing an indication of the particular non-standard command modifier in an entry of a map associated with a logical block address of the command, and storing a shadow copy of the map in a memory of the computing host.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/081-589-442-246-714,Patent Application,yes,0,6,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F3/06;;G06F12/00,,0,0,,,,ACTIVE
37,US,A1,US 2014/0208007 A1,183-621-695-802-606,2014-07-24,2014,US 201414158827 A,2014-01-19,US 201414158827 A;;US 201361755442 P,2013-01-22,MANAGEMENT OF AND REGION SELECTION FOR WRITES TO NON-VOLATILE MEMORY,"Management of and region selection for writes to non-volatile memory of an SSD improves performance, reliability, unit cost, and/or development cost of an SSD. A controller receives and determines characteristics of writes (e.g. by analyzing the write data, the write data source, and/or by receiving a hint) and selects a region based on the determined characteristics and properties of regions of non-volatile memory. For example, a controller receives writes determined to be read-only data and selects regions of non-volatile memory containing cells that are likely to have write failures. By placing read-only data in write failure prone regions, the likelihood of an error is reduced, thus improving reliability. As another example, a controller receives writes hinted to be uncompressible and selects regions of non-volatile memory containing uncompressible data.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-01-14),https://lens.org/183-621-695-802-606,Patent Application,yes,24,40,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F3/06,711/103,3,0,,,"'Using the Appropriate Wear Leveling to Extend Product Lifespan' Presented by: Bill Roman, Datalight Software Architect, August 2009.;;'Error Analysis and Retention-Aware Error Management for NAND Flash Memory' by Yu Cai et al., Intel Technology Journal, Volumn 17, Issue 1, 2013.;;'The Inconvenient Truths of NAND Flash Memory' by Jim Cooke, Micron Technology, Inc., August 2007.",ACTIVE
38,TW,A,TW 201443641 A,186-905-855-946-814,2014-11-16,2014,TW 103102158 A,2014-01-21,US 201361755442 P,2013-01-22,Management of and region selection for writes to non-volatile memory,"Management of and region selection for writes to non-volatile memory of an SSD improves performance, reliability, unit cost, and/or development cost of an SSD. A controller receives and determines characteristics of writes (e.g. by analyzing the write data, the write data source, and/or by receiving a hint) and selects a region based on the determined characteristics and properties of regions of non-volatile memory. For example, a controller receives writes determined to be read-only data and selects regions of non-volatile memory containing cells that are likely to have write failures. By placing read-only data in write failure prone regions, the likelihood of an error is reduced, thus improving reliability. As another example, a controller receives writes hinted to be uncompressible and selects regions of non-volatile memory containing uncompressible data.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,,https://lens.org/186-905-855-946-814,Patent of Addition,no,0,5,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,G06F12/02;;G06F3/06,,0,0,,,,INACTIVE
39,TW,B,TW I537724 B,033-389-037-499-032,2016-06-11,2016,TW 103102158 A,2014-01-21,US 201361755442 P,2013-01-22,Management of and region selection for writes to non-volatile memory,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,,https://lens.org/033-389-037-499-032,Granted Patent,no,0,9,11,11,0,G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0608;;G06F3/0679;;G06F12/0246;;G06F2212/1016;;G06F2212/1044;;G06F2212/7201;;G06F2212/7202;;G06F2212/7208;;G06F2212/7211;;G06F3/0616;;G06F3/064;;G06F3/0619;;G06F3/0653,,,0,0,,,,INACTIVE
40,US,S,US D0767164 S,112-999-697-524-602,2016-09-20,2016,US 201529544437 F,2015-11-03,US 201529544437 F,2015-11-03,Culture dish,,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/112-999-697-524-602,Design Right,no,0,14,1,1,0,,,2402;;D24/226,0,0,,,,ACTIVE
41,KR,A,KR 20140084337 A,013-833-182-857-863,2014-07-04,2014,KR 20147015582 A,2012-10-04,US 201161543707 P;;US 2012/0058583 W,2011-10-05,SELF-JOURNALING AND HIERARCHICAL CONSISTENCY FOR NON-VOLATILE STORAGE,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/013-833-182-857-863,Patent Application,no,0,0,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/08,,0,0,,,,INACTIVE
42,CN,A,CN 103392207 A,032-690-975-938-712,2013-11-13,2013,CN 201280009888 A,2012-10-04,US 2012/0058583 W;;US 201161543707 P,2011-10-05,Self-journaling and hierarchical consistency for non-volatile storage,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/032-690-975-938-712,Patent Application,no,3,14,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G11C16/02;;G06F12/00;;G11C16/06,,0,0,,,,INACTIVE
43,US,A1,US 2024/0070141 A1,136-623-114-434-214,2024-02-29,2024,US 202318239471 A,2023-08-29,US 202318239471 A;;US 202263402599 P,2022-08-31,SYSTEMS AND METHODS FOR GENERATING INTERRELATED NOTIONAL DATA,"Disclosed herein are systems and methods for generating notional data. The method includes: receiving seed data of one or more object types in a base dataframe; defining one or more functional relationships associated with the one or more object types, at least one functional relationship of the one or more functional relationships specifying a change to seed data of one object type of the one or more object types; generating data of the one or more object types based at least in part on the seed data in the base dataframe and the one or more functional relationships; and generating the notional data based at least in part on the generated data of the one or more object types.",PALANTIR TECHNOLOGIES INC,COHEN HANNAH;;NOVICK MYLES;;SCHWAB TIMOTHY,PALANTIR TECHNOLOGIES INC (2023-06-21),https://lens.org/136-623-114-434-214,Patent Application,yes,0,0,1,1,0,G06F16/2365;;G06F21/60;;G06F16/213,G06F16/21;;G06F16/23;;G06F21/60,,0,0,,,,PENDING
44,WO,A2,WO 2014/100517 A2,123-727-648-366-601,2014-06-26,2014,US 2013/0076754 W,2013-12-19,US 201213721688 A,2012-12-20,METHOD FOR PROMPTING PHOTOGRAPHS OF EVENTS,"A computer-implemented method, computer program product, and computing system is provided for interacting with images having similar content. In an embodiment, a method may include identifying one or more event attributes associated with an ongoing event. The method may also include determining one or more statistical characteristics associated with the one or more of the event attributes. The method may further include generating a prompt to an event participant to take a photograph during the ongoing event based on, at least in part, the one or more statistical characteristics.",GOOGLE INC,COHEN DAVE;;ST CLAIR TIMOTHY SEPKOSKI,,https://lens.org/123-727-648-366-601,Patent Application,yes,0,0,4,4,0,H04N23/661;;H04N23/64;;H04N23/64;;H04N23/661,H04N5/232,,0,0,,,,PENDING
45,US,B2,US 9814276 B2,154-633-562-512-820,2017-11-14,2017,US 201414580876 A,2014-12-23,US 201414580876 A,2014-12-23,Convertible garment and method of converting same,"A convertible garment and a method of converting a convertible garment is disclosed. A convertible garment includes a piece of fabric possessing a periphery, and a plurality of fasteners disposed on the piece of fabric along the periphery at substantially regular intervals. One of the plurality of fasteners is configured to fasten to each of the other fasteners to form armholes. The convertible garment is configured to adopt a first configuration in which the fasteners are not fastened to one another so that the convertible garment is wearable as a scarf. The convertible garment is configured to adopt a second configuration in which one of the plurality of fasteners is fastened to each of the other fasteners so that the convertible garment is wearable as a vest.",G-III APPAREL GROUP LTD,JAMES TIMOTHY;;VOLOSHINA MARINA;;COHEN SHANA,G-III APPAREL GROUP LTD (2014-12-23),https://lens.org/154-633-562-512-820,Granted Patent,yes,57,4,3,3,0,A41D23/00;;A41D23/00;;A41D15/00;;A41D15/00,A41D23/00;;A41D15/00,,4,0,,,"International Search Report and Written Opinion of the Searching Authority dated Feb. 19, 2016 in the corresponding International Application No. PCT/US15/67376. (9 pages, in English).;;“Creating Bits of Envy” (Blogspot) Feb. 2, 2014. Retrieved from the internet on Feb. 9, 2016. <www.creatingbitsofenvy.blogspto.com?>(35 pages, in English).;;“Multi-Way Sweater Scarf” Vivi Designs Inc (Vivi); Dec. 6, 2013; Retrieved from the Internet on Feb. 9, 2016. <http://www.vividesigninc.com/includes/62500Brochure.pdf> (7 pages, in English).;;“Frugal Fashion—Wear your scarf as a Vest” (Couponing 101); Apr. 29, 2013; Retrieved from the internet on Feb. 9, 2016 <http://www.couponing101.com/frugal-fashion-wear-your-scarf-as-a-vest/> (6 pages, in English).",INACTIVE
46,US,B2,US 10514864 B2,191-073-717-811-040,2019-12-24,2019,US 201715661079 A,2017-07-27,US 201715661079 A;;US 201313936010 A;;US 2012/0049905 W;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P,2011-08-09,I/O device and computing host interoperation,"Methods, systems and computer-readable storage media for receiving, via an external interface of a storage device, a command from a computing host, the command including at least one non-standard command modifier, executing the command according to a particular non-standard command modifier, storing an indication of the particular non-standard command modifier in an entry of a map associated with a logical block address of the command, and storing a shadow copy of the map in a memory of the computing host.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/191-073-717-811-040,Granted Patent,yes,64,3,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F12/1027;;G06F3/06;;G06F12/00,,38,0,,,"OCZ Technology; “SSDs—Write Amplification, Trim and GC,” Mar. 2010 (retrieved from http://www.oczenterprise.com/whitepapers/ssds-writeamplification-trim-and-gc.pdf, using Internet Archive Wayback Machine Mar. 28, 2014), 3 pgs.;;“Write Amplification,” Wikipedia (retrieved from http://en.wikipedia.org/wiki/Write_amplification and converted to pdf format Apr. 7, 2014), 14 pgs.;;Cohen, Earl T.; Advisory Action for U.S. Appl. No. 13/936,010, filed Jul. 5, 2013, dated Oct. 14, 2015, 3 pgs.;;Cohen, Earl T.; Final Office Action for U.S. Appl. No. 13/936,010, filed Jul. 5, 2013, dated Jun. 17, 2015, 15 pgs.;;Cohen, Earl T.; Notice of Allowance for Taiwanese Application No. 101128817, filed Aug. 9, 2012, dated Jan. 16, 2017, 3 pgs.;;Cohen, Earl T.; U.S. Patent Application entitled: I/O Device and Computing Host Interoperation, having U.S. Appl. No. 13/936,010, filed Jul. 5, 2013, 166 pgs.;;) Cohen, Earl T.; International Search Report and Written Opinion for PCT/US2012/058583, filed Oct. 4, 2012, dated Feb. 25, 2013, 8 pgs.;;Cohen, Earl T.; Final Office Action for U.S. Appl. No. 14/237,331, filed Feb. 5, 2014, dated Dec. 9, 2014, 27 pgs.;;Cohen, Earl T.; Final Office Action for U.S. Appl. No. 14/237,331, filed Feb. 5, 2014, dated Jun. 10, 2015, 15 pgs.;;Cohen, Earl T.; International Search Report and Written Opinion for PCT/US2012/049905, filed Aug. 8, 2012, dated Jan. 3, 2013, 9 pgs.;;Cohen, Earl T.; Issue Notification for U.S. Appl. No. 14/237,331, filed Feb. 5, 2014, dated Jun. 22, 2016, 1 pg.;;Cohen, Earl T.; Non-Final Office Action for U.S. Appl. No. 14/237,331, filed Feb. 5, 2014, dated Nov. 27, 2015, 29 pgs.;;Cohen, Earl T.; Non-Final Office Action for U.S. Appl. No. 14/237,331, filed Feb. 5, 2014, dated May 30, 2014, 18 pgs.;;Cohen, Earl T.; Notice of Allowance for U.S. Appl. No. 14/237,331, filed Feb. 5, 2014, dated Mar. 16, 2016, 6 pgs.;;Smith, Kent, “Understanding SSD Over Provisioning,” Proceedings Flash Memory Summit 2012, Aug. 2012, 16 pgs.;;Cohen, Earl T.; U.S. Provisional Application entitled: I/O Device and Computing Host Interoperation, having U.S. Appl. No. 61/521,739, filed Aug. 9, 2011, 78 pgs. (see MPEP § 609.04(a) (citing “Waiver of the Copy Requirement”).).;;Cohen, Earl T.; U.S. Provisional Application entitled: I/O Device and Computing Host Interoperation, having U.S. Appl. No. 61/531,551, filed Sep. 6, 2011, 124 pgs. (see MPEP § 609.04(a) (citing “Waiver of the Copy Requirement”).).;;Cohen, Earl T.; U.S. Provisional Application entitled: I/O Device and Computing Hose Interoperation, having U.S. Appl. No. 61/543,666, filed Oct. 5, 2011, 126 pgs. (see MPEP § 609.04(a) (citing “Waiver of the Copy Requirement”).).;;Agrawal, et al, “Design Tradeoff's for SSD Performance,” Proceedings of the 2008 USENIX Annual Technical Conference, Jun. 2008, 14 pgs.;;LSI Corporation; Chinese Office Action for serial No. 201280049511.1, filed Aug. 8, 2012, dated Nov. 4, 2014, 18 pgs.;;Cohen, Earl T.; Office Action for Taiwanese Application No. 10521148350, filed Aug. 9, 2012, dated Sep. 20, 2016, 6 pgs.;;Cohen, et al; International Preliminary Report on Patentability for PCT/US2012/049905, filed Aug. 8, 2012, dated Feb. 11, 2014, 6 pgs.;;Smith Kent, “Garbage Collection: Understanding Foreground vs. Background GC and Other Related Elements,” Proceedings Flash Memory Summit 2011, Aug. 2011, 9 pgs.;;Frankie, et al, “SSD Trim Commands Considerably Improve Overprovisioning,” Proceedings Flash Memory Summit 2011, Aug. 2011, 19 pgs.;;IEEE, “band” definition, IEEE Standard Dictionary of Electrical and Electronics Terms, Nov. 3, 1998, p. 80, IEE, Inc. New York, NY, 3 sheets total (1 sheet of content, 2 sheets of title pages).;;Layton, Jeffrey, “Anatomy of SSD's,” Linux Magazine, Oct. 27, 2009 (Retrieved from http://www.linux-mag.com/id/7590/2 and converted to pdf format Apr. 7, 2014), 4 pgs.;;LSI Corporation; Extended European Search Report for serial No. 14151725.0, dated Apr. 22, 2014, 6 pgs.;;LSI Corporation; International Search Report and Written Opinion for PCT/US2012/034601, filed Apr. 22, 2012, dated Nov. 30, 2012, 7 pgs.;;LSI Corporation; Office Action for Chinese patent application No. 201280009888.4, filed Oct. 4, 2012, dated Mar. 10, 2014, 17 pgs.;;LSI Corporation; Office Action for Korean Patent Application No. 10-2013-7029137, dated Jun. 27, 2014, 7 pgs.;;LSI Corporation; Office Action for Taiwan Patent Application No. 101128817, dated Jul. 14, 2014, 17 pgs.;;LSI Corporation; Search Report for Chinese Patent Application No. 201280009888.4, filed Oct. 4, 2012, dated Feb. 28, 2014, 4 pgs.;;Mehling, Herman, “Solid State Drives Get Faster with TRIM,” Jan. 27, 2010 (retrieved from http://www.enterprisestorageforum.com/technology/features/article.php/3861181/Solid-State-Drives-Get-Faster-with-TRIM.htm and converted to pdf format Apr. 7, 2014), 4 pgs.;;LSI Corporation; Office Action for Taiwan Patent Application No. 101114992, dated Jun. 27, 2014, 8 pgs.;;LSI Corporation; Office Action for Taiwan Patent Application No. 101137008, dated Jul. 31, 2014, 10 pgs.;;LSI Corporation; Office Action for Chinese Patent Application No. 2012800314652, dated May 4, 2014, 14 pgs.;;Shimpi, Anand Lal, “The Impact of Spare Area on SandForce, More Capacity at No Performance Loss?” May 3, 2010 (retrieved from http://www.anandtech.com/show/3690/the-impact-of-spare-area-on-sandforce-more-capacity-at-no-performance-loss and converted to pdf), 14 pgs.;;Simionescu, Horia; Notice of Allowance for Korean Patent Applicatio nno. 10-2013-0022004, filed Feb. 28, 2013, dated Mar. 28, 2019, 3 pages.",ACTIVE
47,US,B2,US 9886383 B2,026-718-779-603-813,2018-02-06,2018,US 201514611258 A,2015-02-01,US 201514611258 A;;US 201313988019 A;;US 2012/0058583 W;;US 201161543707 P,2011-10-05,Self-journaling and hierarchical consistency for non-volatile storage,"A non-volatile storage system having Non-Volatile Memory (NVM) provides self-journaling and hierarchical consistency, enabling low-latency recovery and force unit access handshake. Mappings between host addresses and addresses in the NVM are maintained via one or more map entries, enabling locating of host data written to the NVM. Objects stored in the NVM include sufficient information to recover the object solely within the object itself. The NVM is managed as one or more data streams, a map stream, and a checkpoint stream. Host data is written to the data streams, map entries are written to the map stream, and checkpoints of map entries and other data structures are written to the checkpoint stream. Time markers embedded in the streams enable determination, during recovery, that selected portions of the streams are inconsistent with each other and are to be discarded.",SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/026-718-779-603-813,Granted Patent,yes,9,3,16,21,0,G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0619;;G06F3/0643;;G06F3/0659;;G06F3/0679;;G06F3/0688;;G06F12/0246;;G06F12/08;;G11C16/06;;G06F2212/1032;;G06F2212/7201;;G06F2212/7207;;G06F12/0292;;G06F3/0643;;G06F3/0679;;G06F3/0659;;G06F3/0688;;G06F3/0619;;G06F12/0246;;G06F11/07;;G11C16/02;;G06F12/0815;;G06F2212/621,G06F12/0815,,2,0,,,"Cohen, International Search Report, PCT/US12/58583, dated Oct. 4, 2012, 10 pages.;;Cohen, Written Opinion, PCT/US12/58583, dated Oct. 4, 2012, 10 pages.",ACTIVE
48,US,S,US D0767161 S,070-545-850-982-493,2016-09-20,2016,US 201529544427 F,2015-11-03,US 201529544427 F,2015-11-03,Culture dish,,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,SCHIMMEL TIMOTHY;;COHEN JACQUES;;CECCHI MICHAEL,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/070-545-850-982-493,Design Right,no,0,4,1,1,0,,,2402;;D24/226,0,0,,,,ACTIVE
49,US,A1,US 2014/0108703 A1,131-390-672-027-553,2014-04-17,2014,US 201213652301 A,2012-10-15,US 31637310 P;;US 201113053175 A;;US 201161543707 P;;US 201213652301 A,2010-03-22,Scalable Data Structures for Control and Management of Non-Volatile Storage,"Scalable control/management data structures enable optimizing performance and/or attempting to achieve a particular performance target of an SSD in accordance with host interfacing, number of NVM devices, NVM characteristics and size, and NVM aging and performance decline. Pre-scaled data structures are included in SSD controller firmware loadable at system initialization. Static data structure configurations enable load-once-operate-for-product-lifetime operation for consumer applications. Dynamic configurations provide sequences of data structures pre-scaled to optimize operation as NVM ages and performance declines. Pre-configured adjustments in data structure size included in consecutive configurations periodically replace earlier configurations at least one time during product lifetime, producing a periodic rescaling of data structure size to track changes in aging NVM. Optionally, sizes of some data structures are decreased as NVM usage increases, enabling an increase in translation layer mapping structure sizes, reducing accesses to translation tables in NVM, and reducing write amplification.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-10-15),https://lens.org/131-390-672-027-553,Patent Application,yes,9,75,4,21,0,G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/0292;;G06F12/00;;Y02D10/00;;G06F12/0292;;G06F3/0616;;G06F3/0644;;G06F3/0688;;G06F12/0246;;G06F2212/7206;;G06F2212/7207;;G06F2212/7208;;G06F2212/7211;;G06F12/00;;Y02D10/00;;G06F3/0619;;G06F3/0634;;G06F3/0655,G06F12/00,711/103;;X711E12008,1,0,,,"Shin et al, ""FTL Design Exploration in Reconfigurable High-Performance SSD for Server Applications"", ICS'09 June 8-12 2009, ACM 978-1-60558-498-0/09/06, Pages 338-349.",ACTIVE
50,US,A1,US 2017/0052912 A1,189-224-706-519-507,2017-02-23,2017,US 201615245852 A,2016-08-24,US 201615245852 A;;US 201414209028 A;;US 201361786073 P,2013-03-14,ENHANCED QUEUE MANAGEMENT,"A paired queue apparatus and method comprising request and response queues wherein queue head and tail pointer update values are communicated through an enhanced pointer word data format providing pointer indicator information and optional auxiliary information in a single transfer, wherein auxiliary information provides additional system communication without consuming additional bandwidth. Auxiliary information is optionally contained in a response data entry written to a response queue or in a request entry written to a request queue.",SEAGATE TECHNOLOGY LLC,CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/189-224-706-519-507,Patent Application,yes,1,6,4,4,0,G06F13/362;;G06F13/362;;G06F3/0611;;G06F3/0659;;G06F3/0688;;G06F13/1642;;G06F13/1642;;G06F13/364;;G06F13/4282;;G06F13/4282,G06F13/362;;G06F3/06;;G06F13/42,,0,0,,,,ACTIVE
51,US,B1,US 6448069 B1,056-436-416-194-46X,2002-09-10,2002,US 59038900 A,2000-06-09,US 59038900 A,2000-06-09,Embryo-culturing apparatus and method,"
    An embryo culturing method and apparatus enables a plurality of embryos to be grown in communal clusters in a culturing container. The embryos are kept separate from each other in open interconnected compartments that are disposed in the culture container. Each compartment is contained in a structure having a plurality of interconnected compartments, and each compartment is sized to contain a single embryo. The culturing container will contain a plurality of the compartmentalized structures. The method and apparatus of this invention includes a culturing container, such as a Petrie dish, in which the embryos are grown. The Petrie dish preferably contains a plurality of the embryo-culturing compartmentalized structures which can be positioned in the Petrie dish in a predetermined pattern. For example, the compartmentalized structuress can be positioned in the Petrie dish at the 12 O'Clock, 2 O'Clock, 4 O'Clock, 8 O'Clock and 10 O'clock positions, or in any other planned deployment. The individual structures can be individually identified by letters, for example, such as A, B, C, D, etc. Each compartmentalized structure can contain a plurlaity, for example four, compartments which are interconnected for fluid exchange, but which are sized to restrain migration of an embryo from one compartment to another. The compartments in each structure can be identified by numerals, i.,e., 1, 2, 3 and 4. Thus each compartment in each structure would have a unique identifier code, such as A1, B2, C3, and the like; or 1-4, 5-8, 9-12, or the like. Any identifier system can be used which will enable the individual embryos to be distinguished one from another. After the embryos are placed in the compartments in each structure, each of the structures is covered with a drop of an embryo-enhancing growth nutrient so that each of the embryos in any one structure is exposed to a common growth nutrient, and each embryo in each compartmentalized structure can share growth by-products with each of the other embryos in the same compartmentalized structure. 
",GENX INTERNAT CORP,CECCHI MICHAEL D;;COHEN JACQUES;;SCHIMMEL TIMOTHY,LIFEGLOBAL GROUP LLC F/K/A IVFONLINE.COM LLC (2017-11-17);;COOPERSURGICAL INC (2018-04-03);;GENX INTERNATIONAL INC (2000-05-23),https://lens.org/056-436-416-194-46X,Granted Patent,yes,3,35,1,1,0,C12M23/10;;C12M23/10;;C12M21/06;;C12M21/06,C12M3/04,435/305.2;;435/29;;435/366;;435/373;;435/288.5;;435/297.5,0,0,,,,EXPIRED
52,PL,T3,PL 1926590 T3,028-596-762-537-194,2015-02-27,2015,PL 06804091 T,2006-09-22,US 71983905 P;;EP 06804091 A;;US 2006/0037166 W,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,,ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/028-596-762-537-194,Patent Application,no,0,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B5/16;;B32B27/08;;B32B27/30,,0,0,,,,PENDING
53,WO,A2,WO 2012/075200 A2,151-364-148-195-784,2012-06-07,2012,US 2011/0062726 W,2011-11-30,US 41884610 P;;US 201161433918 P,2010-12-01,DYNAMIC HIGHER-LEVEL REDUNDANCY MODE MANAGEMENT WITH INDEPENDENT SILICON ELEMENTS,"A Solid-State Disk (SSD) controller enables dynamic higher-level redundancy mode management with independent silicon elements to provide graceful degradation as non-volatile (e.g. flash) memory elements fail during operation of an SSD implemented by the controller. Higher-level error correction provides correction of lower-level uncorrectable errors. If a failure of one of the non-volatile memory elements is detected, then the higher-level error correction is dynamically transitioned from operating in a current mode to operating in a new mode. The transition includes one or more of reducing free space available on the SSD, rearranging data storage of the SSD, recovering/storing failed user data (if possible), and determining/storing revised higher-level error correction information. Operation then continues in the new mode. If another failure of the non-volatile memory elements is detected, then another transition is made to another new mode.",SANDFORCE INC;;WERNER JEREMY;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,WERNER JEREMY;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/151-364-148-195-784,Patent Application,yes,0,26,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F12/16;;G06F11/08,,1,0,,,See references of EP 2646922A4,PENDING
54,EP,A2,EP 1926590 A2,005-029-644-953-095,2008-06-04,2008,EP 06804091 A,2006-09-22,US 2006/0037166 W;;US 71983905 P,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,,ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/005-029-644-953-095,Patent Application,yes,0,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B5/16;;B32B27/08;;B32B27/30,,0,0,,,,ACTIVE
55,EP,A4,EP 2296703 A4,069-366-189-713-602,2012-09-05,2012,EP 09743744 A,2009-05-08,US 2009/0043273 W;;US 5342708 P;;US 16318009 P;;US 5195608 P,2008-05-09,IGF-II/GF-IIE BINDING PROTEINS,,DYAX CORP;;COMMW SCIENT IND RES ORG,DRANSFIELD DANIEL;;COHEN EDWARD;;ADAMS TIMOTHY;;COSGROVE LEAH,,https://lens.org/069-366-189-713-602,Search Report,no,2,0,11,11,0,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,A61K39/395;;C07K16/00;;C12P21/08,,3,2,068-835-715-462-077;;054-017-149-062-112,10.1210/jcem.87.8.8783;;10.1210/jc.87.8.3867;;12161524;;10.1158/1535-7163.mct-09-1134;;20515953,"SUNDEEP KHOSLA ET AL: ""Use of Site-Specific Antibodies to Characterize the Circulating Form of Big Insulin-Like Growth Factor II in Patients with Hepatitis C-Associated Osteosclerosis"", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM,, vol. 87, no. 8, 1 August 2002 (2002-08-01), pages 3867 - 3870, XP008147568, ISSN: 0021-972X, DOI: 10.1210/JC.87.8.3867;;DRANSFIELD DANIEL T ET AL: ""A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines In vitro and In vivo"", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 6, June 2010 (2010-06-01), pages 1809 - 1819, XP002680461, ISSN: 1535-7163;;See also references of WO 2009137758A2",DISCONTINUED
56,EP,B1,EP 1926590 B1,075-423-272-717-802,2014-08-13,2014,EP 06804091 A,2006-09-22,US 2006/0037166 W;;US 71983905 P,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,,ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/075-423-272-717-802,Granted Patent,yes,3,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B5/16;;B32B27/08;;B32B27/30,,0,0,,,,ACTIVE
57,WO,A3,WO 2007/038383 A3,164-747-299-015-648,2007-09-07,2007,US 2006/0037166 W,2006-09-22,US 71983905 P,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,The invention relates to a composite consisting of an impact-modified acrylic capstock or film on a thermoplastic olefin (TPO). A tie-layer containing a functionalized olefin-acrylic is used to improve the adhesion of the acrylic layer to the TPO and to improve the overall melt processing of the three-layer composite.,ARKEMA FRANCE;;COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/164-747-299-015-648,Search Report,yes,2,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B27/08;;B32B5/16,,0,0,,,,PENDING
58,US,B2,US 9272490 B2,163-291-915-629-493,2016-03-01,2016,US 6654206 A,2006-09-22,US 6654206 A;;US 71983905 P;;US 2006/0037166 W,2005-09-23,Acrylic/thermoplastic olefin composite,The invention relates to a composite consisting of an impact-modified acrylic capstock or film on a thermoplastic olefin (TPO). A tie-layer containing a functionalized olefin-acrylic is used to improve the adhesion of the acrylic layer to the TPO and to improve the overall melt processing of the three-layer composite.,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON;;ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,TRINSEO EUROPE GMBH (2021-07-05),https://lens.org/163-291-915-629-493,Granted Patent,yes,7,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B9/04;;B29C47/00;;B32B27/30,,3,0,,,"Pardos Marketing: Market Overview: Multilayer Films, Rapra, Brussels 2005. Rapra International Conference Nov. 8-9, 2005, Brussels Belgium. http://www.pardos-marketing.com/paper-b03.htm.;;Amit Dharia, ""Influence of Mixing Conditions and Composition on the Phase Structure and Properties of Thermoplastic Olefin Blends""-ANTEC '99 Conference Proceedings, New York City, May 2-6, 1999, vol. II Material.;;Wikipedia:About-Wikipedia, the free encyclopedia. Retrieved on May 14, 2012. http://en.wikipedia.org/wiki/Wikipedia:About.",ACTIVE
59,EP,A4,EP 1926590 A4,015-628-365-446-338,2011-10-19,2011,EP 06804091 A,2006-09-22,US 2006/0037166 W;;US 71983905 P,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,,ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/015-628-365-446-338,Search Report,no,1,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B5/16;;B32B27/08;;B32B27/30,,0,0,,,,ACTIVE
60,WO,A3,WO 2009/137758 A3,059-761-118-467-587,2010-03-18,2010,US 2009/0043273 W,2009-05-08,US 5342708 P;;US 16318009 P;;US 5195608 P,2008-05-09,IGF-II/GF-IIE BINDING PROTEINS,Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor.,DYAX CORP;;COMMW SCIENT IND RES ORG;;DRANSFIELD DANIEL;;COHEN EDWARD;;ADAMS TIMOTHY;;COSGROVE LEAH,DRANSFIELD DANIEL;;COHEN EDWARD;;ADAMS TIMOTHY;;COSGROVE LEAH,,https://lens.org/059-761-118-467-587,Search Report,yes,3,0,11,11,0,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,C07K16/00;;A61K39/395;;C12P21/08,,0,0,,,,PENDING
61,EP,A2,EP 2296703 A2,088-686-037-095-229,2011-03-23,2011,EP 09743744 A,2009-05-08,US 2009/0043273 W;;US 5342708 P;;US 16318009 P;;US 5195608 P,2008-05-09,IGF-II/GF-IIE BINDING PROTEINS,,DYAX CORP;;COMMW SCIENT IND RES ORG,DRANSFIELD DANIEL;;COHEN EDWARD;;ADAMS TIMOTHY;;COSGROVE LEAH,,https://lens.org/088-686-037-095-229,Patent Application,yes,0,0,11,11,94,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,A61K39/395;;C07K16/00;;C12P21/08,,0,0,,,,DISCONTINUED
62,US,A1,US 2008/0220274 A1,023-988-926-204-021,2008-09-11,2008,US 6654206 A,2006-09-22,US 6654206 A;;US 71983905 P;;US 2006/0037166 W,2005-09-23,Acrylic/Thermoplastic Olefin Composite,The invention relates to a composite consisting of an impact-modified acrylic capstock or film on a thermoplastic olefin (TPO). A tie-layer containing a functionalized olefin-acrylic is used to improve the adhesion of the acrylic layer to the TPO and to improve the overall melt processing of the three-layer composite.,ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,TRINSEO EUROPE GMBH (2021-07-05),https://lens.org/023-988-926-204-021,Patent Application,yes,8,16,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B27/30;;B29C47/00,428/500;;156/244.11,3,0,,,"Pardos Marketing: Market Overview: MULTILAYER FILMS, RAPRA, BRUSSELS 2005. Rapra International Conference8th-9th November 2005, Brussels Belgium. http://www.pardos-marketing.com/paper_b03.htm;;Amit Dharia, ""Influence of Mixing Conditions and Composition on the Phase Structure and Properties of Thermoplastic Olefin Blends"" - ANTEC '99 Conference Proceedings, New York City, May 2-6, 1999, Vol II Material.;;Wikipedia:About - Wikipedia, the free encyclopedia. Retrieved on 5/14/2012. http://en.wikipedia.org/wiki/Wikipedia:About",ACTIVE
63,CN,A,CN 103348330 A,182-235-836-256-230,2013-10-09,2013,CN 201180066679 A,2011-11-30,US 2011/0062726 W;;US 41884610 P;;US 201161433918 P,2010-12-01,Dynamic higher-level redundancy mode management with independent silicon elements,"A Solid-State Disk (SSD) controller enables dynamic higher-level redundancy mode management with independent silicon elements to provide graceful degradation as non-volatile (e.g. flash) memory elements fail during operation of an SSD implemented by the controller. Higher-level error correction provides correction of lower-level uncorrectable errors. If a failure of one of the non-volatile memory elements is detected, then the higher-level error correction is dynamically transitioned from operating in a current mode to operating in a new mode. The transition includes one or more of reducing free space available on the SSD, rearranging data storage of the SSD, recovering/storing failed user data (if possible), and determining/storing revised higher-level error correction information. Operation then continues in the new mode. If another failure of the non-volatile memory elements is detected, then another transition is made to another new mode.",LSI CORP,WERNER JEREMY;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/182-235-836-256-230,Patent Application,no,4,5,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F12/16;;G06F11/08,,0,0,,,,INACTIVE
64,AU,A1,AU 2009/244091 A1,051-179-592-892-48X,2009-11-12,2009,AU 2009/244091 A,2009-05-08,US 5342708 P;;US 16318009 P;;US 5195608 P;;US 2009/0043273 W,2008-05-09,IGF-II/GF-IIE binding proteins,,COMMW SCIENT IND RES ORG;;DYAX CORP,ADAMS TIMOTHY;;COSGROVE LEAH;;COHEN EDWARD;;DRANSFIELD DANIEL,,https://lens.org/051-179-592-892-48X,Patent Application,no,0,0,11,11,0,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,C07K16/00;;A61K38/22;;A61K39/395;;C12P21/08,,0,0,,,,INACTIVE
65,WO,A3,WO 2012/075200 A3,106-501-658-670-537,2012-08-16,2012,US 2011/0062726 W,2011-11-30,US 41884610 P;;US 201161433918 P,2010-12-01,DYNAMIC HIGHER-LEVEL REDUNDANCY MODE MANAGEMENT WITH INDEPENDENT SILICON ELEMENTS,"A Solid-State Disk (SSD) controller enables dynamic higher-level redundancy mode management with independent silicon elements to provide graceful degradation as non-volatile (e.g. flash) memory elements fail during operation of an SSD implemented by the controller. Higher-level error correction provides correction of lower-level uncorrectable errors. If a failure of one of the non-volatile memory elements is detected, then the higher-level error correction is dynamically transitioned from operating in a current mode to operating in a new mode. The transition includes one or more of reducing free space available on the SSD, rearranging data storage of the SSD, recovering/storing failed user data (if possible), and determining/storing revised higher-level error correction information. Operation then continues in the new mode. If another failure of the non-volatile memory elements is detected, then another transition is made to another new mode.",LSI CORP;;WERNER JEREMY;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,WERNER JEREMY;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/106-501-658-670-537,Search Report,yes,4,2,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F12/16;;G06F11/08,,1,0,,,See also references of EP 2646922A4,PENDING
66,US,A1,US 2014/0136884 A1,145-736-292-094-416,2014-05-15,2014,US 201213729966 A,2012-12-28,US 201213729966 A;;US 201213677938 A,2012-11-15,READ DISTURB HANDLING FOR NON-VOLATILE SOLID STATE MEDIA,"Described embodiments track a read disturb limit of a solid-state media coupled to a media controller. The media controller receives a read operation from a host device. In response to the received read operation, the media controller determines one or more associated regions of the solid-state media accessed by the read operation and reads the associated regions to provide read data to the host device. Based on a probability value corresponding to each of the associated regions, the media controller selectively increments a read count of each of the associated regions. Based upon each read count, the media controller determines whether each region has reached a read disturb limit. If a given region has reached the read disturb limit, the media controller relocates data of the given region to a free region of the solid-state media. Otherwise, the media controller maintains the data in the given region.",LSI CORP,WERNER JEREMY;;COHEN EARL T;;CANEPA TIMOTHY L,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-12-28),https://lens.org/145-736-292-094-416,Patent Application,yes,3,46,1,39,0,G11C16/0483;;G11C16/3422;;G11C16/349;;G06F11/2094;;G11C16/349;;G11C16/3422;;G11C16/0483,G06F11/20,714/6.11,0,0,,,,DISCONTINUED
67,JP,A,JP 2014077020 A,178-384-775-608-62X,2014-05-01,2014,JP 2014016462 A,2014-01-31,US 5342708 P;;US 16318009 P;;US 5195608 P,2008-05-09,IGF-II/IGF-IIE BINDING PROTEINS,"PROBLEM TO BE SOLVED: To provide IGF-II/IGF-IIE binding proteins.SOLUTION: Proteins that bind to IGF-II and/or IGF-IIE, and a method of using such proteins, are disclosed. A novel method for treating a cancer is also disclosed. A cancer is treated by IGF-II/IGF-IIE binding proteins and additional therapy that is for example administering a growth hormone/growth hormone-releasing hormone pathway modulator, or inhibitor of an epidermal growth factor receptor or the like. In one aspect, this disclosure is characterized in proteins (for example, isolated proteins) that bind to IGF-II and IGF-IIE (for example, human IGF-II and IGF-IIE) and that include at least one immunoglobulin variable domain.",DYAX CORP;;COMMW SCIENT IND RES ORG,DANIEL DRANSFIELD;;EDWARD COHEN;;TIMOTHY ADAMS;;LEAH COSGROVE,,https://lens.org/178-384-775-608-62X,Patent Application,no,0,0,11,11,94,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,C07K16/22;;A61K38/00;;A61K39/395;;A61K45/00;;A61P35/00;;A61P43/00;;C07K16/46;;C12N15/09,,0,0,,,,PENDING
68,CA,A1,CA 2623223 A1,027-864-313-216-370,2007-04-05,2007,CA 2623223 A,2006-09-22,US 71983905 P;;US 2006/0037166 W,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,,ARKEMA FRANCE,WHITE ELTON;;COHEN LESLIE A;;CAVANAUGH TIMOTHY J,,https://lens.org/027-864-313-216-370,Patent Application,no,0,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B5/16;;B32B27/08,,0,0,,,,ACTIVE
69,WO,A2,WO 2009/137758 A2,113-559-472-461-919,2009-11-12,2009,US 2009/0043273 W,2009-05-08,US 5342708 P;;US 16318009 P;;US 5195608 P,2008-05-09,IGF-II/GF-IIE BINDING PROTEINS,Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor.,DYAX CORP;;COMMW SCIENT IND RES ORG;;DRANSFIELD DANIEL;;COHEN EDWARD;;ADAMS TIMOTHY;;COSGROVE LEAH,DRANSFIELD DANIEL;;COHEN EDWARD;;ADAMS TIMOTHY;;COSGROVE LEAH,,https://lens.org/113-559-472-461-919,Patent Application,yes,2,8,11,11,0,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,A61K38/22,,3,2,068-835-715-462-077;;054-017-149-062-112,10.1210/jcem.87.8.8783;;10.1210/jc.87.8.3867;;12161524;;10.1158/1535-7163.mct-09-1134;;20515953,"SUNDEEP ET AL., J. CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 87, no. 8, 1 August 2002 (2002-08-01), pages 3867 - 3870;;DRANSFIELD ET AL., MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 6, June 2010 (2010-06-01), pages 1809 - 1819;;See also references of EP 2296703A4",PENDING
70,WO,A2,WO 2007/038383 A2,190-767-075-872-203,2007-04-05,2007,US 2006/0037166 W,2006-09-22,US 71983905 P,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,The invention relates to a composite consisting of an impact-modified acrylic capstock or film on a thermoplastic olefin (TPO). A tie-layer containing a functionalized olefin-acrylic is used to improve the adhesion of the acrylic layer to the TPO and to improve the overall melt processing of the three-layer composite.,ARKEMA FRANCE;;COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/190-767-075-872-203,Patent Application,yes,0,2,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B27/30,,0,0,,,,PENDING
71,CA,C,CA 2623223 C,034-766-656-061-010,2014-07-22,2014,CA 2623223 A,2006-09-22,US 71983905 P;;US 2006/0037166 W,2005-09-23,ACRYLIC/THERMOPLASTIC OLEFIN COMPOSITE,The invention relates to a composite consisting of an impact-modified acrylic capstock or film on a thermoplastic olefin (TPO). A tie-layer containing a functionalized olefin-acrylic is used to improve the adhesion of the acrylic layer to the TPO and to improve the overall melt processing of the three-layer composite.,ARKEMA FRANCE,COHEN LESLIE A;;CAVANAUGH TIMOTHY J;;WHITE ELTON,,https://lens.org/034-766-656-061-010,Granted Patent,no,0,0,10,10,0,Y10T428/31855;;B32B27/30;;Y10T428/31855;;B32B27/08;;B32B27/306;;B32B27/32;;B32B2333/04;;B32B2323/00;;B32B27/30,B32B27/08,,0,0,,,,ACTIVE
72,AU,B2,AU 2009/244091 B2,067-413-242-643-209,2014-11-27,2014,AU 2009/244091 A,2009-05-08,US 5342708 P;;US 16318009 P;;US 5195608 P;;US 2009/0043273 W,2008-05-09,IGF-II/GF-IIE binding proteins,Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor.,COMMW SCIENT IND RES ORG;;DYAX CORP,COHEN EDWARD;;COSGROVE LEAH;;ADAMS TIMOTHY;;DRANSFIELD DANIEL,,https://lens.org/067-413-242-643-209,Granted Patent,no,1,0,11,11,0,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,C07K16/00;;A61K38/22;;A61K39/395;;C12P21/08,,1,1,068-835-715-462-077,10.1210/jcem.87.8.8783;;10.1210/jc.87.8.3867;;12161524,"SUNDEEP KHOSLA ET AL: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 87, no. 8, 1 August 2002 (2002-08-01 ), pages 3867-3870,",INACTIVE
73,AU,A1,AU 2016/285447 A1,034-101-152-033-167,2018-01-25,2018,AU 2016/285447 A,2016-06-15,US 201562186048 P;;US 2016/0037570 W,2015-06-29,Method for forming particles with cross-linked coatings for cosmetic applications,"The present invention relates to a method for forming coated particles, comprising the steps of: agitating a volume of core particles while heating to a constant average temperature of about 40",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/034-101-152-033-167,Patent Application,no,0,0,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00,,0,0,,,,DISCONTINUED
74,KR,A,KR 20140061498 A,033-326-814-620-418,2014-05-21,2014,KR 20147009043 A,2012-08-08,US 201161521739 P;;US 201161531551 P;;US 201161543666 P;;US 2012/0049905 W,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,,https://lens.org/033-326-814-620-418,Patent Application,no,0,0,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F12/00,,0,0,,,,ACTIVE
75,EP,A1,EP 2742429 A1,007-500-748-168-635,2014-06-18,2014,EP 12821517 A,2012-08-08,US 201161521739 P;;US 201161531551 P;;US 201161543666 P;;US 2012/0049905 W,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,,https://lens.org/007-500-748-168-635,Patent Application,yes,0,1,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F13/14;;G06F3/06;;G06F12/00,,0,0,,,,DISCONTINUED
76,AU,A1,AU 2016/285446 A1,044-584-567-807-840,2018-01-18,2018,AU 2016/285446 A,2016-06-15,US 201562186035 P;;US 2016/0037566 W,2015-06-29,Particles with cross-linked coatings for cosmetic applications,"The present invention relates to a cosmetic composition comprising core particles in a cosmetically or pharmaceutically acceptable carrier, wherein the core particles comprise a heat-curable coating which is the reaction product of a vinyl-functional silicone polymer, a hydride-functional crosslinker, and a metal catalyst.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/044-584-567-807-840,Patent Application,no,0,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/89;;A61K8/19;;A61K8/27;;A61K8/29;;A61Q19/00,,0,0,,,,DISCONTINUED
77,CN,A,CN 107787216 A,013-692-193-555-303,2018-03-09,2018,CN 201680038869 A,2016-06-15,US 201562186035 P;;US 2016/0037566 W,2015-06-29,Particles with cross-linked coatings for cosmetic applications,"The present invention relates to a cosmetic composition comprising core particles in a cosmetically or pharmaceutically acceptable carrier, wherein the core particles comprise a heat-curable coating which is the reaction product of a vinyl-functional silicone polymer, a hydride-functional crosslinker, and a metal catalyst.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/013-692-193-555-303,Patent Application,no,14,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/27;;A61K8/02;;A61K8/29;;A61K8/895;;A61Q19/00,,0,0,,,,DISCONTINUED
78,EP,A4,EP 2742429 A4,083-578-404-425-331,2015-03-25,2015,EP 12821517 A,2012-08-08,US 201161521739 P;;US 201161531551 P;;US 201161543666 P;;US 2012/0049905 W,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,,https://lens.org/083-578-404-425-331,Search Report,no,2,0,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F13/14;;G06F3/06;;G06F12/00,,1,0,,,See also references of WO 2013022915A1,DISCONTINUED
79,EP,A2,EP 0248596 A2,117-653-701-417-847,1987-12-09,1987,EP 87304722 A,1987-05-28,US 86808386 A;;US 86827986 A,1986-05-29,Durable epoxy (meth) acrylic polymer with oxirane-containing terminal groups and preparation.,"ABA triblock polymers that have glycidyl methacrylate (GMA) as the A segments and standard (meth)-acrylate monomers as the B segment are made by group transfer polymerization, using a monofunctional initiator to make the A, then AB, then ABA segments, or a difunctional initiator to make the B then ABA segments. Alternatively, a coupling agent can be used to connect AB segments at the. B group after a monofunctional initiator reacts A and B or an epoxy-containing initiator reacts with a B segment.",DU PONT,SPINELLI HARRY JOSEPH;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/117-653-701-417-847,Patent Application,yes,0,21,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
80,WO,A1,WO 2017/003687 A1,124-864-316-566-751,2017-01-05,2017,US 2016/0037566 W,2016-06-15,US 201562186035 P,2015-06-29,PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,"The present invention relates to a cosmetic composition comprising core particles in a cosmetically or pharmaceutically acceptable carrier, wherein the core particles comprise a heat-curable coating which is the reaction product of a vinyl-functional silicone polymer, a hydride-functional crosslinker, and a metal catalyst.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/124-864-316-566-751,Patent Application,yes,5,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/89;;A61K8/19;;A61K8/27;;A61K8/29;;A61Q19/00,,1,0,,,See also references of EP 3313368A4,PENDING
81,KR,A,KR 20140044933 A,120-314-622-246-666,2014-04-15,2014,KR 20147006222 A,2012-08-08,US 201161521739 P;;US 201161531551 P;;US 201161543666 P;;US 2012/0049905 W,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,,https://lens.org/120-314-622-246-666,Patent Application,no,0,0,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F12/00,,0,0,,,,INACTIVE
82,EP,A3,EP 0248596 A3,000-360-050-302-20X,1990-02-14,1990,EP 87304722 A,1987-05-28,US 86808386 A;;US 86827986 A,1986-05-29,DURABLE EPOXY (METH) ACRYLIC POLYMER WITH OXIRANE-CONTAINING TERMINAL GROUPS AND PREPARATION,"ABA triblock polymers that have glycidyl methacrylate (GMA) as the A segments and standard (meth)-acrylate monomers as the B segment are made by group transfer polymerization, using a monofunctional initiator to make the A, then AB, then ABA segments, or a difunctional initiator to make the B then ABA segments. Alternatively, a coupling agent can be used to connect AB segments at the. B group after a monofunctional initiator reacts A and B or an epoxy-containing initiator reacts with a B segment.",E.I. DU PONT DE NEMOURS AND COMPANY,"SPINELLI, HARRY JOSEPH;;COSTELLO, TIMOTHY DAVID;;COHEN,GORDON MARK",,https://lens.org/000-360-050-302-20X,Search Report,yes,1,1,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
83,US,B2,US 9389805 B2,163-580-225-145-070,2016-07-12,2016,US 201214237331 A,2012-08-08,US 201214237331 A;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P;;US 2012/0049905 W,2011-08-09,I/O device and computing host interoperation,"An I/O device is coupled to a computing host. In some embodiments, the device is enabled to utilize memory of the computing host not directly coupled to the device to store information such as a shadow copy of a map of the device and/or state of the device. Storage of the shadow copy of the map enables one or both of the device and the computing host to utilize the shadow copy of the map, such as to decrease read latency. Storage of the state enables the device to save volatile state that would otherwise be lost when the device enters a low-power state. In some embodiments, the device implements one or more non-standard modifiers of standard commands. The non-standard modifiers modify the execution of the standard commands, providing features not present in a host protocol having only the standard commands.",COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL;;SEAGATE TECHNOLOGY LLC,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,SANDFORCE INC (2011-10-24);;SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-01-04),https://lens.org/163-580-225-145-070,Granted Patent,yes,57,54,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F13/16;;G06F3/06;;G06F12/00,,26,0,,,"International Search Report in the parent PCT/US2012/049905, 4 pages.;;The Written Opinion in the parent PCT/US2012/049905, 5 pages.;;IEEE, ""band"" definition, IEEE Standard Dictionary of Electrical and Electronics Terms, Nov. 3, 1988, p. 80, IEEE, Inc., New York, NY, 3 sheets total (1 sheet of content, 2 sheets of title pages).;;Office Action of the Intellectual Property Office ROC (Taiwan) Patent Application No. 101128817 including Search Report, Jul. 14, 2014, 17 pages.;;European Search Report in EP 14151725.0, 6 pages.;;International Search Report and the Writien Opinion for PCT/US12/58583, 10 pages.;;CN Office Action (10 pgs. English translation and 7 pgs. CN original) of Mar. 10, 2014 of CN national entry of PCT/US12/58583, 17 pgs. total.;;CN Search Report (2 pgs. English translation and 2 pgs. CN original) of Feb 28, 2014 of CN national entry of PCT/US12/58583, 4 pgs. total.;;KR Notice (3 pgs. English translation and 4 pgs. KR original) of Jun. 27, 2014 of KR national entry of PCT/US12/58583, 7 pgs. total.;;International Search Report for PCT/US2012/034601, 3 pages.;;Written Opinion for PCT/US2012/034601, 4 pages.;;Agrawal et al, ""Design Tradeoffs for SSD Performance,"" Proceedings of the 2008 USENIX Annual Technical Conference, Jun. 2008, 14 pages.;;Mehling, Herman, ""Solid State Drives Get Faster with TRIM,"" Jan. 27, 2010 (retrieved from http://www.enterprisestorageforum.com/technology/features/article.php/38611 81 /Solid-State-Drives-Get-Faster-with-TRIM. htm and converted to pdf format Apr. 7, 2014), 4 pages.;;Layton, Jeffrey, ""Anatomy of SSDs,"" Linux Magazine, Oct. 27, 2009 (Retrieved from http://www.linux-mag.com/id/7590/2 and converted to pdf format Apr. 2014), 4 pages.;;Shimpi, Anand Lal, ""The Impact of Spare Area on SandForce, More Capacity at No Performance Loss?"" May 3, 2010 (retrieved from http://www.anandtech.com/show/3690/the-impact-of-spare-area-on-sandforce-more-capacity-at-no-performance-loss and converted to pdf format Apr. 7, 2014), 14 pages.;;Frankie et al, ""SSD Trim Commands Considerably Improve Overprovisioning,"" Proceedings Flash Memory Summit 2011, Aug. 2011, 19 pages.;;Smith, Kent, ""Garbage Collection: Understanding Foreground vs. Background GC and Other Related Elements,"" Proceedings Flash Memory Summit 2011, Aug. 2011, 9 pages.;;Smith, Kent, ""Understanding SSD Over Provisioning,"" Proceedings Flash Memory Summit 2012, Aug. 2012, 16 pages.;;""SSDs-Write Amplification, Trim and GC,"" Mar. 2010 (retrieved from http://www.oczenterprise.com/whitepapers/ssds-writeamplification-trim-and-gc.pdf, using Internet Archive Wayback Machine Mar. 28, 2014), 3 pages.;;""Write Amplification,"" Wikipedia (retrieved from http://en.wikipedia.org/wiki/Write-amplification and converted to pdf format Apr. 7, 2014), 14 pages.;;Dec. 3, 2014 List of References Used in Art Rejections.;;Office Action of the State Intellectual Property Office of the People's Republic of China Patent Application No. 2012800314652 including Search Report, May 4, 2014, 14 pages.;;Office Action of the Intellectual Property Office ROC (Taiwan) Patent Application No. 101114992 including Search Report, mailed unknown date in 2014, 8 pages.;;Office Action of the Intellectual Property Office ROC (Taiwan) Patent Application No. 101137008 including Search Report, Jul. 28, 2014, 10 pages.;;Chinese Office Action for serial No. 201280049511.1, filed Aug. 8, 2012, mailed Nov. 4, 2014, 18 pgs.;;Cohen, et al; International Preliminary Report on Patentability for PCT/US2012/049905, filed Aug. 8, 2012, mailed Feb. 11, 2014, 6 pgs.",ACTIVE
84,KR,A,KR 20180011872 A,018-554-268-112-141,2018-02-02,2018,KR 20187002248 A,2016-06-15,US 201562186035 P;;US 2016/0037566 W,2015-06-29,화장품 적용을 위한 가교된 코팅을 갖는 입자,"본 발명은 화장품용으로 또는 제약상 허용되는 담체 중에 코어 입자를 포함하는 화장품 조성물에 관한 것으로서, 상기 코어 입자는 비닐-관능성 실리콘 중합체, 수소화물-관능성 가교제 및 금속 촉매의 반응 생성물인 열경화성 코팅을 포함한다.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/018-554-268-112-141,Patent Application,no,0,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/89;;A61K8/19;;A61K8/27;;A61K8/29;;A61Q19/00,,0,0,,,,DISCONTINUED
85,WO,A1,WO 2013/022915 A1,175-960-135-143-127,2013-02-14,2013,US 2012/0049905 W,2012-08-08,US 201161521739 P;;US 201161531551 P;;US 201161543666 P,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,"An I/O device is coupled to a computing host. In some embodiments, the device is enabled to utilize memory of the computing host not directly coupled to the device to store information such as a shadow copy of a map of the device and/or state of the device. Storage of the shadow copy of the map enables one or both of the device and the computing host to utilize the shadow copy of the map, such as to decrease read latency. Storage of the state enables the device to save volatile state that would otherwise be lost when the device enters a low-power state. In some embodiments, the device implements one or more non-standard modifiers of standard commands. The non-standard modifiers modify the execution of the standard commands, providing features not present in a host protocol having only the standard commands.",LSI CORP;;COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,,https://lens.org/175-960-135-143-127,Patent Application,yes,4,15,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F13/14;;G06F12/00,,1,0,,,See also references of EP 2742429A4,PENDING
86,US,A1,US 2018/0168995 A1,053-783-523-819-426,2018-06-21,2018,US 201615736729 A,2016-06-15,US 201615736729 A;;US 201562186035 P;;US 2016/0037566 W,2015-06-29,Particles With Cross-Linked Coatings For Cosmetic Applications,"The present invention relates to a cosmetic composition comprising core particles in a cosmetically or pharmaceutically acceptable carrier, wherein the core particles comprise a heat-curable coating which is the reaction product of a vinyl-functional silicone polymer, a hydride-functional crosslinker, and a metal catalyst.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/053-783-523-819-426,Patent Application,yes,0,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/895;;A61K8/02;;A61K8/27;;A61K8/29;;A61Q19/00,,0,0,,,,DISCONTINUED
87,CA,A1,CA 2990163 A1,074-775-344-242-205,2017-01-05,2017,CA 2990163 A,2016-06-15,US 201562186048 P;;US 2016/0037570 W,2015-06-29,METHOD FOR FORMING PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,"The present invention relates to a method for forming coated particles, comprising the steps of: agitating a volume of core particles while heating to a constant average temperature of about 40oC. Once particles are generally evenly mixed, with no apparent agglomeration, the vinyl-functional silicone polymer, hydride-functional crosslinker, and metal catalyst are combined in a premix under continuous propeller-mixing. The vinyl-functional silicone polymer, hydride-functional crosslinker, and metal catalyst premix is then siphoned into the main vessel, containing the heated core particles, at rate that ensures no clumping or agglomeration of the particulates. Once even coating has been achieved, the main vessel is heated to an average temperature of about 80oC, then cooled back down to room temperature (about 20oC-28oC). The coated material is then passed through a 45µm sieve to remove any large particulates that may be present.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/074-775-344-242-205,Patent Application,no,0,0,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00,,0,0,,,,DISCONTINUED
88,TW,A,TW 201314464 A,108-288-010-919-419,2013-04-01,2013,TW 101128817 A,2012-08-09,US 201161521739 P;;US 201161531551 P;;US 201161543666 P,2011-08-09,I/O device and computing host interoperation,"An I/O device is coupled to a computing host. In some embodiments, the device is enabled to utilize memory of the computing host not directly coupled to the device to store information such as a shadow copy of a map of the device and/or state of the device. Storage of the shadow copy of the map enables one or both of the device and the computing host to utilize the shadow copy of the map, such as to decrease read latency. Storage of the state enables the device to save volatile state that would otherwise be lost when the device enters a low-power state. In some embodiments, the device implements one or more non-standard modifiers of standard commands. The non-standard modifiers modify the execution of the standard commands, providing features not present in a host protocol having only the standard commands.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE;;RAAM FARBOD MICHAEL,,https://lens.org/108-288-010-919-419,Patent of Addition,no,0,3,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F13/14;;G06F12/08,,0,0,,,,INACTIVE
89,CA,A1,CA 2990162 A1,002-259-730-150-613,2017-01-05,2017,CA 2990162 A,2016-06-15,US 201562186035 P;;US 2016/0037566 W,2015-06-29,PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,"The present invention relates to a cosmetic composition comprising core particles in a cosmetically or pharmaceutically acceptable carrier, wherein the core particles comprise a heat-curable coating which is the reaction product of a vinyl-functional silicone polymer, a hydride-functional crosslinker, and a metal catalyst.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/002-259-730-150-613,Patent Application,no,0,0,10,10,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;A61K2800/651;;A61K2800/623;;A61K2800/412;;A61Q17/04;;A61K8/0241;;C09C3/12;;A61K2800/412;;A61K8/29;;A61K8/27;;A61Q19/00;;A61K2800/651;;A61K2800/623;;A61K8/895;;A61K8/89;;A61K8/29;;A61K8/27;;A61K8/19;;A61Q19/00;;A61K2800/622;;A61K2800/651;;A61K8/29;;A61K8/27;;A61Q19/00;;A61K2800/651;;A61K2800/623;;A61K8/0241;;A61K2800/412;;A61Q17/04;;C09C3/12;;A61K8/895,A61K8/89;;A61K8/19;;A61K8/27;;A61K8/29;;A61Q19/00,,0,0,,,,DISCONTINUED
90,US,A1,US 2014/0325117 A1,055-756-890-988-36X,2014-10-30,2014,US 201313889521 A,2013-05-08,US 201313889521 A;;US 201361817441 P,2013-04-30,FLASH TRANSLATION LAYER WITH LOWER WRITE AMPLIFICATION,"A method of associating a logical block address with a physical location in a non-volatile memory includes (A) in response to a write request comprising a respective logical block address in a logical block address space and respective data to be written to the non-volatile memory, determining a physical location in the non-volatile memory to store the respective data of the write request, (B) adding an entry to a journal, such that the added entry trails any entries already in the journal and the added entry has a respective logical block address field set to the respective logical block address of the write request and a respective physical location field set to the determined physical location, and (C) updating one of a plurality of second-level map pages in a two-level map according to the respective logical block address of the write request with the determined physical location.",LSI CORP,CANEPA TIMOTHY L;;COHEN EARL T;;TANG ALEX G,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-05-07),https://lens.org/055-756-890-988-36X,Patent Application,yes,1,91,2,2,0,G06F2212/7201;;G06F12/0246;;G06F12/0246;;G06F2212/7201,G06F12/02,711/103,0,0,,,,ACTIVE
91,CN,C,CN 100352817 C,116-405-055-109-671,2007-12-05,2007,CN 03807363 A,2003-03-27,US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HTLF agonists,,LILLY CO ELI,PHILIP COHEN MICHAEL;;TIMOTHY KOHLMAN DANIEL;;XI LIANG SIDNEY,,https://lens.org/116-405-055-109-671,Granted Patent,no,2,6,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
92,CN,A,CN 103858116 A,128-501-535-666-552,2014-06-11,2014,CN 201280049511 A,2012-08-08,US 2012/0049905 W;;US 201161521739 P;;US 201161531551 P;;US 201161543666 P,2011-08-09,I/o device and computing host interoperation,"An I/O device is coupled to a computing host. In some embodiments, the device is enabled to utilize memory of the computing host not directly coupled to the device to store information such as a shadow copy of a map of the device and/or state of the device. Storage of the shadow copy of the map enables one or both of the device and the computing host to utilize the shadow copy of the map, such as to decrease read latency. Storage of the state enables the device to save volatile state that would otherwise be lost when the device enters a low-power state. In some embodiments, the device implements one or more non-standard modifiers of standard commands. The non-standard modifiers modify the execution of the standard commands, providing features not present in a host protocol having only the standard commands.",LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,,https://lens.org/128-501-535-666-552,Patent Application,no,6,17,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F13/14;;G06F12/00,,0,0,,,,ACTIVE
93,US,B1,US 6623956 B1,015-003-174-022-292,2003-09-23,2003,US 69359500 A,2000-10-20,US 69359500 A,2000-10-20,Embryo-culturing incubator assembly,"
    An embryo culturing incubator is provided with a shelf configuration that enhances air circulation inside of the incubator, and enables unimpeded access to the individual embryo culture plates that are disposed on the shelves in the incubator. The incubator has an access door which allows one contact with the embryo culture plates on the incubator shelves. The shelves are configured so as to provide a useful free space between the inner surface of the incubator door and the frontal surface of the shelves in the incubator. The size of the free space allows a technician to reach all of the culture plates in the incubator without interfering with other culture plates in the incubator. The free space also allows for exemplary air circulation inside of the incubator. 
",GENX INTERNATIONAL INC,CECCHI MICHAEL D;;COHEN JACQUES;;SCHIMMEL TIMOTHY;;MEZEZI MONICA,LIFEGLOBAL GROUP LLC (2013-09-30);;IVFONLINE LLC DBA LIFEGLOBAL (2013-04-22);;LIFEGLOBAL GROUP LLC F/K/A IVFONLINE.COM LLC (2017-11-17);;LIFEGLOBAL GROUP LLC F/K/A LIFEGLOBAL LLC (2017-11-17);;COOPERSURGICAL INC (2018-04-03);;GENX INTERNATIONAL INC (2001-02-01);;IVFONLINE LLC [PROPERLY IVFONLINE.COM LLC] (2017-11-17),https://lens.org/015-003-174-022-292,Granted Patent,yes,9,19,1,1,0,C12M21/06;;C12M23/48;;C12M41/14;;Y10S435/809;;C12M41/14;;C12M21/06;;C12M23/48;;Y10S435/809,C12M1/00,435/303.1;;435/809;;422/104;;422/99,0,0,,,,EXPIRED
94,US,A1,US 2014/0181327 A1,088-761-038-528-193,2014-06-26,2014,US 201214237331 A,2012-08-08,US 201214237331 A;;US 201161543666 P;;US 201161531551 P;;US 201161521739 P;;US 2012/0049905 W,2011-08-09,I/O DEVICE AND COMPUTING HOST INTEROPERATION,"An I/O device is coupled to a computing host. In some embodiments, the device is enabled to utilize memory of the computing host not directly coupled to the device to store information such as a shadow copy of a map of the device and/or state of the device. Storage of the shadow copy of the map enables one or both of the device and the computing host to utilize the shadow copy of the map, such as to decrease read latency. Storage of the state enables the device to save volatile state that would otherwise be lost when the device enters a low-power state. In some embodiments, the device implements one or more non-standard modifiers of standard commands. The non-standard modifiers modify the execution of the standard commands, providing features not present in a host protocol having only the standard commands.",COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL;;LSI CORP,COHEN EARL T;;CANEPA TIMOTHY L;;RAAM FARBOD MICHAEL,SANDFORCE INC (2011-10-24);;SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-01-04),https://lens.org/088-761-038-528-193,Patent Application,yes,6,16,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,G06F3/06,710/5,0,0,,,,ACTIVE
95,KR,A,KR 20180011362 A,154-558-684-178-51X,2018-01-31,2018,KR 20187002249 A,2016-06-15,US 201562186048 P;;US 2016/0037570 W,2015-06-29,화장품 적용을 위한 가교된 코팅을 갖는 입자를 형성하는 방법,"본 발명은 약 40℃의 일정한 평균 온도로 가열하면서 소정 부피의 코어 입자를 진탕시키는 단계를 포함하는, 코팅된 입자를 형성하는 방법에 관한 것이다. 입자가 명백한 응집화없이 전반적으로 균일하게 혼합되면, 비닐-관능성 실리콘 중합체, 수소화물-관능성 가교제 및 금속 촉매를 연속적인 프로펠러-혼합하에 프리믹스로 조합한다. 이어서, 미립자의 군집화 또는 응집화가 없도록 보장하는 속도에서, 비닐-관능성 실리콘 중합체, 수소화물-관능성 가교제 및 금속 촉매 프리믹스를 가열된 코어 입자를 함유하는 주 용기로 사이펀화한다. 균일한 코팅이 달성되면, 주 용기를 약 80℃의 평균 온도로 가열한 다음, 실온 (약 20℃-28℃)으로 다시 냉각시킨다. 이어서, 코팅된 물질을 45㎛ 체에 통과시켜, 존재할 수 있는 임의의 큰 미립자를 제거한다.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/154-558-684-178-51X,Patent Application,no,0,0,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00,,0,0,,,,DISCONTINUED
96,US,B2,US 9213633 B2,198-719-128-413-428,2015-12-15,2015,US 201313889521 A,2013-05-08,US 201313889521 A;;US 201361817441 P,2013-04-30,Flash translation layer with lower write amplification,"A method of associating a logical block address with a physical location in a non-volatile memory includes (A) in response to a write request comprising a respective logical block address in a logical block address space and respective data to be written to the non-volatile memory, determining a physical location in the non-volatile memory to store the respective data of the write request, (B) adding an entry to a journal, such that the added entry trails any entries already in the journal and the added entry has a respective logical block address field set to the respective logical block address of the write request and a respective physical location field set to the determined physical location, and (C) updating one of a plurality of second-level map pages in a two-level map according to the respective logical block address of the write request with the determined physical location.",SEAGATE TECHNOLOGY LLC,CANEPA TIMOTHY L;;COHEN EARL T;;TANG ALEX G,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-05-07),https://lens.org/198-719-128-413-428,Granted Patent,yes,10,15,2,2,0,G06F2212/7201;;G06F12/0246;;G06F12/0246;;G06F2212/7201,G06F12/02,,0,0,,,,ACTIVE
97,TW,B,TW I584125 B,014-077-503-961-617,2017-05-21,2017,TW 101128817 A,2012-08-09,US 201161521739 P;;US 201161531551 P;;US 201161543666 P,2011-08-09,I/o device and computing host interoperation,,LSI CORP,COHEN EARL T;;CANEPA TIMOTHY LAWRENCE;;RAAM FARBOD MICHAEL,,https://lens.org/014-077-503-961-617,Granted Patent,no,2,2,19,30,0,G06F3/0659;;G06F3/0659;;G06F3/0607;;G06F3/0607;;G06F3/0611;;G06F3/067;;G06F3/0679;;G06F3/0679;;G06F12/00;;G06F12/1027,,,0,0,,,,INACTIVE
98,CN,A,CN 107809995 A,033-487-028-213-45X,2018-03-16,2018,CN 201680038682 A,2016-06-15,US 201562186048 P;;US 2016/0037570 W,2015-06-29,METHOD FOR FORMING PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,"The present invention relates to a method for forming coated particles, comprising the steps of: agitating a volume of core particles while heating to a constant average temperature of about 40oC. Once particles are generally evenly mixed, with no apparent agglomeration, the vinyl-functional silicone polymer, hydride-functional crosslinker, and metal catalyst are combined in a premix under continuous propeller-mixing. The vinyl-functional silicone polymer, hydride-functional crosslinker, and metal catalyst premix is then siphoned into the main vessel, containing the heated core particles, at rate that ensures no clumping or agglomeration of the particulates. Once even coating has been achieved, the main vessel is heated to an average temperature of about 80oC, then cooled back down to roomtemperature (about 20oC-28oC). The coated material is then passed through a 45 [miu] sieve to remove any large particulates that may be present.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/033-487-028-213-45X,Patent Application,no,14,0,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04,,1,0,,,"P.MIKULASEK等: ""“The influence of pH and temperature on the rheology and stability of aqueous titanium dioxide dispersions”"", 《CHEMICAL ENGINEERING JOURNAL》",DISCONTINUED
99,CN,A,CN 1642939 A,085-980-348-970-244,2005-07-20,2005,CN 03807363 A,2003-03-27,US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HTLF agonists,,LILLY CO ELI,PHILIP COHEN MICHAEL;;TIMOTHY KOHLMAN DANIEL;;XI LIANG SIDNEY,,https://lens.org/085-980-348-970-244,Patent Application,no,0,18,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
100,US,B1,US 8403326 B1,154-156-855-366-629,2013-03-26,2013,US 201113290690 A,2011-11-07,US 201113290690 A,2011-11-07,Game table,"A game table comprises a playing surface, two ramps, and two target boards arranged along a longitudinal axis of the game table. The two ramps are disposed between the two target boards, and the playing surface is disposed between the two ramps. The playing surface is substantially flat, and each of the two ramps rises upward away from the playing surface. Each of the two target boards, in turn, defines a respective set of openings therein. Two sidewalls are disposed on opposing sides of the playing surface and rise up therefrom.",FLANAGAN TIMOTHY D;;COHEN BENJAMIN I;;TRACHTA ANDREW M,FLANAGAN TIMOTHY D;;COHEN BENJAMIN I;;TRACHTA ANDREW M,COHEN BENJAMIN I (2012-03-24);;FLANAGAN TIMOTHY D (2012-03-24),https://lens.org/154-156-855-366-629,Granted Patent,yes,13,6,1,1,0,A63F7/06;;A63F7/06;;A63F7/0672;;A63F7/0672;;A63F7/20;;A63F7/20;;A63F7/30;;A63F7/30,A63F7/06;;A63F7/20;;A63F7/30;;A63F7/36,273123R;;X273118 R;;273/108.1;;273/108.51;;273/108.54;;273/317;;273/317.1;;273/348;;273/398;;273/401;;273/402;;X273119 R,0,0,,,,INACTIVE
101,WO,A1,WO 2017/003688 A1,166-157-626-431-95X,2017-01-05,2017,US 2016/0037570 W,2016-06-15,US 201562186048 P,2015-06-29,METHOD FOR FORMING PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,"The present invention relates to a method for forming coated particles, comprising the steps of: agitating a volume of core particles while heating to a constant average temperature of about 40 o C. Once particles are generally evenly mixed, with no apparent agglomeration, the vinyl-functional silicone polymer, hydride-functional crosslinker, and metal catalyst are combined in a premix under continuous propeller-mixing. The vinyl-functional silicone polymer, hydride-functional crosslinker, and metal catalyst premix is then siphoned into the main vessel, containing the heated core particles, at rate that ensures no clumping or agglomeration of the particulates. Once even coating has been achieved, the main vessel is heated to an average temperature of about 80 o C, then cooled back down to room temperature (about 20 o C-28 o C). The coated material is then passed through a 45µm sieve to remove any large particulates that may be present.",ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID,,https://lens.org/166-157-626-431-95X,Patent Application,yes,5,2,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00,,1,0,,,See also references of EP 3313354A4,PENDING
102,US,A1,US 2015/0062839 A1,079-869-776-755-812,2015-03-05,2015,US 201314078412 A,2013-11-12,US 201314078412 A;;US 201361873785 P,2013-09-04,METHOD AND SYSTEM FOR ATTACHING FLEXIBLE CIRCUITS TO A MOUNTING SURFACE,"A method and system for securing a flexible circuit to a mounting structure is disclosed. The system can include a surface-mount device, flexible circuit, stiffener, and bracket. The stiffener is used as an intermediate coupling device between the flexible circuit and bracket. The flexible circuit is coupled to the stiffener with a heat-activated adhesive. Next, the surface-mount device is mounted to the flexible circuit with surface-mounting techniques. A peripheral area of the stiffener is then welded to the bracket. The bracket in turn can be fastened to the enclosure of an electronic device.",APPLE INC,MERZ NICHOLAS G;;MALEK SHAYAN;;COHEN SAWYER I;;LUI TIMOTHY,APPLE INC (2013-10-28),https://lens.org/079-869-776-755-812,Patent Application,yes,15,2,2,2,0,B23K1/0016;;B23K1/0016;;B23K26/22;;B23K26/22;;B23K26/32;;B23K26/32;;B23K26/323;;B23K26/323;;B23K2101/18;;B23K2101/18;;B23K2101/42;;B23K2101/42;;B23K2103/04;;B23K2103/04;;B23K2103/05;;B23K2103/05;;B23K2103/20;;B23K2103/20;;B23K2103/50;;B23K2103/50;;H05K1/189;;H05K1/189;;H05K3/0061;;H05K3/0061;;H05K2201/10053;;H05K2201/10053;;H05K2201/10083;;H05K2201/10083;;H05K2201/2009;;H05K2201/2009,H05K1/18;;B23K31/02,361/749;;228/175;;174/254,0,0,,,,INACTIVE
103,WO,A3,WO 2012/099937 A3,099-011-624-694-115,2012-09-13,2012,US 2012/0021682 W,2012-01-18,US 201161433918 P,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,"Higher-level redundancy information computation enables a Solid-State Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero ""index"" as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",LSI CORP;;WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/099-011-624-694-115,Search Report,yes,3,0,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/00;;G06F11/08;;G06F12/16,,0,0,,,,PENDING
104,US,B2,US 8656101 B2,114-171-867-429-142,2014-02-18,2014,US 201213979805 A,2012-01-18,US 201213979805 A;;US 201161433918 P;;US 2012/0021682 W,2011-01-18,Higher-level redundancy information computation,"Higher-level redundancy information computation enables a Solid-State Disk (SSD)controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero “index” as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL;;LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-07-09),https://lens.org/114-171-867-429-142,Granted Patent,yes,19,9,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/08,711/114;;711/111,7,0,,,"International Search Report in the related PCT/US2011/062726, 3 pages.;;The Written Opinion in the related PCT/US2011/062726, 3 pages.;;International Search Report and the Written Opinion in the related PCT/US2011/057914, 9 pages.;;Nternational Search Report and the Written Opinion in the parent PCT/US12/21682, 9 pages.;;Devang Panchigar ""EMC Symmetrix DMX-RAID 6 Implementation"" Feb. 27, 2009, http://storagenerve.com/2009/02/27/emc-symmetrix-dmx-raid-6-implementation/, 9 pages.;;H. Peter Anvin, ""The mathematics of RAID-6"" Last updated Dec. 20, 2011, https://www.kernel.org/pub/linux/kernel/people/hpa/raid6.pdf, accessed on Sep. 30, 2013, 9 pages.;;Advanced Computer & Network Corporation, ""RAID Level 6: Independent Data Disks with Two Independent Parity Schemes"", http://www.acnc.com/raidedu/6, accessed on Sep. 30, 2013, 2 pages.",ACTIVE
105,CA,A1,CA 2723722 A1,023-593-633-172-672,2009-11-12,2009,CA 2723722 A,2009-05-08,US 5342708 P;;US 16318009 P;;US 5195608 P;;US 2009/0043273 W,2008-05-09,IGF-II/GF-IIE BINDING PROTEINS,Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor.,DYAX CORP;;COMMW SCIENT IND RES ORG,DRANSFIELD DANIEL T;;COHEN EDWARD H;;ADAMS TIMOTHY;;COSGROVE LEAH,,https://lens.org/023-593-633-172-672,Patent Application,no,0,0,11,11,94,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,A61K39/395;;C07K16/00;;C12P21/08,,0,0,,,,DISCONTINUED
106,US,A1,US 2013/0290618 A1,051-424-566-823-09X,2013-10-31,2013,US 201213979805 A,2012-01-18,US 201213979805 A;;US 201161433918 P;;US 2012/0021682 W,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,"Higher-level redundancy information computation enables a Solid-State Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero “index” as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL;;LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2013-07-09),https://lens.org/051-424-566-823-09X,Patent Application,yes,0,26,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/02,711/103,0,0,,,,ACTIVE
107,CN,A,CN 103415844 A,108-979-041-249-334,2013-11-27,2013,CN 201280012139 A,2012-01-18,US 2012/0021682 W;;US 201161433918 P,2011-01-18,Higher-level redundancy information computation,"Higher-level redundancy information computation enables a Solid-State Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero ""index"" as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field).; The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/108-979-041-249-334,Patent Application,no,7,5,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/00;;G06F11/08;;G06F12/16,,0,0,,,,INACTIVE
108,KR,A,KR 20130118370 A,138-805-237-649-67X,2013-10-29,2013,KR 20137021636 A,2012-01-18,US 201161433918 P;;US 2012/0021682 W,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,,LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/138-805-237-649-67X,Patent Application,no,0,0,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F11/08;;G06F12/16,,0,0,,,,INACTIVE
109,US,B2,US 9713851 B2,085-939-673-262-589,2017-07-25,2017,US 201314078412 A,2013-11-12,US 201314078412 A;;US 201361873785 P,2013-09-04,Method and system for attaching flexible circuits to a mounting surface,"A method and system for securing a flexible circuit to a mounting structure is disclosed. The system can include a surface-mount device, flexible circuit, stiffener, and bracket. The stiffener is used as an intermediate coupling device between the flexible circuit and bracket. The flexible circuit is coupled to the stiffener with a heat-activated adhesive. Next, the surface-mount device is mounted to the flexible circuit with surface-mounting techniques. A peripheral area of the stiffener is then welded to the bracket. The bracket in turn can be fastened to the enclosure of an electronic device.",APPLE INC,MERZ NICHOLAS G;;MALEK SHAYAN;;COHEN SAWYER I;;LUI TIMOTHY,APPLE INC (2013-10-28),https://lens.org/085-939-673-262-589,Granted Patent,yes,18,0,2,2,0,B23K1/0016;;B23K1/0016;;B23K26/22;;B23K26/22;;B23K26/32;;B23K26/32;;B23K26/323;;B23K26/323;;B23K2101/18;;B23K2101/18;;B23K2101/42;;B23K2101/42;;B23K2103/04;;B23K2103/04;;B23K2103/05;;B23K2103/05;;B23K2103/20;;B23K2103/20;;B23K2103/50;;B23K2103/50;;H05K1/189;;H05K1/189;;H05K3/0061;;H05K3/0061;;H05K2201/10053;;H05K2201/10053;;H05K2201/10083;;H05K2201/10083;;H05K2201/2009;;H05K2201/2009,B23K1/00;;B23K26/22;;B23K26/32;;B23K26/323;;B23K101/18;;B23K101/42;;B23K103/00;;B23K103/04;;B23K103/20;;H05K1/18;;H05K3/00,,1,0,,,"Allyson Kazmucha, “How to fix a stuck or broken On/Off button on a GSM/AT&T iPhone 4”, dated Jul. 21, 2012.",INACTIVE
110,WO,A2,WO 2012/099937 A2,101-446-450-042-661,2012-07-26,2012,US 2012/0021682 W,2012-01-18,US 201161433918 P,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,"Higher-level redundancy information computation enables a Solid-State Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero ""index"" as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",LSI CORP;;WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/101-446-450-042-661,Patent Application,yes,0,23,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/00;;G06F11/08;;G06F12/16,,0,0,,,,PENDING
111,EP,A2,EP 2666091 A2,047-437-225-442-465,2013-11-27,2013,EP 12736920 A,2012-01-18,US 201161433918 P;;US 2012/0021682 W,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,,LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/047-437-225-442-465,Patent Application,yes,0,0,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/00;;G06F11/08;;G06F12/16,,0,0,,,,DISCONTINUED
112,KR,A,KR 20140094661 A,043-268-232-551-387,2014-07-30,2014,KR 20147019498 A,2012-01-18,US 201161433918 P;;US 2012/0021682 W,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,,LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY;;COHEN EARL,,https://lens.org/043-268-232-551-387,Patent Application,no,0,0,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F11/08;;G06F12/16,,0,0,,,,INACTIVE
113,US,A1,US 2011/0165145 A1,105-689-311-511-677,2011-07-07,2011,US 99169109 A,2009-05-08,US 99169109 A;;US 5195608 P;;US 5342708 P;;US 16318009 P;;US 2009/0043273 W,2008-05-09,IGF-II/IGF-IIE BINDING PROTEINS,Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor.,DRANSFIELD DANIEL T;;COHEN EDWARD H;;ADAMS TIMOTHY;;COSGROVE LEAH,DRANSFIELD DANIEL T;;COHEN EDWARD H;;ADAMS TIMOTHY;;COSGROVE LEAH,"COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (""CSIRO"") (2011-02-09);;DYAX CORP (2011-01-13)",https://lens.org/105-689-311-511-677,Patent Application,yes,11,1,11,11,94,A61K39/3955;;A61K45/06;;A61K2039/505;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/55;;C07K2317/56;;C07K2317/73;;C07K2317/92;;A61P35/00;;A61P43/00;;C07K16/22;;C07K2317/56;;A61K2039/505;;C07K2317/55;;A61K39/3955;;C07K2317/21;;A61K45/06;;C07K2299/00;;C07K2317/73;;C07K2317/92,A61K39/395;;A61K38/16;;A61P35/00;;C07K14/00;;C07K16/00,424/130.1;;530/350;;530/387.1;;514/19.3;;514/11.3,2,1,068-835-715-462-077,10.1210/jcem.87.8.8783;;10.1210/jc.87.8.3867;;12161524,"GenBank CAA00082.1, June 1993.;;Khosla, S., et al. Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. Journal of Clinical Endocrinology and Metabolism, 2002, Vol. 87, p. 3867-3870.",DISCONTINUED
114,US,A,US 5239563 A,184-967-223-116-354,1993-08-24,1993,US 72607691 A,1991-07-05,US 72607691 A,1991-07-05,Plasma momentum meter for momentum flux measurements,"Invention comprises an instrument in which momentum flux onto a biasable target plate is transferred via a suspended quartz tube onto a sensitive force transducer--a capacitance-type pressure gauge. The transducer is protected from thermal damage, arcing and sputtering, and materials used in the target and pendulum are electrically insulating, rigid even at elevated temperatures, and have low thermal conductivity. The instrument enables measurement of small forces (10.sup.-5 to 10.sup.3 N) accompanied by high heat fluxes which are transmitted by energetic particles with 10's of eV of kinetic energy in a intense magnetic field and pulsed plasma environment.",US ENERGY,ZONCA FULVIO;;COHEN SAMUEL A;;BENNETT TIMOTHY;;TIMBERLAKE JOHN R,UNITED STATES OF AMERICA THE AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (1993-03-17);;UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF ENERGY (1991-07-23),https://lens.org/184-967-223-116-354,Granted Patent,yes,10,1,1,1,0,H05H1/0006;;Y02E30/10;;H05H1/0006,H05H1/00,376/143;;376/153;;376/154;;376/100;;73/579;;73/581,2,1,142-724-724-688-983,10.2172/7094012,"Cohen, S. A. et al., An Instrument for Measuring the Momentum Flux from Atomic and Charged Particle Jets, Jul., 1990, pp. 2 17.;;Paul et al., Measurement of Density and Mean Molecular Velocity in an Atomic Beam (translated from the German), Zeitschrift fuer Physik 124 (1948), No. 7 12, 691 699.",EXPIRED
115,EP,B1,EP 1761562 B1,022-864-178-107-865,2013-09-11,2013,EP 05723364 A,2005-02-22,US 2005/0005361 W;;US 54635404 P,2004-02-19,CONFORMATION SPECIFIC ANTIBODIES,,DYAX CORP,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,DYAX CORP. (2013-05-22),https://lens.org/022-864-178-107-865,Granted Patent,yes,0,0,15,15,0,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;C07K16/00;;C07K16/28;;C07K16/46,,2,2,027-477-313-726-928;;042-715-619-182-374,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;9676574;;10.1007/s000180050183,"RUDIKOFF S ET AL: ""Single amino acid substitution altering antigen-binding specificity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979;;C. G. GAHMBERG ET AL: ""Leukocyte integrins and inflammation"", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 54, no. 6, 1 June 1998 (1998-06-01), pages 549 - 555, XP055017439, ISSN: 1420-682X, DOI: 10.1007/s000180050183",ACTIVE
116,US,A1,US 2018/0135003 A1,011-244-186-644-058,2018-05-17,2018,US 201715840812 A,2017-12-13,US 201715840812 A;;US 201514789591 A;;US 201462020048 P,2014-07-02,Gas Recirculation System for an Incubated Controlled Environment,"A gas recirculation system for an incubated controlled environment for the development of human embryos, the system comprising: a first mixing box; a second mixing box in fluid communication with the first mixing box; a manifold in fluid communication with the second mixing box; a plurality of incubation chambers in fluid communication with the manifold, the incubation chambers configured to maintain the proper temperature for the safe and proper growth of human embryos; a return manifold in fluid communication with the plurality of incubation chambers and in fluid communication with the first mixing box; and where the gas recirculation system is configured to monitor and maintain the plurality of incubation chambers at the proper provides a proper gas mixture and gas flow for the incubation of human embryos in the incubation chambers CO2, N2 and O2 gas levels for the safe and proper growth of human embryos.",LIFEGLOBAL GROUP LLC,CECCHI MICHAEL;;SCHIMMEL TIMOTHY;;MEZZEZI MONICA;;COHEN JACQUES;;CECCHI MICHAEL R,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/011-244-186-644-058,Patent Application,yes,0,0,2,2,0,C12M41/34;;C12M41/34;;C12M41/14;;C12M41/14,C12M1/34;;C12M1/00,,0,0,,,,DISCONTINUED
117,CA,C,CA 2554965 C,089-408-585-623-893,2015-08-11,2015,CA 2554965 A,2005-02-22,US 54635404 P;;US 2005/0005361 W,2004-02-19,ANTIBODIES SPECIFIC FOR ACTIVATED CONFORMATION OF LFA-1,"Leukocyte integrin LFA-1 is known to bind a number of cognate ligands including inflammation-associated cell surface molecule 1 (ICAM-1). LFA-1 is a protein which comprises an integrin-I domain, which has a high ligand affinity when in an open / active conformation. Disclosed herein are antibodies that bind specifically to LFA-1 when in the open / active conformation, and not the closed / inactive conformation.",CBR INST FOR BIOMED RES INC;;DYAX CORP,RONDON ISAAC J;;SHIMAOKA MOTOMU;;SPRINGER TIMOTHY A;;COHEN EDWARD H,,https://lens.org/089-408-585-623-893,Granted Patent,no,0,0,15,15,62,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,C07K16/28;;A61K39/395;;A61K49/06;;A61P29/00;;A61P37/06;;G01N33/53,,0,0,,,,INACTIVE
118,EP,A4,EP 3313368 A4,078-921-300-496-80X,2018-12-12,2018,EP 16818445 A,2016-06-15,US 201562186035 P;;US 2016/0037566 W,2015-06-29,PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,,ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID;;MIKAYLOVA YELENA,,https://lens.org/078-921-300-496-80X,Search Report,no,3,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/89;;A61K8/19;;A61K8/27;;A61K8/29;;A61Q19/00,,1,0,,,See also references of WO 2017003687A1,DISCONTINUED
119,US,A1,US 2012/0302293 A1,184-103-219-659-307,2012-11-29,2012,US 201113118286 A,2011-05-27,US 201113118286 A,2011-05-27,HAPTIC ALERT DEVICE HAVING A LINEAR VIBRATOR,"A vibrator designed to be integrated into a portable electronic device as part of a haptic alert device has a linear electric motor that is coupled to actively drive a moveable weight in back-and-forth directions to produce the desired vibration. A lock mechanism has a restraining member that is biased into a lock position, which prevents the moveable weight from moving in the back-and-forth directions when the vibrator is inactive. Other embodiments are also described and claimed.",JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y;;APPLE INC,JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,APPLE INC (2011-05-25),https://lens.org/184-103-219-659-307,Patent Application,yes,1,16,6,6,0,B06B1/045;;B06B1/045;;H04M1/0202;;H04M1/0202;;H04M19/047;;H04M19/047,H04B1/38;;H04B3/36,455/567;;340/407.1,0,0,,,,ACTIVE
120,US,B2,US 7927591 B2,010-363-668-594-669,2011-04-19,2011,US 58995605 A,2005-02-22,US 58995605 A;;US 54635404 P;;US 2005/0005361 W,2004-02-19,Conformation specific antibodies,"The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.",CBR INST FOR BIOMEDICAL RES INC,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,DYAX CORP (2005-01-10);;CBR INSTITUTE FOR BIOMEDICAL RESEARCH INC. THE (2006-02-07),https://lens.org/010-363-668-594-669,Granted Patent,yes,3,2,15,15,61,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;C07K16/28;;C07K16/46,424/133.1;;424/143.1;;530/387.3;;530/388.22;;530/388.7,10,9,009-746-604-420-355;;027-960-937-319-909;;062-170-867-080-500;;051-707-000-800-833;;005-405-010-898-254;;015-239-659-590-870;;027-477-313-726-928;;095-334-545-560-259;;045-942-104-775-903,10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1006/jmbi.2000.3512;;10677285;;10.4049/jimmunol.156.9.3285;;8617951;;12079396;;10.1016/s0022-2836(02)00264-4;;8114766;;10.1016/0161-5890(94)90001-9;;10.4049/jimmunol.150.3.880;;8423344;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1006/jmbi.1996.0548;;8876650;;12850000;;10.1016/s0006-291x(03)01131-8,"Klimka et al.,Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. British Journal of Cancer (2000) 83:252-260.;;Beiboer et al.,Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J. Mol., Biol. (2000) 296:833-849).;;Brown et al. Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation? J. Immuno. May 1996, 3285-91.;;Vajdos et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J. Mol. Biol. 2002, Jul. 5, 320(2):415-28 at 416.;;Eduardo Padlan, Anatomy of the antibody molecule. Mol Immunol. Feb. 1994;31(3):169-217.;;Portolano et al., Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain ""roulette"". J Immunol. Feb. 1, 1993;150(3):880-7.;;Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.;;Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.;;MacCallum et al. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol., 262, 732-745, 1996.;;Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 307:198-205, 2003.",INACTIVE
121,US,A1,US 2011/0212112 A1,049-569-384-130-079,2011-09-01,2011,US 201113042623 A,2011-03-08,US 201113042623 A;;US 58995607 A;;US 2005/0005361 W;;US 54635404 P,2004-02-19,CONFORMATION SPECIFIC ANTIBODIES,"The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.",CBR INST FOR BIOMEDICAL RES INC,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,,https://lens.org/049-569-384-130-079,Patent Application,yes,3,0,15,15,61,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;A61P29/00;;C07K16/28;;C12N5/078,424/173.1;;435/375,3,1,020-908-771-944-188,pmc1618580;;10.1016/s0002-9440(10)63325-1;;15277234,"Kevil et al. Loss of LFA-1, but not Mac-1, Protects MRL/MpJ-Faslpr Mice from Autoimmune Disease. American Journal of Pathology, Vol. 165(2):609-616, 2004.;;Connolly MK, Anti-LFA-1 treatment inhibits autoantibody production but does not prolong life in Lupus-prone NZB/NZW mice. American Association of Immunologists. Absract No. 979, 1993.;;The Jin Lab. UAN polymer nanoparticles for targeted delivery of anti-inflammatory drugs. Pages 1-2, 2/9/2012.",INACTIVE
122,US,A1,US 2017/0002306 A1,109-535-112-803-267,2017-01-05,2017,US 201514789591 A,2015-07-01,US 201462020048 P,2014-07-02,Gas Recirculation System for an Incubated Controlled Environment,"A gas recirculation system for an incubated controlled environment, the system comprising: a first mixing box; a second mixing box in fluid communication with the first mixing box; a manifold in fluid communication with the second mixing box; a plurality of incubation chambers in fluid communication with the manifold; a return manifold in fluid communication with the plurality of incubation chambers and in fluid communication with the first mixing box. A gas recirculation system for an incubated controlled environment, the system comprising: a first mixing box; a second mixing box in fluid communication with the first mixing box; an inlet port in fluid communication with the second mixing box; a plurality of incubation chamber inlet ports; an incubation chamber in fluid communication with the plurality of incubation chamber inlet ports; a plurality of incubation chamber outlet ports in fluid communication with the incubation chamber; a check valve in fluid communication with the plurality of incubation outlet ports, and in fluid communication with the second mixing box. A gas recirculation system for an incubated controlled environment, the system comprising: a pump; a filter in fluid communication with the pump; a sensor box in fluid communication with the filter; a pH sensor box in fluid communication with the sensor box, the pH sensor box comprising a container with embryo culture media and a pH sensor configured to determine the pH of the embryo culture media; a regulator in fluid communication with the pH sensor box; an embryo chamber in fluid communication with the regulator; a second pH sensor box in fluid communication with the regulator, the pH sensor box comprising a container with embryo culture media and a pH sensor configured to determine the pH of the embryo culture media. A gas recirculation system for an incubated controlled environment, the system comprising: a means for monitoring the O2 and CO2 concentration of gases in the incubated controlled environment; a means for injecting CO2, N2, and/or O2 into the incubated controlled environment via a mixing box; a means for adjusting the CO2, N2, and O2 levels in the incubated controlled environment. A gas recirculation system for an incubated controlled environment of claim 16 , further comprising: a means for introducing CO2, N2, and/or O2 into the incubated environment in order to maintain about 5% of CO2; about 90% of N2; and/or about 5% of O2 in the incubated environment.",CECCHI MICHAEL;;SCHIMMEL TIMOTHY;;MEZZEZI MONICA;;COHEN JACQUES;;CECCHI MICHAEL R,CECCHI MICHAEL;;SCHIMMEL TIMOTHY;;MEZZEZI MONICA;;COHEN JACQUES;;CECCHI MICHAEL R,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/109-535-112-803-267,Patent Application,yes,8,4,2,2,0,C12M41/34;;C12M41/34;;C12M41/14;;C12M41/14,C12M1/00;;C12M1/34,,0,0,,,,DISCONTINUED
123,US,S,US D0525973 S,144-427-728-808-032,2006-08-01,2006,US 23663205 F,2005-08-18,US 23663205 F,2005-08-18,Display unit,,MOTOROLA INC,JULIAN MATTHEW M;;SWEENEY TIMOTHY J;;KAZMA SHLOMO;;COHEN-MATZLIAH NISSIM,MOTOROLA SOLUTIONS INC (2005-08-09),https://lens.org/144-427-728-808-032,Design Right,no,0,1,1,1,0,,,1402;;D14/371,0,0,,,,EXPIRED
124,CA,A1,CA 3212425 A1,147-800-222-122-49X,2022-09-22,2022,CA 3212425 A,2022-03-18,US 202163162967 P;;US 2022/0071219 W,2021-03-18,"SYSTEM AND METHOD FOR PAYMENT DEVICE ISSUANCE, LIFECYCLE MANAGEMENT, AND USE","A method for payment device issuance, lifecycle management, and use may include a financial institution computer program: issuing a numberless, physical first financial instrument that is restricted to in-person transactions having a first primary account number (PAN) stored in a chip to a customer; issuing a digital, second financial instrument to an electronic wallet for the customer having a second PAN that is different from the first PAN; receiving a notification that the first financial instrument or the second financial instrument has been lost or compromised; in response to the first financial instrument being lost/compromised, reissuing the first financial instrument with a third PAN, wherein the second PAN for the second financial instrument is unchanged; and in response to the second financial instrument being lost/compromised, reissuing the second financial instrument with a fourth PAN, wherein the first PAN for the first financial instrument is unchanged.",JPMORGAN CHASE BANK NA,NOAH MOHAMED;;JAVED ABDULLAH;;SMITH DAN COHEN;;CHEUNG TIMOTHY;;LIU WANPENG,,https://lens.org/147-800-222-122-49X,Patent Application,no,0,0,5,5,0,G06Q20/36;;G06Q20/02;;G06Q20/3265;;G06Q20/24;;G06Q20/3821;;G06Q20/38215;;G06Q20/3829;;G06Q20/425,G06Q20/02;;G06Q20/32;;G06Q20/36,,0,0,,,,PENDING
125,ZA,B,ZA 873835 B,161-385-869-197-582,1989-01-25,1989,ZA 873835 A,1987-05-27,US 86827986 A,1986-05-29,DURABLE EPOXY(METH)ACRYLIC POLYMER WITH OXIRANE-CONTAINING TERMINAL GROUPS AND PREPARATION,,DU PONT,SPINELLI HARRY JOSEPH;;HARRY JOSEPH SPINELLI;;HUTCHINS CLYDE SPENCER;;CLYDE SPENCER HUTCHINS;;COSTELLO TIMOTHY DAVID;;TIMOTHY DAVID COSTELLO;;COHEN GORDON MARK;;GORDON MARK COHEN,,https://lens.org/161-385-869-197-582,Granted Patent,no,0,0,1,36,0,,C08F/;;C08G/,,0,0,,,,EXPIRED
126,TW,A,TW 201251276 A,021-982-859-162-350,2012-12-16,2012,TW 101118866 A,2012-05-25,US 201113118286 A,2011-05-27,Haptic alert device having a linear vibrator,"A vibrator designed to be integrated into a portable electronic device as part of a haptic alert device has a linear electric motor that is coupled to actively drive a moveable weight in back-and-forth directions to produce the desired vibration. A lock mechanism has a restraining member that is biased into a lock position, which prevents the moveable weight from moving in the back-and-forth directions when the vibrator is inactive. Other embodiments are also described and claimed.",APPLE INC,JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,,https://lens.org/021-982-859-162-350,Patent of Addition,no,0,0,6,6,0,B06B1/045;;B06B1/045;;H04M1/0202;;H04M1/0202;;H04M19/047;;H04M19/047,H02K33/02;;H04M1/02,,0,0,,,,ACTIVE
127,US,A1,US 2022/0300959 A1,062-029-053-323-54X,2022-09-22,2022,US 202217655421 A,2022-03-18,US 202217655421 A;;US 202163162967 P,2021-03-18,"SYSTEM AND METHOD FOR PAYMENT DEVICE ISSUANCE, LIFECYCLE MANAGEMENT, AND USE","A method for payment device issuance, lifecycle management, and use may include a financial institution computer program: issuing a numberless, physical first financial instrument that is restricted to in-person transactions having a first primary account number (PAN) stored in a chip to a customer; issuing a digital, second financial instrument to an electronic wallet for the customer having a second PAN that is different from the first PAN; receiving a notification that the first financial instrument or the second financial instrument has been lost or compromised; in response to the first financial instrument being lost/compromised, reissuing the first financial instrument with a third PAN, wherein the second PAN for the second financial instrument is unchanged; and in response to the second financial instrument being lost/compromised, reissuing the second financial instrument with a fourth PAN, wherein the first PAN for the first financial instrument is unchanged.",JPMORGAN CHASE BANK NA,NOAH MOHAMED;;JAVED ABDULLAH;;SMITH DAN COHEN;;CHEUNG TIMOTHY;;LIU WANPENG,,https://lens.org/062-029-053-323-54X,Patent Application,yes,0,0,5,5,0,G06Q20/36;;G06Q20/02;;G06Q20/3265;;G06Q20/24;;G06Q20/3821;;G06Q20/38215;;G06Q20/3829;;G06Q20/425,G06Q20/38;;G06Q20/24;;G06Q20/42,,0,0,,,,PENDING
128,EP,A4,EP 3313354 A4,107-966-011-527-242,2018-12-05,2018,EP 16818446 A,2016-06-15,US 201562186048 P;;US 2016/0037570 W,2015-06-29,METHOD FOR FORMING PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,,ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID;;MIKAYLOVA YELENA,,https://lens.org/107-966-011-527-242,Search Report,no,3,0,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00,,1,0,,,See also references of WO 2017003688A1,DISCONTINUED
129,CN,A,CN 116250236 A,153-500-835-219-190,2023-06-09,2023,CN 202180063932 A,2021-08-30,US 202063083747 P;;US 202117201944 A;;US 2021/0048245 W,2020-09-25,Instance adaptive image and video compression using machine learning system,"Techniques are described for compressing data using a machine learning system and tuning the machine learning system to compress data. An example process may include receiving, by a neural network compression system (e.g., trained on a training data set), input data for compression by the neural network compression system. The process may include determining a set of updates for the neural network compression system, the set of updates including updated model parameters tuned using the input data. The process may include generating, by the neural network compression system, a first bitstream including a compressed version of the input data using a potential priori. The process may also include generating, by the neural network compression system, a second bitstream comprising a compressed version of the updated model parameter using the potential priori and a model priori. The process may include outputting the first bitstream and the second bitstream for transmission to a receiver.",QUALCOMM INC,VAN ROSENDAHL TIMOTHY J;;HUIJBEN INGRID ADRIANUS MARIA;;COHEN TODD S,,https://lens.org/153-500-835-219-190,Patent Application,no,0,0,5,5,0,H04N19/13;;H04N19/147;;H04N19/463;;H04N19/91;;G06N3/084;;G06N3/047;;G06N3/045;;H04N19/13;;H04N19/147;;H04N19/463;;H04N19/184;;G06T9/002;;G06N3/045;;G06N3/0455;;G06N3/084;;G06N3/047;;G06N3/088;;G06T2207/20084;;H04N19/184;;G06N3/088;;G06N3/045,H04N19/147,,0,0,,,,PENDING
130,CA,A1,CA 2554965 A1,009-259-637-674-943,2005-09-01,2005,CA 2554965 A,2005-02-22,US 54635404 P;;US 2005/0005361 W,2004-02-19,CONFORMATION SPECIFIC ANTIBODIES,"The disclosure provides, inter alia, binding proteins (e.g., antibodies) tha t bind to an integrin in an activated conformation, e.g., activated LFA-1 (~aL FA- 1~), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.",DYAX CORP;;CBR INST FOR BIOMED RES INC,RONDON ISAAC J;;SPRINGER TIMOTHY A;;COHEN EDWARD H;;SHIMAOKA MOTOMU,,https://lens.org/009-259-637-674-943,Patent Application,no,0,0,15,15,62,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,C07K16/28;;A61K39/395;;A61K49/06;;A61P29/00;;A61P37/06;;C12N5/06;;C12N5/08;;G01N33/53,,0,0,,,,INACTIVE
131,TW,B,TW I479776 B,003-734-695-402-788,2015-04-01,2015,TW 101118866 A,2012-05-25,US 201113118286 A,2011-05-27,Apparatuses and methods for use as part of a haptic alert device and portable electronic devices,,APPLE INC,JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,,https://lens.org/003-734-695-402-788,Granted Patent,no,4,0,6,6,0,B06B1/045;;B06B1/045;;H04M1/0202;;H04M1/0202;;H04M19/047;;H04M19/047,,,0,0,,,,ACTIVE
132,AU,A1,AU 2022/238576 A1,042-541-736-195-29X,2023-10-05,2023,AU 2022/238576 A,2022-03-18,US 202163162967 P;;US 2022/0071219 W,2021-03-18,"SYSTEM AND METHOD FOR PAYMENT DEVICE ISSUANCE, LIFECYCLE MANAGEMENT, AND USE","A method for payment device issuance, lifecycle management, and use may include a financial institution computer program: issuing a numberless, physical first financial instrument that is restricted to in-person transactions having a first primary account number (PAN) stored in a chip to a customer; issuing a digital, second financial instrument to an electronic wallet for the customer having a second PAN that is different from the first PAN; receiving a notification that the first financial instrument or the second financial instrument has been lost or compromised; in response to the first financial instrument being lost/compromised, reissuing the first financial instrument with a third PAN, wherein the second PAN for the second financial instrument is unchanged; and in response to the second financial instrument being lost/compromised, reissuing the second financial instrument with a fourth PAN, wherein the first PAN for the first financial instrument is unchanged.",JPMORGAN CHASE BANK NA,NOAH MOHAMED;;JAVED ABDULLAH;;SMITH DAN COHEN;;CHEUNG TIMOTHY;;LIU WANPENG,,https://lens.org/042-541-736-195-29X,Patent Application,no,0,0,5,5,0,G06Q20/36;;G06Q20/02;;G06Q20/3265;;G06Q20/24;;G06Q20/3821;;G06Q20/38215;;G06Q20/3829;;G06Q20/425,G06Q20/02;;G06Q20/32;;G06Q20/36,,0,0,,,,PENDING
133,EP,A2,EP 1761562 A2,061-921-805-821-738,2007-03-14,2007,EP 05723364 A,2005-02-22,US 2005/0005361 W;;US 54635404 P,2004-02-19,CONFORMATION SPECIFIC ANTIBODIES,,DYAX CORP;;CBR INST FOR BIOMED RES INC,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,DYAX CORP. (2013-05-22),https://lens.org/061-921-805-821-738,Patent Application,yes,0,0,15,15,61,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;C07K16/00;;C07K16/28;;C07K16/46,,0,0,,,,ACTIVE
134,WO,A3,WO 2012/166327 A3,136-774-218-845-876,2013-06-27,2013,US 2012/0037575 W,2012-05-11,US 201113118286 A,2011-05-27,HAPTIC ALERT DEVICE HAVING A LINEAR VIBRATOR,"A vibrator designed to be integrated into a portable electronic device as part of a haptic alert device has a linear electric motor that is coupled to actively drive a moveable weight in back-and-forth directions to produce the desired vibration. A lock mechanism has a restraining member that is biased into a lock position, which prevents the moveable weight from moving in the back-and-forth directions when the vibrator is inactive. The lock mechanism may be controlled by a second electric motor.",APPLE INC;;JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,,https://lens.org/136-774-218-845-876,Search Report,no,3,0,6,6,0,B06B1/045;;B06B1/045;;H04M1/0202;;H04M1/0202;;H04M19/047;;H04M19/047,B06B1/12,,0,0,,,,PENDING
135,EP,A1,EP 4309107 A1,002-320-454-318-917,2024-01-24,2024,EP 22715946 A,2022-03-18,US 202163162967 P;;US 2022/0071219 W,2021-03-18,"SYSTEM AND METHOD FOR PAYMENT DEVICE ISSUANCE, LIFECYCLE MANAGEMENT, AND USE",,JPMORGAN CHASE BANK NA,NOAH MOHAMED;;JAVED ABDULLAH;;SMITH DAN COHEN;;CHEUNG TIMOTHY;;LIU WANPENG,,https://lens.org/002-320-454-318-917,Patent Application,yes,0,0,5,5,0,G06Q20/36;;G06Q20/02;;G06Q20/3265;;G06Q20/24;;G06Q20/3821;;G06Q20/38215;;G06Q20/3829;;G06Q20/425,G06Q20/02;;G06Q20/32;;G06Q20/36,,0,0,,,,PENDING
136,WO,A1,WO 2022/198237 A1,033-562-798-222-130,2022-09-22,2022,US 2022/0071219 W,2022-03-18,US 202163162967 P,2021-03-18,"SYSTEM AND METHOD FOR PAYMENT DEVICE ISSUANCE, LIFECYCLE MANAGEMENT, AND USE","A method for payment device issuance, lifecycle management, and use may include a financial institution computer program: issuing a numberless, physical first financial instrument that is restricted to in-person transactions having a first primary account number (PAN) stored in a chip to a customer; issuing a digital, second financial instrument to an electronic wallet for the customer having a second PAN that is different from the first PAN; receiving a notification that the first financial instrument or the second financial instrument has been lost or compromised; in response to the first financial instrument being lost/compromised, reissuing the first financial instrument with a third PAN, wherein the second PAN for the second financial instrument is unchanged; and in response to the second financial instrument being lost/compromised, reissuing the second financial instrument with a fourth PAN, wherein the first PAN for the first financial instrument is unchanged.",JPMORGAN CHASE BANK NA,NOAH MOHAMED;;JAVED ABDULLAH;;SMITH DAN COHEN;;CHEUNG TIMOTHY;;LIU WANPENG,,https://lens.org/033-562-798-222-130,Patent Application,yes,4,0,5,5,0,G06Q20/36;;G06Q20/02;;G06Q20/3265;;G06Q20/24;;G06Q20/3821;;G06Q20/38215;;G06Q20/3829;;G06Q20/425,G06Q20/02;;G06Q20/32;;G06Q20/36,,0,0,,,,PENDING
137,EP,A1,EP 3313368 A1,053-412-722-635-993,2018-05-02,2018,EP 16818445 A,2016-06-15,US 201562186035 P;;US 2016/0037566 W,2015-06-29,PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,,ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID;;MIKAYLOVA YELENA,,https://lens.org/053-412-722-635-993,Patent Application,yes,0,0,10,10,0,A61K8/27;;A61K8/89;;A61K8/895;;A61K8/895;;A61K8/0241;;A61K8/0241;;A61K8/0241;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/27;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/29;;A61K8/895;;A61K2800/412;;A61K2800/412;;A61K2800/412;;A61K2800/622;;A61K2800/623;;A61K2800/623;;A61K2800/623;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61K2800/651;;A61Q17/04;;A61Q17/04;;A61Q19/00;;A61Q19/00;;A61Q19/00;;A61Q19/00;;C09C3/12;;C09C3/12,A61K8/89;;A61K8/19;;A61K8/27;;A61K8/29;;A61Q19/00,,0,0,,,,DISCONTINUED
138,WO,A2,WO 2012/166327 A2,144-681-615-447-617,2012-12-06,2012,US 2012/0037575 W,2012-05-11,US 201113118286 A,2011-05-27,HAPTIC ALERT DEVICE HAVING A LINEAR VIBRATOR,"A vibrator designed to be integrated into a portable electronic device as part of a haptic alert device has a linear electric motor that is coupled to actively drive a moveable weight in back-and-forth directions to produce the desired vibration. A lock mechanism has a restraining member that is biased into a lock position, which prevents the moveable weight from moving in the back-and-forth directions when the vibrator is inactive. Other embodiments are also described and claimed.",APPLE INC;;JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,,https://lens.org/144-681-615-447-617,Patent Application,yes,0,0,6,6,0,H04M1/0202;;H04M19/047;;B06B1/045;;H04M1/0202;;H04M19/047;;B06B1/045,B06B1/12,,0,0,,,,PENDING
139,EP,A4,EP 1761562 A4,042-065-624-005-83X,2009-03-25,2009,EP 05723364 A,2005-02-22,US 2005/0005361 W;;US 54635404 P,2004-02-19,CONFORMATION SPECIFIC ANTIBODIES,,DYAX CORP;;CBR INST FOR BIOMED RES INC,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,DYAX CORP. (2013-05-22),https://lens.org/042-065-624-005-83X,Search Report,no,1,0,15,15,0,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;C07K16/00;;C07K16/28;;C07K16/46,,3,3,020-452-502-050-052;;067-031-180-273-340;;103-442-462-781-538,pmc33413;;11353828;;10.1073/pnas.101130498;;16888085;;10.1189/jlb.1105649;;pmc1712386;;10.1038/nbt1067;;15723048,"SHIMAOKA MOTOMU ET AL: ""Reversibly locking a protein fold in an active conformation with a disulfide bond: Integrin alphaL I domains with high affinity and antagonist activity in vivo"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6009 - 6014, XP002209620, ISSN: 0027-8424;;HUANG LILI ET AL: ""Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1"", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 80, no. 4, October 2006 (2006-10-01), pages 905 - 914, XP002514182, ISSN: 0741-5400;;HOET R M ET AL: ""Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity"", NATURE BIOTECHNOLOGY MARCH 2005 NATURE PUBLISHING GROUP US, vol. 23, no. 3, March 2005 (2005-03-01), pages 344 - 348, XP002514183",ACTIVE
140,US,A1,US 2008/0069777 A1,065-618-002-682-619,2008-03-20,2008,US 58995605 A,2005-02-22,US 58995605 A;;US 54635404 P;;US 2005/0005361 W,2004-02-19,Conformation Specific Antibodies,"The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.",COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,DYAX CORP (2005-01-10);;CBR INSTITUTE FOR BIOMEDICAL RESEARCH INC. THE (2006-02-07),https://lens.org/065-618-002-682-619,Patent Application,yes,2,18,15,15,61,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;A61K49/16;;A61P37/00;;C07K16/28;;C12N5/00;;G01N33/53,424/9.34;;424/130.1;;424/172.1;;424/9.1;;435/375;;435/7.24;;530/387.1,0,0,,,,INACTIVE
141,EP,A1,EP 3313354 A1,004-445-079-972-360,2018-05-02,2018,EP 16818446 A,2016-06-15,US 201562186048 P;;US 2016/0037570 W,2015-06-29,METHOD FOR FORMING PARTICLES WITH CROSS-LINKED COATINGS FOR COSMETIC APPLICATIONS,,ELC MAN LLC,BALIAN RAFFI;;GRAY TIMOTHY;;TSOLIS PETER;;COHEN ISAAC DAVID;;MIKAYLOVA YELENA,,https://lens.org/004-445-079-972-360,Patent Application,yes,0,0,9,9,0,A61K8/0241;;A61K8/27;;A61K8/29;;A61K8/895;;A61Q19/00;;C09D143/04;;A61K2800/43;;A61K2800/412;;A61K2800/10;;A61K2800/624;;A61K2800/651;;A61Q19/00;;A61K8/0241;;A61K2800/10;;A61K2800/412;;A61K2800/624;;A61K2800/651;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K8/0283;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00;;A61K2800/65;;A61K8/895;;C09D143/04;;A61K8/29;;A61K8/27;;A61K2800/43;;A61K2800/10;;A61K2800/651;;A61K2800/624;;A61K2800/412;;A61K8/0241;;A61Q19/00,A61K8/02;;A61K8/27;;A61K8/29;;A61K8/89;;A61Q19/00,,0,0,,,,DISCONTINUED
142,US,B2,US 8247185 B2,107-737-126-616-49X,2012-08-21,2012,US 201113042623 A,2011-03-08,US 201113042623 A;;US 58995607 A;;US 2005/0005361 W;;US 54635404 P,2004-02-19,Conformation specific antibodies,"The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1 ”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.",COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU;;DYAX CORP;;CBR INST FOR BIOMED RES INC,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,,https://lens.org/107-737-126-616-49X,Granted Patent,yes,4,0,15,15,61,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;C12Q1/68;;C07K16/28,435/7.1;;424/130.1;;424/143.1;;424/144.1,18,16,020-908-771-944-188;;009-746-604-420-355;;027-960-937-319-909;;062-170-867-080-500;;051-707-000-800-833;;005-405-010-898-254;;015-239-659-590-870;;027-477-313-726-928;;095-334-545-560-259;;045-942-104-775-903;;087-531-575-080-910;;048-907-099-662-677;;019-757-974-667-271;;004-842-226-879-561;;024-820-708-196-593;;047-224-464-274-447,pmc1618580;;10.1016/s0002-9440(10)63325-1;;15277234;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1006/jmbi.2000.3512;;10677285;;10.4049/jimmunol.156.9.3285;;8617951;;12079396;;10.1016/s0022-2836(02)00264-4;;8114766;;10.1016/0161-5890(94)90001-9;;10.4049/jimmunol.150.3.880;;8423344;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1006/jmbi.1996.0548;;8876650;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1073/pnas.121186998;;11391003;;pmc34438;;pmc1599901;;10.1073/pnas.0605716103;;16963559;;11226250;;10.1073/pnas.041618598;;pmc30149;;10.1073/pnas.041606398;;pmc30148;;11226249;;10.1074/jbc.m512472200;;pmc1599852;;16505487;;14499114;;10.1016/s1074-7613(03)00238-3,"Kevil et al. Loss of LFA-1, but not Mac-1, Protects MRL/MpJ-Faslpr Mice from Autoimmune Disease. American Journal of Pathology, vol. 165(2):609-616, 2004.;;Connolly MK, Anti-LFA-1 treatment inhibits autoantibody production but does not prolong life in Lupus-prone NZB/NZW mice. American Association of Immunologists. Absract No. 979, 1993.;;The Jin Lab. UAN polymer nanoparticles for targeted delivery of anti-inflammatory drugs. pp. 1-2, Feb. 9, 2012.;;Klimka et al., ""Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning"", British Journal of Cancer (2000) 83:252-260.;;Beiboer et al., ""Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent"", J. Mol. Biol. (2000) 296:833-849.;;Brown et al., ""Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation"", J. Immuno. May 1996, 3285-91.;;Vajdos et al., ""Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis"", J. Mol. Biol. Jul. 5, 2002, 320(2): 415-28 at 416.;;Eduardo Padlan, ""Anatomy of the antibody molecule"", Mol. Immunol. Feb. 1994 31(3): 169-217.;;Portolano et al., ""Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain ""roulette"""", J. Immunol. Feb. 1, 1993 150(3):880-7.;;Rudikoff et al., Single amino acid substitution altering antigen-binding specifity. Proc. Natl. Acad. Sci. USA, 79 (6):1979-1983, Mar. 1982.;;MacCallum et al., ""Antibody-antigen interactions: contact analysis and binding site topography"", J. Mol. Biol. 262, 732-745, 1996.;;Casset et al., ""A peptide mimetic of an anti-CD4 monoclonal antibody by rational design"", Biochemical and Biophysical Research Communications, 307:198-205, 2003.;;Jun et al., ""Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion"", Proc. Natl. Acad. Sci. U.S.A. Jun. 2001, vol. 98, No. 12, pp. 6830-6835.;;Shimaoka et al., ""AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes"", Proc. Natl. Acad. Sci. U.S.A. Sep. 19, 2006, vol. 103, No. 38, pp. 13991-13996.;;Lu et al., ""Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin doamins"", Proc. Natl. Acad. Sci. U.S.A. Feb. 27, 2001, vol. 98, No. 5, pp. 2393-2398.;;Lu et al., ""An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond"", Proc. Natl. Acad. Sci. U.S.A. Feb. 27, 2001, vol. 98, No. 5, pp. 2387-2392.;;Salas et al., ""Transition from rolling to firm adhesion can be mimicked by extension of integrin alphaLbeta2 in an intermediate affinity state"", J. Biol. Chem. Apr. 21, 2006, vol. 281, No. 16, pp. 10876-10882.;;Shimaoka et al., ""Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and active signals in one direction and block them in the other"", Immunity, Sep. 2003, vol. 19, No. 3, pp. 391-402.",INACTIVE
143,US,B2,US 8963695 B2,192-872-496-102-685,2015-02-24,2015,US 201113118286 A,2011-05-27,US 201113118286 A,2011-05-27,Haptic alert device having a linear vibrator,"A vibrator designed to be integrated into a portable electronic device as part of a haptic alert device has a linear electric motor that is coupled to actively drive a moveable weight in back-and-forth directions to produce the desired vibration. A lock mechanism has a restraining member that is biased into a lock position, which prevents the moveable weight from moving in the back-and-forth directions when the vibrator is inactive. Other embodiments are also described and claimed.",JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y;;APPLE INC,JOHNSON TIMOTHY M;;PEREZ YEHONATAN;;COHEN SAWYER I;;SHUKLA ASHUTOSH Y,APPLE INC (2011-05-25),https://lens.org/192-872-496-102-685,Granted Patent,yes,17,4,6,6,0,B06B1/045;;B06B1/045;;H04M1/0202;;H04M1/0202;;H04M19/047;;H04M19/047,H04B3/36;;B06B1/04;;H04M1/00;;H04M1/02;;H04M9/00;;H04M19/04,340/407.1;;455/567;;379/391;;379/392;;379/393,5,1,043-711-832-536-440,10.1109/intmag.2005.1463534,"International Preliminary Report on Patentability (Chapter I) for corresponding International Application No. PCT/US2012/037575, mailing date Dec. 12, 2013, 9 pages.;;PCT International Search Report and Written Opinion (dated Apr. 10, 2013), International Application No. PCT/US2012/037575, International Filing Date-May 11, 2012, (14 pages).;;Kim, J. H., et al., ""Development of the Conical Spring Linear Vibrator (CSLV) for Mobile Phone"", Magnetics Conference 2005. INTERMAG Asia 2005. Digests of the IEEE International, Apr. 4-8, 2005, on pp. 211-212, ISBN: 0-7803-9009-1, 1 page.;;TW Office Action (dated Jun. 10, 2014), Application No. 101118866, Date Filed-May 25, 2012, (12 pages).;;Apple Inc., ROC (Taiwan) Application No. 101118866; Office Action and Search Report received on Oct. 16, 2014.",ACTIVE
144,WO,A3,WO 2005/079515 A3,054-484-323-597-255,2007-12-06,2007,US 2005/0005361 W,2005-02-22,US 54635404 P,2004-02-19,CONFORMATION SPECIFIC ANTIBODIES,"The disclosure provides, inter alia , binding proteins ( e.g. , antibodies) that bind to an integrin in an activated conformation, e.g. , activated LFA-1 (“aLFA-1”), e.g. , relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g. , inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g. , an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.",CBR INST FOR BIOMED RES INC;;DYAX CORP;;COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,COHEN EDWARD H;;RONDON ISAAC J;;SPRINGER TIMOTHY A;;SHIMAOKA MOTOMU,,https://lens.org/054-484-323-597-255,Search Report,yes,2,0,15,15,0,A61K2039/505;;C07K16/2845;;C07K2317/32;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/92;;C07K2317/76;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;C07K16/2845;;C07K2317/55;;C07K2317/56;;C07K2317/92;;C07K2317/32;;A61K2039/505;;C07K2317/565;;C07K2317/76,A61K39/395;;C07K16/00;;C07K16/28;;C07K16/46,,6,6,087-531-575-080-910;;048-907-099-662-677;;019-757-974-667-271;;004-842-226-879-561;;024-820-708-196-593;;047-224-464-274-447,10.1073/pnas.121186998;;11391003;;pmc34438;;pmc1599901;;10.1073/pnas.0605716103;;16963559;;11226250;;10.1073/pnas.041618598;;pmc30149;;10.1073/pnas.041606398;;pmc30148;;11226249;;10.1074/jbc.m512472200;;pmc1599852;;16505487;;14499114;;10.1016/s1074-7613(03)00238-3,"JUN ET AL.: ""Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion"", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 12, 5 June 2001 (2001-06-05), pages 6830 - 6835, XP008091856;;SHIMAOKA ET AL.: ""AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes"", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 38, 19 September 2006 (2006-09-19), pages 13991 - 13996, XP008091849;;LU ET AL.: ""Locking in alternate conformations of the integrin alphaLbeta2 I with disulfide bonds reveals functional relationships among integrin domains"", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2393 - 2398, XP002209619;;LU ET AL.: ""An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformationa with a disulfide bond"", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2387 - 2392, XP002209618;;SALAS ET AL.: ""Transition from rolling to firm adhesion can be mimicked by extension of integrin alphaLbeta2 in an intermediate affinity state"", J. BIOL. CHEM., vol. 281, no. 16, 21 April 2006 (2006-04-21), pages 10876 - 10882, XP008091426;;SHIMAOKA ET AL.: ""Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other"", IMMUNITY, vol. 19, no. 3, September 2003 (2003-09-01), pages 391 - 402, XP008091510",PENDING
145,CN,A,CN 115211115 A,118-639-102-493-296,2022-10-18,2022,CN 202180017106 A,2021-01-15,US 202062984673 P;;US 202017091570 A;;US 2021/0013599 W,2020-03-03,Video compression using loop-based machine learning system,"Techniques for coding video content using a loop-based machine learning tool are described herein. In some embodiments, an apparatus may include a neural network system including an encoder portion and a decoder portion. The encoder portion may determine, based on an input video frame for a current time step of an operation of the neural network system, reconstructed motion estimation data from a previous time step of the operation, reconstructed residual data from the previous time step of the operation, and loop state data from at least one loop layer of a decoder portion of the neural network system from a previous time step of operation to generate output data for a current time step of operation of the neural network system. A decoder portion of the neural network system may generate a reconstructed video frame for a current time step of the operation based on the output data and loop state data from a previous time step of the operation.",QUALCOMM INC,GOLINSKY ALEXANDER W;;YANG YANG;;PRYZA RAKESH;;SOUTIER GEORGE K;;VAN ROOSENDAAL TIMOTHY JOHN;;COHEN TIMOTHY S,,https://lens.org/118-639-102-493-296,Patent Application,no,0,1,9,9,0,H04N19/436;;H04N19/503;;G06N3/084;;G06N3/044;;G06N3/045;;H04N19/463;;H04N19/503;;H04N19/42;;H04N19/137;;H04N19/85;;H04N19/172;;G06N3/084;;G06N3/044;;G06N3/045;;H04N19/42;;H04N19/137;;G06N3/08;;H04N19/85;;H04N19/172,H04N19/503;;H04N19/436,,0,0,,,,PENDING
146,EP,A1,EP 2449977 A1,046-097-174-434-240,2012-05-09,2012,EP 12151530 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"A compound barb medical device (620) comprising: an elongate body (610) wherein the elongate body includes an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body and defining an inner surface, the inner surface including: a first portion (620a) disposed at a first orientation relative to a first longitudinal axis of the elongate body, wherein the first portion is disposed at a first angle from about 31 degrees to about 38 degrees relative to the first longitudinal axis of the elongate body; and a second portion (620b) disposed at a second orientation relative to a second longitudinal axis of the elongate body, wherein the second portion is disposed at a second angle from about 1 degree to about 8 degrees relative to the second longitudinal axis of the elongate body; and wherein the medical device is formed of absorbable materials, non-absorbable materials and combinations thereof.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/046-097-174-434-240,Patent Application,yes,6,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,DISCONTINUED
147,EP,A1,EP 2449975 A1,183-903-801-490-972,2012-05-09,2012,EP 12151525 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device,"A compound barb medical device comprising an elongated body and at least one compound barb extending from the elongated body wherein said compound barbs project from the medical device towards at least one end and wherein at least one end of the medical device comprises a loop.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/183-903-801-490-972,Patent Application,yes,6,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,DISCONTINUED
148,US,A1,US 2018/0112164 A1,195-901-595-841-52X,2018-04-26,2018,US 201615334953 A,2016-10-26,US 201615334953 A,2016-10-26,"Device for Observation, Imaging and Uninterrupted Culturing of Embryos and Cells","A device for the observation, imaging and uninterrupted culturing of embryos and cells, the device comprising: an incubator; a mixing box located above the incubator; gas sensors located in the mixing box; solenoid valves attached to the mixing box; a first clear panel located on the top of the incubator, and configured to allow one to see into the incubator; a first light source located above the first clear panel, and the first light source configured to provide light into the incubator; a door attached to the incubator, the door configured to provide access to the inside of the incubator, and the door located below the access door; a rotatable platter located below the incubator, the rotatable platter comprising: a first insert configured to removably sit on the platter; a first culture dish configured to removably sit in the first insert; a second insert configured to removably sit on the platter; a second culture dish configured to removably sit in the second insert; a first moveable camera located under the rotatable platter, and configured to view a culture dish located generally directly above the first moveable camera, and the first moveable camera generally in alignment with the first light source; a computer in communication with the first moveable camera, rotatable platter, sensors, solenoid valves, touchscreen display, and light source. A device for the observation, imaging and uninterrupted culturing of embryos and cells, the device comprising: a top portion, the top portion comprising: a housing; a horizontal surface on the housing; an angled surface abutting the horizontal surface; an access door located generally on the housing; a first heating surface located on the horizontal surface; a touch screen display located on the angled surface; a middle portion abutting the top portion; the middle portion comprising: an incubator; a mixing box located above the incubator; gas sensors located in the mixing box; solenoid valves attached to the mixing box; a first clear panel located on the top of the incubator, and configured to allow one to see into the incubator; a first light source located above the first clear panel, and the first light source configured to provide light into the incubator; a door attached to the incubator, the door configured to provide access to the inside of the incubator, and the door located below the access door; a bottom portion abutting the middle portion, the bottom portion comprising: a rotatable platter, the rotatable platter comprising: a first insert configured to removably sit on the platter; a first culture dish configured to removably sit in the first insert; a second insert configured to removably sit on the platter; a second culture dish configured to removably sit in the second insert; a first moveable camera located under the rotatable platter, and configured to view a culture dish located generally directly above the first moveable camera, and the first moveable camera generally in alignment with the first light source; a computer in communication with the camera, rotatable platter, sensors, solenoid valves, touchscreen display, and light source.",CECCHI MICHAEL D;;SCHIMMEL TIMOTHY;;COHEN JACQUES;;MEZEZI MONICA;;CECCHI MICHAEL RYAN,CECCHI MICHAEL D;;SCHIMMEL TIMOTHY;;COHEN JACQUES;;MEZEZI MONICA;;CECCHI MICHAEL RYAN,LIFEGLOBAL GROUP LLC (2017-10-31);;COOPERSURGICAL INC (2018-04-03),https://lens.org/195-901-595-841-52X,Patent Application,yes,0,9,1,1,0,C12M41/36;;C12M23/22;;C12M23/50;;C12M23/48;;C12M31/02;;C12M41/34;;C12M41/14;;C12M23/22;;C12M23/50;;C12M23/48;;C12M31/02;;C12M41/34;;C12M41/14;;G01N21/84;;C12M41/36,C12M1/00;;C12M1/34;;C12M3/00;;G01N21/84,,0,0,,,,DISCONTINUED
149,NO,D0,NO 872236 D0,146-140-789-334-074,1987-05-27,1987,NO 872236 A,1987-05-27,US 86808386 A;;US 86827986 A,1986-05-29,RESISTENT EPOXY(METH)ACRYLPOLYMER MED OXIRAN-HOLDIGE ENDEGRUPPER OG FREMGANGSMAATE FOR FREMSTILLING AV POLYMEREN.,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/146-140-789-334-074,Patent Application,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
150,US,B2,US 9105305 B2,143-801-654-651-378,2015-08-11,2015,US 201113989659 A,2011-11-30,US 201113989659 A;;US 41884610 P;;US 201161433918 P;;US 2011/0062726 W,2010-12-01,Dynamic higher-level redundancy mode management with independent silicon elements,"A Solid-State Disk (SSD) controller enables dynamic higher-level redundancy mode management with independent silicon elements to provide graceful degradation as non-volatile (e.g. flash) memory elements fail during operation of an SSD implemented by the controller. Higher-level error correction provides correction of lower-level uncorrectable errors. If a failure of one of the non-volatile memory elements is detected, then the higher-level error correction is dynamically transitioned from operating in a current mode to operating in a new mode. The transition includes one or more of reducing free space available on the SSD, rearranging data storage of the SSD, recovering/storing failed user data (if possible), and determining/storing revised higher-level error correction information. Operation then continues in the new mode. If another failure of the non-volatile memory elements is detected, then another transition is made to another new mode.",WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T;;SEAGATE TECHNOLOGY LLC,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,SANDFORCE INC (2011-12-07);;SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-01-04),https://lens.org/143-801-654-651-378,Granted Patent,yes,56,12,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F11/00;;G06F11/10;;G11B20/18;;H03M13/35,,13,0,,,"International Search Report in the parent PCT/US11/62726, 3 pages.;;Written Opinion in the parent PCT/US11/62726, 3 pages.;;Devang Panchigar ""EMC Symmetrix DMX-RAID 6 Implementation"" Feb. 27, 2009, http://storagenerve.com/2009/02/27/emc-symmetrix-dmx-raid-6-implementation/, 9 pages.;;H. Peter Anvin, ""The mathematics of RAID-6"" Last updated Dec. 20, 2011, https://www.kernel.org/pub/linux/kernel/people/hpa/raid6.pdf, accessed on Sep. 30, 2013, 9 pages.;;Advanced Computer & Network Corporation, ""RAID Level 6: Independent Data Disks with Two Independent Parity Schemes"", http://www.acnc.com/raidedu/6, accessed on Sep. 30, 2013, 2 pages.;;International Search Report and the Written Opinion for PCT/US12/21682, 9 pages.;;International Search Report and the Written Opinion in PCT/US2011/057914, 9 pages.;;Office Action and Search Report for CN2011800666799, Apr. 18, 2014, 16 pages.;;European Search Report for EP11837032, Jun. 23, 2014, 6 pages.;;Notice to File a Response, Korean Intellectual Property Office for KR 10-2013-7013372, Aug. 21, 2014, 10 pages.;;International Search Report and Written Opinion in PCT/US2013/051720, 10 pages.;;International Search Report and Written Opinion in PCT|US2013/051726, 9 pages.;;Dec. 10, 2014 List of References Used in Art Rejections, 1 pg.",INACTIVE
151,BR,A,BR 8702725 A,144-723-404-875-841,1988-03-01,1988,BR 8702725 A,1987-05-27,US 86827986 A;;US 86808386 A,1986-05-29,POLIMERO EM BLOCO ABA E PROCESSO PARA SUA PREPARACAO,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLEYDE SPENCER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/144-723-404-875-841,Patent Application,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
152,US,A1,US 2017/0363684 A1,010-223-489-074-591,2017-12-21,2017,US 201615188386 A,2016-06-21,US 201615188386 A,2016-06-21,BITWISE ROTATING SCAN SECTION FOR MICROELECTRONIC CHIP TESTING AND DIAGNOSTICS,"According to an embodiment of the present invention, a computer-implemented method for testing a microelectronic chip is described. The method may include dividing, via a processor running a scanning engine, a plurality of sections of the microelectronic chip. Each of the plurality of sections includes at least two latch sets in at least one scan chain. The method may further include determining, via the processor, based on the dividing, whether each of the plurality of sections fail a data test. The determining comprises interleaving the plurality of sections by scanning, via the processor, an alternating latch set from each scan chain in a first section, and scanning an alternating latch set from each scan chain in a second section.",IBM,COHEN TODD L;;KUSKO MARY P;;RAJEEV HARI K;;TAYLOR TIMOTHY C,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-06-14),https://lens.org/010-223-489-074-591,Patent Application,yes,0,1,2,2,0,G01R31/318558;;G01R31/3177;;G01R31/31723;;G01R31/318558,G01R31/3177;;G01R31/317,,0,0,,,,ACTIVE
153,US,B2,US 10107860 B2,104-585-095-187-717,2018-10-23,2018,US 201615188386 A,2016-06-21,US 201615188386 A,2016-06-21,Bitwise rotating scan section for microelectronic chip testing and diagnostics,"According to an embodiment of the present invention, a computer-implemented method for testing a microelectronic chip is described. The method may include dividing, via a processor running a scanning engine, a plurality of sections of the microelectronic chip. Each of the plurality of sections includes at least two latch sets in at least one scan chain. The method may further include determining, via the processor, based on the dividing, whether each of the plurality of sections fail a data test. The determining comprises interleaving the plurality of sections by scanning, via the processor, an alternating latch set from each scan chain in a first section, and scanning an alternating latch set from each scan chain in a second section.",IBM,COHEN TODD L;;KUSKO MARY P;;RAJEEV HARI K;;TAYLOR TIMOTHY C,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-06-14),https://lens.org/104-585-095-187-717,Granted Patent,yes,13,0,2,2,0,G01R31/318558;;G01R31/3177;;G01R31/31723;;G01R31/318558,G01R31/3177;;G01R31/317,,5,5,059-497-782-948-661;;123-085-701-711-717;;028-297-508-394-175;;047-381-013-964-309;;015-719-846-252-837,10.1109/ats.2016.58;;10.1109/ats.2000.893666;;10.1109/natw.2015.17;;10.1109/date.2004.1269215;;10.1007/s10617-011-9073-7,"R. Cantoro, M. Palena, P. Pasini and M. S. Reorda, “Test Time Minimization in Reconfigurable Scan Networks,” 2016 IEEE 25th Asian Test Symposium (ATS), Hiroshima, 2016, pp. 119-124.;;Kuen-Jong Lee, Tsung-Chu Haung and Jih-Jeen Chen, “Peak-power reduction for multiple-scan circuits during test application,” Proceedings of the Ninth Asian Test Symposium, Taipei, 2000, pp. 453-458.;;Chillarige et al. “A Novel Failure Diagnosis Approach for Low Pin Count and Low Power Compression Architectures.” Test Workshop (NATW), 2015 IEEE 24th North Atlantic. 2015.;;Goel et al. “Test infrastructure design for the nexperia home platform pnx8550 system chip.” Proceedings of the conference on Design, automation and test in Europe—vol. 3. IEEE Computer Society 2004.;;Hansson et al., “A quantitative evaluation of a network on chip design flow for multi-core consumer multimedia applications.” Design Automation for Embedded Systems 15.2 (2011) pp. 159-190.",ACTIVE
154,EP,A2,EP 2646922 A2,181-955-041-485-039,2013-10-09,2013,EP 11844502 A,2011-11-30,US 41884610 P;;US 201161433918 P;;US 2011/0062726 W,2010-12-01,DYNAMIC HIGHER-LEVEL REDUNDANCY MODE MANAGEMENT WITH INDEPENDENT SILICON ELEMENTS,,LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/181-955-041-485-039,Patent Application,yes,0,0,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F12/16;;G06F11/08;;G06F11/10,,0,0,,,,DISCONTINUED
155,DK,A,DK 271587 A,058-645-748-462-348,1987-11-30,1987,DK 271587 A,1987-05-27,US 86827986 A;;US 86808386 A,1986-05-29,FREMSTILLING AF HOLDBAR EPOXY-(METH)ACRYLPOLYMER MED OXIRAN-HOLDIGE ENDESTILLEDE GRUPPER,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENSER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/058-645-748-462-348,Patent Application,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
156,EP,A4,EP 2646922 A4,093-521-834-691-029,2015-11-25,2015,EP 11844502 A,2011-11-30,US 41884610 P;;US 201161433918 P;;US 2011/0062726 W,2010-12-01,DYNAMIC HIGHER-LEVEL REDUNDANCY MODE MANAGEMENT WITH INDEPENDENT SILICON ELEMENTS,,LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/093-521-834-691-029,Search Report,no,4,0,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F12/16;;G06F11/08;;G06F11/10,,0,0,,,,DISCONTINUED
157,NO,L,NO 872236 L,131-054-555-144-432,1987-11-30,1987,NO 872236 A,1987-05-27,US 86808386 A;;US 86827986 A,1986-05-29,VAERBESTANDIG EPOXY(METH)ACRYLPOLYMER MED OXIRAN-HOLDIGE ENDEGRUPPER OG FREMGANGSMAATE FOR FREMSTILLING AV POLYMEREN.,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/131-054-555-144-432,Abstract,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
158,EP,B1,EP 2449979 B1,075-469-648-597-997,2015-12-09,2015,EP 12151532 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device,,COVIDIEN LP,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/075-469-648-597-997,Granted Patent,yes,3,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
159,KR,A,KR 20130114681 A,086-013-281-451-388,2013-10-17,2013,KR 20137017048 A,2011-11-30,US 41884610 P;;US 201161433918 P;;US 2011/0062726 W,2010-12-01,DYNAMIC HIGHER-LEVEL REDUNDANCY MODE MANAGEMENT WITH INDEPENDENT SILICON ELEMENTS,,LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/086-013-281-451-388,Patent Application,no,1,0,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F11/08;;G06F12/16,,0,0,,,,ACTIVE
160,DE,A1,DE 102015122823 A1,128-561-752-178-189,2016-07-28,2016,DE 102015122823 A,2015-12-23,US 201514595584 A,2015-01-13,"Verfahren und System zur reflektometriebasierten Überwachung, Intrusionserfassung und Mitteilungsauthentifizierung eines Kommunikationsnetzwerks","Systeme und Verfahren werden bereitgestellt zum Überwachen und Erfassen von Intrusionen und Authentifizieren von Mitteilungen in einem Kommunikationsnetzwerk eines Fahrzeugs. Eine Vielzahl von Signalen, welche über das Kommunikationsnetzwerk zwischen einem elektronischen Steuermodul und einem entfernten elektronischen Steuermodul übertragen werden, wird überwacht. Reflektometrie-Merkmalssätze werden von der Vielzahl der Signale extrahiert und mit einem Repositorium von vorbestimmten Kommunikationsnetzwerk-Merkmalssätzen verglichen, um einen Diskrepanzwert zu erzeugen. Der Diskrepanzwert wird mit einem vorbestimmten Schwellwert verglichen und ein authentifiziertes Ereignis tritt ein, wenn der Diskrepanzwert innerhalb des vorbestimmten Schwellwertbereichs liegt. Wenn der Diskrepanzwert außerhalb des vorbestimmten Schwellwertbereichs liegt, tritt ein markiertes Ereignis und wird aufgezeichnet.",GM GLOBAL TECH OPERATIONS LLC,LAIFENFELD MOSHE;;POLEVOY YUVAL;;JULSON TIMOTHY D;;BALTES KEVIN M;;COHEN OMER,,https://lens.org/128-561-752-178-189,Patent Application,no,0,0,6,6,0,H04L9/3247;;H04L63/1416;;H04B10/071;;H04L63/1416;;H04L63/1425;;H04B10/071;;H04B1/3822;;H04L63/08;;H04L63/123;;H04L63/1416;;H04L63/1425;;H04L67/12,H04L12/26,,0,0,,,,ACTIVE
161,US,B2,US 9578047 B2,053-263-279-288-811,2017-02-21,2017,US 201514595584 A,2015-01-13,US 201514595584 A,2015-01-13,"Method and system for reflectometry based communication network monitoring, intrusion detection, and message authentication","Systems and methods are provided for monitoring and detecting intrusions and authenticating messages on a communication network of a vehicle. A plurality of signals transmitted over communications network between an electronic control module and a remote electronic module are monitored. Reflectometry feature sets are extracted from the plurality of signals and compared to a repository of predetermined communication network feature sets to generate a mismatch value. The mismatch value is compared to a predetermined threshold range and an authenticated event occurs when the mismatch value is within the predetermined threshold range. When the mismatch value is outside the predetermined threshold range, a flagged event occurs and is recorded.",GM GLOBAL TECH OPERATIONS LLC,LAIFENFELD MOSHE;;POLEVOY YUVAL;;JULSON TIMOTHY D;;BALTES KEVIN M;;COHEN OMER,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2015-01-07),https://lens.org/053-263-279-288-811,Granted Patent,yes,16,4,6,6,0,H04L9/3247;;H04L63/1416;;H04B10/071;;H04L63/1416;;H04L63/1425;;H04B10/071;;H04B1/3822;;H04L63/08;;H04L63/123;;H04L63/1416;;H04L63/1425;;H04L67/12,H04L29/06;;H04B1/3822;;H04L29/08,,0,0,,,,ACTIVE
162,EP,A1,EP 2449978 A1,087-939-774-325-318,2012-05-09,2012,EP 12151531 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"A suture comprising: an elongate body including an outer surface; at least one barb extending from the elongated body and defining an inner surface, the inner surface including: a substantially linear first portion disposed at a first orientation relative to a first longitudinal axis of the elongate body, wherein the first portion is disposed at a first angle from about 31 degrees to about 38 degrees relative to the first longitudinal axis of the elongate body; and a substantially linear second portion disposed at a second orientation relative to a second longitudinal axis of the elongate body, wherein the second portion is disposed at a second angle from about 1 degree to about 8 degrees relative to the second longitudinal axis of the elongate body; wherein the barbs are equally spaced and project towards one end of the suture, wherein at least one end of the suture comprises a loop; and wherein the suture is formed of absorbable materials, non-absorbable materials and combinations thereof.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/087-939-774-325-318,Patent Application,yes,6,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,DISCONTINUED
163,AU,A,AU 1987/073484 A,081-977-036-793-266,1987-12-03,1987,AU 1987/073484 A,1987-05-28,US 86808386 A;;US 86827986 A,1986-05-29,EPOXY ACRYLIC/ACRYLIC/EPOXY ACRYLIC BLOCK COPOLYMERS,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/081-977-036-793-266,Patent Application,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,EXPIRED
164,US,B1,US 8028826 B1,110-764-532-737-694,2011-10-04,2011,US 69626510 A,2010-01-29,US 69626510 A,2010-01-29,Storage system for 25mm IM cartridges,"An improved 25 mm linked cartridge IM ammunition storage system, using existing ammunition cans, that simplifies the design of the storage system, and utilizes standoffs to separate the base of each cartridge from the ends of the ammunition can—thereby allowing the cartridges base IM venting system to vent properly, avoiding pressure build-up, and reducing the risk of explosion or detonation of the propellant.",US ARMY,WOO TIMOTHY;;MOY LEON;;COHEN ALAN N;;PRILLAMAN DANIEL LEE;;MORALES CHRISTINA,U.S. GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (2010-03-05),https://lens.org/110-764-532-737-694,Granted Patent,yes,8,5,1,1,0,F42B39/26;;F42B39/26;;F42B39/14;;F42B39/14;;F42B39/22;;F42B39/22;;Y10S224/931,F42B39/00,206/3;;206/589;;206/593;;224/931,1,0,,,"DTIC ""Technical Report ARAED-TR-93002"" dated Jun. 25, 1993.",INACTIVE
165,EP,A1,EP 2642397 A1,023-556-269-754-71X,2013-09-25,2013,EP 13158041 A,2013-03-06,US 201261614545 P;;US 201261614548 P;;US 201213566204 A,2012-03-23,System for dynamically adaptive caching,"The present disclosure is directed to a system for dynamically adaptive caching. The system includes a storage device having a physical capacity for storing data received from a host. The system may also include a control module for receiving data from the host and compressing the data to a compressed data size. Alternatively, the data may also be compressed by the storage device. The control module may be configured for determining an amount of available space on the storage device and also determining a reclaimed space, the reclaimed space being according to a difference between the size of the data received from the host and the compressed data size. The system may also include an interface module for presenting a logical capacity to the host. The logical capacity has a variable size and may include at least a portion of the reclaimed space.
",LSI CORP,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL;;CANEPA TIMOTHY,,https://lens.org/023-556-269-754-71X,Patent Application,yes,4,2,9,30,0,G06F12/08;;G06F12/0871;;G06F13/14;;G06F2212/1044;;G06F2212/401;;G06F2212/502;;G06F2212/657,G06F12/08;;G06F12/0871,,0,0,,,,DISCONTINUED
166,TW,A,TW 201241615 A,072-075-444-788-678,2012-10-16,2012,TW 101102013 A,2012-01-18,US 201161433918 P,2011-01-18,Higher-level redundancy information computation,"Higher-level redundancy information computation enables a solid-state Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD implemented in part by the controller. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data (e.g. a stripe) to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero ''index'' as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/072-075-444-788-678,Patent of Addition,no,0,6,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F11/16,,0,0,,,,PENDING
167,CN,A,CN 115336266 A,036-726-721-950-305,2022-11-11,2022,CN 202180022319 A,2021-03-23,US 202063011685 P;;US 202063034618 P;;US 202017070589 A;;US 2021/0023680 W,2020-04-17,Parallelized rate distortion optimized quantization using deep learning,"The video encoder determines scaled transform coefficients, where determining scaled transform coefficients includes scaling transform coefficients of a block of video data according to a given quantization step. The video encoder determines scalar quantized coefficients, wherein determining the scalar quantized coefficients includes applying scalar quantization to the scaled transform coefficients of the block. Further, the video encoder applies a neural network that determines, for each respective transform coefficient of the block, a respective set of probabilities. Each probability set for each transform coefficient includes a respective probability value for each of the plurality of possible adjustment values. The input of the neural network includes scaled transform coefficients and scalar quantized coefficients. A video encoder determines a quantization level for a particular transform coefficient of a block based on a set of probabilities for the particular transform coefficient.",QUALCOMM INC,CHIANFAR DAVID;;WIGGERS AARON J;;SYED ASIM;;COHEN TIMOTHY S;;PRYZA RAKESH,,https://lens.org/036-726-721-950-305,Patent Application,no,0,0,8,8,0,H04N19/117;;H04N19/124;;H04N19/147;;H04N19/157;;H04N19/176;;H04N19/18;;H04N19/463;;H04N19/48;;H04N19/80;;G06F30/27;;H04N19/61;;G06N3/084;;G06N3/082;;G06N3/045;;H04N19/124;;H04N19/147;;H04N19/157;;H04N19/117;;H04N19/176;;H04N19/18;;H04N19/463;;H04N19/48;;H04N19/80;;H04N19/13;;H04N19/61;;G06N3/045;;G06N3/047;;G06N3/084;;G06N3/082;;G06N5/01;;G06T9/002;;H04N19/176;;H04N19/61;;H04N19/124;;H04N19/18;;H04N19/13;;G06N3/02;;G06F30/27;;G05B13/00;;H04Q2213/343;;H04Q2213/13343;;Y10S706/00;;G06N3/047,H04N19/124;;H04N19/117;;H04N19/147;;H04N19/157;;H04N19/176;;H04N19/18;;H04N19/463;;H04N19/48,,0,0,,,,PENDING
168,US,A1,US 2014/0237166 A1,041-335-458-009-851,2014-08-21,2014,US 201414181252 A,2014-02-14,US 201414181252 A;;US 201313979805 A;;US 2012/0021682 W;;US 201161433918 P,2011-01-18,HIGHER-LEVEL REDUNDANCY INFORMATION COMPUTATION,"Higher-level redundancy information computation enables a Solid-State Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero “index” as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,SEAGATE TECHNOLOGY LLC (2014-09-02),https://lens.org/041-335-458-009-851,Patent Application,yes,2,1,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/02,711/103,0,0,,,,ACTIVE
169,EP,A1,EP 2449976 A1,191-045-985-722-804,2012-05-09,2012,EP 12151526 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device,"A compound barb medical device comprising an elongated body and a combination of compound barbs and single angle barbs formed along the length of the suture in specified or random patterns.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/191-045-985-722-804,Patent Application,yes,7,2,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
170,EP,A1,EP 2449981 A1,100-813-151-877-242,2012-05-09,2012,EP 12151537 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"A compound barb medical device comprising: an elongate body wherein the elongate body includes an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body and defining an inner surface, the elongated body including: a first cut angle of from about 0 degrees to about 90 degrees, preferably from about 30 degrees to 40 degrees, preferably from about 31 degrees to about 38 degrees relative to the longitudinal axis of the elongate body; and a second cut angle of from about 0 degrees to about 90 degrees, preferably from about 1 degree to about 10 degrees, preferably from about 1 degree to about 8 degrees relative to the longitudinal axis of the elongate body; and wherein the medical device is formed of absorbable materials, non-absorbable materials and combinations thereof.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/100-813-151-877-242,Patent Application,yes,6,2,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,DISCONTINUED
171,AU,B2,AU 600728 B2,180-100-192-366-870,1990-08-23,1990,AU 1987/073484 A,1987-05-28,US 86808386 A;;US 86827986 A,1986-05-29,EPOXY ACRYLIC/ACRYLIC/EPOXY ACRYLIC BLOCK COPOLYMERS,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/180-100-192-366-870,Granted Patent,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,EXPIRED
172,EP,B1,EP 2449980 B1,135-300-687-673-535,2016-09-14,2016,EP 12151535 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method of manufacturing,,COVIDIEN LP,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/135-300-687-673-535,Granted Patent,yes,1,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
173,DE,B4,DE 102015122823 B4,039-291-993-818-796,2023-08-31,2023,DE 102015122823 A,2015-12-23,US 201514595584 A,2015-01-13,"Verfahren und System zur reflektometriebasierten Überwachung, Intrusionserfassung und Mitteilungsauthentifizierung eines Kommunikationsnetzwerks","Ein Verfahren von einem Überwachen und Erfassen von Intrusionen in einem Kommunikationsnetzwerk, umfassend:- Überwachen einer Vielzahl von Kommunikationskanälen in dem Kommunikationsnetzwerk mit einem Reflektometer, wobei die Kommunikationskanäle jeweils eine Vielzahl von Signalen zwischen einem elektronischen Steuermodul und einem entfernten elektronischen Steuermodul übertragen;- Extrahieren eines Reflektometrie-Merkmalssatzes von jedem der Vielzahl der Signale, welche über jeden der Kommunikationskanäle übertragen werden;- Vergleichen der extrahierten Reflektometrie-Merkmalssätze mit einem Repositorium von vorbestimmten Kommunikationsnetzwerk-Merkmalssätzen, um einen Diskrepanzwert zu erzeugen;- Bestimmen, dass ein authentifiziertes Ereignis eingetreten ist, wenn der Diskrepanzwert innerhalb eines vorbestimmten Schwellwertbereichs liegt, und Fortsetzen, die Vielzahl von Kommunikationskanälen zu überwachen;- Bestimmen, dass ein markiertes Ereignis eingetreten ist, wenn der Diskrepanzwert außerhalb des vorbestimmten Schwellwertbereichs liegt; und- Aufzeichnen des markierten Ereignisses in einem Speichermodul.",GM GLOBAL TECH OPERATIONS LLC,LAIFENFELD MOSHE;;POLEVOY YUVAL;;JULSON TIMOTHY D;;BALTES KEVIN M;;COHEN OMER,,https://lens.org/039-291-993-818-796,Granted Patent,no,1,0,6,6,0,H04L9/3247;;H04L63/1416;;H04B10/071;;H04L63/1416;;H04L63/1425;;H04B10/071;;H04B1/3822;;H04L63/08;;H04L63/123;;H04L63/1416;;H04L63/1425;;H04L67/12,H04L43/02;;B60R16/023;;G01R31/11;;H04B1/3822;;H04B10/071;;H04L9/40;;H04L41/06;;H04L43/00;;H04L43/04;;H04L43/06;;H04L43/16,,0,0,,,,ACTIVE
174,TW,A,TW 201232264 A,094-977-148-346-729,2012-08-01,2012,TW 100144228 A,2011-12-01,US 41884610 P;;US 201161433918 P,2010-12-01,Dynamic higher-level redundancy mode management with independent silicon elements,"A Solid-State Disk (SSD) controller enables dynamic higher-level redundancy mode management with independent silicon elements to provide graceful degradation as non-volatile (e.g. flash) memory elements fail during operation of an SSD implemented by the controller. Higher-level error correction provides correction of lower-level uncorrectable errors. If a failure of one of the non-volatile memory elements is detected, then the higher-level error correction is dynamically transitioned from operating in a current mode to operating in a new mode. The transition includes one or more of reducing free space available on the SSD, rearranging data storage of the SSD, recovering/storing failed user data (if possible), and determining/storing revised higher-level error correction information. Operation then continues in the new mode. If another failure of the non-volatile memory elements is detected, then another transition is made to another new mode.",LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,,https://lens.org/094-977-148-346-729,Patent of Addition,no,0,3,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G06F12/16;;G06F12/02,,0,0,,,,PENDING
175,EP,A1,EP 2449980 A1,162-020-899-755-164,2012-05-09,2012,EP 12151535 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method of manufacturing,"A compound barb medical device comprising: an elongated body; at least one barb extending from the elongated body and defining an inner surface, the inner surface including: a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, a second portion disposed at a second orientation relative to the longitudinal axis, and a third portion disposed at a third orientation relative to the longitudinal axis.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/162-020-899-755-164,Patent Application,yes,7,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
176,EP,A1,EP 2449979 A1,045-298-191-410-050,2012-05-09,2012,EP 12151532 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device,"A suture comprising: an elongate body including an outer surface; at least one barb extending from the elongated body and defining an inner surface, the inner surface including: a substantially linear first portion disposed at a first orientation relative to a first longitudinal axis of the elongate body, wherein the first portion is disposed at a first angle from about 31 degrees to about 38 degrees relative to the first longitudinal axis of the elongate body; and a substantially linear second portion disposed at a second orientation relative to a second longitudinal axis of the elongate body, wherein the second portion is disposed at a second angle from about 1 degree to about 8 degrees relative to the second longitudinal axis of the elongate body; wherein the barbs are equally spaced and project towards one end of the suture, wherein at least one end of the suture comprises a loop; and wherein the suture is formed of absorbable materials, non-absorbable materials and combinations thereof.
",TYCO HEALTHCARE,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/045-298-191-410-050,Patent Application,yes,6,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
177,US,S,US D0514108 S,164-945-550-852-76X,2006-01-31,2006,US 20553804 F,2004-05-17,US 20553804 F,2004-05-17,Housing for a communication interface adapter or similar articles,,MOTOROLA INC,BAHAR DALIT;;ASSIF LIOR;;COHEN-GERS SHLOMO;;MCKEOWN TIMOTHY E;;SHOVAL AVIV,MOTOROLA MOBILITY LLC (2010-07-31);;MOTOROLA INC (2004-08-15),https://lens.org/164-945-550-852-76X,Design Right,no,0,4,1,1,0,,,1402;;D14/433,0,0,,,,EXPIRED
178,EP,B1,EP 2449976 B1,185-955-312-272-074,2015-09-16,2015,EP 12151526 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device,,COVIDIEN LP,COHEN MATTHEW;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/185-955-312-272-074,Granted Patent,yes,4,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
179,US,A1,US 2013/0246839 A1,000-823-199-488-143,2013-09-19,2013,US 201113989659 A,2011-11-30,US 201113989659 A;;US 41884610 P;;US 201161433918 P;;US 2011/0062726 W,2010-12-01,DYNAMIC HIGHER-LEVEL REDUNDANCY MODE MANAGEMENT WITH INDEPENDENT SILICON ELEMENTS,"A Solid-State Disk (SSD) controller enables dynamic higher-level redundancy mode management with independent silicon elements to provide graceful degradation as non-volatile (e.g. flash) memory elements fail during operation of an SSD implemented by the controller. Higher-level error correction provides correction of lower-level uncorrectable errors. If a failure of one of the non-volatile memory elements is detected, then the higher-level error correction is dynamically transitioned from operating in a current mode to operating in a new mode. The transition includes one or more of reducing free space available on the SSD, rearranging data storage of the SSD, recovering/storing failed user data (if possible), and determining/storing revised higher-level error correction information. Operation then continues in the new mode. If another failure of the non-volatile memory elements is detected, then another transition is made to another new mode.",WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T;;LSI CORP,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,SANDFORCE INC (2011-12-07);;SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-01-04),https://lens.org/000-823-199-488-143,Patent Application,yes,9,20,13,37,0,G06F11/08;;G06F11/1044;;G11B20/1883;;G06F11/1044;;G06F11/108;;G06F11/108;;G06F12/16;;H03M13/353;;H03M13/353,G11B20/18,714/6.13,0,0,,,,INACTIVE
180,CA,C,CA 1291285 C,049-131-604-194-220,1991-10-22,1991,CA 537595 A,1987-05-21,US 86808386 A,1986-05-29,PREPARATION OF DURABLE EPOXY (METH)ACRYLIC POLYMER WITH OXIRANE-CONTAINING TERMINAL GROUPS,"TITLE Preparation of durable Epoxy (Meth)Acrylic Polymer with Oxirane -Containing Terminal Groups A process for the preparation of an acrylic, curable epoxy resin having an ABA block copolymer structure, wherein each A block end segment contains a terminal oxirane group and the B block centre segment is of acrylate or methacrylate units, using group transfer polymerization, is disclosed. Epoxy resins may be used in coatings, adhesives, castings, laminates and the like",DU PONT,SPINELLI HARRY J;;HUTCHINS CLYDE S;;COSTELLO TIMOTHY D;;COHEN GORDON M,,https://lens.org/049-131-604-194-220,Granted Patent,no,0,0,3,36,0,,C08F297/00;;C07C/;;C08F293/00;;C08F297/06;;C08G59/32;;C08L/,D34002018    M,0,0,,,,EXPIRED
181,DK,D0,DK 271587 D0,106-886-485-819-291,1987-05-27,1987,DK 271587 A,1987-05-27,US 86827986 A;;US 86808386 A,1986-05-29,FREMSTILLING AF HOLDBAR EPOXY-(METH)ACRYLPOLYMER MED OXIRAN-HOLDIGE ENDESTILLEDE GRUPPER,,DU PONT,SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENSER;;COSTELLO TIMOTHY DAVID;;COHEN GORDON MARK,,https://lens.org/106-886-485-819-291,Patent Application,no,0,0,11,36,0,C08F293/005;;C08F293/00,C08F293/00,,0,0,,,,DISCONTINUED
182,US,A1,US 2016/0205117 A1,021-897-903-824-90X,2016-07-14,2016,US 201514595584 A,2015-01-13,US 201514595584 A,2015-01-13,"METHOD AND SYSTEM FOR REFLECTOMETRY BASED COMMUNICATION NETWORK MONITORING, INTRUSION DETECTION, AND MESSAGE AUTHENTICATION","Systems and methods are provided for monitoring and detecting intrusions and authenticating messages on a communication network of a vehicle. A plurality of signals transmitted over communications network between an electronic control module and a remote electronic module are monitored. Reflectometry feature sets are extracted from the plurality of signals and compared to a repository of predetermined communication network feature sets to generate a mismatch value. The mismatch value is compared to a predetermined threshold range and an authenticated event occurs when the mismatch value is within the predetermined threshold range. When the mismatch value is outside the predetermined threshold range, a flagged event occurs and is recorded.",GM GLOBAL TECH OPERATIONS INC,LAIFENFELD MOSHE;;POLEVOY YUVAL;;JULSON TIMOTHY D;;BALTES KEVIN M;;COHEN OMER,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2015-01-07),https://lens.org/021-897-903-824-90X,Patent Application,yes,0,24,6,6,0,H04L9/3247;;H04L63/1416;;H04B10/071;;H04L63/1416;;H04L63/1425;;H04B10/071;;H04B1/3822;;H04L63/08;;H04L63/123;;H04L63/1416;;H04L63/1425;;H04L67/12,H04L29/06;;H04B1/3822;;H04L29/08,,0,0,,,,ACTIVE
183,US,B2,US 9183140 B2,159-126-287-312-546,2015-11-10,2015,US 201414181252 A,2014-02-14,US 201414181252 A;;US 201313979805 A;;US 2012/0021682 W;;US 201161433918 P,2011-01-18,Higher-level redundancy information computation,"Higher-level redundancy information computation enables a Solid-State Disk (SSD) controller to provide higher-level redundancy capabilities to maintain reliable operation in a context of failures of non-volatile (e.g. flash) memory elements during operation of an SSD. A first portion of higher-level redundancy information is computed using parity coding via an XOR of all pages in a portion of data to be protected by the higher-level redundancy information. A second portion of the higher-level redundancy information is computed using a weighted-sum technique, each page in the portion being assigned a unique non-zero “index” as a weight when computing the weighted-sum. Arithmetic is performed over a finite field (such as a Galois Field). The portions of the higher-level redundancy information are computable in any order, such as an order based on order of read operation completion of non-volatile memory elements.",SEAGATE TECHNOLOGY LLC,WERNER JEREMY ISAAC NATHANIEL;;BARYUDIN LEONID;;CANEPA TIMOTHY LAWRENCE;;COHEN EARL T,SEAGATE TECHNOLOGY LLC (2014-09-02),https://lens.org/159-126-287-312-546,Granted Patent,yes,47,4,15,37,0,G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246;;G06F12/16;;G06F11/08;;G06F11/1044;;G06F11/108;;G06F11/2094;;G06F12/0246,G06F12/02;;G06F11/10;;G06F11/20,,11,0,,,"European Search Report for EP11837032, Jun. 23, 2014, 6 pages.;;Notice to File a Response, Korean Intellectual Property Office for KR 10-2013-7013372, Aug. 21, 2014, 10 pages.;;International Search Report and Written Opinion in PCT/US2013/051720, 10 pages.;;International Search Report and Written Opinion in PCT/US2013/051726, 9 pages.;;Feb. 6, 2015 List of References Used in Art Rejections, 1 pg.;;International Search Report and the Written Opinion for PCT/US12/21682, 9 pages.;;Office Action and Search Report for CN2011800666799, Apr. 18, 2014, 16 pages.;;International Preliminary Report on Patentability for PCT/US2012/021682, filed Jan. 18, 2012, mailed Jul. 23, 2013, 5 pgs.;;LSI Corporation; Korean Office Action for 10-2014-7019498, filed Jul. 14, 2014, mailed Dec. 8, 2014, 7 pgs.;;LSI Corporation; Korea Office Action for serial No. 10-2013-7021636, filed Jun. 20, 2014, mailed Jan. 13, 2014, 5 pgs.;;Werner, et al; Japanese Office Action for serial No. 2013-550554, filed Jan. 18, 2012, mailed Mar. 10, 2015, 4 pgs.",ACTIVE
184,CN,A,CN 105791266 A,173-873-809-138-685,2016-07-20,2016,CN 201610019922 A,2016-01-13,US 201514595584 A,2015-01-13,"Method And System For Reflectometry Based Communication Network Monitoring, Intrusion Detection, And Message Authentication","Systems and methods are provided for monitoring and detecting intrusions and authenticating messages on a communication network of a vehicle. A plurality of signals transmitted over communications network between an electronic control module and a remote electronic module are monitored. Reflectometry feature sets are extracted from the plurality of signals and compared to a repository of predetermined communication network feature sets to generate a mismatch value. The mismatch value is compared to a predetermined threshold range and an authenticated event occurs when the mismatch value is within the predetermined threshold range. When the mismatch value is outside the predetermined threshold range, a flagged event occurs and is recorded.",GM GLOBAL TECH OPERATIONS LLC,KEVIN M BALTES;;OMER COHEN;;TIMOTHY D JULSON;;MOSHE LAIFENFELD;;YUVAL POLEVOY,,https://lens.org/173-873-809-138-685,Patent Application,no,4,6,6,6,0,H04L9/3247;;H04L63/1416;;H04B10/071;;H04L63/1416;;H04L63/1425;;H04B10/071;;H04B1/3822;;H04L63/08;;H04L63/123;;H04L63/1416;;H04L63/1425;;H04L67/12,H04L29/06;;H04L9/32,,0,0,,,,ACTIVE
185,AR,A1,AR 108864 A1,162-383-466-811-696,2018-10-03,2018,AR P170101736 A,2017-06-22,US 201662353910 P,2016-06-23,AGENTES ANTIBACTERIANOS,"Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal aceptable farmacéuticamente, hidrato, solvato, profármaco, estereoisómero, o tautómero del mismo, donde: X es S(O)q o NR⁶; A es C₆₋₁₀ arilo, heteroarilo, C₃₋₇ cicloalquilo, C₄₋₇ cicloalquenilo, o heterocicloalquilo, donde el arilo, heteroarilo, cicloalquilo, cicloalquenilo, o heterocicloalquilo está sustituido opcionalmente con uno o más R⁷; B es -CºC=R³, -CºC-CºC-R³, -CºC-CH=CH-R³, C₁₋₄ alquilo, C₁₋₄ haloalquilo, -OR⁸, -S(O)ʳR⁸, halógeno, C₆₋₁₀ arilo, heteroarilo, o -SF₅, donde el arilo o heteroarilo está sustituido opcionalmente con R²; R¹ es H, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, C₁₋₄ haloalcoxi, -(CH₂)ₘ-C₃₋₇ cicloalquilo, -(CH₂)ₘ-heterocicloalquilo, -O(CH₂)ₘ-C₃₋₇ cicloalquilo, -O(CH₂)ₘ-heterocicloalquilo, halógeno, -S(O)ₚ-C₁₋₄ alquilo, -OH, -(CH₂)ₙNH₂, -(CH₂)ₙ-C₁₋₄ alquilamino, o -(CH₂)ₙ-C₁₋₄ dialquilamino; R² es C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, C₁₋₄ haloalcoxi, halógeno, -OH, -NH₂, o -CN; R³ es H, C₁₋₄ alquilo, C₃₋₇ cicloalquilo, heterocicloalquilo, o heteroarilo, donde el alquilo está sustituido opcionalmente con uno o más R⁴, y donde el cicloalquilo, heterocicloalquilo, o heteroarilo está sustituido opcionalmente con uno o más R⁵; cada R⁴ es en forma independiente en cada caso -OH, -NH₂, C₁₋₄ alcoxi, C₁₋₄ alquilamino, o C₁₋₄ dialquilamino; cada R⁵ es en forma independiente en cada caso C₁₋₄ alquilo, C₁₋₄ haloalquilo, C₁₋₄ alcoxi, C₁₋₄ haloalcoxi, halógeno, C₁₋₄ hidroxialquilo, -C(O)H, -C(=O)C₁₋₄ alquilo, -OH, -NH₂, C₁₋₄ alquilamino, C₁₋₄ dialquilamino, o -S(O)ₚ-C₁₋₄ alquilo; R⁶ es H, C₁₋₄ alquilo, C₁₋₄ hidroxialquilo, -C(O)H, -C(O)C₁₋₄ alquilo, -S(O)ʳ-C₁₋₄ alquilo, o -C(O)OC₁₋₄ alquilo; cada R⁷ es en forma independiente en cada caso C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, C₁₋₄ haloalcoxi, o halógeno; o dos R⁷ en átomos adyacentes junto con los átomos a los que están unidos forman un anillo C₆₋₁₀ arilo opcionalmente sustituido con uno o más R⁹; o dos R⁷ en átomos adyacentes junto con los átomos a los que están unidos forman un anillo heteroarilo opcionalmente sustituido con uno o más R⁹; o dos R⁷ en átomos adyacentes junto con los átomos a los que están unidos forman un anillo C₄₋₈ cicloalquilo opcionalmente sustituido con uno o más R⁹; o dos R⁷ en átomos adyacentes junto con los átomos a los que están unidos forman un anillo heterocicloalquilo opcionalmente sustituido con uno o más R⁹; R⁸ es C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, C₁₋₄ haloalquilo, o C₃₋₆ cicloalquilo, donde el alquilo, alquenilo, o alquinilo está sustituido opcionalmente con uno o más sustituyentes seleccionados entre el grupo que consiste en C₃₋₇ cicloalquilo y heterocicloalquilo; cada R⁹ es en forma independiente en cada caso C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, C₁₋₄ haloalcoxi, o halógeno; cada R’ es C₁₋₄ alquilo; o es 1 ó 2; s es 0, 1, ó 2; cada q, p, y r es en forma independiente en cada caso 0, 1, ó 2; y cada m y n es en forma independiente en cada caso 0, 1, 2, ó 3.",ACHAOGEN INC,HILDEBRANDT DARIN JAMES;;KANE TIMOTHY ROBERT;;MACHAJEWSKI TIMOTHY D;;CHOI TAYLOR ANN JOO;;KONRADI ANDREI W;;COHEN FREDERICK,,https://lens.org/162-383-466-811-696,Patent Application,no,0,0,3,3,0,A61P31/04;;C07D331/04;;C07D205/04,C07D331/04;;A61K31/38;;A61K31/381;;A61K31/397;;A61K31/4025;;A61P31/04;;C07D205/04;;C07D207/12;;C07D409/12;;C07F9/547,,0,0,,,,PENDING
186,TW,A,TW 201803847 A,111-066-504-121-583,2018-02-01,2018,TW 106120880 A,2017-06-22,US 201662353910 P,2016-06-23,Antibacterial agents,"The disclosure relates to antibacterial compounds having the Formula: where R1, R', A, B, X, s, and o are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.",ACHAOGEN INC,COHEN FREDERICK;;KONRADI ANDREI W;;CHOI TAYLOR ANN JOO;;MACHAJEWSKI TIMOTHY D;;KANE TIMOTHY ROBERT;;HILDEBRANDT DARIN JAMES,,https://lens.org/111-066-504-121-583,Patent of Addition,no,0,1,3,3,0,A61P31/04;;C07D331/04;;C07D205/04,C07D205/04;;A61K31/38;;A61K31/381;;A61K31/397;;A61K31/4535;;A61K31/496;;A61K31/67;;A61P31/04;;C07D331/04;;C07D333/48;;C07D409/12;;C07F9/6553,,0,0,,,,PENDING
187,WO,A1,WO 2017/223349 A1,150-146-281-390-43X,2017-12-28,2017,US 2017/0038815 W,2017-06-22,US 201662353910 P,2016-06-23,ANTIBACTERIAL AGENTS,"The disclosure relates to antibacterial compounds having the Formula (I), where R1, R', A, B, X, s, and o are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.",ACHAOGEN INC,COHEN FREDERICK;;KONRADI ANDREI W;;CHOI TAYLOR ANN JOO;;MACHAJEWSKI TIMOTHY D;;KANE TIMOTHY ROBERT;;HILDEBRANDT DARIN JAMES,,https://lens.org/150-146-281-390-43X,Patent Application,yes,25,8,3,3,0,A61P31/04;;C07D331/04;;C07D205/04,C07D331/04;;A61K31/397;;A61P31/04;;C07D205/04,,5,3,052-786-510-319-542;;063-057-186-495-585;;077-295-491-167-117,10.1074/jbc.275.15.11002;;10753902;;10.1016/s0966-842x(98)01230-x;;9587193;;10.1002/0471220574,"JACKMAN ET AL., J. BIOL. CHEM., vol. 275, no. 15, 2000, pages 11002 - 11009;;WYCKOFF ET AL., TRENDS IN MICROBIOLOGY, vol. 6, no. 4, 1998, pages 154 - 159;;T. W. GREENE; P. G. M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;;E. L. ELIEL; S. H. WILEN; L. N. MANDER: ""Stereochemistry of Organic Compounds"", 1994, WILEY-INTERSCIENCE;;REMINGTON: ""The Science and Practice of Pharmacy, Mack Publishing Company"", 1995",PENDING
188,CN,A,CN 116207762 A,003-667-692-773-666,2023-06-02,2023,CN 202211432361 A,2022-11-15,US 202117539535 A,2021-12-01,Control of dark start auxiliary battery for bi-directional power transfer inverter,The invention provides control of a dark start auxiliary battery for a bi-directional power transfer inverter. A power system includes: a bidirectional power transfer inverter that receives grid power and is electrically connectable with electric vehicle power supply equipment; and an auxiliary battery electrically connected with the bidirectional power transfer inverter and supplying power to the bidirectional power transfer inverter and electric vehicle power supply equipment when the grid power is not available.,FORD GLOBAL TECH LLC,HARRIS TIMOTHY;;SALTER STUART C;;O 'GORMAN ROBERT;;PUNG PETER;;HOWARD-COHEN KATHERINE,,https://lens.org/003-667-692-773-666,Patent Application,no,0,0,4,4,0,H02J3/322;;H02J3/32;;H02J9/06;;H02J7/00712;;H02J7/0068;;B60L58/10;;H01M10/615;;H01M10/633;;H01M10/625;;H01M10/44;;H01M2220/20;;Y02T10/7072;;Y02T10/70;;H02J3/381;;H02J7/007194;;H02J3/322;;H02J7/0048;;H02J7/00712;;H02J7/35;;B60R16/033;;B60L55/00;;B60L53/53;;B60L53/51;;B60L3/0092;;H01M2220/10;;H01M10/615;;H01M10/627;;H01M2220/20;;H01M10/465;;H01M10/443;;H02J7/007194;;H01M2220/10;;B60L1/02;;B60L58/12;;B60L53/53;;B60L55/00;;B60R16/033;;H02J7/00712;;H02J3/381;;H02J3/322;;H02J7/0048;;H01M10/615;;H01M10/627;;H01M10/443;;H01M10/465;;H02J2300/24;;B60L58/27,H02J3/32;;B60L58/10;;H01M10/44;;H01M10/615;;H01M10/625;;H01M10/633;;H02J7/00;;H02J9/06,,0,0,,,,PENDING
189,CA,C,CA 2949904 C,085-734-903-627-151,2018-12-18,2018,CA 2949904 A,2009-02-18,US 2996408 P;;US 36196209 A;;CA 2654655 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device comprising: an elongated body; at least one barb extending from the elongated body and defining an inner surface, the inner surface including: a first linear portion disposed at a first orientation relative to a longitudinal axis of the elongated body, a second linear portion disposed at a second orientation relative to the longitudinal axis, and a third linear portion disposed at a third orientation relative to the longitudinal axis.",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/085-734-903-627-151,Granted Patent,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,,0,0,,,,INACTIVE
190,US,B2,US 10729429 B2,092-403-216-272-747,2020-08-04,2020,US 201715658449 A,2017-07-25,US 201715658449 A;;US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/092-403-216-272-747,Granted Patent,yes,174,4,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,39,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"Australian Examination Report from Appl. No. AU 2015200379 dated Apr. 8, 2016.;;Extended European Search Report from EP Appl. No. 16159329.8-1654 dated Jul. 7, 2016.;;European Examination Report from Appl. No. 11250329.7-1654 dated Aug. 17, 2016.;;Canadian Office Action from Appl. No. CA 2,733,805 dated Jul. 28, 2016.;;Australian Examination Report from Appl. No. AU 2015200379 dated Jun. 24, 2016.;;Canadian Office Action from Appl. No. 2,654,655 dated Mar. 23, 2016.;;Austalian Examination Report from Appl. No. 2015200379 dated Feb. 4, 2016.;;First Office Action, and English Translation, from Chinese Applicaiton No. 201410073521X dated Jun. 23, 2015.;;Australian Examination Report dated May 15, 2015 in Application No. AU 2011201185.;;Japanese Final Official Action with English translation dated Apr. 9, 2015 from Application No. JP 2011-061379.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, “An Innovative Surgical Suture and Needle . . . ” 12(4), pp. 211-229 (2002).;;George Odian, “Principles of Polymerization,” III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report for corresponding EP 07 25 4321, date of completion is Apr. 20, 2009.;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.;;European Search Report, Application No. 10014285.0 dated Mar. 27, 2014.;;European Examination Report issued on Oct. 12, 2017 in Appl. No. EP 16 159 329.8 (4 pp.).;;Australian Examination Report issued in Appl. No. AU 2017202006 dated Oct. 11, 2017 (3 pages).;;European Office Action issued in corresponding Appl. No. EP 16 159 329.8 dated Dec. 5, 2019 (4 pages).",ACTIVE
191,US,B2,US 9050082 B2,112-956-874-734-134,2015-06-09,2015,US 201414257030 A,2014-04-21,US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/112-956-874-734-134,Granted Patent,yes,138,3,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,26,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle . . . "" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization,"" III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report for corresponding EP 07 25 4321, date of completion is Apr. 20, 2009.;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.;;European Search Report, Application No. 10014285.0 dated Mar. 27, 2014.",ACTIVE
192,US,B2,US 8726481 B2,134-867-556-665-00X,2014-05-20,2014,US 201213348006 A,2012-01-11,US 201213348006 A;;US 17836108 A;;US 99417307 P,2007-09-17,Method of forming barbs on a suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;COVIDIEN LP,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/134-867-556-665-00X,Granted Patent,yes,51,6,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B23P25/00;;A61B17/04,29/458;;606/228,5,0,,,"European Search Report for EP 08253030.4-2310 date of completion is Sep. 18, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for EP 12164986.7-2310 date of completion is Jun. 22, 2012 (6 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.",ACTIVE
193,US,B2,US 8632567 B2,176-888-427-883-699,2014-01-21,2014,US 201213593688 A,2012-08-24,US 201213593688 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/176-888-427-883-699,Granted Patent,yes,100,3,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,606/228,23,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"U.S. Appl. No. 60/994,173, filed Sep. 2007, Maiorino et al.;;R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle Evaluation and Selection Program"" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization,"" III Edition, pp. 569-573 (1991).;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.",ACTIVE
194,US,A1,US 2009/0241041 A1,186-338-558-372-828,2009-09-24,2009,US 5210208 A,2008-03-20,US 5210208 A,2008-03-20,POSITION CODE BASED CONTENT DEVELOPMENT METHOD AND TOOL,"Computerized content development methods and tools are disclosed. In one embodiment, a method includes generating a title by assigning one or more functions to respective portions of one or more position-coded pages through a graphical user interface which does not require a code level programming, and automatically converting the title to a format operable by computing device which interacts with a printed medium of the position-coded pages to perform the functions.",LEAPFROG ENTPR INC,COZINE ANDY;;MUSOLF TOM;;FREDENBURG TIMOTHY;;COHEN TAMAR;;KUGELGEN BRUCE VON;;SCHUERHOLZ DON,LEAPFROG ENTERPRISES INC (2008-03-06),https://lens.org/186-338-558-372-828,Patent Application,yes,4,0,1,1,0,G06F3/0483;;G06F3/0483;;G06F3/03545;;G06F3/03545,G06F3/00,715/762,0,0,,,,DISCONTINUED
195,US,B2,US 11861450 B2,038-887-801-426-546,2024-01-02,2024,US 202217987042 A,2022-11-15,US 202217987042 A;;US 202117140843 A,2021-01-04,Multiplexed quick response (“QR”) code experience derivation,"An optical code scanner being operated using an algorithm is provided. The scanner may scan an optical label. The label may include machine-readable code. The scanner may derive a single set of instructions from the code or multiple sets of instructions from the code. The scanner may process the code. The processing may upload a set of instructions from the code to the scanner and store the set of instructions in an instructions library. The scanner may also derive a picture associated with the instructions and store the picture in the library. The scanner may display a plurality of pictures. Each of the pictures may correspond to a set of uploaded instructions stored on the scanner. Each of the plurality of pictures may be selectable by a user. In response to a user selection of a picture, the scanner may be configured to execute the uploaded instructions that correspond to the selected picture.",THE DTX COMPANY,COHEN NEIL WAYNE;;LEMMON TIMOTHY J;;SHING DAVID;;DUPLESSIE ANDREW;;DEVLIN PATRIK ANDREW,,https://lens.org/038-887-801-426-546,Granted Patent,yes,87,0,4,4,0,G06F21/56;;G06F2221/034;;G06K19/14;;G06K19/06037;;H04L9/3247;;G09C5/00;;G06K7/1417;;G06F2221/034;;H04L9/0861;;G06F21/56,G06K7/14;;G06F21/56;;H04L9/08,,21,1,081-219-474-303-287,10.1016/j.procs.2016.04.081,"Inderscience Enterprises Ltd., Wickramasinghe et al., “A Mathematical Model for Computational Aesthetics,” pp. 310-324, 2010, Int. J. Computational Vision and Robotics, vol. 1, No. 3.;;Elsevier, Maity et al., “A Computational Model to Predict Aesthetic Quality of Text Elements of GUI,” pp. 152-159, 2016, Procedia Computer Science 84 (2016), www.sciencedirect.com.;;AI Shack, Utkarsh Sinha, “Scanning QR Codes,” 2010, https://aishack.in/tutorials/scanning-qr-codes-1/.;;AIA Vision Online, “The Most Common Causes of Unreadable Barcodes,” Apr. 15, 2015, https://www.visiononline.org/vision-resources-details.cfm?content id=5404.;;Workwithcolor.com, “Color Properties/Terminology,” Retrieved on Jun. 8, 2020, http://www.workwithcolor.com/color-properties-definitions-0101.htm,.;;The Eurographics Association, Florian Hoenig, “Defining Computational Aesthetics,” 2005, Computational Aesthetics in Graphics, Visualization and Imaging (2005), www.diglib.eg.org.;;DataGenetics, “Wounded QR Codes,” Nov. 2013, http://datagenetics.com/blog/november12013/index.html.;;QR Code Monkey, “6 Reasons Why Your QR Code Is Not Working,” Retrieved on Jun. 9, 2020, https://www.grcode-monkey.com/6-reasons-why-your-qr-code-is-not-working.;;TechSpot, Inc., Mark Turner, “QR Codes Explained,” Sep. 3, 2018, https://www.techspot.com/guides/1676-qr-code-explained/.;;Medium.com, Sciforce, “Computational Aesthetics: Shall We Let Computers Measure Beauty?,” Jun. 12, 2020, https://medium.com/sciforce/computational-aesthetics-shall-we-let-computers-measure-beauty-db2205989fb.;;Thonky.com, “Module Placement in Matrix,” Retrieved on Jun. 8, 2020, https://www.thonky.com/qr-code-tutorial/module-placement-matrix.;;Keyence Corporation of America, “What Is a QR Code,” Retrieved on Jun. 8, 2020, https://www.keyence.com/ss/products/auto_id/barcode_lecture/basic_2d/gr/.;;Wikimedia Foundation, Inc., “QR Code,” Retrieved on Jun. 3, 2020, https://en.wikipedia.org/wiki/QR_code.;;Wikimedia Foundation, Inc., Walter Tuveli, “QR Code—Structure,” 2012, https://en.wikipedia.org/wiki/QR_code#/media/File:QRCode-2-Structure.png.;;Wikimedia Foundation, Inc., “ShotCode,” Retrieved on Aug. 6, 2021, https://en.wikipedia.org/wiki/ShotCode#searchInput.;;Medium.com, Punit Pathak, “ETL-Understanding It and Effectively Using It,” Jan. 7, 2019, https://medium.com/hashmapinc/etl-understanding-it-and-effectively-using-it-f827a5b3e54d.;;Strathmore University (Nairobi, Kenya), Kizi Dimira Othuon, “Improving Customer Experience Using an Android Barcode Reader Application,” Apr. 2018, https://su-plus.strathmore.edu/bitstream/handle/11071/5978/Improving%20customer%20shopping%20experience%20using%20an%20Android%20barcode%20reader%20application.pdf?sequence=1&isAllowed=y.;;Westboroughtv.org, Horrigan, Aidan, “Mr. WHS 2020,” Jun. 12, 2020, https://westboroughtv.org/mr-whs-2020-2/.;;Facebook.com, Wa, Izakaya, “QR codes for the dinner menu and lunch menu at Memorial!” Jul. 24, 2020, https://m.facebook.com/196433773873837/posts/qr-codes-for-the-dinner-menu-and-lunch-menu-at-memorial.1730306280486571.;;Ispot.tv, “StockX TV Spot, ‘Flowcode: Never Sold Out,”’ Mar. 27, 2020, https://www.ispot.tv/ad/nVly/stockx-flowcode-never-sold-out.;;Nyp.org, “#FitForTheFrontline Challenge Unites Nation's Top Medical Centers to Support Frontline Healthcare Workers,” May 28, 2020, https://www.nyp.org/news/fit-for-the-frontline-challenge.",ACTIVE
196,US,A1,US 2009/0076543 A1,046-656-182-315-493,2009-03-19,2009,US 17836108 A,2008-07-23,US 17836108 A;;US 99417307 P,2007-09-17,Method of Forming Barbs on a Suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,TYCO HEALTHCARE,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/046-656-182-315-493,Patent Application,yes,26,31,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,A61B17/04,606/228,0,0,,,,ACTIVE
197,US,A1,US 2023/0077182 A1,051-510-660-863-013,2023-03-09,2023,US 202217987042 A,2022-11-15,US 202217987042 A;;US 202117140843 A,2021-01-04,"MULTIPLEXED QUICK RESPONSE (""QR"") CODE EXPERIENCE DERIVATION","An optical code scanner being operated using an algorithm is provided. The scanner may scan an optical label. The label may include machine-readable code. The scanner may derive a single set of instructions from the code or multiple sets of instructions from the code. The scanner may process the code. The processing may upload a set of instructions from the code to the scanner and store the set of instructions in an instructions library. The scanner may also derive a picture associated with the instructions and store the picture in the library. The scanner may display a plurality of pictures. Each of the pictures may correspond to a set of uploaded instructions stored on the scanner. Each of the plurality of pictures may be selectable by a user. In response to a user selection of a picture, the scanner may be configured to execute the uploaded instructions that correspond to the selected picture.",THE DTX COMPANY,COHEN NEIL WAYNE;;LEMMON TIMOTHY J;;SHING DAVID;;DUPLESSIE ANDREW;;DEVLIN PATRIK ANDREW,,https://lens.org/051-510-660-863-013,Patent Application,no,1,0,4,4,0,G06F21/56;;G06F2221/034;;G06K19/14;;G06K19/06037;;H04L9/3247;;G09C5/00;;G06K7/1417;;G06F2221/034;;H04L9/0861;;G06F21/56,G06K7/14;;G06F21/56;;H04L9/08,,0,0,,,,ACTIVE
198,CN,A,CN 116260171 A,051-931-188-047-172,2023-06-13,2023,CN 202211427044 A,2022-11-15,US 202117539518 A,2021-12-01,Bidirectional power transfer inverter and electric vehicle power supply equipment,The invention provides a bidirectional power transfer inverter and electric vehicle power supply equipment. A power system includes: a bidirectional power transfer inverter that receives grid power; and an auxiliary battery electrically connected to the bidirectional power transfer inverter. The auxiliary battery supplies power to the bi-directional power transfer inverter to activate circuitry of the bi-directional power transfer inverter when the grid power is unavailable.,FORD GLOBAL TECH LLC,HARRIS TIMOTHY;;SALTER STUART C;;O 'GORMAN ROBERT;;PUNG PETER;;HOWARD-COHEN KATHERINE,,https://lens.org/051-931-188-047-172,Patent Application,no,0,0,3,3,0,H02J3/322;;B60L55/00;;H02M7/66;;H02J2310/48;;Y02T10/7072;;Y02T10/70;;H02M1/327;;H02M7/48;;B60L55/00;;B60L53/51;;B60L53/53;;B60L3/0092;;B60L53/63;;B60L53/62;;B60L53/66;;B60L53/63;;B60L53/305;;H02M7/797;;B60L53/66;;B60L55/00;;B60L53/62,H02J3/32;;B60L55/00;;H02M7/66,,0,0,,,,PENDING
199,CN,A,CN 116533789 A,096-997-429-315-268,2023-08-04,2023,CN 202310056163 A,2023-01-20,US 202217584665 A,2022-01-26,Charging adapter for supporting bidirectional energy transfer between multiple energy units,"The present disclosure provides a charging adapter for supporting bi-directional energy transfer between a plurality of energy units. A charging adapter may be provided as part of a bi-directional energy transfer system for charging multiple vehicles from a single power source. Exemplary charging adapters may enable intelligent charging of multiple vehicles from a power source through various configurations (e.g., daisy chain, multiplexing, etc.) and strategies (e.g., sequence, parallel, staged, etc. The microcontroller of the charging adapter may act as a master controller for energy flow through a bi-directional energy transfer system, where other connected devices, such as charging sources, vehicles, and other charging adapters, are configured to act as peripheral control devices. The charging adapter may implement an AC coupling design in which a common voltage bus is used to splice energy to other charging adapters for bidirectional energy transfer.",FORD GLOBAL TECH LLC,SALTER STUART C;;O 'GORMAN ROBERT;;HARRIS TIMOTHY;;PUNG PETER;;HOWARD-COHEN KATHERINE,,https://lens.org/096-997-429-315-268,Patent Application,no,0,0,3,3,0,B60L53/16;;B60L53/18;;B60L53/66;;B60L53/60;;Y02T10/7072;;Y02T10/70;;Y02T90/14;;B60L53/14;;B60L53/65;;B60L55/00;;B60L53/16;;B60L53/18;;B60L53/66;;B60L53/16;;B60L53/66;;B60L53/18;;B60L55/00,B60L53/16;;B60L53/18;;B60L53/60;;B60L53/66,,0,0,,,,PENDING
200,JP,A,JP 2013200868 A,144-855-801-824-815,2013-10-03,2013,JP 2013054867 A,2013-03-18,US 201261614545 P;;US 201261614548 P;;US 201213566204 A,2012-03-23,SYSTEM FOR DYNAMICALLY ADAPTIVE CACHING,"PROBLEM TO BE SOLVED: To provide a system for dynamically adaptive caching.SOLUTION: A system 300 includes a storage device having a physical capacity for storing data received from a host 308. The system may also include a control module 304 for receiving data from the host and compressing the data to a compressed data size. Alternatively, the data may also be compressed by a storage device 302. The control module may be configured to determine the amount of available space on the storage device and also determine a reclaimed space. The reclaimed space accords with a difference between the size of the data received from the host and the compressed data size. The system may also include an interface module 306 for presenting a logical capacity to the host. The logical capacity has a variable size and may include at least a portion of the reclaimed space.",LSI CORP,HORIA SIMIONESCU;;MARK ISH;;LUCA BERT;;ROBERT QUINN;;EARL T COHEN;;TIMOTHY CANEPA,,https://lens.org/144-855-801-824-815,Patent Application,no,6,3,9,30,0,G06F12/08;;G06F12/0871;;G06F13/14;;G06F2212/1044;;G06F2212/401;;G06F2212/502;;G06F2212/657,G06F12/02;;G06F12/00;;G06F12/04;;G06F12/0871,,0,0,,,,ACTIVE
201,JP,A,JP 2009195700 A,028-098-257-508-235,2009-09-03,2009,JP 2009037161 A,2009-02-19,US 2996408 P;;US 36196209 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"<P>PROBLEM TO BE SOLVED: To provide a suture thread with a barb for use in medical procedure and to manufacture it. <P>SOLUTION: This compound barb medical device includes an elongated body having at least one barb, wherein the barb is extended from the elongated body, the barb defining an inner surface, the inner surface including a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis, and a third portion disposed at a third orientation relative to the longitudinal axis. <P>COPYRIGHT: (C)2009,JPO&INPIT",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/028-098-257-508-235,Patent Application,no,6,7,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61L17/00,,0,0,,,,DISCONTINUED
202,US,A1,US 2015/0133998 A1,058-742-855-129-668,2015-05-14,2015,US 201514591995 A,2015-01-08,US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/058-742-855-129-668,Patent Application,yes,0,1,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,606/228,0,0,,,,ACTIVE
203,US,B2,US 8273105 B2,120-772-523-015-430,2012-09-25,2012,US 36196209 A,2009-01-29,US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/120-772-523-015-430,Granted Patent,yes,100,104,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,606/228,21,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle . . . "" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization,"" III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).",ACTIVE
204,EP,A2,EP 2289428 A2,003-010-291-761-764,2011-03-02,2011,EP 10014285 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"A compound barb medical device (12) comprising: an elongated body (14); at least one barb (12) extending from the elongated body and defining an inner surface, the inner surface including: a first portion (12a) disposed at a first orientation defining first angle α relative to a longitudinal axis of the elongated body, a second portion (12b) disposed at a second orientation defining second angle β relative to the longitudinal axis, and a third portion (12c) disposed at a third orientation defining third angle γ relative to the longitudinal axis, wherein the second angle β is less than the first angle α and the third angle γ is less than the second angle β.
",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/003-010-291-761-764,Patent Application,yes,3,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
205,US,A1,US 2012/0132054 A1,080-684-631-384-306,2012-05-31,2012,US 201213362452 A,2012-01-31,US 201213362452 A;;US 201213348006 A;;US 17836108 A;;US 99417307 P,2007-09-17,Method of Forming Barbs on a Suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;TYCO HEALTHCARE,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/080-684-631-384-306,Patent Application,yes,2,8,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B26D3/08,83/880,0,0,,,,ACTIVE
206,US,A1,US 2009/0035178 A1,164-234-393-515-039,2009-02-05,2009,US 2623504 A,2004-12-30,US 2623504 A,2004-12-30,PROCESS FOR THE DESTRUCTION OF MICROORGANISMS ON A PRODUCT,A process for the destruction of microorganisms on a product using ultrasonic energy is disclosed. The process comprises contacting a product with an ultrasonic horn assembly and generating ultrasonic energy sufficient to result in a microorganism destruction rate of at least a 1-log kill.,KIMBERLY CLARK CO,BLENKE TIMOTHY JAMES;;EHLERT TOM;;TANNER JAMES JAY;;KOENIG DAVID W;;COHEN BERNARD,KIMBERLY-CLARK WORLDWIDE INC (2004-12-29),https://lens.org/164-234-393-515-039,Patent Application,yes,13,1,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/00,422/22,0,0,,,,INACTIVE
207,US,A1,US 2009/0210006 A1,030-230-886-518-521,2009-08-20,2009,US 36196209 A,2009-01-29,US 36196209 A;;US 2996408 P,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/030-230-886-518-521,Patent Application,yes,14,82,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,606/232;;606/228,0,0,,,,ACTIVE
208,CA,A1,CA 2949904 A1,047-818-377-556-268,2009-08-20,2009,CA 2949904 A,2009-02-18,US 2996408 P;;US 36196209 A;;CA 2654655 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,,TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/047-818-377-556-268,Patent Application,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,,0,0,,,,INACTIVE
209,CN,A,CN 115829193 A,169-530-921-275-859,2023-03-21,2023,CN 202211070040 A,2022-09-02,US 202117477802 A,2021-09-17,COMMON VEHICLE POWER MANAGEMENT,"The present disclosure provides ""common vehicle power management"". A computer is programmed to assign a plurality of electric vehicles having associated electric machines to a location to perform a task based on electrical quantities of the electric vehicles and the electric machines and expected energy consumption of the electric vehicles to travel to the location and the electric machines to perform the task at the location; and responding to the condition that the sum of the electric quantity of the first electric vehicle and the electric motor associated with the first electric vehicle is less than the sum of the expected energy consumption of the first electric vehicle when the first electric vehicle travels to a first position and the electric motor associated with the first electric vehicle performs the task at the first position, a second electric vehicle is instructed to travel to a second location where the first electric vehicle will be located.",FORD GLOBAL TECH LLC,SALTER STUART C;;O 'GORMAN RICHARD;;HARRIS TIMOTHY;;POON PETER;;HOWARD-COHEN KATHERINE,,https://lens.org/169-530-921-275-859,Patent Application,no,0,0,4,4,0,Y02T10/70;;Y02T10/7072;;G08G1/202;;G08G1/205;;B60L1/006;;B60L2260/54;;B60L2260/52;;B60L2240/62;;B60L2200/40;;B60L58/13;;G08G1/202;;G08G1/205;;B60L2260/54;;B60L58/14;;B60L2260/52;;G01C21/3469,G06Q10/063;;G06Q50/06,,0,0,,,,PENDING
210,EP,B1,EP 3053531 B1,016-029-960-093-882,2023-08-09,2023,EP 16159329 A,2009-02-20,US 2996408 P;;US 36196209 A;;EP 10014285 A;;EP 09250460 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE,,COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;BUCHTER MARK S,,https://lens.org/016-029-960-093-882,Granted Patent,yes,4,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
211,US,B2,US 9527221 B2,085-846-412-650-927,2016-12-27,2016,US 201414254272 A,2014-04-16,US 201414254272 A;;US 201213348006 A;;US 17836108 A;;US 99417307 P,2007-09-17,Method of forming barbs on a suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,COVIDIEN LP,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/085-846-412-650-927,Granted Patent,yes,58,1,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B26D3/08;;A61B17/00;;A61B17/06,,10,0,,,"European Search Report for EP 08253030.4-2310 date of completion is Sep. 18, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for EP 12164986.7-2310 date of completion is Jun. 22, 2012 (6 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9376 dated Sep. 12, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.;;Canadian Office Action from Application No. 2,639,445 dated Jun. 25, 2015.;;Chinese Office Action, and English language translation, from Application No. 201310187814.6 dated Jul. 3, 2015.;;Chinese Office Action, and English Translation, from Chinese Application No. 201310187814.6 dated Dec. 28, 2015.;;EP Communication from Appl. No. 12164986.7 dated Jun. 22, 2016.",ACTIVE
212,US,B2,US 8161618 B2,147-375-466-813-145,2012-04-24,2012,US 17836108 A,2008-07-23,US 17836108 A;;US 99417307 P,2007-09-17,Method of forming barbs on a suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;TYCO HEALTHCARE,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/147-375-466-813-145,Granted Patent,yes,29,17,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B23P25/00;;A61B17/04,29/458;;606/228,2,0,,,"European Search Report for EP 08253030.4-2310 date of completion is Sep. 18, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).",ACTIVE
213,US,A1,US 2013/0042064 A1,145-677-219-505-12X,2013-02-14,2013,US 201213566204 A,2012-08-03,US 201213566204 A;;US 201161521739 P;;US 201161531551 P;;US 201161543666 P;;US 201261614545 P;;US 201261614548 P,2011-08-09,SYSTEM FOR DYNAMICALLY ADAPTIVE CACHING,"The present disclosure is directed to a system for dynamically adaptive caching. The system includes a storage device having a physical capacity for storing data received from a host. The system may also include a control module for receiving data from the host and compressing the data to a compressed data size. Alternatively, the data may also be compressed by the storage device. The control module may be configured for determining an amount of available space on the storage device and also determining a reclaimed space, the reclaimed space being according to a difference between the size of the data received from the host and the compressed data size. The system may also include an interface module for presenting a logical capacity to the host. The logical capacity has a variable size and may include at least a portion of the reclaimed space.",LSI CORP;;SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-08-03),https://lens.org/145-677-219-505-12X,Patent Application,yes,1,17,2,30,0,G06F12/0871;;G06F12/0871;;G06F2212/401;;G06F2212/401,G06F12/08,711/118;;X711E12017,0,0,,,,ACTIVE
214,US,B2,US 8739389 B2,177-629-007-266-571,2014-06-03,2014,US 201113213287 A,2011-08-19,US 201113213287 A;;US 36196209 A;;US 72747510 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/177-629-007-266-571,Granted Patent,yes,137,6,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,B23P13/04,29/558,24,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for corresponding EP 07 25 4321, date of completion is Apr. 20, 2009.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle . . . "" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization,"" III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.;;European Search Report, Application No. 10014285.0 dated Mar. 27, 2014.",ACTIVE
215,CA,C,CA 2654655 C,015-200-544-544-577,2018-05-15,2018,CA 2654655 A,2009-02-18,US 2996408 P;;US 36196209 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/015-200-544-544-577,Granted Patent,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,,0,0,,,,INACTIVE
216,EP,A3,EP 2289428 A3,038-084-242-072-489,2014-04-30,2014,EP 10014285 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"A compound barb medical device (12) comprising: an elongated body (14); at least one barb (12) extending from the elongated body and defining an inner surface, the inner surface including: a first portion (12a) disposed at a first orientation defining first angle α relative to a longitudinal axis of the elongated body, a second portion (12b) disposed at a second orientation defining second angle β relative to the longitudinal axis, and a third portion (12c) disposed at a third orientation defining third angle γ relative to the longitudinal axis, wherein the second angle β is less than the first angle α and the third angle γ is less than the second angle β.
",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/038-084-242-072-489,Search Report,yes,4,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
217,CN,A,CN 103876797 A,057-687-397-384-032,2014-06-25,2014,CN 201410073521 A,2009-02-18,US 2996408 P;;US 36196209 A;;CN 200910009542 A,2008-02-20,Compound Barb Medical Device And Method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",TYCO HEALTHCARE,KOSA TIMOTHY D;;MAIORINO NICHOLAS;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;BUCHTER MARK S,,https://lens.org/057-687-397-384-032,Patent Application,no,0,5,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,,0,0,,,,ACTIVE
218,JP,A,JP 2015006462 A,069-600-943-061-064,2015-01-15,2015,JP 2014198040 A,2014-09-29,US 99417307 P;;US 17836108 A,2007-09-17,METHOD FOR FORMING SPINES ON SUTURE THREAD,PROBLEM TO BE SOLVED: To provide a method for forming spines on a suture thread by using ultrasonic energy.SOLUTION: A method for forming a medical device having spines includes the steps of providing a blank workpiece and forming at least one spine on the blank workpiece. The step of forming at least one spine on the blank workpiece is performed by imparting vibrational energy to a tool and contacting the tool with the blank workpiece at a predetermined angle such that the tool cuts into the surface of the blank workpiece.,COVIDIEN LP,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,,https://lens.org/069-600-943-061-064,Patent Application,no,0,0,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,A61L17/00,,0,0,,,,PENDING
219,CN,B,CN 102688073 B,147-343-697-855-346,2015-02-11,2015,CN 201210202463 A,2009-02-18,US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,,COVIDIEN LP,MATTHEW D COHEN;;NICHOLAS MAIORINO;;TIMOTHY D KOSA;;MARK S BUCHTER;;MICHAEL PRIMAVERA,,https://lens.org/147-343-697-855-346,Granted Patent,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,,0,0,,,,ACTIVE
220,CN,A,CN 103324586 A,166-930-475-612-15X,2013-09-25,2013,CN 201310093364 A,2013-03-22,US 201261614545 P;;US 201261614548 P;;US 201213566204 A,2012-03-23,System for dynamically adaptive caching,"The present disclosure is directed to a system for dynamically adaptive caching. The system includes a storage device having a physical capacity for storing data received from a host. The system may also include a control module for receiving data from the host and compressing the data to a compressed data size. Alternatively, the data may also be compressed by the storage device. The control module may be configured for determining an amount of available space on the storage device and also determining a reclaimed space, the reclaimed space being according to a difference between the size of the data received from the host and the compressed data size. The system may also include an interface module for presenting a logical capacity to the host. The logical capacity has a variable size and may include at least a portion of the reclaimed space.",LSI CORP,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,,https://lens.org/166-930-475-612-15X,Patent Application,no,5,4,9,30,0,G06F12/08;;G06F12/0871;;G06F13/14;;G06F2212/1044;;G06F2212/401;;G06F2212/502;;G06F2212/657,G06F12/08;;G06F12/0871;;G06F13/16,,0,0,,,,ACTIVE
221,US,B2,US 11660088 B2,181-174-135-225-981,2023-05-30,2023,US 202016931648 A,2020-07-17,US 202016931648 A;;US 201715658449 A;;US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/181-174-135-225-981,Granted Patent,yes,175,2,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,44,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"Australian Examination Report from Appl. No. AU 2015200379 dated Apr. 8, 2016.;;Extended European Search Report from EP Appl. No. 16159329.8-1654 dated Jul. 7, 2016.;;European Examination Report from Appl. No. 11250329.7-1654 dated Aug. 17, 2016.;;Canadian Office Action from Appl. No. CA 2,733,805 dated Jul. 28, 2016.;;Australian Examination Report from Appl. No. AU 2015200379 dated Jun. 24, 2016.;;Canadian Office Action from Appl. No. 2,654,655 dated Mar. 23, 2016.;;Austalian Examination Report from Appl. No. 2015200379 dated Feb. 4, 2016.;;First Office Action, and English Translation, from Chinese Applicaiton No. 201410073521X dated Jun. 23, 2015.;;Australian Examination Report dated May 15, 2015 in Application No. AU 2011201185.;;Japanese Final Official Action with English translation dated Apr. 9, 2015 from Application No. JP 2011-061379.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, “An Innovative Surgical Suture and Needle . . . ” 12(4), pp. 211-229 (2002).;;George Odian, “Principles of Polymerization,” III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report for corresponding EP 07 25 4321, date of completion is Apr. 20, 2009.;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.;;European Search Report, Application No. 10014285.0 dated Mar. 27, 2014.;;European Examination Report dated Oct. 12, 2017 in Appl. No. EP 16 159 329.8 (4 pp.).;;Australian Examination Report issued in Appl. No. AU 2017202006 dated Oct. 11, 2017 (3 pages).;;European Office Action issued in corresponding Appl. No. EP 16 159 329.8 dated Dec. 5, 2019 (4 pages).;;This application is a Division of, U.S. Appl. No. 15/658,449, filed Jul. 25, 2017, Patented, now U.S. Pat. No. 10,729,429.;;Is a continuation of, U.S. Appl. No. 14/591,995, filed Jan. 8, 2015, Patented, now U.S. Pat. No. 9,713,467.;;Is a continuation of, U.S. Appl. No. 14/257,030, filed Apr. 21, 2014, Patented, now U.S. Pat. No. 9,050,082.;;Is a continuation of, U.S. Appl. No. 13/213,287, filed Aug. 19, 2011, Patented, now U.S. Pat. No. 8,739,389.;;Is a Division of, U.S. Appl. No. 12/361,962, filed Jan. 29, 2009, Patented, now U.S. Pat. No. 8,273,105.",ACTIVE
222,US,B2,US 8443506 B2,008-829-637-783-686,2013-05-21,2013,US 201213362452 A,2012-01-31,US 201213362452 A;;US 201213348006 A;;US 17836108 A;;US 99417307 P,2007-09-17,Method of forming barbs on a suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;COVIDIEN LP,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/008-829-637-783-686,Granted Patent,yes,53,3,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B23P25/00;;A61B17/04,29/458;;606/228,5,0,,,"European Search Report for EP 08253030.4-2310 date of completion is Sep. 18, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for EP 12164986.7-2310 date of completion is Jun. 22, 2012 (6 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9376 dated Sep. 12, 2012.",ACTIVE
223,TW,B,TW I263497 B,024-153-460-973-670,2006-10-11,2006,TW 92106334 A,2003-03-21,US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,"The present invention relates to compounds of formula I, or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula, R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or 01-03 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ,,https://lens.org/024-153-460-973-670,Granted Patent,no,0,1,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61K31/435;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
224,US,B2,US 11593579 B2,053-354-372-072-402,2023-02-28,2023,US 202117140843 A,2021-01-04,US 202117140843 A,2021-01-04,Multiplexed quick response (“QR”) code experience derivation,"An optical code scanner being operated using an algorithm is provided. The scanner may scan an optical label. The label may include machine-readable code. The scanner may derive a single set of instructions from the code or multiple sets of instructions from the code. The scanner may process the code. The processing may upload a set of instructions from the code to the scanner and store the set of instructions in an instructions library. The scanner may also derive a picture associated with the instructions and store the picture in the library. The scanner may display a plurality of pictures. Each of the pictures may correspond to a set of uploaded instructions stored on the scanner. Each of the plurality of pictures may be selectable by a user. In response to a user selection of a picture, the scanner may be configured to execute the uploaded instructions that correspond to the selected picture.",THE DTX COMPANY,COHEN NEIL WAYNE;;LEMMON TIMOTHY J;;SHING DAVID;;DUPLESSIE ANDREW;;DEVLIN PATRIK ANDREW,THE DTX COMPANY (2021-01-04),https://lens.org/053-354-372-072-402,Granted Patent,yes,79,0,4,4,0,G06F21/56;;G06F2221/034;;G06K19/14;;G06K19/06037;;H04L9/3247;;G09C5/00;;G06K7/1417;;G06F2221/034;;H04L9/0861;;G06F21/56,G06K7/14;;G06F21/56;;H04L9/08,,21,1,081-219-474-303-287,10.1016/j.procs.2016.04.081,"Inderscience Enterprises Ltd., Wickramasinghe et al., “A Mathematical Model for Computational Aesthetics,” pp. 310-324, 2010, Int. J. Computational Vision and Robotics, vol. 1, No. 3.;;Elsevier, Maity et al., “A Computational Model to Predict Aesthetic Quality of Text Elements of GUI,” pp. 152-159, 2016, Procedia Computer Science 84 (2016), www.sciencedirect.com.;;AI Shack, Utkarsh Sinha, “Scanning QR Codes,” 2010, https://aishack.in/tutorials/scanning-qr-codes-1/.;;AIA Vision Online, “The Most Common Causes of Unreadable Barcodes,” Apr. 15, 2015, https://www.visiononline.org/vision-resources-details.cfm?content_id=5404.;;Workwithcolor.Com, “Color Properties/Terminology,” Retrieved on Jun. 8, 2020, http://www.workwithcolor.com/color-properties-definitions-0101.htm,.;;The Eurographics Association, Florian Hoenig, “Defining Computational Aesthetics,” 2005, Computational Aesthetics in Graphics, Visualization and Imaging (2005), www.diglib.eg.org.;;DataGenetics, “Wounded QR Codes,” Nov. 2013, http://datagenetics.com/blog/november12013/index.html.;;QR Code Monkey, “6 Reasons Why Your QR Code Is Not Working,” Retrieved on Jun. 9, 2020, https://www.qrcode-monkey.com/6-reasons-why-your-qr-code-is-not-working.;;TechSpot, Inc., Mark Turner, “QR Codes Explained,” Sep. 3, 2018, https://www.techspot.com/guides/1676-qr-code-explained/.;;Medium.com, Sciforce, “Computational Aesthetics: Shall We Let Computers Measure Beauty?,” Jun. 12, 2020, https://medium.com/sciforce/computational-aesthetics-shall-we-let-computers-measure-beauty-db2205989fb.;;Thonky.com, “Module Placement in Matrix,” Retrieved on Jun. 8, 2020, https://ww.thonky.com/qr-code-tutorial/module-placement-matrix.;;Keyence Corporation of America, “What Is a Qr Code,” Retrieved on Jun. 8, 2020, https://www.keyence.com/ss/products/auto_id/barcode_lectare/basic_2d/qr/.;;Wikimedia Foundation, Inc., “QR Code,” Retrieved on Jun. 3, 2020, https://en.wikipedia.org/wiki/QR_code.;;Wikimedia Foundation, Inc., Walter Tuveli, “QR Code—Structure,” 2012, https://en.wikipedia.org/wiki/QR_code#/media/File:QRCode-2-Structure.png.;;Wikimedia Foundation, Inc., “ShotCode,” Retrieved on Aug. 6, 2021, https://en.wikipedia.org/wiki/ShotCode#searchInput.;;Medium.com, Punit Pathak, “ETL—Understanding It and Effectively Using It,” Jan. 7, 2019, https://medium.com/hashmapinc/etl-understanding-it-and-effectively-using-it-f827a5b3e54d.;;Strathmore University (Nairobi, Kenya), Kizi Dimira Othuon, “Improving Customer Experience Using an Android Barcode Reader Application,” Apr. 2018, https://su-plus.strathmore.edu/bitstream/handle/11071/5978/Improving%20customer%20shopping%20experience%20using%20an%20Android%20barcode%20reader%20application.pdf?sequence=1&isAllowed=y.;;Westboroughtv.org, Horrigan, Aidan, “Mr. WHS 2020,” Jun. 12, 2020, https://westboroughtv.org/mr-whs-2020-2/.;;Facebook.com, Wa, lzakaya, “QR codes for the dinner menu and lunch menu at Memorial!” Jul. 24, 2020, https://m.facebook.com/196433773873837/posts/qr-codes-for-the-dinner-menu-and-lunch-menu-at-memorial.1730306280486571.;;Ispot.tv, “StockX TV Spot, ‘Flowcode: Never Sold Out,’” Mar. 27, 2020, https://www.ispot.tv/ad/nVly/stockx-flowcode-never-sold-out.;;Nyp.org, “#FitForTheFrontline Challenge Unites Nation's Top Medical Centers to Support Frontline Healthcare Workers,” May 28, 2020, https://www.nyp.org/news/fit-for-the-frontline-challenge.",ACTIVE
225,EP,B1,EP 2092895 B1,057-829-990-866-594,2015-01-21,2015,EP 09250460 A,2009-02-20,US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,,COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/057-829-990-866-594,Granted Patent,yes,4,0,2,49,0,A61B17/06166;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
226,US,B2,US 9158695 B2,071-491-479-379-264,2015-10-13,2015,US 201213566204 A,2012-08-03,US 201213566204 A;;US 201161521739 P;;US 201161531551 P;;US 201161543666 P;;US 201261614545 P;;US 201261614548 P,2011-08-09,System for dynamically adaptive caching,"The present disclosure is directed to a system for dynamically adaptive caching. The system includes a storage device having a physical capacity for storing data received from a host. The system may also include a control module for receiving data from the host and compressing the data to a compressed data size. Alternatively, the data may also be compressed by the storage device. The control module may be configured for determining an amount of available space on the storage device and also determining a reclaimed space, the reclaimed space being according to a difference between the size of the data received from the host and the compressed data size. The system may also include an interface module for presenting a logical capacity to the host. The logical capacity has a variable size and may include at least a portion of the reclaimed space.",SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY;;SEAGATE TECHNOLOGY LLC,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2012-08-03),https://lens.org/071-491-479-379-264,Granted Patent,yes,6,1,2,30,0,G06F12/0871;;G06F12/0871;;G06F2212/401;;G06F2212/401,G06F12/00;;G06F12/08,,1,1,002-895-503-709-998,10.1145/1755913.1755915,"Makatos, Thanos, et al., ""Using Transparent Compression to Improve SSD-based I/O Caches"", EuroSys '10, Apr. 13-16, ACM 978-1-60558-577-2/10/04, Apr. 2010, 14 pages.",ACTIVE
227,CA,A1,CA 2654655 A1,090-124-293-155-339,2009-08-20,2009,CA 2654655 A,2009-02-18,US 2996408 P;;US 36196209 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",TYCO HEALTHCARE,KOSA TIMOTHY D;;MAIORINO NICHOLAS;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;BUCHTER MARK S,,https://lens.org/090-124-293-155-339,Patent Application,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,,0,0,,,,INACTIVE
228,CA,A1,CA 2639445 A1,105-365-951-898-098,2009-03-17,2009,CA 2639445 A,2008-09-10,US 99417307 P;;US 17836108 A,2007-09-17,METHOD OF FORMING BARBS ON A SUTURE,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.</ SDOAB>,TYCO HEALTHCARE,KOSA TIMOTHY D;;MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL,,https://lens.org/105-365-951-898-098,Patent Application,no,0,0,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,A61B17/04;;A61F2/06;;A61F2/82,,0,0,,,,ACTIVE
229,JP,A,JP 2009066421 A,171-184-013-328-321,2009-04-02,2009,JP 2008238607 A,2008-09-17,US 99417307 P;;US 17836108 A,2007-09-17,METHOD OF FORMING BARBS ON SUTURE,"<P>PROBLEM TO BE SOLVED: To provide a method of forming barbs on a suture using ultrasonic energy. <P>SOLUTION: A method is provided for forming a medical device 10 having barbs 12 which includes the steps of providing a blank workpiece 29 and forming at least one barb 12 on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. <P>COPYRIGHT: (C)2009,JPO&INPIT",TYCO HEALTHCARE,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,,https://lens.org/171-184-013-328-321,Patent Application,no,7,11,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,A61L17/00;;A61B17/04,,1,0,,,JPN6013023776; 精密工学会大会学術講演会講演論文集， Ｖｏｌ．２００６ 秋季 Ｐａｇｅ．Ｊ６７ （２００６．０９．０４）,INACTIVE
230,EP,B1,EP 2289428 B1,000-367-690-276-400,2019-08-14,2019,EP 10014285 A,2009-02-20,EP 09250460 A;;US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,,COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/000-367-690-276-400,Granted Patent,yes,4,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
231,EP,A1,EP 2092895 A1,024-147-551-025-632,2009-08-26,2009,EP 09250460 A,2009-02-20,US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.
",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/024-147-551-025-632,Patent Application,yes,7,3,2,49,0,A61B17/06166;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
232,US,A1,US 2014/0224094 A1,086-173-053-439-072,2014-08-14,2014,US 201414257030 A,2014-04-21,US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/086-173-053-439-072,Patent Application,yes,39,1,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,83/880,0,0,,,,ACTIVE
233,US,A1,US 2012/0323272 A1,007-729-720-960-87X,2012-12-20,2012,US 201213593688 A,2012-08-24,US 201213593688 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/007-729-720-960-87X,Patent Application,yes,1,7,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61L17/00,606/228,0,0,,,,ACTIVE
234,KR,A,KR 20130108117 A,065-357-461-442-398,2013-10-02,2013,KR 20130022004 A,2013-02-28,US 201213566204 A;;US 201261614545 P;;US 201261614548 P,2012-03-23,SYSTEM FOR DYNAMICALLY ADAPTIVE CACHING,"PURPOSE: A system for dynamical caching is provided to perform the caching of a storage system even when a data size changes due to the compression of data. CONSTITUTION: A storage device (302) comprises physical capacity for storing data from a host. A compression module compresses the data from the host with a compacted data size. A control module (304) receives the data from the host, and determines the volume of an available space in the storage device. An interface module (306) provides logical capacity to the host, and the logical capacity comprises a variable size with a part of a recovered space. [Reference numerals] (302) Storage unit; (304) Control module; (306) Interface module; (308) Host",LSI CORP,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,,https://lens.org/065-357-461-442-398,Patent Application,no,1,2,9,30,0,G06F12/08;;G06F12/0871;;G06F13/14;;G06F2212/1044;;G06F2212/401;;G06F2212/502;;G06F2212/657,G06F12/08;;G06F12/0871;;G06F13/14,,0,0,,,,ACTIVE
235,US,B2,US 9713467 B2,086-511-713-997-256,2017-07-25,2017,US 201514591995 A,2015-01-08,US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/086-511-713-997-256,Granted Patent,yes,173,4,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04;;A61B17/00;;A61B17/06,,36,1,038-883-790-728-523,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784,"Australian Examination Report from Appl. No. AU 2015200379 issued Apr. 8, 2016.;;Extended European Search Report from EP Appl. No. 16159329.8-1654 dated Jul. 7, 2016.;;European Examination Report from Appl. No. 11250329.7-1654 dated Aug. 17, 2016.;;Canadian Office Action from Appl. No. CA 2,733,805 dated Jul. 28, 2016.;;Australian Examination Report from Appl. No. AU 2015200379 issued Jun. 24, 2016.;;Canadian Office Action from Appl. No. 2,654,655 dated Mar. 23, 2016.;;Austalian Examination Report from Appl. No. 2015200379 issued Feb. 4, 2016.;;First Office Action, and English Translation, from Chinese Applicaiton No. 201410073521X issued Jun. 23, 2015.;;Australian Examination Report issued May 15, 2015 in Application No. AU 2011201185.;;Japanese Final Official Action with English translation mailed Apr. 9, 2015 from Application No. JP 2011-061379.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R.R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, “An Innovative Surgical Suture and Needle . . . ” 12(4), pp. 211-229 (2002).;;George Odian, “Principles of Polymerization,” III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for Appln. No. 09251035.3 dated Jun. 3, 2009.;;European Search Report for Appln. No. 09250460 dated Jun. 2, 2009.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;European Search Report for EP 10 25 0848 dated Aug. 12, 2010 (completed Jul. 26, 2010) (3 pages).;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report for corresponding EP 07 25 4321, date of completion is Apr. 20, 2009.;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.;;European Search Report, Application No. 10014285.0 dated Mar. 27, 2014.",ACTIVE
236,US,A1,US 2023/0309990 A1,088-371-106-423-366,2023-10-05,2023,US 202318200679 A,2023-05-23,US 202318200679 A;;US 202016931648 A;;US 201715658449 A;;US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/088-371-106-423-366,Patent Application,yes,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,,0,0,,,,PENDING
237,CN,A,CN 115923543 A,131-984-511-578-686,2023-04-07,2023,CN 202211174344 A,2022-09-26,US 202117492823 A,2021-10-04,Energy transfer system and method including fully integrated supply,"The present disclosure relates to an energy transfer system and method including a fully integrated supply device. An exemplary system includes a supply device having a vehicle port, a converter, and an isolation transformer. The vehicle port is configured to electrically couple the supply device to an electrically powered vehicle.",FORD GLOBAL TECH LLC,SALTER STUART C;;O 'GORMAN ROBERT;;HARRIS TIMOTHY;;PUNG PETER;;HOWARD-COHEN KATHERINE,,https://lens.org/131-984-511-578-686,Patent Application,no,0,0,3,3,0,B60L53/14;;B60L53/60;;Y02T90/14;;Y02T10/70;;Y02T10/7072;;B60L53/30;;B60L53/51;;B60L53/60;;B60L53/14;;B60L53/51,B60L53/00;;B60L53/22;;B60L53/51,,0,0,,,,PENDING
238,TW,A,TW 201342063 A,199-689-490-466-479,2013-10-16,2013,TW 102105705 A,2013-02-19,US 201261614545 P;;US 201261614548 P;;US 201213566204 A,2012-03-23,System for dynamically adaptive caching,"The present disclosure is directed to a system for dynamically adaptive caching. The system includes a storage device having a physical capacity for storing data received from a host. The system may also include a control module for receiving data from the host and compressing the data to a compressed data size. Alternatively, the data may also be compressed by the storage device. The control module may be configured for determining an amount of available space on the storage device and also determining a reclaimed space, the reclaimed space being according to a difference between the size of the data received from the host and the compressed data size. The system may also include an interface module for presenting a logical capacity to the host. The logical capacity has a variable size and may include at least a portion of the reclaimed space.",LSI CORP,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,,https://lens.org/199-689-490-466-479,Patent of Addition,no,0,0,9,30,0,G06F12/08;;G06F12/0871;;G06F13/14;;G06F2212/1044;;G06F2212/401;;G06F2212/502;;G06F2212/657,G06F12/08;;G06F12/0871,,0,0,,,,INACTIVE
239,TW,B,TW I584120 B,141-838-148-682-784,2017-05-21,2017,TW 102105705 A,2013-02-19,US 201261614545 P;;US 201261614548 P;;US 201213566204 A,2012-03-23,Method and system for dynamically adaptive caching,,LSI CORP,SIMIONESCU HORIA;;ISH MARK;;BERT LUCA;;QUINN ROBERT;;COHEN EARL T;;CANEPA TIMOTHY,,https://lens.org/141-838-148-682-784,Granted Patent,no,4,0,9,30,0,G06F12/08;;G06F12/0871;;G06F13/14;;G06F2212/1044;;G06F2212/401;;G06F2212/502;;G06F2212/657,G06F12/0871,,0,0,,,,INACTIVE
240,CA,C,CA 2639445 C,157-119-047-396-754,2018-02-06,2018,CA 2639445 A,2008-09-10,US 99417307 P;;US 17836108 A,2007-09-17,METHOD OF FORMING BARBS ON A SUTURE,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,TYCO HEALTHCARE,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,,https://lens.org/157-119-047-396-754,Granted Patent,no,0,0,23,23,0,A61B17/06166;;A61B2017/00526;;A61B2017/06176;;A61B2017/00893;;Y10T29/49885;;Y10T29/49;;Y10T83/0333;;Y10T83/02;;Y10T83/0385;;Y10T83/0341;;B26D3/08;;Y10T29/49885;;Y10T29/49;;Y10T83/0333;;Y10T83/02;;Y10T83/0385;;Y10T83/0341;;A61B17/06166;;A61B2017/00526;;A61B2017/06176;;A61B2017/00893;;B26D3/08,A61B17/04;;A61F2/06;;A61F2/848;;A61L17/00;;B21F11/00;;B21F25/00;;B26D3/08;;B26D3/12,,0,0,,,,ACTIVE
241,US,A1,US 2017/0319203 A1,146-978-361-310-150,2017-11-09,2017,US 201715658449 A,2017-07-25,US 201715658449 A;;US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/146-978-361-310-150,Patent Application,yes,1,13,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
242,US,A1,US 2014/0224095 A1,187-487-987-825-018,2014-08-14,2014,US 201414254272 A,2014-04-16,US 201414254272 A;;US 201213348006 A;;US 17836108 A;;US 99417307 P,2007-09-17,Method of Forming Barbs on a Suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,COVIDIEN LP,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/187-487-987-825-018,Patent Application,yes,3,1,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B26D3/08,83/886;;83/879,0,0,,,,ACTIVE
243,US,A1,US 2022/0215190 A1,199-462-141-595-639,2022-07-07,2022,US 202117140843 A,2021-01-04,US 202117140843 A,2021-01-04,"MULTIPLEXED QUICK RESPONSE (""QR"") CODE EXPERIENCE DERIVATION","An optical code scanner being operated using an algorithm is provided. The scanner may scan an optical label. The label may include machine-readable code. The scanner may derive a single set of instructions from the code or multiple sets of instructions from the code. The scanner may process the code. The processing may upload a set of instructions from the code to the scanner and store the set of instructions in an instructions library. The scanner may also derive a picture associated with the instructions and store the picture in the library. The scanner may display a plurality of pictures. Each of the pictures may correspond to a set of uploaded instructions stored on the scanner. Each of the plurality of pictures may be selectable by a user. In response to a user selection of a picture, the scanner may be configured to execute the uploaded instructions that correspond to the selected picture.",THE DTX COMPANY,COHEN NEIL WAYNE;;LEMMON TIMOTHY J;;SHING DAVID;;DUPLESSIE ANDREW;;DEVLIN PATRIK ANDREW,THE DTX COMPANY (2021-01-04),https://lens.org/199-462-141-595-639,Patent Application,yes,0,15,4,4,0,G06F21/56;;G06F2221/034;;G06K19/14;;G06K19/06037;;H04L9/3247;;G09C5/00;;G06K7/1417;;G06F2221/034;;H04L9/0861;;G06F21/56,G06K7/14;;G06F21/56;;H04L9/08,,0,0,,,,ACTIVE
244,US,A1,US 2020/0345351 A1,040-476-171-257-957,2020-11-05,2020,US 202016931648 A,2020-07-17,US 202016931648 A;;US 201715658449 A;;US 201514591995 A;;US 201414257030 A;;US 201113213287 A;;US 36196209 A;;US 2996408 P,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/040-476-171-257-957,Patent Application,yes,4,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,,0,0,,,,ACTIVE
245,CN,A,CN 102688073 A,074-926-345-283-215,2012-09-26,2012,CN 201210202463 A,2009-02-18,US 2996408 P;;US 36196209 A,2008-02-20,Compound barb medical device and method,"The invention provides a compound barb medical device and method. The compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",TYCO HEALTHCARE,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/074-926-345-283-215,Patent Application,no,3,1,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06,,0,0,,,,ACTIVE
246,EP,A1,EP 3053531 A1,090-387-830-669-955,2016-08-10,2016,EP 16159329 A,2009-02-20,US 2996408 P;;US 36196209 A;;EP 10014285 A;;EP 09250460 A,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"A compound barb medical device comprising: an elongate body wherein the elongate body is a monofilament suture including an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body and defining an inner surface, the inner surface including: a first portion disposed at a first orientation relative to a first longitudinal axis of the elongate body, wherein the first portion is disposed at a first angle from about 0 degrees to about 90 degrees relative to the first longitudinal axis of the elongate body; and a second portion disposed at a second orientation relative to a second longitudinal axis of the elongate body, wherein the second portion is disposed at a second angle from about 0 degrees to about 90 degrees relative to the second longitudinal axis of the elongate body.
",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;BUCHTER MARK S,,https://lens.org/090-387-830-669-955,Patent Application,yes,4,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
247,CN,A,CN 103315785 A,162-897-116-532-695,2013-09-25,2013,CN 201310187814 A,2008-09-17,US 99417307 P;;US 17836108 A;;CN 200810212367 A,2007-09-17,Method of forming barbs on suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,COVIDIEN LP,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,,https://lens.org/162-897-116-532-695,Patent Application,no,4,7,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,A61B17/04,,0,0,,,,ACTIVE
248,US,B2,US 7497990 B2,014-996-702-562-00X,2009-03-03,2009,US 2623504 A,2004-12-30,US 2623504 A,2004-12-30,Process for the destruction of microorganisms on a product,A process for the destruction of microorganisms on a product using ultrasonic energy is disclosed. The process comprises contacting a product with an ultrasonic horn assembly and generating ultrasonic energy sufficient to result in a microorganism destruction rate of at least a 1-log kill.,KIMBERLY CLARK CO,BLENKE TIMOTHY JAMES;;EHLERT TOM;;TANNER JAMES JAY;;KOENIG DAVID W;;COHEN BERNARD,KIMBERLY-CLARK WORLDWIDE INC (2004-12-29),https://lens.org/014-996-702-562-00X,Granted Patent,yes,18,0,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/00;;B29C65/00;;C09C1/00;;C12Q1/68;;F28D21/00,422/22;;422/2;;422/204;;422/157.42;;422/157.15;;435/6;;156/73.2,2,1,111-195-091-917-735,10.1007/s10019-002-0214-2,"Kelli Hoover et al., Destruction of bacterial spores by phenomenally high efficiency non-contact ultrasonic transducers, Materials Research Innovations (2002) 6:291-295; published online Oct. 23, 2002.;;International Search Report from PCT/US2005/043750, dated May 4, 2006.",INACTIVE
249,US,A1,US 2011/0307007 A1,048-574-422-624-492,2011-12-15,2011,US 201113213287 A,2011-08-19,US 201113213287 A;;US 36196209 A;;US 72747510 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,"A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.",COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2009-01-22),https://lens.org/048-574-422-624-492,Patent Application,yes,37,6,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,606/228,0,0,,,,ACTIVE
250,US,A1,US 2012/0118123 A1,049-353-363-318-109,2012-05-17,2012,US 201213348006 A,2012-01-11,US 201213348006 A;;US 17836108 A;;US 99417307 P,2007-09-17,Method of Forming Barbs on a Suture,A method is provided for forming a barbed medical device which includes the steps of providing a blank workpiece and forming at least one barb on the blank workpiece by applying vibrational energy to a tool and bringing the tool and the blank workpiece into contact with each other at an angle such that the tool cuts into the surface of the blank workpiece. A barbed medical device formed by this method is also provided.,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D;;TYCO HEALTHCARE,MAIORINO NICHOLAS;;BUCHTER MARK S;;COHEN MATTHEW D;;PRIMAVERA MICHAEL;;KOSA TIMOTHY D,COVIDIEN LP (2008-07-15),https://lens.org/049-353-363-318-109,Patent Application,yes,0,9,23,23,0,A61B17/06166;;A61B17/06166;;A61B2017/00526;;A61B2017/00526;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B26D3/08;;B26D3/08;;Y10T29/49;;Y10T29/49;;Y10T29/49885;;Y10T29/49885;;Y10T83/02;;Y10T83/02;;Y10T83/0333;;Y10T83/0333;;Y10T83/0341;;Y10T83/0341;;Y10T83/0385;;Y10T83/0385,B26D3/14;;B23P15/00,83/861;;29/592,0,0,,,,ACTIVE
251,ES,T3,ES 2530890 T3,048-950-196-299-869,2015-03-06,2015,ES 09250460 T,2009-02-20,US 2996408 P;;US 36196209 A,2008-02-20,Dispositivo médico con lengüeta compuesta y método,"Un dispositivo médico (620) con lengüeta compuesta que comprende: un cuerpo alargado (610) en donde el cuerpo alargado es una sutura de monofilamento que incluye una superficie exterior; al menos una lengüeta que se extiende desde el cuerpo alargado y que define una superficie interior, la superficie interior incluye: una primera parte lineal (620a) dispuesta en una primera orientación con relación a un eje longitudinal del cuerpo alargado (610); y una segunda parte lineal (620b) dispuesta con una segunda orientación con relación al eje longitudinal del cuerpo alargado (610), caracterizado por que la primera parte lineal está dispuesta con un primer ángulo de aproximadamente 30 grados hasta aproximadamente 50 grados con relación al eje longitudinal del cuerpo alargado (610) y una relación de la profundidad de corte desde aproximadamente el 1% hasta aproximadamente el 40% del diámetro del cuerpo alargado (610), y por que la segunda parte lineal está dispuesta con un segundo ángulo de aproximadamente 0 grados hasta aproximadamente 90 grados con relación al eje longitudinal del cuerpo alargado (610) y una relación de la profundidad de corte desde aproximadamente el 5% hasta aproximadamente el 50% del diámetro del cuerpo alargado (610).",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/048-950-196-299-869,Granted Patent,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/06;;A61B17/00,,0,0,,,,ACTIVE
252,WO,A1,WO 2018/023081 A1,013-415-834-858-094,2018-02-01,2018,US 2017/0044534 W,2017-07-28,US 201662368331 P,2016-07-29,"6-PHENYLPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AS ANTIBACTERIAL AGENTS","The disclosure relates to antibacterial compounds having the Formula (I), where R1, R2, R3, R4, R8, n, and p are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.",ACHAOGEN INC;;COHEN FREDERICK;;KANE TIMOTHY ROBERT;;DOZZO PAOLA;;HILDEBRANDT DARIN JAMES;;LINSELL MARTIN SHERINGHAM;;MACHAJEWSKI TIMOTHY D;;MCENROE GLENN A,COHEN FREDERICK;;KANE TIMOTHY ROBERT;;DOZZO PAOLA;;HILDEBRANDT DARIN JAMES;;LINSELL MARTIN SHERINGHAM;;MACHAJEWSKI TIMOTHY D;;MCENROE GLENN A,,https://lens.org/013-415-834-858-094,Patent Application,yes,1,2,1,1,0,A61P31/04;;C07D471/04,C07D471/04;;A61K31/519;;A61P31/04,,9,7,019-189-555-622-850;;086-692-098-427-600;;019-189-555-622-850;;083-477-465-700-453;;052-191-546-682-180;;021-739-403-250-512;;077-295-491-167-117,19164768;;10.1073/pnas.0811275106;;pmc2644107;;19875284;;10.1016/j.bmcl.2009.10.057;;19164768;;10.1073/pnas.0811275106;;pmc2644107;;10.1074/jbc.m402989200;;15066985;;pmc3243065;;10.1016/j.bioorg.2011.08.004;;21920581;;16983687;;10.1002/jcb.21077;;pmc3837461;;10.1002/0471220574,"J. RICHARD MILLER ET AL: ""A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore"", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 106, no. 6, 10 February 2009 (2009-02-10), US, pages 1737 - 1742, XP055410979, ISSN: 0027-8424, DOI: 10.1073/pnas.0811275106;;CHENG ET AL., BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 6507 - 6514;;MILLER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 106, no. 6, 2009, pages 1737 - 1742;;FREIBERG ET AL., J BIOL. CHEM., vol. 279, no. 25, 2004, pages 26066 - 26073;;FAWAZ ET AL., BIOORG. CHEM., vol. 39, 2011, pages 185 - 191;;TONG ET AL., J. CELL. BIOCHEM., vol. 99, 2006, pages 1476 - 1488;;T. W. GREENE; P. G. M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;;E. L. ELIEL; S. H. WILEN; L. N. MANDER: ""Stereochemistry of Organic Compounds"";;REMINGTON: ""The Science and Practice of Pharmacy"", 1995, MACK PUBLISHING COMPANY",PENDING
253,US,A1,US 2021/0256086 A1,033-090-074-799-919,2021-08-19,2021,US 202117178955 A,2021-02-18,US 202117178955 A;;US 202062978136 P,2020-02-18,REFACTORING OF STATIC MACHINE-READABLE CODES,"Methods, devices and systems for computing interactive customized content in response to a scan of a machine-readable label are provided. Illustrative methods may include receiving, from a user, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan, a redirect Uniform Resource Locator (URL). Methods may include generating, based on a user profile and a redirect service that is accessed using the redirect URL, comprising the customized content associated with the scan. Methods may include redirecting the user to a target landing page URL, and providing, to the user through a browser on the mobile device, a target landing page that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;PRZEKOP RICHARD JAMES;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J,THE DTX COMPANY (2021-02-16),https://lens.org/033-090-074-799-919,Patent Application,yes,0,13,3,7,0,G06F16/9554;;G06F16/9566;;G06F16/9535;;G06F16/9554;;G06F16/9558;;G06F16/9566;;G06K19/06009;;G06K19/06037,G06F16/955;;G06F16/9535;;G06K19/06,,0,0,,,,ACTIVE
254,EP,B1,EP 1835940 B1,031-353-273-925-956,2009-02-11,2009,EP 05826151 A,2005-12-02,US 2005/0043750 W;;US 2623504 A,2004-12-30,PROCESS FOR THE DESTRUCTION OF MICROORGANISMS ON A PRODUCT USING ULTRASONIC ENERGY,,KIMBERLY CLARK CO,BLENKE TIMOTHY JAMES;;EHLERT THOMAS D;;TANNER JAMES J;;KOENIG DAVID W;;COHEN BERNARD,,https://lens.org/031-353-273-925-956,Granted Patent,yes,5,0,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/025;;A23L3/30;;B01J19/10;;B65B55/04,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 015, no. 512 (C-0898), 26 December 1991 (1991-12-26) & JP 03 224570 A (CHIYODA SEISAKUSHO:KK), 3 October 1991 (1991-10-03);;PATENT ABSTRACTS OF JAPAN vol. 015, no. 377 (C-0870), 24 September 1991 (1991-09-24) & JP 03 151836 A (HONDA ELECTRON CO LTD), 28 June 1991 (1991-06-28)",ACTIVE
255,US,A1,US 2014/0275681 A1,045-415-026-700-783,2014-09-18,2014,US 201414204753 A,2014-03-11,US 201414204753 A;;US 201361783720 P,2013-03-14,METHODS FOR TREATING A METATHESIS FEEDSTOCK WITH METAL ALKOXIDES,"Various methods are provided for treating and reacting a metathesis feedstock. In one embodiment, the method includes providing a feedstock comprising a natural oil, chemically treating the feedstock with a metal alkoxide under conditions sufficient to diminish catalyst poisons in the feedstock, and, following the treating, combining a metathesis catalyst with the feedstock under conditions sufficient to metathesize the feedstock.",ELEVANCE RENEWABLE SCIENCES,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,ELEVANCE RENEWABLE SCIENCES INC (2014-10-07);;MATERIA INC (2014-09-10);;WILMAR TRADING PTE LTD (2020-05-29),https://lens.org/045-415-026-700-783,Patent Application,yes,6,30,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,C07C6/04,585/324,1,1,090-527-081-098-64X,10.1039/jr9630001192,"Davies, A.G.; Hall, C.D. âPeroxides of Elements other than Carbon. Part X. Organoperoxyaluminum Compounds as Intermediates in Redox Reactionsâ, J. Chem. Soc. (1963), pp. 1192-1197.",ACTIVE
256,US,B2,US 11347823 B2,098-495-968-174-313,2022-05-31,2022,US 202117399285 A,2021-08-11,US 202117399285 A;;US 202117178955 A;;US 202062978136 P,2020-02-18,Refactoring of static machine-readable codes,"Methods, devices and systems for computing interactive customized content in response to a scan, or multiple scans, of a machine-readable label are provided. Illustrative methods may include receiving, from a user or group of users, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan or scans, one, or more than one, redirect Uniform Resource Locator(s) (URL(s)). Methods may include generating, based on a user profile or group of user profiles and a redirect service that is accessed using the redirect URL, customized content associated with the scan. Methods may include redirecting the user or users to one or more target landing page URL(s), and providing to the user or users, through a browser on the mobile device or mobile devices, one or more than one target landing page(s) that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;PRZEKOP RICHARD JAMES;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J,THE DTX COMPANY (2021-08-15),https://lens.org/098-495-968-174-313,Granted Patent,yes,9,10,4,7,0,G06F16/9554;;G06F16/9566;;G06F16/9554;;G06F16/9558;;G06F16/954;;G06K19/06009;;G06F16/958,G06F16/95;;G06F16/954;;G06F16/955;;G06F16/958;;G06K19/06,,0,0,,,,ACTIVE
257,US,A1,US 2022/0292158 A1,108-029-976-200-676,2022-09-15,2022,US 202217828143 A,2022-05-31,US 202217828143 A;;US 202117399285 A;;US 202117178955 A;;US 202062978136 P,2020-02-18,REFACTORING OF STATIC MACHINE-READABLE CODES,"Methods, devices and systems for computing interactive customized content in response to a scan, or multiple scans, of a machine-readable label are provided. Illustrative methods may include receiving, from a user or group of users, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan or scans, one, or more than one, redirect Uniform Resource Locator(s) (URL(s)). Methods may include generating, based on a user profile or group of user profiles and a redirect service that is accessed using the redirect URL, customized content associated with the scan. Methods may include redirecting the user or users to one or more target landing page URL(s), and providing to the user or users, through a browser on the mobile device or mobile devices, one or more than one target landing page(s) that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;PRZEKOP RICHARD JAMES;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J,,https://lens.org/108-029-976-200-676,Patent Application,yes,0,0,4,7,0,G06F16/9554;;G06F16/9566;;G06F16/9554;;G06F16/9558;;G06F16/954;;G06K19/06009;;G06F16/958,G06F16/955;;G06F16/958;;G06K19/06,,0,0,,,,ACTIVE
258,US,A1,US 2012/0212895 A1,124-106-167-330-995,2012-08-23,2012,US 201113183278 A,2011-07-14,US 201113183278 A;;US 201161445511 P,2011-02-22,LOW Z LINEAR VIBRATOR,A low Z linear vibrator is described well suited for use in small form factor portable devices such as a smartphone. The low Z vibrator can be configured to include a beam structure that can be attached to a vibratory mass and a low profile actuator. The low profile actuator can cause the vibratory mass to oscillate in a well-defined and predictable manner.,COHEN SAWYER;;SHUKLA ASHUTOSH YUGESH;;PLETENETSKYY ANDRIY;;MERZ NICHOLAS;;JOHNSON TIMOTHY MICHAEL;;PEREZ YEHONATAN;;APPLE INC,COHEN SAWYER;;SHUKLA ASHUTOSH YUGESH;;PLETENETSKYY ANDRIY;;MERZ NICHOLAS;;JOHNSON TIMOTHY MICHAEL;;PEREZ YEHONATAN,APPLE INC (2011-06-21),https://lens.org/124-106-167-330-995,Patent Application,yes,19,12,2,2,0,B06B1/12;;Y10T29/49826;;H04M1/026;;H10N30/20;;Y10T29/49826;;B06B1/12;;H10N30/20;;H04M1/026,B23P17/04;;H05K7/00;;H01L41/00,361/679.02;;29/428;;310/323.01,7,3,181-570-554-295-516;;010-385-426-605-430;;049-150-814-387-059,10.1117/12.851848;;22622989;;10.1109/tuffc.2012.2289;;10.3390/s90806046;;22454571;;pmc3312429,"Halmai, Attila, and Attila Luk�cs. ""New linear-electromagnetic actuator used for cellular phones."" Mechanical Engineering 51.1 (2008): 19-22.;;Suybangdum, P., P. Smithmaitrie, and P. Laoratanakul. ""Dual piezoelecttic actuators for the traveling wave ultrasonic linear motor."" Fourth International Conference on Experimental Mechanics. International Society for Optics and Photonics, 2009.;;Smithmaitrie, Pruittikorn, et al. ""Design and performance testing of an ultrasonic linear motor with dual piezoelectric actuators."" Ultrasonics, Ferroelectrics, and Frequency Control, IEEE Transactions on 59.5 (2012): 1033-1042.;;Ansari, M. Z, and Cho, C. ""Deflection, Frequency and Stress Characteristics of Rectangular, Triangular and Step Profile Microcantilevers for Biosensors"". Sensors 2009. p6046-6057.;;""Forced Vibration of a Cantilever Beam with a Lumped Mass at Free End"". Sakshat Virtual Labs. Indian Institute of Technology Guwahati. 2011;;Kyrychko, Y.N. et al. ""Modelling real-time dynamic substructuring using partial delay differential equations"". Proc. R. Soc. A (2007). Vol. 463. p 1509-1523.;;Roundy. S et al. ""Improving Power Output for Vibration-Based Energy Scavengers"". IEEE Pervasive Computing - Feb 2005. p28-35.",ACTIVE
259,GB,B,GB 2371134 B,073-437-128-520-129,2003-12-17,2003,GB 0208207 A,2000-09-22,US 0025928 W;;US 40429899 A;;US 53167800 A,1999-09-24,Software development system for facilitating selection of components,,PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY A;;SANDUSKY MARC SHANE,,https://lens.org/073-437-128-520-129,Granted Patent,no,3,0,6,13,0,G06F8/34;;G06F8/71,G06F9/44,G4A APGL          PGL,2,2,031-590-421-729-279;;008-415-162-305-380,10.1109/2.42014;;10.1109/4434.656779,"KRAMER J ET AL: ""GRAPHICAL CONFIGURATION PROGRAMMING"" COMPUTER, US, IEEE COMPUTER SOCIETY, VOL.22 NO.10 (1.10.89) PP53-65 XP000072735 ISSN:0018-9162;;LOQUES O ET AL: ""P-RIO: A MODULAR PARALLEL-PROGRAMMING ENVIRONMENT"" IEEE CONCURRENCY, US, IEEE SERVICE CENTRE, VOL.6 NO.1 1998, PP47-56, XP000737884 ISSN:1092-3063",EXPIRED
260,GB,A,GB 2371134 A,175-844-425-375-542,2002-07-17,2002,GB 0208207 A,2000-09-22,US 0025928 W;;US 40429899 A;;US 53167800 A,1999-09-24,Software development system for facilitating selection of components,"A software development system develops a product from core library of source code elements, the core library being categorized into components having one or more features. A configurator develops configuration state data based on a designated platform type and the source code elements. A graphical user interface displays a visual and logical representation of the product according to the configuration state data, including visual indications of any unresolved dependencies. A product make routine then generates the product from the source code elements according to the configuration state data.",PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY A;;SANDUSKY MARC SHANE,,https://lens.org/175-844-425-375-542,Patent Application,no,3,0,6,13,0,G06F8/34;;G06F8/71,G06F9/44,G4A APGL          PGL;;G4A APL           PL,2,2,031-590-421-729-279;;008-415-162-305-380,10.1109/2.42014;;10.1109/4434.656779,"KRAMER J ET AL: ""GRAPHICAL CONFIGURATION PROGRAMMING"" COMPUTER, US, IEEE COMPUTER SOCIETY, VOL.22 NO.10 (1.10.89) PP53-65 XP000072735 ISSN:0018-9162;;LOQUES O ET AL: ""P-RIO: A MODULAR PARALLEL-PROGRAMMING ENVIRONMENT"" IEEE CONCURRENCY, US, IEEE SERVICE CENTRE, VOL.6 NO.1 1998, PP47-56, XP000737884 ISSN:1092-3063",EXPIRED
261,WO,A1,WO 2021/168087 A1,019-753-109-845-127,2021-08-26,2021,US 2021/0018539 W,2021-02-18,US 202062978136 P,2020-02-18,REFACTORING OF STATIC MACHINE-READABLE CODES,"Methods, devices and systems for computing interactive customized content in response to a scan of a machine-readable label are provided. Illustrative methods may include receiving, from a user, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan, a redirect Uniform Resource Locator (URL). Methods may include generating, based on a user profile and a redirect service that is accessed using the redirect URL, comprising the customized content associated with the scan. Methods may include redirecting the user to a target landing page URL, and providing, to the user through a browser on the mobile device, a target landing page that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J;;PRZEKOP RICHARD JAMES,,https://lens.org/019-753-109-845-127,Patent Application,yes,5,0,3,7,0,G06F16/9554;;G06F16/9566;;G06F16/9535;;G06F16/9554;;G06F16/9558;;G06F16/9566;;G06K19/06009;;G06K19/06037,G06F15/16;;G10L21/00;;H04L29/08,,1,0,,,"OTHUON KIZI DIMIRA: ""Improving Customer Shopping Experience using an Android Barcode Reader Application"", DISSERTATION, STRATHMORE UNIVERSITY, NAIROBI, KENYA, 1 April 2018 (2018-04-01), XP055849026, Retrieved from the Internet <URL:https://su-plus.strathmore.edu/bitstream/handle/11071/5978/Improving%20customer%20shopping%20experience%20using%20an%20Android%20barcode%20reader%20application.pdf?sequence=1&isAllowed=y>",PENDING
262,EP,A1,EP 2970782 A1,176-871-720-075-69X,2016-01-20,2016,EP 14714097 A,2014-03-11,US 201361783720 P;;US 2014/0023339 W,2013-03-14,METHODS FOR TREATING A METATHESIS FEEDSTOCK WITH METAL ALKOXIDES,,ELEVANCE RENEWABLE SCIENCES,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,"WILMAR TRADING PTE LTD, SG (2020-09-23);;WILMAR TRADING PTE LTD; SG (2020-11-30)",https://lens.org/176-871-720-075-69X,Patent Application,yes,0,0,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,C10G25/00;;C07C6/02;;C10G3/00;;C10G29/16,,0,0,,,,ACTIVE
263,WO,A1,WO 2001/023998 A1,177-080-739-384-105,2001-04-05,2001,US 0025928 W,2000-09-22,US 40429899 A;;US 53167800 A,1999-09-24,SOFTWARE DEVELOPMENT SYSTEM FOR FACILITATING SELECTION OF COMPONENTS,"A software development system develops a product from core library of source code elements, the core library being categorized into components having one or more features. A configurator develops configuration state data based on a designated platform type and the source code elements. A graphical user interface displays a visual and logical representation of the product according to the configuration state data, including visual indications of any unresolved dependencies. A product make routine then generates the product from the source code elements according to the configuration state data.",PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,,https://lens.org/177-080-739-384-105,Patent Application,yes,3,17,6,13,0,G06F8/34;;G06F8/71,G06F9/44,,2,2,031-590-421-729-279;;008-415-162-305-380,10.1109/2.42014;;10.1109/4434.656779,"KRAMER J ET AL: ""GRAPHICAL CONFIGURATION PROGRAMMING"", COMPUTER,US,IEEE COMPUTER SOCIETY, LONG BEACH., CA, US, vol. 22, no. 10, 1 October 1989 (1989-10-01), pages 53 - 65, XP000072735, ISSN: 0018-9162;;LOQUES O ET AL: ""P-RIO: A MODULAR PARALLEL-PROGRAMMING ENVIRONMENT"", IEEE CONCURRENCY,US,IEEE SERVICE CENTER, PISCATAWAY, NY, vol. 6, no. 1, 1998, pages 47 - 56, XP000737884, ISSN: 1092-3063",PENDING
264,US,B2,US 11120095 B2,073-068-286-242-688,2021-09-14,2021,US 202117178955 A,2021-02-18,US 202117178955 A;;US 202062978136 P,2020-02-18,Refactoring of static machine-readable codes,"Methods, devices and systems for computing interactive customized content in response to a scan of a machine-readable label are provided. Illustrative methods may include receiving, from a user, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan, a redirect Uniform Resource Locator (URL). Methods may include generating, based on a user profile and a redirect service that is accessed using the redirect URL, comprising the customized content associated with the scan. Methods may include redirecting the user to a target landing page URL, and providing, to the user through a browser on the mobile device, a target landing page that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;PRZEKOP RICHARD JAMES;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J,THE DTX COMPANY (2021-02-16),https://lens.org/073-068-286-242-688,Granted Patent,yes,14,10,3,7,0,G06F16/9554;;G06F16/9566;;G06F16/9535;;G06F16/9554;;G06F16/9558;;G06F16/9566;;G06K19/06009;;G06K19/06037,G06F16/95;;G06F16/9535;;G06F16/955;;G06K19/06,,3,0,,,"www.medium.com, Punit Pathak, “ETL—Understanding It and Effectively Using It,” https://medium.com/hashmapinc/etl-understanding-it-and-effectively-using-it-f827a5b3e54d, Jan. 7, 2019.;;Strathmore University (Nairobi, Kenya), Kizi Dimira Othuon, “Improving Customer Experience Using an Android Barcode Reader Application,” https://su-plus.strathmore.edu/bitstream/handle/11071/5978/Improving%20customer%20shopping%20experience%20using%20an%20Android%20barcode%20reader%20application.pdf?sequence=l&isAllowed=y, Apr. 2018.;;International Searching Authority (ISA/US), International Search Report for International Application No. PCT/US2021/018539, dated May 7, 2021.",ACTIVE
265,US,B2,US 9944860 B2,171-832-663-087-85X,2018-04-17,2018,US 201414204753 A,2014-03-11,US 201414204753 A;;US 201361783720 P,2013-03-14,Methods for treating a metathesis feedstock with metal alkoxides,"Various methods are provided for treating and reacting a metathesis feedstock. In one embodiment, the method includes providing a feedstock comprising a natural oil, chemically treating the feedstock with a metal alkoxide under conditions sufficient to diminish catalyst poisons in the feedstock, and, following the treating, combining a metathesis catalyst with the feedstock under conditions sufficient to metathesize the feedstock.",ELEVANCE RENEWABLE SCIENCES,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,ELEVANCE RENEWABLE SCIENCES INC (2014-10-07);;MATERIA INC (2014-09-10);;WILMAR TRADING PTE LTD (2020-05-29),https://lens.org/171-832-663-087-85X,Granted Patent,yes,16,3,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,C10G3/00;;C10G25/00;;C10G29/16,,2,1,090-527-081-098-64X,10.1039/jr9630001192,"Davies, A.G.; Hall, C.D. “Peroxides of Elements other than Carbon. Part X. Organoperoxyaluminum Compounds as Intermediates in Redox Reactions”, J. Chem. Soc. (1963), pp. 1192-1197.;;International Search Report and Written Opinion of the International Searching Authority issued in PCT Patent Application No. PCT/US2014/023339, dated Jun. 11, 2014, 10 pages.",ACTIVE
266,US,A1,US 2009/0209563 A1,003-749-999-180-338,2009-08-20,2009,US 22191908 A,2008-08-07,US 22191908 A;;US 50977004 A;;US 0308455 W;;US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,"The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl;R 4 is hydrogen, halo, or C 1 -C 3 alkyl;R 5 is hydrogen or C 1 -C 3 alkyl;R 6 is hydrogen or C 1 -C 6 alkyl; andn is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;XU YAO-CHANG,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;XU YAO-CHANG,ELI LILLY AND COMPANY (2009-03-10),https://lens.org/003-749-999-180-338,Patent Application,yes,21,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,514/274;;546/194;;546/193;;514/318,0,0,,,,DISCONTINUED
267,EP,A1,EP 1835940 A1,115-972-855-555-754,2007-09-26,2007,EP 05826151 A,2005-12-02,US 2005/0043750 W;;US 2623504 A,2004-12-30,PROCESS FOR THE DESTRUCTION OF MICROORGANISMS ON A PRODUCT USING ULTRASONIC ENERGY,,KIMBERLY CLARK CO,BLENKE TIMOTHY JAMES;;EHLERT THOMAS D;;TANNER JAMES J;;KOENIG DAVID W;;COHEN BERNARD,,https://lens.org/115-972-855-555-754,Patent Application,yes,0,0,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/025;;A23L3/30;;B01J19/10;;B65B55/04,,1,0,,,See references of WO 2006073645A1,ACTIVE
268,TW,B,TW 523685 B,177-959-758-309-036,2003-03-11,2003,TW 89119651 A,2000-10-17,US 40429899 A;;US 53167800 A,1999-09-24,"A software development system that presents a logical view of project components, facilitates their selection, and signals missing links prior to compilation","A software development system develops a product from core library of source code elements, the core library being categorized into components having one or more features. A configurator develops configuration state data based on a designated platform type and the source code elements. A graphical user interface displays a visual and logical representation of the product according to the configuration state data, including visual indications of any unresolved dependencies. A product make routine then generates the product from the source code elements according to the configuration state data.",PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,,https://lens.org/177-959-758-309-036,Granted Patent,no,0,1,6,13,0,G06F8/34;;G06F8/71,G06F9/44,,0,0,,,,EXPIRED
269,WO,A1,WO 2006/073645 A1,134-605-612-014-966,2006-07-13,2006,US 2005/0043750 W,2005-12-02,US 2623504 A,2004-12-30,PROCESS FOR THE DESTRUCTION OF MICROORGANISMS ON A PRODUCT USING ULTRASONIC ENERGY,A process for the destruction of microorganisms on a product using ultrasonic energy is disclosed. The process comprises contacting a product with an ultrasonic horn assembly and generating ultrasonic energy sufficient to result in a microorganism destruction rate of at least a 1-log kill.,KIMBERLY CLARK CO;;BLENKE TIMOTHY JAMES;;EHLERT THOMAS D;;TANNER JAMES J;;KOENIG DAVID W;;COHEN BERNARD,BLENKE TIMOTHY JAMES;;EHLERT THOMAS D;;TANNER JAMES J;;KOENIG DAVID W;;COHEN BERNARD,,https://lens.org/134-605-612-014-966,Patent Application,yes,5,5,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/025;;A23L3/30;;B01J19/10;;B65B55/04,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 015, no. 512 (C - 0898) 26 December 1991 (1991-12-26);;PATENT ABSTRACTS OF JAPAN vol. 015, no. 377 (C - 0870) 24 September 1991 (1991-09-24)",PENDING
270,CN,A,CN 105189708 A,193-303-450-616-214,2015-12-23,2015,CN 201480014858 A,2014-03-11,US 2014/0023339 W;;US 201361783720 P,2013-03-14,Methods for treating a metathesis feedstock with metal alkoxides,"Various methods are provided for treating and reacting a metathesis feedstock. In one embodiment, the method includes providing a feedstock comprising a natural oil, chemically treating the feedstock with a metal alkoxide under conditions sufficient to diminish catalyst poisons in the feedstock, and, following the treating, combining a metathesis catalyst with the feedstock under conditions sufficient to metathesize the feedstock.",ELEVANCE RENEWABLE SCIENCES,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,,https://lens.org/193-303-450-616-214,Patent Application,no,4,0,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,C10G25/00;;C07C6/02;;C10G3/00;;C10G29/16,,0,0,,,,DISCONTINUED
271,EP,B1,EP 2970782 B1,194-981-329-111-053,2017-11-08,2017,EP 14714097 A,2014-03-11,US 201361783720 P;;US 2014/0023339 W,2013-03-14,METHODS FOR TREATING A METATHESIS FEEDSTOCK WITH METAL ALKOXIDES,,ELEVANCE RENEWABLE SCIENCES,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,"WILMAR TRADING PTE LTD, SG (2020-09-23);;WILMAR TRADING PTE LTD; SG (2020-11-30)",https://lens.org/194-981-329-111-053,Granted Patent,yes,3,0,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,C10G25/00;;C07C6/02;;C10G3/00;;C10G29/16,,0,0,,,,ACTIVE
272,US,B2,US 10051095 B2,064-002-807-029-447,2018-08-14,2018,US 201113183278 A,2011-07-14,US 201113183278 A;;US 201161445511 P,2011-02-22,Low Z linear vibrator,A low Z linear vibrator is described well suited for use in small form factor portable devices such as a smartphone. The low Z vibrator can be configured to include a beam structure that can be attached to a vibratory mass and a low profile actuator. The low profile actuator can cause the vibratory mass to oscillate in a well-defined and predictable manner.,COHEN SAWYER;;SHUKLA ASHUTOSH YUGESH;;PLETENETSKYY ANDRIY;;MERZ NICHOLAS;;JOHNSON TIMOTHY MICHAEL;;PEREZ YEHONATAN;;APPLE INC,COHEN SAWYER;;SHUKLA ASHUTOSH YUGESH;;PLETENETSKYY ANDRIY;;MERZ NICHOLAS;;JOHNSON TIMOTHY MICHAEL;;PEREZ YEHONATAN,APPLE INC (2011-06-21),https://lens.org/064-002-807-029-447,Granted Patent,yes,24,0,2,2,0,B06B1/12;;Y10T29/49826;;H04M1/026;;H10N30/20;;Y10T29/49826;;B06B1/12;;H10N30/20;;H04M1/026,H04M1/00;;B06B1/12;;H01L41/09;;H04M1/02,,3,3,108-670-954-441-35X;;181-570-554-295-516;;010-385-426-605-430,10.3311/pp.me.2007-1.03;;10.1117/12.851848;;22622989;;10.1109/tuffc.2012.2289,"Halmai, Attila, and Attila Lukács. “New linear-electromagnetic actuator used for cellular phones.” Mechanical Engineering 51.1 (2008): 19-22.;;Suybangdum, P., P. Smithmaitrie, and P. Laoratanakul. “Dual piezoelecttic actuators for the traveling wave ultrasonic linear motor.” Fourth International Conference on Experimental Mechanics. International Society for Optics and Photonics, 2009.;;Smithmaitrie, Pruittikorn, et al. “Design and performance testing of an ultrasonic linear motor with dual piezoelectric actuators.” Ultrasonics, Ferroelectrics, and Frequency Control, IEEE Transactions on 59.5 (2012): 1033-1042.",ACTIVE
273,KR,A,KR 20070089973 A,102-638-956-063-964,2007-09-04,2007,KR 20077014887 A,2005-12-02,US 2623504 A,2004-12-30,PROCESS FOR THE DESTRUCTION OF MICROORGANISMS ON A PRODUCT USING ULTRASONIC ENERGY,A process for the destruction of microorganisms on a product using ultrasonic energy is disclosed. The process comprises contacting a product with an ultrasonic horn assembly and generating ultrasonic energy sufficient to result in a microorganism destruction rate of at least a 1-log kill.,KIMBERLY CLARK CO,BLENKE TIMOTHY JAMES;;EHLERT THOMAS D;;TANNER JAMES J;;KOENIG DAVID W;;COHEN BERNARD,,https://lens.org/102-638-956-063-964,Patent Application,no,0,0,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/025;;A23L3/30;;B01J19/10;;B65B55/04,,0,0,,,,INACTIVE
274,US,B2,US 11920524 B2,046-912-945-343-784,2024-03-05,2024,US 17231742,2021-04-15,,,"Multi-fuel, fuel injection system for a turbine engine",An assembly is provided for a turbine engine with a flowpath. This turbine engine assembly includes a fuel injection system. The fuel injection system includes a first fuel injector and a second fuel injector. The fuel injection system is configured to provide the first fuel injector with first fuel and provide the second fuel injector with second fuel. The first fuel may be or include ammonia. The second fuel is different than the first fuel. The second fuel may be or include hydrogen gas. The first fuel injector is configured to direct the first fuel into the flowpath for combustion. The second fuel injector is configured to direct the second fuel into the flowpath for combustion.,Raytheon Technologies Corporation,Lance L. Smith;;Timothy S. Snyder;;Jeffrey M. Cohen;;Peter Cocks;;Sean C. Emerson,RTX CORPORATION (2021-04-15),https://lens.org/046-912-945-343-784,Granted Patent,yes,19,0,1,1,0,F02C9/40;;F02C7/22,F02C9/40;;F02C7/22,,1,0,,,"“Liquid Hydrogen as a Propulsion Fuel, 1945-1959”, https://history.nasa.gov/SP-4404/ch8-3.htm.",UNKNOWN
275,US,B1,US 8550004 B1,129-009-574-568-658,2013-10-08,2013,US 201213487688 A,2012-06-04,US 201213487688 A;;US 90524910 A;;US 25362509 P,2009-10-21,Riveted cartridge venting,"An IM type steel cartridge whose base contains a central bore there through—within which bore is a steel base plug holding a primer cup, the base plug being held in place by a low melt, 220 to 250 degree F. melt eutectic solder—wherein, if the cartridge is subjected to an unforeseen thermal or kinetic event, the solder will melt, the base plug ejected, and the propellant will vent rather than explode. The solder bond between the base plug and the cartridge case within which it is held is capable of resisting the from about 72,000, to up to 90,000 psi, force generated within the firing chamber of the weapon by the ignition and firing of the cartridge.",WOO TIMOTHY;;MOY LEON;;ELMASRI BISHARA;;MORALES CHRISTINA;;COHEN ALAN N;;PRILLAMAN DANIEL LEE;;US ARMY,WOO TIMOTHY;;MOY LEON;;ELMASRI BISHARA;;MORALES CHRISTINA;;COHEN ALAN N;;PRILLAMAN DANIEL LEE,U.S. GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (2012-09-27),https://lens.org/129-009-574-568-658,Granted Patent,yes,13,5,1,1,0,F42B39/20;;F42B39/20,F42B39/20,102/430;;102/481,0,0,,,,INACTIVE
276,US,A1,US 2021/0374206 A1,006-265-125-644-160,2021-12-02,2021,US 202117399285 A,2021-08-11,US 202117399285 A;;US 202117178955 A;;US 202062978136 P,2020-02-18,REFACTORING OF STATIC MACHINE-READABLE CODES,"Methods, devices and systems for computing interactive customized content in response to a scan, or multiple scans, of a machine-readable label are provided. Illustrative methods may include receiving, from a user or group of users, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan or scans, one, or more than one, redirect Uniform Resource Locator(s) (URL(s)). Methods may include generating, based on a user profile or group of user profiles and a redirect service that is accessed using the redirect URL, customized content associated with the scan. Methods may include redirecting the user or users to one or more target landing page URL(s), and providing to the user or users, through a browser on the mobile device or mobile devices, one or more than one target landing page(s) that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;PRZEKOP RICHARD JAMES;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J,THE DTX COMPANY (2021-08-15),https://lens.org/006-265-125-644-160,Patent Application,yes,0,0,4,7,0,G06F16/9554;;G06F16/9566;;G06F16/9554;;G06F16/9558;;G06F16/954;;G06K19/06009;;G06F16/958,G06F16/955;;G06F16/958;;G06K19/06,,0,0,,,,ACTIVE
277,US,A1,US 2022/0333534 A1,150-321-515-282-315,2022-10-20,2022,US 202117231742 A,2021-04-15,US 202117231742 A,2021-04-15,"MULTI-FUEL, FUEL INJECTION SYSTEM FOR A TURBINE ENGINE",An assembly is provided for a turbine engine with a flowpath. This turbine engine assembly includes a fuel injection system. The fuel injection system includes a first fuel injector and a second fuel injector. The fuel injection system is configured to provide the first fuel injector with first fuel and provide the second fuel injector with second fuel. The first fuel may be or include ammonia. The second fuel is different than the first fuel. The second fuel may be or include hydrogen gas. The first fuel injector is configured to direct the first fuel into the flowpath for combustion. The second fuel injector is configured to direct the second fuel into the flowpath for combustion.,RAYTHEON TECH CORP,SMITH LANCE L;;SNYDER TIMOTHY S;;COHEN JEFFREY M;;COCKS PETER;;EMERSON SEAN C,RTX CORPORATION (2021-04-15),https://lens.org/150-321-515-282-315,Patent Application,yes,6,3,1,1,0,F02C7/22;;F02C9/40;;F02C3/22;;F02C3/24;;F02C9/40;;F02C7/22,F02C9/40;;F02C7/22,,0,0,,,,ACTIVE
278,WO,A1,WO 2001/093031 A1,173-289-139-166-042,2001-12-06,2001,US 0109094 W,2001-03-20,US 53167800 A,2000-03-20,"A SOFTWARE DEVELOPMENT SYSTEM THAT PRESENTS A LOGICAL VIEW OF PROJECT COMPONENTS, FACILITATES THEIR SELECTION, AND SIGNALS MISSING LINKS PRIOR TO COMPILATION","A software development system (100) develops a product from core library of source code elements (900) the core library being categorized into components having one or more features. A configurator (700) develops configuration state data based on a designated platform type and the source code elements. A graphical user interface (200) displays a visual and logical representation of the product (1000) according to the configuration state data, include visual indications of any unresolved dependencies. A product make (800) routine then generates the product from the source code elements according to the configuration state data.",PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,,https://lens.org/173-289-139-166-042,Patent Application,yes,3,5,6,13,0,G06F8/34;;G06F8/71,G06F9/44,,1,0,,,See also references of EP 1266284A4,PENDING
279,CN,A,CN 115940366 A,009-547-531-096-221,2023-04-07,2023,CN 202211178543 A,2022-09-26,US 202117492940 A,2021-10-04,Bidirectional energy transfer system and method using supply device,"The invention provides a bidirectional energy transfer system and method using a supply device. A bi-directional energy transfer system includes a supply device having a vehicle port, an inverter port, a converter, and an isolation transformer. The vehicle port is configured to electrically couple the supply device to an electrically powered vehicle. The inverter port is configured to electrically couple the supply device to an inverter separate from the supply device.",FORD GLOBAL TECH LLC,SALTER STUART C;;O 'GORMAN ROBERT J;;HARRIS TIMOTHY;;PUNG PETER;;HOWARD-COHEN KATHERINE,,https://lens.org/009-547-531-096-221,Patent Application,no,0,0,4,4,0,Y02T10/70;;Y02T10/7072;;Y02T90/14;;B60L55/00;;B60L2210/12;;B60L2210/14;;B60L2210/40;;B60L53/14;;B60L53/30;;B60L55/00;;B60L53/14;;B60L2210/14;;B60L2210/12;;B60L2210/40,H02J7/02;;B60L53/14;;H02J3/32;;H02J7/35;;H02M3/335;;H02M7/217;;H02M7/537,,0,0,,,,PENDING
280,US,B2,US 11620352 B2,021-188-946-220-186,2023-04-04,2023,US 202217828143 A,2022-05-31,US 202217828143 A;;US 202117399285 A;;US 202117178955 A;;US 202062978136 P,2020-02-18,Refactoring of static machine-readable codes,"Methods, devices and systems for computing interactive customized content in response to a scan, or multiple scans, of a machine-readable label are provided. Illustrative methods may include receiving, from a user or group of users, a scan of a machine-readable optical label captured using a camera of a mobile device. Methods may include determining, based on the scan or scans, one, or more than one, redirect Uniform Resource Locator(s) (URL(s)). Methods may include generating, based on a user profile or group of user profiles and a redirect service that is accessed using the redirect URL, customized content associated with the scan. Methods may include redirecting the user or users to one or more target landing page URL(s), and providing to the user or users, through a browser on the mobile device or mobile devices, one or more than one target landing page(s) that includes the customized content.",THE DTX COMPANY,ASKARIAN AHMAD;;PRZEKOP RICHARD JAMES;;COHEN NEIL WAYNE;;DEVLIN PATRIK ANDREW;;LEMMON TIMOTHY J,,https://lens.org/021-188-946-220-186,Granted Patent,yes,82,0,4,7,0,G06F16/9554;;G06F16/9566;;G06F16/9554;;G06F16/9558;;G06F16/954;;G06K19/06009;;G06F16/958,G06F16/955;;G06F16/954;;G06F16/958;;G06K19/06,,22,1,081-219-474-303-287,10.1016/j.procs.2016.04.081,"Inderscience Enterprises Ltd., Wickramasinghe et al., “A Mathematical Model for Computational Aesthetics,” pp. 310-324, 2010, Int. J. Computational Vision and Robotics, vol. 1, No. 3.;;Elsevier, Maity et al., “A Computational Model to Predict Aesthetic Quality of Text Elements of GUI,” pp. 152-159, 2016, Procedia Computer Science 84 (2016), www.sciencedirect.com.;;AI Shack, Utkarsh Sinha, “Scanning QR Codes,” 2010, https://aishack.in/tutorials/scanning-qr-codes-1/.;;AIA Vision Online, “The Most Common Causes of Unreadable Barcodes,” Apr. 15, 2015, https://www.visiononline.org/vision-resources-details.cfm?content_id=5404.;;Workwithcolor.com, “Color Properties/Terminology,” Retrieved on Jun. 8, 2020, http://www.workwithcolor.com/color-properties-definitons-0101.htm.;;The Eurographics Association, Florian Hoenig, “Defining Computational Aesthetics,” 2005, Computational Aesthetics in Graphics, Visualization and Imaging (2005), www.diglib.eg.org.;;DataGenetics, “Wounded QR Codes,” Nov. 2013, http://datagenetics.com/blog/november12013/index.html.;;QR Code Monkey, “6 Reasons Why Your QR Code Is Not Working,” Retrieved on Jun. 9, 2020, https://www.qrcode-monkey.com/6-reasons-why-your-qr-code-is-not-working.;;TechSpot, Inc., Mark Turner, “QR Codes Explained,” Sep. 3, 2018, https://www.techspot.com/guides/1676-qr-code-explained/.;;Medium.com, Sciforce, “Computational Aesthetics: Shall We Let Computers Measure Beauty?,” Jun. 12, 2020, https://medium.com/sciforce/computational-aesthetics-shall-we-let-computers-measure-beauty-db2205989fb.;;Thonky.com, “Module Placement in Matrix,” Retrieved on Jun. 8, 2020, https://www.thonky.com/qr-code-tutorial/modale-placement-matrix.;;Keyence Corporation of America, “What Is a QR Code,” Retrieved on Jun. 8, 2020, https://www.keyence.com/ss/products/auto_id/barcode_lecture/basic_2d/qr/.;;Wikimedia Foundation, Inc., “QR Code,” Retrieved on Jun. 3, 2020, https://en.wikipedia.org/wiki/QR_code.;;Wikimedia Foundation, Inc., Walter Tuveli, “QR Code—Structure,” 2012, https://en.wikipedia.org/wiki/QR_code#/media/File:QRCode-2-Structure.png.;;Wikimedia Foundation, Inc., “ShotCode,” https://en.wikipedia.org/wiki/ShotCode#searchInput, Retrieved on Aug. 6, 2021.;;Medium.com, Punit Pathak, “ETL—Understanding It and Effectively Using It,” Jan. 7, 2019, https://medium.com/hashmapinc/etl-understanding-it-and-effectively-using-it-f827a5b3e54d.;;Strathmore University (Nairobi, Kenya), Kizi Dimira Othuon, “Improving Customer Experience Using an Android Barcode Reader Application,” Apr. 2018, https://su-plus.strathmore.edu/bitstream/handle/11071/5978/Improving%20customer%20shopping%20experience%20using%20an%20Android%20barcode%20reader%20application.pdf?sequence=1&isAllowed=y.;;Westboroughtv.org, Horrigan, Aidan, “Mr. WHS 2020,” Jun. 12, 2020, https://westboroughtv.org/mr-whs-2020-2/.;;Facebook.com, Wa, lzakaya, “QR codes for the dinner menu and lunch menu at Memorial!” Jul. 24, 2020, https://m.facebook.com/196433773873837/posts/qr-codes-for-the-dinner-menu-and-lunch-menu-at-memorial.1730306280486571.;;Ispot.tv, “StockX TV Spot, ‘Flowcode: Never Sold Out,’” Mar. 27, 2020, https://www.ispot.tv/ad/nVly/stockx-flowcode-never-sold-out.;;Nyp.org, “#FitForTheFrontline Challenge Unites Nation's Top Medical Centers to Support Frontline Healthcare Workers,” May 28, 2020, https://www.nyp.org/news/fit-for-the-frontline-challenge.;;International Searching Authority (ISA/US), International Search Report for International Application No. PCT/US2021/018539, dated May 7, 2021.",ACTIVE
281,US,B1,US 6487713 B1,107-013-747-751-121,2002-11-26,2002,US 40429899 A,1999-09-24,US 40429899 A,1999-09-24,"Software development system that presents a logical view of project components, facilitates their selection, and signals missing links prior to compilation","
    A software development system develops a product from core library of source code elements, the core library being categorized into components having one or more features. A configurator develops configuration state data based on a designated platform type and the source code elements. A graphical user interface displays a visual and logical representation of the product according to the configuration state data, includine visual indications of any unresolved dependencies. A product make routine then generates the product from the source code elements according to the configuration state data. 
",PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,PHOENIX TECHNOLOGIES LTD (2000-01-03),https://lens.org/107-013-747-751-121,Granted Patent,yes,13,353,1,13,0,G06F8/34;;G06F8/71;;G06F8/34;;G06F8/71,G06F9/44,717/105,5,5,018-100-922-411-917;;000-999-598-422-116;;111-759-353-218-178;;031-590-421-729-279;;008-415-162-305-380,10.1145/142621.142634;;10.1145/93605.93618;;10.1109/vl.1994.363608;;10.1109/2.42014;;10.1109/4434.656779,"Miyashita et al. Declarative Programming of Graphical Interfaces by Visual Examples. ACM. 1992. pp. 107-116.*;;Agrawal et al. OdeView: The Graphical Interface to Ode. ACM. 1990. pp. 34-43.*;;Viehstaedt et al. Interaction in Really Graphical User Interfaces. IEEE. 1994. pp. 270-277.*;;Kramer J. et al. ""Graphical Configuration Programming"" Computer, US, IEEE Computer Society, Long Beach, CA, US, vol. 22, No. 10, Oct. 1, 1989, pp. 53-65.;;Loques O. et al. ""P-RIO: A Modular Parallel-Programming Environment"" IEEE Concurrency, US, IEEE Service Center, Piscataway, NY, vol. 6, No. 1, 1998, pp. 47-56.",EXPIRED
282,MY,A,MY 172162 A,136-532-217-361-077,2019-11-15,2019,MY PI2015001912 A,2014-03-11,US 2014/0023339 W;;US 201361783720 P,2013-03-14,METHODS FOR TREATING A METATHESIS FEEDSTOCK WITH METAL ALKOXIDES,"Various methods are provided for treating and reacting a metathesis feedstock. In one embodiment, the method includes providing a feedstock comprising a natural oil, chemically treating the feedstock with a metal alkoxide under conditions sufficient to diminish catalyst poisons in the feedstock, and, following the treating, combining a metathesis catalyst with the feedstock under conditions sufficient to metathesize the feedstock.",WILMAR TRADING PTE LTD,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,,https://lens.org/136-532-217-361-077,Granted Patent,no,0,0,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,,,0,0,,,,ACTIVE
283,EP,A4,EP 1266284 A4,185-805-191-231-298,2003-08-06,2003,EP 01922536 A,2001-03-20,US 0109094 W;;US 53167800 A,2000-03-20,"A SOFTWARE DEVELOPMENT SYSTEM THAT PRESENTS A LOGICAL VIEW OF PROJECT COMPONENTS, FACILITATES THEIR SELECTION, AND SIGNALS MISSING LINKS PRIOR TO COMPILATION",,PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,,https://lens.org/185-805-191-231-298,Search Report,no,3,0,6,13,0,G06F8/34;;G06F8/71,G06F9/44,,3,2,031-590-421-729-279;;008-415-162-305-380,10.1109/2.42014;;10.1109/4434.656779,"KRAMER J ET AL: ""GRAPHICAL CONFIGURATION PROGRAMMING"", COMPUTER,US,IEEE COMPUTER SOCIETY, LONG BEACH., CA, US, vol. 22, no. 10, 1 October 1989 (1989-10-01), pages 53 - 65, XP000072735, ISSN: 0018-9162;;LOQUES O ET AL: ""P-RIO: A MODULAR PARALLEL-PROGRAMMING ENVIRONMENT"", IEEE CONCURRENCY,US,IEEE SERVICE CENTER, PISCATAWAY, NY, vol. 6, no. 1, 1998, pages 47 - 56, XP000737884, ISSN: 1092-3063;;See also references of WO 0193031A1",DISCONTINUED
284,EP,A1,EP 1266284 A1,013-969-589-645-136,2002-12-18,2002,EP 01922536 A,2001-03-20,US 0109094 W;;US 53167800 A,2000-03-20,"A SOFTWARE DEVELOPMENT SYSTEM THAT PRESENTS A LOGICAL VIEW OF PROJECT COMPONENTS, FACILITATES THEIR SELECTION, AND SIGNALS MISSING LINKS PRIOR TO COMPILATION",,PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,,https://lens.org/013-969-589-645-136,Patent Application,yes,0,0,6,13,0,G06F8/34;;G06F8/71,G06F9/44,,0,0,,,,DISCONTINUED
285,AU,A,AU 2001/049327 A,142-126-375-011-869,2001-12-11,2001,AU 2001/049327 A,2001-03-20,US 53167800 A;;US 0109094 W,2000-03-20,"A software development system that presents a logical view of project components, facilitates their selection, and signals missing links prior to compilation",,PHOENIX TECH LTD,COHEN FRANCES;;BOMBET MARC ABRAHAM;;LUSINSKY ROBERT DENNIS;;LEWIS TIMOTHY ANDREW;;SANDUSKY MARC SHANE,,https://lens.org/142-126-375-011-869,Patent Application,no,0,0,6,13,0,G06F8/34;;G06F8/71,G06F9/44,,0,0,,,,PENDING
286,DE,D1,DE 602005012735 D1,156-212-041-009-784,2009-03-26,2009,DE 602005012735 T,2005-12-02,US 2623504 A;;US 2005/0043750 W,2004-12-30,VERFAHREN ZUR ZERSTÖRUNG DER MIKROORGANISMEN AUF EINEM PRODUKT MIT ULTRASCHALLENERGIE,,KIMBERLY CLARK CO,BLENKE TIMOTHY JAMES;;EHLERT THOMAS D;;TANNER JAMES J;;KOENIG DAVID W;;COHEN BERNARD,,https://lens.org/156-212-041-009-784,Granted Patent,no,0,0,8,8,0,A23L3/30;;A23L3/30;;A23L3/30;;A61L2/025;;A61L2/025;;A61L2/025,A61L2/025;;A23L3/30;;B01J19/10;;B65B55/04,,0,0,,,,ACTIVE
287,WO,A1,WO 2014/150470 A1,190-833-243-612-949,2014-09-25,2014,US 2014/0023339 W,2014-03-11,US 201361783720 P,2013-03-14,METHODS FOR TREATING A METATHESIS FEEDSTOCK WITH METAL ALKOXIDES,"Various methods are provided for treating and reacting a metathesis feedstock. In one embodiment, the method includes providing a feedstock comprising a natural oil, chemically treating the feedstock with a metal alkoxide under conditions sufficient to diminish catalyst poisons in the feedstock, and, following the treating, combining a metathesis catalyst with the feedstock under conditions sufficient to metathesize the feedstock.",ELEVANCE RENEWABLE SCIENCES,COHEN STEVEN A;;ANDERSON DONDE R;;WANG ZHE;;CHAMPAGNE TIMOTHY M;;UNG THAY A,,https://lens.org/190-833-243-612-949,Patent Application,yes,13,3,7,7,0,C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;Y02P30/20;;C10G3/45;;Y02P30/20;;C10G25/003;;C10G29/16;;C10G2300/1014;;C10G2300/1018;;C10G3/45,C07C6/02;;C10G25/00;;C10G3/00;;C10G29/16,,0,0,,,,PENDING
288,US,B1,US 6757822 B1,037-993-312-907-106,2004-06-29,2004,US 58655800 A,2000-05-31,US 58655800 A,2000-05-31,"System, method and computer program product for secure communications using a security service provider manager","
    A system, method and computer program product are provided for managing the use of a plurality of security service providers during network communication. A first security service provider is utilized for affording secure communication between applications using a network. During operation, the system is monitored for events relating to the secure communication between the applications. Upon the detection of an event, a second security service provider is utilized for affording secure communication between the applications using the network. 
",NETWORKS ASSOC TECH INC,FEIERTAG RICHARD J;;THOMAS ROSHAN;;RHO JAISOOK;;COHEN EVE L;;ROSSET SEBASTIEN T;;REDMOND TIMOTHY,NVIDIA (2000-05-01);;NETWORKS ASSOCIATES TECHNOLOGY INC (2002-01-18);;MCAFEE INC (2004-11-19),https://lens.org/037-993-312-907-106,Granted Patent,yes,12,80,1,1,0,H04L63/1408;;H04L63/1441;;H04L63/1408;;H04L63/1441,H04L29/06,713/152;;713/164;;713/201;;709/224;;709/227,2,0,,,"Common Data Security Architecture Specification 1.0, Oct. 1996, Intel Corporation.*;;Microsoft Corporation; ""Microsoft CryptoAPI Overview""; Mar. 5, 1998; Microsoft Corporation.",EXPIRED
289,AU,A,AU 1987/075128 A,036-283-771-900-613,1987-12-22,1987,AU 1987/075128 A,1987-05-21,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS,,DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/036-283-771-900-613,Patent Application,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,EXPIRED
290,WO,A1,WO 2022/013642 A1,144-493-786-370-644,2022-01-20,2022,IB 2021055220 W,2021-06-14,US 202062705806 P,2020-07-16,PHOSPHATE-CONTAINING COPOLYMERS FOR VIRULENCE SUPPRESSION,"Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.",3M INNOVATIVE PROPERTIES CO,LASKOWSKI CARL A;;GILLARD TIMOTHY M;;PARTHASARATHY RANJANI V;;COHEN HANNAH C;;KRUZIKI MAX A,,https://lens.org/144-493-786-370-644,Patent Application,yes,3,0,4,4,0,C08G65/3353;;C08G65/22;;A61P31/04;;A61K31/80;;A61L2300/216;;A61L2300/404;;A61L2300/606;;A61L31/10;;A61L31/16;;A61L29/16;;A61L29/085;;A61L27/54;;A61L27/34;;A61K31/80;;C08G65/08;;C08G65/327;;C08G81/00;;C08G2650/58,C08G65/335;;A61K31/765;;A61P31/04;;C08G65/22,,4,4,002-131-552-489-864;;169-668-107-870-807;;139-223-755-733-800;;020-371-704-584-226,pmc3910877;;24277029;;10.1128/aac.02183-13;;10.1021/ma061040b;;10.1002/pola.23660;;10.1021/ja026835m;;12175215,"ALEXANDER ZABORIN ET AL: ""Phosphate-Containing Polyethylene Glycol Polymers Prevent Lethal Sepsis by Multidrug-Resistant Pathogens"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, no. 2, 25 November 2013 (2013-11-25), US, pages 966 - 977, XP055482017, ISSN: 0066-4804, DOI: 10.1128/AAC.02183-13;;HALACHEVA S ET AL: ""Poly(glycidol)-based analogues to pluronic block copolymers. Synthesis and aqueous solution properties"", MACROMOLECULES, AMERICAN CHEMICAL SOCIETY, US, vol. 39, 3 October 2006 (2006-10-03), pages 6845 - 6852, XP002549306, ISSN: 0024-9297, [retrieved on 20060831], DOI: 10.1021/MA061040B;;WANG Y ET AL: ""Synthesis and thermoresponsive behaviours of biodegradable Pluronic Analogs"", JOURNAL OF POLYMER SCIENCE A: POLYMER CHEMISTRY,, vol. 47, 1 January 2009 (2009-01-01), pages 6168 - 6179, XP002789491;;FREY, J. AM. CHEM. SOC., vol. 124, 2002, pages 9698",PENDING
291,WO,A1,WO 1995/008125 A1,071-887-470-764-722,1995-03-23,1995,US 9410507 W,1994-09-16,US 12314593 A;;US 22785494 A,1993-09-17,PRINTED CIRCUIT BOARD TESTER,"An apparatus and method are disclosed for testing connections between printed circuit boards and components mounted thereon. A conductive loop is formed by forward biasing a parasitic diode that is inherently present between an integrated circuit (IC) lead and the ground plane of the IC. A magnetic field is created by an antenna mounted above the component to be tested. When the antenna is energized by an RF source, a voltage is induced in the conductive loop if the loop is continuous, i.e., if all of the connections are properly made. The voltage in the loop is measured and compared to a selected threshold to produce a pass/fail indication. This tester may be implemented as an improvement to a standard type of 'bed-of-nails' printed circuit board tester. The antenna may be implemented as an array of spiral loop antennas, with adjacent antennas producing magnetic fields that are 90 degrees out of phase with each other.",TERADYNE INC,SHEEN TIMOTHY W;;CHEN JIANN-NENG;;COHEN STEPHEN A;;BAGLINO MICHAEL A;;WRINN JOSEPH F,,https://lens.org/071-887-470-764-722,Patent Application,yes,7,59,9,9,0,G01R31/303;;G01R31/315;;G01R31/70;;G01R31/315;;G01R31/303;;G01R31/70,G01R31/04;;G01R31/303;;G01R31/02;;G01R31/312;;G01R31/315,,0,0,,,,PATENTED
292,KR,B1,KR 910002674 B1,156-459-558-441-590,1991-05-03,1991,KR 880700093 A,1988-01-28,US 86808386 A;;US 896087 A;;US 4895887 A;;US 8701158 W,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS,,DU PONT,COHEN GORDON M;;REICH HANS J;;SPINELL HARRY J;;HUTCHINS CLYDE S;;COSTELLO TIMOTHY O,,https://lens.org/156-459-558-441-590,Granted Patent,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,EXPIRED
293,WO,A1,WO 2015/095850 A1,160-524-460-650-59X,2015-06-25,2015,US 2014/0071760 W,2014-12-20,US 201361918952 P;;US 201414173108 A,2013-12-20,METHOD TO DISTRIBUTE USER DATA AND ERROR CORRECTION DATA OVER DIFFERENT PAGE TYPES BY LEVERAGING ERROR RATE VARIATIONS,An apparatus includes a memory and a controller. The memory includes a plurality of memory devices. Each memory device has a plurality of page types. The plurality of page types are classified based on error rate variations. The controller may be configured to write user data and error-correction data to the memory. The user data and the error-correction data are organized as a super-page. The super-page includes a plurality of sub-pages. The plurality of sub-pages are written across the plurality of memory devices such that the plurality of sub-pages are stored using more than one of the plurality of page types.,SEAGATE TECHNOLOGY LLC,CAI YU;;CHEN NING;;WU YUNXIANG;;HARATSCH ERICH F;;COHEN EARL T;;CANEPA TIMOTHY L,,https://lens.org/160-524-460-650-59X,Patent Application,yes,5,1,3,3,0,G06F11/108;;G06F11/108;;G06F11/1048;;G06F11/1068;;G06F11/1072,G11C29/42,,0,0,,,,PENDING
294,AU,A,AU 1991/076139 A,114-158-981-106-674,1991-08-01,1991,AU 1991/076139 A,1991-04-29,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS,,DU PONT,COHEN GORDON MARK;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID;;REICH HANS JURGEN,,https://lens.org/114-158-981-106-674,Patent Application,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,EXPIRED
295,US,A,US 5631572 A,004-380-053-674-619,1997-05-20,1997,US 22785494 A,1994-04-15,US 22785494 A;;US 12314593 A,1993-09-17,Printed circuit board tester using magnetic induction,"An apparatus and method are disclosed for testing connections between printed circuit boards and components mounted thereon. A conductive loop is formed by forward biasing a parasitic diode that is inherently present between an integrated circuit (IC) lead and the ground plane of the IC. A magnetic field is created by an antenna mounted above the component to be tested. When the antenna is energized by an RF source, a voltage is induced in the conductive loop if the loop is continuous, i.e., if all of the connections are properly made. The voltage in the loop is measured and compared to a selected threshold to produce a pass/fail indication. This tester may be implemented as an improvement to a standard type of ""bed-of-nails"" printed circuit board tester. The antenna may be implemented as an array of spiral loop antennas, with adjacent antennas producing magnetic fields that are 90 degrees out of phase with each other.",TERADYNE INC,SHEEN TIMOTHY W;;CHEN JIANN-NENG;;COHEN STEPHEN A;;BAGLINO MICHAEL A;;WRINN JOSEPH F,TERADYNE INC (1994-05-19),https://lens.org/004-380-053-674-619,Granted Patent,yes,15,103,9,9,0,G01R31/303;;G01R31/315;;G01R31/70;;G01R31/315;;G01R31/303;;G01R31/70,G01R31/04;;G01R31/02;;G01R31/303;;G01R31/312;;G01R31/315,324/754;;324/95,0,0,,,,EXPIRED
296,NO,D0,NO 880368 D0,128-114-101-163-149,1988-01-28,1988,NO 880368 A,1988-01-28,US 86808386 A;;US 896087 A;;US 4895887 A;;US 8701158 W,1986-05-29,ACYLERING OG SULFONERING AV SILYLKETENACETALER.,,DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/128-114-101-163-149,Patent Application,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,DISCONTINUED
297,EP,B1,EP 0719418 B1,147-788-991-155-641,2002-12-04,2002,EP 94928611 A,1994-09-16,US 9410507 W;;US 12314593 A;;US 22785494 A,1993-09-17,PRINTED CIRCUIT BOARD TESTER,,TERADYNE INC,SHEEN TIMOTHY W;;CHEN JIANN-NENG;;COHEN STEPHEN A;;BAGLINO MICHAEL A;;WRINN JOSEPH F,,https://lens.org/147-788-991-155-641,Granted Patent,yes,7,1,9,9,0,G01R31/303;;G01R31/315;;G01R31/70;;G01R31/315;;G01R31/303;;G01R31/70,G01R31/02;;G01R31/04;;G01R31/303;;G01R31/312;;G01R31/315,,0,0,,,,EXPIRED
298,EP,A4,EP 0272285 A4,000-496-372-343-306,1990-04-10,1990,EP 87903641 A,1987-05-21,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS.,,DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/000-496-372-343-306,Search Report,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,2,0,,,No further relevant documents have been disclosed.;;See also references of WO 8707265A1,DISCONTINUED
299,NO,L,NO 880368 L,066-721-846-653-625,1988-03-28,1988,NO 880368 A,1988-01-28,US 86808386 A;;US 896087 A;;US 4895887 A;;US 8701158 W,1986-05-29,ACYLERING OG SULFONERING AV SILYLKETENACETALER.,,DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/066-721-846-653-625,Abstract,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,DISCONTINUED
300,US,A1,US 2023/0357500 A1,098-287-643-021-857,2023-11-09,2023,US 202118004910 A,2021-06-14,US 202118004910 A;;US 202062705806 P;;IB 2021055220 W,2020-07-16,PHOSPHATE-CONTAINING COPOLYMERS FOR VIRULENCE SUPPRESSION,"Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.",3M INNOVATIVE PROPERTIES COMPANY,LASKOWSKI CARL A;;GILLARD TIMOTHY M;;PARTHASARATHY RANJANI V;;COHEN HANNAH C;;KRUZIKI MAX A,3M INNOVATIVE PROPERTIES COMPANY (2022-01-14),https://lens.org/098-287-643-021-857,Patent Application,yes,0,0,4,4,0,C08G65/3353;;C08G65/22;;A61P31/04;;A61K31/80;;A61L2300/216;;A61L2300/404;;A61L2300/606;;A61L31/10;;A61L31/16;;A61L29/16;;A61L29/085;;A61L27/54;;A61L27/34;;A61K31/80;;C08G65/08;;C08G65/327;;C08G81/00;;C08G2650/58,C08G65/327;;A61K31/80;;C08G65/08;;C08G81/00,,0,0,,,,PENDING
301,EP,A1,EP 4182377 A1,142-205-298-513-923,2023-05-24,2023,EP 21739438 A,2021-06-14,US 202062705806 P;;IB 2021055220 W,2020-07-16,PHOSPHATE-CONTAINING COPOLYMERS FOR VIRULENCE SUPPRESSION,,3M INNOVATIVE PROPERTIES COMPANY,LASKOWSKI CARL A;;GILLARD TIMOTHY M;;PARTHASARATHY RANJANI V;;COHEN HANNAH C;;KRUZIKI MAX A,,https://lens.org/142-205-298-513-923,Patent Application,yes,0,0,4,4,0,C08G65/3353;;C08G65/22;;A61P31/04;;A61K31/80;;A61L2300/216;;A61L2300/404;;A61L2300/606;;A61L31/10;;A61L31/16;;A61L29/16;;A61L29/085;;A61L27/54;;A61L27/34;;A61K31/80;;C08G65/08;;C08G65/327;;C08G81/00;;C08G2650/58,C08G65/335;;A61K31/765;;A61P31/04;;C08G65/22,,0,0,,,,PENDING
302,US,B2,US 9262268 B2,063-430-081-721-438,2016-02-16,2016,US 201414173108 A,2014-02-05,US 201414173108 A;;US 201361918952 P,2013-12-20,Method to distribute user data and error correction data over different page types by leveraging error rate variations,An apparatus includes a memory and a controller. The memory includes a plurality of memory devices. Each memory device has a plurality of page types. The plurality of page types are classified based on error rate variations. The controller may be configured to write user data and error-correction data to the memory. The user data and the error-correction data are organized as a super-page. The super-page includes a plurality of sub-pages. The plurality of sub-pages are written across the plurality of memory devices such that the plurality of sub-pages are stored using more than one of the plurality of page types.,SEAGATE TECHNOLOGY LLC,CAI YU;;CHEN NING;;WU YUNXIANG;;HARATSCH ERICH F;;COHEN EARL T;;CANEPA TIMOTHY L,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-02-05),https://lens.org/063-430-081-721-438,Granted Patent,yes,12,8,3,3,0,G06F11/108;;G06F11/108;;G06F11/1048;;G06F11/1068;;G06F11/1072,G06F11/10,,0,0,,,,ACTIVE
303,EP,A1,EP 0719418 A1,081-078-172-961-077,1996-07-03,1996,EP 94928611 A,1994-09-16,US 9410507 W;;US 12314593 A;;US 22785494 A,1993-09-17,PRINTED CIRCUIT BOARD TESTER,,TERADYNE INC,SHEEN TIMOTHY W;;CHEN JIANN-NENG;;COHEN STEPHEN A;;BAGLINO MICHAEL A;;WRINN JOSEPH F,,https://lens.org/081-078-172-961-077,Patent Application,yes,0,1,9,9,0,G01R31/303;;G01R31/315;;G01R31/70;;G01R31/315;;G01R31/303;;G01R31/70,G01R31/02;;G01R31/04;;G01R31/303;;G01R31/312;;G01R31/315,,0,0,,,,EXPIRED
304,WO,A1,WO 1987/007265 A1,000-017-404-963-067,1987-12-03,1987,US 8701158 W,1987-05-21,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS,"Process for the preparation of beta-ketoesters or beta-sulfonylesters wherein silylketene acetals, including ''living'' (meth)acrylic polymers prepared by Group Transfer Polymerization (GTP), are reacted with an acyl compound, such as diphenyl terephthalate, or a sulfonyl compound such as benzene bis-sulfonyl fluoride, in the presence of a GTP-effective (oxy)anion catalyst such as bifluoride or m-chlorobenzoate. The keto- or sulfonylester products include capped ''living'' polymers, telechelic polymers, such as alpha, omega-dihydroxy polymethyl (meth)acrylate, chain-extended polymers, and branched or block copolymers. Telechelic polymers are useful for preparing cross-linked or block polymers by reaction of the functional end groups. AB block polymers, for example from methyl methacrylate and n-butyl acrylate, can also be prepared by coupling different polymeric silylketene acetals prepared by GTP with a diacyl compound such as diphenyl terephthalate. ABA block copolymers can be prepared by first preparing an AB block polymeric silylketene acetal by GTP, then coupling with a diacyl compound as just described. Especially useful ABA block copolymers have end segments (A) which are oxirane-containing (meth)acrylic moieties such as glycidyl methacrylate, separated by a central segment (B) which is a (meth)acrylic moiety without oxirane groups, such as methyl methacrylate. AB block copolymers containing hard and soft segments provide tough, flexible materials for adhesives and coatings. An ABA block copolymer having epoxy groups at the ends of the polymer chain provides enhanced toughness, and the triblock structure imparts improved outdoor durability in the use of these polymers as surface coatings, adhesives, castings, laminates and encapsulants for electronic parts.",DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/000-017-404-963-067,Patent Application,yes,10,2,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,C2C CAA;;C3J JCA           JCA;;C3P PFL           PFL;;C3W W225A;;C3W W229A;;U1S S1346;;U1S S1367;;U1S S1389;;U1S S1394;;U1S S3009,2,0,,,"CHEMICAL ABSTRACTS, Volume 61, No. 33, issued August 1964 (Columbus, Ohio, USA, GELIN, RENE et al, ""Preparation of beta-Oxo Diesters and beta-Diketone Esters"", the Abstract No. 4209, Compt. Rend. 258(19), 4783-4 (1964).;;See also references of EP 0272285A4",PENDING
305,ES,T3,ES 2185667 T3,073-261-931-718-306,2003-05-01,2003,ES 94928611 T,1994-09-16,US 12314593 A;;US 22785494 A,1993-09-17,APARATO PARA PROBAR UNA PLACA DE CIRCUITO IMPRESO.,"SE PRESENTA UN APARATO Y UN METODO PARA COMPROBAR LAS CONEXIONES ENTRE TARJETAS DE CIRCUITO IMPRESO Y LOS COMPONENTES MONTADOS SOBRE LAS MISMAS. UN CIRCUITO CONDUCTOR SE FORMA PARA DESVIAR HACIA ADELANTE UN DIODO PARASITICO QUE ESTA INHERENTEMENTE PRESENTE ENTRE UN TERMINAL DE CONEXION DE UN CIRCUITO INTEGRADO (IC) Y EL PLANO DE TIERRA DEL IC. SE CREA UN CAMPO MAGNETICO MEDIANTE UNA ANTENA MONTADA ENCIMA DEL COMPONENTE A COMPROBAR. CUANDO LA ANTENA ES DOTADA DE ENERGIA MEDIANTE UNA FUENTE DE RADIOFRECUENCIA, SE INDUCE UN VOLTAJE EN EL CIRCUITO CONDUCTOR SI EL CIRCUITO ES CONTINUO, POR EJEMPLO, SI TODAS LAS CONEXIONES ESTA APROPIADAMENTE HECHAS. EL VOLTAJE EN EL CIRCUITO SE MIDE Y SE COMPARA CON UN LIMITE SELECCIONADO PARA PRODUCIR UNA INDICACION DE FALLO. ESTE COMPROBADOR PUEDE IMPLEMENTARSE COMO UNA MEJORA A UN COMPROBADOR DE CIRCUITO IMPRESO ESTANDAR DEL TIPO DE ""LECHO DE PUNTAS"". LA ANTENA PUEDE IMPLEMENTARSE COMO UNA MATRIZ DE ANTENAS DE CIRCUITO, CON ANTENAS ADYACENTES QUE PRODUCEN CAMPOS MAGNETICOS QUE ESTAN 90 (GRADOS) FUERA DE FASE ENTRE UNAS Y OTRAS.",TERADYNE INC,SHEEN TIMOTHY W;;CHEN JIANN-NENG;;COHEN STEPHEN A;;BAGLINO MICHAEL A;;WRINN JOSEPH F,,https://lens.org/073-261-931-718-306,Granted Patent,no,0,0,9,9,0,G01R31/303;;G01R31/315;;G01R31/70;;G01R31/315;;G01R31/303;;G01R31/70,G01R31/02;;G01R31/04;;G01R31/303;;G01R31/312;;G01R31/315,,0,0,,,,EXPIRED
306,AU,B2,AU 612581 B2,179-502-212-818-990,1991-07-18,1991,AU 1987/075128 A,1987-05-21,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS,,DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/179-502-212-818-990,Granted Patent,no,3,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,EXPIRED
307,TW,B,TW 516174 B,194-806-272-394-225,2003-01-01,2003,TW 90102679 A,2001-02-07,US 50272900 A,2000-02-11,Diffusion barrier layer and semiconductor device containing same,"A semiconductor device containing a diffusion barrier layer is provided. The semiconductor device includes at least a semiconductor substrate containing conductive metal elements; and a diffusion barrier layer applied to at least a portion of the substrate in contact with the conductive metal elements, the diffusion barrier layer having an upper surface and a lower surface and a central portion, and being formed from silicon, carbon, nitrogen and hydrogen with the nitrogen being non-uniformly distributed throughout the diffusion barrier layer. Thus, the nitrogen is more concentrated near the lower and upper surfaces of the diffusion barrier layer as compared to the central portion of the diffusion barrier layer. Methods for making the semiconductor devices are also provided.",IBM,COHEN STEVEN ALAN;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;GATES STEPHEN MCCONNELL;;GIGNAC LYNNE MARIE,,https://lens.org/194-806-272-394-225,Granted Patent,no,0,0,13,13,0,H01L21/76826;;H01L21/76832;;H01L21/76834;;H01L23/53228;;H01L2924/0002;;H01L21/0217;;H01L21/28;;H01L21/3185;;H01L21/76834;;H01L21/76832;;H01L23/53228;;H01L21/76826;;H01L2924/0002,H01L21/28;;H01L21/31;;H01L21/316;;H01L21/318;;H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,EXPIRED
308,US,A1,US 2015/0178149 A1,092-297-659-039-358,2015-06-25,2015,US 201414173108 A,2014-02-05,US 201414173108 A;;US 201361918952 P,2013-12-20,METHOD TO DISTRIBUTE USER DATA AND ERROR CORRECTION DATA OVER DIFFERENT PAGE TYPES BY LEVERAGING ERROR RATE VARIATIONS,An apparatus includes a memory and a controller. The memory includes a plurality of memory devices. Each memory device has a plurality of page types. The plurality of page types are classified based on error rate variations. The controller may be configured to write user data and error-correction data to the memory. The user data and the error-correction data are organized as a super-page. The super-page includes a plurality of sub-pages. The plurality of sub-pages are written across the plurality of memory devices such that the plurality of sub-pages are stored using more than one of the plurality of page types.,LSI CORP,CAI YU;;CHEN NING;;WU YUNXIANG;;HARATSCH ERICH F;;COHEN EARL T;;CANEPA TIMOTHY L,SEAGATE TECHNOLOGY LLC (2014-09-02);;LSI CORPORATION (2014-02-05),https://lens.org/092-297-659-039-358,Patent Application,yes,8,48,3,3,0,G06F11/108;;G06F11/108;;G06F11/1048;;G06F11/1068;;G06F11/1072,G06F11/10,,0,0,,,,ACTIVE
309,EP,A1,EP 0272285 A1,127-979-745-746-653,1988-06-29,1988,EP 87903641 A,1987-05-21,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS.,"Procédé de préparation de bêta-cétoesters ou de bêta-sulfonylesters dans lequel des acétales de silylcétène, comprenant des polymères (méth)acryliques ''vivants'' préparés par Polymérisation par Transfert de Groupe (GTP), réagissent avec un composé d'acyle, tel que du diphényle téréphtalate, ou un composé de sulfonyle tel que du fluorure bis-sulfonyle de benzène, en présence d'un catalyseur contenant un (oxy)anion actif dans une GTP tel qu'un bifluorure ou du m-chlorobenzoate. Les produits à base de céto- ou de sulfonylester comprennent des polymères coiffés ''vivants'', des polymères téléchéliques, tels que l'alpha, oméga-dihydroxy polyméthyle (méth)acrylate, des polymères à chaîne étendue et des copolymères blocs ou ramifiés. Les polymères téléchéliques sont utiles dans la préparation de polymères blocs ou réticulés par la réaction des groupes terminaux fonctionnels. Les polymères blocs AB, dérivant par exemple du méthacrylate de méthyle et de l'acrylate de n-butyle peuvent être préparés également en couplant différents acétales polymères de silylcétène obtenus par GTP avec un composé de diacyle tel que le diphényle téréphtalate. Des copolymères blocs ABA peuvent être obtenus en préparant d'abord un acétale polymère de silylcétène à bloc AB par GTP, et en le couplant ensuite avec un composé de diacyle ainsi qu'il a été décrit ci-dessus. Des copolymères blocs ABA particulièrement utiles présentent des segments terminaux (A) qui sont des moitiés (méth)acryliques contenant de l'oxyrane telles que le méthacrylate de glycidyle, séparées par un segment central (B) qui est une moitié (méth)acrylique dépourvue de groupes oxyrane, tels que le méthacrylate de méthyle. Les copolymères blocs AB contenant des segments durs et souples permettent de produire des matériaux résistants et flexibles pouvant être utilisés comme adhésifs et comme revêtements. Un copolymère bloc ABA possédant des groupes époxy aux extrémités de la chaîne du polymère présente une meilleure résistance, et la structure à trois blocs augmente la",DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/127-979-745-746-653,Patent Application,yes,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,DISCONTINUED
310,CN,A,CN 115803034 A,049-047-450-432-828,2023-03-14,2023,CN 202180049238 A,2021-06-14,US 202062705806 P;;IB 2021055220 W,2020-07-16,Phosphate ester-containing copolymers for toxicity inhibition,"The invention provides a phosphate ester-containing copolymer, a medical composition containing the phosphate ester-containing copolymer, and a method for inhibiting the toxicity of a microorganism. Administration and/or application of the medical composition may be used to prevent, mitigate or treat microbial infections by inhibiting virulence. Phosphate ester-containing copolymers are prepared by phosphorylating random copolymers or random copolymerization blocks containing monomeric units of propylene oxide and glycidyl.",3M INNOVATIVE PROPERTIES COMPANY,LASKOWSKI CARL A;;GILLARD TIMOTHY M;;PARTHASARATHY RANJANI V;;COHEN HANNAH C;;KRUKIC MAX A,,https://lens.org/049-047-450-432-828,Patent Application,no,0,0,4,4,0,C08G65/3353;;C08G65/22;;A61P31/04;;A61K31/80;;A61L2300/216;;A61L2300/404;;A61L2300/606;;A61L31/10;;A61L31/16;;A61L29/16;;A61L29/085;;A61L27/54;;A61L27/34;;A61K31/80;;C08G65/08;;C08G65/327;;C08G81/00;;C08G2650/58,A61K31/765,,0,0,,,,PENDING
311,NO,D0,NO 911451 D0,056-277-328-106-348,1991-04-12,1991,NO 911451 A,1991-04-12,NO 911451 A;;NO 880368 A;;US 86808386 A;;US 896087 A;;US 4895887 A;;US 8701158 W,1986-05-29,FREMGANGSMAATE FOR FREMSTILLING AV EN ABA-BLOKK-KOPOLYMER MED ET MIDTSEGMENT MELLOM TO ENDESEGMENTER.,,DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/056-277-328-106-348,Patent Application,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,DISCONTINUED
312,NO,L,NO 911451 L,068-306-730-278-610,1988-03-28,1988,NO 911451 A,1991-04-12,NO 911451 A;;NO 880368 A;;US 86808386 A;;US 896087 A;;US 4895887 A;;US 8701158 W,1986-05-29,FREMGANGSMAATE FOR FREMSTILLING AV EN ABA-BLOKK-KOPOLYMER MED ET MIDTSEGMENT MELLOM TO ENDESEGMENTER.,"Fremgangsmåte for fremstilling av en ABA-blokk-kopolymer med et midtsegment mellom to endesegmenter, hvor hvert endesegment er en oxiranholdig acryl- eller methacryldel, og hvor midtsegmentet er en acryl- eller methacryldel som ikke inneholder oxi-rangrupper.BA-blokk-kopolymeren fremstilles ved omsetning av be-standdelene ved hjelp av gruppeover-føringspolymerisasjonsteknikker, idet en monofunksjonell initiator anvendes med egnede monomerer for å polymeri-sere sammen og i rekkefølge et første endesegment og deretter et midtseg-. ment, hvoretter det tilsettes koblingsmiddel for å bringe to midtsegmenter til å reagere med hverandre for dannelse av ABA-blokk-kopolyme-ren, eller en oxiranholdig initiator omsettes med egnede monomerer for polymerisering med midtsegmentet, hvoretter koblingsmiddel tilsettes for å bringe to midtsegmenter til å reagere med hverandre for dannelse av AB-blokk-kopolymeren.",DU PONT,COHEN GORDON MARK;;REICH HANS JURGEN;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID,,https://lens.org/068-306-730-278-610,Abstract,no,0,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,DISCONTINUED
313,AU,B2,AU 626496 B2,070-961-037-513-662,1992-07-30,1992,AU 1991/076139 A,1991-04-29,US 896087 A;;US 4895887 A;;US 86808386 A,1986-05-29,ACYLATION AND SULFONATION OF SILYLKETENE ACETALS,,DU PONT,COHEN GORDON MARK;;SPINELLI HARRY JOSEPH;;HUTCHINS CLYDE SPENCER;;COSTELLO TIMOTHY DAVID;;REICH HANS JURGEN,,https://lens.org/070-961-037-513-662,Granted Patent,no,2,0,16,36,0,C08F293/005,C07C69/738;;C07C67/00;;C07C69/716;;C07C313/00;;C07F7/00;;C08F/;;C08F293/00;;C08F297/02,,0,0,,,,EXPIRED
314,TW,B,TW I705071 B,039-930-605-571-292,2020-09-21,2020,TW 104134978 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Modified fgf-21 polypeptides and uses thereof,,BRISTOL MYERS SQUIBB CO,MORIN PAUL;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY;;CHRISTIAN ROSE;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/039-930-605-571-292,Granted Patent,no,3,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,,,0,0,,,,ACTIVE
315,US,A,US 5553306 A,015-102-272-032-885,1996-09-03,1996,US 30151294 A,1994-09-07,US 30151294 A;;US 99817592 A,1992-12-29,Method and apparatus for controlling parallel port drivers in a data processing system,"A parallel port interface for utilization between a first device and a second device designated by a user for transmitting a digital signal from the device to the second device. The parallel port interface includes a switchable driver circuit for transmitting the digital signal, which includes a first circuit for emulating an open collector circuit and a second circuit for emulating a totem pole circuit. The switchable driver circuit is controlled by a logic control circuit that automatically selects either the first circuit or the second circuit for transmitting the digital signal in response to the digital signal and a designation of the second device.",IBM,CLAFFEY-COHEN MARGARET;;LE PHAT T;;LOUIE TIMOTHY J;;NEEL II ALAN F;;WARD JAMES P,,https://lens.org/015-102-272-032-885,Granted Patent,yes,17,2,1,1,0,G06F13/4072;;G06F13/4072,G06F13/40,395/828;;X364DIG  1;;364/235;;364/238.2;;364/239.2;;364/240.7;;364/241;;395/284;;307/412,0,0,,,,EXPIRED
316,US,E,US RE040387 E,054-575-383-272-536,2008-06-17,2008,US 14950105 A,2005-06-09,US 14950105 A;;US 5739002 A;;US 26422801 P;;US 29001901 P,2001-01-25,"Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones","The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.",BRISTOL MYERS SQUIBB CO,BANDYOPADHYAY REBANTA;;MALLOY TIMOTHY M;;PANAGGIO ANDREA;;RAGHAVAN KRISHNASWAMY SRINIVAS;;VARIA SAILESH AMILAL;;COHEN MARVIN BARRY,,https://lens.org/054-575-383-272-536,Amended Patent,yes,48,0,34,132,0,A61K9/0095;;A61K31/425;;A61K31/427;;A61K47/10;;A61K47/44;;A61P35/00;;A61P43/00;;A61K31/425;;A61K47/44;;A61K9/0095;;A61K31/425;;A61K47/10;;A61K31/427,A61K9/00;;A61K31/425;;A61K9/08;;C07D491/044;;A61K9/10;;A61K9/28;;A61K31/33;;A61K31/335;;A61K31/427;;A61K31/497;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/44;;A61P35/00;;A61P43/00;;C07D493/04,514/365;;514/183;;514/254.07;;514/450,67,55,028-297-036-715-742;;089-988-872-488-130;;041-061-996-088-969;;108-736-198-818-236;;086-743-773-649-563;;106-313-919-903-725;;094-776-265-623-085;;039-007-085-295-44X;;096-642-908-089-525;;070-222-500-565-765;;023-914-080-628-362;;006-017-811-177-280;;058-866-316-570-918;;035-540-156-860-152;;013-405-968-928-634;;062-324-846-375-982;;028-731-229-293-063;;062-705-816-902-277;;151-775-210-023-294;;020-801-481-079-560;;064-346-126-335-173;;000-212-078-526-673;;100-870-475-754-40X;;041-347-536-963-842;;071-778-178-970-411;;071-778-178-970-411;;067-213-258-953-555;;165-570-740-926-449;;125-862-894-940-861;;094-265-873-178-208;;090-260-169-218-351;;030-977-061-045-964;;053-300-439-664-215;;042-839-137-569-263;;038-483-331-314-249;;042-419-917-598-187;;045-622-028-760-618;;041-433-843-465-721;;023-318-712-348-49X;;032-370-103-491-498;;063-229-386-630-92X;;064-075-338-095-384;;155-778-065-778-613;;078-726-772-143-128;;062-366-595-804-636;;068-954-838-322-578;;013-629-908-912-190;;019-293-517-474-324;;067-630-188-546-731;;093-544-729-500-35X;;171-944-604-529-239;;057-210-362-309-19X;;010-610-302-184-740;;008-940-881-772-95X;;004-385-899-157-757,9063071;;10.3322/canjclin.46.6.343;;8917020;;9363042;;8835634;;10.1254/jjp.71.89;;10.1002/anie.199628011;;10.1039/c2970000144a;;7757983;;10.1246/cl.1974.883;;10.1002/chin.197844151;;10.1021/jo00884a046;;10.1002/anie.199615671;;34182693;;10.1002/(sici)1521-3773(19990712)38:13/14<1971::aid-anie1971>3.0.co;2-x;;10.1055/s-1992-21397;;10.1074/jbc.272.4.2534;;8999970;;10.1021/jo00808a005;;10.1016/s0040-4039(00)99853-8;;10.1021/jo00905a040;;10.1021/jo00411a001;;10.1021/ja964275j;;10.1002/anie.199623991;;10.1002/anie.199705251;;10.1002/anie.199720971;;10.1021/ja971109i;;10.1021/ja971110h;;9153390;;10.1038/387268a0;;9153390;;10.1038/387268a0;;10.1021/jo00376a110;;10.1246/cl.1982.157;;10.1002/anie.199705231;;10.1055/s-1990-21128;;10.1021/ja00773a045;;10.1002/anie.199707571;;10.1002/anie.199720931;;10.1002/anie.199701661;;15989649;;10.1517/13543784.6.7.867;;11667778;;10.1021/jo961674o;;10.1021/cen-v074n052.p024;;10.1016/s0040-4039(96)02493-8;;10.1055/s-1997-5757;;10.1016/s0040-4039(96)02494-x;;10.1002/chin.199647256;;11667777;;10.1021/jo961673w;;10.1021/ja971946k;;10.1002/prac.19973390118;;10.1016/s0040-4039(96)02156-9;;10.1351/pac199971060989;;10400321;;10.1016/s0968-0896(98)00153-9;;10.1002/chem.19960021121;;10.1016/s0040-4039(97)00285-2;;10.1002/(sici)1521-3765(19990903)5:9<2483::aid-chem2483>3.0.co;2-n;;10.1002/(sici)1521-3765(19990903)5:9<2492::aid-chem2492>3.3.co;2-i;;9662505;;10.1016/s1074-5521(98)90070-9;;10.1016/s0304-419x(00)00009-3;;10799747;;10.1002/chem.19970031212;;10.1002/(sici)1521-3773(19980817)37:15<2014::aid-anie2014>3.0.co;2-2;;29711063;;10.1002/(sici)1521-3773(19980817)37:15<2014::aid-anie2014>3.3.co;2-u,"Martindale, The Extra Pharmacopoeia, 28<SUP>th </SUP>edition, published 1982 by the Pharmaceutical Press, pp. 640-641.;;Medline Abstract No. 97217050, Kumar, Indian Journal of Experimental Biology, (May 1996) 34(5), 391-402.;;Medline Abstract No. 97074593, Smith et al., CA: A Cancer Journal for Clinicians, (Nov.-Dec. 1996), 46(6), 343-63.;;Medline Abstract No. 1998029329, Rickels et al., Journal of Clinical Psychiatry, (1997) 58 Suppl. 11, 4-10.;;Medline Abstract No. 96432582, Oka et al., Japanese Journal of Pharmacology, (Jun. 1996) 71(2), 89-100.;;Cecil Textbook of Medicine, 21<SUP>st </SUP>Edition, vol. 1, published 2000 by W. B. Saunders Company, pp. 1060-1074.;;U.S. Appl. No. 08/856,533, Nicolaou et al., filed May 14, 1997.;;U.S. Appl. No. 08/923,869, Nicolaou et al., filed Sep. 4, 1997.;;U.S. Appl. No. 60/032,864, Nicolaou et al., filed Dec. 13, 1996.;;Balog, A., et al., ""Total Synthesis of (-)-Epothilone A"", Angew. Chem. Int. Ed. Engl.,vol. 35, No. 23/24, 2801-2803 (1996).;;Bertini, F., et al., ""Alekens from Epoxides by Reductive Elimination with Magnesium Bromide-Magnesium Amalgam"", Chem. Commun., 144 (1970).;;Bollag, D.M., et al., ""Epothilones, A New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action"", Cancer Res. 55, No. 11, 2325-2333 (1995).;;Fujisawa, T., et al., ""Deoxygenation of Epoxides to Olefins with FeCI<SUB>2</SUB>-n-BuLi System"", Chem. Lett., 883-886 (1974).;;Fujiwara, Y., et al., ""Reductive Coupling of Carbonyl Compounds to Olefins by Tungsten Hexachloride-Lithium Aluminum Hydride and Some Tungsten and Molybdenum Carbonyls"", J. Org. Chem., vol. 43, No. 12, 2477-2479 (1978).;;Gladysz, J. A., et al., ""Deoxygenation of Epoxides by Metal Atom Cocondensation"", J. Org. Chem., vol. 41, No. 22, 3647-3648 (1976).;;Holfe, G., et al., ""Epothilone A and B -Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution"", Angew. Chem. Int. Ed. Engl., vol. 35, no. 13/14, 1567-1569 (1996).;;Hofle, G., et al., ""N-Oxidation of Epothilone A-C and O-Acyl Rearrangement to C-19 and C-21-Substituted Epothilones"", Angew. Chem. Int. Ed., vol. 38, No. 13/14, 1971-1974 (1999).;;Inokuchi, T., et al., ""Opening of Epoxides to Olefins or Halohydrins with Vanadium(ii)-Tetrahydrofurofuran or Vanadium(III)-Tetrahydrofuran Complexes"", Synlett, No. 6, 510-512 (1992).;;Kowalaski. R. J., et al., ""Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol(R))"" J. Biol. Chem., vol. 272, No. 4, 2534-2541 (1997).;;Kupchan, S. M., et al., ""Reductive Elimination of Epoxides to Olefins with Zinc-Copper Couple"", J. Org. Chem., vol. 36, No. 9, 1187-1190 (1971).;;Martin, M. G., et al., ""Epoxides as Alkene Protecting Goups. A Mild and Efficient Deoxygenation"", Tetrahedron Letters, vol. 25, No. 3, 251-254 (1984).;;McMurry, J. E., et al., ""Reduction of Epoxides to Olefins with Low Valent Titanium"", J. Org. Chem., vol. 40, No. 17, 2555-2556 (1975).;;McMurry, J. E., et al., ""Some Deoxygenation Reactions with Low-Valent Titanium (TiCI<SUB>3</SUB>/LiAIH<SUB>4</SUB>)"", J. Org. Chem., vol. 43, No. 17, 3249-3254 (1978).;;Meng, D., et al., ""Remote Effects in Macrolide Formation Through Ring-Forming Olefin Methathesis: An Application to the Synthesis of Fully Active Epothilone Congeners"", J. Am. Chem. Soc., vol. 119, No. 11, 2733-2734 (1997).;;Nicolaou, K. C., et al., ""An Approach to Epothilones Based on Olefin Methathesis"",Angew. Chem. Int. Ed. Engl., vol. 35, No. 20, 2399-2401 (1996).;;Nicolaou, K. C., et al., ""Total Synthesis of Epothilone A: The Macrolactonization Approach"", Angew. Chem. Int. Ed. Engl., vol. 36, No. 5, 525-527 (1997).;;Nicolaou, K. C., et al., ""Designed Epothilones: Combinatorial Synthesis, Tubulin Assembly Properties, and Cytotoxic Action against Taxol-Resistant Tumor Cells"", Angew. Chem. Int. Ed. Engl., vol. 36, No. 19, 2097-2103 (1997).;;Nicolaou, K. C., et al., ""The Olefin Methathesis Approach to Epothilone A and Its Analogues"", J. Am. Chem. Soc., vol. 119, No. 34, 7960-7973 (1997).;;Nicolaou, K. C., et al., ""Total Synthesis of Epothilones A and B via a Macrolactonization-Based Strategy"", J. Am. Chem. Soc., vol. 119, No. 34, 7974-7991 (1997).;;Nicolaou, K. C., et al., ""Synthesis of Epothilones A and B in Solid and Solution Phase"", Nature, vol. 387, 268-272 (1997).;;Nicolaou, K. C., et al., ""Synthesis of Epothilones A and B in Solid and Solution Phase"" (Correction to Nature 387, 268-272 (1997)), Nature, 390, 100 (1997).;;Raucher, S., et al., ""Total Synthesis of (+)-Dihydrocostunolide via Tandem Cope-Claisen Rearrangement"", J. Org. Chem., vol. 51, No. 26, 5503-5505 (1986).;;Sato, M., et al., ""Reduction of Organic Compounds with Low-Valent Niobium (NbCl<SUB>5</SUB>/NaAIH<SUB>4</SUB>)"" Chem. Letters, 157-160 (1982).;;Schnizer, D., et al., ""Total Synthesis of (-)-Epothilone A"", Angew Chem. Int. Ed. Engl., vol. 36, No. 5, 523-524 (1997).;;Schobert, R., et al., ""Reduction and Isomerization of Oxiranes and alpha-Diazoketones by Various Early Transition Metallocenes"", Synlett, vol. 8, 465-466 (1990).;;Sharpless, K. B., et al., ""Lower Valent Tungsten Halides. A New Class of Reagents for Deoxygenation of Organic Molecules"", J. Amer. Chem. Soc., vol. 94, No. 18, 6538-6540 (1972).;;Su, D.-S., et al., ""Total Synthesis of (-)-Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure-Activity Relationships of the Epothilones"", Angew. Chem. Int. Ed. Engl., vol. 36, No. 7, 757-759 (1997).;;Su, D.-S, et al., ""Structure-Activity Relationships of the Epothilones and the First In Vivo Comparison with Paclitaxel"", Angew. Chem. Int. Ed. Engl., vol. 36, No. 19, 2093-2096 (1997).;;Victory, S. F., et al., ""Relative Stereochemistry and Solution Conformation of the Novel Paciltaxel-Like Antimitotic Agent Epothilone A"", Bioorg. Med. Chem. Letts., vol. 6, No. 7, 893-898 (1996).;;Winkler, J. D., et al., ""A Model For The Taxol (Paclitataxel)/Epothilone Pharmacophore"", Bioorg. Med. Chem. Letts., vol. 6, No. 24, 2963-2966 (1996).;;Yang, Z., et al., ""Total Synthesis of Epothilone A: The Olefin Metathesis Approach"",Angew. Chem. Int. Ed. Engl., vol. 36, No. 1/2, 166-168 (1997).;;Bollag, D., et al., ""Epothilone, A New Structural Class of Microtubule Stabilizer"", Abstract, Proc. Am. Assoc. Cancer Res., vol. 36, 86 Meet. 454 (1995).;;Bollag, D., ""Epothilones: Novel Microtubule-Stabilising Agents"", Expert Opin. Invest. Drugs, vol. 6, No. 7, 867-873 (1997).;;Bertinato, P., et al., ""Studies Toward a Synthesis of Epothilone A: Stereocontrolled Assembly of the Acyl Region and Models for Macrocyclization"", J. Org. Chem., vol. 6, No. 23, 8000-8001 (1996).;;Chemical & Engineering News, ""Epothilone Epiphany: Total Synthesis"", vol. 74, No. 52, 24-26 (1996).;;Chemical & Engineering News, ""First Total Synthesis of Epothilone B"", vol. 75, No. 13, 23 (1997).;;Chemical & Engineering News, ""Solid-Phase Epothilone Synthesis Used to Create Analog Library"", vol. 75, No. 20, 33 (1997).;;Claus, E., et al., ""Sythesis of the C1-C9 Segment of Epothilons"", Tetrahedron Lett., vol. 38, No. 8, 1359-1362 (1997).;;De Brabander, J., et al., ""Towards a Synthesis of Epothilone A: Rapid Assembly of the C1-C6 and C7-C12 Fragments"", Synlett, vol. 7, 824-826 (1997).;;Gabriel, T. and Wessjohann, L., ""The Chromium-Reformatsky Reaction: Asymmetric Synthesis of the Aldol Fragment of the Cytotoxic Epothilons from 3-(2-Bromoacyl)-2-Oxazolidinones"", Tetrahedron Lett., vol. 38, No. 8, 1363-1366 (1997).;;Gerth, K., et al., ""Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangiusm cellulosum (Myxobacterial) Production, Physico-chemical and Biological Properties"", J. Antibiotics, vol. 49, No. 6, 560-563 (1996).;;Marshall, A., ""Total Synthesis of Epothilone"", Nature Biotechnology, vol. 15, No. 3, 205 (1997).;;Meng, D., et al., ""Studies Toward a Synthesis of Epothilone A: Use of Hydropyran Templates for the Management of Acyclic-Stereochemical Relationships"", J. Org. Chem., vol. 61, No. 23, 7998-7999 (1996).;;Meng, D., et al., ""Total Synthesis of Epothilones A and B"", J. Am. Chem. Soc., vol. 119, No. 42, 10073-10092 (1997).;;Mensching, S., and Kalesse, M., ""Generation of Thiazoles by Colmn Dehydrogenation of Thiazolidines with MnO<SUB>2</SUB>"", J. Parkt. Chem., vol. 339, No. 1, 96-97 (1997).;;Mulzer, J. and Mantoulidis, A., ""Synthesis of the C(1)-C(9) Segment of the Cytotoxic Macrolides Epothilon A and B"", Tetrahedron Lett., vol. 37, No. 51, 9197-9182 (1996).;;Nicolaou, K., et al., ""Chemistry, Biology and Medicine of Selected Tubulin Polymerizing Agents"", Pure Appl. Chem., vol. 71, No. 6, 989-997 (1999).;;Nicolaou, K., et al., ""Total Synthesis of Epothilone E and Related Side-chain Modified Analogues Via a Stille Coupling Based Strategy"", Bioorg. Med. Chem., vol. 7, No. 5, 665-697 (1999).;;Schinzer, D., et al., ""Studies Towards the Total Synthesis of Epothilones: Asymmetric Synthesis of the Key Fragments"", Chem. Eug. J., vol. 2, No. 22, 1477-1482 (1996).;;Taylor, R., and Haley, J., ""Towards the Synthesis of Epothilone A: Enantioselective Preperation of the Thiazole Sidechain and Macrocyclic Ring Closure"", Tetrahedron Lett., vol. 38, No. 12, 2061-2064 (1997).;;Schinzer, D., et al., ""Synthesis of (-)-Epothilone A"", Chem. Eug. J., vol. 5, No. 9, 2483-2491 (1999).;;Schinzer, D., et al., ""Synthesis of (-)-Epothilone B"", Chem. Eur. J., vol. 5, No. 9, 2492-2500 (1999).;;Nicolaou, K. C., et al., ""Synthesis and Biological Properties of C12, 13-Cyclopropylepothilone A and Related Epothilones"", Chemistry & Biology, vol. 5, No. 7, 365-372 (1998).;;Altmann, K.H., et al., ""Epothilones and Related Structures-A New Class of Microtubule Inhibitors With Patent In Vivo Antitumor Activity,"" Biochim. Biophys Acta, 1470 (2000).;;Nicolaou et al., ""Total Synthesis of Epothilone E and Analogs with Modified Side Chains Through The Stille Coupling Reaction"", Angew. Chem. Int. Ed. 37, 84-87 (1998).;;Nicolaou et al., ""Total Synthesis of Oxazole- and Cyclopropane-Containing Epothilone B Analogues by the Macrolactonization Approach"", Chemistry, European Journal, vol. 3, No. 12, 1971-1986 (1997).;;Nicolaou et al., ""Chemical Biology of Epothilones"", Angew. Chem. Int. Ed., 37, 2014-2045 (1988).",PENDING
317,ES,T3,ES 2277074 T3,019-570-422-543-326,2007-07-01,2007,ES 03721402 T,2003-03-27,US 36908802 P,2002-03-29,PIRIDINOILPIPERIDINAS COM AGONISTAS DE 5-HT1F.,"Un compuesto de formula I o una sal de adición de ácido farmacéuticamente aceptable del mismo, en la que; R1 es alquilo C1-C6, alquilo C1-C6 sustituido, cicloalquilo C3-C7, cicloalquilo C3-C7 sustituido, cicloalquil C3-C7-alquilo C1-C3, cicloalquil C3-C7-alquilo C1-C3 sustituido, fenilo, fenilo sustituido, heterociclo, o heterociclo sustituido; R2 es hidrógeno, alquilo C1-C3, cicloalquil C3-C6-alquilo C1-C3, o un grupo de fórmula II R3 es hidrógeno o alquilo C1-C3; R4 es hidrógeno, halo, o alquilo C1-C3; R5 es hidrógeno o alquilo C1-C3; R6 es hidrógeno o alquilo C1-C6; y n es un número entero de 1 a 6 inclusive.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG,,https://lens.org/019-570-422-543-326,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
318,US,A1,US 2010/0081037 A1,156-729-862-325-540,2010-04-01,2010,US 24165308 A,2008-09-30,US 24165308 A,2008-09-30,BATTERY MANAGEMENT FOR OPTIMIZING BATTERY AND SERVICE LIFE,"The provision of a mode in silver zinc batteries where a user can access extra capacity as an emergency reserve for times when extra capacity is needed. While this temporarily increases capacity, it does not detrimentally affect cycle life over the longer term, and it permits a silver zinc battery to essentially mimic the long term capacity and cycle life characteristics of a lithium ion battery while still affording inherent advantages associated with silver zinc batteries. In a variant embodiment, this ability to temporarily increase capacity is optimally employed at the end of a battery life cycle in a controlled “roll-off” that accords additional cycles of battery service life. In another variant embodiment, the general capability to control capacity is employed to gradually decrease the available capacity of a battery over the life of the battery, to thereby extend the battery service life.",LENOVO SINGAPORE PTE LTD,JAKES PHILIP J;;CROMER DARYL;;WONG TIN-LUP;;CARLSON JEREMY R;;COHEN MARK E;;HUMPHREY TIMOTHY,LENOVO PC INTERNATIONAL LIMITED (2013-10-01);;LENOVO (SINGAPORE) PTE. LTD (2008-09-29);;ZPOWER LLC (2015-06-11);;RIOT ENERGY INC (2021-05-17);;LENOVO PC INTERNATIONAL (2013-10-01),https://lens.org/156-729-862-325-540,Patent Application,yes,3,3,2,2,0,H01M10/32;;H01M10/44;;H01M10/448;;H01M10/48;;Y02E60/10;;H01M10/44;;H01M10/448;;H01M10/32;;H01M10/48,H01M6/02,429/50;;429/61,0,0,,,,ACTIVE
319,TW,A,TW 201625667 A,066-091-382-440-408,2016-07-16,2016,TW 104134978 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY;;CHRISTIAN ROSE;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/066-091-382-440-408,Patent of Addition,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/18;;A61K47/48,,0,0,,,,ACTIVE
320,US,A1,US 2013/0203246 A1,134-707-367-542-972,2013-08-08,2013,US 201313826874 A,2013-03-14,US 201313826874 A;;US 201113027797 A,2011-02-15,SEMICONDUCTOR CHIP WITH GRAPHENE BASED DEVICES IN AN INTERCONNECT STRUCTURE OF THE CHIP,"A semiconductor structure includes a first dielectric material including at least one first conductive region contained therein. The structure also includes at least one graphene containing semiconductor device located atop the first dielectric material. The at least one graphene containing semiconductor device includes a graphene layer that overlies and is in direct with the first conductive region. The structure further includes a second dielectric material covering the at least one graphene containing semiconductor device and portions of the first dielectric material. The second dielectric material includes at least one second conductive region contained therein, and the at least one second conductive region is in contact with a conductive element of the at least one graphene containing semiconductor device.",IBM;;IBM,DIMITRAKOPOULOS CHRISTOS D;;COHEN GUY;;GATES STEPHEN M;;GRILL ALFRED;;MCARDLE TIMOTHY J;;SUNG CHUN-YUNG,GLOBALFOUNDRIES U.S. INC (2020-10-22);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/134-707-367-542-972,Patent Application,yes,0,3,4,4,0,H01L29/1606;;H01L29/41766;;H01L29/42356;;H01L29/66431;;H01L2924/00013;;H01L29/778;;H01L29/42356;;H01L29/41766;;H01L29/66431;;H01L29/1606;;H01L2924/00013;;H01L29/778;;H01L21/02527,H01L21/02,438/478,0,0,,,,ACTIVE
321,AR,A1,AR 104475 A1,147-019-333-544-171,2017-07-26,2017,AR P150103456 A,2015-10-23,US 201462068296 P,2014-10-24,POLIPÉPTIDOS FGF-21 MODIFICADOS Y SUS USOS,"Polipéptidos FGF-21 (factor de crecimiento de fibroblastos-21) modificados y sus usos, por ejemplo, para el tratamiento de enfermedades asociadas a la fibrosis. Se describen polipéptidos FGF-21 modificados que contienen una eliminación interna y opcionalmente un péptido de reemplazo, opcionalmente modificado con al menos un aminoácido codificado de manera no natural, y/u opcionalmente fusionado a un componente de fusión. Ácido nucleico; célula; método; composición.",BRISTOL MYERS SQUIBB CO,JOHN KRUPINSKI;;RAY CAMPHAUSEN;;DASA LIPOVSEK;;ROSE CHRISTIAN;;TIMOTHY REILLY;;RANJAN MUKHERJEE;;DANIEL COHEN;;PAUL MORIN,,https://lens.org/147-019-333-544-171,Patent Application,no,0,1,1,64,0,,C07K14/50;;A61K38/18;;A61K45/06;;A61P7/00;;C12N5/10;;C12N15/12;;C12P21/02,,0,0,,,,PENDING
322,UY,A,UY 36370 A,185-381-228-196-89X,2016-04-29,2016,UY 36370 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,POLIPÉPTIDOS FGF-21 MODIFICADOS Y SUS USOS,"Se proporcionan polipéptidos FGF-21 modificados y sus usos, por ejemplo, para el tratamiento de enfermedades asociadas a la fibrosis. Se describen polipéptidos FGF-21 modificados que contienen una eliminación interna y opcionalmente un péptido de reemplazo, opcionalmente modificado con al menos un aminoácido codificado de manera no natural, y/u opcionalmente fusionado a un componente de fusión.",BRISTOL MYERS SQUIBB COMPANY UNA CORPORACIÓN DEL ESTADO DE DELAWARE,PAUL MORIN;;DANIEL COHEN;;RANJAN MUKHERJEE;;TIMOTHY REILLY;;ROSE CHRISTIAN;;DA LIPOVSEK;;RAY CAMPHAUSEN;;JOHN KRUPINSKI,,https://lens.org/185-381-228-196-89X,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61P1/00;;A61K38/18;;A61K47/48;;A61P3/00;;C07K14/50;;C12N5/10;;C12N15/70;;C12N15/81;;C12N15/85;;C12P21/02,,0,0,,,,DISCONTINUED
323,US,B2,US 8481186 B2,068-291-630-026-150,2013-07-09,2013,US 24165308 A,2008-09-30,US 24165308 A,2008-09-30,Battery management for optimizing battery and service life,"The provision of a mode in silver zinc batteries where a user can access extra capacity as an emergency reserve for times when extra capacity is needed. While this temporarily increases capacity, it does not detrimentally affect cycle life over the longer term, and it permits a silver zinc battery to essentially mimic the long term capacity and cycle life characteristics of a lithium ion battery while still affording inherent advantages associated with silver zinc batteries. In a variant embodiment, this ability to temporarily increase capacity is optimally employed at the end of a battery life cycle in a controlled “roll-off” that accords additional cycles of battery service life. In another variant embodiment, the general capability to control capacity is employed to gradually decrease the available capacity of a battery over the life of the battery, to thereby extend the battery service life.",JAKES PHILIP J;;CROMER DARYL;;WONG TIN-LUP;;CARLSON JEREMY R;;COHEN MARK E;;HUMPHREY TIMOTHY;;LENOVO SINGAPORE PTE LTD,JAKES PHILIP J;;CROMER DARYL;;WONG TIN-LUP;;CARLSON JEREMY R;;COHEN MARK E;;HUMPHREY TIMOTHY,LENOVO PC INTERNATIONAL LIMITED (2013-10-01);;LENOVO (SINGAPORE) PTE. LTD (2008-09-29);;ZPOWER LLC (2015-06-11);;RIOT ENERGY INC (2021-05-17);;LENOVO PC INTERNATIONAL (2013-10-01),https://lens.org/068-291-630-026-150,Granted Patent,yes,3,6,2,2,0,H01M10/32;;H01M10/44;;H01M10/448;;H01M10/48;;Y02E60/10;;H01M10/44;;H01M10/448;;H01M10/32;;H01M10/48,H01M2/00,429/61;;429/50;;429/60;;429/90,0,0,,,,ACTIVE
324,CN,A,CN 116262448 A,065-539-222-165-247,2023-06-16,2023,CN 202211550732 A,2022-12-05,US 202117550216 A,2021-12-14,Bidirectional energy transfer systems and methods utilizing wire assemblies,"The present disclosure provides a bi-directional energy transfer system and method utilizing a wire assembly. A bi-directional energy transfer system includes a wire assembly of the bi-directional energy transfer system that transfers power from a device to at least one battery array within a traction battery of an electrically powered vehicle when the wire assembly is operated in a first condition, and that transfers power from the device to at least one battery array within a traction battery of the electrically powered vehicle when the wire assembly is operated in a second condition. The wire assembly transfers power from the at least one battery array to the device. The wire assembly may include a relay powered by the at least one battery array when the wire assembly is operating in the second condition.",FORD GLOBAL TECH LLC,RICHARD MO;;HARRIS TIMOTHY;;O 'GORMAN ROBERT J;;SALTER STUART C;;HOWARD-COHEN KATHERINE;;PUNG PETER,,https://lens.org/065-539-222-165-247,Patent Application,no,0,0,3,3,0,B60L53/18;;B60L55/00;;B60L53/20;;Y02T10/7072;;Y02T10/70;;Y02T90/14;;H02J7/0068;;H02J2310/48;;B60L53/18;;B60L55/00;;B60L2210/42;;B60L55/00;;B60L53/18;;H02J2207/20;;B60L2210/42;;H02J2310/12;;H02J7/0068,B60L53/18;;B60L53/20;;B60L55/00,,0,0,,,,PENDING
325,US,B2,US 8658488 B2,178-488-464-068-300,2014-02-25,2014,US 201313826874 A,2013-03-14,US 201313826874 A;;US 201113027797 A,2011-02-15,Method for forming semiconductor chip with graphene based devices in an interconnect structure of the chip,"A graphene layer is provided onto at least an upper surface of a first dielectric material which includes at least one first conductive region contained therein. At least one semiconductor device is formed using the graphene layer as an element of the at least one semiconductor device. After forming the at least one semiconductor device, a second dielectric material is formed covering the graphene layer, the at least one semiconductor device, and portions of the first dielectric material. The second dielectric that is formed includes at least one second conductive region contained therein, and the at least one second conductive region is in contact with a conductive element of the at least one semiconductor device.",IBM,DIMITRAKOPOULOS CHRISTOS D;;COHEN GUY;;GATES STEPHEN M;;GRILL ALFRED;;MCARDLE TIMOTHY J;;SUNG CHUN-YUNG,GLOBALFOUNDRIES U.S. INC (2020-10-22);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/178-488-464-068-300,Granted Patent,yes,2,4,4,4,0,H01L29/1606;;H01L29/41766;;H01L29/42356;;H01L29/66431;;H01L2924/00013;;H01L29/778;;H01L29/42356;;H01L29/41766;;H01L29/66431;;H01L29/1606;;H01L2924/00013;;H01L29/778;;H01L21/02527,H01L21/8238,438/199;;438/197;;438/198;;438/590;;X438E29255,2,2,006-585-476-226-393;;087-721-736-366-678,10.1021/nn901585p;;20099904;;20562870;;10.1038/nnano.2010.132,"Caldwell, J. D. et al., Technique for the Dry Transfer of Epitaxial Graphene onto Arbitrary Substrates, ACS Nano, 2010, pp. 1108-1114, vol. 4, No. 2.;;Bae, S. et al., Roll-to-roll production of 30-inch graphene films for transparent electrodes, Nature Nanotechnology, Aug. 2010, pp. 574-578, vol. 5.",ACTIVE
326,ES,T3,ES 2945662 T3,100-706-721-888-530,2023-07-05,2023,ES 17840058 T,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,Dispositivo para la impresión de un artículo cosmético tridimensional a partir de un material de construcción que comprende una fórmula cosmética,"Un dispositivo que imprime un artículo cosmético tridimensional a partir de un material de construcción que incluye una fórmula cosmética tiene una extrusora, una placa de construcción, un controlador y un sistema de posicionamiento. El controlador está programado para indicar al sistema de posicionamiento que posicione la extrusora en relación con la placa de construcción. La extrusora incluye un sistema de extrusión de pistón. El material de construcción se proporciona a la extrusora como una barra preformada. El material de construcción se extruye sobre un sustrato para formar el artículo. La placa de construcción incluye un sistema de dimensionamiento para recibir sustratos de varios tamaños. (Traducción automática con Google Translate, sin valor legal)",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/100-706-721-888-530,Granted Patent,no,0,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/106;;B29C35/16;;B29C64/209;;B29C64/245;;B29C64/364;;B29L31/00;;B33Y30/00,,0,0,,,,ACTIVE
327,WO,A1,WO 2018/031405 A1,026-210-049-504-242,2018-02-15,2018,US 2017/0045498 W,2017-08-04,US 201662374153 P,2016-08-12,DEVICE FOR PRINTING A THREE DIMENSIONAL COSMETIC ARTICLE FROM A BUILD MATERIAL COMPRISING A COSMETIC FORMULA,"A device printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/026-210-049-504-242,Patent Application,yes,9,4,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00,,1,0,,,See also references of EP 3496932A4,PENDING
328,CN,A,CN 114030176 A,005-307-896-068-305,2022-02-11,2022,CN 202111311577 A,2017-08-04,US 201662374153 P;;CN 201780063437 A,2016-08-12,Device for printing three dimensional cosmetic article from build material comprising cosmetic formula,"A device for printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/005-307-896-068-305,Patent Application,no,4,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00;;B33Y10/00;;B33Y30/00;;B33Y50/02,,0,0,,,,PENDING
329,GB,A,GB 2584009 A,005-122-674-096-481,2020-11-18,2020,GB 202004178 A,2018-08-24,US 201762551107 P;;US 201762563025 P;;US 201862652161 P;;US 2018/0047969 W,2017-08-28,Aminoglycosides and uses thereof,"Provided herein are aminoglycoside compounds, such as compounds of formula (I), (II), (III), (IV), (IVa), (V), (VI), (VIIa), or (VIIb) or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers of any of the foregoing, useful as therapeutic or prophylactic agents. Also provided herein are methods for their preparation. The compounds may be useful in treating a bacterial infection in a subject, for example a Gram-negative bacterial infection.",REVAGENIX INC,LOGAN ANDREWS;;ANDREW CALABRESE;;TIMOTHY ROBERT KANE;;RYAN CIRZ;;FREDERICK COHEN;;MICHAEL LOPEZ;;JOHN KNOX;;NIKOLAI EVDOKIMOV,"REVAGENIX, INC (2020-05-20)",https://lens.org/005-122-674-096-481,Patent Application,no,3,0,5,5,0,C07H15/232;;C07H15/26;;A61P31/04;;A61P31/04;;C07H15/232;;C07H15/26;;A61P31/04;;C07H15/232;;C07H15/26,A61K31/7028;;A61K31/7034;;A61K31/7036;;C07H15/226;;C07H15/228,,0,0,,,,PENDING
330,EP,A4,EP 3496932 A4,152-686-510-691-122,2019-09-11,2019,EP 17840058 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,DEVICE FOR PRINTING A THREE DIMENSIONAL COSMETIC ARTICLE FROM A BUILD MATERIAL COMPRISING A COSMETIC FORMULA,,ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/152-686-510-691-122,Search Report,no,5,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/106;;B29C35/16;;B29C64/209;;B29C64/245;;B29C64/364;;B29L31/00;;B33Y30/00,,1,0,,,See also references of WO 2018031405A1,ACTIVE
331,US,B2,US 8440999 B2,027-787-298-851-280,2013-05-14,2013,US 201113027797 A,2011-02-15,US 201113027797 A,2011-02-15,Semiconductor chip with graphene based devices in an interconnect structure of the chip,"A semiconductor structure includes a first dielectric material including at least one first conductive region contained therein. The structure also includes at least one graphene containing semiconductor device located atop the first dielectric material. The at least one graphene containing semiconductor device includes a graphene layer that overlies and is in direct with the first conductive region. The structure further includes a second dielectric material covering the at least one graphene containing semiconductor device and portions of the first dielectric material. The second dielectric material includes at least one second conductive region contained therein, and the at least one second conductive region is in contact with a conductive element of the at least one graphene containing semiconductor device.",DIMITRAKOPOULOS CHRISTOS D;;COHEN GUY M;;GATES STEPHEN M;;GRILL ALFRED;;MCARDLE TIMOTHY J;;SUNG CHUN-YUNG;;IBM,DIMITRAKOPOULOS CHRISTOS D;;COHEN GUY M;;GATES STEPHEN M;;GRILL ALFRED;;MCARDLE TIMOTHY J;;SUNG CHUN-YUNG,GLOBALFOUNDRIES U.S. INC (2020-10-22);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-02-14);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/027-787-298-851-280,Granted Patent,yes,1,11,4,4,0,H01L29/1606;;H01L29/41766;;H01L29/42356;;H01L29/66431;;H01L2924/00013;;H01L29/778;;H01L29/42356;;H01L29/41766;;H01L29/66431;;H01L29/1606;;H01L2924/00013;;H01L29/778;;H01L21/02527,H01L29/78,257/24;;257/29;;257/347;;257/369;;257/76,2,2,006-585-476-226-393;;087-721-736-366-678,10.1021/nn901585p;;20099904;;20562870;;10.1038/nnano.2010.132,"Caldwell, J. D. et al., Technique for the Dry Transfer of Epitaxial Graphene onto Arbitrary Substrates, ACS Nano, 2010, pp. 1108-1114, vol. 4, No. 2.;;Bae, S. et al., Roll-to-roll production of 30-inch graphene films for transparent electrodes, Nature Nanotechnology, Aug. 2010, pp. 574-578, vol. 5.",ACTIVE
332,US,A1,US 2012/0205626 A1,003-558-365-768-859,2012-08-16,2012,US 201113027797 A,2011-02-15,US 201113027797 A,2011-02-15,SEMICONDUCTOR CHIP WITH GRAPHENE BASED DEVICES IN AN INTERCONNECT STRUCTURE OF THE CHIP,"A semiconductor structure includes a first dielectric material including at least one first conductive region contained therein. The structure also includes at least one graphene containing semiconductor device located atop the first dielectric material. The at least one graphene containing semiconductor device includes a graphene layer that overlies and is in direct with the first conductive region. The structure further includes a second dielectric material covering the at least one graphene containing semiconductor device and portions of the first dielectric material. The second dielectric material includes at least one second conductive region contained therein, and the at least one second conductive region is in contact with a conductive element of the at least one graphene containing semiconductor device.",DIMITRAKOPOULOS CHRISTOS D;;COHEN GUY M;;GATES STEPHEN M;;GRILL ALFRED;;MCARDLE TIMOTHY J;;SUNG CHUN-YUNG;;IBM,DIMITRAKOPOULOS CHRISTOS D;;COHEN GUY M;;GATES STEPHEN M;;GRILL ALFRED;;MCARDLE TIMOTHY J;;SUNG CHUN-YUNG,GLOBALFOUNDRIES U.S. INC (2020-10-22);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-02-14);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/003-558-365-768-859,Patent Application,yes,1,41,4,4,0,H01L29/1606;;H01L29/41766;;H01L29/42356;;H01L29/66431;;H01L2924/00013;;H01L29/778;;H01L29/42356;;H01L29/41766;;H01L29/66431;;H01L29/1606;;H01L2924/00013;;H01L29/778;;H01L21/02527,H01L29/78;;H01L21/20,257/24;;438/478;;X257E29255;;X257E2109,0,0,,,,ACTIVE
333,AU,A1,AU 2017/308739 A1,039-421-613-763-870,2019-03-07,2019,AU 2017/308739 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,Device for printing a three dimensional cosmetic article from a build material comprising a cosmetic formula,"A device printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/039-421-613-763-870,Patent Application,no,0,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00,,0,0,,,,ACTIVE
334,EP,B1,EP 3496932 B1,080-059-215-789-511,2023-04-12,2023,EP 17840058 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,DEVICE FOR PRINTING A THREE DIMENSIONAL COSMETIC ARTICLE FROM A BUILD MATERIAL COMPRISING A COSMETIC FORMULA,,ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/080-059-215-789-511,Granted Patent,yes,3,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/106;;B29C35/16;;B29C64/209;;B29C64/245;;B29C64/364;;B29L31/00;;B33Y30/00,,0,0,,,,ACTIVE
335,GB,B,GB 2584009 B,020-898-449-083-803,2022-03-23,2022,GB 202004178 A,2018-08-24,US 201762551107 P;;US 201762563025 P;;US 201862652161 P;;US 2018/0047969 W,2017-08-28,Aminoglycosides and uses thereof,,REVAGENIX INC,LOGAN ANDREWS;;ANDREW CALABRESE;;TIMOTHY ROBERT KANE;;RYAN CIRZ;;FREDERICK COHEN;;MICHAEL LOPEZ;;JOHN KNOX;;NIKOLAI EVDOKIMOV,"REVAGENIX, INC (2020-05-20)",https://lens.org/020-898-449-083-803,Granted Patent,no,3,0,5,5,0,C07H15/232;;C07H15/26;;A61P31/04;;A61P31/04;;C07H15/232;;C07H15/26;;A61P31/04;;C07H15/232;;C07H15/26,A61K31/7028;;A61K31/7034;;A61K31/7036;;C07H15/226;;C07H15/228;;C07H15/26,,0,0,,,,PENDING
336,WO,A1,WO 2019/046126 A1,046-716-563-371-749,2019-03-07,2019,US 2018/0047969 W,2018-08-24,US 201762551107 P;;US 201762563025 P;;US 201862652161 P,2017-08-28,AMINOGLYCOSIDES AND USES THEREOF,"Provided herein are aminoglycoside compounds, such as compounds of formula (I), (II), (III), (IV), (IVa), (V), (VI), (VIIa), or (VIIb) or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers of any of the foregoing, useful as therapeutic or prophylactic agents. Also provided herein are methods for their preparation. The compounds may be useful in treating a bacterial infection in a subject, for example a Gram-negative bacterial infection.",ACHAOGEN INC,ANDREWS LOGAN;;CALABRESE ANDREW;;KANE TIMOTHY ROBERT;;CIRZ RYAN;;COHEN FREDERICK;;LOPEZ MICHAEL;;KNOX JOHN;;EVDOKIMOV NIKOLAI,,https://lens.org/046-716-563-371-749,Patent Application,yes,3,3,5,5,0,C07H15/232;;C07H15/26;;A61P31/04;;A61P31/04;;C07H15/232;;C07H15/26;;A61P31/04;;C07H15/232;;C07H15/26,A61K31/7028;;A61K31/7034;;A61K31/7036;;C07H15/226;;C07H15/228,,0,0,,,,PENDING
337,EP,A1,EP 3496932 A1,107-820-379-576-833,2019-06-19,2019,EP 17840058 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,DEVICE FOR PRINTING A THREE DIMENSIONAL COSMETIC ARTICLE FROM A BUILD MATERIAL COMPRISING A COSMETIC FORMULA,,ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/107-820-379-576-833,Patent Application,yes,0,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00,,0,0,,,,ACTIVE
338,US,B1,US 11414450 B1,051-179-484-897-056,2022-08-16,2022,US 201816642879 A,2018-08-24,US 201816642879 A;;US 201862652161 P;;US 201762563025 P;;US 201762551107 P;;US 2018/0047969 W,2017-08-28,Aminoglycosides and uses thereof,"Provided herein are aminoglycoside compounds, such as compounds of formula (I), (II), (III), (IV), (IVa), (V), (VI), (VIIa), or (VIIb) or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers of any of the foregoing, useful as therapeutic or prophylactic agents. Also provided herein are methods for their preparation. The compounds may be useful in treating a bacterial infection in a subject, for example a Gram-negative bacterial infection.",REVAGENIX INC,ANDREWS LOGAN;;CALABRESE ANDREW;;KANE TIMOTHY ROBERT;;CIRZ RYAN;;COHEN FREDERICK;;LOPEZ MICHAEL;;KNOX JOHN;;EVDOKIMOV NIKOLAI,ACHAOGEN INC (2018-09-24);;REVAGENIX INC (2019-12-19),https://lens.org/051-179-484-897-056,Granted Patent,yes,49,0,5,5,0,C07H15/232;;C07H15/26;;A61P31/04;;A61P31/04;;C07H15/232;;C07H15/26;;A61P31/04;;C07H15/232;;C07H15/26,C07H15/232;;A61P31/04;;C07H15/22;;C07H15/26,,13,11,044-078-920-759-658;;004-374-923-989-083;;057-153-200-948-898;;060-549-679-397-360;;057-663-865-680-03X;;113-402-046-959-858;;002-840-751-610-104;;001-798-919-451-934;;006-573-393-244-088;;028-644-852-991-263;;013-622-237-638-087,10.1021/jm00385a015;;3543366;;10.1021/ja972599h;;24439205;;10.1016/j.chembiol.2014.01.002;;29296992;;pmc5818290;;10.1039/c7cs00407a;;10.1086/315124;;10558951;;29091410;;pmc5831329;;10.1021/jacs.7b09890;;10.1021/cb5003416;;25019242;;2953976;;10.1038/327389a0;;10.1021/jacs.8b00148;;10.1021/jacs.8b00148.s001;;29377682;;28343384;;10.1021/acsinfecdis.6b00214.s001;;pmc5526222;;10.1021/acsinfecdis.6b00214;;17456024;;10.2174/092986707780362817,"Allen et al. Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. J Med Chem. Feb. 1987;30(2):333-40.;;Alper et al. Probing the Specificity of Aminoglycoside—Ribosomal RNA Interactions with Designed Synthetic Analogs. J Am Chem Soc 120(9):1965-1978 (Feb. 24, 1998). DOI: https://doi.org/10.1021/ja972599h.;;Anish et al. Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol. Jan. 16, 2014;21(1):38-50.doi: 10.1016/j.chembiol.2014.01.002.;;Chandrika et al. Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities. Chem Soc Rev. Feb. 19, 2018;47(4):1189-1249.doi: 10.1039/c7cs00407a.;;Hamouda et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis. Dec. 1999;180(6):1939-49.doi: 10.1086/315124.;;Kim et al. Reaction Catalyzed by GenK, a Cobalamin-Dependent Radical S-Adenosyl-l-methionine Methyltransferase in the Biosynthetic Pathway of Gentamicin, Proceeds with Retention of Configuration. J Am Chem Soc. Nov. 15, 2017;139(45):16084-16087 and Supplementary Material, pp. S1-S52.doi: 10.1021/jacs.7b09890. Epub Nov. 7, 2017.;;Maianti et al. Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial neomycin analogs. ACS Chem Biol. Sep. 19, 2014;9(9):2067-73.doi: 10.1021/cb5003416. Epub Jul. 14, 2014.;;Moazed et al. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature. Jun. 4-10, 1987;327(6121):389-94.doi: 10.1038/327389a0.;;PCT/US2018/047969 International Search Report and Written Opinion dated Dec. 4, 2018.;;PCT/US2018/047993 International Search Report and Written Opinion dated Dec. 6, 2018.;;Qin et al. Total Synthesis of a Densely Functionalized Plesiomonas shigelloides Serotype 51 Aminoglycoside Trisaccharide Antigen. J. Am. Chem. Soc. 140(8):3120-3127 (Jan. 29, 2018). DOI: https://doi.org/10.1021/jacs.8b00148.;;Sati et al. N6′, N6″, and O4′ Modifications to Neomycin Affect Ribosomal Selectivity without Compromising Antibacterial Activity. ACS Infect. Dis. 2017, 3, 5, 368-377 with Supporting Information, pp. S1-S71 (Mar. 27, 2017). DOI: https://doi.org/10.1021/acsinfecdis.6b00214.;;Silva et al. New insights into aminoglycoside antibiotics and derivatives. Curr Med Chem. 2007;14(10) :1101-19.doi: 10.2174/092986707780362817.",ACTIVE
339,US,A1,US 2018/0043612 A1,114-842-390-167-281,2018-02-15,2018,US 201715669105 A,2017-08-04,US 201715669105 A;;US 201662374153 P,2016-08-12,DEVICE FOR PRINTING A THREE DIMENSIONAL COSMETIC ARTICLE FROM A BUILD MATERIAL COMPRISING A COSMETIC FORMULA,"A device printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,ELC MANAGEMENT LLC (2017-10-02),https://lens.org/114-842-390-167-281,Patent Application,yes,11,16,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/106;;B29C64/209;;B29C64/386;;B33Y30/00;;B33Y50/02,,0,0,,,,DISCONTINUED
340,TW,A,TW 202124419 A,196-612-817-910-419,2021-07-01,2021,TW 109129002 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY;;CHRISTIAN ROSE;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/196-612-817-910-419,Patent of Addition,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/18;;A61K47/50,,0,0,,,,PENDING
341,KR,A,KR 20190027947 A,077-018-869-779-196,2019-03-15,2019,KR 20197006704 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,화장품 제형을 포함하는 빌드 물질로부터 3차원 화장용품을 인쇄하기 위한 장치,"화장품 제형을 포함하는 빌드 물질로부터 3차원 화장용품을 인쇄하는 장치는 압출기, 빌드 플레이트, 제어기 및 위치결정 시스템을 갖는다. 제어기는, 위치결정 시스템이 압출기를 빌드 플레이트에 대해 위치시키도록 지시하게 프로그래밍된다. 압출기는 피스톤 압출 시스템을 포함한다. 빌드 물질은 미리 형성된 스틱으로서 압출기에 제공된다. 빌드 물질은 화장용품을 형성하기 위해 기판 상에 압출된다. 빌드 플레이트는 다양한 크기들의 기판들을 수용하기 위한 크기결정 시스템을 포함한다.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/077-018-869-779-196,Patent Application,no,4,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00,,0,0,,,,ACTIVE
342,AU,B2,AU 2017/308739 B2,091-283-776-393-774,2020-07-02,2020,AU 2017/308739 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,Device for printing a three dimensional cosmetic article from a build material comprising a cosmetic formula,"A device printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/091-283-776-393-774,Granted Patent,no,2,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00,,0,0,,,,ACTIVE
343,CA,A1,CA 3033383 A1,037-193-310-617-548,2018-02-15,2018,CA 3033383 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,DEVICE FOR PRINTING A THREE DIMENSIONAL COSMETIC ARTICLE FROM A BUILD MATERIAL COMPRISING A COSMETIC FORMULA,"A device printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/037-193-310-617-548,Patent Application,no,0,0,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393,,0,0,,,,PENDING
344,CN,A,CN 109843554 A,042-969-265-382-116,2019-06-04,2019,CN 201780063437 A,2017-08-04,US 201662374153 P;;US 2017/0045498 W,2016-08-12,Device for printing a three dimensional cosmetic article from a build material comprising a cosmetic formula,"A device printing a three dimensional cosmetic article from a build material including a cosmetic formula has an extruder, a build plate, a controller and a positioning system. The controller is programmed to instruct the positioning system to position the extruder relative to the build plate. The extruder includes a piston extrusion system. The build material is provided to the extruder as a pre-formed stick. The build material is extruded onto a substrate to form the article. The build plate includes a sizing system for receiving substrates of various sizes.",ELC MAN LLC,GRAY TIMOTHY PATRICK;;COHEN ISAAC DAVID;;MARTINS AGOSTINHO;;VICTOR BRUCE LAURENCE;;CURTISS CHARLES AARON;;PAPPAS MADALYN ELLICE,,https://lens.org/042-969-265-382-116,Patent Application,no,7,3,16,16,0,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B33Y10/00;;B33Y30/00;;B33Y50/02;;B29L2031/718;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29C64/364;;B29C64/245;;B33Y30/00;;B29C64/209;;B29C64/106;;B29C64/118;;B29C64/245;;B29C64/209;;B29C64/393;;B29C64/227;;B29L2031/718;;B29C35/16;;B29C2035/1658;;B29L2031/718;;B29C64/245;;B29C64/364;;B33Y30/00;;B33Y50/02;;B29C64/386;;B29C64/209;;B29C64/106,B29C64/118;;B29C64/209;;B29C64/227;;B29C64/245;;B29C64/393;;B29L31/00,,0,0,,,,ACTIVE
345,DO,A,DO P2004000976 A,060-810-524-975-185,2005-03-31,2005,DO 2004000976 A,2004-08-11,DO 2004000976 A,2004-08-11,2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENCENOS SUSTITUIDOS COMO AGONISTAS DE 5-HT1F.,"La presente invención se refiere a compuestos de fórmula I: o una sal de adición de ácido farmaceuticamente aceptable de los mismos, donde: X es -C(R3~= a -N=; R' es alquiIo(CZ-C6), alquilo(CZ-C6) sustituido, cicloalquilo(C3-C7), cicloalquilo(C3-C7) sustituido, fenilo, fenilo sustituido, heterociclo, o heterociclo sustituido; R2 es hidrógeno, n-alquilo(Ci-C3), cicloalquil(C3-C6)-alquilo(C1-C3), o un grupo de fórmula II con la condicion de que cuando R' es alquilo(C2-C6) o alquilo(Cr-C6) sustituido, R2 es hidrogeno o metilo; R3a R3b y cuando X es -C(R3e)= R3e son cada uno independientemente hidrógeno, fluoro, o metilo, con la condición de que no mas de uno de R3a R3b, y Rio puede ser diferente de hidrógeno; R° es hidrógeno o alquilo(Ci-C3); R5 es hidrógeno, alquilo(C1-C3) o cicloalquilcarbonilo(C1-C3), con la condición de que cuando R3a es diferente de hidrógeno, R5 es hidrógeno; RS es hidrógeno o alquilo(Ci-C6); y n es un número entero de 1 a 6 inclusive. Los compuestos de Ia presente invención son útiles para activar receptores 5-HTIF, inhibir la extravasación de proteinas neuronales, y para el tratamiento o prevención de migrana en un mamífero.",LILLY CO ELI,HUDZIAK KEVIN JOHN;;BLANCO PILLADO MARIA JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE,,https://lens.org/060-810-524-975-185,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
346,SG,A,SG 10201911083W A,178-823-477-258-096,2020-01-30,2020,SG 10201911083W A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/178-823-477-258-096,Unknown,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,,,0,0,,,,PENDING
347,SI,T1,SI 3412302 T1,176-594-827-874-771,2021-09-30,2021,SI 201531634 T,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 18177893 A,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/176-594-827-874-771,Granted Patent,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K45/00;;A61K47/00;;C07K14/00,,0,0,,,,ACTIVE
348,EP,A1,EP 3412302 A1,199-247-639-337-889,2018-12-12,2018,EP 18177893 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 15790415 A;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/199-247-639-337-889,Patent Application,yes,91,0,60,64,316,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,97,77,022-997-664-996-345;;029-041-317-917-380;;095-163-015-743-716;;006-516-075-151-31X;;005-001-316-365-345;;008-135-071-759-92X;;019-590-397-412-17X;;056-201-471-905-934;;028-373-705-126-470;;032-728-154-591-070;;028-862-168-091-90X;;056-201-471-905-934;;065-530-651-566-523;;017-940-142-904-249;;082-902-765-648-368;;077-140-409-267-690;;027-033-711-563-119;;189-306-471-756-979;;037-612-698-436-922;;078-020-406-613-471;;169-736-421-398-039;;001-168-243-787-836;;034-132-141-339-939;;078-886-911-253-419;;050-491-094-261-212;;081-098-345-341-182;;035-328-575-802-514;;040-712-467-075-177;;014-268-011-522-679;;113-394-540-007-150;;064-029-904-826-616;;135-885-609-471-475;;013-885-021-097-853;;139-370-722-026-325;;113-394-540-007-150;;000-267-213-967-50X;;013-885-021-097-853;;017-239-464-122-703;;029-171-836-207-263;;079-141-143-704-263;;032-412-591-971-193;;015-214-531-219-780;;006-451-527-297-818;;056-370-822-404-873;;142-164-397-210-970;;081-092-403-760-75X;;031-118-508-476-586;;010-929-566-271-076;;099-108-177-239-268;;013-885-021-097-853;;018-934-238-795-193;;084-748-487-156-928;;025-834-245-974-873;;006-095-947-008-535;;005-638-542-147-993;;093-724-494-618-609;;048-439-321-617-128;;012-388-439-961-094;;019-590-397-412-17X;;011-020-186-750-886;;018-471-026-674-340;;018-471-026-674-340;;063-797-097-486-664;;046-036-272-703-281;;023-157-064-831-058;;030-425-987-723-110;;135-885-609-471-475;;005-316-633-999-516;;067-220-965-320-998;;041-750-601-903-10X;;051-260-923-190-254;;005-660-045-470-037;;000-221-503-463-330;;072-022-751-553-845;;041-750-601-903-10X;;050-741-722-639-562;;004-965-380-380-515,1911037;;9427842;;10.1016/s0079-6603(08)61031-4;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;12845521;;10.1007/s00441-003-0756-7;;10858549;;10.1016/s0167-4781(00)00067-1;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;8554512;;10.1042/bj3120725;;pmc1136174;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/0022-2836(70)90057-4;;5420325;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1358/dof.2009.034.08.1394557;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;pmc334719;;2830593;;10.1093/nar/16.3.791;;8347599;;10.1021/bi00082a015;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;10.1038/nbt0202-177;;11821864;;10.1021/ja028050m;;12465973;;7473593;;10.1021/jm00023a005;;10.1021/ja01523a064;;10.1021/jo00241a009;;10.1016/0223-5234(91)90030-q;;10.1021/jo00269a022;;10.1002/chin.198535327;;10.1016/s0040-4020(01)90305-9;;1469691;;10.1021/jm00102a014;;10.1021/bi0300231;;12779328;;10.1021/bc00015a010;;1381617;;10.1021/bc00014a008;;1325188;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/ja01511a053;;10.1021/ja00119a001;;10.1021/ja961216x;;10.1021/bc00014a008;;1325188;;10.1126/science.276.5315.1125;;9173543;;10.1021/ja00119a001;;10.1021/ar9901570;;11560472;;10.1021/jo034984x;;14604354;;9129118;;10.1016/s0024-3205(96)00595-4;;12920298;;10.1126/science.1084772;;10.1021/ja021381e;;12630856;;12148987;;10.1021/ja027007w;;10.1016/b978-0-08-052349-1.00116-5;;10.1021/jo011148j;;11975567;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1126/science.287.5460.2007;;10720325;;10.1021/ja0370037;;14505376;;10.1016/s0040-4020(96)01195-7;;10.1021/ja00119a001;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1038/370389a0;;8047147;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1016/s0021-9258(18)68577-1;;3372509;;19915550;;10.1038/nbt.1588;;8613964;;10.1016/s0022-1759(96)00217-7;;9032414;;12119302;;10.1074/jbc.m205854200;;8554512;;10.1042/bj3120725;;pmc1136174;;10.1021/ja029433n;;12580587;;10.2337/diab.31.1.s1;;7160533;;10.2337/diab.31.1.s1;;7160533;;1568242;;10.1016/0092-8674(92)90402-x;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;2250094;;10.1093/oxfordjournals.jhered.a111019;;10.1126/science.164.3880.719;;5778021;;10.1021/ja01511a053;;13428781;;10.1016/s0021-9258(18)64849-5;;15915461;;10.1002/hep.20701;;10.1016/j.cmet.2013.04.005;;23663741;;23663742;;pmc3667496;;10.1016/j.cmet.2013.03.019;;21520200;;10.1002/hep.24376;;pmc4014460;;10.1074/jbc.m704165200;;17623664;;pmc2496965;;10.1073/pnas.0701600104;;pmc1855074;;17452648;;10.1016/j.cmet.2013.04.005;;23663741;;17933712;;22787375;;pmc3390728;;10.3346/jkms.2012.27.7.784,"BAIRD ET AL., CANCER CELLS, vol. 3, 1991, pages 239 - 243;;MCKEEHAN ET AL., PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 59, 1998, pages 135 - 176;;BURGESS, W. H. ET AL., ANNU. REV. BIOCHEM., vol. 58, 1989, pages 575 - 606;;REUSS ET AL., CELL TISSUE RES., vol. 313, 2003, pages 139 - 157;;NISHIMURA ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1492, 2000, pages 203 - 206;;KHARITONENKOV ET AL., J CLIN INVEST., vol. 115, no. 6, June 2005 (2005-06-01), pages 1627 - 35;;GIMENO; MOLLER, TRENDS ENDOCRINOL METAB., vol. 25, no. 6, June 2014 (2014-06-01), pages 303 - 11;;HECHT ET AL., PLOS ONE, vol. 7, no. 11, 2012, pages e49345;;""Immunogenicity Assessment for Therapeutic Protein Products"", August 2014, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES;;""Therapeutic Protein Immunogenicity Focus Group Newsletter"", vol. 1, December 2011, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, pages: 3;;KURTZHALS, BIOCHEM.J., vol. 312, 1995, pages 725 - 731;;ALTSCHUL ET AL., J MOL BIOL., vol. 215, no. 3, 5 October 1990 (1990-10-05), pages 403 - 10;;SMITH; WATERMAN, J MOL BIOL., vol. 147, no. 1, 25 March 1981 (1981-03-25), pages 195 - 7;;NEEDLEMAN; WUNSCH, J MOL BIOL., vol. 48, no. 3, March 1970 (1970-03-01), pages 443 - 53;;""Polyethylene Glycol and Derivatives for Biomedical Applications"", 2001, SHEARWATER CORPORATION'S CATALOG;;CREIGHTON: ""Proteins: Structures and Molecular Properties"", December 1993, W H FREEMAN & CO.;;ALTSCHUL ET AL., NUC. ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, pages 403 - 410;;FYFE, M.C.T. ET AL., DRUGS OF THE FUTURE, vol. 34, no. 8, 2009, pages 641 - 653;;BARANY ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 189 - 193;;SAYERS, J.R. ET AL.: ""5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis"", NUCLEIC ACIDS RES, vol. 16, 1988, pages 791 - 802, XP001314878;;MA ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 7939;;KOWAL; OLIVER, NUCL. ACID. RES., vol. 25, 1997, pages 4685;;HIRAO ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 177 - 182;;WU, Y. ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 14626 - 14630;;FESSENDON; FESSENDON: ""Organic Chemistry"", 1982, WILLARD GRANT PRESS;;MARCH: ""Advanced Organic Chemistry"", 1985, WILEY AND SONS;;CAREY; SUNDBERG: ""Advanced Organic Chemistry"", 1990, PLENUM PRESS;;MATSOUKAS ET AL., J. MED. CHEM., vol. 38, 1995, pages 4660 - 4669;;KING, F.E.; KIDD, D.A.A.: ""A New Synthesis of Glutamine and of γ-Dipeptides of Glutamic Acid from Phthylated Intermediates"", J. CHEM. SOC., 1949, pages 3315 - 3319;;FRIEDMAN, O.M.; CHATTENJI, R.: ""Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents"", J. AM. CHEM. SOC., vol. 81, 1959, pages 3750 - 3752;;CRAIG, J.C. ET AL.: ""Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino]quinoline (Chloroquine)"", J. ORG. CHEM, vol. 53, 1988, pages 1167 - 1170;;AZOULAY, M.; VILMONT, M.; FRAPPIER, F.: ""Glutamine analogues as Potential Antimalarials"", EUR. J. MED. CHEM., vol. 26, 1991, pages 201 - 5, XP023870208, DOI: doi:10.1016/0223-5234(91)90030-Q;;KOSKINEN, A.M.P.; RAPOPORT, H.: ""Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues"", J. ORG. CHEM., vol. 54, 1989, pages 1859 - 1866;;CHRISTIE, B.D.; RAPOPORT, H.: ""Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization"", J. ORG. CHEM., vol. 50, 1985, pages 1239 - 1246, XP002168706, DOI: doi:10.1021/jo00208a017;;BARTON ET AL.: ""Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives"", TETRAHEDRON, vol. 43, 1987, pages 4297 - 4308, XP001008711, DOI: doi:10.1016/S0040-4020(01)90305-9;;SUBASINGHE ET AL.: ""Quisqualic acid analogues: synthesis of betaheterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site"", J. MED. CHEM., vol. 35, 1992, pages 4602 - 7, XP002198373, DOI: doi:10.1021/jm00102a014;;ZHANG, Z. ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 6735 - 6746;;GAERTNER ET AL., BIOCONJUG. CHEM., vol. 3, 1992, pages 262 - 268;;GEOGHEGAN, K.; STROH, J., BIOCONJUG. CHEM., vol. 3, 1992, pages 138 - 146;;GAERTNER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 7224 - 7230;;JENCKS, W. P., J. AM. CHEM. SOC., vol. 81, 1959, pages 475 - 481;;SHAO, J.; TAM, J. P., J. AM. CHEM. SOC., vol. 117, 1995, pages 3893 - 3899;;CORNISH, V. W. ET AL., .L. AM. CHEM. SOC., vol. 118, 1996, pages 8150 - 8151;;GEOGHEGAN, K. F.; STROH, J. G., BIOCONJUG. CHEM., vol. 3, 1992, pages 138 - 146;;MAHAL, L. K. ET AL., SCIENCE, vol. 276, 1997, pages 1125 - 1128;;SHAO, J.; TAM, J., J. AM. CHEM. SOC., vol. 117, 1995, pages 3893 - 3899;;H. HANG; C. BERTOZZI, ACC. CHEM. RES., vol. 34, 2001, pages 727 - 736;;M. CARRASCO; R. BROWN, J. ORG. CHEM., vol. 68, 2003, pages 8853 - 8858;;ROSENTHAL, G., LIFE SCI., vol. 60, 1997, pages 1635 - 1641;;CHIN J. ET AL., SCIENCE, vol. 301, 2003, pages 964 - 7;;WANG, Q. ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 3192 - 3193;;CHIN, J. W. ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 9026 - 9027;;PADWA, A.: ""COMPREHENSIVE ORGANIC SYNTHESIS"", vol. 4, 1991, pages: 1069 - 1109;;HUISGEN, R., 1,3-DIPOLAR CYCLOADDITION CHEMISTRY, 1984, pages 1 - 176;;TORNOE, C. W. ET AL., J. ORG. CHEM., vol. 67, 2002, pages 3057 - 3064;;ROSTOVTSEV ET AL., ANGEW. CHEM. INT. ED., vol. 41, 2002, pages 2596 - 2599;;E. SAXON; C. BERTOZZI, SCIENCE, vol. 287, 2000, pages 2007 - 2010;;DEITERS, A. ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 11782 - 11783;;KAYSER, B. ET AL., TETRAHEDRON, vol. 53, no. 7, 1997, pages 2475 - 2484;;J. SHAO; J. TAM, J. AM. CHEM. SOC., vol. 117, no. 14, 1995, pages 3893 - 3899;;LIU, D.R.; SCHULTZ, P.G.: ""Progress toward the evolution of an organism with an expanded genetic code"", PNAS UNITED STATES, vol. 96, 1999, pages 4780 - 4785, XP001040352, DOI: doi:10.1073/pnas.96.9.4780;;STEMMER: ""Rapid evolution of a protein in vitro by DNA shuffling"", NATURE, vol. 370, no. 4, 1994, pages 389 - 391, XP002082182, DOI: doi:10.1038/370389a0;;STEMMER: ""DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution"", PROC. NATL. ACAD. SCI. USA., vol. 91, 1994, pages 10747 - 10751, XP002912215, DOI: doi:10.1073/pnas.91.22.10747;;SPENCER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 7862 - 7867;;SCHELLENBERGER ET AL., NAT BIOTECHNOL., vol. 27, no. 12, December 2009 (2009-12-01), pages 1186 - 90;;MAKRIDES ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996, pages 534 - 542;;SJOLANDER ET AL., J, IMMUNOL. METHODS, vol. 201, 1997, pages 115 - 123;;DENNIS ET AL., .L. BIOL. CHEM., vol. 277, 2002, pages 35035 - 35043;;KURTZHALS ET AL., BIOCHEM. J., vol. 312, 1995, pages 725 - 731;;H. LIU ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 1702 - 1703;;COLEMAN, DIABETES, vol. 31, no. 1, 1982;;E. SHAFRIR: ""Diabetes Mellitus"", 1990, ELSEVIER SCIENCE PUBLISHING CO., INC., pages: 299 - 340;;COLEMAN, DIABETES, vol. 31, 1982, pages 1;;E. SHAFRIR: ""Diabetes Mellitus"", 1990, ELSEVIER SCIENCE PUBLISHING CO., INC., pages: 299 - 340;;FRIEDMAN ET AL., CELL, vol. 69, 1992, pages 217 - 220;;TRUETT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 7806;;COLEMAN ET AL., J. HEREDITY, vol. 81, 1990, pages 424;;OLNEY, SCIENCE, vol. 164, 1969, pages 719;;CAMERON ET AL., CLI. EXP. PHARMACOL. PHYSIOL., vol. 5, 1978, pages 41;;GOODMAN, L. S.; GILMAN, A.; BRUNTON, L. L.; LAZO, J. S.; PARKER, K. L.: ""Goodman & Gilman's the pharmacological basis of therapeutics"", 2006, MCGRAW-HILL;;HOWLAND, R. D.; MYCEK, M. J.; HARVEY, R. A.; CHAMPE, P. C.; MYCEK, M. J.: ""Pharmacology. Lippincott's illustrated reviews"", 2006, LIPPINCOTT WILLIAMS & WILKINS;;GOLAN, D. E.: ""Principles of pharmacology: the pathophysiologic basis of drug therapy"", 2008, LIPPINCOTT WILLIAMS & WILKINS;;MILLER, J.H., GENE, 1986;;JENCKS, W., J. AM. CHEM. SOC., vol. 81, 1959, pages 475;;WEBSTER: ""Predicting Long-Term Storage Stability of Therapeutic Proteins"", PHARMACEUTICAL TECHNOLOGY, vol. 37, no. 11, 2 November 2013 (2013-11-02), pages 42 - 48;;FOLCH J. ET AL., J. BIOL. CHEM., vol. 226, 1957, pages 497;;KLEINER DE ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313;;LIN ET AL., CELL METAB., vol. 17, 2013, pages 779 - 789;;HOLLAND ET AL., CELL METAB, vol. 17, 2013, pages 790 - 797;;SANYAL AJ. ET AL., HEPATOLOGY, vol. 54, 2011, pages 344;;KLEINER DE. ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313;;KUROSU ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 26687 - 26695;;OGAWA ET AL., PROC. NATL. ACAD. OF SCI., USA, vol. 104, 2007, pages 7432 - 7437;;LIN, Z. ET AL., CELL METAB., vol. 17, 2013, pages 779 - 789;;NINICHUK ET AL., EUR J MED RES, vol. 12, 2007, pages 351 - 355;;CHAE ET AL., J KOREAN MED SCI., vol. 27, 2012, pages 784 - 787",ACTIVE
349,US,B2,US 9585800 B2,199-079-490-555-764,2017-03-07,2017,US 201514754421 A,2015-06-29,US 201514754421 A;;US 201414332276 A,2014-07-15,Mobility securement system,"A mobility securement system, and method for securing a wheelchair or other mobility device, and its passenger, within a public or private vehicle. In various embodiments, the system includes one or two attachment members, one or two vehicle anchor assemblies and, potentially, at least one fixed or moveable bumper, and may further include a barrier. A tensioning assembly is operably connected to at least one attachment member and vehicle anchor assembly. One or more moveable bumpers may articulate to apply a force against the mobility device, and one attachment member may be hidden behind a stored position of a moveable bumper.",4ONE LLC,HAMMARSKJOLD CHRISTIAN;;BALEF VLAD;;BRZEZNIAK STANLEY;;KRUEGER JEFFREY;;MOFFA MICHAEL D;;SMITH-COHEN DAN;;VIDRI PAUL;;MURPHY TIMOTHY J,USSC ACQUISITION CORP (2017-10-18);;4ONE LLC (2015-06-29),https://lens.org/199-079-490-555-764,Granted Patent,yes,67,10,4,11,0,A61G3/0808;;A61G3/0808;;A61G3/08;;A61G2220/16;;B60P3/06;;B60P3/073;;B60P3/079;;B60P7/0807;;B60P7/0823;;B60P7/0892;;B60P7/135,B60P7/08;;A61G3/08,,0,0,,,,ACTIVE
350,WO,A2,WO 2016/065326 A2,014-072-053-714-930,2016-04-28,2016,US 2015/0057228 W,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/014-072-053-714-930,Patent Application,yes,79,22,60,64,302,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00,,98,75,022-997-664-996-345;;029-041-317-917-380;;095-163-015-743-716;;006-516-075-151-31X;;005-001-316-365-345;;004-100-004-646-006;;008-135-071-759-92X;;019-590-397-412-17X;;056-201-471-905-934;;028-373-705-126-470;;032-728-154-591-070;;028-862-168-091-90X;;056-201-471-905-934;;065-530-651-566-523;;017-940-142-904-249;;082-902-765-648-368;;077-140-409-267-690;;027-033-711-563-119;;189-306-471-756-979;;037-612-698-436-922;;179-552-640-659-549;;169-736-421-398-039;;001-168-243-787-836;;034-132-141-339-939;;078-886-911-253-419;;050-491-094-261-212;;081-098-345-341-182;;035-328-575-802-514;;040-712-467-075-177;;014-268-011-522-679;;113-394-540-007-150;;064-029-904-826-616;;135-885-609-471-475;;013-885-021-097-853;;139-370-722-026-325;;113-394-540-007-150;;000-267-213-967-50X;;013-885-021-097-853;;013-885-021-097-853;;017-239-464-122-703;;029-171-836-207-263;;079-141-143-704-263;;032-412-591-971-193;;015-214-531-219-780;;006-451-527-297-818;;056-370-822-404-873;;142-164-397-210-970;;081-092-403-760-75X;;031-118-508-476-586;;010-929-566-271-076;;099-108-177-239-268;;013-885-021-097-853;;018-934-238-795-193;;084-748-487-156-928;;025-834-245-974-873;;006-095-947-008-535;;093-724-494-618-609;;048-439-321-617-128;;012-388-439-961-094;;019-590-397-412-17X;;011-020-186-750-886;;018-471-026-674-340;;063-797-097-486-664;;046-036-272-703-281;;023-157-064-831-058;;030-425-987-723-110;;135-885-609-471-475;;041-750-601-903-10X;;051-260-923-190-254;;067-220-965-320-998;;000-221-503-463-330;;072-022-751-553-845;;041-750-601-903-10X;;050-741-722-639-562;;004-965-380-380-515,1911037;;9427842;;10.1016/s0079-6603(08)61031-4;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;12845521;;10.1007/s00441-003-0756-7;;10858549;;10.1016/s0167-4781(00)00067-1;;pmc138918;;11276432;;10.1186/gb-2001-2-3-reviews3005;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;8554512;;10.1042/bj3120725;;pmc1136174;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/0022-2836(70)90057-4;;5420325;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1358/dof.2009.034.08.1394557;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;pmc334719;;2830593;;10.1093/nar/16.3.791;;8347599;;10.1021/bi00082a015;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;10.1038/nbt0202-177;;11821864;;10.1021/ja028050m;;12465973;;10.1039/jr9490003315;;10.1021/ja01523a064;;10.1021/jo00241a009;;10.1016/0223-5234(91)90030-q;;10.1021/jo00269a022;;10.1002/chin.198535327;;10.1016/s0040-4020(01)90305-9;;1469691;;10.1021/jm00102a014;;10.1021/bi0300231;;12779328;;10.1021/bc00015a010;;1381617;;10.1021/bc00014a008;;1325188;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/ja01511a053;;10.1021/ja00119a001;;10.1021/ja961216x;;10.1021/bc00014a008;;1325188;;10.1126/science.276.5315.1125;;9173543;;10.1021/ja00119a001;;10.1021/ja00119a001;;10.1021/ar9901570;;11560472;;10.1021/jo034984x;;14604354;;9129118;;10.1016/s0024-3205(96)00595-4;;12920298;;10.1126/science.1084772;;10.1021/ja021381e;;12630856;;12148987;;10.1021/ja027007w;;10.1016/b978-0-08-052349-1.00116-5;;10.1021/jo011148j;;11975567;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1126/science.287.5460.2007;;10720325;;10.1021/ja0370037;;14505376;;10.1016/s0040-4020(96)01195-7;;10.1021/ja00119a001;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1038/370389a0;;8047147;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1016/s0021-9258(18)68577-1;;3372509;;8613964;;10.1016/s0022-1759(96)00217-7;;9032414;;12119302;;10.1074/jbc.m205854200;;8554512;;10.1042/bj3120725;;pmc1136174;;10.1021/ja029433n;;12580587;;10.2337/diab.31.1.s1;;7160533;;1568242;;10.1016/0092-8674(92)90402-x;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;2250094;;10.1093/oxfordjournals.jhered.a111019;;10.1126/science.164.3880.719;;5778021;;10.1021/ja01511a053;;10.1016/j.cmet.2013.04.005;;23663741;;23663742;;pmc3667496;;10.1016/j.cmet.2013.03.019;;15915461;;10.1002/hep.20701;;10.1074/jbc.m704165200;;17623664;;pmc2496965;;10.1073/pnas.0701600104;;pmc1855074;;17452648;;10.1016/j.cmet.2013.04.005;;23663741;;17933712;;22787375;;pmc3390728;;10.3346/jkms.2012.27.7.784,"BAIRD ET AL., CANCER CELLS, vol. 3, 1991, pages 239 - 243;;MCKEEHAN ET AL., PROG. NUCLEIC ACID RES. MOL. BIOL, vol. 59, 1998, pages 135 - 176;;BURGESS, W. H. ET AL., ANNU. REV. BIOCHEM., vol. 58, 1989, pages 575 - 606;;REUSS ET AL., CELL TISSUE RES., vol. 313, 2003, pages 139 - 157;;NISHIMURA ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1492, 2000, pages 203 - 206;;ORNITZ; ITOH, GENOME BIOLOGY, vol. 2, no. 3, 2001;;KHARITONENKOV ET AL., J CLIN INVEST., vol. 1 15, no. 6, June 2005 (2005-06-01), pages 1627 - 35;;GIMENO; MOLLER, TRENDS ENDOCRINOL METAB, vol. 25, no. 6, June 2014 (2014-06-01), pages 303 - 1 1;;HECHT ET AL., PLOS ONE, vol. 7, no. 1, 2012, pages E49345;;IMMUNOGENICITY ASSESSMENT FOR THERAPEUTIC PROTEIN PRODUCTS, August 2014 (2014-08-01);;SUBRAMANYAM: ""Therapeutic Protein Immunogenicity Focus Group Newsletter"", vol. 1, December 2011, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS;;KURTZHALS, BIOCHEM.J., vol. 312, 1995, pages 725 - 731;;ALTSCHUL ET AL., J MOL BIOL., vol. 215, no. 3, 5 October 1990 (1990-10-05), pages 403 - 10;;SMITH; WATERMAN, J MOL BIOL., vol. 147, no. 1, 25 March 1981 (1981-03-25), pages 195 - 7;;NEEDLEMAN; WUNSCH, J MOL BIOL., vol. 48, no. 3, March 1970 (1970-03-01), pages 443 - 53;;""Shearwater Corporation's catalog"", 2001, article ""Polyethylene Glycol and Derivatives for Biomedical Applications"";;ALTSCHUL ET AL., NUC. ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ALTSCHUL ET AL., J. FOF. BIOL, vol. 215, 1990, pages 403 - 410;;SMITH; WATERMAN, J MOL BIOL., vol. 147, no. I, 25 March 1981 (1981-03-25), pages 195 - 7;;FYFE, M.C.T ET AL., DRUGS OF THE FUTURE, vol. 34, no. 8, 2009, pages 641 - 653;;BARANY ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 189 - 193;;SAYERS, J.R. ET AL.: ""5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis"", NUCLEIC ACIDS RES, vol. 16, 1988, pages 791 - 802, XP001314878;;MA ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 7939;;KOWAL; OLIVER, NUCL. ACID. RES., vol. 25, 1997, pages 4685;;HIRAO ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 177 - 182;;WU, Y. ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 14626 - 14630;;FESSENDON; FESSENDON: ""Organic Chemistry, 2nd ed."", 1982, WILLARD GRANT PRESS;;MARCH: ""Advanced Organic Chemistry, 3rd ed."", 1985, WILEY AND SONS;;CAREY; SUNDBERG: ""Advanced Organic Chemistry, 3rd ed."", 1990, PLENUM PRESS;;MATSOUKAS ET AL.: ""In vivo incorporation of Unnatural Amino Acids"", J. MED. CHEM., vol. 38, 1995, pages 4660 - 4669;;KING, F.E; KIDD, D.A.A: ""A New Synthesis of Glutamine and of ?-Dipeptides of Glutamic Acidfrom Phthylated Intermediates"", J. CHEM. SOC., 1949, pages 3315 - 3319;;FRIEDMAN, O.M.; CHATTERRJI, R.: ""Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents"", J. AM. CHEM. SOC., vol. 81, 1959, pages 3750 - 3752;;CRAIG, J.C. ET AL.: ""Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino]quinoline (Chloroquine)"", J. ORG. CHEM., vol. 53, 1988, pages 1167 - 1170;;AZOULAY, M.; VILMONT, M.; FRAPPIER, F.: ""Glutamine analogues as Potential Antimalarials"", EUR. J. MED. CHEM., vol. 26, 1991, pages 201 - 5, XP023870208, DOI: doi:10.1016/0223-5234(91)90030-Q;;KOSKINEN, A.M.P.; RAPOPORT, H.: ""Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues"", J. ORG. CHEM., vol. 54, 1989, pages 1859 - 1866;;CHRISTIE, B.D.; RAPOPORT, H.: ""Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization"", J. ORG. CHEM., vol. 50, 1985, pages 1239 - 1246, XP002168706, DOI: doi:10.1021/jo00208a017;;BARTON ET AL.: ""Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives"", TETRAHEDRON, vol. 43, 1987, pages 4297 - 4308, XP001008711, DOI: doi:10.1016/S0040-4020(01)90305-9;;SUBASINGHE ET AL.: ""Quisqualic acid analogues: synthesis of betaheterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site"", J. MED. CHEM., vol. 35, 1992, pages 4602 - 7, XP002198373, DOI: doi:10.1021/jm00102a014;;ZHANG, Z. ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 6735 - 6746;;GAERTNER ET AL., BIOCONJUG. CHEM., vol. 3, 1992, pages 262 - 268;;GEOGHEGAN, K.; STROH, J., BIOCONJUG. CHEM., vol. 3, 1992, pages 138 - 146;;GAERTNER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 7224 - 7230;;JENCKS, W. P., J. AM. CHEM. SOC., vol. 81, 1959, pages 475 - 481;;SHAO, J.; TAM, J. P., J. AM. CHEM. SOC., vol. 117, 1995, pages 3893 - 3899;;CORNISH, V. W. ET AL., J. AM. CHEM. SOC., vol. 118, 1996, pages 8150 - 8151;;GEOGHEGAN, K. F.; STROH, J. G., BIOCONJUG. CHEM., vol. 3, 1992, pages 138 - 146;;MAHAL, L. K. ET AL., SCIENCE, vol. 276, 1997, pages 1125 - 1128;;SHAO, J.; TAM, J., J. AM. CHEM. SOC., vol. 117, 1995, pages 3893 - 3899;;SHAO, J.; TARN, J., J. AM. CHEM. SOC., vol. 117, 1995, pages 3893 - 3899;;H. HANG; C. BERTOZZI, ACC. CHEM. RES., vol. 34, 2001, pages 727 - 736;;M. CARRASCO; R. BROWN, J. ORG. CHEM., vol. 68, 2003, pages 8853 - 8858;;ROSENTHAL, G., LIFE SCI., vol. 60, 1997, pages 1635 - 1641;;CHIN J. ET AL., SCIENCE, vol. 301, 2003, pages 964 - 7;;WANG, Q. ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 3192 - 3193;;CHIN, J. W. ET AL., JAM. CHEM. SOC., vol. 124, 2002, pages 9026 - 9027;;PADWA, A.: ""COMPREHENSIVE ORGANIC SYNTHESIS"", vol. 4, 1991, pages: 1069 - 1109;;HUISGEN, R.: ""1,3-D POL R CYCLOADDITION CHEMISTRY"", 1984, pages: 1 - 176;;TORNOE, C. W. ET AL., J. ORG. CHEM., vol. 67, 2002, pages 3057 - 3064;;ROSTOVTSEV ET AL., ANGEW. CHEM. INT. ED., vol. 41, 2002, pages 2596 - 2599;;E. SAXON; C. BERTOZZI, SCIENCE, vol. 287, 2000, pages 2007 - 2010;;DEITERS, A. ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 11782 - 11783;;KAYSER, B. ET AL., TETRAHEDRON, vol. 53, no. 7, 1997, pages 2475 - 2484;;J. SHAO; J. TAM, J. AM. CHEM. SOC., vol. 117, no. 14, 1995, pages 3893 - 3899;;LIU, D.R.; SCHULTZ, P.G: ""Progress toward the evolution of an organism with an expanded genetic code"", PNAS UNITED STATES, vol. 96, 1999, pages 4780 - 4785, XP001040352, DOI: doi:10.1073/pnas.96.9.4780;;STEMMER: ""Rapid evolution of a protein in vitro by DNA shuffling"", NATURE, vol. 370, no. 4, 1994, pages 389 - 391, XP002082182, DOI: doi:10.1038/370389a0;;STEMMER: ""DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution"", PROC. NATL. ACAD. SCI. USA., vol. 91, 1994, pages 10747 - 10751, XP002912215, DOI: doi:10.1073/pnas.91.22.10747;;SPENCER ET AL., J BIOL. CHEM., vol. 263, 1988, pages 7862 - 7867;;SCHELLENBERGER ET AL., NAT BIOTECHNOL., vol. 27, no. 12, December 2009 (2009-12-01), pages L 186 - 90;;MAKRIDES ET AL., J PHARMACOL. EXP. THER., vol. 277, 1996, pages 534 - 542;;SJOLANDER ET AL., J, IMMUNOL. METHODS, vol. 201, 1997, pages 115 - 123;;DENNIS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 35035 - 35043;;KURTZHALS ET AL., BIOCHEM. J., vol. 312, 1995, pages 725 - 731;;H. LIU ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 1702 - 1703;;COLEMAN, DIABETES, vol. 31, 1982, pages 1;;E. SHAFRIR: ""Diabetes Mellitus"", 1990, ELSEVIER SCIENCE PUBLISHING CO., INC., pages: 299 - 340;;COLEMAN: ""Diabetes"", vol. 31, 1982, pages: 1;;E. SHAFRIR: ""Diabetes Mellitus"", 1990, ELSEVIER SCIENCE PUBLISHING CO., INC., pages: 299 - 340;;FRIEDMAN ET AL., CELL, vol. 69, 1992, pages 217 - 220;;TRUETT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 7806;;COLEMAN ET AL., J. HEREDITY, vol. 81, 1990, pages 424;;OLNEY, SCIENCE, vol. 164, 1969, pages 719;;CAMERON ET AL., CLI. EXP. PHARMACOL. PHYSIOL., vol. 5, 1978, pages 41;;E. SHAFRIR: ""Diabetes Mellitus"", vol. 4, 1990, ELSEVIER SCIENCE PUBLISHING CO., INC., pages: 299 - 340;;GOODMAN, L. S.; GILMAN, A.; BRUNTON, L. L.; LAZO, J. S.; PARKER, K. L.: ""Goodman & Gilman's the pharmacological basis of therapeutics"", 2006, MCGRAW-HILL;;HOWLAND, R. D.; MYCEK, M. J.; HARVEY, R. A.; CHAMPE, P. C.; MYCEK, M. J.: ""Pharmacology. Lippincott's illustrated reviews"", 2006, LIPPINCOTT WILLIAMS & WILKINS;;GOLAN, D. E: ""Principles of pharmacology: the pathophysiologic basis of drug therapy"", 2008, LIPPINCOTT WILLIAMS & WILKINS;;MILLER, J.H., GENE, 1986;;JENCKS, W., J. AM. CHEM. SOC., vol. 81, 1959, pages 475;;WEBSTER: ""Predicting Long-Term Storage Stability of Therapeutic Proteins"", PHARMACEUTICAL TECHNOLOGY, vol. 37, no. 11, 2 November 2013 (2013-11-02), pages 42 - 48;;LIN ET AL., CELL METAB, vol. 17, 2013, pages 779 - 789;;HOLLAND ET AL., CELL METAB, vol. 17, 2013, pages 790 - 797;;KLEINER DE ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313;;LIN ET AL., CELL METAB., vol. 17, 2013, pages 779 - 789;;KUROSU ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 26687 - 26695;;OGAWA ET AL., PROC. NATL. ACAD. OF SCI., USA, vol. 104, 2007, pages 7432 - 7437;;LIN, Z. ET AL., CELL METAB., vol. 17, 2013, pages 779 - 789;;NINICHUK ET AL., EUR J MED RES, vol. 12, 2007, pages 351 - 355;;CHAE ET AL., J KOREAN MED SCI., vol. 27, 2012, pages 784 - 787",PENDING
351,US,B2,US 10377806 B2,014-230-077-137-497,2019-08-13,2019,US 201815979881 A,2018-05-15,US 201815979881 A;;US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201562141383 P;;US 201562141337 P;;US 201462068526 P;;US 201462068523 P;;US 201462068514 P;;US 201462068296 P;;US 201462068534 P,2014-10-24,Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/014-230-077-137-497,Granted Patent,yes,410,4,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/18;;A61K38/00;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,442,413,014-651-132-335-556;;003-209-696-707-713;;128-415-609-095-377;;078-753-778-060-01X;;008-135-071-759-92X;;104-335-738-580-036;;007-480-305-123-598;;072-942-676-077-691;;056-201-471-905-934;;028-862-168-091-90X;;070-383-251-783-098;;028-567-118-036-513;;005-712-635-226-116;;090-754-759-154-175;;050-825-529-117-306;;028-540-973-166-319;;045-951-701-636-236;;150-512-327-210-48X;;022-997-664-996-345;;047-237-206-017-563;;017-940-142-904-249;;081-098-345-341-182;;010-847-093-078-575;;027-829-588-585-761;;153-232-460-964-283;;158-261-806-420-924;;126-128-839-153-523;;006-504-311-182-612;;098-808-864-401-942;;122-388-810-565-095;;126-434-971-916-802;;062-095-790-501-25X;;083-348-315-692-16X;;085-498-590-431-913;;096-352-881-129-295;;141-785-095-849-82X;;104-063-848-067-130;;069-591-544-766-903;;027-127-290-904-954;;010-872-968-433-256;;037-574-244-923-342;;095-163-015-743-716;;018-560-322-257-247;;078-629-783-492-046;;032-905-603-444-928;;068-050-852-096-624;;029-171-836-207-263;;028-668-540-796-174;;028-668-540-796-174;;001-076-067-628-36X;;005-893-666-286-846;;004-965-380-380-515;;079-996-842-246-699;;039-289-782-216-880;;043-632-912-449-253;;006-451-527-297-818;;032-412-591-971-193;;050-491-094-261-212;;061-186-684-189-36X;;041-610-673-797-380;;048-739-184-191-048;;061-770-380-357-689;;023-157-064-831-058;;005-785-820-497-820;;030-617-186-856-219;;004-571-213-214-147;;117-298-184-780-248;;139-370-722-026-325;;022-717-243-626-689;;001-168-243-787-836;;003-692-671-892-767;;146-959-413-651-106;;009-255-453-457-663;;022-597-328-979-199;;097-412-635-296-694;;015-907-704-662-089;;026-151-208-979-214;;101-171-874-734-776;;007-242-440-136-566;;010-401-085-673-837;;036-787-898-930-499;;010-929-566-271-076;;027-221-602-638-634;;100-286-864-518-416;;012-388-439-961-094;;055-509-434-690-182;;032-004-299-797-893;;030-979-115-550-499;;022-879-584-224-460;;084-341-539-493-404;;088-437-095-235-130;;027-177-154-094-913;;020-026-183-926-325;;019-911-024-298-495;;120-184-720-533-797;;030-130-464-546-217;;110-094-292-858-47X;;091-231-835-456-006;;005-631-024-674-820;;101-575-504-070-651;;005-426-365-134-686;;005-316-633-999-516;;008-878-757-321-700;;008-340-022-598-528;;004-574-009-337-856;;063-797-097-486-664;;169-736-421-398-039;;105-994-509-610-153;;040-375-581-789-283;;029-884-043-437-78X;;013-673-906-914-932;;093-281-504-176-200;;005-433-555-845-783;;064-029-904-826-616;;014-268-011-522-679;;047-362-058-327-502;;059-408-333-766-70X;;062-061-052-321-497;;042-364-181-188-082;;113-394-540-007-150;;001-833-327-326-444;;089-193-344-157-806;;007-026-917-931-385;;113-109-583-058-980;;110-902-470-115-883;;047-294-079-836-486;;002-425-038-765-735;;038-346-034-366-375;;066-146-798-965-262;;021-089-222-463-71X;;007-168-099-008-401;;031-957-451-453-064;;109-373-051-579-919;;030-859-841-509-259;;045-237-747-815-813;;017-239-464-122-703;;002-921-094-507-370;;050-017-203-544-775;;104-277-007-929-625;;008-135-071-759-92X;;018-958-246-350-086;;059-853-971-443-396;;023-907-179-348-058;;052-839-106-430-915;;075-807-103-343-793;;080-050-592-171-046;;031-166-703-585-08X;;189-306-471-756-979;;041-428-113-293-001;;038-037-978-931-264;;019-654-552-765-603;;036-786-233-907-636;;018-078-335-572-806;;099-290-765-461-205;;030-761-388-449-490;;051-260-923-190-254;;052-143-608-436-131;;008-226-221-097-647;;078-209-348-576-455;;089-633-612-001-004;;120-710-247-962-517;;002-945-101-700-774;;037-194-000-791-81X;;146-280-751-006-918;;182-139-657-761-848;;043-147-746-491-691;;041-189-067-181-870;;012-637-499-221-105;;135-885-609-471-475;;022-238-533-842-744;;048-389-287-506-180;;018-989-643-656-697;;041-329-647-699-213;;043-596-978-783-486;;019-779-601-634-917;;053-128-465-484-881;;058-589-196-667-041;;099-108-177-239-268;;026-597-138-156-613;;046-158-519-832-735;;062-670-857-477-054;;084-734-056-460-170;;032-045-779-752-652;;033-733-139-064-996;;009-333-452-920-135;;010-850-616-527-606;;095-359-992-848-941;;083-360-261-831-129;;068-601-220-787-847;;011-377-674-907-872;;040-687-947-392-591;;179-552-640-659-549;;015-623-518-697-144;;025-944-755-967-03X;;035-537-674-004-113;;067-220-965-320-998;;007-005-818-132-358;;141-920-816-342-666;;006-873-363-111-668;;078-886-911-253-419;;023-874-622-768-279;;053-908-725-120-441;;027-033-711-563-119;;084-382-055-323-434;;015-841-839-428-08X;;017-399-857-000-881;;094-876-980-967-766;;053-901-990-601-316;;114-407-414-536-306;;092-380-940-527-529;;035-330-063-258-167;;009-136-082-279-13X;;055-788-913-950-003;;050-513-346-896-80X;;031-933-089-611-974;;079-944-676-961-034;;000-133-235-371-009;;081-452-111-536-816;;019-590-397-412-17X;;074-470-423-479-932;;128-901-299-587-74X;;010-020-681-821-091;;042-423-418-475-539;;041-750-601-903-10X;;068-821-001-542-983;;018-934-238-795-193;;011-020-186-750-886;;117-492-031-514-87X;;065-162-993-535-51X;;081-507-984-297-637;;027-990-295-239-719;;001-466-527-996-328;;027-826-420-479-03X;;077-140-409-267-690;;087-464-638-639-025;;025-146-253-241-793;;000-267-213-967-50X;;093-724-494-618-609;;124-275-393-571-41X;;068-521-955-594-560;;031-066-822-995-403;;034-499-243-336-537;;078-020-406-613-471;;045-362-643-830-026;;127-640-340-609-818;;029-041-317-917-380;;012-193-937-990-576;;013-039-312-104-66X;;030-226-878-795-594;;011-923-052-324-723;;011-552-704-333-933;;138-638-667-066-487;;012-668-687-960-29X;;020-473-776-487-596;;029-402-092-523-225;;021-724-385-934-424;;003-036-556-540-859;;000-647-267-694-484;;066-662-118-303-62X;;053-660-915-978-91X;;097-773-387-318-439;;010-159-493-399-221;;036-036-233-972-857;;064-538-717-151-364;;122-373-655-693-959;;003-813-666-853-382;;074-744-973-712-298;;160-519-052-068-705;;044-306-689-778-275;;129-273-407-931-838;;032-728-154-591-070;;020-704-332-523-176;;095-036-407-766-923;;050-741-722-639-562;;005-001-316-365-345;;029-653-102-379-412;;082-863-413-822-327;;130-557-982-448-359;;010-503-176-197-239;;026-396-339-084-010;;088-434-038-364-143;;110-622-018-928-961;;026-367-037-139-802;;017-729-084-063-643;;053-887-446-496-059;;111-109-974-501-414;;041-461-899-032-384;;030-425-987-723-110;;007-181-598-202-221;;004-100-004-646-006;;014-169-184-148-626;;056-370-822-404-873;;092-760-851-706-263;;065-097-473-442-493;;030-660-067-609-024;;164-403-066-288-611;;031-584-564-704-369;;047-580-366-679-441;;085-764-009-624-439;;027-314-030-808-345;;052-947-986-013-690;;000-234-931-492-675;;073-419-783-934-185;;048-666-647-905-365;;093-509-508-230-620;;087-477-650-364-59X;;033-756-776-033-780;;017-561-716-268-836;;040-635-027-762-84X;;046-731-814-106-92X;;006-516-075-151-31X;;000-870-842-639-900;;009-738-327-233-69X;;028-294-432-381-795;;014-729-984-201-416;;074-582-134-846-704;;101-797-963-804-734;;012-080-214-127-41X;;079-141-143-704-263;;048-183-620-015-85X;;081-092-403-760-75X;;017-185-661-050-007;;022-944-275-314-68X;;042-751-409-162-883;;032-459-914-054-209;;007-339-268-863-200;;005-660-045-470-037;;051-315-531-263-042;;034-330-993-923-294;;031-118-508-476-586;;082-902-765-648-368;;020-682-017-511-509;;137-791-867-210-863;;106-136-224-518-463;;005-638-542-147-993;;011-243-931-881-746;;059-478-289-803-609;;073-102-472-393-46X;;008-076-695-732-453;;112-039-702-206-214;;007-496-126-787-125;;070-434-249-460-174;;013-885-021-097-853;;016-759-138-450-894;;015-801-694-447-055;;019-627-964-331-373;;082-984-043-695-164;;037-740-603-895-357;;011-657-979-926-27X;;003-242-603-416-269;;083-634-098-131-485;;048-439-321-617-128;;110-630-331-648-229;;020-065-207-907-092;;031-075-424-243-630;;028-373-705-126-470;;006-095-947-008-535;;024-253-203-317-101;;055-852-081-735-610;;025-834-245-974-873;;084-748-487-156-928;;115-802-414-738-000;;035-328-575-802-514;;018-351-785-584-614;;094-815-381-871-763;;081-753-724-687-173;;079-274-785-935-791;;063-155-730-882-853;;067-127-654-169-729;;048-972-529-594-020;;054-304-933-298-139;;017-049-171-562-572;;099-270-483-107-007;;142-164-397-210-970;;104-283-497-946-575;;046-036-272-703-281;;075-912-302-795-48X;;111-570-270-686-786;;077-066-325-033-341;;029-811-479-361-870;;000-654-286-546-079;;012-837-528-765-07X;;069-296-641-163-256;;039-149-059-983-63X;;065-815-544-501-870;;019-394-264-649-327;;046-262-147-203-697;;008-125-648-563-747;;030-861-724-466-58X;;015-214-531-219-780;;028-383-058-454-759;;135-513-407-563-622;;058-530-733-727-374;;013-392-307-146-301;;063-864-581-855-676;;003-416-495-423-02X;;016-250-517-165-602;;037-612-698-436-922;;077-722-555-854-551;;038-624-922-825-362;;035-070-408-027-340;;049-937-366-109-256;;010-030-039-052-116;;061-267-522-126-985;;089-860-020-044-940;;025-612-997-745-121;;040-712-467-075-177;;013-754-548-416-363;;030-425-714-928-399;;035-769-575-764-291;;096-395-044-694-051;;092-139-783-170-608;;034-492-937-769-693,10.1111/jgh.12271;;24251707;;10.1093/abbs/gmu097;;25355486;;10.1016/j.febslet.2008.11.023;;19059246;;10.1021/bc300603k;;23594041;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;6467175;;10.2337/diacare.25.5.869;;11978683;;24248463;;10.1210/en.2013-1828;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;6363212;;10.1016/0378-1119(83)90222-6;;11880038;;10.1016/s1074-5521(02)00094-7;;10.1002/macp.1978.021790204;;10.1023/a:1015825027737;;2052513;;7763976;;10.1016/0958-1669(93)90011-k;;10.2337/diacare.15.6.755;;1600835;;1560827;;10.1038/356537a0;;10.1021/ja00202a052;;1911037;;6220717;;10.1016/0006-291x(83)91828-4;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;10.1016/s0040-4020(01)90305-9;;10.1126/science.3140377;;3140377;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;6757758;;10.1038/300706a0;;10.1016/s0040-4039(01)90461-7;;10.1016/0003-2697(83)90131-8;;6193731;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.3.co;2-c;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.0.co;2-5;;9050787;;10.2337/diabetes.45.11.1572;;10.2337/diab.45.11.1572;;8866563;;875032;;10.1016/s0022-2836(77)80200-3;;10.1016/0197-0186(94)90047-7;;7950964;;10.1016/s0021-9258(18)82348-1;;8340419;;10.1038/nsb0594-283;;7664033;;2994214;;10.1126/science.2994214;;1733123;;10.1093/ajcn/55.2.538s;;10.3109/03639049209046327;;8352595;;10.1146/annurev.bi.62.070193.002411;;1332541;;10.1016/0003-2697(92)90433-8;;10.1006/jmbi.1997.1132;;9245591;;10.1111/j.1432-1033.1995.0788h.x;;10.1111/j.1432-1033.1995.tb20622.x;;7607253;;10.1096/fasebj.13.1.41;;9872928;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;10.1006/prep.1997.0744;;9226723;;10.1016/s0169-409x(03)00108-x;;14499706;;10.1111/j.1440-1681.1978.tb00650.x;;639358;;pmc252500;;2993646;;10.1128/jvi.56.1.153-160.1985;;10.1021/jo034984x;;14604354;;10.1016/0076-6879(87)54086-1;;2828857;;10.1016/0076-6879(87)54086-1;;2828857;;3541892;;10.1042/bj2370001;;pmc1146940;;2438771;;10.1126/science.2438771;;22787375;;pmc3390728;;10.3346/jkms.2012.27.7.784;;7030620;;10.3109/10409238109108703;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203;;12148987;;10.1021/ja027007w;;12920298;;10.1126/science.1084772;;10.1002/chin.198535327;;10.1016/s0958-1669(00)00200-7;;11287238;;10.1016/s0958-1669(98)80109-2;;9664053;;8703002;;10.1074/jbc.271.36.21969;;3286212;;10.2165/00003495-198835030-00003;;2250094;;10.1093/oxfordjournals.jhered.a111019;;7160534;;10.2337/diab.31.1.s24;;17036574;;10.1016/s0025-6196(11)61176-2;;10.1126/science.3685986;;3685986;;10.1002/anie.199506211;;10.1021/ja961216x;;1785831;;10.1111/j.1749-6632.1991.tb49017.x;;10.1021/jo00241a009;;pmc369166;;3915774;;10.1128/mcb.5.12.3376-3385.1985;;10.1128/mcb.5.12.3376;;10.1038/1921227a0;;13882203;;10.1242/dev.121.2.439;;7768185;;8850022;;10.1385/0-89603-332-5:369;;pmc215567;;10.1128/jb.158.3.1165-1167.1984;;6327630;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.3.co;2-9;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.0.co;2-i;;10506413;;10966479;;10.1146/annurev.biochem.69.1.923;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1128/jb.154.2.737-742.1983;;pmc217523;;6841315;;8314773;;10.1016/s0021-9258(19)85209-2;;7623902;;10.1056/nejm199508313330902;;10.1021/ja0370037;;14505376;;15501033;;10.1016/j.bmcl.2004.09.059;;1458545;;12119302;;10.1074/jbc.m205854200;;10.1111/j.1749-6632.1991.tb49014.x;;1785800;;10.1089/neu.1996.13.309;;8835798;;9398858;;10.1038/ng1297-491;;10.1126/science.1057718;;11313495;;11102869;;10.1016/s1367-5931(00)00148-4;;10.1021/bi9617973;;9116020;;10.1038/nrd1088;;12750738;;10.1128/mcb.10.4.1633-1641.1990;;10.1128/mcb.10.4.1633;;1690848;;pmc362268;;pmc311518;;10.1093/nar/14.12.5115;;3460029;;1883529;;10.1007/bf01024990;;2187475;;10.1016/0076-6879(91)02017-4;;1784180;;10.1126/science.1553546;;1553546;;9989500;;10.1016/s0092-8674(00)80962-9;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1002/bit.260290911;;18576565;;13428781;;10.1016/s0021-9258(18)64849-5;;12754376;;pmc164450;;10.1073/pnas.1132122100;;10.1016/j.chembiol.2003.11.004;;14652071;;2647707;;10.1007/bf02628459;;1568242;;10.1016/0092-8674(92)90402-x;;10.1021/ja01523a064;;10.1007/978-3-642-71589-1_3;;3816299;;10.1093/nar/16.14.6987;;3405755;;pmc338346;;3862099;;10.1073/pnas.82.17.5824;;pmc390645;;17878606;;10.1507/endocrj.kr07e-002;;10.1002/pro.5560070223;;9521119;;pmc2143905;;8741989;;10.1021/bc950074d;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/bc00015a010;;1381617;;10.1016/s1074-5521(97)90312-4;;9375252;;10.1016/s0002-9343(97)00254-4;;9428832;;1444338;;10.1007/bf00584464;;8661131;;10.1006/geno.1996.0349;;10.1021/bc00014a008;;1325188;;8891346;;161245;;10.1016/0378-1119(79)90009-x;;10.1016/j.tem.2014.03.001;;24709036;;8269798;;10.2337/diacare.16.10.1387;;10.1099/00221287-132-12-3459;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;10.1016/0076-6879(90)85003-7;;2116575;;1785812;;10.1111/j.1749-6632.1991.tb49016.x;;1366535;;10.1038/nbt0490-343;;9558343;;10.1021/bi972685u;;10.1126/science.281.5374.269;;9657724;;3889852;;10.1093/nar/13.9.3305;;pmc341236;;10.1006/prep.2002.1624;;12071713;;pmc2946115;;20882112;;10.1002/anie.199728251;;10.1074/jbc.m003696200;;11006270;;10.1021/ar9901570;;11560472;;10.1021/bi035320k;;10.1021/bi035320k.s001;;14730967;;10.1016/s0021-9258(17)30417-9;;248056;;10.1021/ar00024a001;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;10.1021/bi00419a012;;3061451;;10.1002/j.1460-2075.1990.tb08287.x;;2184035;;pmc551863;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;17036573;;10.1016/s0025-6196(11)61175-0;;10.1016/0065-2571(69)90016-8;;4244004;;11883961;;10.1006/bbrc.2002.6607;;10.1073/pnas.75.4.1929;;347451;;pmc392455;;10.1038/nbt0202-177;;11821864;;6254992;;10.1016/s0021-9258(19)70246-4;;10.1021/ja00976a035;;5980877;;10.1016/s1367-5931(02)00376-9;;12470735;;10.1021/ja9813109;;10.1021/ja992204p;;363146;;10.1021/bi00616a007;;6256394;;10.1016/s0021-9258(19)69976-x;;23663742;;pmc3667496;;10.1016/j.cmet.2013.03.019;;10.1006/bbrc.1998.8239;;9514906;;pmc383928;;10.1073/pnas.76.8.3829;;386351;;1577399;;10.1055/s-2007-1003271;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;7758582;;10.1016/0014-5793(95)00408-2;;8003476;;10.1021/bi00189a013;;7530860;;10.1126/science.7530860;;10.1056/nejm199803263381303;;9516221;;412251;;10.1126/science.412251;;10.1128/jb.153.1.163-168.1983;;pmc217353;;6336730;;10.1126/science.7939659;;7939659;;8703034;;10.1074/jbc.271.36.22203;;10.1021/ja01511a053;;10.1002/macp.1979.021800528;;10.1111/j.1365-2265.1991.tb03490.x;;1889135;;10.1126/science.6238407;;6238407;;10.1146/annurev.bi.54.070185.003025;;2992359;;10.1146/annurev.biochem.54.1.565;;10.1021/ar00158a001;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;16773196;;10.3892/ijo.29.1.163;;9223335;;pmc21577;;10.1073/pnas.94.15.8179;;10.1016/s0040-4020(96)01195-7;;3894007;;pmc554210;;10.1002/j.1460-2075.1985.tb03653.x;;17036575;;10.1016/s0025-6196(11)61177-4;;10.1172/jci23606;;pmc1088017;;15902306;;17068132;;10.1210/en.2006-1168;;pmc3986619;;24749049;;10.1016/j.molmet.2013.12.003;;23536797;;pmc3594191;;10.1371/journal.pone.0058575;;10.1016/s0040-4020(00)00833-4;;11752401;;10.1073/pnas.012583299;;pmc117506;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.3.co;2-j;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.0.co;2-s;;10577472;;10.1023/a:1005624811710;;10835240;;10.1021/bp000031y;;10.1002/bit.1121;;10.1002/bit.1121.abs;;11410855;;23825123;;10.1210/en.2012-2276;;10.1039/jr9490003315;;389741;;10.1016/0378-1119(79)90029-5;;2216760;;pmc332298;;10.1093/nar/18.19.5667;;1422046;;15915461;;10.1002/hep.20701;;12754495;;10.1038/nsb934;;10.1080/00397919208019100;;10.1016/s1367-5931(00)00141-1;;11102863;;10.1021/jo00269a022;;9185859;;10.1016/s0378-1119(97)00019-x;;16076449;;10.1016/j.ymeth.2005.04.001;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;pmc30127;;11226228;;10.1073/pnas.031488298;;10.1016/0092-8674(84)90283-6;;6386179;;10.1016/0076-6879(87)54084-8;;3323812;;3165526;;10.1093/nar/16.14.7207;;pmc338387;;6096830;;pmc320472;;10.1093/nar/12.24.9441;;8305530;;10.1021/bc00024a025;;3095839;;10.1073/pnas.83.22.8604;;pmc386979;;10.1007/s001250050498;;8781766;;10.1007/bf00418542;;10.1021/bi026856t;;12693945;;10.1016/0021-9673(86)80093-0;;3488324;;10.1016/0076-6879(87)54085-x;;3323813;;3881765;;10.1073/pnas.82.2.488;;pmc397064;;10.1002/jobm.3620250210;;10.1074/jbc.c500457200;;16436388;;pmc2637204;;pmc367493;;3023819;;10.1128/mcb.6.1.142;;10.1128/mcb.6.1.142-149.1986;;8554512;;10.1042/bj3120725;;pmc1136174;;17036578;;10.1016/s0025-6196(11)61180-4;;10.1002/jbm.820150212;;7348718;;10.2144/99261bm05;;9894589;;10.1016/s0958-1669(98)80035-9;;9821278;;10.1016/j.cmet.2013.04.005;;23663741;;10.1006/abio.1997.2428;;9417773;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1021/ja029433n;;12580587;;8632803;;10.1038/381442a0;;pmc307151;;7659531;;10.1093/nar/23.15.3067;;10.1016/s1097-2765(01)00369-0;;11684012;;10.1038/85080;;11224539;;2497580;;10.1016/0042-6822(89)90348-6;;10.1016/0006-8993(91)90784-s;;1723639;;8347599;;10.1021/bi00082a015;;10.7326/0003-4819-128-3-199802010-00002;;9454525;;11273699;;pmc7125544;;10.1006/jmbi.2001.4518;;10.1126/science.276.5315.1125;;9173543;;8613964;;12810643;;pmc386678;;3532104;;10.1073/pnas.83.19.7177;;10.1099/0022-1317-70-12-3501;;2691634;;10.2337/diacare.24.3.489;;11289473;;7473593;;10.1021/jm00023a005;;10.1016/s1044-5765(05)80035-1;;17036576;;10.1016/s0025-6196(11)61178-6;;9427842;;10.1016/s0079-6603(08)61031-4;;17036577;;10.1016/s0025-6196(11)61179-8;;10.1021/ja9925150;;9310317;;10.1242/dev.124.17.3221;;10.1021/ja0025806;;10.1021/ja0284153;;12537491;;10954682;;7663123;;10.1146/annurev.bb.24.060195.002251;;10.1146/annurev.biophys.24.1.435;;9581754;;10.1016/s0896-6273(00)81001-6;;10.1146/annurev.micro.42.1.177;;10.1146/annurev.mi.42.100188.001141;;3059993;;2695080;;10.1002/bies.950110404;;3030893;;10.1016/0378-1119(86)90356-2;;10.1111/j.1464-5491.1994.tb00333.x;;7955995;;10933852;;10.1006/abio.2000.4667;;9473496;;10.1006/bbrc.1998.8073;;6337369;;10.1073/pnas.80.1.1;;pmc393297;;10764591;;10.1006/jmbi.2000.3658;;10.1038/302543a0;;6403870;;10.1002/jcp.20847;;17063460;;pmc3266413;;22210323;;10.2337/db11-0838;;14652075;;10.1016/j.chembiol.2003.10.010;;pmc341328;;10.1093/nar/14.24.9679;;3027659;;10.1021/ja00246a064;;6322300;;10.1126/science.6322300;;pmc320064;;6473105;;10.1093/nar/12.15.6159;;10.1016/0022-2836(70)90057-4;;5420325;;4973231;;10.1016/s0021-9258(18)93152-2;;10.1016/s0167-4889(02)00256-2;;12183061;;17933712;;10858549;;10.1016/s0167-4781(00)00067-1;;10.1016/s0167-4781(98)00255-3;;9931477;;10.1056/nejm199411033311803;;7935656;;9593693;;10.1074/jbc.273.22.13570;;10.1126/science.2649980;;2649980;;7716551;;10.1126/science.7716551;;10.21236/ada299991;;10.1093/protein/1.3.151;;3333844;;10.1021/ja9940064;;10.1021/ja001450u;;9660775;;10.1074/jbc.273.29.18161;;10.1093/oxfordjournals.jbchem.a022221;;9832608;;10.1016/s0021-9258(18)89400-5;;3838308;;9187149;;10.1242/dev.124.11.2235;;10.1126/science.164.3880.719;;5778021;;10.1021/bk-1997-0680.ch012;;pmc138918;;11276432;;10.1186/gb-2001-2-3-reviews3005;;8883961;;10.1016/0169-328x(96)00108-8;;10.1016/b978-0-08-052349-1.00116-5;;6307823;;10.1016/0378-1119(83)90107-5;;11948130;;pmc42512;;7877976;;10.1073/pnas.92.5.1327;;10.1002/1522-2675(20000906)83:9<2277::aid-hlca2277>3.0.co;2-l;;9591139;;10.2144/98245rr03;;10.1016/0003-2697(82)90240-8;;6289696;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;8431294;;11356929;;10.1038/bjc.1992.272;;pmc1977825;;1380282;;10.1038/343033a0;;1688644;;10.1093/bioinformatics/18.7.980;;12117796;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;10490103;;10.1016/s0092-8674(00)80051-3;;10.1021/ja00965a060;;3194752;;10.1126/science.3194752;;10.1146/annurev.ge.18.120184.001133;;6084980;;10.1074/jbc.270.50.29813;;8530375;;12845521;;10.1007/s00441-003-0756-7;;8798573;;10.1074/jbc.271.39.23607;;10.1016/s0021-9673(01)95395-6;;6355135;;3614380;;10.1038/328731a0;;9356443;;10.1073/pnas.94.23.12297;;pmc24913;;10.1021/ja00007a055;;10.1007/bf00331655;;10.1002/yea.320080602;;1502852;;9129118;;10.1016/s0024-3205(96)00595-4;;10.1006/mcpr.1994.1013;;7935517;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1074/jbc.271.37.22376;;8798399;;12409460;;10.1093/nar/gkf589;;pmc135798;;3165194;;10.1093/nar/16.14.6361;;pmc338301;;10.1074/jbc.271.38.23169;;8798511;;12244330;;10.1038/nbt742;;21520200;;10.1002/hep.24376;;pmc4014460;;10.1007/bf02921514;;2024978;;10.1021/ma00056a005;;10.1126/science.287.5460.2007;;10720325;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/nar/16.3.803;;pmc334720;;2830594;;10.1016/s0021-9258(18)62817-0;;5528240;;10480527;;10.2337/diacare.22.9.1568;;19915550;;10.1038/nbt.1588;;10.1006/prep.1997.0851;;9535699;;10.1006/prep.1995.1002;;7756834;;10.1126/science.1566069;;1566069;;10.1161/01.cir.97.7.645;;9495299;;9516220;;10.1056/nejm199803263381302;;10.1016/0076-6879(87)35063-3;;3600302;;10.1002/dmrr.288;;12112940;;10.1021/ja00119a001;;10664452;;10.1016/s0014-5793(00)01120-0;;10.1038/292128a0;;6264321;;803646;;10.1038/254034a0;;6201207;;10.1002/bip.360220167;;10.1038/88129;;11329016;;9425898;;10.1038/ng0198-45;;10.1093/genetics/122.1.19;;2659436;;pmc1203683;;10.1128/jvi.68.2.766-775.1994;;pmc236513;;8289380;;10.1016/s0022-1759(96)00217-7;;9032414;;pmc38518;;10.1073/pnas.93.18.9850;;8790420;;6318086;;pmc370086;;10.1128/mcb.3.12.2156;;10.1128/mcb.3.12.2156-2165.1983;;3002241;;10.1146/annurev.ge.19.120185.002231;;10.1146/annurev.genet.19.1.423;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/s0021-9258(18)68577-1;;3372509;;10.1074/jbc.270.8.4121;;7876162;;10.1007/978-1-4684-3417-0_9;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1038/370389a0;;8047147;;10.1016/0022-2836(86)90385-2;;3537305;;1469691;;10.1021/jm00102a014;;10.1021/ja00203a067;;3156376;;pmc397196;;10.1073/pnas.82.4.1074;;10.1021/ja010731e;;11472182;;7482665;;10.1161/01.str.26.11.2154;;7737407;;10.1016/0014-5793(95)00324-3;;11317312;;29712367;;10.1002/1521-3773(20010417)40:8<1494::aid-anie1494>3.0.co;2-x;;3001650;;10.1093/nar/13.24.8765;;pmc318950;;pmc318949;;10.1093/nar/13.24.8749;;3001649;;6368319;;10.1016/0378-1119(83)90191-9;;10.1016/0168-3659(85)90001-x;;10.1021/jo011148j;;11975567;;7620563;;10.1385/0-89603-272-8:97;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;6248420;;10.1016/0378-1119(80)90133-x;;10.1016/s1046-5928(02)00641-1;;12651100;;10.1074/jbc.271.33.19991;;8702716;;8402094;;10.1002/bjs.1800800812;;10.1038/nbt0290-135;;1366557;;10.1056/nejmoa011300;;11794168;;9645477;;10.1016/s0014-5793(98)00489-x;;10.1021/ja992749j;;10.1128/jb.130.2.946-947.1977;;400800;;pmc235301;;10.1007/bf02798546;;4026282;;3128641;;10.1099/0022-1317-69-4-765;;pmc140882;;12518054;;10.1073/pnas.0234824100;;10.1126/science.1060077;;11313494;;10.1021/ja021381e;;12630856;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/0378-1119(85)90140-4;;3891521;;10.1002/(sici)1097-0177(199709)210:1<41::aid-aja5>3.0.co;2-1;;9286594;;10.1016/s0960-9822(95)00102-3;;7583099;;0007583099;;10.1021/bc00023a002;;8274513;;10.1016/0141-0229(92)90049-t;;1368988;;10.1038/321718a0;;10.1021/ja028050m;;12465973;;18840786;;10.2337/db08-0392;;pmc2606881;;pmc344858;;6324193;;10.1073/pnas.81.5.1470;;pmc327233;;10.1093/nar/9.3.731;;6164048;;1785805;;10.1111/j.1749-6632.1991.tb49015.x;;10.1016/0014-3057(83)90016-2;;10.1021/bc00032a002;;7599259;;10.2337/diacare.24.4.720;;11315837;;24189035;;10.1016/j.drudis.2013.10.021;;10.1021/bi0300231;;12779328;;6225933;;10.1016/b978-0-12-765560-4.50036-8;;10.1016/0076-6879(83)00074-9;;6757864;;pmc326938;;10.1093/nar/10.20.6487;;10.1016/0076-6879(87)54083-6;;3323811;;10.1016/j.cmet.2013.08.005;;24011069;;10.3410/f.734650074.793563632;;10.1016/s0140-6736(18)31785-9;;30554783;;pmc6587787;;10.1002/oby.22344;;30520566,"Hashimoto et al. (J. Gastroenterol. Hepatol. 28(Suppl. 4): 64-70, 2013) (Year: 2013).;;Zhu et al. Acta Biochim. Biophys. Sin. 46(12): 1041-1048, 2014.;;Yie J, Wang W, Deng L, Tam LT, Stevens J, Chen MM, Li Y, Xu J, Lindberg R, Hecht R, Veniant M. “Understanding the Physical Interactions in the FGF21/FGFR/β-Klotho Complex: Structural Requirements and Implications in FGF21 Signaling.” Chemical biology & drug design. Apr. 1, 2012;79(4):398-410.;;Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, Steavenson S, Smith S, Winters D, Fisher S, Cai L. “FGF21 N- and C-termini play different roles in receptor interaction and activation.” FEBS letters. Jan. 5, 2009;583(1):19-24.;;Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J. “Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling.” Nature. Jan. 17, 2018.;;Xu J, Bussiere J, Yie J, Sickmier A, An P, Belouski E, Stanislaus S, Walker KW. “Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.” Bioconjugate chemistry. May 9, 2013;24(6):915-25.;;Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C. “Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes.” PLoS One. Nov. 27, 2012;7(11):e49345.;;Abuchowski, A. et al., “Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates”, Cancer Biochem. Biophys., Jun. 1984, 7(2): 175-86.;;Ahrén et al., “Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes”, Diabetes Care, 2002, 25(5): 869-75.;;Alisi, A. et al., “Commentary: FGF21 Holds Promises for Treating Obesity-related Insulin Resistance and Hepatosteatosis”, Endocrinology, Nov. 18, 2013, doi: 10.1210/en.2013-1828.;;Altschul, S.F. et al., “Basic local alignment search tool”, J. Mol. Biol., Oct. 5, 1990, 215(3): 403-10.;;Altschul, S.F. et al., “Gapped BLAST and Psi-BLAST: a new generation of protein database search programs”, Nucleic Acids Res., Sep. 1, 1997, 25(17): 3389-402.;;Amann, E. et al., “Vectors bearing a nybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli”, Gene, Nov. 1983, 25(2-3): 167-78.;;Anderson, J.C. et al., “Exploring the limits of codon and anticodon size”, Chem. Biol., Feb. 2002, 9(2): 237-44.;;Andresz, H. et al., “Chemische Synthese verzweigter Polysaccharide, 5: Kopplung von Oligosacchariden und Amylose an verschiedene Träer durch Hydrazonbindung”, Makromol. Chem. 1978, 179: 301, Abstract.;;Arakawa et al., “Protein-solvent interactions in pharmaceutical formulations”, Pharm. Res., 1991, 8(3): 285-291.;;Arnold, F.H., “Protein engineering for unusual environments”, Curr. Opin. Biotechnol., Aug. 1993, 4(4): 450-5.;;Azoulay, M. et al., “Glutamine analogues as Potential Antimalarials”, Eur. J. Med. Chem., 1991, 26(2): 201-5.;;Badman, M.K. et al., “Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States”, Cell Metabolism, Jun. 2007, 5: 426-437.;;Bailey, “Biguanides and NIDDM”, Diabetes Care, 1992, 15:755-72.;;Bain et al., “Ribosome-mediated incorporation of a non-standard amino acid into a peptide through expansion of the genetic code”, Nature, 1992, 356(6369): 537-539.;;Bain, J.D. et al., “Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide”, J. Am. Chem. Soc., 1989; 111(20): 8013-8014.;;Baird et al., “The fibroblast growth factor family”, Cancer Cells, 1991, 3(6): 239-43.;;Ballance, D.J. et al., “Transformation of Aspergillus nidulans by the orotidine-5′-phosphate decarboxylase gene of Neurospora crassa”, Biochem. Biophys. Res. Commun., Apr. 15, 1983, 112(1): 284-9.;;Barany, F. et al., “Genetic disease detection and DNA amplification using cloned thermostable ligase”, Proc. Natl. Acad. Sci. USA, Jan. 1, 1991, 88(1): 189-93.;;Barton, D.H.R. et al., “Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives”, Tetrahedron, 1987, 43: 4297-4308.;;Bass, S. et al., “Mutant Trp repressors with new DNA-binding specificities”, Science, 1988, 242: 240-245.;;Batzer, M.A. et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus”, Nucleic Acids Res., Sep. 25, 1991, 19(18): 5081.;;Beach, D. et al., “Functionally homologous cell cycle control genes in budding and fission yeast”, Nature, Dec. 1982, 300: 706-709.;;Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis”, Tetrahedron Letts., 1981, 22(20): 1859-1862.;;Beauchamp, C.O. et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal. Biochem., May 1983, 131(1): 25-33.;;Belluardo et al., “Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis”, J. Comp. Neurol. (1997) 379(2): 226-46.;;Berkowitz et al., “Effect of troglitazone on insulin sensitivity an dpancreatic beta-cell.function in women at high risk for NIDDM”, Diabetes, 1996, 45(11): 1572-9.;;Bernstein, F.C. et al., “The protein data bank: a computer-based archival file for macromolecular structures”, J. Mol. Biol., 1977, 112: 535-542.;;Biagini et al., The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes, Neurochem. Int., 1994, 25(1): 17-22.;;Boissel, J.P. et al., “Erythroprotein structure-function relationships. Mutant proteins that test a model of tertiary structure”, Jul. 25, 1993, 268(21): 15983-93.;;Boles, J.O. et al., “Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase”, Nat. Struct Biol., May 1994, 1(5): 283-4.;;Botstein, D. and D. Shortle, “Strategies and applications of in vitro mutagenesis”, Science, Sep. 20, 1985, 229(4719): 1193-201.;;Bray, “Drug treatment of obesity”, Am. J. Clin. Nutr., 1992, 55(2 Suppl): 538S-544S.;;Broadhead et al., “The Spray Drying of Pharmaceuticals”, Drug Dev. Ind. Pharm., 1992, 18(11/12):1169-1206.;;Brunner, J. et al., “New photolabeling and crosslinking methods”, Annu. Rev. Biochem., 1993, 62: 483-514.;;Buchner, J. et al., “A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies”, Anal. Biochem., 1992, 205(2): 263-270.;;Bückmann et al., “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),” Makromol. Chem., 1981, 182: 1379-84.;;Budisa, N. et al., “Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins”, J. Mol. Biol., Jul. 25, 1997, 270(4): 616-23.;;Budisa, N. et al., “High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli”, Eur. J. Biochem., Jun. 1, 1995, 230(2): 788-96.;;Budisa, N. et al., “Toward the experimental codon reassignment in vivo: protein.building with an expanded amino acid repertoire”, FASEB J., Jan. 1999, 13(1): 41-51.;;Burgess et al., “The Heparin Binding (Fibroblast) Growth Factor Family of Proteins”, Annu. Rev. Biochem., 1989, 58: 575-606.;;Cai, X-Y et al., “Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-Inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells”, Protein Expression and Purifcation, 1997, 10(2): 263-74.;;Caliceti, P. and F.M. Veronese, “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates”, Adv. Drug. Deliv. Rev., Sep. 26, 2003, 55(10): 1261-1277.;;Cameron et al., “Effects of monosodium glutamate-induced obesity in mice on carbohydrate metabolism in insulin secretion”, Clin. Exp. Pharmacol. Physiol., 1978, 5(1): 41-51.;;Carbonell, L.F. et al., “Baculovirus-mediated expression of bacterial genes in dipteran.And mammalian cells”, J. Virol., Oct. 1985, 56(1): 153-60.;;Carrasco, M. and R. Brown, “A Versatile Set of Aminoxy Amino Acids for the Synthesis of Neuropeptides”, J. Org. Chem., 2003, 68(23): 8853-8858.;;Carter, P. et al., “Improved oligonucleotide site-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987, 154: 382-403.;;Carter, P., “Improved oligonucleotide-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987, 154: 382-403.;;Carter, P., “Site-directed mutagenesis”, Biochem J., Jul. 1, 1986, 237(1): 1-7.;;Cech, “The chemistry of self-splicing RNA and RNA enzymes”, Science, Jun. 19, 1987, 236(4808): 1532-9.;;Chae, H-W. et al., “Spot Urine Albumin to Creatine Ratio and Serum Cystatin C are Effective for Detection of Diabetic Nephropathy in Childhood Diabetic Patients”, J Korean Med Sci. 2012, 27: 784-787.;;Chaiken, I.M., “Semisynthetic peptides and proteins”, CRC Crit. Rev. Biochem., 1981, 11(3): 255-301.;;Chin, J.W. and P.G. Schultz, “In vivo photocrosslinking with unnatural amino acid mutagenesis”, Chembiochem, Nov. 4, 2002, 3(11): 1135-7.;;Chin, J.W. et al., “Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli”, Proc. Natl. Acad. Sci. USA, Aug. 20, 2002, 99(17): 11020-4. Epub. Aug. 1, 2002.;;Chin, J.W. et al., “Addition of p-azido-L-phenylalanine to the genetic code of E. coli”, J. Am. Chem. Soc., Aug. 7, 2002, 124(31): 9026-7.;;Chin, J.W. et al., “An expanded eukaryotic genetic code”, Science, Aug. 15, 2003, 301(5635): 964-7.;;Christie, B.D. and H. Rapoport, “Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization”, J. Org. Chem., 1985, 50(8): 1239-1246.;;Clark, E.D.B., “Protein refolding for industrial processes”, Curr. Opin. Biotechnol., Apr. 2001, 12(2): 202-207.;;Clark, E.D.B., “Refolding of recombinant proteins”, Curr. Opin. Biotechnol., Apr. 1, 1998, 9(2): 157-163.;;Clark, R. et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”, J. Biol. Chem., Sep. 6, 1996, 271(36): 21969-77.;;Clissod et al., “Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential”, Drugs, 1988, 35:214-23.;;Coleman et al., “Fat(fat) and tubby(tub): two autosomal recessive mutations causing obesity syndromes in the mouse”, J. Hered., 1990, 81(6): 424-7.;;Coleman et al., “Other Potentially Useful Rodents as Models for the Study of Human Diabetes Mellitus”, Diabetes, 1982, 31(Suppl 1 Pt 2): 24-25.;;Collazo-Clavell, M.L. et al., “Assessment and Preparation of Patients for Bariatric Surgery”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S11-S17.;;Corey, D.R. and P.G. Schultz, “Generation of a hybrid sequence-specific single-stranded deoxyribonuclease”, Science, 1987, 238(4832): 1401-1403.;;Cornish, V.W. et al., “Probing Protein Sturcture and Function with an Expanded Genetic Code”, Angew. Chem. Int. Ed. Engl., 34(6): 621-33.;;Cornish, V.W. et al., “Site-Specific Protein Modification Using a Ketone Handle”, J. Am. Chem. Soc., 1996, 118(34): 8150-8151.;;Coulier et al., “The FGF6 gene with the FGF multigene family”, Ann. NY Acad. Sci., 1991, 638:53-61.;;Craig, J.C. et al., “Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino] quinoline (Chloroquinine)”, J. Org. Chem., 1988, 53(6): 1167-1170.;;Cregg, J.M. et al., “Pichia pastoris as a host system for transformations”, Mol. Cell Biol., Dec. 1985, 5(12): 3376-85.;;Crick, F.H.C. et al., “General nature of the genetic code for proteins”, Nature, Dec. 30, 1961, 192: 1127-32.;;Crossley et al., “The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo”, Development, 1995, 121(2): 439-51.;;Dale et al., “Oligonucleotide-directed random mutagenesis using the phophorothioate method”, Methods Mol. Biol., 1996, 57: 369-374.;;Das, S. et al., “Transformation of Kluyveromyces fragilis”, J. Bacteriol., Jun. 1984, 158(3): 1165-7.;;Davis, G.D. et al., “New fusion protein systems designed to give soluble expression in Eschericia coli”, Biotechnol. Bioeng., Nov. 20, 1999, 65(4): 382-388.;;Dawson et al., “Synthesis of native proteins by chemical ligation”, Annu. Rev. Biochem., 2000, 69: 923-60.;;De Boer, H.A. et al., “The tac promoter: a functional hybrid derived from the trp and the lac promoters”, Proc. Natl. Acad. Sci. USA, Jan. 1983, 80(1): 21-5.;;De Louvencourt, L. et al., “Transformation of Kluyveromyces lactis by killer plasmid DNA”, J. Bacteriol., May 1983, 154(2): 737-42.;;Debinski, W. et al., “A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin”, J. Biol. Chem., Jul. 5, 1993, 268(10): 14065-70.;;DeFronzo et al., “Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group”, N. Engl. J. Med., 1995, 333(9): 541-9.;;Deiters, A. et al., “Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cerevisiae”, J. Am. Chem. Soc., 2003, 125(39): 11782-11783.;;Deiters, A., “Site-specific PEGylation of proteins contianing unnatural amino acids”, Bioorg. Med. Chem. Lett., Dec. 6, 2004, 14(23): 5743-5.;;Delgado, C. et al., “The uses and properties of PEG-linked proteins”, Crit Rev. Ther. Drug. Carrier Syst., 1992, 9(3-4): 249-304.;;Dennis, M.S. et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins”, J. Biol. Chem., Sep. 20, 2002, 277(38): 35035-43, Epub Jul. 15, 2002.;;Dickson et al., “Expression, processing, and properties of int-2”, Ann. NY Acad. Sci., 1991, 638:18-26.;;Dietrich et al., “Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats”, J. Neurotrauma, 1996, 13(6): 309-16.;;Dolphin, C.T. et al., “Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome”, Nat. Genet., Dec. 1997, 17(4): 491-4.;;Doring, V. et al., “Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway”, Science, Apr. 20, 2001, 292(5516): 501-4.;;Dougherty, D.A., “Unnatural amino acids as probes of protein structure and function”, Curr. Opin. Chem. Biol., Dec. 2000, 4(6): 645-52.;;Drummond et al., “Liposomal drug delivery systems for cancer therapy”, B. Teicher (ed.): Cancer Drug Discovery and Development, 2002, 161-213.;;Duewel, H. et al., “Incorporation of trifluoromethionine into a phage lysozyme: implications and a new marker for use in protein 19F NMR”, Biochemistry, Mar. 18, 1997, 36(11): 3404-16.;;Duncan, R., “The dawning era of polymer therapeutics”, Nat Rev. Drug. Discov., May 2003, 2(5): 347-60.;;Edwards et al., “A bacterial amber suppressor in Saccharomyces cerevisiae is selectively recognized by a bacterial aminoacyl-tRNA synthetase”, Mol. Cell Biol., 1990, 10(4): 1633-41.;;Eghtedarzadeh, M.K. and S. Henikoff, “Use of oligonucleotides to generate large deletions”, Nucleic Acids Res., Jun. 25, 1986, 14(12): 5115.;;Elling, L. and M.R. Kula, “Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies”, Biotechnol. Appl. Biochem., Jun. 1991, 13(3): 354-62.;;Elliott, S. et al., “Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization”, J. Protein. Chem., Feb. 1990, 9(1): 95-104.;;Ellman, J.A. et al., “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins”, Methods in Enz., 1992, 202: 301-336.;;Ellman, J.A. et al., “Site-specific incorporation of novel backbone structures into proteins”, Science, Jan. 10, 1992, 255(5041): 197-200.;;England, P.M. et al., “Backbone mutation in transmembrane domains of a ligand-gated.ion channel: implications for the mechanisms of gating”, Cell, Jan. 8, 1999, 96(1): 89-98.;;Eppstein et al., “Biological Activity of Liposome-Encapsulated Murine Interferon is Mediated by a Cell Membrane Receptor”, Proc. Natl. Acad. Sci USA, 1985, 82: 3688-3692.;;European Patent Office, “Invitation to Pay Additional Fees”, Form PCT/ISA/206, International Application No. PCT/US2015/057228, dated Feb. 10, 2016.;;Fieschko, J.C. et al., “Controlled expression and purification of human immune interferon from high-cell-density fermentations of Saccharomyces cerevisiae”, Biotech Bioeng., 1987, 29(9): 1113-21.;;Folch, J. et al., “A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues”, J. Biol. Chem. 1957;226: 497-509.;;Forster, A.C. et al., “Programming peptidomimetic syntheses by translating genetic codes designed de novo”, Proc. Natl. Acad. Sci. USA, May 27, 2003, 100(11): 6353-7. Epub May 16, 2003.;;Frankel, A. et al., “Encodamers: unnatural peptide oligomers encoded in RNA”, Chem. Biol., Nov. 2003, 10(11): 1043-50.;;Fraser, M.J. et al., “Expression of eucaryotic genes in insect cell cultures”, In Vitro Cell. Dev. Biol., 1989, 25: 225-235.;;Friedman et al., “Tackling a weighty problem”, Cell, 1992, 69: 217-220.;;Friedman, O.M. and R. Chatterrji, “Synthesis of Derivatives of Glutamate as Model Substrates for Anti-Tumor Agents”, J. Am. Chem. Soc., 1959, 81(14): 3750-3752.;;Friesen et al., “The regulation of baculovirus gene expression”, Curr. Top. Microbiol. Immunol., 1986, 131: 31-49.;;Fritz, H.J. et al., “Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro”, Nucleic Acids Res., Jul. 25, 1988, 16(14B): 6987-99.;;Fromm, M. et al., “Expression of Genes Transferred into Monocot and Dicot Plant Cells by Electroporation”, Proc. Natl. Acad. Sci. USA, 1985, 82: 5824-8.;;Fukumoto, S., “Actions and Mode of Actions of FGF19 Subfamily Members”, Endocrine Journal, 2008; 55(1): 23-31.;;Furter, R., “Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli”, Protein Sci., Feb. 1998, 7(2): 419-26.;;Gaertner, H.F. and R.E. Offord, “Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins”, Bioconjug. Chem., Jan.-Feb. 1996, 7(1): 38-44.;;Gaertner, H.F. et al., “Chemo-enzymatic backbone of engineering of proteins. Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor”, J. Biol. Chem., Mar. 11, 1994, 269(10): 7224-30.;;Gaertner, H.F. et al., “Construciton of protein analogues by site-specific condensation of unprotected fragments”, Bioconjug. Chem., May-Jun. 1992, 3(3): 262-8.;;Gallivan, J.P. et al., “Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins”, Chem. Biol., Oct. 1997, 4(10): 739-49.;;Garber et al., “Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial”, Am. J. Med., 1997, 102: 491-97.;;Gellissen, G. et al., “Heterologous protein production in yeast”, Antoine Van Leeuwenhoek, Aug. 1992, 62(1-2): 79-93.;;Gemel et al., “Structure and sequence of human FGF8”, Genomics, 1996, 35:253-257.;;Geoghegan, K.F. and J.G. Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modifcation at N-terminal serine”, Bioconjug. Chem., Mar.-Apr. 1992, 3(2): 138-146.;;Ghosh et al., “Molecular cloning and characterization of human FGF8 alternative messenger RNA forms”, Cell Growth and Differentiation, 1996, 7(10): 1425-1434.;;Gillam, S. and M. Smith, “Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum oligodeoxyribonucleotide length”, Gene, 1979, 8(1): 81-97.;;Gimeno, R.E. and Moller, D.E., “FGF21-bsed pharmacotherapy—potential utility for metabolic disorders”, Trends Endocrinol Metab. Jun. 2014;25(6):303-11.;;Giugliano et al., “Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women”, Diabetes Care, 1993, 16:1387-90.;;Gleeson, M.A. et al., “Transformation of the methylotrophic yeast hansenula polymorphica”, J. Gen. Microbiol., 1986, 132: 3459-3465.;;Goeddel, D.V. et al., “Synthesis of human fibroblast interferon by E. coli”, Nucleic Acids Res., Sep. 25, 1980, 8(18): 4057-74.;;Goeddel, D.V., “Systems for heterologous gene expression”, Methods Enzymol., 1990, 185: 3-7.;;Goldfarb et al., “Expression and possible functions of the FGF-5 gene”, Ann. NY. Acad. Sci., 1991, 638:38-52.;;Goodson, R.J. and N.V. Katre, “Site-directed pegylation of recombinant interleukin-2 at its glycosylation site”, Biotechnology (NY), Apr. 1990, 8(4): 343-346.;;Graves, S.W. et al., “Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase”, Biochemistry, Apr. 28, 1998, 37(17): 6050-6058.;;Griffin, B.A. et al., “Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells”, Science, 1998, 281:269-272.;;Grundström, T. et al., “Oligonucleotide-directed mutagenesis by microscale ‘shot-gun’ gene synthesis”, Nucleic Acids Res., May 10, 1985, 13(9): 3305-3316.;;Gu, Z. et al., “Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies”, Protein Expr. Purif., Jun. 2002, 25(1): 174-9.;;Guckian, K.M. and E.T. Kool, “High Precise Shape Mimicry by a Difluorotoluene Deoxynucleoside, and Replication-Competent Substitute for Thymidine”, Angew. Chem. Int. Ed. Engl., 1998, 36(24): 2825-8.;;Hamano-Takaku, F. et al., “A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine” J. Biol. Chem., Dec. 22, 2000, 275(51): 40324-8.;;Hang, H.C. and C.R. Bertozzi, “Chemoselective approaches to glycoprotein assembly”, Acc. Chem. Res., Sep. 2001, 34(9): 727-36.;;Harmer et al., “The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity”, Biochemistry, 2004, 43:629-640.;;Harris, J.M. et al., “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives”, J. Polym. Sci. Chem. Ed., 1984, 22:341-352.;;Harris, J.M., “Laboratory Synthesis of Polyethylene Glycol Derivatives”, JMS-Rev. Macromol. Chem. Phys., 1985, C25(3): 325-373.;;Hecht et al., “Chemical aminoacylation of tRNA's”, J. Biol. Chem., 1978, 253(13): 4517-20.;;Hecht, “Probing the synthetic capabilities of a center of biochemical catalysis”, Acc. Chem. Res., 1992, 25(12): 545-552.;;Hecht, R. et al., “Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes”, PLoS One. 2012;7(11):e49345.;;Heckler et al., “Ribosomal binding and dipeptide formation by misacylated tRNA(Phe)'s”, Biochemistry, 1988, 27(19): 7254-62.;;Hendrickson, W.A. et al., “Selenomethionyl proteins produced for analysis of multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure”, EMBO J., May 1990, 9(5): 1665-72.;;Henikoff, S. and J.G. Henikoff, “Amino Acid Substitution Matrices from Protein Blocks”, Proc. Natl. Acad. Sci. USA, 1992, 89: 10915-9.;;Hensrud, D.D. and Klein, S., “Extreme Obesity: A New Medical Crisis in the United States”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S5-S10.;;Hess, B. et al., “Cooperation of glycolytic enzymes”, J. Adv. Enzyme Reg., 1969, 7: 149-67.;;Hinke et al., “Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1”, Biochem. Biophys. Res. Commun., 2002, 291(5): 1302-8.;;Hinnen, A. et al., “Transformation of yeast”, Proc. Natl. Acad. Sci. USA, Apr. 1978, 75(4): 1929-33.;;Hirao, I. et al., “An unnatural base pair for incoporating amino acid analogues into proteins”, Nat. Biotechnol., Feb. 2002, 20(2): 177-82.;;Hitzeman, R.A. et al., “Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological screening technique”, J. Biol. Chem., Dec. 25, 1980, 255(24): 12073-80.;;Hoffmann, K and H. Bohn, “Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment”, J. Am. Chem., 1966, 88(24): 5914-5919.;;Hohsaka, T. and M. Sisido, “Incorporation of non-natural amino acids into proteins”, Curr. Opin. Chem. Biol., Dec. 2002, 6(6): 809-15.;;Hohsaka, T. et al., “Efficient Incorporation of Nonnatural Amino Acids with Large Aromatic Groups into Streptavidin in In Vitro Protein Synthesizing Systems”, J. Am. Chem. Soc., 1999, 121(1): 34-40.;;Hohsaka, T. et al., “Incorporation of Two Different Nonnatural Amino Acids Independently into a Single Protein through Extension of the Genetic Code”, J. Am. Chem. Soc., 1999, 151(51): 12194-12195.;;Holland, M.J. and J.P. Holland “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceralehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase”, Biochemistry, Nov. 14, 1978, 17(23): 4900-7.;;Holland, M.J. et al., “The primary structures of two yeast enolase genes. Homology between the 5′ noncoding flanking regions of yeast enolase and glyceraldehyde-3-phosphate dehydrogenase genes”, J. Biol. Chem., Feb. 10, 1981, 256(3): 1358-95.;;Holland, W.L. et al., “An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice”, Cell Metab. 2013; 17: 790-797.;;Hoshikawa et al., “Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain”, Biochem. Biophys. Res. Commun., 1998, 244(1): 187-91.;;Hsiao, C.L. and J. Carbon, “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”, Proc. Natl. Acad. Sci. USA, Aug. 1979, 76(8): 3829-33.;;Hubinger et al., “The effect of etomoxir on insulin sensitivity in type 2 diabetic patients”, Hormone Metab. Res., 1992, 24:115-18.;;Huisgen, R. in 1,3-Dipolar Cycloaddition Chemistry, vol. 1, 1984; Ed. A. Padwa; John.Wiley and Sons, New York, 1-176.;;Hwang, K.J. et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study”, Proc. Natl. Acad. Sci. USA, Jul. 1980, 77(7): 4030-4.;;Ibba, M. and H. Hennecke, “Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids”, FEBS Lett., May 15, 1995, 364(3): 272-5.;;Ibba, M. et al., “Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase”, Biochemistry, Jun. 14, 1994, 33(23): 7107-12.;;Illangakekare et al., “Aminoacyl-RNA Synthesis Catalyzed by an RNA”, Science, 1995, 267:643-647.;;Inzucchi et al., “Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus”, New Engl. J. Med., 1998, 335:867-72.;;Itakura et al., “Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin”, Science, 1997, 198:1056-1063.;;Ito, H. et al., “Transformation of intact yeast cells treated with alkali cations”, J. Bacteriol., 1983, 153(1): 163-8.;;Jackson, D.Y. et al., “A designated peptide ligase for total synthesis of ribonuclease A with unnatural catalytic residues”, Science, Oct. 14, 1994, 266(1583): 243-7.;;Jakobsson, P.J. et al., “Identification and characterization of a novel human microsomal glutathione S-transferase with keukotriene C4 synthetase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase”, J. Biol. Chem., Sep. 6, 1996, 271(36): 22203-10.;;Jencks, W.P., “Studies on the Mechanism of Oxime and Semicarbazone Formation”, J. Am. Chem. Soc., 1959, 81(2): 475-481.;;Joppich, M. et al., “Peptides Flanked by Two Polymer Chains, 1; Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups”, Makromol. Chem., 1979, 180:1381-4.;;Jung et al., “The management of obesity”, Clinical Endocrinology, 1991, 35: 11-20.;;Kaiser, E.T. and D.S. Lawrence, “Chemical mutation of enzyme active sites”, Science, Nov. 2, 1984, 226(4674): 505-11.;;Kaiser, E.T. et al., “The chemical modification of enzymatic specificitiy”, Annu. Rev. Biochem., 1985, 54: 565-95.;;Kaiser, E.T., “Synthetic approaches to biologically active peptides and proteins including enzymes”, Acc. Chem. Res., 1989, 22(2): 47-54.;;Karlin, S. and S.F. Altschul, “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci. USA, Jun. 15, 1993, 90(12): 5873-7.;;Katoh et al., “FGF signaling network in the gastrointestinal tract (review)”, Int'l. J. Oncology, 2006, 29: 163-168.;;Kawamata et al., “Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction”, Proc. Natl. Acad. Sci., 1997, 94(15): 8179-84.;;Kayser, B. et al., “Alkyne bridged alpha-amino acids by palladium mediated coupling of alkynes with N-t-Boc-4-iodo-phenylalanine methyl ester”, Tetrahedron, 1997, 53(7): 2475-2484.;;Kelly, J.M. and M.J. Hynes, “Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans”, Embo J., 1985, 4(2): 475-479.;;Kendrick, M.L. and Dakin, G.F., “Surgical Approaches to Obesity”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S18-S24.;;Kharitonekov et al., “FGF-21 as a novel metabolic regulator”, J. Clin. Investigation, Jun. 1, 2005, 115(6): 1627-1635.;;Kharitonekov et al., “The Metabolic State of Diabetic Monkeys is Regulated by Fibroblast Growth Factor-21”, Endocrinology, Feb. 1, 2007, 148(2): 774-781.;;Kharitonenkov, A. and Adams, A.C., “Inventing new medicines: The FGF21 story”, Mol. Metab., Avail. Online Dec. 27, 2013, 3(2014): 221-229.;;Kharitonenkov, A. et al., “Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319”, Plos One, Mar. 2013, 8(3) e58575: 1-10.;;Kiick, K.L. and D.A. Tirrell, “Protein Engineering by In Vivo Incorporation of Non-Natural Amino Acids: Control of Incorporation of Methionine Analogues by Methionyl-tRNA Synthetase”, Tetrahedron, 2000, 56: 9487-9493.;;Kiick, K.L. et al., “Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation”, Proc. Natl. Acad. Sci. USA, Jan. 8, 2002, 99(1): 19-24. Epub Dec. 18, 2001.;;Kim, D.M and J.R. Swartz, “Prolonging cell-free protein synthesis with a novel ATP regeneration system”, Biotechnol. Bioeng., 1999, 66(3): 180-8.;;Kim, D.M. and J.R. Swartz, “Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli”, Biotechnology Letters, 2000, 22:1537-1542.;;Kim, D.M. and J.R. Swartz, “Prolonging cell-free protein synthesis by selective reagent additions”, Biotechnol. Prog., May-Jun. 2000, 16(3): 385-90.;;Kim, D.M. and J.R. Swartz, “Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis”, Biotechnol. Bioeng., Aug. 20, 2001, 74(4): 309-16.;;Kim, H.W. et al., “Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice”, Endocrinology, Sep. 2013, 154(9): 3366-3376.;;King, F.E. and D.A.A. Kidd, “A New Synthesis of Glutamine and of gamma-Dipeptides of Glutamic Acid from Phthylated Intermediates”, J. Chem. Soc. 1949, 3315-3319. et al.",ACTIVE
352,MX,A,MX 2017004947 A,059-785-055-156-453,2017-06-29,2017,MX 2017004947 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF.,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,DASA LIPOVSEK;;RAY CAMPHAUSEN;;PAUL E MORIN;;RANJAN MUKHERJEE;;DANIEL COHEN;;TIMOTHY P REILLY;;ROSE C CHRISTIAN;;JOHN KRUPINSKI,,https://lens.org/059-785-055-156-453,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,PENDING
353,EP,B1,EP 3412302 B1,129-280-960-369-815,2021-05-12,2021,EP 18177893 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 15790415 A;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN;;MORIN PAUL E,,https://lens.org/129-280-960-369-815,Granted Patent,yes,4,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,ACTIVE
354,LT,T,LT 3412302 T,143-095-831-096-155,2021-07-26,2021,LT 18177893 T,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/143-095-831-096-155,Unknown,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,PENDING
355,HU,T2,HU E055311 T2,055-375-199-194-603,2021-11-29,2021,HU E18177893 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/055-375-199-194-603,Amended Patent,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,PENDING
356,AU,A1,AU 2022/252771 A1,081-635-503-619-882,2022-11-03,2022,AU 2022/252771 A,2022-10-13,AU 2022/252771 A;;AU 2020/210152 A;;AU 2015/335603 A;;US 201462068296 P;;US 201562141383 P;;US 201562141337 P;;US 201462068534 P;;US 201462068526 P;;US 201462068514 P;;US 201462068523 P;;US 2015/0057228 W,2014-10-24,Modified FGF-21 Polypeptides and Uses Thereof,"Attorney Docket No.: 43270.2213 Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/081-635-503-619-882,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00,,0,0,,,,PENDING
357,PE,A1,PE 20170950 A1,080-575-987-913-640,2017-07-13,2017,PE 2017000743 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,POLIPEPTIDOS DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS 2 (FGF-21) MODIFICADOS Y USOS DE LOS MISMOS,"Se refiere a un polipeptido FGF-21 modificado que comprende un polipeptido que tiene una secuencia de aminoacidos de SEQ ID NO: 1-7, donde dicha secuencia a su vez comprende: i) una supresion interna de 5 a 19 aminoacidos contiguos en donde tal supresion interna esta dentro de una region correspondiente a los aminoacidos 116 a 134 de la SEQ ID NO: 1; y ii) 9 o menos sustituciones, supresiones y/o inserciones de aminoacidos adicionales. Tambien se refiere a un acido nucleico, a una celula hospedera, a una composicion farmaceutica y a un metodo de tratamiento. Dicho polipeptido es util en el tratamiento de trastornos tales como la obesidad, diabetes, pancreatitis, entre otros",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/080-575-987-913-640,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,PENDING
358,US,A1,US 2017/0029479 A1,105-278-319-668-445,2017-02-02,2017,US 201615215329 A,2016-07-20,US 201615215329 A;;US 201514921796 A;;US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Modified FGF-21 Polypeptides Comprising an Internal Deletion and Uses Thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/105-278-319-668-445,Patent Application,yes,0,0,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50,,0,0,,,,ACTIVE
359,US,B2,US 10189883 B2,127-396-495-520-963,2019-01-29,2019,US 201715460917 A,2017-03-16,US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Therapeutic uses of modified FGF-21 polypeptides,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/127-396-495-520-963,Granted Patent,yes,412,7,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/18;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50,,438,410,104-335-738-580-036;;007-480-305-123-598;;072-942-676-077-691;;056-201-471-905-934;;028-862-168-091-90X;;070-383-251-783-098;;028-567-118-036-513;;005-712-635-226-116;;090-754-759-154-175;;050-825-529-117-306;;028-540-973-166-319;;045-951-701-636-236;;150-512-327-210-48X;;022-997-664-996-345;;047-237-206-017-563;;017-940-142-904-249;;081-098-345-341-182;;010-847-093-078-575;;027-829-588-585-761;;153-232-460-964-283;;158-261-806-420-924;;126-128-839-153-523;;006-504-311-182-612;;098-808-864-401-942;;122-388-810-565-095;;126-434-971-916-802;;062-095-790-501-25X;;083-348-315-692-16X;;085-498-590-431-913;;096-352-881-129-295;;141-785-095-849-82X;;104-063-848-067-130;;069-591-544-766-903;;027-127-290-904-954;;010-872-968-433-256;;037-574-244-923-342;;095-163-015-743-716;;018-560-322-257-247;;078-629-783-492-046;;032-905-603-444-928;;068-050-852-096-624;;029-171-836-207-263;;028-668-540-796-174;;028-668-540-796-174;;001-076-067-628-36X;;005-893-666-286-846;;004-965-380-380-515;;079-996-842-246-699;;039-289-782-216-880;;043-632-912-449-253;;006-451-527-297-818;;032-412-591-971-193;;050-491-094-261-212;;061-186-684-189-36X;;041-610-673-797-380;;048-739-184-191-048;;061-770-380-357-689;;023-157-064-831-058;;005-785-820-497-820;;030-617-186-856-219;;004-571-213-214-147;;117-298-184-780-248;;139-370-722-026-325;;022-717-243-626-689;;001-168-243-787-836;;003-692-671-892-767;;146-959-413-651-106;;009-255-453-457-663;;022-597-328-979-199;;097-412-635-296-694;;015-907-704-662-089;;026-151-208-979-214;;101-171-874-734-776;;007-242-440-136-566;;010-401-085-673-837;;036-787-898-930-499;;010-929-566-271-076;;027-221-602-638-634;;100-286-864-518-416;;012-388-439-961-094;;055-509-434-690-182;;032-004-299-797-893;;030-979-115-550-499;;022-879-584-224-460;;084-341-539-493-404;;088-437-095-235-130;;027-177-154-094-913;;020-026-183-926-325;;019-911-024-298-495;;120-184-720-533-797;;030-130-464-546-217;;110-094-292-858-47X;;091-231-835-456-006;;005-631-024-674-820;;101-575-504-070-651;;005-426-365-134-686;;005-316-633-999-516;;008-878-757-321-700;;008-340-022-598-528;;004-574-009-337-856;;063-797-097-486-664;;169-736-421-398-039;;105-994-509-610-153;;040-375-581-789-283;;029-884-043-437-78X;;013-673-906-914-932;;093-281-504-176-200;;005-433-555-845-783;;064-029-904-826-616;;014-268-011-522-679;;047-362-058-327-502;;059-408-333-766-70X;;062-061-052-321-497;;042-364-181-188-082;;113-394-540-007-150;;001-833-327-326-444;;089-193-344-157-806;;007-026-917-931-385;;113-109-583-058-980;;110-902-470-115-883;;047-294-079-836-486;;002-425-038-765-735;;038-346-034-366-375;;066-146-798-965-262;;021-089-222-463-71X;;007-168-099-008-401;;031-957-451-453-064;;109-373-051-579-919;;030-859-841-509-259;;045-237-747-815-813;;017-239-464-122-703;;002-921-094-507-370;;050-017-203-544-775;;104-277-007-929-625;;008-135-071-759-92X;;018-958-246-350-086;;059-853-971-443-396;;023-907-179-348-058;;052-839-106-430-915;;075-807-103-343-793;;080-050-592-171-046;;031-166-703-585-08X;;189-306-471-756-979;;041-428-113-293-001;;038-037-978-931-264;;019-654-552-765-603;;036-786-233-907-636;;018-078-335-572-806;;099-290-765-461-205;;030-761-388-449-490;;051-260-923-190-254;;052-143-608-436-131;;008-226-221-097-647;;078-209-348-576-455;;089-633-612-001-004;;120-710-247-962-517;;002-945-101-700-774;;037-194-000-791-81X;;146-280-751-006-918;;182-139-657-761-848;;043-147-746-491-691;;041-189-067-181-870;;012-637-499-221-105;;135-885-609-471-475;;022-238-533-842-744;;048-389-287-506-180;;018-989-643-656-697;;041-329-647-699-213;;043-596-978-783-486;;019-779-601-634-917;;053-128-465-484-881;;058-589-196-667-041;;099-108-177-239-268;;026-597-138-156-613;;046-158-519-832-735;;062-670-857-477-054;;084-734-056-460-170;;032-045-779-752-652;;033-733-139-064-996;;009-333-452-920-135;;010-850-616-527-606;;095-359-992-848-941;;083-360-261-831-129;;068-601-220-787-847;;011-377-674-907-872;;040-687-947-392-591;;179-552-640-659-549;;015-623-518-697-144;;025-944-755-967-03X;;035-537-674-004-113;;067-220-965-320-998;;007-005-818-132-358;;141-920-816-342-666;;006-873-363-111-668;;078-886-911-253-419;;023-874-622-768-279;;053-908-725-120-441;;027-033-711-563-119;;084-382-055-323-434;;015-841-839-428-08X;;017-399-857-000-881;;094-876-980-967-766;;053-901-990-601-316;;114-407-414-536-306;;092-380-940-527-529;;035-330-063-258-167;;009-136-082-279-13X;;055-788-913-950-003;;050-513-346-896-80X;;031-933-089-611-974;;079-944-676-961-034;;000-133-235-371-009;;081-452-111-536-816;;019-590-397-412-17X;;074-470-423-479-932;;128-901-299-587-74X;;010-020-681-821-091;;042-423-418-475-539;;041-750-601-903-10X;;068-821-001-542-983;;018-934-238-795-193;;011-020-186-750-886;;117-492-031-514-87X;;065-162-993-535-51X;;081-507-984-297-637;;027-990-295-239-719;;001-466-527-996-328;;027-826-420-479-03X;;077-140-409-267-690;;087-464-638-639-025;;025-146-253-241-793;;000-267-213-967-50X;;093-724-494-618-609;;124-275-393-571-41X;;068-521-955-594-560;;031-066-822-995-403;;034-499-243-336-537;;078-020-406-613-471;;045-362-643-830-026;;127-640-340-609-818;;029-041-317-917-380;;012-193-937-990-576;;013-039-312-104-66X;;030-226-878-795-594;;011-923-052-324-723;;011-552-704-333-933;;138-638-667-066-487;;012-668-687-960-29X;;020-473-776-487-596;;029-402-092-523-225;;021-724-385-934-424;;003-036-556-540-859;;000-647-267-694-484;;066-662-118-303-62X;;053-660-915-978-91X;;097-773-387-318-439;;010-159-493-399-221;;036-036-233-972-857;;064-538-717-151-364;;122-373-655-693-959;;003-813-666-853-382;;074-744-973-712-298;;160-519-052-068-705;;044-306-689-778-275;;129-273-407-931-838;;032-728-154-591-070;;020-704-332-523-176;;095-036-407-766-923;;050-741-722-639-562;;005-001-316-365-345;;029-653-102-379-412;;082-863-413-822-327;;130-557-982-448-359;;010-503-176-197-239;;026-396-339-084-010;;088-434-038-364-143;;110-622-018-928-961;;026-367-037-139-802;;017-729-084-063-643;;053-887-446-496-059;;111-109-974-501-414;;041-461-899-032-384;;030-425-987-723-110;;007-181-598-202-221;;004-100-004-646-006;;014-169-184-148-626;;056-370-822-404-873;;092-760-851-706-263;;065-097-473-442-493;;030-660-067-609-024;;164-403-066-288-611;;031-584-564-704-369;;047-580-366-679-441;;085-764-009-624-439;;027-314-030-808-345;;052-947-986-013-690;;000-234-931-492-675;;073-419-783-934-185;;048-666-647-905-365;;093-509-508-230-620;;087-477-650-364-59X;;033-756-776-033-780;;017-561-716-268-836;;040-635-027-762-84X;;046-731-814-106-92X;;006-516-075-151-31X;;000-870-842-639-900;;009-738-327-233-69X;;028-294-432-381-795;;014-729-984-201-416;;074-582-134-846-704;;101-797-963-804-734;;012-080-214-127-41X;;079-141-143-704-263;;048-183-620-015-85X;;081-092-403-760-75X;;017-185-661-050-007;;022-944-275-314-68X;;042-751-409-162-883;;032-459-914-054-209;;007-339-268-863-200;;005-660-045-470-037;;051-315-531-263-042;;034-330-993-923-294;;031-118-508-476-586;;082-902-765-648-368;;020-682-017-511-509;;137-791-867-210-863;;106-136-224-518-463;;005-638-542-147-993;;011-243-931-881-746;;059-478-289-803-609;;073-102-472-393-46X;;008-076-695-732-453;;112-039-702-206-214;;007-496-126-787-125;;070-434-249-460-174;;013-885-021-097-853;;016-759-138-450-894;;015-801-694-447-055;;019-627-964-331-373;;082-984-043-695-164;;037-740-603-895-357;;011-657-979-926-27X;;003-242-603-416-269;;083-634-098-131-485;;048-439-321-617-128;;110-630-331-648-229;;020-065-207-907-092;;031-075-424-243-630;;028-373-705-126-470;;006-095-947-008-535;;024-253-203-317-101;;055-852-081-735-610;;025-834-245-974-873;;084-748-487-156-928;;115-802-414-738-000;;035-328-575-802-514;;018-351-785-584-614;;094-815-381-871-763;;081-753-724-687-173;;079-274-785-935-791;;063-155-730-882-853;;067-127-654-169-729;;048-972-529-594-020;;054-304-933-298-139;;017-049-171-562-572;;099-270-483-107-007;;142-164-397-210-970;;104-283-497-946-575;;046-036-272-703-281;;075-912-302-795-48X;;111-570-270-686-786;;077-066-325-033-341;;029-811-479-361-870;;000-654-286-546-079;;012-837-528-765-07X;;069-296-641-163-256;;039-149-059-983-63X;;065-815-544-501-870;;019-394-264-649-327;;046-262-147-203-697;;008-125-648-563-747;;030-861-724-466-58X;;015-214-531-219-780;;028-383-058-454-759;;135-513-407-563-622;;058-530-733-727-374;;013-392-307-146-301;;063-864-581-855-676;;003-416-495-423-02X;;016-250-517-165-602;;037-612-698-436-922;;077-722-555-854-551;;038-624-922-825-362;;035-070-408-027-340;;049-937-366-109-256;;010-030-039-052-116;;061-267-522-126-985;;089-860-020-044-940;;025-612-997-745-121;;040-712-467-075-177;;013-754-548-416-363;;030-425-714-928-399;;035-769-575-764-291;;128-415-609-095-377;;078-753-778-060-01X;;008-135-071-759-92X;;014-651-132-335-556;;003-209-696-707-713,6467175;;10.2337/diacare.25.5.869;;11978683;;24248463;;10.1210/en.2013-1828;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;6363212;;10.1016/0378-1119(83)90222-6;;11880038;;10.1016/s1074-5521(02)00094-7;;10.1002/macp.1978.021790204;;10.1023/a:1015825027737;;2052513;;7763976;;10.1016/0958-1669(93)90011-k;;10.2337/diacare.15.6.755;;1600835;;1560827;;10.1038/356537a0;;10.1021/ja00202a052;;1911037;;6220717;;10.1016/0006-291x(83)91828-4;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;10.1016/s0040-4020(01)90305-9;;10.1126/science.3140377;;3140377;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;6757758;;10.1038/300706a0;;10.1016/s0040-4039(01)90461-7;;10.1016/0003-2697(83)90131-8;;6193731;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.3.co;2-c;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.0.co;2-5;;9050787;;10.2337/diabetes.45.11.1572;;10.2337/diab.45.11.1572;;8866563;;875032;;10.1016/s0022-2836(77)80200-3;;10.1016/0197-0186(94)90047-7;;7950964;;10.1016/s0021-9258(18)82348-1;;8340419;;10.1038/nsb0594-283;;7664033;;2994214;;10.1126/science.2994214;;1733123;;10.1093/ajcn/55.2.538s;;10.3109/03639049209046327;;8352595;;10.1146/annurev.bi.62.070193.002411;;1332541;;10.1016/0003-2697(92)90433-8;;10.1006/jmbi.1997.1132;;9245591;;10.1111/j.1432-1033.1995.0788h.x;;10.1111/j.1432-1033.1995.tb20622.x;;7607253;;10.1096/fasebj.13.1.41;;9872928;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;10.1006/prep.1997.0744;;9226723;;10.1016/s0169-409x(03)00108-x;;14499706;;10.1111/j.1440-1681.1978.tb00650.x;;639358;;pmc252500;;2993646;;10.1128/jvi.56.1.153-160.1985;;10.1021/jo034984x;;14604354;;10.1016/0076-6879(87)54086-1;;2828857;;10.1016/0076-6879(87)54086-1;;2828857;;3541892;;10.1042/bj2370001;;pmc1146940;;2438771;;10.1126/science.2438771;;22787375;;pmc3390728;;10.3346/jkms.2012.27.7.784;;7030620;;10.3109/10409238109108703;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203;;12148987;;10.1021/ja027007w;;12920298;;10.1126/science.1084772;;10.1002/chin.198535327;;10.1016/s0958-1669(00)00200-7;;11287238;;10.1016/s0958-1669(98)80109-2;;9664053;;8703002;;10.1074/jbc.271.36.21969;;3286212;;10.2165/00003495-198835030-00003;;2250094;;10.1093/oxfordjournals.jhered.a111019;;7160534;;10.2337/diab.31.1.s24;;17036574;;10.1016/s0025-6196(11)61176-2;;10.1126/science.3685986;;3685986;;10.1002/anie.199506211;;10.1021/ja961216x;;1785831;;10.1111/j.1749-6632.1991.tb49017.x;;10.1021/jo00241a009;;pmc369166;;3915774;;10.1128/mcb.5.12.3376-3385.1985;;10.1128/mcb.5.12.3376;;10.1038/1921227a0;;13882203;;10.1242/dev.121.2.439;;7768185;;8850022;;10.1385/0-89603-332-5:369;;pmc215567;;10.1128/jb.158.3.1165-1167.1984;;6327630;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.3.co;2-9;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.0.co;2-i;;10506413;;10966479;;10.1146/annurev.biochem.69.1.923;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1128/jb.154.2.737-742.1983;;pmc217523;;6841315;;8314773;;10.1016/s0021-9258(19)85209-2;;7623902;;10.1056/nejm199508313330902;;10.1021/ja0370037;;14505376;;15501033;;10.1016/j.bmcl.2004.09.059;;1458545;;12119302;;10.1074/jbc.m205854200;;10.1111/j.1749-6632.1991.tb49014.x;;1785800;;10.1089/neu.1996.13.309;;8835798;;9398858;;10.1038/ng1297-491;;10.1126/science.1057718;;11313495;;11102869;;10.1016/s1367-5931(00)00148-4;;10.1021/bi9617973;;9116020;;10.1038/nrd1088;;12750738;;10.1128/mcb.10.4.1633-1641.1990;;10.1128/mcb.10.4.1633;;1690848;;pmc362268;;pmc311518;;10.1093/nar/14.12.5115;;3460029;;1883529;;10.1007/bf01024990;;2187475;;10.1016/0076-6879(91)02017-4;;1784180;;10.1126/science.1553546;;1553546;;9989500;;10.1016/s0092-8674(00)80962-9;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1002/bit.260290911;;18576565;;13428781;;10.1016/s0021-9258(18)64849-5;;12754376;;pmc164450;;10.1073/pnas.1132122100;;10.1016/j.chembiol.2003.11.004;;14652071;;2647707;;10.1007/bf02628459;;1568242;;10.1016/0092-8674(92)90402-x;;10.1021/ja01523a064;;10.1007/978-3-642-71589-1_3;;3816299;;10.1093/nar/16.14.6987;;3405755;;pmc338346;;3862099;;10.1073/pnas.82.17.5824;;pmc390645;;17878606;;10.1507/endocrj.kr07e-002;;10.1002/pro.5560070223;;9521119;;pmc2143905;;8741989;;10.1021/bc950074d;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/bc00015a010;;1381617;;10.1016/s1074-5521(97)90312-4;;9375252;;10.1016/s0002-9343(97)00254-4;;9428832;;1444338;;10.1007/bf00584464;;8661131;;10.1006/geno.1996.0349;;10.1021/bc00014a008;;1325188;;8891346;;161245;;10.1016/0378-1119(79)90009-x;;10.1016/j.tem.2014.03.001;;24709036;;8269798;;10.2337/diacare.16.10.1387;;10.1099/00221287-132-12-3459;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;10.1016/0076-6879(90)85003-7;;2116575;;1785812;;10.1111/j.1749-6632.1991.tb49016.x;;1366535;;10.1038/nbt0490-343;;9558343;;10.1021/bi972685u;;10.1126/science.281.5374.269;;9657724;;3889852;;10.1093/nar/13.9.3305;;pmc341236;;10.1006/prep.2002.1624;;12071713;;pmc2946115;;20882112;;10.1002/anie.199728251;;10.1074/jbc.m003696200;;11006270;;10.1021/ar9901570;;11560472;;10.1021/bi035320k;;10.1021/bi035320k.s001;;14730967;;10.1016/s0021-9258(17)30417-9;;248056;;10.1021/ar00024a001;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;10.1021/bi00419a012;;3061451;;10.1002/j.1460-2075.1990.tb08287.x;;2184035;;pmc551863;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;17036573;;10.1016/s0025-6196(11)61175-0;;10.1016/0065-2571(69)90016-8;;4244004;;11883961;;10.1006/bbrc.2002.6607;;10.1073/pnas.75.4.1929;;347451;;pmc392455;;10.1038/nbt0202-177;;11821864;;6254992;;10.1016/s0021-9258(19)70246-4;;10.1021/ja00976a035;;5980877;;10.1016/s1367-5931(02)00376-9;;12470735;;10.1021/ja9813109;;10.1021/ja992204p;;363146;;10.1021/bi00616a007;;6256394;;10.1016/s0021-9258(19)69976-x;;23663742;;pmc3667496;;10.1016/j.cmet.2013.03.019;;10.1006/bbrc.1998.8239;;9514906;;pmc383928;;10.1073/pnas.76.8.3829;;386351;;1577399;;10.1055/s-2007-1003271;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;7758582;;10.1016/0014-5793(95)00408-2;;8003476;;10.1021/bi00189a013;;7530860;;10.1126/science.7530860;;10.1056/nejm199803263381303;;9516221;;412251;;10.1126/science.412251;;10.1128/jb.153.1.163-168.1983;;pmc217353;;6336730;;10.1126/science.7939659;;7939659;;8703034;;10.1074/jbc.271.36.22203;;10.1021/ja01511a053;;10.1002/macp.1979.021800528;;10.1111/j.1365-2265.1991.tb03490.x;;1889135;;10.1126/science.6238407;;6238407;;10.1146/annurev.bi.54.070185.003025;;2992359;;10.1146/annurev.biochem.54.1.565;;10.1021/ar00158a001;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;16773196;;10.3892/ijo.29.1.163;;9223335;;pmc21577;;10.1073/pnas.94.15.8179;;10.1016/s0040-4020(96)01195-7;;3894007;;pmc554210;;10.1002/j.1460-2075.1985.tb03653.x;;17036575;;10.1016/s0025-6196(11)61177-4;;10.1172/jci23606;;pmc1088017;;15902306;;17068132;;10.1210/en.2006-1168;;pmc3986619;;24749049;;10.1016/j.molmet.2013.12.003;;23536797;;pmc3594191;;10.1371/journal.pone.0058575;;10.1016/s0040-4020(00)00833-4;;11752401;;10.1073/pnas.012583299;;pmc117506;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.3.co;2-j;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.0.co;2-s;;10577472;;10.1023/a:1005624811710;;10835240;;10.1021/bp000031y;;10.1002/bit.1121;;10.1002/bit.1121.abs;;11410855;;23825123;;10.1210/en.2012-2276;;10.1039/jr9490003315;;389741;;10.1016/0378-1119(79)90029-5;;2216760;;pmc332298;;10.1093/nar/18.19.5667;;1422046;;15915461;;10.1002/hep.20701;;12754495;;10.1038/nsb934;;10.1080/00397919208019100;;10.1016/s1367-5931(00)00141-1;;11102863;;10.1021/jo00269a022;;9185859;;10.1016/s0378-1119(97)00019-x;;16076449;;10.1016/j.ymeth.2005.04.001;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;pmc30127;;11226228;;10.1073/pnas.031488298;;10.1016/0092-8674(84)90283-6;;6386179;;10.1016/0076-6879(87)54084-8;;3323812;;3165526;;10.1093/nar/16.14.7207;;pmc338387;;6096830;;pmc320472;;10.1093/nar/12.24.9441;;8305530;;10.1021/bc00024a025;;3095839;;10.1073/pnas.83.22.8604;;pmc386979;;10.1007/s001250050498;;8781766;;10.1007/bf00418542;;10.1021/bi026856t;;12693945;;10.1016/0021-9673(86)80093-0;;3488324;;10.1016/0076-6879(87)54085-x;;3323813;;3881765;;10.1073/pnas.82.2.488;;pmc397064;;10.1002/jobm.3620250210;;10.1074/jbc.c500457200;;16436388;;pmc2637204;;pmc367493;;3023819;;10.1128/mcb.6.1.142;;10.1128/mcb.6.1.142-149.1986;;8554512;;10.1042/bj3120725;;pmc1136174;;17036578;;10.1016/s0025-6196(11)61180-4;;10.1002/jbm.820150212;;7348718;;10.2144/99261bm05;;9894589;;10.1016/s0958-1669(98)80035-9;;9821278;;10.1016/j.cmet.2013.04.005;;23663741;;10.1006/abio.1997.2428;;9417773;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1021/ja029433n;;12580587;;8632803;;10.1038/381442a0;;pmc307151;;7659531;;10.1093/nar/23.15.3067;;10.1016/s1097-2765(01)00369-0;;11684012;;10.1038/85080;;11224539;;2497580;;10.1016/0042-6822(89)90348-6;;10.1016/0006-8993(91)90784-s;;1723639;;8347599;;10.1021/bi00082a015;;10.7326/0003-4819-128-3-199802010-00002;;9454525;;11273699;;pmc7125544;;10.1006/jmbi.2001.4518;;10.1126/science.276.5315.1125;;9173543;;8613964;;12810643;;pmc386678;;3532104;;10.1073/pnas.83.19.7177;;10.1099/0022-1317-70-12-3501;;2691634;;10.2337/diacare.24.3.489;;11289473;;7473593;;10.1021/jm00023a005;;10.1016/s1044-5765(05)80035-1;;17036576;;10.1016/s0025-6196(11)61178-6;;9427842;;10.1016/s0079-6603(08)61031-4;;17036577;;10.1016/s0025-6196(11)61179-8;;10.1021/ja9925150;;9310317;;10.1242/dev.124.17.3221;;10.1021/ja0025806;;10.1021/ja0284153;;12537491;;10954682;;7663123;;10.1146/annurev.bb.24.060195.002251;;10.1146/annurev.biophys.24.1.435;;9581754;;10.1016/s0896-6273(00)81001-6;;10.1146/annurev.micro.42.1.177;;10.1146/annurev.mi.42.100188.001141;;3059993;;2695080;;10.1002/bies.950110404;;3030893;;10.1016/0378-1119(86)90356-2;;10.1111/j.1464-5491.1994.tb00333.x;;7955995;;10933852;;10.1006/abio.2000.4667;;9473496;;10.1006/bbrc.1998.8073;;6337369;;10.1073/pnas.80.1.1;;pmc393297;;10764591;;10.1006/jmbi.2000.3658;;10.1038/302543a0;;6403870;;10.1002/jcp.20847;;17063460;;pmc3266413;;22210323;;10.2337/db11-0838;;14652075;;10.1016/j.chembiol.2003.10.010;;pmc341328;;10.1093/nar/14.24.9679;;3027659;;10.1021/ja00246a064;;6322300;;10.1126/science.6322300;;pmc320064;;6473105;;10.1093/nar/12.15.6159;;10.1016/0022-2836(70)90057-4;;5420325;;4973231;;10.1016/s0021-9258(18)93152-2;;10.1016/s0167-4889(02)00256-2;;12183061;;17933712;;10858549;;10.1016/s0167-4781(00)00067-1;;10.1016/s0167-4781(98)00255-3;;9931477;;10.1056/nejm199411033311803;;7935656;;9593693;;10.1074/jbc.273.22.13570;;10.1126/science.2649980;;2649980;;7716551;;10.1126/science.7716551;;10.21236/ada299991;;10.1093/protein/1.3.151;;3333844;;10.1021/ja9940064;;10.1021/ja001450u;;9660775;;10.1074/jbc.273.29.18161;;10.1093/oxfordjournals.jbchem.a022221;;9832608;;10.1016/s0021-9258(18)89400-5;;3838308;;9187149;;10.1242/dev.124.11.2235;;10.1126/science.164.3880.719;;5778021;;10.1021/bk-1997-0680.ch012;;pmc138918;;11276432;;10.1186/gb-2001-2-3-reviews3005;;8883961;;10.1016/0169-328x(96)00108-8;;10.1016/b978-0-08-052349-1.00116-5;;6307823;;10.1016/0378-1119(83)90107-5;;11948130;;pmc42512;;7877976;;10.1073/pnas.92.5.1327;;10.1002/1522-2675(20000906)83:9<2277::aid-hlca2277>3.0.co;2-l;;9591139;;10.2144/98245rr03;;10.1016/0003-2697(82)90240-8;;6289696;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;8431294;;11356929;;10.1038/bjc.1992.272;;pmc1977825;;1380282;;10.1038/343033a0;;1688644;;10.1093/bioinformatics/18.7.980;;12117796;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;10490103;;10.1016/s0092-8674(00)80051-3;;10.1021/ja00965a060;;3194752;;10.1126/science.3194752;;10.1146/annurev.ge.18.120184.001133;;6084980;;10.1074/jbc.270.50.29813;;8530375;;12845521;;10.1007/s00441-003-0756-7;;8798573;;10.1074/jbc.271.39.23607;;10.1016/s0021-9673(01)95395-6;;6355135;;3614380;;10.1038/328731a0;;9356443;;10.1073/pnas.94.23.12297;;pmc24913;;10.1021/ja00007a055;;10.1007/bf00331655;;10.1002/yea.320080602;;1502852;;9129118;;10.1016/s0024-3205(96)00595-4;;10.1006/mcpr.1994.1013;;7935517;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1074/jbc.271.37.22376;;8798399;;12409460;;10.1093/nar/gkf589;;pmc135798;;3165194;;10.1093/nar/16.14.6361;;pmc338301;;10.1074/jbc.271.38.23169;;8798511;;12244330;;10.1038/nbt742;;21520200;;10.1002/hep.24376;;pmc4014460;;10.1007/bf02921514;;2024978;;10.1021/ma00056a005;;10.1126/science.287.5460.2007;;10720325;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/nar/16.3.803;;pmc334720;;2830594;;10.1016/s0021-9258(18)62817-0;;5528240;;10480527;;10.2337/diacare.22.9.1568;;19915550;;10.1038/nbt.1588;;10.1006/prep.1997.0851;;9535699;;10.1006/prep.1995.1002;;7756834;;10.1126/science.1566069;;1566069;;10.1161/01.cir.97.7.645;;9495299;;9516220;;10.1056/nejm199803263381302;;10.1016/0076-6879(87)35063-3;;3600302;;10.1002/dmrr.288;;12112940;;10.1021/ja00119a001;;10664452;;10.1016/s0014-5793(00)01120-0;;10.1038/292128a0;;6264321;;803646;;10.1038/254034a0;;6201207;;10.1002/bip.360220167;;10.1038/88129;;11329016;;9425898;;10.1038/ng0198-45;;10.1093/genetics/122.1.19;;2659436;;pmc1203683;;10.1128/jvi.68.2.766-775.1994;;pmc236513;;8289380;;10.1016/s0022-1759(96)00217-7;;9032414;;pmc38518;;10.1073/pnas.93.18.9850;;8790420;;6318086;;pmc370086;;10.1128/mcb.3.12.2156;;10.1128/mcb.3.12.2156-2165.1983;;3002241;;10.1146/annurev.ge.19.120185.002231;;10.1146/annurev.genet.19.1.423;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/s0021-9258(18)68577-1;;3372509;;10.1074/jbc.270.8.4121;;7876162;;10.1007/978-1-4684-3417-0_9;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1038/370389a0;;8047147;;10.1016/0022-2836(86)90385-2;;3537305;;1469691;;10.1021/jm00102a014;;10.1021/ja00203a067;;3156376;;pmc397196;;10.1073/pnas.82.4.1074;;10.1021/ja010731e;;11472182;;7482665;;10.1161/01.str.26.11.2154;;7737407;;10.1016/0014-5793(95)00324-3;;11317312;;29712367;;10.1002/1521-3773(20010417)40:8<1494::aid-anie1494>3.0.co;2-x;;3001650;;10.1093/nar/13.24.8765;;pmc318950;;pmc318949;;10.1093/nar/13.24.8749;;3001649;;6368319;;10.1016/0378-1119(83)90191-9;;10.1016/0168-3659(85)90001-x;;10.1021/jo011148j;;11975567;;7620563;;10.1385/0-89603-272-8:97;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;6248420;;10.1016/0378-1119(80)90133-x;;10.1016/s1046-5928(02)00641-1;;12651100;;10.1074/jbc.271.33.19991;;8702716;;8402094;;10.1002/bjs.1800800812;;10.1038/nbt0290-135;;1366557;;10.1056/nejmoa011300;;11794168;;9645477;;10.1016/s0014-5793(98)00489-x;;10.1021/ja992749j;;10.1128/jb.130.2.946-947.1977;;400800;;pmc235301;;10.1007/bf02798546;;4026282;;3128641;;10.1099/0022-1317-69-4-765;;pmc140882;;12518054;;10.1073/pnas.0234824100;;10.1126/science.1060077;;11313494;;10.1021/ja021381e;;12630856;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/0378-1119(85)90140-4;;3891521;;10.1002/(sici)1097-0177(199709)210:1<41::aid-aja5>3.0.co;2-1;;9286594;;10.1016/s0960-9822(95)00102-3;;7583099;;0007583099;;10.1021/bc00023a002;;8274513;;10.1016/0141-0229(92)90049-t;;1368988;;10.1038/321718a0;;10.1021/ja028050m;;12465973;;18840786;;10.2337/db08-0392;;pmc2606881;;pmc344858;;6324193;;10.1073/pnas.81.5.1470;;pmc327233;;10.1093/nar/9.3.731;;6164048;;1785805;;10.1111/j.1749-6632.1991.tb49015.x;;10.1016/0014-3057(83)90016-2;;10.1021/bc00032a002;;7599259;;10.2337/diacare.24.4.720;;11315837;;24189035;;10.1016/j.drudis.2013.10.021;;10.1021/bi0300231;;12779328;;6225933;;10.1016/b978-0-12-765560-4.50036-8;;10.1016/0076-6879(83)00074-9;;6757864;;pmc326938;;10.1093/nar/10.20.6487;;10.1016/0076-6879(87)54083-6;;3323811;;10.1016/j.febslet.2008.11.023;;19059246;;10.1021/bc300603k;;23594041;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;10.1111/jgh.12271;;24251707;;10.1093/abbs/gmu097;;25355486,"Abuchowski, A. et al., “Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates”, Cancer Biochem. Biophys., Jun. 1984, 7(2): 175-86.;;Ahrén et al., “Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes”, Diabetes Care, 2002, 25(5): 869-75.;;Alisi, A. et al., “Commentary: FGF21 Holds Promises for Treating Obesity-related Insulin Resistance and Hepatosteatosis”, Endocrinology, Nov. 18, 2013, doi: 10.1210/en.2013-1828.;;Altschul, S.F. et al., “Basic local alignment search tool”, J. Mol. Biol., Oct. 5, 1990, 215(3): 403-10.;;Altschul, S.F. et al., “Gapped BLAST and Psi-BLAST: a new generation of protein database search programs”, Nucleic Acids Res., Sep. 1, 1997, 25(17): 3389-402.;;Amann, E. et al., “Vectors bearing a nybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli”, Gene, Nov. 1983, 25(2-3): 167-78.;;Anderson, J.C. et al., “Exploring the limits of codon and anticodon size”, Chem. Biol., Feb. 2002, 9(2): 237-44.;;Andresz, H. et al., “Chemische Synthese verzweigter Polysaccharide, 5: Kopplung von Oligosacchariden and Amylose an verschiedene Träer durch Hydrazonbindung”, Makromol. Chem. 1978, 179: 301, Abstract.;;Arakawa et al., “Protein-solvent interactions in pharmaceutical formulations”, Pharm. Res., 1991, 8(3): 285-291.;;Arnold, F.H., “Protein engineering for unusual environments”, Curr. Opin. Biotechnol., Aug. 1993, 4(4): 450-5.;;Azoulay, M. et al., “Glutamine analogues as Potential Antimalarials”, Eur. J. Med. Chem., 1991, 26(2): 201-5.;;Badman, M.K. et al., “Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States”, Cell Metabolism, Jun. 2007, 5: 426-437.;;Bailey, “Biguanides and NIDDM”, Diabetes Care, 1992, 15:755-72.;;Bain et al., “Ribosome-mediated incorporation of a non-standard amino acid into a peptide through expansion of the genetic code”, Nature, 1992, 356(6369): 537-539.;;Bain, J.D. et al., “Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide”, J. Am. Chem. Soc., 1989; 111(20): 8013-8014.;;Baird et al., “The fibroblast growth factor family”, Cancer Cells, 1991, 3(6): 239-43.;;Ballance, D.J. et al., “Transformation of Aspergillus nidulans by the orotidine-5′-phosphate decarboxylase gene of Neurospora crassa”, Biochem. Biophys. Res. Commun., Apr. 15, 1983, 112(1): 284-9.;;Barany, F. et al., “Genetic disease detection and DNA amplification using cloned thermostable ligase”, Proc. Natl. Acad. Sci. USA, Jan. 1, 1991, 88(1): 189-93.;;Barton, D.H.R. et al., “Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives”, Tetrahedron, 1987, 43:4297-4308.;;Bass, S. et al., “Mutant Trp repressors with new DNA-binding specificities”, Science, 1988, 242: 240-245.;;Batzer, M.A. et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at The 3′-terminus”, Nucleic Acids Res., Sep. 25, 1991, 19(18): 5081.;;Beach, D. et al., “Functionally homologous cell cycle control genes in budding and fission yeast”, Nature, Dec. 1982, 300: 706-709.;;Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis”, Tetrahedron Letts., 1981, 22(20): 1859-1862.;;Beauchamp, C.O. et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal. Biochem., May 1983, 131(1): 25-33.;;Belluardo et al., “Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis”, J. Comp. Neurol. (1997) 379(2): 226-46.;;Berkowitz et al., “Effect of troglitazone on insulin sensitivity an dpancreatic beta-cell function in women at high risk for NIDDM”, Diabetes, 1996, 45(11): 1572-9.;;Bernstein, F.C. et al., “The protein data bank: a computer-based archival file for macromolecular structures”, J. Mol. Biol., 1977, 112: 535-542.;;Biagini et al., The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes, Neurochem. Int., 1994, 25(1): 17-22.;;Boissel, J.P. et al., “Erythroprotein structure-function relationships. Mutant proteins that test a model of tertiary structure”, Jul. 25, 1993, 268(21): 15983-93.;;Boles, J.O. et al., “Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase”, Nat Struct Biol., May 1994, 1(5): 283-4.;;Botstein, D. and D. Shortle, “Strategies and applications of in vitro mutagenesis”, Science, Sep. 20, 1985, 229(4719): 1193-201.;;Bray, “Drug treatment of obesity”, Am. J. Clin. Nutr., 1992, 55(2 Suppl): 538S-544S.;;Broadhead et al., “The Spray Drying of Pharmaceuticals”, Drug Dev. Ind. Pharm., 1992, 18(11/12):1169-1206.;;Brunner, J. et al., “New photolabeling and crosslinking methods”, Annu. Rev. Biochem., 1993, 62: 483-514.;;Buchner, J. et al., “A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies”, Anal. Biochem., 1992, 205(2): 263-270.;;Bückmann et al., “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),” Makromol. Chem., 1981, 182: 1379-84.;;Budisa, N. et al., “Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins”, J. Mol. Biol., Jul. 25, 1997, 270(4): 616-23.;;Budisa, N. et al., “High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli”, Eur. J. Biochem., Jun. 1, 1995, 230(2): 788-96.;;Budisa, N. et al., “Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire”, FASEB J., Jan. 1999, 13(1): 41-51.;;Burgess et al., “The Heparin Binding (Fibroblast) Growth Factor Family of Proteins”, Annu. Rev. Biochem., 1989, 58: 575-606.;;Cai, X-Y et al., “Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-Inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells”, Protein Expression and Purifcation, 1997, 10(2): 263-74.;;Caliceti, P. and F.M. Veronese, “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates”, Adv. Drug. Deliv. Rev., Sep. 26, 2003, 55(10): 1261-1277.;;Cameron et al., “Effects of monosodium glutamate-induced obesity in mice on carbohydrate metabolism in insulin secretion”, Clin. Exp. Pharmacol. Physiol., 1978, 5(1): 41-51.;;Carbonell, L.F. et al., “Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells”, J. Virol., Oct. 1985, 56(1): 153-60.;;Carrasco, M. and R. Brown, “A Versatile Set of Aminoxy Amino Acids for the Synthesis of Neuropeptides”, J. Org. Chem., 2003, 68(23): 8853-8858.;;Carter, P. et al., “Improved oligonucleotide site-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987, 154: 382-403.;;Carter, P., “Improved oligonucleotide-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987, 154: 382-403.;;Carter, P., “Site-directed mutagenesis”, Biochem J., Jul. 1, 1986, 237(1): 1-7.;;Cech, “The chemistry of self-splicing RNA and RNA enzymes”, Science, Jun. 19, 1987, 236(4808): 1532-9.;;Chae, H-W. et al., “Spot Urine Albumin to Creatine Ratio and Serum Cystatin C are Effective for Detection of Diabetic Nephropathy in Childhood Diabetic Patients”, J Korean Med Sci. 2012, 27: 784-787.;;Chaiken, I.M., “Semisynthetic peptides and proteins”, CRC Grit. Rev. Biochem., 1981, 11(3): 255-301.;;Chin, J.W. and P.G. Schultz, “In vivo photocrosslinking with unnatural amino acid mutagenesis”, Chembiochem, Nov. 4, 2002, 3(11): 1135-7.;;Chin, J.W. et al., “Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli”, Proc. Natl. Acad. Sci. USA, Aug. 20, 2002, 99(17): 11020-4. Epub. Aug. 1, 2002.;;Chin, J.W. et al., “Addition of p-azido-L-phenylalanine to the genetic code of E. coli”, J. Am. Chem. Soc., Aug. 7, 2002, 124(31): 9026-7.;;Chin, J.W. et al., “An expanded eukaryotic genetic code”, Science, Aug. 15, 2003, 301(5635): 964-7.;;Christie, B.D. and H. Rapoport, “Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization”, J. Org. Chem., 1985, 50(8): 1239-1246.;;Clark, E.D.B., “Protein refolding for industrial processes”, Curr. Opin. Biotechnol., Apr. 2001, 12(2): 202-207.;;Clark, E.D.B., “Refolding of recombinant proteins”, Curr. Opin. Biotechnol., Apr. 1, 1998, 9(2): 157-163.;;Clark, R. et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”, J. Biol. Chem., Sep. 6, 1996, 271(36): 21969-77.;;Clissod et al., “Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential”, Drugs, 1988, 35:214-23.;;Coleman et al., “Fat(fat) and tubby(tub): two autosomal recessive mutations causing obesity syndromes in the mouse”, J. Hered., 1990, 81(6): 424-7.;;Coleman et al., “Other Potentially Useful Rodents as Models for the Study of Human Diabetes Mellitus”, Diabetes, 1982, 31(Suppl 1 Pt 2): 24-25.;;Collazo-Clavell, M.L. et al., “Assessment and Preparation of Patients for Bariatric Surgery”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S11-517.;;Corey, D.R. and P.G. Schultz, “Generation of a hybrid sequence-specific single-stranded deoxyribonuclease”, Science, 1987, 238(4832): 1401-1403.;;Cornish, V.W. et al., “Probing Protein Sturcture and Function with an Expanded Genetic Code”, Angew. Chem. Int. Ed. Engl., 34(6): 621-33.;;Cornish, V.W. et al., “Site-Specific Protein Modification Using a Ketone Handle”, J. Am. Chem. Soc., 1996, 118(34): 8150-8151.;;Coulier et al., “The FGF6 gene with the FGF multigene family”, Ann. NY Acad. Sci., 1991, 638:53-61.;;Craig, J.C. et al., “Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino] quinoline (Chloroquinine)”, J. Org. Chem., 1988, 53(6): 1167-1170.;;Cregg, J.M. et al., “Pichia pastoris as a host system for transformations”, Mol. Cell Biol., Dec. 1985, 5(12): 3376-85.;;Crick, F.H.C. et al., “General nature of the genetic code for proteins”, Nature, Dec. 30, 1961, 192: 1127-32.;;Crossley et al., “The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo”, Development, 1995, 121(2): 439-51.;;Dale et al., “Oligonucleotide-directed random mutagenesis using the phophorothioate method”, Methods Mol. Biol., 1996, 57: 369-374.;;Das, S. et al., “Transformation of Kluyveromyces fragilis”, J. Bacteriol., Jun. 1984, 158(3): 1165-7.;;Davis, G.D. et al., “New fusion protein systems designed to give soluble expression in Eschericia coli”, Biotechnol. Bioeng., Nov. 20, 1999, 65(4): 382-388.;;Dawson et al., “Synthesis of native proteins by chemical ligation”, Annu. Rev. Biochem., 2000, 69: 923-60.;;De Boer, H.A. et al., “The tac promoter: a functional hybrid derived from the trp and the lac promoters”, Proc. Natl. Acad. Sci. USA, Jan. 1983, 80(1): 21-5.;;De Louvencourt, L. et al., “Transformation of Kluyveromyces lactis by killer plasmid DNA”, J. Bacteriol., May 1983, 154(2): 737-42.;;Debinski, W. et al., “A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin”, J. Biol. Chem., Jul. 5, 1993, 268(10): 14065-70.;;DeFronzo et al., “Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group”, N. Engl. J. Med., 1995, 333(9): 541-9.;;Deiters, A. et al., “Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cerevisiae”, J. Am. Chem. Soc., 2003, 125(39): 11782-11783.;;Deiters, A., “Site-specific PEGylation of proteins contianing unnatural amino acids”, Bioorg. Med. Chem. Lett., Dec. 6, 2004, 14(23): 5743-5.;;Delgado, C. et al., “The uses and properties of PEG-linked proteins”, Crit. Rev. Ther. Drug. Carrier Syst., 1992, 9(3-4): 249-304.;;Dennis, M.S. et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins”, J. Biol. Chem., Sep. 20, 2002, 277(38): 35035-43, Epub Jul. 15, 2002.;;Dickson et al., “Expression, processing, and properties of int-2”, Ann. NY Acad. Sci., 1991, 638:18-26.;;Dietrich et al., “Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats”, J. Neurotrauma, 1996, 13(6): 309-16.;;Dolphin, C.T. et al., “Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome”, Nat. Genet., Dec. 1997, 17(4): 491-4.;;Doring, V. et al., “Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway”, Science, Apr. 20, 2001, 292(5516): 501-4.;;Dougherty, D.A., “Unnatural amino acids as probes of protein structure and function”, Curr. Opin. Chem. Biol., Dec. 2000, 4(6): 645-52.;;Drummond et al., “Liposomal drug delivery systems for cancer therapy”, B. Teicher (ed.): Cancer Drug Discovery and Development, 2002, 161-213.;;Duewel, H. et al., “Incorporation of trifluoromethionine into a phage lysozyme: implications and a new marker for use in protein 19F NMR”, Biochemistry, Mar. 18, 1997, 36(11): 3404-16.;;Duncan, R., “The dawning era of polymer therapeutics”, Nat. Rev. Drug. Discov., May 2003, 2(5): 347-60.;;Edwards et al., “A bacterial amber suppressor in Saccharomyces cerevisiae is selectively recognized by a bacterial aminoacyl-tRNA synthetase”, Mol. Cell Biol., 1990, 10(4): 1633-41.;;Eghtedarzadeh, M.K. and S. Henikoff, “Use of oligonucleotides to generate large deletions”, Nucleic Acids Res., Jun. 25, 1986, 14(12): 5115.;;Elling, L. and M.R. Kula, “Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies”, Biotechnol. Appl. Biochem., Jun. 1991, 13(3): 354-62.;;Elliott, S. et al., “Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization”, J. Protein. Chem., Feb. 1990, 9(1): 95-104.;;Ellman, J.A. et al., “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins”, Methods in Enz., 1992, 202: 301-336.;;Ellman, J.A. et al., “Site-specific incorporation of novel backbone structures into proteins”, Science, Jan. 10, 1992, 255(5041): 197-200.;;England, P.M. et al., “Backbone mutation in transmembrane domains of a ligand-gated ion channel: implications for the mechanisms of gating”, Cell, Jan. 8, 1999, 96(1): 89-98.;;Eppstein et al., “Biological Activity of Liposome-Encapsulated Murine Interferon is Mediated by a Cell Membrane Receptor”, Proc. Natl. Acad. Sci USA, 1985, 82: 3688-3692.;;European Patent Office, “Invitation to Pay Additional Fees”, Form PCT/ISA/206, International Application No. PCT/US2015/057228, dated Feb. 10, 2016.;;Fieschko, J.C. et al., “Controlled expression and purification of human immune interferon from high-cell-density fermentations of Saccharomyces cerevisiae”, Biotech. Bioeng., 1987, 29(9): 1113-21.;;Folch, J. et al., “A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues”, J. Biol. Chem. 1957;226: 497-509.;;Forster, A.C. et al., “Programming peptidomimetic syntheses by translating genetic codes designed de novo”, Proc. Natl. Acad. Sci. USA, May 27, 2003, 100(11): 6353-7. Epub May 16, 2003.;;Frankel, A. et al., “Encodamers: unnatural peptide oligomers encoded in RNA”, Chem. Biol., Nov. 2003, 10(11): 1043-50.;;Fraser, M.J. et al., “Expression of eucaryotic genes in insect cell cultures”, In Vitro Cell. Dev. Biol., 1989, 25: 225-235.;;Friedman et al., “Tackling a weighty problem”, Cell, 1992, 69: 217-220.;;Friedman, O.M. and R. Chatterrji, “Synthesis of Derivatives of Glutamate as Model Substrates for Anti-Tumor Agents”, J. Am. Chem. Soc., 1959, 81(14): 3750-3752.;;Friesen et al., “The regulation of baculovirus gene expression”, Curr. Top. Microbiol. Immunol., 1986, 131: 31-49.;;Fritz, H.J. et al., “Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro”, Nucleic Acids Res., Jul. 25, 1988, 16(14B): 6987-99.;;Fromm, M. et al., “Expression of Genes Transferred into Monocot and Dicot Plant Cells by Electroporation”, Proc. Natl. Acad. Sci. USA, 1985, 82: 5824-8.;;Fukumoto, S., “Actions and Mode of Actions of FGF19 Subfamily Members”, Endocrine Journal, 2008; 55(1): 23-31.;;Furter, R., “Expansion of the genetic code: site-directed p-fluoro-phenylalanine Incorporation in Escherichia coli”, Protein Sci., Feb. 1998, 7(2): 419-26.;;Gaertner, H.F. and R.E. Offord, “Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins”, Bioconjug. Chem., Jan.-Feb. 1996, 7(1): 38-44.;;Gaertner, H.F. et al., “Chemo-enzymatic backbone of engineering of proteins. Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor”, J. Biol. Chem., Mar. 11, 1994, 269(10): 7224-30.;;Gaertner, H.F. et al., “Construciton of protein analogues by site-specific condensation of unprotected fragments”, Bioconjug. Chem., May-Jun. 1992, 3(3): 262-8.;;Gallivan, J.P. et al., “Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins”, Chem. Biol., Oct. 1997, 4(10): 739-49.;;Garber et al., “Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial”, Am. J. Med., 1997, 102: 491-97.;;Gellissen, G. et al., “Heterologous protein production in yeast”, Antoine Van Leeuwenhoek, Aug. 1992, 62(1-2): 79-93.;;Gemel et al., “Structure and sequence of human FGF8”, Genomics, 1996, 35:253-257.;;Geoghegan, K.F. and J.G. Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modifcation at N-terminal serine”, Bioconjug. Chem., Mar.-Apr. 1992, 3(2): 138-146.;;Ghosh et al., “Molecular cloning and characterization of human FGF8 alternative messenger RNA forms”, Cell Growth and Differentiation, 1996, 7(10): 1425-1434.;;Gillam, S. and M. Smith, “Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum oligodeoxyribonucleotide length”, Gene, 1979, 8(1): 81-97.;;Gimeno, R.E. and Moller, D.E., “FGF21-bsed pharmacotherapy—potential utility for metabolic disorders”, Trends Endocrinol Metab. Jun. 2014;25(6):303-11.;;Giugliano et al., “Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women”, Diabetes Care, 1993, 16:1387-90.;;Gleeson, M.A. et al., “Transformation of the methylotrophic yeast hansenula polymorphica”, J. Gen. Microbiol., 1986, 132: 3459-3465.;;Goeddel, D.V. et al., “Synthesis of human fibroblast interferon by E. coli”, Nucleic Acids.Res., Sep. 25, 1980, 8(18): 4057-74.;;Goeddel, D.V., “Systems for heterologous gene expression”, Methods Enzymol., 1990, 185: 3-7.;;Goldfarb et al., “Expression and possible functions of the FGF-5 gene”, Ann. NY. Acad. Sci., 1991, 638:38-52.;;Goodson, R.J. and N.V. Katre, “Site-directed pegylation of recombinant interleukin-2 at its glycosylation site”, Biotechnology (NY), Apr. 1990, 8(4): 343-346.;;Graves, S.W. et al., “Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase”, Biochemistry, Apr. 28, 1998, 37(17): 6050-6058.;;Griffin, B.A. et al., “Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells”, Science, 1998, 281:269-272.;;Grundström, T. et al., “Oligonucleotide-directed mutagenesis by microscale ‘shot-gun’ gene synthesis”, Nucleic Acids Res., May 10, 1985, 13(9): 3305-3316.;;Gu, Z. et al., “Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies”, Protein Expr. Purif., Jun. 2002, 25(1): 174-9.;;Guckian, K.M. and E.T. Kool, “High Precise Shape Mimicry by a Difluorotoluene Deoxynucleoside, and Replication-Competent Substitute for Thymidine”, Angew. Chem. Int. Ed. Engl., 1998, 36(24): 2825-8.;;Hamano-Takaku, F. et al., “A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine” J. Biol. Chem., Dec. 22, 2000, 275(51): 40324-8.;;Hang, H.C. and C.R. Bertozzi, “Chemoselective approaches to glycoprotein assembly”, Acc. Chem. Res., Sep. 2001, 34(9): 727-36.;;Harmer et al., “The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity”, Biochemistry, 2004, 43:629-640.;;Harris, J.M. et al., “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives”, J. Polym. Sci. Chem. Ed., 1984, 22:341-352.;;Harris, J.M., “Laboratory Synthesis of Polyethylene Glycol Derivatives”, JMS-Rev. Macromol. Chem. Phys., 1985, C25(3): 325-373.;;Hecht et al., “Chemical aminoacylation of tRNA's”, J. Biol. Chem., 1978, 253(13): 4517-20.;;Hecht, “Probing the synthetic capabilities of a center of biochemical catalysis”, Acc. Chem. Res., 1992, 25(12): 545-552.;;Hecht, R. et al., “Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes”, PLoS One. 2012;7(11):e49345.;;Heckler et al., “Ribosomal binding and dipeptide formation by misacylated tRNA(Phe)'s”, Biochemistry, 1988, 27(19): 7254-62.;;Hendrickson, W.A. et al., “Selenomethionyl proteins produced for analysis of multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure”, EMBO J., May 1990, 9(5): 1665-72.;;Henikoff, S. and J.G. Henikoff, “Amino Acid Substitution Matrices from Protein Blocks”, Proc. Natl. Acad. Sci. USA, 1992, 89: 10915-9.;;Hensrud, D.D. and Klein, S., “Extreme Obesity: A New Medical Crisis in the United States”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S5-S10.;;Hess, B. et al., “Cooperation of glycolytic enzymes”, J. Adv. Enzyme Reg., 1969, 7: 149-67.;;Hinke et al., “Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1”, Biochem. Biophys. Res. Commun., 2002, 291(5): 1302-8.;;Hinnen, A. et al., “Transformation of yeast”, Proc. Natl. Acad. Sci. USA, Apr. 1978, 75(4): 1929-33.;;Hirao, I. et al., “An unnatural base pair for incoporating amino acid analogues into proteins”, Nat Biotechnol., Feb. 2002, 20(2): 177-82.;;Hitzeman, R.A. et al., “Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological screening technique”, J. Biol.Chem., Dec. 25, 1980, 255(24): 12073-80.;;Hoffmann, K. and H. Bohn, “Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment”, J. Am. Chem., 1966, 88(24): 5914-5919.;;Hohsaka, T. and M. Sisido, “Incorporation of non-natural amino acids into proteins”, Curr. Opin. Chem. Biol., Dec. 2002, 6(6): 809-15.;;Hohsaka, T. et al., “Efficient Incorporation of Nonnatural Amino Acids with Large Aromatic Groups into Streptavidin in In Vitro Protein Synthesizing Systems”, J. Am. Chem. Soc., 1999, 121(1): 34-40.;;Hohsaka, T. et al., “Incorporation of Two Different Nonnatural Amino Acids Independently into a Single Protein through Extension of the Genetic Code”, J. Am. Chem. Soc., 1999, 151(51): 12194-12195.;;Holland, M.J. and J.P. Holland “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceralehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase”, Biochemistry, Nov. 14, 1978, 17(23): 4900-7.;;Holland, M.J. et al., “The primary structures of two yeast enolase genes. Homology between the 5′ noncoding flanking regions of yeast enolase and glyceraldehyde-3-phosphate dehydrogenase genes”, J. Biol. Chem., Feb. 10, 1981, 256(3): 1358-95.;;Holland, W.L. et al., “An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice”, Cell Metab. 2013; 17: 790-797.;;Hoshikawa et al., “Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain”, Biochem. Biophys. Res. Commun., 1998, 244(1): 187-91.;;Hsiao, C.L. and J. Carbon, “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”, Proc. Natl. Acad. Sci. USA, Aug. 1979, 76(8): 3829-33.;;Hubinger et al., “The effect of etomoxir on insulin sensitivity in type 2 diabetic patients”, Hormone Metab. Res., 1992, 24:115-18.;;Huisgen, R. In 1,3-Dipolar Cycloaddition Chemistry, vol. 1, 1984; Ed. A. Padwa; John Wiley and Sons, New York, 1-176.;;Hwang, K.J. et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study”, Proc. Natl. Acad. Sci. USA, Jul. 1980, 77(7): 4030-4.;;Ibba, M. and H. Hennecke, “Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids”, FEBS Lett., May 15, 1995, 364(3): 272-5.;;Ibba, M. et al., “Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase”, Biochemistry, Jun. 14, 1994, 33(23): 7107-12.;;Illangakekare et al., “Aminoacyl-RNA Synthesis Catalyzed by an RNA”, Science, 1995, 267:643-647.;;Inzucchi et al., “Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus”, New Engl. J. Med., 1998, 335:867-72.;;Itakura et al., “Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin”, Science, 1997, 198:1056-1063.;;Ito, H. et al., “Transformation of intact yeast cells treated with alkali cations”, J. Bacteriol., 1983, 153(1): 163-8.;;Jackson, D.Y. et al., “A designated peptide ligase for total synthesis of ribonuclease A with unnatural catalytic residues”, Science, Oct. 14, 1994, 266(1583): 243-7.;;Jakobsson, P.J. et al., “Identification and characterization of a novel human microsomal glutathione S-transferase with keukotriene C4 synthetase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase”, J. Biol. Chem., Sep. 6, 1996, 271(36): 22203-10.;;Jencks, W.P., “Studies on the Mechanism of Oxime and Semicarbazone Formation”, J. Am. Chem. Soc., 1959, 81(2): 475-481.;;Joppich, M. et al., “Peptides Flanked by Two Polymer Chains, 1; Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups”, Makromol. Chem., 1979, 180:1381-4.;;Jung et al., “The management of obesity”, Clinical Endocrinology, 1991, 35: 11-20.;;Kaiser, E.T. and D.S. Lawrence, “Chemical mutation of enzyme active sites”, Science, Nov. 2, 1984, 226(4674): 505-11.;;Kaiser, E.T. et al., “The chemical modification of enzymatic specificitiy”, Annu. Rev. Biochem., 1985, 54: 565-95.;;Kaiser, E.T., “Synthetic approaches to biologically active peptides and proteins including enzymes”, Acc. Chem. Res., 1989, 22(2): 47-54.;;Karlin, S. and S.F. Altschul, “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci. USA, Jun. 15, 1993, 90(12): 5873-7.;;Katoh et al., “FGF signaling network in the gastrointestinal tract (review)”, Int'l. J. Oncology, 2006, 29: 163-168.;;Kawamata et al., “Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction”, Proc. Natl. Acad. Sci., 1997, 94(15): 8179-84.;;Kayser, B. et al., “Alkyne bridged alpha-amino acids by palladium mediated coupling of alkynes with N-t-Boc-4-iodo-phenylalanine methyl ester”, Tetrahedron, 1997, 53(7): 2475-2484.;;Kelly, J.M. and M.J. Hynes, “Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans”, EMBO J., 1985, 4(2): 475-479.;;Kendrick, M.L. and Dakin, G.F., “Surgical Approaches to Obesity”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S18-S24.;;Kharitonekov et al., “FGF-21 as a novel metabolic regulator”, J. Clin. Investigation, Jun. 1, 2005, 115(6): 1627-1635.;;Kharitonekov et al., “The Metabolic State of Diabetic Monkeys is Regulated by Fibroblast Growth Factor-21”, Endocrinology, Feb. 1, 2007, 148(2): 774-781.;;Kharitonenkov, A. and Adams, A.C., “Inventing new medicines: The FGF21 story”, Mol. Metab., Avail. Online Dec. 27, 2013, 3(2014): 221-229.;;Kharitonenkov, A. et al., “Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319”, Plos One, Mar. 2013, 8(3) e58575: 1-10.;;Kiick, K.L. and D.A. Tirrell, “Protein Engineering by In Vivo Incorporation of Non-Natural Amino Acids: Control of Incorporation of Methionine Analogues by Methionyl-tRNA Synthetase”, Tetrahedron, 2000, 56: 9487-9493.;;Kiick, K.L. et al., “Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation”, Proc. Natl. Acad. Sci. USA, Jan. 8, 2002, 99(1): 19-24. Epub Dec. 18, 2001.;;Kim, D.M and J.R. Swartz, “Prolonging cell-free protein synthesis with a novel ATP regeneration system”, Biotechnol. Bioeng., 1999, 66(3): 180-8.;;Kim, D.M. and J.R. Swartz, “Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli”, Biotechnology Letters, 2000, 22:1537-1542.;;Kim, D.M. and J.R. Swartz, “Prolonging cell-free protein synthesis by selective reagent additions”, Biotechnol. Prog., May-Jun. 2000, 16(3): 385-90.;;Kim, D.M. and J.R. Swartz, “Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis”, Biotechnol. Bioeng., Aug. 20, 2001, 74(4): 309-16.;;Kim, H.W. et al., “Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice”, Endocrinology, Sep. 2013, 154(9): 3366-3376.;;King, F.E. and D.A.A. Kidd, “A New Synthesis of Glutamine and of gamma-Dipeptides of Glutamic Acid from Phthylated Intermediates”, J. Chem. Soc. 1949, 3315-3319.;;Kingsman, A.J. et al., “Replication in Saccharomyces cerevisiae of plasmid pBR313 carrying DNA from the yeast trpl region”, Gene, Oct. 1979, 7(2): 141-52.;;Kitts, P.A. et al., “Linearization of baculovirus DNA enhance the recovery of recombinant virus expression vectors”, Nucleic Acids Res., Oct. 11, 1990, 18(19): 5667-72.;;Klein, T.M. et al., “High-velocity microprojectiles for delivering nucleic acids into living cells”, Nature, 1987, 327(6117): 70-73.;;Kleiner, D.E. et al., “Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease”, Hepatology, 2005; 41:1313-1321.;;Kobayashi, T. et al., “Structural basis for orthogonal tRNA synthesis for genetic code expansion”, Nature Stuctural Biology, 2003, 10(6): 425-432.;;Kogan, T.P., “The synthesis of substituted methoxy-poly(ethyleneglycol) derivatives suitable for selective protein modification”, Synthetic Comm., 1992, 22(16): 2417-24.;;Kool, E.T., “Synthetically modified DNAs are substrates for polymers”, Curr. Opin. Chem. Biol., Dec. 2000, 4(6): 602-8.;;Koskinen, A.M.P. and H. Rapoport, “Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues”, J. Org. Chem., 1989, 54(8): 1859-1866.;;Kost, T.A. et al., “Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system”, Gene, Apr. 29, 1997, 190(1): 139-44. et al.",ACTIVE
360,KR,A,KR 20170070227 A,027-228-857-158-204,2017-06-21,2017,KR 20177013555 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,FGF-21 MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"변형된 FGF-21 폴리펩티드 및 그의, 예를 들어 섬유증과 연관된 질환의 치료에 있어서의 용도가 제공된다. 내부 결실 및 임의로 대체 펩티드를 함유하고, 임의로 적어도 1개의 비-자연 코딩 아미노산으로 변형되고/거나, 임의로 융합 파트너와 융합된 변형된 FGF-21 폴리펩티드 가 개시되어 있다.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/027-228-857-158-204,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00;;A61K38/18;;A61K45/06;;A61K47/50,,0,0,,,,ACTIVE
361,EP,A1,EP 3909596 A1,094-743-005-496-234,2021-11-17,2021,EP 21162746 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 18177893 A;;EP 15790415 A;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/094-743-005-496-234,Patent Application,yes,91,0,60,64,316,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,77,64,022-997-664-996-345;;029-041-317-917-380;;095-163-015-743-716;;006-516-075-151-31X;;005-001-316-365-345;;008-135-071-759-92X;;019-590-397-412-17X;;056-201-471-905-934;;028-373-705-126-470;;032-728-154-591-070;;028-862-168-091-90X;;056-201-471-905-934;;065-530-651-566-523;;017-940-142-904-249;;082-902-765-648-368;;077-140-409-267-690;;027-033-711-563-119;;189-306-471-756-979;;037-612-698-436-922;;018-471-026-674-340;;023-157-064-831-058;;078-020-406-613-471;;169-736-421-398-039;;001-168-243-787-836;;034-132-141-339-939;;078-886-911-253-419;;050-491-094-261-212;;081-098-345-341-182;;035-328-575-802-514;;040-712-467-075-177;;113-394-540-007-150;;064-029-904-826-616;;135-885-609-471-475;;013-885-021-097-853;;139-370-722-026-325;;000-267-213-967-50X;;017-239-464-122-703;;029-171-836-207-263;;079-141-143-704-263;;032-412-591-971-193;;010-929-566-271-076;;046-036-272-703-281;;142-164-397-210-970;;081-092-403-760-75X;;031-118-508-476-586;;099-108-177-239-268;;018-934-238-795-193;;084-748-487-156-928;;025-834-245-974-873;;006-095-947-008-535;;005-638-542-147-993;;093-724-494-618-609;;048-439-321-617-128;;012-388-439-961-094;;019-590-397-412-17X;;063-797-097-486-664;;030-425-987-723-110;;005-316-633-999-516;;067-220-965-320-998;;005-660-045-470-037;;000-221-503-463-330;;072-022-751-553-845;;050-741-722-639-562;;004-965-380-380-515,1911037;;9427842;;10.1016/s0079-6603(08)61031-4;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;12845521;;10.1007/s00441-003-0756-7;;10858549;;10.1016/s0167-4781(00)00067-1;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;8554512;;10.1042/bj3120725;;pmc1136174;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/0022-2836(70)90057-4;;5420325;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1358/dof.2009.034.08.1394557;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;pmc334719;;2830593;;10.1093/nar/16.3.791;;8347599;;10.1021/bi00082a015;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;10.1038/nbt0202-177;;11821864;;10.1021/ja028050m;;12465973;;10.2337/diab.31.1.s1;;7160533;;2250094;;10.1093/oxfordjournals.jhered.a111019;;7473593;;10.1021/jm00023a005;;10.1021/ja01523a064;;10.1021/jo00241a009;;10.1016/0223-5234(91)90030-q;;10.1021/jo00269a022;;10.1002/chin.198535327;;10.1016/s0040-4020(01)90305-9;;1469691;;10.1021/jm00102a014;;10.1021/bi0300231;;12779328;;10.1021/bc00014a008;;1325188;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/ja01511a053;;10.1021/ja00119a001;;10.1021/ja961216x;;10.1126/science.276.5315.1125;;9173543;;10.1021/ar9901570;;11560472;;10.1021/jo034984x;;14604354;;9129118;;10.1016/s0024-3205(96)00595-4;;12920298;;10.1126/science.1084772;;10.1021/ja0370037;;14505376;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;10.1021/jo011148j;;11975567;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1126/science.287.5460.2007;;10720325;;10.1016/s0040-4020(96)01195-7;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1038/370389a0;;8047147;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1016/s0021-9258(18)68577-1;;3372509;;19915550;;10.1038/nbt.1588;;8613964;;10.1016/s0022-1759(96)00217-7;;9032414;;12119302;;10.1074/jbc.m205854200;;8554512;;10.1042/bj3120725;;pmc1136174;;1568242;;10.1016/0092-8674(92)90402-x;;10.1126/science.164.3880.719;;5778021;;13428781;;10.1016/s0021-9258(18)64849-5;;15915461;;10.1002/hep.20701;;21520200;;10.1002/hep.24376;;pmc4014460;;10.1074/jbc.m704165200;;17623664;;pmc2496965;;10.1073/pnas.0701600104;;pmc1855074;;17452648;;17933712;;22787375;;pmc3390728;;10.3346/jkms.2012.27.7.784,"BAIRD ET AL., CANCER CELLS, vol. 3, 1991, pages 239 - 243;;MCKEEHAN ET AL., PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 59, 1998, pages 135 - 176;;BURGESS, W. H. ET AL., ANNU. REV. BIOCHEM., vol. 58, 1989, pages 575 - 606;;REUSS ET AL., CELL TISSUE RES, vol. 313, 2003, pages 139 - 157;;NISHIMURA ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1492, 2000, pages 203 - 206;;KHARITONENKOV ET AL., J CLIN INVEST, vol. 115, no. 6, June 2005 (2005-06-01), pages 1627 - 35;;GIMENOMOLLER, TRENDS ENDOCRINOL METAB, vol. 25, no. 6, June 2014 (2014-06-01), pages 303 - 11;;HECHT ET AL., PLOS ONE, vol. 7, no. 11, 2012, pages e49345;;""Immunogenicity Assessment for Therapeutic Protein Products"", August 2014, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES;;""Therapeutic Protein Immunogenicity Focus Group Newsletter"", vol. 1, December 2011, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS;;KURTZHALS, BIOCHEM.J., vol. 312, 1995, pages 725 - 731;;ALTSCHUL ET AL., J MOL BIOL, vol. 215, no. 3, 5 October 1990 (1990-10-05), pages 403 - 10;;SMITHWATERMAN, J MOL BIOL, vol. 147, no. 1, 25 March 1981 (1981-03-25), pages 195 - 7;;NEEDLEMANWUNSCH, J MOL BIOL, vol. 48, no. 3, March 1970 (1970-03-01), pages 443 - 53;;CREIGHTON: ""Proteins: Structures and Molecular Properties"", December 1993, W H FREEMAN & CO.;;ALTSCHUL ET AL., NUC. ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;FYFE, M.C.T. ET AL., DRUGS OF THE FUTURE, vol. 34, no. 8, 2009, pages 641 - 653;;BARANY ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 189 - 193;;SAYERS, J.R. ET AL.: ""5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis"", NUCLEIC ACIDS RES, vol. 16, 1988, pages 791 - 802, XP001314878;;MA ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 7939;;KOWALOLIVER, NUCL. ACID. RES., vol. 25, 1997, pages 4685;;HIRAO ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 177 - 182;;CHIN, J. W. ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 14626 - 14630;;COLEMAN, DIABETES, vol. 31, 1982, pages 1;;COLEMAN ET AL., J. HEREDITY, vol. 81, 1990, pages 424 - 340;;MATSOUKAS ET AL., J. MED. CHEM., vol. 38, 1995, pages 4660 - 4669;;KING, F.E.KIDD, D.A.A.: ""A New Synthesis of Glutamine and of γ-Dipeptides of Glutamic Acid from Phthylated Intermediates"", J. CHEM. SOC., 1949, pages 3315 - 3319;;FRIEDMAN, O.M.CHATTENJI, R.: ""Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents"", J. AM. CHEM. SOC., vol. 81, 1959, pages 3750 - 3752, XP055737782, DOI: 10.1021/ja01523a064;;CRAIG, J.C. ET AL.: ""Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino]quinoline (Chloroquine)"", J. ORG. CHEM, vol. 53, 1988, pages 1167 - 1170;;AZOULAY, M.VILMONT, M.FRAPPIER, F.: ""Glutamine analogues as Potential Antimalarials"", EUR. J. MED. CHEM., vol. 26, 1991, pages 201 - 5, XP023870208, DOI: 10.1016/0223-5234(91)90030-Q;;KOSKINEN, A.M.P.RAPOPORT, H.: ""Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues"", J. ORG. CHEM., vol. 54, 1989, pages 1859 - 1866;;CHRISTIE, B.D.RAPOPORT, H.: ""Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization"", J. ORG. CHEM., vol. 50, 1985, pages 1239 - 1246, XP002168706, DOI: 10.1021/jo00208a017;;BARTON ET AL.: ""Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives"", TETRAHEDRON, vol. 43, 1987, pages 4297 - 4308, XP001008711, DOI: 10.1016/S0040-4020(01)90305-9;;SUBASINGHE ET AL.: ""Quisqualic acid analogues: synthesis of betaheterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site"", J. MED. CHEM., vol. 35, 1992, pages 4602 - 7, XP002198373, DOI: 10.1021/jm00102a014;;ZHANG, Z. ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 6735 - 6746;;GEOGHEGAN, K. F.STROH, J. G., BIOCONJUG. CHEM., vol. 3, 1992, pages 138 - 146;;GAERTNER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 7224 - 7230;;JENCKS, W. P., J. AM. CHEM. SOC., vol. 81, 1959, pages 475 - 481;;SHAO, J.TAM, J. P., J. AM. CHEM. SOC., vol. 117, no. 14, 1995, pages 3893 - 3899;;CORNISH, V. W. ET AL., L. AM. CHEM. SOC., vol. 118, 1996, pages 8150 - 8151;;MAHAL, L. K. ET AL., SCIENCE, vol. 276, 1997, pages 1125 - 1128;;H. HANGC. BERTOZZI, ACC. CHEM. RES., vol. 34, 2001, pages 727 - 736;;M. CARRASCOR. BROWN, J. ORG. CHEM., vol. 68, 2003, pages 8853 - 8858;;ROSENTHAL, G., LIFE SCI, vol. 60, 1997, pages 1635 - 1641;;CHIN J. ET AL., SCIENCE, vol. 301, 2003, pages 964 - 7;;DEITERS, A. ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 11782 - 11783;;TRUETT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 7806 - 1109;;HUISGEN, R: ""1,3-DIPOLAR CYCLOADDITION CHEMISTRY"", 1984, pages: 1 - 176;;TORNOE, C. W. ET AL., J. ORG. CHEM., vol. 67, 2002, pages 3057 - 3064;;ROSTOVTSEV ET AL., ANGEW. CHEM. INT. ED., vol. 41, 2002, pages 2596 - 2599;;E. SAXONC. BERTOZZI, SCIENCE, vol. 287, 2000, pages 2007 - 2010;;KAYSER, B. ET AL., TETRAHEDRON, vol. 53, no. 7, 1997, pages 2475 - 2484;;LIU, D.R.SCHULTZ, P.G.: ""Progress toward the evolution of an organism with an expanded genetic code"", PNAS UNITED STATES, vol. 96, 1999, pages 4780 - 4785, XP001040352, DOI: 10.1073/pnas.96.9.4780;;STEMMER: ""Rapid evolution of a protein in vitro by DNA shuffling"", NATURE, vol. 370, no. 4, 1994, pages 389 - 391, XP002082182, DOI: 10.1038/370389a0;;STEMMER: ""DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution"", PROC. NATL. ACAD. SCI. USA., vol. 91, 1994, pages 10747 - 10751, XP002912215, DOI: 10.1073/pnas.91.22.10747;;SPENCER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 7862 - 7867;;SCHELLENBERGER ET AL., NAT BIOTECHNOL., vol. 27, no. 12, December 2009 (2009-12-01), pages 1186 - 90;;MAKRIDES ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996, pages 534 - 542;;SJOLANDER ET AL., J, IMMUNOL. METHODS, vol. 201, 1997, pages 115 - 123;;DENNIS ET AL., L. BIOL. CHEM., vol. 277, 2002, pages 35035 - 35043;;KURTZHALS ET AL., BIOCHEM. J., vol. 312, 1995, pages 725 - 731;;FRIEDMAN ET AL., CELL, vol. 69, 1992, pages 217 - 220;;OLNEY, SCIENCE, vol. 164, 1969, pages 719;;CAMERON ET AL., CLI. EXP. PHARMACOL. PHYSIOL., vol. 5, 1978, pages 41;;HOWLAND, R. D.MYCEK, M. J.HARVEY, R. A.CHAMPE, P. C.MYCEK, M. J.: ""Goodman & Gilman's the pharmacological basis of therapeutics"", 2006, LIPPINCOTT WILLIAMS & WILKINS;;GOLAN, D. E.: ""Principles of pharmacology: the pathophysiologic basis of drug therapy"", 2008, LIPPINCOTT WILLIAMS & WILKINS;;MILLER, J.H., GENE, 1986;;WEBSTER: ""Predicting Long-Term Storage Stability of Therapeutic Proteins"", PHARMACEUTICAL TECHNOLOGY, vol. 37, 2 November 2013 (2013-11-02), pages 42 - 48;;FOLCH J ET AL., J. BIOL. CHEM., vol. 226, 1957, pages 497;;KLEINER DE ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313;;HOLLAND ET AL., CELL METAB, vol. 17, 2013, pages 779 - 789;;SANYAL AJ ET AL., HEPATOLOGY, vol. 54, 2011, pages 344;;KUROSU ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 26687 - 26695;;OGAWA ET AL., PROC. NATL. ACAD. OF SCI., USA, vol. 104, 2007, pages 7432 - 7437;;NINICHUK ET AL., EUR J MED RES, vol. 12, 2007, pages 351 - 355;;CHAE ET AL., J KOREAN MED SCI, vol. 27, 2012, pages 784 - 787",PENDING
362,CL,A1,CL 2017000999 A1,113-040-597-397-155,2018-03-16,2018,CL 2017000999 A,2017-04-21,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.,"<p>LA PRESENTE INVENCIÓN SE REFIERE A POLIPÉPTIDOS FGF-21 MODIFICADOS Y USOS DE LOS MISMOS, POR EJEMPLO, PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LA FIBROSIS. SE DESCRIBEN POLIPÉPTIDOS FGF-21 MODIFICADOS QUE CONTIENEN UNA SUPRESIÓN INTERNA Y OPCIONALMENTE UN PÉPTIDO DE REEMPLAZO, OPCIONALMENTE MODIFICADO CON AL MENOS UN AMINOÁCIDO CODIFICADO DE MANERA NO NATURAL, Y/U OPCIONALMENTE FUSIONADO A UN COMPONENTE DE FUSIÓN.</p>",BRISTOL MYERS SQUIBB CO,CAMPHAUSEN RAY;;LIPOVSEK DASA;;MUKHERJEE RANJAN;;MORIN PAUL E;;COHEN DANIEL;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;KRUPINSKI JOHN,,https://lens.org/113-040-597-397-155,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,PENDING
363,US,A1,US 2016/0016499 A1,135-261-520-224-683,2016-01-21,2016,US 201514754421 A,2015-06-29,US 201514754421 A;;US 201414332276 A,2014-07-15,MOBILITY SECUREMENT SYSTEM,"A mobility securement system, and method for securing a wheelchair or other mobility device, and its passenger, within a public or private vehicle. In various embodiments, the system includes one or two attachment members, one or two vehicle anchor assemblies and, potentially, at least one fixed or moveable bumper, and may further include a barrier. A tensioning assembly is operably connected to at least one attachment member and vehicle anchor assembly. One or more moveable bumpers may articulate to apply a force against the mobility device, and one attachment member may be hidden behind a stored position of a moveable bumper.",4ONE LLC,HAMMARSKJOLD CHRISTIAN;;BALEF VLAD;;BRZEZNIAK STANLEY;;KRUEGER JEFFREY;;MOFFA MICHAEL D;;SMITH-COHEN DAN;;VIDRI PAUL;;MURPHY TIMOTHY J,USSC ACQUISITION CORP (2017-10-18);;4ONE LLC (2015-06-29),https://lens.org/135-261-520-224-683,Patent Application,yes,2,9,4,11,0,A61G3/0808;;A61G3/0808;;A61G3/08;;A61G2220/16;;B60P3/06;;B60P3/073;;B60P3/079;;B60P7/0807;;B60P7/0823;;B60P7/0892;;B60P7/135,B60P3/079;;B60P7/08;;B60P7/16,,0,0,,,,ACTIVE
364,US,A1,US 2018/0243375 A1,157-916-989-389-402,2018-08-30,2018,US 201815979881 A,2018-05-15,US 201815979881 A;;US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201562141383 P;;US 201562141337 P;;US 201462068526 P;;US 201462068523 P;;US 201462068514 P;;US 201462068296 P;;US 201462068534 P,2014-10-24,Modified FGF-21 Polypeptides and Uses Thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/157-916-989-389-402,Patent Application,yes,0,1,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/18,,0,0,,,,ACTIVE
365,BR,A2,BR 112017008157 A2,073-254-667-381-525,2017-12-19,2017,BR 112017008157 A,2015-10-23,US 2015/0057228 W;;US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,polipeptídeos de fgf-21 modificados e usos dos mesmos,"são fornecidos polipeptídeos de fgf-21 modificados e usos dos mesmos, por exemplo, para o tratamento de doenças associadas à fibrose. são descritos polipeptídeos de fgf-21 modificados que contêm uma eliminação interna e opcionalmente um peptídeo de substituição, opcionalmente modificado com pelo menos um aminoácido não naturalmente codificado e/ou opcionalmente fundido com um parceiro de fusão.",BRISTOL MYERS SQUIBB CO,DANIEL COHEN;;DASA LIPOVSEK;;JOHN KRUPINSKI;;PAUL E MORIN;;RANJAN MUKHERJEE;;RAY CAMPHAUSEN;;ROSE C CHRISTIAN;;TIMOTHY P REILLY,,https://lens.org/073-254-667-381-525,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,DISCONTINUED
366,CO,A2,CO 2017004489 A2,160-546-286-830-524,2017-09-20,2017,CO 2017004489 A,2017-05-03,US 2015/0057228 W;;US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Polipéptidos fgf-21 modificados,"La presente invención se refiere a polipéptidos FGF-21 modificados y usos de los mismos, por ejemplo, para el tratamiento de enfermedades asociadas a la fibrosis. Se describen polipéptidos FGF-21 modificados que contienen una supresión interna y opcionalmente un péptido de reemplazo, opcionalmente modificado con al menos un aminoácido codificado de manera no natural, y/u opcionalmente fusionado a un componente de fusión.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/160-546-286-830-524,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,PENDING
367,CN,A,CN 114853868 A,035-738-747-520-217,2022-08-05,2022,CN 202210088395 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;CN 201580070276 A;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of fibrosis-related diseases. Modified FGF-21 polypeptides containing an internal deletion and optionally a replacement peptide are disclosed, optionally modified with at least one non-naturally encoded amino acid and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DAVID;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/035-738-747-520-217,Patent Application,no,2,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50,,2,1,082-340-378-650-984,24685265;;10.1016/j.biomaterials.2014.03.023,"高德民等: ""多肽类药物结构稳定性的研究进展"", 中国医药生物技术, vol. 2, no. 5, pages 380 - 382;;LINTAO SONG，ET AL.: ""A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog"", BIOMATERIALS, vol. 5, no. 19, pages 5206 - 5215, XP028847278, DOI: 10.1016/j.biomaterials.2014.03.023",PENDING
368,AU,B2,AU 2020/210152 B2,109-540-116-803-21X,2022-07-21,2022,AU 2020/210152 A,2020-07-27,AU 2020/210152 A;;AU 2015/335603 A;;US 201462068296 P;;US 201562141383 P;;US 201562141337 P;;US 201462068534 P;;US 201462068526 P;;US 201462068514 P;;US 201462068523 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/109-540-116-803-21X,Granted Patent,no,1,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00,,0,0,,,,ACTIVE
369,US,B2,US 9434778 B2,186-129-669-738-756,2016-09-06,2016,US 201514921796 A,2015-10-23,US 201514921796 A;;US 201462068526 P;;US 201462068534 P;;US 201562141383 P;;US 201462068514 P;;US 201462068523 P;;US 201562141337 P;;US 201462068296 P,2014-10-24,Modified FGF-21 polypeptides comprising an internal deletion and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/186-129-669-738-756,Granted Patent,yes,99,19,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K39/395;;A61K45/06;;A61K47/48;;C07K14/50,,99,92,018-351-785-584-614;;094-815-381-871-763;;081-753-724-687-173;;079-274-785-935-791;;063-155-730-882-853;;067-127-654-169-729;;048-972-529-594-020;;054-304-933-298-139;;017-049-171-562-572;;099-270-483-107-007;;142-164-397-210-970;;104-283-497-946-575;;046-036-272-703-281;;075-912-302-795-48X;;111-570-270-686-786;;077-066-325-033-341;;029-811-479-361-870;;000-654-286-546-079;;012-837-528-765-07X;;069-296-641-163-256;;039-149-059-983-63X;;065-815-544-501-870;;019-394-264-649-327;;046-262-147-203-697;;008-125-648-563-747;;030-861-724-466-58X;;015-214-531-219-780;;028-383-058-454-759;;135-513-407-563-622;;058-530-733-727-374;;013-392-307-146-301;;063-864-581-855-676;;003-416-495-423-02X;;016-250-517-165-602;;038-624-922-825-362;;035-070-408-027-340;;049-937-366-109-256;;010-030-039-052-116;;061-267-522-126-985;;089-860-020-044-940;;040-712-467-075-177;;013-754-548-416-363;;030-425-714-928-399;;035-769-575-764-291;;104-335-738-580-036;;007-480-305-123-598;;056-201-471-905-934;;028-862-168-091-90X;;070-383-251-783-098;;028-567-118-036-513;;005-712-635-226-116;;090-754-759-154-175;;050-825-529-117-306;;028-540-973-166-319;;045-951-701-636-236;;150-512-327-210-48X;;022-997-664-996-345;;047-237-206-017-563;;017-940-142-904-249;;081-098-345-341-182;;010-847-093-078-575;;027-829-588-585-761;;153-232-460-964-283;;158-261-806-420-924;;126-128-839-153-523;;006-504-311-182-612;;098-808-864-401-942;;122-388-810-565-095;;126-434-971-916-802;;062-095-790-501-25X;;083-348-315-692-16X;;085-498-590-431-913;;096-352-881-129-295;;141-785-095-849-82X;;104-063-848-067-130;;069-591-544-766-903;;027-127-290-904-954;;010-872-968-433-256;;037-574-244-923-342;;095-163-015-743-716;;018-560-322-257-247;;078-629-783-492-046;;032-905-603-444-928;;068-050-852-096-624;;029-171-836-207-263;;028-668-540-796-174;;001-137-247-333-266;;001-076-067-628-36X;;005-893-666-286-846;;079-996-842-246-699;;039-289-782-216-880;;043-632-912-449-253,10.1021/ja00203a067;;3156376;;pmc397196;;10.1073/pnas.82.4.1074;;10.1021/ja010731e;;11472182;;7482665;;10.1161/01.str.26.11.2154;;7737407;;10.1016/0014-5793(95)00324-3;;11317312;;29712367;;10.1002/1521-3773(20010417)40:8<1494::aid-anie1494>3.0.co;2-x;;3001650;;10.1093/nar/13.24.8765;;pmc318950;;pmc318949;;10.1093/nar/13.24.8749;;3001649;;6368319;;10.1016/0378-1119(83)90191-9;;10.1016/0168-3659(85)90001-x;;10.1021/jo011148j;;11975567;;7620563;;10.1385/0-89603-272-8:97;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;6248420;;10.1016/0378-1119(80)90133-x;;10.1016/s1046-5928(02)00641-1;;12651100;;10.1074/jbc.271.33.19991;;8702716;;8402094;;10.1002/bjs.1800800812;;10.1038/nbt0290-135;;1366557;;10.1056/nejmoa011300;;11794168;;9645477;;10.1016/s0014-5793(98)00489-x;;10.1021/ja992749j;;10.1128/jb.130.2.946-947.1977;;400800;;pmc235301;;10.1007/bf02798546;;4026282;;3128641;;10.1099/0022-1317-69-4-765;;pmc140882;;12518054;;10.1073/pnas.0234824100;;10.1126/science.1060077;;11313494;;10.1021/ja021381e;;12630856;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/0378-1119(85)90140-4;;3891521;;10.1002/(sici)1097-0177(199709)210:1<41::aid-aja5>3.0.co;2-1;;9286594;;10.1016/s0960-9822(95)00102-3;;7583099;;0007583099;;10.1021/bc00023a002;;8274513;;10.1016/0141-0229(92)90049-t;;1368988;;10.1038/321718a0;;pmc344858;;6324193;;10.1073/pnas.81.5.1470;;pmc327233;;10.1093/nar/9.3.731;;6164048;;1785805;;10.1111/j.1749-6632.1991.tb49015.x;;10.1016/0014-3057(83)90016-2;;10.1021/bc00032a002;;7599259;;10.2337/diacare.24.4.720;;11315837;;10.1021/bi0300231;;12779328;;6225933;;10.1016/b978-0-12-765560-4.50036-8;;10.1016/0076-6879(83)00074-9;;6757864;;pmc326938;;10.1093/nar/10.20.6487;;10.1016/0076-6879(87)54083-6;;3323811;;6467175;;10.2337/diacare.25.5.869;;11978683;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;6363212;;10.1016/0378-1119(83)90222-6;;11880038;;10.1016/s1074-5521(02)00094-7;;10.1002/macp.1978.021790204;;10.1023/a:1015825027737;;2052513;;7763976;;10.1016/0958-1669(93)90011-k;;10.2337/diacare.15.6.755;;1600835;;1560827;;10.1038/356537a0;;10.1021/ja00202a052;;1911037;;6220717;;10.1016/0006-291x(83)91828-4;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;10.1016/s0040-4020(01)90305-9;;10.1126/science.3140377;;3140377;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;6757758;;10.1038/300706a0;;10.1016/s0040-4039(01)90461-7;;10.1016/0003-2697(83)90131-8;;6193731;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.3.co;2-c;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.0.co;2-5;;9050787;;10.2337/diabetes.45.11.1572;;10.2337/diab.45.11.1572;;8866563;;875032;;10.1016/s0022-2836(77)80200-3;;10.1016/0197-0186(94)90047-7;;7950964;;10.1016/s0021-9258(18)82348-1;;8340419;;10.1038/nsb0594-283;;7664033;;2994214;;10.1126/science.2994214;;1733123;;10.1093/ajcn/55.2.538s;;10.3109/03639049209046327;;8352595;;10.1146/annurev.bi.62.070193.002411;;1332541;;10.1016/0003-2697(92)90433-8;;10.1006/jmbi.1997.1132;;9245591;;10.1111/j.1432-1033.1995.0788h.x;;10.1111/j.1432-1033.1995.tb20622.x;;7607253;;10.1096/fasebj.13.1.41;;9872928;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;10.1006/prep.1997.0744;;9226723;;10.1016/s0169-409x(03)00108-x;;14499706;;10.1111/j.1440-1681.1978.tb00650.x;;639358;;pmc252500;;2993646;;10.1128/jvi.56.1.153-160.1985;;10.1021/jo034984x;;14604354;;10.1016/0076-6879(87)54086-1;;2828857;;pmc321798;;10.1093/nar/13.12.4431;;2989795;;3541892;;10.1042/bj2370001;;pmc1146940;;2438771;;10.1126/science.2438771;;7030620;;10.3109/10409238109108703;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203,"Switzer, C. et al., ""Enzymatic incorporation of a new base pair into DNA and RNA"", J. Am. Chem. Soc., 1989, 111(21): 8322-8323.;;Tabor, S. and Richardson, C.C., ""A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes"", Proc. Natl. Acad. Sci. USA, Feb. 1985, 82(4): 1074-8.;;Tae, E.L. et al., ""Efforts toward Expansion of the Genetic Alphabet: Replication of DNA with Three Base Pairs"", J. Am. Chem. Soc., 2001, 123(3): 7439-7440.;;Tanaka, R. et al., ""Basic fibroblast growth factor increases regional cerebral blood flow and reduces infarct size after experimental ischemia in a rat model"", Stroke, 1995, 26: 2154-2159.;;Tanaka, A. et al., ""Human androgen-induced growth factor in prostate and breast cancer cells: its molecular cloning and growth properties"", FEBS Lett., 1995, 363: 226-230.;;Tang, Y. et al., ""Fluorinated Coiled-Coil Protiens Prepared In Vivo Display Enhanced Thermal and Chemical Stability"", Angew. Chem. Int. Ed. Engl., Apr. 17, 2001, 40(8): 1494-1496.;;Taylor, J.W. et al., ""The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA"", Nucleic Acids Res., Dec. 20, 1985, 13(24): 8765-85.;;Taylor, J.W. et al., ""The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA"", Nucleic Acids Res., Dec. 20, 1985, 13(24): 8749-64.;;Tijssen, P., ""Overview of principles of hybridization and the strategy of nucleic acid assays"", in Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Probes, v. 24, Part I, 1993, Elsevier Science Publishers, Amsterdam, 19-78.;;Tilburn, J. et al., ""Transformation by integration in Aspergillus nidulans"", Gene, Dec. 1983, 26(2-3): 205-21.;;Tilkins, M.L et al., ""Transfection of Mammalian and Invertebrate Cells Using Cationic Lipids"", Cell Biology: A Laboratory Handbook, 1998, 2nd Ed., vol. 4: 145-154.;;Tondelli, L. et al., ""Poly(ethylene Glycol) Imidazolyl Formates as Oligomeric Drug-Binding Matrices"", J. Controlled Release 1985, 1(4): 251-257.;;Tornøe, C.W. et al., ""Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides"", J. Org. Chem., May 3, 2002, 67(9): 3057-3064.;;Trotter, K.M. and Wood, H.A., ""Transfection techniques for producing recombinant baculoviruses"", in Methods in Molecular Biology-Baculovirus Expression Protocols, vol. 39 (1995); Ed. C.D. Richardson, 97-107.;;Truett, G.E. et al., ""Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene liabetes (db)"", PNAS USA, 1991, 88: 7806-09.;;Tschumper, G. and Carbon, J., ""Sequence of a yeast DNA fragment containing a chromosomal recplicator and the TRP1 gene"", Gene 1980, 10(2): 157-166.;;Tsumoto, K et al., ""Practical considerations in refolding proteins from inclusion bodies"", Protein Expr. Purif., Mar. 2003, 28(1): 1-8.;;Turcatti, G. et al., ""Probing the structure and function of the tachykinin neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at specific sites"", J. Biol. Chem., Aug. 16, 1996, 271(33): 19991-8.;;Uhl, E. et al., ""Basic fibroblast growth factor accelerates wound healing in chronically ischaemic tissue"", Br. J. Surg., 1993, 80: 977-980.;;Van Den Berg, J.A. et al., ""Kluyveromyces as a host for heterologous gene expression: expression and secretion of prochymosin"", Biotechnology (NY), Feb. 1990, 8(2): 135-139.;;Van den Berghe, G.V. et al., ""Intensive insulin therapy in the critically ill patients"", N. Engl. J. Med., 2001, 345(19): 1359-67.;;Van Hest, J.C.M. and Tirrell, D.A., ""Efficient introduction of alkene functionality into proteins in vivo"", FEBS Lett. May 22, 1998, 428(1-2): 68-70.;;Van Hest, J.C.M. et al., ""Efficient incorporation of Unsaturated Methionine Analogues into Proteins in Vivo"", J. Am. Chem. Soc., 2000, 122(7): 1282-1288.;;Van Solingen, P. and van der Plaat, J.B., ""Fusion of yeast spheroplasts"", J. Bacteriol. May 1977, 130(2): 946-947.;;Veronese, F.M. et al., ""Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchlorofomates and modification of ribonuclease and superoxide dismutase"", Appl. Biochem. Biotechnol., Apr. 1985, 11(2): 141-152.;;Vlak, J.M. et al., ""Functional studies on the p10 gene of Autographa californica nuclear polyhedrosis virus using a recombinant expressing a p10-beta-galactosidase fusion gene"", J. Gen. Virol., Apr. 1988, 69(Pt. 4): 765-776.;;Wang, L and Shultz, P.G., ""Expanding the genetic code"", Chem. Commun. (Camb.), Jan. 7, 2002, 1:1-11.;;Wang, L et al., ""Addition of the keto functional group to the genetic code of Escherichia coli"", Proc. Natl. Acad. Sci, 2003, 100(1): 56-61.;;Wang, L. et al., ""Expanding the genetic code of Escherichia coli"", Science. Apr. 20, 2001, 292(5516): 498-500.;;Wang, Q. et al., ""Bioconjugation by Copper(I)-Catalyzed Azide-Alkyne [3+2] Cycloaddition"", J. Am. Chem. Soc., 2003, 125(11): 3192-3193.;;Wang, W., ""Instability, stabilization, and formulation of liquid protein pharmaceuticals"", Int. J. Pharm., Aug. 20, 1999, 185(2): 129-88.;;Weissmann, C., ""The cloning of interferon and other mistakes"", in Interferon 3, 1981. Ed. I. Gresser; Academic Press, London, 101-134.;;Wells, J.A. et al., ""Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites"", Gene. 1985, 34(2-3): 315-23.;;Wells, J.A. et al., ""Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin"", Phil. Trans. R. Soc. Lond. A 1986. 317:415-423.;;Wilke, T.A. et al., ""Expression of fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3) in the developing head and face"", Dev. Dynam., 1997, 210: 41-52.;;Wilkie, A.O.M. et al., ""Functions of fibroblast growth factors and their receptors"", Current Biology, 1995, 5(5): 500-507.;;Woghiren, C. et al., ""Protected thiol-polytheylene glycol: a new activated polymer for reversible protein modification"", Bioconjug. Chem., Sep.-Oct. 1993, 4(5): 314-8.;;Wong, S.S. and Wong, L-J.C., ""Chemical crosslinking and the stabilization of proteins and enzymes"", Enzyme Microb. Technol., Nov. 1992, 14(11): 866-874.;;Wright, K., ""Biotechnology: Insect virus as super-vector?"", Nature, 1986, 321(6072): 718.;;Yelton, M.M. et al., ""Transformation of Aspergillus nidulans by using a trpC plasmid"", Proc. Natl. Acad. Sci. USA, Mar. 1984, 81(5): 1470-4.;;Yelverton, E. et al, ""Bacterial synthesis of a novel human leukocyte interferon"", Nucleic Acids Res., Feb. 11, 1981, 9(3): 731-741.;;Yoshida, T. et al., ""Characterization of the hst-1 gene and its product"", Ann. NY Acad. Sci., 1991, 638:27-37.;;Zalipsky, S. et al., ""Attachment of drugs to polyethylene glycols"", Eur. Polymer Journal, 1983, 19(12): 1177-83.;;Zalipsky, S., ""Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates"", Bioconjug. Chem., Mar.-Apr. 1995, 6(2): 150-165.;;Zander, M. et al. ""Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes"", Diabetes Care, 2001, 24(4): 720-5.;;Zhang, Z. et al., ""A new strategy for the site-specific modification of proteins in vivo"", Biochemistry. Jun. 10, 2003, 42(22): 6735-46.;;Zoller, M.J. and Smith, M., ""Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors"", Methods Enzymol., 1983, 100: 468-500.;;Zoller, M.J. and Smith, M., ""Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the producaiton of point mutations in any fragment of DNA"", Nucleic Acids Res., Oct. 25, 1982, 10(20): 6487-500.;;Zoller, M.J. and Smith, M., ""Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template"", Methods Enzymol., 1987, 154: 329-50.;;Abuchowski, A. et al., ""Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates"", Cancer Biochem. Biophys., Jun. 1984, 7(2): 175-86.;;Ahrén, B. et al., ""Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes"", Diabetes Care, 2002, 25(5): 869-75.;;Altschul, S.F. et al., ""Basic local alignment search tool"", J. Mol. Biol., Oct. 5, 1990, 215(3): 403-10.;;Altschul, S.F. et al., ""Gapped BLAST and PSI-BLAST: a new generation of protein database search programs"", Nucleic Acids Res., Sep. 1, 1997, 25(17): 3389-3402.;;Amann, E. et al., ""Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli"", Gene, Nov. 1983, 25(2-3): 167-78.;;Anderson, J.C. et al., ""Exploring the limits of codon and anticodon size"", Chem. Biol., Feb. 2002, 9(2): 237-44.;;Andresz, H. et al., ""Chemische Synthese verzweigter Polysaccharide, 5: Kopplung von Oligosacchariden und Amylose an verschiedene Träer durch Hydrazonbindung"", Makromol. Chem. 1978, 179: 301.;;Arakawa et al., ""Protein-solvent interactions in pharmaceutical formulations"", Pharm. Res., 1991, 8(3): 285-291.;;Arnold, F.H., ""Protein engineering for unusual environments"", Curr. Opin. Biotechnol., Aug. 1993, 4(4): 450-5.;;Azoulay, M. et al., ""Glutamine analogues as Potential Antimalarials"", Eur. J. Med. Chem., 1991, 26(2): 201-5.;;Bailey, ""Biguanides and NIDDM"", Diabetes Care, 1992, 15(6):755-72.;;Bain, J.D. et al., ""Ribosome-mediated incorporation of a non-standard amino acid into a peptide through expansion of the genetic code"", Nature, 1992, 356(6369): 537-539.;;Bain, J.D. et al., ""Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide"", J. Am. Chem. Soc., 1989; 111(20): 8013-8014.;;Baird, A. and Klagsbum, M., ""The fibroblast growth factor family"", Cancer Cells, 1991, 3(6): 239-43.;;Ballance, D.J. et al., ""Transformation of Aspergillus nidulans by the orotidine-5'-phosphate decarboxylase gene of Neurospora crassa"", Biochem. Biophys. Res. Commun., Apr. 15, 1983, 112(1): 284-9.;;Barany, F. et al., ""Genetic disease detection and DNA amplification using cloned thermostable ligase"", Proc. Natl. Acad. Sci. USA, Jan. 1, 1991, 88(1): 189-93.;;Barton, D.H.R. et al., ""Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives"", Tetrahedron, 1987, 43(19): 4297-4308.;;Bass, S. et al., ""Mutant Trp repressors with new DNA-binding specificities"", Science, 1988, 242: 240-245.;;Batzer, M.A. et al., ""Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'-terminus"", Nucleic Acids Res., Sep. 25, 1991, 19(18): 5081.;;Beach, D. et al., ""Functionally homologous cell cycle control genes in budding and fission yeast"", Nature, Dec. 1982, 300: 706-709.;;Beaucage, S.L. and Caruthers, M.H., ""Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis"", Tetrahedron Letts., 1981, 22(20): 1859-1862.;;Beauchamp, C.O. et al., ""A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin"", Anal. Biochem., May 1983, 131(1): 25-33.;;Belluardo, N. et al., ""Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis"", J. Comp. Neurol. (1997) 379(2): 226-46.;;Berkowitz, K. et al., ""Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM"", Diabetes, 1996, 45(11): 1572-9.;;Bernstein, F.C. et al., ""The protein data bank: a computer-based archival file for macromolecular structures"", J. Mol. Biol., 1977, 112: 535-542.;;Biagini, G. et al., The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes, Neurochem. Int., 1994, 25(1): 17-22.;;Boissel, J.P. et al., ""Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure"", Jul. 25, 1993, 268(21): 15983-93.;;Boles, J.O. et al., ""Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase"", Nat. Struct. Biol., May 1994, 1(5): 283-4.;;Botstein, D. and Shortle, D., ""Strategies and applications of in vitro mutagenesis"", Science, Sep. 20, 1985, 229(4719): 1193-201.;;Bray, G.A., ""Drug treatment of obesity"", Am. J. Clin. Nutr., 1992, 55(2 Suppl): 538S-544S.;;Broadhead, J., ""The Spray Drying of Pharmaceuticals"", Drug Dev. Ind. Pharm., 1992, 18(11&12):1169-1206.;;Brunner, J. et al., ""New photolabeling and crosslinking methods"", Annu. Rev. Biochem., 1993, 62: 483-514.;;Buchner, J. et al., ""A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain Immunotoxins from renaturation of bacterial inclusion bodies"", Anal. Biochem., 1992, 205(2): 263-270.;;Bückmann, A.F. and Morr, M., ""Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),"" Makromol. Chem., 1981, 182: 1379-84.;;Budisa, N. et al., ""Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins"", J. Mol. Biol., Jul. 25, 1997, 270(4): 616-23.;;Budisa, N. et al., ""High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli"", Eur. J. Biochem., Jun. 1, 1995, 230(2): 788-96.;;Budisa, N. et al., ""Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire"", FASEB J., Jan. 1999, 13(1): 41-51.;;Burgess, W.H. and Maciag, T., ""The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins"", Annu. Rev. Biochem., 1989, 58: 575-606.;;Cai, X-Y et al., ""Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-Inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells"", Protein Expression and Purifcation, 1997, 10(2): 263-74.;;Caliceti, P. and Veronese, F.M., ""Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates"", Adv. Drug. Deliv. Rev., Sep. 26, 2003, 55(10): 1261-1277.;;Cameron, D.P. et al., ""Effects of monosodium glutamate-induced obesity in mice on carbohydrate metabolism in insulin secretion"", Clin. Exp. Pharmacol. Physiol., 1978, 5(1): 41-51.;;Carbonell, L.F. et al., ""Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells"", J. Virol., Oct. 1985, 56(1): 153-60.;;Carrasco, M.R. and Brown, R.T., ""A Versatile Set of Aminoxy Amino Acids for the Synthesis of Neoglycopeptides"", J. Org. Chem., 2003, 68(23): 8853-8858.;;Carter, P., ""Improved oligonucleotide-directed mutagenesis using M13 vectors"", Methods Enzymol., 1987, 154: 382-403.;;Carter, P., ""Improved oligonucleotide site-directed mutagenesis using M13 vectors"", Nucleic Acids Res., 1985, 13(12): 4431-4443.;;Carter, P., ""Site-directed mutagenesis"", Biochem J., Jul. 1, 1986, 237(1): 1-7.;;Cech, T.R., ""The chemistry of self-splicing RNA and RNA enzymes"", Science, Jun. 19, 1987, 236(4808): 1532-9.;;Chaiken, I.M., ""Semisynthetic peptides and proteins"", CRC Crit. Rev. Biochem., 1981, 11(3): 255-301.;;Chin, J.W. and Schultz, P.G., ""In vivo photocrosslinking with unnatural amino acid mutagenesis"", Chembiochem, Nov. 4, 2002, 3(11): 1135-7.;;Chin, J.W. et al., ""Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli"", Proc. Natl. Acad. Sci. USA, Aug. 20, 2002, 99(17): 11020-4. Epub. Aug. 1, 2002.",ACTIVE
370,CY,T1,CY 1124309 T1,161-864-939-852-203,2022-07-22,2022,CY 211100616 T,2021-07-07,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 15790415 A;;US 2015/0057228 W,2014-10-24,ΤΡΟΠΟΠΟΙΗΜΕΝΑ ΠΟΛΥΠΕΠΤΙΔΙΑ FGF-21 ΚΑΙ ΧΡΗΣΕΙΣ ΕΞ ΑΥΤΩΝ,"Τροποποιημένα πολυπεπτίδια FGF-21 και χρήσεις εξ αυτών παρέχονται, για παράδειγμα, για την αγωγή παθήσεων που σχετίζονται με ίνωση. Τροποποιημένα πολυπεπτίδια FGF-21 αποκαλύπτονται που περιέχουν ένα πεπτίδιο εσωτερικής απαλοιφής και προαιρετικώς αντικατάστασης, προαιρετικώς τροποποιημένο με τουλάχιστον ένα μη-φυσικώς εγκωδικευθέν αμινοξύ, και/ή προαιρετικώς που συντήκεται σε έναν εταίρο σύντηξης.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN;;COHEN DANIEL,,https://lens.org/161-864-939-852-203,Granted Patent,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,ACTIVE
371,US,B2,US 10702429 B2,002-697-212-585-780,2020-07-07,2020,US 201715409076 A,2017-01-18,US 201715409076 A;;US 201514754421 A;;US 201414332276 A,2014-07-15,Mobility securement system,"A mobility securement system, and method configured to secure a wheelchair or other mobility device, and its passenger, within a public or private vehicle. In various embodiments, the system includes one or two attachment members, one or two vehicle anchor assemblies and, potentially, at least one fixed or moveable bumper, and may further include a barrier. A tensioning assembly is operably connected to at least one attachment member and vehicle anchor assembly. One or more moveable bumpers are configured to articulate to apply a force against the mobility device, and one attachment member may be hidden behind a stored position of a moveable bumper.",4ONE LLC;;USSC ACQUISITION CORP,HAMMARSKJOLD CHRISTIAN;;BALEF VLAD;;BRZEZNIAK STANLEY;;KRUEGER JEFFREY;;MOFFA MICHAEL D;;SMITH-COHEN DAN;;VIDRI PAUL;;MURPHY TIMOTHY J,USSC ACQUISITION CORP (2017-10-18);;4ONE LLC (2015-06-29),https://lens.org/002-697-212-585-780,Granted Patent,yes,69,1,4,11,0,A61G3/0808;;A61G3/0808;;A61G3/08;;A61G2220/16;;B60P3/06;;B60P3/073;;B60P3/079;;B60P7/0807;;B60P7/0823;;B60P7/0892;;B60P7/135,B60P7/08;;A61G3/08;;B60P3/06;;B60P3/073;;B60P3/079;;B60P7/135,,0,0,,,,ACTIVE
372,CN,A,CN 110078814 A,027-767-471-399-278,2019-08-02,2019,CN 201811440663 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;CN 201580070276 A,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/027-767-471-399-278,Patent Application,no,2,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K45/06;;A61K47/60;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P11/00;;A61P13/12;;C12N15/12,,0,0,,,,PENDING
373,AU,B2,AU 2015/335603 B2,115-272-603-287-354,2020-04-30,2020,AU 2015/335603 A,2015-10-23,US 201462068296 P;;US 201562141383 P;;US 201562141337 P;;US 201462068534 P;;US 201462068526 P;;US 201462068514 P;;US 201462068523 P;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/115-272-603-287-354,Granted Patent,no,1,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00,,0,0,,,,ACTIVE
374,CN,A,CN 107108710 A,084-274-212-128-950,2017-08-29,2017,CN 201580070276 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/084-274-212-128-950,Patent Application,no,4,9,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K45/06;;A61K47/60;;A61P1/16;;A61P3/04;;A61P3/10;;A61P9/00;;A61P9/04;;A61P11/00;;A61P13/12;;C12N15/12,,2,0,,,"LINTAO SONG等: ""A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog"", 《BIOMATERIALS》;;叶贤龙: ""聚乙二醇修饰的成纤维细胞生长因子-21的降血糖作用"", 《生物化学与生物物理进展》",ACTIVE
375,CA,A1,CA 2965502 A1,157-412-156-881-014,2016-04-28,2016,CA 2965502 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/157-412-156-881-014,Patent Application,no,0,0,60,64,302,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,PENDING
376,EA,B1,EA 036697 B1,191-023-617-979-967,2020-12-09,2020,EA 201790895 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/191-023-617-979-967,Granted Patent,no,2,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,ACTIVE
377,JP,A,JP 2020182462 A,184-524-185-222-929,2020-11-12,2020,JP 2020082076 A,2020-05-07,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"To provide activity and production of FGF-21 polypeptides, production of an FGF-21 polypeptide with improved biological or pharmacological properties, such as an improved therapeutic half-life, and methods of treating or preventing disorders.SOLUTION: Provided herein are modified FGF-21 polypeptides comprising a polypeptide having an amino acid sequence selected from specific sequences, except that the amino acid sequence comprises: (i) an internal deletion of 5-19 adjacent amino acids, where the internal deletion is within a region corresponding to amino acids 116 to 134 of a specific sequence, where the internal deletion is replaced by a replacement peptide having a length of 0-12 amino acids; and (ii) 9 or fewer additional amino acid substitutions, deletions and/or insertions.SELECTED DRAWING: Figure 3",BRISTOL MYERS SQUIBB CO,PAUL E MORIN;;DANIEL COHEN;;RANJAN MUKHERJEE;;TIMOTHY P REILLY;;ROSE C CHRISTIAN;;DASA LIPOVSEK;;RAY CAMPHAUSEN;;JOHN KRUPINSKI,,https://lens.org/184-524-185-222-929,Patent Application,no,2,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C12N15/12;;A61K31/133;;A61K31/155;;A61K31/4439;;A61K31/445;;A61K31/7034;;A61K38/22;;A61K38/28;;A61K45/00;;A61K47/54;;A61K47/60;;A61K47/64;;A61K47/65;;A61K47/68;;A61P1/04;;A61P1/16;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P25/00;;A61P27/02;;A61P27/12;;A61P29/00;;A61P43/00;;C07K14/50;;C07K16/00;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/62;;C12N15/63;;C12P21/02,,0,0,,,,ACTIVE
378,WO,A3,WO 2016/065326 A3,029-756-569-071-149,2016-06-16,2016,US 2015/0057228 W,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/029-756-569-071-149,Search Report,yes,2,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00,,0,0,,,,PENDING
379,US,A1,US 2017/0189486 A1,079-550-197-013-334,2017-07-06,2017,US 201715460917 A,2017-03-16,US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/079-550-197-013-334,Patent Application,yes,0,5,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/18,,0,0,,,,ACTIVE
380,PL,T3,PL 3412302 T3,097-384-528-876-006,2021-11-02,2021,PL 18177893 T,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 18177893 A;;EP 15790415 A;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/097-384-528-876-006,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,PENDING
381,US,A1,US 2017/0128290 A1,131-859-370-484-201,2017-05-11,2017,US 201715409076 A,2017-01-18,US 201715409076 A;;US 201514754421 A;;US 201414332276 A,2014-07-15,MOBILITY SECUREMENT SYSTEM,"A mobility securement system, and method configured to secure a wheelchair or other mobility device, and its passenger, within a public or private vehicle. In various embodiments, the system includes one or two attachment members, one or two vehicle anchor assemblies and, potentially, at least one fixed or moveable bumper, and may further include a barrier. A tensioning assembly is operably connected to at least one attachment member and vehicle anchor assembly. One or more moveable bumpers are configured to articulate to apply a force against the mobility device, and one attachment member may be hidden behind a stored position of a moveable bumper.",4ONE LLC,HAMMARSKJOLD CHRISTIAN;;BALEF VLAD;;BRZEZNIAK STANLEY;;KRUEGER JEFFREY;;MOFFA MICHAEL D;;SMITH-COHEN DAN;;VIDRI PAUL;;MURPHY TIMOTHY J,USSC ACQUISITION CORP (2017-10-18);;4ONE LLC (2015-06-29),https://lens.org/131-859-370-484-201,Patent Application,yes,1,4,4,11,0,A61G3/0808;;A61G3/0808;;A61G3/08;;A61G2220/16;;B60P3/06;;B60P3/073;;B60P3/079;;B60P7/0807;;B60P7/0823;;B60P7/0892;;B60P7/135,A61G3/08;;B60P7/08,,0,0,,,,ACTIVE
382,AU,A1,AU 2015/335603 A1,143-348-171-226-18X,2017-05-04,2017,AU 2015/335603 A,2015-10-23,US 201462068296 P;;US 201562141383 P;;US 201562141337 P;;US 201462068534 P;;US 201462068526 P;;US 201462068514 P;;US 201462068523 P;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/143-348-171-226-18X,Patent Application,no,0,1,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00,,0,0,,,,ACTIVE
383,US,A1,US 2022/0185856 A1,167-118-716-729-092,2022-06-16,2022,US 202117555633 A,2021-12-20,US 202117555633 A;;US 201916455990 A;;US 201815979881 A;;US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201562141383 P;;US 201562141337 P;;US 201462068526 P;;US 201462068523 P;;US 201462068514 P;;US 201462068296 P;;US 201462068534 P,2014-10-24,Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/167-118-716-729-092,Patent Application,yes,5,1,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64,,0,0,,,,PENDING
384,DK,T3,DK 3412302 T3,000-628-237-834-059,2021-07-12,2021,DK 18177893 T,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;EP 15790415 A,2014-10-24,MODIFICEREDE FGF-21-POLYPEPTIDER OG ANVENDELSER DERAF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/000-628-237-834-059,Granted Patent,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,ACTIVE
385,US,B2,US 11248031 B2,017-625-892-545-345,2022-02-15,2022,US 201916455990 A,2019-06-28,US 201916455990 A;;US 201815979881 A;;US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201562141383 P;;US 201562141337 P;;US 201462068526 P;;US 201462068523 P;;US 201462068514 P;;US 201462068296 P;;US 201462068534 P,2014-10-24,Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/017-625-892-545-345,Granted Patent,yes,416,3,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/18;;A61K38/00;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,445,416,096-395-044-694-051;;092-139-783-170-608;;034-492-937-769-693;;086-268-238-549-755;;128-415-609-095-377;;034-180-357-801-690;;078-753-778-060-01X;;008-135-071-759-92X;;014-651-132-335-556;;003-209-696-707-713;;082-340-378-650-984;;104-335-738-580-036;;007-480-305-123-598;;072-942-676-077-691;;056-201-471-905-934;;028-862-168-091-90X;;070-383-251-783-098;;028-567-118-036-513;;005-712-635-226-116;;090-754-759-154-175;;050-825-529-117-306;;028-540-973-166-319;;045-951-701-636-236;;150-512-327-210-48X;;022-997-664-996-345;;047-237-206-017-563;;017-940-142-904-249;;081-098-345-341-182;;010-847-093-078-575;;027-829-588-585-761;;153-232-460-964-283;;158-261-806-420-924;;126-128-839-153-523;;006-504-311-182-612;;098-808-864-401-942;;122-388-810-565-095;;126-434-971-916-802;;062-095-790-501-25X;;083-348-315-692-16X;;085-498-590-431-913;;096-352-881-129-295;;141-785-095-849-82X;;104-063-848-067-130;;069-591-544-766-903;;027-127-290-904-954;;010-872-968-433-256;;037-574-244-923-342;;095-163-015-743-716;;018-560-322-257-247;;078-629-783-492-046;;032-905-603-444-928;;068-050-852-096-624;;029-171-836-207-263;;028-668-540-796-174;;028-668-540-796-174;;001-076-067-628-36X;;005-893-666-286-846;;004-965-380-380-515;;079-996-842-246-699;;039-289-782-216-880;;043-632-912-449-253;;006-451-527-297-818;;032-412-591-971-193;;050-491-094-261-212;;061-186-684-189-36X;;041-610-673-797-380;;048-739-184-191-048;;061-770-380-357-689;;023-157-064-831-058;;005-785-820-497-820;;030-617-186-856-219;;004-571-213-214-147;;117-298-184-780-248;;139-370-722-026-325;;022-717-243-626-689;;001-168-243-787-836;;003-692-671-892-767;;146-959-413-651-106;;009-255-453-457-663;;022-597-328-979-199;;097-412-635-296-694;;015-907-704-662-089;;026-151-208-979-214;;101-171-874-734-776;;007-242-440-136-566;;010-401-085-673-837;;036-787-898-930-499;;010-929-566-271-076;;027-221-602-638-634;;100-286-864-518-416;;012-388-439-961-094;;055-509-434-690-182;;032-004-299-797-893;;030-979-115-550-499;;022-879-584-224-460;;084-341-539-493-404;;088-437-095-235-130;;027-177-154-094-913;;020-026-183-926-325;;019-911-024-298-495;;120-184-720-533-797;;030-130-464-546-217;;110-094-292-858-47X;;091-231-835-456-006;;005-631-024-674-820;;101-575-504-070-651;;005-426-365-134-686;;005-316-633-999-516;;008-878-757-321-700;;008-340-022-598-528;;004-574-009-337-856;;063-797-097-486-664;;169-736-421-398-039;;105-994-509-610-153;;040-375-581-789-283;;029-884-043-437-78X;;013-673-906-914-932;;093-281-504-176-200;;005-433-555-845-783;;064-029-904-826-616;;014-268-011-522-679;;047-362-058-327-502;;059-408-333-766-70X;;062-061-052-321-497;;042-364-181-188-082;;113-394-540-007-150;;001-833-327-326-444;;089-193-344-157-806;;007-026-917-931-385;;113-109-583-058-980;;110-902-470-115-883;;047-294-079-836-486;;002-425-038-765-735;;038-346-034-366-375;;066-146-798-965-262;;021-089-222-463-71X;;007-168-099-008-401;;031-957-451-453-064;;109-373-051-579-919;;030-859-841-509-259;;045-237-747-815-813;;017-239-464-122-703;;002-921-094-507-370;;050-017-203-544-775;;104-277-007-929-625;;008-135-071-759-92X;;018-958-246-350-086;;059-853-971-443-396;;023-907-179-348-058;;052-839-106-430-915;;075-807-103-343-793;;080-050-592-171-046;;031-166-703-585-08X;;189-306-471-756-979;;041-428-113-293-001;;038-037-978-931-264;;019-654-552-765-603;;036-786-233-907-636;;018-078-335-572-806;;099-290-765-461-205;;030-761-388-449-490;;051-260-923-190-254;;052-143-608-436-131;;008-226-221-097-647;;078-209-348-576-455;;089-633-612-001-004;;120-710-247-962-517;;002-945-101-700-774;;037-194-000-791-81X;;146-280-751-006-918;;182-139-657-761-848;;043-147-746-491-691;;041-189-067-181-870;;012-637-499-221-105;;135-885-609-471-475;;022-238-533-842-744;;048-389-287-506-180;;018-989-643-656-697;;041-329-647-699-213;;043-596-978-783-486;;019-779-601-634-917;;053-128-465-484-881;;058-589-196-667-041;;099-108-177-239-268;;026-597-138-156-613;;046-158-519-832-735;;062-670-857-477-054;;084-734-056-460-170;;032-045-779-752-652;;033-733-139-064-996;;009-333-452-920-135;;010-850-616-527-606;;095-359-992-848-941;;083-360-261-831-129;;068-601-220-787-847;;011-377-674-907-872;;040-687-947-392-591;;179-552-640-659-549;;015-623-518-697-144;;025-944-755-967-03X;;035-537-674-004-113;;067-220-965-320-998;;007-005-818-132-358;;141-920-816-342-666;;006-873-363-111-668;;078-886-911-253-419;;023-874-622-768-279;;053-908-725-120-441;;027-033-711-563-119;;084-382-055-323-434;;015-841-839-428-08X;;017-399-857-000-881;;094-876-980-967-766;;053-901-990-601-316;;114-407-414-536-306;;092-380-940-527-529;;035-330-063-258-167;;009-136-082-279-13X;;055-788-913-950-003;;050-513-346-896-80X;;031-933-089-611-974;;000-133-235-371-009;;000-221-503-463-330;;081-452-111-536-816;;019-590-397-412-17X;;074-470-423-479-932;;128-901-299-587-74X;;010-020-681-821-091;;042-423-418-475-539;;041-750-601-903-10X;;068-821-001-542-983;;018-934-238-795-193;;011-020-186-750-886;;117-492-031-514-87X;;065-162-993-535-51X;;081-507-984-297-637;;027-990-295-239-719;;001-466-527-996-328;;027-826-420-479-03X;;077-140-409-267-690;;087-464-638-639-025;;025-146-253-241-793;;000-267-213-967-50X;;093-724-494-618-609;;124-275-393-571-41X;;068-521-955-594-560;;031-066-822-995-403;;034-499-243-336-537;;078-020-406-613-471;;045-362-643-830-026;;127-640-340-609-818;;029-041-317-917-380;;012-193-937-990-576;;013-039-312-104-66X;;030-226-878-795-594;;011-923-052-324-723;;011-552-704-333-933;;138-638-667-066-487;;012-668-687-960-29X;;020-473-776-487-596;;029-402-092-523-225;;021-724-385-934-424;;003-036-556-540-859;;000-647-267-694-484;;066-662-118-303-62X;;053-660-915-978-91X;;097-773-387-318-439;;010-159-493-399-221;;036-036-233-972-857;;064-538-717-151-364;;122-373-655-693-959;;003-813-666-853-382;;074-744-973-712-298;;160-519-052-068-705;;044-306-689-778-275;;129-273-407-931-838;;032-728-154-591-070;;020-704-332-523-176;;095-036-407-766-923;;050-741-722-639-562;;005-001-316-365-345;;029-653-102-379-412;;082-863-413-822-327;;130-557-982-448-359;;010-503-176-197-239;;026-396-339-084-010;;088-434-038-364-143;;110-622-018-928-961;;026-367-037-139-802;;017-729-084-063-643;;053-887-446-496-059;;111-109-974-501-414;;041-461-899-032-384;;030-425-987-723-110;;004-100-004-646-006;;014-169-184-148-626;;056-370-822-404-873;;092-760-851-706-263;;065-097-473-442-493;;030-660-067-609-024;;164-403-066-288-611;;031-584-564-704-369;;047-580-366-679-441;;085-764-009-624-439;;027-314-030-808-345;;052-947-986-013-690;;000-234-931-492-675;;073-419-783-934-185;;048-666-647-905-365;;093-509-508-230-620;;087-477-650-364-59X;;033-756-776-033-780;;017-561-716-268-836;;040-635-027-762-84X;;046-731-814-106-92X;;006-516-075-151-31X;;000-870-842-639-900;;009-738-327-233-69X;;028-294-432-381-795;;014-729-984-201-416;;074-582-134-846-704;;101-797-963-804-734;;054-621-361-798-611;;012-080-214-127-41X;;079-141-143-704-263;;048-183-620-015-85X;;081-092-403-760-75X;;017-185-661-050-007;;022-944-275-314-68X;;042-751-409-162-883;;032-459-914-054-209;;007-339-268-863-200;;005-660-045-470-037;;051-315-531-263-042;;034-330-993-923-294;;031-118-508-476-586;;082-902-765-648-368;;020-682-017-511-509;;137-791-867-210-863;;106-136-224-518-463;;005-638-542-147-993;;011-243-931-881-746;;059-478-289-803-609;;073-102-472-393-46X;;008-076-695-732-453;;112-039-702-206-214;;007-496-126-787-125;;070-434-249-460-174;;013-885-021-097-853;;016-759-138-450-894;;015-801-694-447-055;;019-627-964-331-373;;082-984-043-695-164;;037-740-603-895-357;;011-657-979-926-27X;;003-242-603-416-269;;083-634-098-131-485;;048-439-321-617-128;;110-630-331-648-229;;020-065-207-907-092;;031-075-424-243-630;;028-373-705-126-470;;006-095-947-008-535;;024-253-203-317-101;;055-852-081-735-610;;025-834-245-974-873;;084-748-487-156-928;;115-802-414-738-000;;035-328-575-802-514;;018-351-785-584-614;;094-815-381-871-763;;081-753-724-687-173;;079-274-785-935-791;;063-155-730-882-853;;067-127-654-169-729;;048-972-529-594-020;;054-304-933-298-139;;017-049-171-562-572;;099-270-483-107-007;;142-164-397-210-970;;104-283-497-946-575;;046-036-272-703-281;;075-912-302-795-48X;;111-570-270-686-786;;077-066-325-033-341;;029-811-479-361-870;;000-654-286-546-079;;012-837-528-765-07X;;069-296-641-163-256;;039-149-059-983-63X;;065-815-544-501-870;;019-394-264-649-327;;046-262-147-203-697;;008-125-648-563-747;;030-861-724-466-58X;;015-214-531-219-780;;028-383-058-454-759;;135-513-407-563-622;;058-530-733-727-374;;013-392-307-146-301;;063-864-581-855-676;;003-416-495-423-02X;;016-250-517-165-602;;037-612-698-436-922;;077-722-555-854-551;;038-624-922-825-362;;035-070-408-027-340;;049-937-366-109-256;;010-030-039-052-116;;061-267-522-126-985;;089-860-020-044-940;;025-612-997-745-121;;040-712-467-075-177;;013-754-548-416-363;;030-425-714-928-399;;035-769-575-764-291,10.1016/j.cmet.2013.08.005;;24011069;;10.3410/f.734650074.793563632;;10.1016/s0140-6736(18)31785-9;;30554783;;pmc6587787;;10.1002/oby.22344;;30520566;;10.1111/j.1747-0285.2012.01325.x;;22248288;;10.1016/j.febslet.2008.11.023;;19059246;;pmc6594174;;29342135;;10.2210/pdb5vak/pdb;;10.1038/nature25010;;10.1021/bc300603k;;23594041;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;10.1111/jgh.12271;;24251707;;10.1093/abbs/gmu097;;25355486;;24685265;;10.1016/j.biomaterials.2014.03.023;;6467175;;10.2337/diacare.25.5.869;;11978683;;24248463;;10.1210/en.2013-1828;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;6363212;;10.1016/0378-1119(83)90222-6;;11880038;;10.1016/s1074-5521(02)00094-7;;10.1002/macp.1978.021790204;;10.1023/a:1015825027737;;2052513;;7763976;;10.1016/0958-1669(93)90011-k;;10.2337/diacare.15.6.755;;1600835;;1560827;;10.1038/356537a0;;10.1021/ja00202a052;;1911037;;6220717;;10.1016/0006-291x(83)91828-4;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;10.1016/s0040-4020(01)90305-9;;10.1126/science.3140377;;3140377;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;6757758;;10.1038/300706a0;;10.1016/s0040-4039(01)90461-7;;10.1016/0003-2697(83)90131-8;;6193731;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.3.co;2-c;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.0.co;2-5;;9050787;;10.2337/diabetes.45.11.1572;;10.2337/diab.45.11.1572;;8866563;;875032;;10.1016/s0022-2836(77)80200-3;;10.1016/0197-0186(94)90047-7;;7950964;;10.1016/s0021-9258(18)82348-1;;8340419;;10.1038/nsb0594-283;;7664033;;2994214;;10.1126/science.2994214;;1733123;;10.1093/ajcn/55.2.538s;;10.3109/03639049209046327;;8352595;;10.1146/annurev.bi.62.070193.002411;;1332541;;10.1016/0003-2697(92)90433-8;;10.1006/jmbi.1997.1132;;9245591;;10.1111/j.1432-1033.1995.0788h.x;;10.1111/j.1432-1033.1995.tb20622.x;;7607253;;10.1096/fasebj.13.1.41;;9872928;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;10.1006/prep.1997.0744;;9226723;;10.1016/s0169-409x(03)00108-x;;14499706;;10.1111/j.1440-1681.1978.tb00650.x;;639358;;pmc252500;;2993646;;10.1128/jvi.56.1.153-160.1985;;10.1021/jo034984x;;14604354;;10.1016/0076-6879(87)54086-1;;2828857;;10.1016/0076-6879(87)54086-1;;2828857;;3541892;;10.1042/bj2370001;;pmc1146940;;2438771;;10.1126/science.2438771;;22787375;;pmc3390728;;10.3346/jkms.2012.27.7.784;;7030620;;10.3109/10409238109108703;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203;;12148987;;10.1021/ja027007w;;12920298;;10.1126/science.1084772;;10.1002/chin.198535327;;10.1016/s0958-1669(00)00200-7;;11287238;;10.1016/s0958-1669(98)80109-2;;9664053;;8703002;;10.1074/jbc.271.36.21969;;3286212;;10.2165/00003495-198835030-00003;;2250094;;10.1093/oxfordjournals.jhered.a111019;;7160534;;10.2337/diab.31.1.s24;;17036574;;10.1016/s0025-6196(11)61176-2;;10.1126/science.3685986;;3685986;;10.1002/anie.199506211;;10.1021/ja961216x;;1785831;;10.1111/j.1749-6632.1991.tb49017.x;;10.1021/jo00241a009;;pmc369166;;3915774;;10.1128/mcb.5.12.3376-3385.1985;;10.1128/mcb.5.12.3376;;10.1038/1921227a0;;13882203;;10.1242/dev.121.2.439;;7768185;;8850022;;10.1385/0-89603-332-5:369;;pmc215567;;10.1128/jb.158.3.1165-1167.1984;;6327630;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.3.co;2-9;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.0.co;2-i;;10506413;;10966479;;10.1146/annurev.biochem.69.1.923;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1128/jb.154.2.737-742.1983;;pmc217523;;6841315;;8314773;;10.1016/s0021-9258(19)85209-2;;7623902;;10.1056/nejm199508313330902;;10.1021/ja0370037;;14505376;;15501033;;10.1016/j.bmcl.2004.09.059;;1458545;;12119302;;10.1074/jbc.m205854200;;10.1111/j.1749-6632.1991.tb49014.x;;1785800;;10.1089/neu.1996.13.309;;8835798;;9398858;;10.1038/ng1297-491;;10.1126/science.1057718;;11313495;;11102869;;10.1016/s1367-5931(00)00148-4;;10.1021/bi9617973;;9116020;;10.1038/nrd1088;;12750738;;10.1128/mcb.10.4.1633-1641.1990;;10.1128/mcb.10.4.1633;;1690848;;pmc362268;;pmc311518;;10.1093/nar/14.12.5115;;3460029;;1883529;;10.1007/bf01024990;;2187475;;10.1016/0076-6879(91)02017-4;;1784180;;10.1126/science.1553546;;1553546;;9989500;;10.1016/s0092-8674(00)80962-9;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1002/bit.260290911;;18576565;;13428781;;10.1016/s0021-9258(18)64849-5;;12754376;;pmc164450;;10.1073/pnas.1132122100;;10.1016/j.chembiol.2003.11.004;;14652071;;2647707;;10.1007/bf02628459;;1568242;;10.1016/0092-8674(92)90402-x;;10.1021/ja01523a064;;10.1007/978-3-642-71589-1_3;;3816299;;10.1093/nar/16.14.6987;;3405755;;pmc338346;;3862099;;10.1073/pnas.82.17.5824;;pmc390645;;17878606;;10.1507/endocrj.kr07e-002;;10.1002/pro.5560070223;;9521119;;pmc2143905;;8741989;;10.1021/bc950074d;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/bc00015a010;;1381617;;10.1016/s1074-5521(97)90312-4;;9375252;;10.1016/s0002-9343(97)00254-4;;9428832;;1444338;;10.1007/bf00584464;;8661131;;10.1006/geno.1996.0349;;10.1021/bc00014a008;;1325188;;8891346;;161245;;10.1016/0378-1119(79)90009-x;;10.1016/j.tem.2014.03.001;;24709036;;8269798;;10.2337/diacare.16.10.1387;;10.1099/00221287-132-12-3459;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;10.1016/0076-6879(90)85003-7;;2116575;;1785812;;10.1111/j.1749-6632.1991.tb49016.x;;1366535;;10.1038/nbt0490-343;;9558343;;10.1021/bi972685u;;10.1126/science.281.5374.269;;9657724;;3889852;;10.1093/nar/13.9.3305;;pmc341236;;10.1006/prep.2002.1624;;12071713;;pmc2946115;;20882112;;10.1002/anie.199728251;;10.1074/jbc.m003696200;;11006270;;10.1021/ar9901570;;11560472;;10.1021/bi035320k;;10.1021/bi035320k.s001;;14730967;;10.1016/s0021-9258(17)30417-9;;248056;;10.1021/ar00024a001;;pmc3507880;;10.1371/journal.pone.0049345;;23209571;;10.1021/bi00419a012;;3061451;;10.1002/j.1460-2075.1990.tb08287.x;;2184035;;pmc551863;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;17036573;;10.1016/s0025-6196(11)61175-0;;10.1016/0065-2571(69)90016-8;;4244004;;11883961;;10.1006/bbrc.2002.6607;;10.1073/pnas.75.4.1929;;347451;;pmc392455;;10.1038/nbt0202-177;;11821864;;6254992;;10.1016/s0021-9258(19)70246-4;;10.1021/ja00976a035;;5980877;;10.1016/s1367-5931(02)00376-9;;12470735;;10.1021/ja9813109;;10.1021/ja992204p;;363146;;10.1021/bi00616a007;;6256394;;10.1016/s0021-9258(19)69976-x;;23663742;;pmc3667496;;10.1016/j.cmet.2013.03.019;;10.1006/bbrc.1998.8239;;9514906;;pmc383928;;10.1073/pnas.76.8.3829;;386351;;1577399;;10.1055/s-2007-1003271;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;7758582;;10.1016/0014-5793(95)00408-2;;8003476;;10.1021/bi00189a013;;7530860;;10.1126/science.7530860;;10.1056/nejm199803263381303;;9516221;;412251;;10.1126/science.412251;;10.1128/jb.153.1.163-168.1983;;pmc217353;;6336730;;10.1126/science.7939659;;7939659;;8703034;;10.1074/jbc.271.36.22203;;10.1021/ja01511a053;;10.1002/macp.1979.021800528;;10.1111/j.1365-2265.1991.tb03490.x;;1889135;;10.1126/science.6238407;;6238407;;10.1146/annurev.bi.54.070185.003025;;2992359;;10.1146/annurev.biochem.54.1.565;;10.1021/ar00158a001;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;16773196;;10.3892/ijo.29.1.163;;9223335;;pmc21577;;10.1073/pnas.94.15.8179;;10.1016/s0040-4020(96)01195-7;;3894007;;pmc554210;;10.1002/j.1460-2075.1985.tb03653.x;;17036575;;10.1016/s0025-6196(11)61177-4;;10.1172/jci23606;;pmc1088017;;15902306;;17068132;;10.1210/en.2006-1168;;pmc3986619;;24749049;;10.1016/j.molmet.2013.12.003;;23536797;;pmc3594191;;10.1371/journal.pone.0058575;;10.1016/s0040-4020(00)00833-4;;11752401;;10.1073/pnas.012583299;;pmc117506;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.3.co;2-j;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.0.co;2-s;;10577472;;10.1023/a:1005624811710;;10835240;;10.1021/bp000031y;;10.1002/bit.1121;;10.1002/bit.1121.abs;;11410855;;23825123;;10.1210/en.2012-2276;;10.1039/jr9490003315;;389741;;10.1016/0378-1119(79)90029-5;;2216760;;pmc332298;;10.1093/nar/18.19.5667;;1422046;;15915461;;10.1002/hep.20701;;12754495;;10.1038/nsb934;;10.1080/00397919208019100;;10.1016/s1367-5931(00)00141-1;;11102863;;10.1021/jo00269a022;;9185859;;10.1016/s0378-1119(97)00019-x;;16076449;;10.1016/j.ymeth.2005.04.001;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;pmc30127;;11226228;;10.1073/pnas.031488298;;10.1016/0092-8674(84)90283-6;;6386179;;10.1016/0076-6879(87)54084-8;;3323812;;3165526;;10.1093/nar/16.14.7207;;pmc338387;;6096830;;pmc320472;;10.1093/nar/12.24.9441;;8305530;;10.1021/bc00024a025;;3095839;;10.1073/pnas.83.22.8604;;pmc386979;;10.1007/s001250050498;;8781766;;10.1007/bf00418542;;10.1021/bi026856t;;12693945;;10.1016/0021-9673(86)80093-0;;3488324;;10.1016/0076-6879(87)54085-x;;3323813;;3881765;;10.1073/pnas.82.2.488;;pmc397064;;10.1074/jbc.c500457200;;16436388;;pmc2637204;;10.1074/jbc.m704165200;;17623664;;pmc2496965;;pmc367493;;3023819;;10.1128/mcb.6.1.142;;10.1128/mcb.6.1.142-149.1986;;8554512;;10.1042/bj3120725;;pmc1136174;;17036578;;10.1016/s0025-6196(11)61180-4;;10.1002/jbm.820150212;;7348718;;10.2144/99261bm05;;9894589;;10.1016/s0958-1669(98)80035-9;;9821278;;10.1016/j.cmet.2013.04.005;;23663741;;10.1006/abio.1997.2428;;9417773;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1021/ja029433n;;12580587;;8632803;;10.1038/381442a0;;pmc307151;;7659531;;10.1093/nar/23.15.3067;;10.1016/s1097-2765(01)00369-0;;11684012;;10.1038/85080;;11224539;;2497580;;10.1016/0042-6822(89)90348-6;;10.1016/0006-8993(91)90784-s;;1723639;;8347599;;10.1021/bi00082a015;;10.7326/0003-4819-128-3-199802010-00002;;9454525;;11273699;;pmc7125544;;10.1006/jmbi.2001.4518;;10.1126/science.276.5315.1125;;9173543;;8613964;;12810643;;pmc386678;;3532104;;10.1073/pnas.83.19.7177;;10.1099/0022-1317-70-12-3501;;2691634;;10.2337/diacare.24.3.489;;11289473;;7473593;;10.1021/jm00023a005;;10.1016/s1044-5765(05)80035-1;;17036576;;10.1016/s0025-6196(11)61178-6;;9427842;;10.1016/s0079-6603(08)61031-4;;17036577;;10.1016/s0025-6196(11)61179-8;;10.1021/ja9925150;;9310317;;10.1242/dev.124.17.3221;;10.1021/ja0025806;;10.1021/ja0284153;;12537491;;10954682;;7663123;;10.1146/annurev.bb.24.060195.002251;;10.1146/annurev.biophys.24.1.435;;9581754;;10.1016/s0896-6273(00)81001-6;;10.1146/annurev.micro.42.1.177;;10.1146/annurev.mi.42.100188.001141;;3059993;;2695080;;10.1002/bies.950110404;;3030893;;10.1016/0378-1119(86)90356-2;;10.1111/j.1464-5491.1994.tb00333.x;;7955995;;10933852;;10.1006/abio.2000.4667;;9473496;;10.1006/bbrc.1998.8073;;6337369;;10.1073/pnas.80.1.1;;pmc393297;;10764591;;10.1006/jmbi.2000.3658;;10.1038/302543a0;;6403870;;10.1002/jcp.20847;;17063460;;pmc3266413;;22210323;;10.2337/db11-0838;;14652075;;10.1016/j.chembiol.2003.10.010;;pmc341328;;10.1093/nar/14.24.9679;;3027659;;10.1021/ja00246a064;;6322300;;10.1126/science.6322300;;pmc320064;;6473105;;10.1093/nar/12.15.6159;;10.1016/0022-2836(70)90057-4;;5420325;;4973231;;10.1016/s0021-9258(18)93152-2;;10.1016/s0167-4889(02)00256-2;;12183061;;17933712;;10858549;;10.1016/s0167-4781(00)00067-1;;10.1016/s0167-4781(98)00255-3;;9931477;;10.1056/nejm199411033311803;;7935656;;9593693;;10.1074/jbc.273.22.13570;;10.1126/science.2649980;;2649980;;7716551;;10.1126/science.7716551;;10.21236/ada299991;;10.1093/protein/1.3.151;;3333844;;10.1021/ja9940064;;10.1021/ja001450u;;9660775;;10.1074/jbc.273.29.18161;;10.1093/oxfordjournals.jbchem.a022221;;9832608;;10.1016/s0021-9258(18)89400-5;;3838308;;9187149;;10.1242/dev.124.11.2235;;10.1126/science.164.3880.719;;5778021;;pmc138918;;11276432;;10.1186/gb-2001-2-3-reviews3005;;8883961;;10.1016/0169-328x(96)00108-8;;10.1016/b978-0-08-052349-1.00116-5;;6307823;;10.1016/0378-1119(83)90107-5;;11948130;;pmc42512;;7877976;;10.1073/pnas.92.5.1327;;10.1002/1522-2675(20000906)83:9<2277::aid-hlca2277>3.0.co;2-l;;9591139;;10.2144/98245rr03;;10.1016/0003-2697(82)90240-8;;6289696;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;8431294;;11356929;;10.1038/bjc.1992.272;;pmc1977825;;1380282;;10.1038/343033a0;;1688644;;10.1093/bioinformatics/18.7.980;;12117796;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;10490103;;10.1016/s0092-8674(00)80051-3;;10.1021/ja00965a060;;3194752;;10.1126/science.3194752;;10.1146/annurev.ge.18.120184.001133;;6084980;;10.1074/jbc.270.50.29813;;8530375;;12845521;;10.1007/s00441-003-0756-7;;8798573;;10.1074/jbc.271.39.23607;;10.1016/s0021-9673(01)95395-6;;6355135;;3614380;;10.1038/328731a0;;9356443;;10.1073/pnas.94.23.12297;;pmc24913;;10.1021/ja00007a055;;10.1007/bf00331655;;10.1515/9783112315972-006;;10.1002/yea.320080602;;1502852;;9129118;;10.1016/s0024-3205(96)00595-4;;10.1006/mcpr.1994.1013;;7935517;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1074/jbc.271.37.22376;;8798399;;12409460;;10.1093/nar/gkf589;;pmc135798;;3165194;;10.1093/nar/16.14.6361;;pmc338301;;10.1074/jbc.271.38.23169;;8798511;;12244330;;10.1038/nbt742;;21520200;;10.1002/hep.24376;;pmc4014460;;10.1007/bf02921514;;2024978;;10.1021/ma00056a005;;10.1126/science.287.5460.2007;;10720325;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/nar/16.3.803;;pmc334720;;2830594;;10.1016/s0021-9258(18)62817-0;;5528240;;10480527;;10.2337/diacare.22.9.1568;;19915550;;10.1038/nbt.1588;;10.1006/prep.1997.0851;;9535699;;10.1006/prep.1995.1002;;7756834;;10.1126/science.1566069;;1566069;;10.1161/01.cir.97.7.645;;9495299;;9516220;;10.1056/nejm199803263381302;;10.1016/0076-6879(87)35063-3;;3600302;;10.1002/dmrr.288;;12112940;;10.1021/ja00119a001;;10664452;;10.1016/s0014-5793(00)01120-0;;10.1038/292128a0;;6264321;;803646;;10.1038/254034a0;;6201207;;10.1002/bip.360220167;;10.1038/88129;;11329016;;9425898;;10.1038/ng0198-45;;10.1093/genetics/122.1.19;;2659436;;pmc1203683;;10.1128/jvi.68.2.766-775.1994;;pmc236513;;8289380;;10.1016/s0022-1759(96)00217-7;;9032414;;pmc38518;;10.1073/pnas.93.18.9850;;8790420;;6318086;;pmc370086;;10.1128/mcb.3.12.2156;;10.1128/mcb.3.12.2156-2165.1983;;3002241;;10.1146/annurev.ge.19.120185.002231;;10.1146/annurev.genet.19.1.423;;10.1016/0022-2836(81)90087-5;;7265238;;10.1016/s0021-9258(18)68577-1;;3372509;;10.1074/jbc.270.8.4121;;7876162;;10.1007/978-1-4684-3417-0_9;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1038/370389a0;;8047147;;10.1016/0022-2836(86)90385-2;;3537305;;1469691;;10.1021/jm00102a014;;10.1021/ja00203a067;;3156376;;pmc397196;;10.1073/pnas.82.4.1074;;10.1021/ja010731e;;11472182;;7482665;;10.1161/01.str.26.11.2154;;7737407;;10.1016/0014-5793(95)00324-3;;11317312;;29712367;;10.1002/1521-3773(20010417)40:8<1494::aid-anie1494>3.0.co;2-x;;3001650;;10.1093/nar/13.24.8765;;pmc318950;;pmc318949;;10.1093/nar/13.24.8749;;3001649;;6368319;;10.1016/0378-1119(83)90191-9;;10.1016/0168-3659(85)90001-x;;10.1021/jo011148j;;11975567;;7620563;;10.1385/0-89603-272-8:97;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;6248420;;10.1016/0378-1119(80)90133-x;;10.1016/s1046-5928(02)00641-1;;12651100;;10.1074/jbc.271.33.19991;;8702716;;8402094;;10.1002/bjs.1800800812;;10.1038/nbt0290-135;;1366557;;10.1056/nejmoa011300;;11794168;;9645477;;10.1016/s0014-5793(98)00489-x;;10.1021/ja992749j;;10.1128/jb.130.2.946-947.1977;;400800;;pmc235301;;10.1007/bf02798546;;4026282;;3128641;;10.1099/0022-1317-69-4-765;;pmc140882;;12518054;;10.1073/pnas.0234824100;;10.1126/science.1060077;;11313494;;10.1021/ja021381e;;12630856;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/0378-1119(85)90140-4;;3891521;;10.1002/(sici)1097-0177(199709)210:1<41::aid-aja5>3.0.co;2-1;;9286594;;10.1016/s0960-9822(95)00102-3;;7583099;;0007583099;;10.1021/bc00023a002;;8274513;;10.1016/0141-0229(92)90049-t;;1368988;;10.1038/321718a0;;10.1021/ja028050m;;12465973;;18840786;;10.2337/db08-0392;;pmc2606881;;pmc344858;;6324193;;10.1073/pnas.81.5.1470;;pmc327233;;10.1093/nar/9.3.731;;6164048;;1785805;;10.1111/j.1749-6632.1991.tb49015.x;;10.1016/0014-3057(83)90016-2;;10.1021/bc00032a002;;7599259;;10.2337/diacare.24.4.720;;11315837;;24189035;;10.1016/j.drudis.2013.10.021;;10.1021/bi0300231;;12779328;;6225933;;10.1016/b978-0-12-765560-4.50036-8;;10.1016/0076-6879(83)00074-9;;6757864;;pmc326938;;10.1093/nar/10.20.6487;;10.1016/0076-6879(87)54083-6;;3323811,"BMS Press Release “Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial” Apr. 2017. 3 pages, https://news.bms.com/press-release/bmy/bristol-myers-squibbs-bms-986036-pegylated-fgf21-shows-consistent-improvement-live.;;Gaich et al., “The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes,” Cell Metab. Sep. 3, 2013;18(3):333-40.;;Sanyal A, et al. “Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with nonalcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial,” Lancet. Dec. 2018. 22;392(10165):2705-2717.;;Charles ED, et al. “Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes Results from a Randomized Phase 2 Study,” Obesity (Silver Spring). Jan. 2019;27(1):41-49.;;Yie J, Wang W, Deng L, Tam LT, Stevens J, Chen MM, Li Y, Xu J, Lindberg R, Hecht R, Veniant M. “Understanding the Physical Interactions in the FGF21/FGFR/B-Klotho Complex: Structural Requirements and Implications in FGF21 Signaling.” Chemical biology & drug design. Apr. 1, 2012 ;79(4):398-410.;;Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, Steavenson S, Smith S, Winters D, Fisher S, Cai L. “FGF21 N-and C-termini play different roles in receptor interaction and activation.” FEBS letters. Jan. 5, 2009;583(1):19-24.;;Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J. “Structures of B-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling.” Nature. Jan. 17, 2018.;;Xu J, Bussiere J, Yie J, Sickmier A, An P, Belouski E, Stanislaus S, Walker KW. “Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.” Bioconjugate chemistry. May 9, 2013;24(6):915-25.;;Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C. “Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes.” PLoS One. Nov. 27, 2012;7(11) e49345.;;Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. Journal of gastroenterology and hepatology. Dec. 2013;28:64-70.;;Zhu S, Ma L, Wu Y, Ye X, Zhang T, Zhang Q, Rasoul LM, Liu Y, Guo M, Zhou B, Ren G. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim Biophys Sin. Oct. 29, 2014;46(12):1041-8.;;Song L, et al. A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog. Biomaterials. Jun. 2014;35(19):5206-15. doi: 10.1016/j.biomaterials.2014.03.023. Epub Mar. 28, 2014. PMID: 24685265.;;Xianlong Ye, et al., The hypoglycemic effect of the PEGylated FGF21, Progress in Biochemistry and Biophysics, vol. 40, No. 4. 2013. pp. 374-385.;;Abuchowski, A. et al., “Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates”, Cancer Biochem. Biophys., Jun. 1984, 7(2): 175-86.;;Ahrén et al., “Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes”, Diabetes Care, 2002, 25(5): 869-75.;;Alisi, A. et al., “Commentary: FGF21 Holds Promises for Treating Obestiy-related Insulin Resistance and Hepatosteatosis”, Endocrinology, Nov. 18, 2013, doi: 10.1210/en.2013-1828.;;Altschul, S.F. et al., “Basic local alignment search tool”, J. Mol. Biol., Oct. 5, 1990, 215(3): 403-10.;;Altschul, S.F. et al., “Gapped BLAST and Psi-BLAST: a new genera database search programs”, Nucleic Acids Res., Sep. 1, 1997, 25(17): 3389-402.;;Amann, E. et al., “Vectors bearing a nybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli”, Gene, Nov. 1983, 25(2-3): 167-78.;;Anderson, J.C. et al., “Exploring the limits of codon and anticodon size”, Chem. Biol., Feb. 2002, 9(2): 237-44.;;Andresz, H. et al., “Chemische Synthese verzweigter Polysaccharide, 5: Kopplung von Oligosacchariden und Amylose an verschiedene Träer durch Hydrazonbindung”, Makromol. Chem. 1978, 179: 301, Abstract.;;Arakawa et al., “Protein-solvent interactions in pharmaceutical formulation”, Pharm. Res., 1991, 8(3): 285-291.;;Arnold, F.H., “Protein engineering for unusual environments”, Curr. Opin. Biotechnol., Aug. 1993, 4(4): 450-5.;;Azoulay, M. et al., “Glutamine analogues as Potential Antimalarials”, Eur. J. Med. Chem., 1991, 26(2): 201-5.;;Badman, M.K. et al., “Hepatic Fibroblast Growth Factor 21 is Regulated by PPARα and is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States”, Cell Metabolism, Jun. 2007,5:426-437.;;Bailey, “Biguanides and NIDDM”, Diabetes Care, 1992, 15:755-72.;;Bain et al., “Ribosome-mediated incorporation of a non-standard amino acid into a peptide through expansion of the genetic code”, Nature, 1992, 356(6369): 537-539.;;Bain, J.D. et al., “Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide”, J. Am. Chem. Soc., 1989; 111(20): 8013-8014.;;Baird et al., “The fibroblast growth factor family”, Cancer Cells, 1991, 3(6): 239-43.;;Ballance, D.J. et al., “Transformation of Aspergillus nidulans by the orotidine-5'-phosphate decarboxylase gene of Neurospora crassa”, Biochem. Biophys. Res. Commun., Apr. 15, 1983, 112(1): 284-9.;;Barany, F. et al., “Genetic disease detection and DNA amplification using cloned thermostable ligase”, Proc. Natl. Acad. Sci. USA, Jan. 1, 1991, 88(1): 189-93.;;Barton, D.H.R. et al., “Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives”,Tetrahedron, 1987, 43: 4297-4308.;;Bass, S. et al, “Mutant Trp repressors with new DNA-binding specificities”, Science, 1988, 242: 240-245.;;Batzer, M.A. et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'-terminus”, Nudeic Acids Res., Sep. 25, 1991,19(18): 5081.;;Beach, D. et al., “Functionally homologous cell cycle control genes in budding and fission yeast”, Nature, Dec. 1982, 300: 706-709.;;Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis”, Tetrahedron Letts., 1981, 22(20): 1859-1862.;;Beauchamp, C.O. et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal. Biochem., May 1983, 131(1): 25-33.;;Belluardo et al., “Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis”, J. Comp. Neurol. (1997) 379(2): 226-46.;;Berkowitz et al., “Effect of troglitazone on insulin sensitivity an dpancreatic beta-cell function in women at high risk for NIDDM”, Diabetes, 1996, 45(11): 1572-9.;;Bernstein, F.C. et al., “The protein data bank: a computer-based archival file for macromolecular structures”, J. Mol. Biol., 1977, 112: 535-542.;;Biagini et al., The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes, Neurochem. Int., 1994, 25(1): 17-22.;;Boissel, J.P. et al., “Erythroprotein structure-function relationships. Mutant proteins that test a model of tertiary structure”, Jul. 25, 1993, 268(21): 15983-93.;;Boles, J.O. et al., “Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase”, Nat. Struct. Biol., May 1994, 1(5): 283-4.;;Botstein, D. and D. Shortle, “Strategies and applications of in vitro mutagenesis”, Science, Sep. 20, 1985, 229(4719): 1193-201.;;Bray, “Drug treatment of obesity”. Am. J. Clin. Nutr., 1992, 55(2 Suppl): 538S-544S.;;Broadhead et al., “The Spray Drying of Pharmaceuticals”, Drug Dev. Ind. Pharm., 1992,18(11/12):1169-1206.;;Brunner, J. et al., “New photolabeling and crosslinking methods”, Annu Rev. Biochem., 1993, 62: 483-514.;;Buchner, J. et al., “A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies”. Anal. Biochem., 1992, 205(2): 263-270.;;Bückmann etal, “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),” Makromol. Chem., 1981, 182: 1379-84.;;Budisa, N. et al., “Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins”, J. Mol. Biol., Jul. 25, 1997, 270(4): 616-23.;;Budisa, N. et al., “High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli”, Eur. J. Biochem., Jun. 1, 1995, 230(2): 788-96.;;Budisa, N. et al., “Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire”, FASEB J., Jan. 1999, 13(1): 41-51.;;Burgess et al., “The Heparin Binding (Fibroblast) Growth Factor Family of Proteins”, Annu. Rev. Biochem., 1989, 58: 575-606.;;Cai, X-Y et al., “Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-Inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells”, Protein Expression and Purifcation, 1997, 10(2): 263-74.;;Caliceti, P. and F.M. Veronese, “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates”, Adv. Drug. Deliv. Rev., Sep. 26, 2003, 55(10): 1261-1277.;;Cameron et al., “Effects of monosodium glutamate-induced obesity in mice on carbohydrate metabolism in insulin secretion”, Clin. Exp. Pharmacol. Physiol., 1978, 5(1): 41-51.;;Carbonell, L.F. et al., “Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells”, J. Virol., Oct. 1985, 56(1): 153-60.;;Carrasco, M. and R. Brown, “A Versatile Set of Aminoxy Amino Acids for the Synthesis of Neuropeptides” J. Org. Chem., 2003, 68(23): 8853-8858.;;Carter, P. et al., “Improvedoligonucleotide site-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987,154: 382-403.;;Carter, P., “Improved oligonucleotide-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987,154: 382-403.;;Carter, P., “Site-directed mutagenesis”, Biochem J., Jul. 1, 1986, 237(1): 1-7.;;Cech, “The chemistry of self-splicing RNA and RNA enzymes”, Science, Jun. 19, 1987, 236(4808): 1532-9.;;Chae, H-W. et al., “Spot Urine Albumin to Creatine Ratio and Serum Cystatin C are Effective for Detection of Diabetic Nephropathy in Childhood Diabetic Patients”, J Korean Med Sci. 2012, 27: 784-787.;;Chaiken, I.M., “Semisynthetic peptides and proteins”, CRC Crit. Rev. Biochem., 1981, 11(3): 255-301.;;Chin, J.W. and P.G. Schultz, “In vivo photocrosslinking until unnatural amino acid mutagenesis”, Chembiochem, Nov. 4, 2002, 3(11): 1135-7.;;Chin, J.W. et al., “Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli”. Proc Natl. Acad. Sci. USA, Aug. 20, 2002, 99(17): 11020-4. Epub. Aug. 1, 2002.;;Chin, J.W. et al., “Addition of p-azido-L-phenylalanine to the genetic code of E. coli”, J. Am. Chem. Soc., Aug. 7, 2002, 124(31): 9026-7.;;Chin, J.W. et al., “An expanded eukaryotic genetic code”, Science, Aug. 15, 2003, 301(5635): 964-7.;;Christie, B.D. and H. Rapoport. “Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization”, J. Org. Chem., 1985, 50(8): 1239-1246.;;Clark, E.D.B., “Protein refolding for industrial processes”, Curr. Opin. Biotechnol., Apr. 2001, 12(2): 202-207.;;Clark, “Refolding of recombinant proteins”, Curr. Opin. Biotechnol., Apr. 1, 1998, 9(2): 157-163.;;Clark, R. et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”, J. Biol. Chem., Sep. 6, 1996, 271[36]: 21969-77.;;Clissod et al., “Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential”, Drugs, 1988, 35:214-23.;;Coleman et al., “Fat(fat) and tubby(tub): two autosomal recessive mutations causing obesity syndromes in the mouse”, J. Hered., 1990, 81(6); 424-7.;;Coleman et al., “Other Potentially Useful Rodents as Models for the Study of Human Diabetes Mellitus”, Diabetes, 1982, 31 (Suppl 1 Pt 2): 24-25.;;Collazo-Clavell, M.L. et al., “Assessment and Preparation of Patients for Bariatric Surgery”, Mayo Clin. Proc., Oct. 2006, 81(10 suppl):S11-S17.;;Corey, D.R. and P.G. Schultz, “Generation of a hybrid sequence-specific single-stranded deoxyribonuclease”. Science, 1987, 238(4832): 1401-1403.;;Cornish, V.W. et al., “Probing Protein Sturcture and Function with an Expanded Genetic Code”, Angew. Chem, Int. Ed. Engl., 34(6): 621-33.;;Cornish, V.W. et al., “Site-Specific Protein Modification Using a Ketone Handle”, J. Am. Chem. Soc., 1996, 118(34): 8150-8151.;;Collier et al., “The FGF6 gene with the FGF multigene family”, Ann. NY Acad. Sci., 1991, 638:53-61.;;Craig, J.C. etal, “Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylammo)-l-methylbutyi]amino] quinoline (Chloroquinine)”, J. Org. Chem., 1988, 53(6): 1167-1170. _ '.;;Cregg, J.M et al., “Pichia pastoris as a hostsystem for transformations”, Mol. Cell Biol., Dec. 1985, 5(12): 3376-85. _.;;Crick, F.H.C et al., “General nature of the genetic code for proteins”, Nature, Dec. 30, 1961,192: 1127-32.;;Crossley et al., “The mouse FgfB gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo”, Development, 1995,121(2): 439-51.;;DALE et al., “Oligonucleotide-directed random mutagenesis using the phophoroth ioate method”, Methods Mol. Biol., 1996,57: 369-374.;;Das, S. etal, “Transformation of Kluyveromyces fragilis”, J. Bacterial, Jun. 1984, 158(3): 1165-7.;;Davis, G.D et al., “New fusion protein systems designed to give soluble expression in Eschericia coli”. Biotech nol. Bioeng., Nov. 20, 1999, 65(4): 382-388.;;DAWSON et al., “Synthesis of native proteins by chemical ligation”, Annu. Rev. Biochem., 2000, 69: 923-60.'.;;De Boer, H.A. etal, “The tac promoter: a functional hybrid derived from the trp and the lac promoters”, Proc. Natl. Acad. Sci. USA, Jan. 1983, 80(1): 21-5.;;De Louvencourt, L et al., “Transformation of Kluyveromyces lactis by killer plasmid Dna”, J. Bacteriol., May 1983,154(2): 737-42.;;Debinski, W. et al., “A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin”, J. Biol. Chem., Jul. 5, 1993, 268(10): 14065-70.;;DeFronzo et al., “Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group”, N. Engl. J. Med., 1995, 333(9): 541-9.;;Deiters, A. et al., “Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cereyisiae”, J. Am. Chem. Soc., 2003, 125(39): 11782-11783.;;Deiters, A., “Site-specific PEGylation of proteins contianing unnatural amino acids”, Bioorg. Med. Chem. Lett., Dec. 6, 2004, 14(23): 5743-5.;;Delgado, C. et al., “The uses and properties of PEG-linked proteins”, Crit. Rev. Ther. Drug. Carrier Syst., 1992,9(3-4): 249-304.;;Dennis, M.S. et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins”, J. Biol. Chem., Sep. 20, 2002, 277(38): 35035-43, Epub Jul. 15, 2002.;;Dickson et al., “Expression, processing and properties of int-2”, Ann. NY Acad. Sci., 1991, 638:18-26.;;Dietrich et al., “Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats”, J. Neurotrauma, 1996, 13(6): 309-16.;;Dolphin, C.T. et al., “Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome”, Nat. Genet., Dec. 1997, 17(4): 491-4.;;Doring, V. et al., “Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway”, Science, Apr. 20, 2001, 292(5516): 501-4.;;Dougherty, D.A., “Unnatural amino acids as probes of protein structure and function”, Curr. Opin. Chem. Biol., Dec. 2000, 4(6): 645-52.;;Drummond et al., “Liposomal drug delivery systems for cancer therapy”, B. Teicher (ed.): Cancer Drug Discovery and Development, 2002, 161-213.;;Duewel, H. et al., “Incorporation of trifluoromethionine into a phage lysozyme; implications and a new marker for use in protein 19F NMR”, Biochemistry, Mar. 18, 1997,36(11): 3404-16.;;Duncan, R., “The dawning era of polymer therapeutics”, Nat Rev. Drug. Discov., May 2003, 2(5): 347-60.;;Edwards et al., “A bacterial amber suppressor in Saccharomyces cerevisiae is selectively recognized by a bacterial aminoacyl-tRNA synthetase”, Mol. Cell Biol., 1990, 10(4): 1633-41.;;Eghtedarzadeh, M.K. and S. Henikoff, “Use of oligonucleotides to generate large deletions”. Nucleic Acids Res., Jun. 25, 1986, 14(12): 5115.;;Elling, L. and M.R. Kula, “Immunoaffinitypartitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies”, Biotechnol. Appl. Biochem., Jun. 1991, 13(3): 354-62.;;Elliott, S. et al., “Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization”, J. Protein. Chem., Feb. 1990,9(1): 95-104.;;Ellman, J.A. et al., “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins”, Methods in Enz., 1992, 202: 301-336.;;Ellman, J.A. et al., “Site-specific incorporation of novel backbone structures into proteins”, Science, Jan. 10, 1992, 255(5041): 197-200.;;England, P.M. et al., “Backbone mutation in transmembrane domains of a ligand-gated ion channel: implications for the mechanisms of gating”, Cell, Jan. 8, 1999, 96(1) 89-98.;;EPPSTEIN et al., “Biological Activity of Liposome-Encapsulated Murine Interferon is Mediated by a Cell Membrane Receptor”, Proc. Natl. Acad. Sci USA, 1985, 82: 3688-3692.;;European Patent Office, “Invitation to Pay Additional Fees”, Form PCT/ISA/206, International Application No. PCT/US2015/057228, Feb. 10, 2016.;;Fieschko, J.C. etal, “Controlled expression and purification of human immune interferon from high-cell-density fermentations of Saccharomyces cerevisiae”. Biotech. Bioeng., 1987, 29(9): 1113-21.;;Folch, J et al., “A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues”,}. Biol. Diem. 1957:226: 497-509.;;Forster A.C. etal, “Programming peptidomimetic syntheses by translating genetic codes designed de novo”, Proc Natl. Acad Sci. USA May 27, 2003, 100(11): 6353-7. Epub May 16, 2003.;;Frankel, A. et al., “Encodamers: unnatural peptide oligomers encoded in RNA”, Chern. Biol, Nov. 2003,10(11): 1043-50.;;Fraser M.} et al., “Expression of eucaryotic genes in insect cell cultures”, In Vitro Cell. Dev. Biol, 1989, 25: 225-235.;;FRIEDMAN et al., “Tackling a weighs problem”, Cell, 1992,69: 217-220.;;Friedman, O.M. and R. Chatterrji, “Synthesis of Derivatives of Glutamate as Model Substrates for Anti-Tumor Agents”,}. Am. Chern. Soc, 1959, 81(14): 3750-3752.;;FRIESEN etal, “The regulation of bacuiovirus gene expression”, Curr. Top. Microbiol. Immunol., 1986,131: 31-49.;;Fritz, H. J. etal, “Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro”, Nucleic Acids Res., Jul. 25, 1988, 16(14B): 6987-99.;;Fromm, M. et al., “Expression of Genes Transferred into Monocotand Dicot Plant Cells by Electroporation”, Proc. Natl. Acad Sci. USA 1985,82: 5824-8.;;Fukumoto, S., “Actions and Mode of Actions of FGF19 Subfamily Members”, Endocrine Journal, 2008; 55(1): 23-31.;;Furter, R., “Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli”. Protein Sci., Feb. 1998,7(2): 419-26.;;Gaertner, H.F. and R.E. Offord, “Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins”, Bioconjug. Chem., Jan.-Feb. 1996, 7(1): 38-44.;;Gaertner, H.F. et al., “Chemo-enzymatic backbone of engineering of proteins. Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor”, J. Biol. Chem., Mar. 11, 1994,269(10): 7224-30.;;Gaertner, H.F. et al., “Construciton of protein analogues by site-specific condensation of unprotected fragments”, Bioconjug. Chem., May-Jun. 1992,3(3): 262-8.;;Gallivan, J.P. et al., “Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins”, Chem. Biol., Oct. 1997, 4(10): 739-49.;;Garber et al., “Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial”, Am. J. Med., 1997,102: 491-97.;;Gellissen, G. et al., “Heterologous protein production in yeast”, Antoine Van Leeuwenhoek, Aug. 1992, 62(1-2): 79-93.;;Gemel et al., “Structure and sequence of human FGF8”, Genomics, 1996, 35:253-257.;;Geoghegan, K.F. and J.G. Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modifcation at N-terminal serine”, Bioconjug. Chem., Mar.-Apr. 1992, 3(2): 138-146.;;Ghosh et al., “Molecular cloning and characterization of human FGF8 alternative messenger RNA forms”. Cell Growth and Differentiation, 1996, 7(10): 1425-1434.;;Gillam, S. and M. Smith, “Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum oligodeoxyribonucleotide length”, Gene, 1979, 8(1): 81-97.;;Gimeno, R.E. and Moller, D.E., “FGF21-bsed pharmacotherapy—potential utility for metabolic disorders”, Trends Endocrinol Metab. Jun. 2014;25(6):303-11.;;Giugliano et al., “Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women”, Diabetes Care, 1993, 16:1387-90.;;Gleeson, M.A. et al., “Transformation of the methylotrophic yeast hansenula polymorphica”,J. Gen. Microbiol., 1986, 132: 3459-3465.;;Goeddel, D.V. et al., “Synthesis of human fibroblast interferon by E. coli”, Nucleic Acids Res.,Sep. 25, 1980, 8(18): 4057-74.;;Goeddel, D.V., “Systems for heterologous gene expression”, Methods Enzymol., 1990, 185: 3-7.;;Goldfarb et al., “Expression and possible functions of the FGF-5 gene”, Ann. NY. Acad. Sci., 1991, 638:38-52.;;Goodson, R.J. and N.V. Katre, “Site-directed pegylation of recombinant interleukin-2 at its glycosylation site”, Biotechnology (NY), Apr. 1990, 8(4): 343-346.;;Graves, S.W. et al., “Expre ssion, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase”, Biochemistry, Apr. 28, 1998,37(17): 6050-6058.;;Griffin, B.A. et al., “Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells”, Science, 1998, 281:269-272.;;Grundström, T. et al., “Oligonucleotide-directed mutagenesis by microscale ‘shot-gun’ gene synthesis”, Nucleic Acids Res., May 10, 1985,13(9): 3305-3316.;;Gu, Z. et at, “Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies”, Protein Expr. Purif., Jun. 2002, 25(1): 174-9.;;Guckian, K.M. and E.T. Kool, “High Precise Shape Mimicry by a Difluorotoluene Deoxynucleoside, and Replication-Competent Substitute for Thymidine”, Angew. Chem. Int. Ed. Engl., 1998,36(24): 2825-8.;;Hamano-Takaku, F. et al., “A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine” J. Biol. Chem., Dec. 22, 2000, 275(51): 40324-8.;;Hang, H.C. and C.R. Bertozzi, “Chemoselective approaches to glycoprotein assembly”, Acc. Chem. Res., Sep. 2001, 34(9): 727-36.;;Harmer et al., “The crystal structure of fibroblast growth factor [FGF] 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity”, Biochemistry, 2004, 43:629-640.;;Harris, J.M. et al., “Synthesis and Characterization of Poly (ethylene Glycol) Derivatives”, J. Polym. Sci. Chem. Ed, 1984, 22:341-352.;;Harris, J.M., “Laboratory Synthesis of Polyethylene Glycol Derivatives”, JMS-Rev. Macromol. Chem. Phys., 1985, C25(3): 325-373.;;Hecht et al., “Chemical aminoacylation of tRNA's”, J. Biol. Chem., 1978,253(13): 4517-20.;;Hecht, “Probing the synthetic capabilities of a center of biochemical catalysis”, Acc. Chem. Res., 1992, 25(12): 545-552.;;Hecht, R. et al., “Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes”, PLoS One. 2012,7(11):e49345.;;Heckler et al., “Ribosomal binding and dipeptide formation by misacylated tRNA(Phe)'s”, Biochemistry, 1988, 27(19): 7254-62.;;Hendrickson, W.A. et al., “Selenomethionyl proteins produced for analysis of multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure”. EMBO J., May 1990,9(5): 1665-72.;;Henikoff, S. and J.G. Henikoff, “Amino Acid Substitution Matrices from Protein Blocks”, Proc. Natl. Acad. Sci. USA, 1992,89: 10915-9.;;Hensrud, D.D. and Klein, S., “Extreme Obesity: A New Medical Crisis in the United States”, Mayo Clin. Proc., Oct. 2006,81(10 suppl):S5-S10.;;Hess, B. et al., “Cooperation of glycolytic enzymes”, J. Adv. Enzyme Reg., 1969, 7: 149-67.;;Hinke et al., “Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1”, Biochem. Biophys. Res. Commun, 2002, 291(5): 1302-8.;;Hinnen, A. et al., “Transformation of yeast”, Proc. Natl. Acad. Sci. USA, Apr. 1978, 75(4): 1929-33.;;Hirao, I. et al., “An unnatural base pair for incoporating amino acid analogues into proteins”, Nat Biotechnol., Feb. 2002, 20(2): 177-82.;;Hitzeman, R.A. et al., “Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological screening technique”, J. Biol. Chem., Dec. 25, 1980, 255(24): 12073-80.;;Hoffmann, K. and H. Bohn, “Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on fee S-protein activating potency of an S-peptide fragment”, J. Am. Chem., 1966, 88(24): 5914-5919.;;Hohsaka, T. and M. Sisido, “Incorporation of non-natural amino acids into proteins”, Curr. Opin. Chem. Biol., Dec. 2002, 6(6): 809-15.;;Hohsaka, T. et al., “Efficient Incorporation of Nonnatural Amino Acids with Large Aromatic Groups into Streptavidin in In Vitro Protein Synthesizing Systems”, J. Am. Chem. Soc., 1999, 121(1): 34-40.;;Hohsaka, T. et al., “Incorporation of Two Different Nonnatural Amino Acids Independently into a Single Protein through Extension of the Genetic Code”, J. Am. Chem. Soc., 1999,151(51): 12194-12195.;;Holland, M.J. and J.P. Holland “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceralehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase”, Biochemistry, Nov. 14, 1978,17(23): 4900-7.;;Holland, M.J. et al., “The primary structures of two yeast enolase genes. Homology between the 5' noncoding flanking regions of yeast enolase and glyceraldehyde-3-phosphate dehydrogenase genes”, J. Biol. Chem., Feb. 10, 1981, 256(3): 1358-95.;;Holland, W.L. et al., “An FGF21-Adiponectin-Gerami de Axis Controls Energy Expenditure and Insulin Action in Mice”, Cell Metab. 2013; 17: 790-797.;;Hoshikawa et al., “Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain”, Biochem. Biophys. Res. Common., 1998, 244(1): 187-91.;;Hsiao, C.L. and J. Carbon, “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”, Proc. Natl. Acad. Sci USA, Aug. 1979, 76(8): 3829-33.;;Hubinger et al., “The effect of etomoxiron insulin sensitivity in type 2 diabetic patients”, Hormone Metab. Res., 1992, 24:115-18.;;Huisgen, R. in 1,3-Dipolar Cycloaddition Chemistry, vol. 1, 1984; Ed A. Padwa; John Wiley and Suns, New York, 1-176.;;Hwang, K.J. et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study”, Proc. Natl. Acad. Sci. USA, Jul. 1980,77(7): 4030-4.;;Ibba, M. and H. Hennecke, “Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids”, FEBS Lett, May 15, 1995, 364(3): 272-5.;;Ibba, M. et al., “Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase”, Biochemistry, Jun. 14, 1994, 33(23): 7107-12.;;Illangakekare et al., “Aminoacyl-RNA Synthesis Catalyzed by an RNA”, Science, 1995, 267:643-647.;;Inzucchi et al., “Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellites”, New Engl. J. Med, 1998, 335:867-72.;;Itakura et al., “Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin”, Science, 1997,198:1056-1063.;;Ito, H et al., “Transformation of intact yeast cells treated with alkali cations”, J. Bacteriol., 1983,153(1): 163-8.;;Jackson, D.Y et al., “A designated peptide ligase for total synthesis of ribonuclease A with unnatural catalytic residues”, Science, Oct. 14, 1994, 266( 1583): 243-7.;;Jakobsson, P.J. et al., “Identification and characterization of a novel human microsomal glutathione S-transferase with keuko triene C4 synthetase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase”, J. Biol. Chem., Sep. 6, 1996, 271(36): 22203-10.;;Jencks, W.P., “Studies on the Mechanism of Oxime and Semicarbazone Formation”, J. Am. Chem. Soc., 1959, 81(2): 475-481.;;Joppich, M. et al., “Peptides Flanked by Two Polymer Chains, 1; Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups”, Makromol. Chem., 1979, 180:1381-4.;;Jung et al., “The management of obesity”, Clinical Endocrinology, 1991, 35; 11-20.;;Kaiser, E.T. and D.S. Lawrence, Chemical mutation of enzyme active sites , Science, Nov. 2, 1984, 226(4674): 505-11.;;Kaiser, E.T. et al., “The chemical modification of enzymatic specificitiy”, Annu. Rev. Biochem., 1985, 54; 565-95.;;Kaiser, E.T., “Synthetic approaches to biologically active peptides and proteins including enzymes”, Acc. Chem. Res., 1989, 22(2): 47-54.;;Karlin, S. and S.F. Altschul, “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Nat. Acad. Sci. OSA, Jun. 15, 1993,90(12): 5873-7.;;Katoh et al., “FGF signaling network in the gastrointestinal tract (review)”, Int'l. J. Oncology, 2006, 29:163-168.;;Kawamata et al.,“ Intraci sternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting follounng focal cerebral infarction”, Proc. Nad. Acad. Sci., 1997, 94(15): 8179-84.;;Kayser, B. et al., “Alkyne bridged alpha-amino acids by palladium mediated coupling of alkynes with N-t-Boc-4-iodo-phenylalanine methyl ester”, Tetrahedron, 1997, 53(7): 2475-2484.;;Kelly, J.M. and M.J. Hynes, “Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans”, Embo J 1985, 4(2): 475-479.;;Kendrick, M.L and Dakin, G.F, “Surgical Approaches to Obesity”, Mayo Clin, Proc., Oct. 2006, 81(10 suppl):S18-S24.;;Kharitonekov et al., “FGF-21 as a novel metabolic regulator”, J. Clin. Investigation, Jun. 1, 2005, 115(6): 1627-1635.;;Kharitonekov et al., “The Metabolic State of Diabetic Monkeys is Regulated by Fibroblast Growth Factor-21”, Endocrinology, Feb. 1, 2007,148(2): 774-781.;;Kharitonenkov, A. and Adams, A.C., “Inventing new medicines: The FGF21 story”, Mol. Metab,, Avail. Online Dec. 27, 2013, 3(2014): 221-229.;;Kharitonenkov, A. et al., “Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319”, Plos One, Mar. 2013,8(3) e58575: 1-10. et al.",ACTIVE
386,SG,A,SG 11201702824U A,012-009-489-462-039,2017-05-30,2017,SG 11201702824U A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/012-009-489-462-039,Unknown,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;C07K14/50,,0,0,,,,PENDING
387,US,B2,US 9631004 B2,040-706-131-962-759,2017-04-25,2017,US 201615215329 A,2016-07-20,US 201615215329 A;;US 201514921796 A;;US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Modified FGF-21 polypeptides comprising an internal deletion and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/040-706-131-962-759,Granted Patent,yes,377,7,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/18;;A61K38/00;;A61K39/395;;A61K45/06;;C07K14/50,,403,382,104-335-738-580-036;;007-480-305-123-598;;056-201-471-905-934;;028-862-168-091-90X;;070-383-251-783-098;;028-567-118-036-513;;005-712-635-226-116;;090-754-759-154-175;;050-825-529-117-306;;028-540-973-166-319;;045-951-701-636-236;;150-512-327-210-48X;;022-997-664-996-345;;047-237-206-017-563;;017-940-142-904-249;;081-098-345-341-182;;010-847-093-078-575;;027-829-588-585-761;;153-232-460-964-283;;158-261-806-420-924;;126-128-839-153-523;;006-504-311-182-612;;098-808-864-401-942;;122-388-810-565-095;;126-434-971-916-802;;062-095-790-501-25X;;083-348-315-692-16X;;085-498-590-431-913;;096-352-881-129-295;;141-785-095-849-82X;;104-063-848-067-130;;069-591-544-766-903;;027-127-290-904-954;;010-872-968-433-256;;037-574-244-923-342;;095-163-015-743-716;;018-560-322-257-247;;078-629-783-492-046;;032-905-603-444-928;;068-050-852-096-624;;029-171-836-207-263;;028-668-540-796-174;;028-668-540-796-174;;001-076-067-628-36X;;005-893-666-286-846;;079-996-842-246-699;;039-289-782-216-880;;043-632-912-449-253;;006-451-527-297-818;;032-412-591-971-193;;050-491-094-261-212;;061-186-684-189-36X;;041-610-673-797-380;;048-739-184-191-048;;061-770-380-357-689;;023-157-064-831-058;;005-785-820-497-820;;004-571-213-214-147;;117-298-184-780-248;;139-370-722-026-325;;022-717-243-626-689;;001-168-243-787-836;;003-692-671-892-767;;146-959-413-651-106;;009-255-453-457-663;;022-597-328-979-199;;097-412-635-296-694;;015-907-704-662-089;;026-151-208-979-214;;101-171-874-734-776;;007-242-440-136-566;;010-401-085-673-837;;036-787-898-930-499;;010-929-566-271-076;;027-221-602-638-634;;100-286-864-518-416;;012-388-439-961-094;;055-509-434-690-182;;032-004-299-797-893;;030-979-115-550-499;;022-879-584-224-460;;084-341-539-493-404;;088-437-095-235-130;;027-177-154-094-913;;020-026-183-926-325;;019-911-024-298-495;;120-184-720-533-797;;030-130-464-546-217;;110-094-292-858-47X;;091-231-835-456-006;;005-631-024-674-820;;101-575-504-070-651;;005-426-365-134-686;;008-878-757-321-700;;008-340-022-598-528;;004-574-009-337-856;;063-797-097-486-664;;169-736-421-398-039;;105-994-509-610-153;;040-375-581-789-283;;029-884-043-437-78X;;013-673-906-914-932;;093-281-504-176-200;;005-433-555-845-783;;064-029-904-826-616;;014-268-011-522-679;;047-362-058-327-502;;059-408-333-766-70X;;062-061-052-321-497;;042-364-181-188-082;;113-394-540-007-150;;001-833-327-326-444;;089-193-344-157-806;;113-109-583-058-980;;110-902-470-115-883;;047-294-079-836-486;;002-425-038-765-735;;038-346-034-366-375;;066-146-798-965-262;;021-089-222-463-71X;;007-168-099-008-401;;031-957-451-453-064;;109-373-051-579-919;;030-859-841-509-259;;045-237-747-815-813;;017-239-464-122-703;;002-921-094-507-370;;050-017-203-544-775;;104-277-007-929-625;;018-958-246-350-086;;059-853-971-443-396;;023-907-179-348-058;;075-807-103-343-793;;080-050-592-171-046;;031-166-703-585-08X;;189-306-471-756-979;;041-428-113-293-001;;038-037-978-931-264;;019-654-552-765-603;;036-786-233-907-636;;018-078-335-572-806;;099-290-765-461-205;;030-761-388-449-490;;052-143-608-436-131;;008-226-221-097-647;;078-209-348-576-455;;089-633-612-001-004;;120-710-247-962-517;;002-945-101-700-774;;037-194-000-791-81X;;146-280-751-006-918;;182-139-657-761-848;;043-147-746-491-691;;041-189-067-181-870;;012-637-499-221-105;;135-885-609-471-475;;022-238-533-842-744;;048-389-287-506-180;;018-989-643-656-697;;041-329-647-699-213;;043-596-978-783-486;;019-779-601-634-917;;053-128-465-484-881;;058-589-196-667-041;;099-108-177-239-268;;026-597-138-156-613;;062-670-857-477-054;;084-734-056-460-170;;009-333-452-920-135;;010-850-616-527-606;;095-359-992-848-941;;083-360-261-831-129;;068-601-220-787-847;;011-377-674-907-872;;179-552-640-659-549;;015-623-518-697-144;;025-944-755-967-03X;;035-537-674-004-113;;007-005-818-132-358;;141-920-816-342-666;;006-873-363-111-668;;078-886-911-253-419;;023-874-622-768-279;;053-908-725-120-441;;027-033-711-563-119;;084-382-055-323-434;;015-841-839-428-08X;;017-399-857-000-881;;094-876-980-967-766;;053-901-990-601-316;;114-407-414-536-306;;092-380-940-527-529;;035-330-063-258-167;;009-136-082-279-13X;;055-788-913-950-003;;050-513-346-896-80X;;031-933-089-611-974;;079-944-676-961-034;;000-133-235-371-009;;081-452-111-536-816;;019-590-397-412-17X;;128-901-299-587-74X;;010-020-681-821-091;;042-423-418-475-539;;068-821-001-542-983;;018-934-238-795-193;;011-020-186-750-886;;117-492-031-514-87X;;065-162-993-535-51X;;081-507-984-297-637;;027-990-295-239-719;;001-466-527-996-328;;027-826-420-479-03X;;077-140-409-267-690;;087-464-638-639-025;;025-146-253-241-793;;000-267-213-967-50X;;093-724-494-618-609;;124-275-393-571-41X;;068-521-955-594-560;;031-066-822-995-403;;034-499-243-336-537;;078-020-406-613-471;;045-362-643-830-026;;029-041-317-917-380;;013-039-312-104-66X;;030-226-878-795-594;;011-923-052-324-723;;011-552-704-333-933;;138-638-667-066-487;;012-668-687-960-29X;;020-473-776-487-596;;029-402-092-523-225;;021-724-385-934-424;;003-036-556-540-859;;000-647-267-694-484;;066-662-118-303-62X;;053-660-915-978-91X;;097-773-387-318-439;;010-159-493-399-221;;036-036-233-972-857;;064-538-717-151-364;;122-373-655-693-959;;003-813-666-853-382;;074-744-973-712-298;;160-519-052-068-705;;044-306-689-778-275;;129-273-407-931-838;;032-728-154-591-070;;020-704-332-523-176;;095-036-407-766-923;;005-001-316-365-345;;029-653-102-379-412;;082-863-413-822-327;;130-557-982-448-359;;010-503-176-197-239;;026-396-339-084-010;;088-434-038-364-143;;110-622-018-928-961;;026-367-037-139-802;;017-729-084-063-643;;053-887-446-496-059;;111-109-974-501-414;;041-461-899-032-384;;030-425-987-723-110;;007-181-598-202-221;;004-100-004-646-006;;014-169-184-148-626;;056-370-822-404-873;;092-760-851-706-263;;065-097-473-442-493;;030-660-067-609-024;;164-403-066-288-611;;031-584-564-704-369;;047-580-366-679-441;;085-764-009-624-439;;027-314-030-808-345;;052-947-986-013-690;;000-234-931-492-675;;073-419-783-934-185;;048-666-647-905-365;;093-509-508-230-620;;087-477-650-364-59X;;033-756-776-033-780;;017-561-716-268-836;;040-635-027-762-84X;;046-731-814-106-92X;;006-516-075-151-31X;;000-870-842-639-900;;009-738-327-233-69X;;028-294-432-381-795;;014-729-984-201-416;;074-582-134-846-704;;101-797-963-804-734;;012-080-214-127-41X;;079-141-143-704-263;;048-183-620-015-85X;;081-092-403-760-75X;;017-185-661-050-007;;022-944-275-314-68X;;042-751-409-162-883;;032-459-914-054-209;;007-339-268-863-200;;051-315-531-263-042;;034-330-993-923-294;;031-118-508-476-586;;082-902-765-648-368;;020-682-017-511-509;;137-791-867-210-863;;106-136-224-518-463;;011-243-931-881-746;;059-478-289-803-609;;073-102-472-393-46X;;008-076-695-732-453;;112-039-702-206-214;;007-496-126-787-125;;070-434-249-460-174;;013-885-021-097-853;;016-759-138-450-894;;015-801-694-447-055;;019-627-964-331-373;;082-984-043-695-164;;037-740-603-895-357;;011-657-979-926-27X;;003-242-603-416-269;;083-634-098-131-485;;048-439-321-617-128;;110-630-331-648-229;;020-065-207-907-092;;031-075-424-243-630;;006-095-947-008-535;;024-253-203-317-101;;055-852-081-735-610;;025-834-245-974-873;;084-748-487-156-928;;115-802-414-738-000;;035-328-575-802-514;;018-351-785-584-614;;094-815-381-871-763;;081-753-724-687-173;;079-274-785-935-791;;063-155-730-882-853;;067-127-654-169-729;;048-972-529-594-020;;054-304-933-298-139;;017-049-171-562-572;;099-270-483-107-007;;142-164-397-210-970;;104-283-497-946-575;;046-036-272-703-281;;075-912-302-795-48X;;111-570-270-686-786;;077-066-325-033-341;;029-811-479-361-870;;000-654-286-546-079;;012-837-528-765-07X;;069-296-641-163-256;;039-149-059-983-63X;;065-815-544-501-870;;019-394-264-649-327;;046-262-147-203-697;;008-125-648-563-747;;030-861-724-466-58X;;015-214-531-219-780;;028-383-058-454-759;;135-513-407-563-622;;058-530-733-727-374;;013-392-307-146-301;;063-864-581-855-676;;003-416-495-423-02X;;016-250-517-165-602;;077-722-555-854-551;;038-624-922-825-362;;035-070-408-027-340;;049-937-366-109-256;;010-030-039-052-116;;061-267-522-126-985;;089-860-020-044-940;;040-712-467-075-177;;013-754-548-416-363;;030-425-714-928-399;;035-769-575-764-291,6467175;;10.2337/diacare.25.5.869;;11978683;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;6363212;;10.1016/0378-1119(83)90222-6;;11880038;;10.1016/s1074-5521(02)00094-7;;10.1002/macp.1978.021790204;;10.1023/a:1015825027737;;2052513;;7763976;;10.1016/0958-1669(93)90011-k;;10.2337/diacare.15.6.755;;1600835;;1560827;;10.1038/356537a0;;10.1021/ja00202a052;;1911037;;6220717;;10.1016/0006-291x(83)91828-4;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;10.1016/s0040-4020(01)90305-9;;10.1126/science.3140377;;3140377;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;6757758;;10.1038/300706a0;;10.1016/s0040-4039(01)90461-7;;10.1016/0003-2697(83)90131-8;;6193731;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.3.co;2-c;;10.1002/(sici)1096-9861(19970310)379:2<226::aid-cne5>3.0.co;2-5;;9050787;;10.2337/diabetes.45.11.1572;;10.2337/diab.45.11.1572;;8866563;;875032;;10.1016/s0022-2836(77)80200-3;;10.1016/0197-0186(94)90047-7;;7950964;;10.1016/s0021-9258(18)82348-1;;8340419;;10.1038/nsb0594-283;;7664033;;2994214;;10.1126/science.2994214;;1733123;;10.1093/ajcn/55.2.538s;;10.3109/03639049209046327;;8352595;;10.1146/annurev.bi.62.070193.002411;;1332541;;10.1016/0003-2697(92)90433-8;;10.1006/jmbi.1997.1132;;9245591;;10.1111/j.1432-1033.1995.0788h.x;;10.1111/j.1432-1033.1995.tb20622.x;;7607253;;10.1096/fasebj.13.1.41;;9872928;;10.1146/annurev.bi.58.070189.003043;;10.1146/annurev.biochem.58.1.575;;2549857;;10.1006/prep.1997.0744;;9226723;;10.1016/s0169-409x(03)00108-x;;14499706;;10.1111/j.1440-1681.1978.tb00650.x;;639358;;pmc252500;;2993646;;10.1128/jvi.56.1.153-160.1985;;10.1021/jo034984x;;14604354;;10.1016/0076-6879(87)54086-1;;2828857;;10.1016/0076-6879(87)54086-1;;2828857;;3541892;;10.1042/bj2370001;;pmc1146940;;2438771;;10.1126/science.2438771;;7030620;;10.3109/10409238109108703;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203;;12148987;;10.1021/ja027007w;;12920298;;10.1126/science.1084772;;10.1002/chin.198535327;;10.1016/s0958-1669(00)00200-7;;11287238;;10.1016/s0958-1669(98)80109-2;;9664053;;8703002;;10.1074/jbc.271.36.21969;;3286212;;10.2165/00003495-198835030-00003;;2250094;;10.1093/oxfordjournals.jhered.a111019;;7160534;;10.2337/diab.31.1.s24;;10.1126/science.3685986;;3685986;;10.1002/anie.199506211;;10.1021/ja961216x;;1785831;;10.1111/j.1749-6632.1991.tb49017.x;;10.1021/jo00241a009;;pmc369166;;3915774;;10.1128/mcb.5.12.3376-3385.1985;;10.1128/mcb.5.12.3376;;10.1038/1921227a0;;13882203;;10.1242/dev.121.2.439;;7768185;;8850022;;10.1385/0-89603-332-5:369;;pmc215567;;10.1128/jb.158.3.1165-1167.1984;;6327630;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.3.co;2-9;;10.1002/(sici)1097-0290(19991120)65:4<382::aid-bit2>3.0.co;2-i;;10506413;;10966479;;10.1146/annurev.biochem.69.1.923;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1128/jb.154.2.737-742.1983;;pmc217523;;6841315;;8314773;;10.1016/s0021-9258(19)85209-2;;7623902;;10.1056/nejm199508313330902;;10.1021/ja0370037;;14505376;;15501033;;10.1016/j.bmcl.2004.09.059;;1458545;;12119302;;10.1074/jbc.m205854200;;10.1111/j.1749-6632.1991.tb49014.x;;1785800;;10.1089/neu.1996.13.309;;8835798;;9398858;;10.1038/ng1297-491;;10.1126/science.1057718;;11313495;;11102869;;10.1016/s1367-5931(00)00148-4;;10.1021/bi9617973;;9116020;;10.1038/nrd1088;;12750738;;10.1128/mcb.10.4.1633-1641.1990;;10.1128/mcb.10.4.1633;;1690848;;pmc362268;;pmc311518;;10.1093/nar/14.12.5115;;3460029;;1883529;;10.1007/bf01024990;;2187475;;10.1016/0076-6879(91)02017-4;;1784180;;10.1126/science.1553546;;1553546;;9989500;;10.1016/s0092-8674(00)80962-9;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1002/bit.260290911;;18576565;;12754376;;pmc164450;;10.1073/pnas.1132122100;;10.1016/j.chembiol.2003.11.004;;14652071;;2647707;;10.1007/bf02628459;;1568242;;10.1016/0092-8674(92)90402-x;;10.1021/ja01523a064;;10.1007/978-3-642-71589-1_3;;3816299;;10.1093/nar/16.14.6987;;3405755;;pmc338346;;3862099;;10.1073/pnas.82.17.5824;;pmc390645;;17878606;;10.1507/endocrj.kr07e-002;;10.1002/pro.5560070223;;9521119;;pmc2143905;;8741989;;10.1021/bc950074d;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1021/bc00015a010;;1381617;;10.1016/s1074-5521(97)90312-4;;9375252;;10.1016/s0002-9343(97)00254-4;;9428832;;1444338;;10.1007/bf00584464;;8661131;;10.1006/geno.1996.0349;;10.1021/bc00014a008;;1325188;;8891346;;161245;;10.1016/0378-1119(79)90009-x;;8269798;;10.2337/diacare.16.10.1387;;10.1099/00221287-132-12-3459;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;10.1016/0076-6879(90)85003-7;;2116575;;1785812;;10.1111/j.1749-6632.1991.tb49016.x;;1366535;;10.1038/nbt0490-343;;9558343;;10.1021/bi972685u;;10.1126/science.281.5374.269;;9657724;;3889852;;10.1093/nar/13.9.3305;;pmc341236;;10.1006/prep.2002.1624;;12071713;;pmc2946115;;20882112;;10.1002/anie.199728251;;10.1074/jbc.m003696200;;11006270;;10.1021/ar9901570;;11560472;;10.1021/bi035320k;;10.1021/bi035320k.s001;;14730967;;10.1016/s0021-9258(17)30417-9;;248056;;10.1021/ar00024a001;;10.1021/bi00419a012;;3061451;;10.1002/j.1460-2075.1990.tb08287.x;;2184035;;pmc551863;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0065-2571(69)90016-8;;4244004;;11883961;;10.1006/bbrc.2002.6607;;10.1073/pnas.75.4.1929;;347451;;pmc392455;;10.1038/nbt0202-177;;11821864;;6254992;;10.1016/s0021-9258(19)70246-4;;10.1021/ja00976a035;;5980877;;10.1016/s1367-5931(02)00376-9;;12470735;;10.1021/ja9813109;;10.1021/ja992204p;;363146;;10.1021/bi00616a007;;6256394;;10.1016/s0021-9258(19)69976-x;;10.1006/bbrc.1998.8239;;9514906;;pmc383928;;10.1073/pnas.76.8.3829;;386351;;1577399;;10.1055/s-2007-1003271;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;7758582;;10.1016/0014-5793(95)00408-2;;8003476;;10.1021/bi00189a013;;7530860;;10.1126/science.7530860;;10.1056/nejm199803263381303;;9516221;;412251;;10.1126/science.412251;;10.1128/jb.153.1.163-168.1983;;pmc217353;;6336730;;10.1126/science.7939659;;7939659;;8703034;;10.1074/jbc.271.36.22203;;10.1021/ja01511a053;;10.1002/macp.1979.021800528;;10.1111/j.1365-2265.1991.tb03490.x;;1889135;;10.1126/science.6238407;;6238407;;10.1146/annurev.bi.54.070185.003025;;2992359;;10.1146/annurev.biochem.54.1.565;;10.1021/ar00158a001;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;16773196;;10.3892/ijo.29.1.163;;9223335;;pmc21577;;10.1073/pnas.94.15.8179;;10.1016/s0040-4020(96)01195-7;;3894007;;pmc554210;;10.1002/j.1460-2075.1985.tb03653.x;;10.1172/jci23606;;pmc1088017;;15902306;;17068132;;10.1210/en.2006-1168;;10.1016/s0040-4020(00)00833-4;;11752401;;10.1073/pnas.012583299;;pmc117506;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.3.co;2-j;;10.1002/(sici)1097-0290(1999)66:3<180::aid-bit6>3.0.co;2-s;;10577472;;10.1023/a:1005624811710;;10835240;;10.1021/bp000031y;;10.1002/bit.1121;;10.1002/bit.1121.abs;;11410855;;10.1039/jr9490003315;;389741;;10.1016/0378-1119(79)90029-5;;2216760;;pmc332298;;10.1093/nar/18.19.5667;;1422046;;12754495;;10.1038/nsb934;;10.1080/00397919208019100;;10.1016/s1367-5931(00)00141-1;;11102863;;10.1021/jo00269a022;;9185859;;10.1016/s0378-1119(97)00019-x;;16076449;;10.1016/j.ymeth.2005.04.001;;9358183;;pmc147087;;10.1093/nar/25.22.4685;;pmc30127;;11226228;;10.1073/pnas.031488298;;10.1016/0092-8674(84)90283-6;;6386179;;10.1016/0076-6879(87)54084-8;;3323812;;3165526;;10.1093/nar/16.14.7207;;pmc338387;;6096830;;pmc320472;;10.1093/nar/12.24.9441;;8305530;;10.1021/bc00024a025;;3095839;;10.1073/pnas.83.22.8604;;pmc386979;;10.1007/s001250050498;;8781766;;10.1007/bf00418542;;10.1021/bi026856t;;12693945;;10.1016/0021-9673(86)80093-0;;3488324;;10.1016/0076-6879(87)54085-x;;3323813;;3881765;;10.1073/pnas.82.2.488;;pmc397064;;10.1002/jobm.3620250210;;10.1074/jbc.c500457200;;16436388;;pmc2637204;;pmc367493;;3023819;;10.1128/mcb.6.1.142;;10.1128/mcb.6.1.142-149.1986;;8554512;;10.1042/bj3120725;;pmc1136174;;10.1002/jbm.820150212;;7348718;;10.2144/99261bm05;;9894589;;10.1016/s0958-1669(98)80035-9;;9821278;;10.1006/abio.1997.2428;;9417773;;pmc21768;;10220370;;10.1073/pnas.96.9.4780;;10.1021/ja029433n;;12580587;;8632803;;10.1038/381442a0;;pmc307151;;7659531;;10.1093/nar/23.15.3067;;10.1016/s1097-2765(01)00369-0;;11684012;;10.1038/85080;;11224539;;2497580;;10.1016/0042-6822(89)90348-6;;10.1016/0006-8993(91)90784-s;;1723639;;8347599;;10.1021/bi00082a015;;10.7326/0003-4819-128-3-199802010-00002;;9454525;;11273699;;pmc7125544;;10.1006/jmbi.2001.4518;;10.1126/science.276.5315.1125;;9173543;;8613964;;12810643;;pmc386678;;3532104;;10.1073/pnas.83.19.7177;;10.1099/0022-1317-70-12-3501;;2691634;;10.2337/diacare.24.3.489;;11289473;;7473593;;10.1021/jm00023a005;;10.1016/s1044-5765(05)80035-1;;9427842;;10.1016/s0079-6603(08)61031-4;;10.1021/ja9925150;;9310317;;10.1242/dev.124.17.3221;;10.1021/ja0025806;;10.1021/ja0284153;;12537491;;10954682;;7663123;;10.1146/annurev.bb.24.060195.002251;;10.1146/annurev.biophys.24.1.435;;9581754;;10.1016/s0896-6273(00)81001-6;;10.1146/annurev.micro.42.1.177;;10.1146/annurev.mi.42.100188.001141;;3059993;;2695080;;10.1002/bies.950110404;;3030893;;10.1016/0378-1119(86)90356-2;;10.1111/j.1464-5491.1994.tb00333.x;;7955995;;10933852;;10.1006/abio.2000.4667;;9473496;;10.1006/bbrc.1998.8073;;6337369;;10.1073/pnas.80.1.1;;pmc393297;;10764591;;10.1006/jmbi.2000.3658;;10.1038/302543a0;;6403870;;10.1002/jcp.20847;;17063460;;pmc3266413;;22210323;;10.2337/db11-0838;;14652075;;10.1016/j.chembiol.2003.10.010;;pmc341328;;10.1093/nar/14.24.9679;;3027659;;10.1021/ja00246a064;;6322300;;10.1126/science.6322300;;pmc320064;;6473105;;10.1093/nar/12.15.6159;;10.1016/0022-2836(70)90057-4;;5420325;;4973231;;10.1016/s0021-9258(18)93152-2;;10.1016/s0167-4889(02)00256-2;;12183061;;10858549;;10.1016/s0167-4781(00)00067-1;;10.1016/s0167-4781(98)00255-3;;9931477;;10.1056/nejm199411033311803;;7935656;;9593693;;10.1074/jbc.273.22.13570;;10.1126/science.2649980;;2649980;;7716551;;10.1126/science.7716551;;10.21236/ada299991;;10.1093/protein/1.3.151;;3333844;;10.1021/ja9940064;;10.1021/ja001450u;;9660775;;10.1074/jbc.273.29.18161;;10.1093/oxfordjournals.jbchem.a022221;;9832608;;10.1016/s0021-9258(18)89400-5;;3838308;;9187149;;10.1242/dev.124.11.2235;;10.1126/science.164.3880.719;;5778021;;10.1021/bk-1997-0680.ch012;;pmc138918;;11276432;;10.1186/gb-2001-2-3-reviews3005;;8883961;;10.1016/0169-328x(96)00108-8;;10.1016/b978-0-08-052349-1.00116-5;;6307823;;10.1016/0378-1119(83)90107-5;;11948130;;pmc42512;;7877976;;10.1073/pnas.92.5.1327;;10.1002/1522-2675(20000906)83:9<2277::aid-hlca2277>3.0.co;2-l;;9591139;;10.2144/98245rr03;;10.1016/0003-2697(82)90240-8;;6289696;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;8431294;;11356929;;10.1038/bjc.1992.272;;pmc1977825;;1380282;;10.1038/343033a0;;1688644;;10.1093/bioinformatics/18.7.980;;12117796;;436836;;10.1111/j.1432-1033.1979.tb12865.x;;10490103;;10.1016/s0092-8674(00)80051-3;;10.1021/ja00965a060;;3194752;;10.1126/science.3194752;;10.1146/annurev.ge.18.120184.001133;;6084980;;10.1074/jbc.270.50.29813;;8530375;;12845521;;10.1007/s00441-003-0756-7;;8798573;;10.1074/jbc.271.39.23607;;10.1016/s0021-9673(01)95395-6;;6355135;;3614380;;10.1038/328731a0;;9356443;;10.1073/pnas.94.23.12297;;pmc24913;;10.1021/ja00007a055;;10.1007/bf00331655;;10.1002/yea.320080602;;1502852;;9129118;;10.1016/s0024-3205(96)00595-4;;10.1006/mcpr.1994.1013;;7935517;;10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4;;12203546;;10.1074/jbc.271.37.22376;;8798399;;12409460;;10.1093/nar/gkf589;;pmc135798;;3165194;;10.1093/nar/16.14.6361;;pmc338301;;10.1074/jbc.271.38.23169;;8798511;;12244330;;10.1038/nbt742;;10.1007/bf02921514;;2024978;;10.1021/ma00056a005;;10.1126/science.287.5460.2007;;10720325;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/nar/16.3.803;;pmc334720;;2830594;;10.1016/s0021-9258(18)62817-0;;5528240;;10480527;;10.2337/diacare.22.9.1568;;10.1006/prep.1997.0851;;9535699;;10.1006/prep.1995.1002;;7756834;;10.1126/science.1566069;;1566069;;10.1161/01.cir.97.7.645;;9495299;;9516220;;10.1056/nejm199803263381302;;10.1016/0076-6879(87)35063-3;;3600302;;10.1002/dmrr.288;;12112940;;10.1021/ja00119a001;;10664452;;10.1016/s0014-5793(00)01120-0;;10.1038/292128a0;;6264321;;803646;;10.1038/254034a0;;6201207;;10.1002/bip.360220167;;10.1038/88129;;11329016;;9425898;;10.1038/ng0198-45;;10.1093/genetics/122.1.19;;2659436;;pmc1203683;;10.1128/jvi.68.2.766-775.1994;;pmc236513;;8289380;;10.1016/s0022-1759(96)00217-7;;9032414;;pmc38518;;10.1073/pnas.93.18.9850;;8790420;;6318086;;pmc370086;;10.1128/mcb.3.12.2156;;10.1128/mcb.3.12.2156-2165.1983;;3002241;;10.1146/annurev.ge.19.120185.002231;;10.1146/annurev.genet.19.1.423;;10.1016/s0021-9258(18)68577-1;;3372509;;10.1074/jbc.270.8.4121;;7876162;;10.1007/978-1-4684-3417-0_9;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1038/370389a0;;8047147;;10.1016/0022-2836(86)90385-2;;3537305;;1469691;;10.1021/jm00102a014;;10.1021/ja00203a067;;3156376;;pmc397196;;10.1073/pnas.82.4.1074;;10.1021/ja010731e;;11472182;;7482665;;10.1161/01.str.26.11.2154;;7737407;;10.1016/0014-5793(95)00324-3;;11317312;;29712367;;10.1002/1521-3773(20010417)40:8<1494::aid-anie1494>3.0.co;2-x;;3001650;;10.1093/nar/13.24.8765;;pmc318950;;pmc318949;;10.1093/nar/13.24.8749;;3001649;;6368319;;10.1016/0378-1119(83)90191-9;;10.1016/0168-3659(85)90001-x;;10.1021/jo011148j;;11975567;;7620563;;10.1385/0-89603-272-8:97;;10.1073/pnas.88.17.7806;;pmc52392;;1881916;;6248420;;10.1016/0378-1119(80)90133-x;;10.1016/s1046-5928(02)00641-1;;12651100;;10.1074/jbc.271.33.19991;;8702716;;8402094;;10.1002/bjs.1800800812;;10.1038/nbt0290-135;;1366557;;10.1056/nejmoa011300;;11794168;;9645477;;10.1016/s0014-5793(98)00489-x;;10.1021/ja992749j;;10.1128/jb.130.2.946-947.1977;;400800;;pmc235301;;10.1007/bf02798546;;4026282;;3128641;;10.1099/0022-1317-69-4-765;;pmc140882;;12518054;;10.1073/pnas.0234824100;;10.1126/science.1060077;;11313494;;10.1021/ja021381e;;12630856;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1016/0378-1119(85)90140-4;;3891521;;10.1002/(sici)1097-0177(199709)210:1<41::aid-aja5>3.0.co;2-1;;9286594;;10.1016/s0960-9822(95)00102-3;;7583099;;0007583099;;10.1021/bc00023a002;;8274513;;10.1016/0141-0229(92)90049-t;;1368988;;10.1038/321718a0;;18840786;;10.2337/db08-0392;;pmc2606881;;pmc344858;;6324193;;10.1073/pnas.81.5.1470;;pmc327233;;10.1093/nar/9.3.731;;6164048;;1785805;;10.1111/j.1749-6632.1991.tb49015.x;;10.1016/0014-3057(83)90016-2;;10.1021/bc00032a002;;7599259;;10.2337/diacare.24.4.720;;11315837;;10.1021/bi0300231;;12779328;;6225933;;10.1016/b978-0-12-765560-4.50036-8;;10.1016/0076-6879(83)00074-9;;6757864;;pmc326938;;10.1093/nar/10.20.6487;;10.1016/0076-6879(87)54083-6;;3323811,"Abuchowski, A. et al., “Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates”, Cancer Biochem. Biophys., Jun. 1984, 7(2): 175-86.;;Ahrén et al., “Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes”, Diabetes Care, 2002, 25(5): 869-75.;;Altschul, S.F. et al., “Basic local alignment search tool”, J. Mol. Biol., Oct. 5, 1990, 215(3): 403-10.;;Altschul, S.F. et al., “Gapped BLAST and Psi-BLAST: a new generation of protein database search programs”, Nucleic Acids Res., Sep. 1, 1997, 25(17): 3389-402.;;Amann, E. et al., “Vectors bearing a nybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli”, Gene, Nov. 1983, 25(2-3): 167-78.;;Anderson, J.C. et al., “Exploring the limits of codon and anticodon size”, Chem. Biol., Feb. 2002, 9(2): 237-44.;;Andresz, H. et al., “Chemische Synthese verzweigter Polysaccharide, 5: Kopplung von Oligosacchariden und Amylose an verschiedene Träer durch Hydrazonbindung”, Makromol. Chem. 1978, 179: 301, Abstract.;;Arakawa et al., “Protein-solvent interactions in pharmaceutical formulations”, Pharm. Res., 1991, 8(3): 285-291.;;Arnold, F.H., “Protein engineering for unusual environments”, Curr. Opin. Biotechnol., Aug. 1993, 4(4): 450-5.;;Azoulay, M. et al., “Glutamine analogues as Potential Antimalarials”, Eur. J. Med. Chem., 1991, 26(2): 201-5.;;Badman, M.K. et al., “Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States”, Cell Metabolism, Jun. 2007, 5: 426-437.;;Bailey, “Biguanides and NIDDM”, Diabetes Care, 1992, 15:755-72.;;Bain et al., “Ribosome-mediated incorporation of a non-standard amino acid into a peptide through expansion of the genetic code”, Nature, 1992, 356(6369):537-539.;;Bain, J.D. et al., “Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide”, J. Am. Chem. Soc., 1989; 111(20): 8013-8014.;;Baird et al., “The fibroblast growth factor family”, Cancer Cells, 1991, 3(6): 239-43.;;Ballance, D.J. et al., “Transformation of Aspergillus nidulans by the orotidine-5′- phosphate decarboxylase gene of Neurospora crassa”, Biochem. Biophys. Res. Commun., Apr. 15, 1983, 112(1): 284-9.;;Barany, F. et al., “Genetic disease detection and DNA amplification using cloned thermostable ligase”, Proc. Natl. Acad. Sci. USA, Jan. 1, 1991, 88(1): 189-93.;;Barton, D.H.R. et al., “Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alphaaminopimelic Acid and Appropriate Unsaturated Derivatives”, Tetrahedron, 1987, 43: 4297-4308.;;Bass, S. et al., “Mutant Trp repressors with new DNA-binding specificities”, Science, 1988, 242: 240-245.;;Batzer, M.A. et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus”, Nucleic Acids Res., Sep. 25, 1991, 19(18): 5081.;;Beach, D. et al., “Functionally homologous cell cycle control genes in budding and fission yeast”, Nature, Dec. 1982, 300: 706-709.;;Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis”, Tetrahedron Letts., 1981, 22(20): 1859-1862.;;Beauchamp, C.O. et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal. Biochem., May 1983, 131(1): 25-33.;;Belluardo et al., “Comparative localization of fibroblast growth factor receptor-1, -2, and -3 mRNAs in the rat brain: in situ hybridization analysis”, J. Comp. Neurol. (1997) 379(2): 226-46.;;Berkowitz et al., “Effect of troglitazone on insulin sensitivity an dpancreatic beta-cell function in women at high risk for NIDDM”, Diabetes, 1996, 45(11): 1572-9.;;Bernstein, F.C. et al., “The protein data bank: a computer-based archival file for macromolecular structures”, J. Mol. Biol., 1977, 112: 535-542.;;Biagini et al., “The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes”, Neurochem. Int., 1994, 25(1): 17-22.;;Boissel, J.P. et al., “Erythroprotein structure-function relationships. Mutant proteins that test a model of tertiary structure”, Jul. 25, 1993, 268(21): 15983-93.;;Boles, J.O. et al., “Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase”, Nat Struct Biol., May 1994, 1(5): 283-4.;;Botstein, D. and D. Shortie, “Strategies and applications of in vitro mutagenesis”, Science, Sep. 20, 1985, 229(4719): 1193-201.;;Bray, “Drug treatment of obesity”, Am. J. Clin. Nutr., 1992, 55(2 Suppl): 538S-544S.;;Broadhead et al., “The Spray Drying of Pharmaceuticals”, Drug Dev. Ind. Pharm., 1992, 18(11/12):1169-1206.;;Brunner, J. et al., “New photolabeling and crosslinking methods”, Annu. Rev. Biochem., 1993, 62: 483-514.;;Buchner, J. et al., “A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies”, Anal. Biochem., 1992, 205(2): 263-270.;;Bückmann et al., “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),” Makromol. Chem., 1981, 182: 1379-84.;;Budisa, N. et al., “Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins”, J. Mol. Biol., Jul. 25, 1997, 270(4): 616-23.;;Budisa, N. et al., “High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli”, Eur. J. Biochem., Jun. 1, 1995, 230(2): 788-96.;;Budisa, N. et al., “Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire”, FASEB J., Jan. 1999, 13(1): 41-51.;;Burgess et al., “The Heparin Binding (Fibroblast) Growth Factor Family of Proteins”, Annu. Rev. Biochem., 1989, 58: 575-606.;;Cai, X-Y et al., “Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-Inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells”, Protein Expression and Purifcation, 1997, 10(2): 263-74.;;Caliceti, P. and F.M. Veronese, “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates”, Adv. Drug. Deliv. Rev., Sep. 26, 2003, 55(10): 1261-1277.;;Cameron et al., “Effects of monosodium glutamate-induced obesity in mice on carbohydrate metabolism in insulin secretion”, Clin. Exp. Pharmacol. Physiol., 1978, 5(1): 41-51.;;Carbonell, L.F. et al., “Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells”, J. Virol., Oct. 1985, 56(1): 153-60.;;Carrasco, M. and R. Brown, “A Versatile Set of Aminoxy Amino Acids for the Synthesis of Neuropeptides”, J. Org. Chem., 2003, 68(23): 8853-8858.;;Carter, P. et al., “Improved oligonucleotide site-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987, 154: 382-403.;;Carter, P., “Improved oligonucleotide-directed mutagenesis using M13 vectors”, Methods Enzymol., 1987, 154: 382-403.;;Carter, P., “Site-directed mutagenesis”, Biochem J., Jul. 1, 1986, 237(1): 1-7.;;Cech, “The chemistry of self-splicing RNA and RNA enzymes”, Science, Jun. 19, 1987, 236(4808): 1532-9.;;Chaiken, I.M., “Semisynthetic peptides and proteins”, CRC Crit Rev. Biochem., 1981, 11(3): 255-301.;;Chin, J.W. and P.G. Schultz, “In vivo photocrosslinking with unnatural amino acid mutagenesis”, Chembiochem, Nov. 4, 2002, 3(11): 1135-7.;;Chin, J.W. et al., “Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli”, Proc. Natl. Acad. Sci. USA, Aug. 20, 2002, 99(17): 11020-4. Epub. Aug. 1, 2002.;;Chin, J.W. et al., “Addition of p-azido-L-phenylalanine to the genetic code of E. coli”, J. Am. Chem. Soc., Aug. 7, 2002, 124(31): 9026-7.;;Chin, J.W. et al., “An expanded eukaryotic genetic code”, Science, Aug. 15, 2003, 301(5635): 964-7.;;Christie, B.D. and H. Rapoport, “Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization”, J. Org. Chem., 1985, 50(8): 1239-1246.;;Clark, E.D.B., “Protein refolding for industrial processes”, Curr. Opin. Biotechnol., Apr. 2001, 12(2): 202-207.;;Clark, E.D.B., “Refolding of recombinant proteins”, Curr. Opin. Biotechnol., Apr. 1, 1998, 9(2): 157-163.;;Clark, R. et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”, J. Biol. Chem., Sep. 6, 1996, 271(36): 21969-77.;;Clissod et al., “Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential”, Drugs, 1988, 35:214-23.;;Coleman et al., “Fat(fat) and tubby(tub): two autosomal recessive mutations causing obesity syndromes in the mouse”, J. Hered., 1990, 81(6): 424-7.;;Coleman et al., “Other Potentially Useful Rodents as Models for the Study of Human Diabetes Mellitus”, Diabetes, 1982, 31(Suppl 1 Pt 2): 24-25.;;Corey, D.R. and P.G. Schultz, “Generation of a hybrid sequence-specific single-stranded deoxyribonuclease”, Science, 1987, 238(4832): 1401-1403.;;Cornish, V.W. et al., “Probing Protein Sturcture and Function with an Expanded Genetic Code”, Angew. Chem. Int. Ed. Engl., 34(6): 621-33.;;Cornish, V.W. et al., “Site-Specific Protein Modification Using a Ketone Handle”, J. Am. Chem. Soc., 1996, 118(34): 8150-8151.;;Coulier et al., “The FGF6 gene with the FGF multigene family”, Ann. NY Acad. Sci., 1991, 638:53-61.;;Craig, J.C. et al., “Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino] quinoline (Chloroquinine)”, J. Org. Chem., 1988, 53(6): 1167-1170.;;Cregg, J.M. et al., “Pichia pastoris as a host system for transformations”, Mol. Cell Biol., Dec. 1985, 5(12): 3376-85.;;Crick, F.H.C. et al., “General nature of the genetic code for proteins”, Nature, Dec. 30, 1961, 192: 1127-32.;;Crossley et al., “The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo”, Development, 1995, 121(2): 439-51.;;Dale et al., “Oligonucleotide-directed random mutagenesis using the phophorothioate method”, Methods Mol. Biol., 1996, 57: 369-374.;;Das, S. et al., “Transformation of Kluyveromyces fragilis”, J. Bacteriol., Jun. 1984, 158(3): 1165-7.;;Davis, G.D. et al., “New fusion protein systems designed to give soluble expression in Eschericia coli”, Biotechnol. Bioeng., Nov. 20, 1999, 65(4): 382-388.;;Dawson et al., “Synthesis of native proteins by chemical ligation”, Annu. Rev. Biochem., 2000, 69: 923-60.;;De Boer, H.A. et al., “The tac promoter: a functional hybrid derived from the trp and the lac promoters”, Proc. Natl. Acad. Sci. USA, Jan. 1983, 80(1): 21-5.;;De Louvencourt, L. et al., “Transformation of Kluyveromyces lactis by killer plasmid DNA”, J. Bacteriol., May 1983, 154(2): 737-42.;;Debinski, W. et al., “A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin”, J. Biol. Chem., Jul. 5, 1993, 268(10): 14065-70.;;DeFronzo et al., “Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group”, N. Engl. J. Med., 1995, 333(9): 541-9.;;Deiters, A. et al., “Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cerevisiae”, J. Am. Chem. Soc., 2003, 125(39): 11782-11783.;;Deiters, A., “Site-specific PEGylation of proteins contianing unnatural amino acids”, Bioorg. Med. Chem. Lett., Dec. 6, 2004, 14(23): 5743-5.;;Delgado, C. et al., “The uses and properties of PEG-linked proteins”, Crit. Rev. Ther. Drug. Carrier Syst, 1992, 9(3-4): 249-304.;;Dennis, M.S. et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins”, J. Biol. Chem., Sep. 20, 2002, 277(38): 35035-43, Epub Jul. 15, 2002.;;Dickson et al., “Expression, processing, and properties of int-2”, Ann. NY Acad. Sci., 1991, 638:18-26.;;Dietrich et al., “Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats”, J. Neurotrauma, 1996, 13(6): 309-16.;;Dolphin, C.T. et al., “Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome”, Nat. Genet., Dec. 1997, 17(4): 491-4.;;Doring, V. et al., “Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway”, Science, Apr. 20, 2001, 292(5516): 501-4.;;Dougherty, D.A., “Unnatural amino acids as probes of protein structure and function”, Curr. Opin. Chem. Biol., Dec. 2000, 4(6): 645-52.;;Drummond et al., “Liposomal drug delivery systems for cancer therapy”, B. Teicher (ed.): Cancer Drug Discovery and Development, 2002, 161-213.;;Duewel, H. et al., “Incorporation of trifluoromethionine into a phage lysozyme: implications and a new marker for use in protein 19F NMR”, Biochemistry, Mar. 18, 1997, 36(11): 3404-16.;;Duncan, R., “The dawning era of polymer therapeutics”, Nat Rev. Drug. Discov., May 2003, 2(5): 347-60.;;Edwards et al., “A bacterial amber suppressor in Saccharomyces cerevisiae is selectively recognized by a bacterial aminoacyl-tRNA synthetase”, Mol. Cell Biol., 1990, 10(4): 1633-41.;;Eghtedarzadeh, M.K. and S. Henikoff, “Use of oligonucleotides to generate large deletions”, Nucleic Acids Res., Jun. 25, 1986, 14(12): 5115.;;Elling, L. and M.R. Kula, “Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies”, Biotechnol. Appl. Biochem., Jun. 1991, 13(3): 354-62.;;Elliott, S. et al., “Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization”, J. Protein. Chem., Feb. 1990, 9(1): 95-104.;;Ellman, J.A. et al., “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins”, Methods in Enz., 1992, 202: 301-336.;;Ellman, J.A. et al., “Site-specific incorporation of novel backbone structures into proteins”, Science, Jan. 10, 1992, 255(5041): 197-200.;;England, P.M. et al., “Backbone mutation in transmembrane domains of a ligand-gated ion channel: implications for the mechanisms of gating”, Cell, Jan. 8, 1999, 96(1): 89-98.;;Eppstein et al., “Biological Activity of Liposome-Encapsulated Murine Interferon is Mediated by a Cell Membrane Receptor”, Proc. Natl. Acad. Sci USA, 1985, 82: 3688-3692.;;European Patent Office, “Invitation to Pay Additional Fees”, Form PCT/ISA/206, International Application No. PCT/US2015/057228, Feb. 10, 2016.;;Fieschko, J.C. et al., “Controlled expression and purification of human immune interferon from high-cell-density fermentations of Saccharomyces cerevisiae”, Biotech. Bioeng., 1987, 29(9): 1113-21.;;Forster, A.C. et al., “Programming peptidomimetic syntheses by translating genetic codes designed de novo”, Proc. Natl. Acad. Sci. USA, May 27, 2003, 100(11): 6353-7. Epub May 16, 2003.;;Frankel, A. et al., “Encodamers: unnatural peptide oligomers encoded in RNA”, Chem. Biol., Nov. 2003, 10(11): 1043-50.;;Fraser, M.J. et al., “Expression of eucaryotic genes in insect cell cultures”, In Vitro Cell. Dev. Biol., 1989, 25: 225-235.;;Friedman et al., “Tackling a weighty problem”, Cell, 1992, 69: 217-220.;;Friedman, O.M. and R. Chatterrji, “Synthesis of Derivatives of Glutamate as Model Substrates for Anti-Tumor Agents”, J. Am. Chem. Soc., 1959, 81(14): 3750-3752.;;Friesen et al., “The regulation of baculovirus gene expression”, Curr. Top. Microbiol. Immunol., 1986, 131: 31-49.;;Fritz, H.J. et al., “Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro”, Nucleic Acids Res., Jul. 25, 1988, 16(14B): 6987-99.;;Fromm, M. et al., “Expression of Genes Transferred into Monocot and Dicot Plant Cells by Electroporation”, Proc. Natl. Acad. Sci. USA, 1985, 82: 5824-8.;;Fukumoto, S., “Actions and Mode of Actions of FGF19 Subfamily Members”, Endocrine Journal, 2008; 55(1): 23-31.;;Furter, R., “Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli”, Protein Sci., Feb. 1998, 7(2): 419-26.;;Gaertner, H.F. and R.E. Offord, “Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins”, Bioconjug. Chem., Jan.-Feb. 1996, 7(1): 38-44.;;Gaertner, H.F. et al., “Chemo-enzymatic backbone of engineering of proteins. Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor”, J. Biol. Chem., Mar. 11, 1994, 269(10): 7224-30.;;Gaertner, H.F. et al., “Construciton of protein analogues by site-specific condensation of unprotected fragments”, Bioconjug. Chem., May-Jun. 1992, 3(3): 262-8.;;Gallivan, J.P. et al., “Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins”, Chem. Biol., Oct. 1997, 4(10): 739-49.;;Garber et al., “Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial”, Am. J. Med., 1997, 102: 491-97.;;Gellissen, G. et al., “Heterologous protein production in yeast”, Antoine Van Leeuwenhoek, Aug. 1992, 62(1-2): 79-93.;;Gemel et al., “Structure and sequence of human FGF8”, Genomics, 1996, 35:253-257.;;Geoghegan, K.F. and J.G. Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modifcation at N-terminal serine”, Bioconjug. Chem., Mar.-Apr. 1992, 3(2): 138-146.;;Ghosh et al., “Molecular cloning and characterization of human FGF8 alternative messenger RNA forms”, Cell Growth and Differentiation, 1996, 7(10): 1425-1434.;;Gillam, S. and M. Smith, “Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum oligodeoxyribonucleotide length”, Gene, 1979, 8(1): 81-97.;;Giugliano et al., “Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women”, Diabetes Care, 1993, 16:1387-90.;;Gleeson, M.A. et al., “Transformation of the methylotrophic yeast hansenula polymorphica”, J. Gen. Microbiol., 1986, 132: 3459-3465.;;Goeddel, D.V. et al., “Synthesis of human fibroblast interferon by E. coli”, Nucleic Acids Res., Sep. 25, 1980, 8(18): 4057-74.;;Goeddel, D.V., “Systems for heterologous gene expression”, Methods Enzymol., 1990, 185: 3-7.;;Goldfarb et al., “Expression and possible functions of the FGF-5 gene”, Ann. NY. Acad. Sci., 1991, 638:38-52.;;Goodson, R.J. and N.V. Katre, “Site-directed pegylation of recombinant interleukin-2 at its glycosylation site”, Biotechnology (NY), Apr. 1990, 8(4): 343-346.;;Graves, S.W. et al., “Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase”, Biochemistry, Apr. 28, 1998, 37(17): 6050-6058.;;Griffin, B.A. et al., “Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells”, Science, 1998, 281:269-272.;;Grundström, T. et al., “Oligonucleotide-directed mutagenesis by microscale ‘shotgun’ gene synthesis”, Nucleic Acids Res., May 10, 1985, 13(9): 3305-3316.;;Gu, Z. et al., “Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies”, Protein Expr. Purif, Jun. 2002, 25(1): 174-9.;;Guckian, K.M. and E.T. Kool, “High Precise Shape Mimicry by a Difluorotoluene Deoxynucleoside, and Replication-Competent Substitute for Thymidine”, Angew. Chem. Int. Ed. Engl., 1998, 36(24): 2825-8.;;Hamano-Takaku, F. et al., “A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine” J. Biol. Chem., Dec. 22, 2000, 275(51): 40324-8.;;Hang, H.C. and C.R. Bertozzi, “Chemoselective approaches to glycoprotein assembly”, Acc. Chem. Res., Sep. 2001, 34(9): 727-36.;;Harmer et al., “The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity”, Biochemistry, 2004, 43:629-640.;;Harris, J.M. et al., “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives”, J. Polym. Sci. Chem. Ed., 1984, 22:341-352.;;Harris, J.M., “Laboratory Synthesis of Polyethylene Glycol Derivatives”, JMS-Rev. Macromol. Chem. Phys., 1985, C25(3): 325-373.;;Hecht et al., “Chemical aminoacylation of tRNA's”, J. Biol. Chem., 1978, 253(13): 4517-20.;;Hecht, “Probing the synthetic capabilities of a center of biochemical catalysis”, Acc. Chem. Res., 1992, 25(12): 545-552.;;Heckler et al., “Ribosomal binding and dipeptide formation by misacylated tRNA(Phe)'s”, Biochemistry, 1988, 27(19): 7254-62.;;Hendrickson, W.A. et al., “Selenomethionyl proteins produced for analysis of multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure”, EMBO J., May 1990, 9(5): 1665-72.;;Henikoff, S. and J.G. Henikoff, “Amino Acid Substitution Matrices from Protein Blocks”, Proc. Natl. Acad. Sci. USA, 1992, 89: 10915-9.;;Hess, B. et al., “Cooperation of glycolytic enzymes”, J. Adv. Enzyme Reg., 1969, 7: 149-67.;;Hinke et al., “Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1”, Biochem. Biophys. Res. Commun., 2002, 291(5): 1302-8.;;Hinnen, A. et al., “Transformation of yeast”, Proc. Natl. Acad. Sci. USA, Apr. 1978, 75(4): 1929-33.;;Hirao, I. et al., “An unnatural base pair for incoporating amino acid analogues into proteins”, Nat Biotechnol., Feb. 2002, 20(2): 177-82.;;Hitzeman, R.A. et al., “Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological screening technique”, J. Biol. Chem., Dec. 25, 1980, 255(24): 12073-80.;;Hoffmann, K and H. Bohn, “Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment”, J. Am. Chem., 1966, 88(24): 5914-5919.;;Hohsaka, T. and M. Sisido, “Incorporation of non-natural amino acids into proteins”, Curr. Opin. Chem. Biol., Dec. 2002, 6(6): 809-15.;;Hohsaka, T. et al., “Efficient Incorporation of Nonnatural Amino Acids with Large Aromatic Groups into Streptavidin in In Vitro Protein Synthesizing Systems”, J. Am. Chem. Soc., 1999, 121(1): 34-40.;;Hohsaka, T. et al., “Incorporation of Two Different Nonnatural Amino Acids Independently into a Single Protein through Extension of the Genetic Code”, J. Am. Chem. Soc., 1999, 151(51): 12194-12195.;;Holland, M.J. and J.P. Holland “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceralehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase”, Biochemistry, Nov. 14, 1978, 17(23): 4900-7.;;Holland, M.J. et al., “The primary structures of two yeast enolase genes. Homology between the 5′ noncoding flanking regions of yeast enolase and glyceraldehyde-3-phosphate dehydrogenase genes”, J. Biol. Chem., Feb. 10, 1981, 256(3): 1358-95.;;Hoshikawa et al., “Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain”, Biochem. Biophys. Res. Commun., 1998, 244(1): 187-91.;;Hsiao, C.L. and J. Carbon, “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”, Proc. Natl. Acad. Sci. USA, Aug. 1979, 76(8): 3829-33.;;Hubinger et al., “The effect of etomoxir on insulin sensitivity in type 2 diabetic patients”, Hormone Metab. Res., 1992, 24:115-18.;;Huisgen, R. In 1,3-Dipolar Cycloaddition Chemistry, vol. 1, 1984; Ed. A. Padwa; John Wiley and Sons, New York, 1-176.;;Hwang, K.J. et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study”, Proc. Natl. Acad. Sci. USA, Jul. 1980, 77(7): 4030-4.;;Ibba, M. and H. Hennecke, “Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids”, FEBS Lett., May 15, 1995, 364(3): 272-5.;;Ibba, M. et al., “Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase”, Biochemistry, Jun. 14, 1994, 33(23): 7107-12.;;Illangakekare et al., “Aminoacyl-RNA Synthesis Catalyzed by an RNA”, Science, 1995, 267:643-647.;;Inzucchi et al., “Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus”, New Engl. J. Med., 1998, 335:867-72.;;Itakura et al., “Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin”, Science, 1997, 198:1056-1063.;;Ito, H. et al., “Transformation of intact yeast cells treated with alkali cations”, J. Bacteriol., 1983, 153(1): 163-8.;;Jackson, D.Y. et al., “A designated peptide ligase for total synthesis of ribonuclease a with unnatural catalytic residues”, Science, Oct. 14, 1994, 266(1583): 243-7.;;Jakobsson, P.J. et al., “Identification and characterization of a novel human microsomal glutathione S-transferase with keukotriene C4 synthetase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase”, J. Biol. Chem., Sep. 6, 1996, 271(36): 22203-10.;;Jencks, W.P., “Studies on the Mechanism of Oxime and Semicarbazone Formation”, J. Am. Chem. Soc., 1959, 81(2): 475-481.;;Joppich, M. et al., “Peptides Flanked by Two Polymer Chains, 1; Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups”, Makromol. Chem., 1979, 180:1381-4.;;Jung et al., “The management of obesity”, Clinical Endocrinology, 1991, 35: 11-20.;;Kaiser, E.T. and D.S. Lawrence, “Chemical mutation of enzyme active sites”, Science, Nov. 2, 1984, 226(4674): 505-11.;;Kaiser, E.T. et al., “The chemical modification of enzymatic specificitiy”, Annu. Rev. Biochem., 1985, 54: 565-95.;;Kaiser, E.T., “Synthetic approaches to biologically active peptides and proteins including enzymes”, Acc. Chem. Res., 1989, 22(2): 47-54.;;Karlin, S. and S.F. Altschul, “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci. USA, Jun. 15, 1993, 90(12): 5873-7.;;Katoh et al., “FGF signaling network in the gastrointestinal tract (review)”, Int'l. J. Oncology, 2006, 29: 163-168.;;Kawamata et al., “Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction”, Proc. Natl. Acad. Sci., 1997, 94(15): 8179-84.;;Kayser, B. et al., “Alkyne bridged alpha-amino acids by palladium mediated coupling of alkynes with N-t-Boc-4-iodo-phenylalanine methyl ester”, Tetrahedron, 1997, 53(7): 2475-2484.;;Kelly, J.M. and M.J. Hynes, “Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans”, EMBO J., 1985, 4(2): 475-479.;;Kharitonekov et al., “FGF-21 as a novel metabolic regulator”, J. Clin. Investigation, Jun. 1, 2005, 115(6): 1627-1635.;;Kharitonekov et al., “The Metabolic State of Diabetic Monkeys is Regulated by Fibroblast Growth Factor-21”, Endocrinology, Feb. 1, 2007, 148(2): 774-781.;;Kiick, K.L. and D.A. Tirrell, “Protein Engineering by In Vivo Incorporation of Non-Natural Amino Acids: Control of Incorporation of Methionine Analogues by Methionyl-tRNA Synthetase”, Tetrahedron, 2000, 56: 9487-9493.;;Kiick, K.L. et al., “Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation”, Proc. Natl. Acad. Sci. USA, Jan. 8, 2002, 99(1): 19-24. Epub Dec. 18, 2001.;;Kim, D.M and J.R. Swartz, “Prolonging cell-free protein synthesis with a novel ATP regeneration system”, Biotechnol. Bioeng., 1999, 66(3): 180-8.;;Kim, D.M. and J.R. Swartz, “Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli”, Biotechnology Letters, 2000, 22:1537-1542.;;Kim, D.M. and J.R. Swartz, “Prolonging cell-free protein synthesis by selective reagent additions”, Biotechnol. Prog., May-Jun. 2000, 16(3): 385-90.;;Kim, D.M. and J.R. Swartz, “Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis”, Biotechnol. Bioeng., Aug. 20, 2001, 74(4): 309-16.;;King, F.E. and D.A.A. Kidd, “A New Synthesis of Glutamine and of gamma-Dipeptides of Glutamic Acid from Phthylated Intermediates”, J. Chem. Soc. 1949, 3315-3319.;;Kingsman, A.J. et al., “Replication in Saccharomyces cerevisiae of plasmid pBR313 carrying DNA from the yeast trpl region”, Gene, Oct. 1979, 7(2): 141-52.;;Kitts, P.A. et al., “Linearization of baculovirus DNA enhance the recovery of recombinant virus expression vectors”, Nucleic Acids Res., Oct. 11, 1990, 18(19): 5667-72.;;Klein, T.M. et al., “High-velocity microprojectiles for delivering nucleic acids into living cells”, Nature, 1987, 327(6117): 70-73.;;Kobayashi, T. et al., “Structural basis for orthogonal tRNA synthesis for genetic code expansion”, Nature Stuctural Biology, 2003, 10(6): 425-432.;;Kogan, T.P., “The synthesis of substituted methoxy-poly(ethyleneglycol) derivatives suitable for selective protein modification”, Synthetic Comm., 1992, 22(16): 2417-24.;;Kool, E.T., “Synthetically modified DNAs are substrates for polymers”, Curr. Opin. Chem. Biol., Dec. 2000, 4(6): 602-8.;;Koskinen, A.M.P. and H. Rapoport, “Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues”, J. Org. Chem., 1989, 54(8): 1859-1866.;;Kost, T.A. et al., “Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system”, Gene, Apr. 29, 1997, 190(1): 139-44.;;Kourouklis et al., “Programmable ribozymes for mischarging tRNA with nonnatural amino acids and their applications to translation”, Methods, 2005, 36: 239-4.;;Kowal et al., “Exploiting unassigned codons in Micrococcus luteus for tRNA-based amino acid mutagenesis”, Nucl. Acid. Res. (1997) 25:4685.;;Kowal et al., “Twenty-first aminoacyl-tRNA synthetase-suppressor tRNA pairs for possible use in site-specific incorporation of amino acid analogues into proteins in eukaryotes and in eubacteria”, PNAS, USA, 2001, 98: 2268-2273.;;Kramer, B. et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of E. coli”, Cell, Oct. 1984, 38(3): 879-87.;;Kramer, W. and H.J. Fritz, “Oligonucleotide-directed construction of mutations via gapped duplex DNA”, Methods Enzymol., 1987, 154:350-67.;;Kramer, W. et al., “Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations”, Nucleic Acids Res., Jul. 25, 1988, 16(14B): 7207.;;Kramer, W. et al., “The gapped duplex DNA approach to oligonucleotide-directed mutation construction”, Nucleic Acids Res., Dec. 21, 1984, 12(24): 9441-56.;;Kreitman, R.J. and I. Pastan “Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin”, Bioconjug Chem., Nov.-Dec. 1993, 4(6): 581-5.;;Krieg, U.C. et al., “Photocrosslinking of the signal sequence of nascent preprolactin to the 54-kilodalton polypeptide of the signal recognition particle”, Proc. Natl. Acad. Sci USA, Nov. 1986, 83(22): 8604-8.;;Kumar et al., “Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients”, Diabetologia, 1996, 39: 701-709.;;Kumita, J.R. et al., “Prevention of Peptide Fibril Formation in an Aqueous Environment by Mutation of a Single Residue to Aib”, Biochemistry, American Chemical Society, 2003. 42: 4492-4498. et al.",ACTIVE
388,ES,T3,ES 2874331 T3,056-745-379-531-509,2021-11-04,2021,ES 18177893 T,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P,2014-10-24,Polipéptidos de FGF-21 modificados y usos de los mismos,"Un polipéptido FGF-21 modificado que comprende el polipéptido de SEQ ID NO:201 en donde el resto de para- acetil-fenilalanina del mismo está enlazado a un resto poli(etilenglicol), para su uso en un método para tratar una enfermedad asociada a fibrosis seleccionada de esteatohepatitis no alcohólica (EHNA), fibrosis hepática y cirrosis en un paciente.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/056-745-379-531-509,Granted Patent,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,ACTIVE
389,EP,A2,EP 3209316 A2,094-410-511-848-997,2017-08-30,2017,EP 15790415 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/094-410-511-848-997,Patent Application,yes,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00,,0,0,,,,DISCONTINUED
390,HR,T1,HR P20211053 T1,107-288-687-182-31X,2021-10-01,2021,HR P20211053 T,2021-07-02,US 201462068296 P;;US 201462068514 P;;US 201462068523 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P;;EP 18177893 A,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/107-288-687-182-31X,Granted Patent,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,ACTIVE
391,CN,A,CN 114805532 A,177-309-072-345-636,2022-07-29,2022,CN 202210088408 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;CN 201580070276 A;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of fibrosis-related diseases. Modified FGF-21 polypeptides containing an internal deletion and optionally a replacement peptide are disclosed, optionally modified with at least one non-naturally encoded amino acid and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DAVID;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/177-309-072-345-636,Patent Application,no,3,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50,,2,1,082-340-378-650-984,24685265;;10.1016/j.biomaterials.2014.03.023,"LINTAO SONG，ET AL.: ""A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog"", BIOMATERIALS, vol. 5, no. 19, pages 5206 - 5215, XP028847278, DOI: 10.1016/j.biomaterials.2014.03.023;;高德民等: ""多肽类药物结构稳定性的研究进展"", 中国医药生物技术, vol. 2, no. 5, pages 380 - 382",PENDING
392,AU,A1,AU 2020/210152 A1,021-391-184-670-722,2020-08-13,2020,AU 2020/210152 A,2020-07-27,AU 2020/210152 A;;AU 2015/335603 A;;US 201462068296 P;;US 201562141383 P;;US 201562141337 P;;US 201462068534 P;;US 201462068526 P;;US 201462068514 P;;US 201462068523 P;;US 2015/0057228 W,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/021-391-184-670-722,Patent Application,no,0,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/00,,0,0,,,,ACTIVE
393,CN,A,CN 114805531 A,070-379-703-380-934,2022-07-29,2022,CN 202210087736 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;CN 201580070276 A;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of fibrosis-related diseases. Modified FGF-21 polypeptides containing an internal deletion and optionally a replacement peptide are disclosed, optionally modified with at least one non-naturally encoded amino acid and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DAVID;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/070-379-703-380-934,Patent Application,no,3,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50,,2,1,082-340-378-650-984,24685265;;10.1016/j.biomaterials.2014.03.023,"LINTAO SONG，ET AL.: ""A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog"", BIOMATERIALS, vol. 35, no. 19, pages 5206 - 5215, XP028847278, DOI: 10.1016/j.biomaterials.2014.03.023;;高德民等: ""多肽类药物结构稳定性的研究进展"", 中国医药生物技术, vol. 2, no. 5, pages 380 - 382",PENDING
394,US,A1,US 2019/0382460 A1,193-735-768-172-798,2019-12-19,2019,US 201916455990 A,2019-06-28,US 201916455990 A;;US 201815979881 A;;US 201715460917 A;;US 201615215329 A;;US 201514921796 A;;US 201562141383 P;;US 201562141337 P;;US 201462068526 P;;US 201462068523 P;;US 201462068514 P;;US 201462068296 P;;US 201462068534 P,2014-10-24,Modified FGF-21 Polypeptides and Uses Thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/193-735-768-172-798,Patent Application,yes,0,2,60,64,394,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64,,0,0,,,,ACTIVE
395,CN,A,CN 114805533 A,029-279-933-304-65X,2022-07-29,2022,CN 202210088433 A,2015-10-23,US 201462068523 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201462068296 P;;US 201562141337 P;;US 201562141383 P;;CN 201580070276 A;;US 2015/0057228 W,2014-10-24,Modified FGF-21 polypeptides and uses thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of fibrosis-related diseases. Modified FGF-21 polypeptides containing an internal deletion and optionally a replacement peptide are disclosed, optionally modified with at least one non-naturally encoded amino acid and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DAVID;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/029-279-933-304-65X,Patent Application,no,3,0,60,64,0,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50,,2,1,082-340-378-650-984,24685265;;10.1016/j.biomaterials.2014.03.023,"LINTAO SONG，ET AL.,: ""A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog"", BIOMATERIALS, vol. 5, no. 19, pages 5206 - 5215, XP028847278, DOI: 10.1016/j.biomaterials.2014.03.023;;高德民等: ""多肽类药物结构稳定性的研究进展"", 中国医药生物技术, vol. 2, no. 5, pages 380 - 382",PENDING
396,US,A1,US 2016/0115213 A1,098-880-005-828-901,2016-04-28,2016,US 201514921796 A,2015-10-23,US 201514921796 A;;US 201462068526 P;;US 201462068534 P;;US 201562141383 P;;US 201462068514 P;;US 201462068523 P;;US 201562141337 P;;US 201462068296 P,2014-10-24,Modified FGF-21 Polypeptides and Uses Thereof,"Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.",BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,BRISTOL-MYERS SQUIBB COMPANY (2015-11-10),https://lens.org/098-880-005-828-901,Patent Application,yes,0,3,60,64,302,A61K45/06;;C07K14/50;;A61K38/00;;A61K38/00;;A61K45/06;;A61K47/60;;C07K14/50;;A61K38/1825;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/02;;A61P27/02;;A61P27/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P5/28;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61P3/10;;A61P3/00;;A61P11/00;;A61P3/06;;A61P1/16;;A61P9/00;;A61K47/64;;A61P5/28;;A61P1/00;;A61P27/12;;A61P9/04;;A61P13/12;;A61P9/10;;A61P17/02;;A61P27/02;;A61P1/04;;A61P17/00;;A61P1/18;;A61K47/60;;A61P3/04;;A61K47/60;;A61K38/00;;A61K38/1825;;A61K45/06;;C07K14/50;;C07K2319/30;;C07K2319/00;;A61K45/06;;A61K38/00;;A61K47/60;;C07K14/50;;C07K2319/00;;C07K2319/30;;A61K38/1825;;A61K47/64,C07K14/50;;A61K38/18,,0,0,,,,ACTIVE
397,RS,B1,RS 62066 B1,119-791-104-337-337,2021-07-30,2021,RS P20210841 A,2015-10-23,US 201462068296 P;;US 201462068514 P;;US 201462068526 P;;US 201462068534 P;;US 201562141337 P;;US 201562141383 P;;EP 18177893 A,2014-10-24,MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,MORIN PAUL E;;COHEN DANIEL;;MUKHERJEE RANJAN;;REILLY TIMOTHY P;;CHRISTIAN ROSE C;;LIPOVSEK DASA;;CAMPHAUSEN RAY;;KRUPINSKI JOHN,,https://lens.org/119-791-104-337-337,Granted Patent,no,0,0,1,64,0,,A61K38/00;;A61K38/18;;A61K45/06;;A61K47/60;;A61K47/64;;C07K14/50,,0,0,,,,ACTIVE
398,US,A1,US 2004/0051178 A1,072-197-160-321-211,2004-03-18,2004,US 66132803 A,2003-09-12,US 66132803 A;;US 70373400 A,2000-11-01,Semiconductor recessed mask interconnect technology,"
   A metal plus low dielectric constant (low-k) interconnect structure is provided for a semiconductor device wherein adjacent regions in a surface separated by a dielectric have dimensions in width and spacing in the sub 250 nanometer range, and in which reduced lateral leakage current between adjacent metal lines, and a lower effective dielectric constant than a conventional structure, is achieved by the positioning of a differentiating or mask member that is applied for the protection of the dielectric in subsequent processing operations, at a position about 2-5 nanometers below a, to be planarized, surface where there will be a lower electric field. The invention is particularly useful in the damascene type device structure in the art wherein adjacent conductors extend from a substrate through an interlevel dielectric material, connections are made in a trench, a diffusion barrier liner is provided in the interlevel dilectric material and masking is employed to protect the dilectric material between conductors during processing operations. 
",IBM,COHEN STEPHEN ALAN;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;GATES STEPHEN MCCONNELL;;HERBST BRIAN WAYNE;;PURUSHOTHAMAN SAMPATH;;WHITEHAIR STANLEY JOSEPH,GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/072-197-160-321-211,Patent Application,yes,8,5,2,2,0,H01L21/76804;;H01L21/76829;;H01L21/76834;;H01L21/76885;;H01L23/5222;;H01L23/5283;;H01L2924/0002;;H01L21/76829;;H01L21/76834;;H01L21/76804;;H01L23/5222;;H01L21/76885;;H01L23/5283;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/528,257/758,0,0,,,,DISCONTINUED
399,AU,A8,AU 2011/201185 A8,184-716-991-232-079,2015-09-24,2015,AU 2011/201185 A,2011-03-16,US 72681510 A,2010-03-18,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD Barbed medical devices (100) include a crown interconnecting a pair of legs and at least one barb (12) extending from each of the legs. The at least one barb may define an inner surface with a first portion (12a) disposed at a first orientation relative to a longitudinal axis of the leg, a second portion (1 2b) disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion (12c) disposed at a third orientation relative to the longitudinal axis of the leg. 12c 12b 12a",COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/184-716-991-232-079,Patent Application,no,4,0,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/04;;A61B17/064,,0,0,,,,INACTIVE
400,TW,B,TW I678745 B,035-840-102-836-418,2019-12-01,2019,TW 104132117 A,2015-09-30,US 201462056773 P,2014-09-29,Non-destructive acoustic metrology for void detection,,RUDOLPH TECHNOLOGIES INC;;UNIV COLORADO REGENTS,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,,https://lens.org/035-840-102-836-418,Granted Patent,no,4,0,6,6,0,G01N29/04;;G01N29/06;;G01N29/0681;;G01N29/069;;G01N29/07;;G01N29/2418;;G01N29/2418;;G01N29/46;;G01N2291/0289;;G01N2291/0289;;H01L22/12;;H01L22/12;;H01L21/76898;;H01L22/20,,,0,0,,,,ACTIVE
401,US,B2,US 10740342 B2,080-583-249-177-397,2020-08-11,2020,US 201715859167 A,2017-12-29,US 201715859167 A;;US 201615253676 A,2016-08-31,"Systems, methods, user interfaces and algorithms for performing database analysis and search of information involving structured and/or semi-structured data","Implementations for searching and analyzing large, object-oriented data sets in an efficient manner involving innovative user interface features and/or search algorithm functionality are disclosed. In one exemplary embodiment, a system may search for information and/or relationships based on specified search criteria and return results that may be displayed dynamically and further filtered or analyzed. Systems may involve object oriented database(s) and a software layer including a specialized user interface between the user and the database(s). The user interface may comprise various tools as well as predefined and configurable features that enable effective search of the data as well as display of search results that are configurable and readily managed to provide immediate and useful search results. The user interface may display the search results and various associated graphical representations and models, and/or provide tools enabling dynamic manipulation and display of search results or underlying object models, among other things.",PALANTIR TECHNOLOGIES INC,YOUSAF TIMOTHY;;MARK ALEXANDER;;HAO SHARON;;COHEN DAVID;;ELDER ANDREW;;LIDOR DANIEL;;OSSHER JOEL;;RICHBOURG CHRISTOPHER;;ZAVILLA JOSHUA;;ZHANG KEVIN,PALANTIR TECHNOLOGIES INC (2017-06-06),https://lens.org/080-583-249-177-397,Granted Patent,yes,142,0,4,4,0,G06F16/248;;G06F16/2428;;G06F3/0482;;G06F16/248,G06F16/24;;G06F3/0482;;G06F16/248,,66,2,076-694-841-541-52X;;096-285-615-897-438,10.1145/76372.76377;;10.1109/pacificvis.2014.40,"Notice of Allowance for U.S. Appl. No. 15/253,676 dated Sep. 21, 2017.;;Official Communication for U.S. Appl. No. 15/253,676 dated Mar. 15, 2017.;;About 80 Minutes, “Palantir in a Number of Parts—Part 6—Graph,” Mar. 21, 2013, pp. 1-6, retrieved from the internet http://about80minutes.blogspot.nl/2013/03/palantir-in-number-of-parts-part-6-graph.html retrieved on Aug. 18, 2015.;;Bluttman et al., “Excel Formulas and Functions for Dummies,” 2005, Wiley Publishing, Inc., pp. 280, 284-286.;;Chung, Chin-Wan, “Dataplex: An Access to Heterogeneous Distributed Databases,” Communications of the ACM, Association for Computing Machinery, Inc., vol. 33, No. 1, Jan. 1, 1990, pp. 70-80.;;Gesher, Ari, “Palantir Screenshots in the Wild: Swing Sightings,” The Palantir Blog, Sep. 11, 2007, pp. 1-12, retrieved from the internet https://www.palantir.com/2007/09/palantir-screenshots/ retrieved on Aug. 18, 2015.;;Hardesty, “Privacy Challenges: Analysis: It's Surprisingly Easy to Identify Individuals from Credit-Card Metadata,” MIT News on Campus and Around the World, MIT News Office, Jan. 29, 2015, 3 pages.;;Jelen, Bill, “Excel 2013 in Depth, Video Enhanced Edition,” Jan. 25, 2013.;;Keylines.com, “An Introduction to KeyLines and Network Visualization,” Mar. 2014, <http://keylines.com/wp-content/uploads/2014/03/KeyLines-White-Paper.pdf> downloaded May 12, 2014 in 8 pages.;;Keylines.com, “KeyLines Datasheet,” Mar. 2014, <http://keylines.com/wp-content/uploads/2014/03/KeyLines-datasheet.pdf> downloaded May 12, 2014 in 2 pages.;;Keylines.com, “Visualizing Threats: Improved Cyber Security Through Network Visualization,” Apr. 2014, <http://keylines.com/wp-content/uploads/2014/04/Visualizing-Threats1.pdf> downloaded May 12, 2014 in 10 pages.;;Palantir Technologies, “Palantir Labs—Timeline,” Oct. 1, 2010, retrieved from the internet https://www.youtube.com/watch?v=JCgDW5bru9M retrieved on Aug. 19, 2015.;;Palmas et al., “An Edge-Bunding Layout for Interactive Parallel Coordinates” 2014 IEEE Pacific Visualization Symposium, pp. 57-64.;;Vose et al., “Help File for ModelRisk Version 5,” 2007, Vose Software, pp. 349-353. [Uploaded in 2 Parts].;;Wikipedia, “Federated Database System,” Sep. 7, 2013, retrieved from the internet on Jan. 27, 2015 http://en.wikipedia.org/w/index.php?title=Federated_database_system&oldid=571954221.;;Wikipedia, “Mobile Web,” Jan. 23, 2015, retrieved from the internet on Mar. 15, 2016 https://en.wikipedia.org/w/index.php?title=Mobile_Web&oldid=643800164.;;Wright et al., “Palantir Technologies VAST 2010 Challenge Text Records—Investigations into Arms Dealing,” Oct. 29, 2010, pp. 1-10, retrieved from the internet http://hcil2.cs.umd.edu/newvarepository/VAST%20Challenge%202010/challenges/MC1%20-%20Investigations%20into%20Arms%20Dealing/entries/Palantir%20Technologies/ retrieved on Aug. 20, 2015.;;Notice of Allowance for U.S. Appl. No. 13/247,987 dated Mar. 17, 2016.;;Notice of Allowance for U.S. Appl. No. 14/320,236 dated Jun. 29, 2016.;;Notice of Allowance for U.S. Appl. No. 14/326,738 dated Nov. 18, 2015.;;Notice of Allowance for U.S. Appl. No. 14/504,103 dated May 18, 2015.;;Notice of Allowance for U.S. Appl. No. 14/923,364 dated May 6, 2016.;;Notice of Allowance for U.S. Appl. No. 14/948,009 dated May 6, 2016.;;Official Communication for European Patent Application No. 14189344.6 dated Feb. 20, 2015.;;Official Communication for European Patent Application No. 14197879.1 dated Apr. 28, 2015.;;Official Communication for European Patent Application No. 14197895.7 dated Apr. 28, 2015.;;Official Communication for European Patent Application No. 14197938.5 dated Apr. 28, 2015.;;Official Communication for European Patent Application No. 15165244.3 dated Aug. 27, 2015.;;Official Communication for European Patent Application No. 15166137.8 dated Sep. 14, 2015.;;Official Communication for European Patent Application No. 16152984.7 dated Mar. 24, 2016.;;Official Communication for New Zealand Patent Application No. 622513 dated Apr. 3, 2014.;;Official Communication for U.S. Appl. No. 14/306,138 dated Sep. 14, 2015.;;Official Communication for U.S. Appl. No. 14/306,138 dated Mar. 17, 2016.;;Official Communication for U.S. Appl. No. 14/306,138 dated Sep. 23, 2014.;;Official Communication for U.S. Appl. No. 14/306,138 dated Dec. 24, 2015.;;Official Communication for U.S. Appl. No. 14/306,138 dated May 26, 2015.;;Official Communication for U.S. Appl. No. 14/306,138 dated Dec. 3, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Feb. 19, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Dec. 24, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Jun. 3, 2016.;;Official Communication for U.S. Appl. No. 14/306,147 dated Aug. 7, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Sep. 9, 2014.;;Official Communication for U.S. Appl. No. 14/306,154 dated Feb. 1, 2016.;;Official Communication for U.S. Appl. No. 14/306,154 dated Mar. 11, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated May 15, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated Nov. 16, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated Mar. 17, 2016.;;Official Communication for U.S. Appl. No. 14/306,154 dated Jul. 6, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated Sep. 9, 2014.;;Official Communication for U.S. Appl. No. 14/319,765 dated Feb. 1, 2016.;;Official Communication for U.S. Appl. No. 14/319,765 dated Sep. 10, 2015.;;Official Communication for U.S. Appl. No. 14/319,765 dated Jun. 16, 2015.;;Official Communication for U.S. Appl. No. 14/319,765 dated Nov. 25, 2014.;;Official Communication for U.S. Appl. No. 14/319,765 dated Feb. 4, 2015.;;Official Communication for U.S. Appl. No. 14/323,935 dated Jun. 22, 2015.;;Official Communication for U.S. Appl. No. 14/323,935 dated Nov. 28, 2014.;;Official Communication for U.S. Appl. No. 14/323,935 dated Mar. 31, 2015.;;Official Communication for U.S. Appl. No. 14/326,738 dated Dec. 2, 2014.;;Official Communication for U.S. Appl. No. 14/326,738 dated Jul. 31, 2015.;;Official Communication for U.S. Appl. No. 14/326,738 dated Mar. 31, 2015.;;Official Communication for U.S. Appl. No. 14/504,103 dated Mar. 31, 2015.;;Official Communication for U.S. Appl. No. 14/504,103 dated Feb. 5, 2015.;;Official Communication for U.S. Appl. No. 14/645,304 dated Jan. 25, 2016.;;Official Communication for U.S. Appl. No. 14/874,690 dated Jun. 1, 2016.;;Official Communication for U.S. Appl. No. 14/874,690 dated Dec. 21, 2015.;;Official Communication for U.S. Appl. No. 14/948,009 dated Feb. 25, 2016.",ACTIVE
402,US,B2,US 9788832 B2,197-565-455-756-692,2017-10-17,2017,US 201414514818 A,2014-10-15,US 201414514818 A;;US 72681510 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.",COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/197-565-455-756-692,Granted Patent,yes,180,2,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/08;;A61B17/00;;A61B17/06;;A61B17/064;;B21G7/02,,36,6,038-883-790-728-523;;078-408-284-487-032;;056-637-733-372-822;;017-262-666-726-279;;040-259-248-838-936;;017-497-355-401-844,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784;;15764819;;10.1126/science.1066102;;11976407;;19498850;;10.1364/opex.13.008204;;15704114;;10.1002/jbm.a.30193;;10.1201/9781420039665.ch2,"Australian Examination Report from Appl. No. AU 2015200379 issued Jun. 24, 2016.;;Extended European Search Report from EP Appl. No. 16159329.8-1654 dated Jul. 7, 2016.;;European Examination Report from Appl. No. 11250329.7-1654 dated Aug. 17, 2016.;;Canadian Office Action from Appl. No. CA 2,733,805 dated Jul. 28, 2016.;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;JLT1204-211-229 (175) : R. R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, “An Innovative Surgical Suture and Needle Evaluation and Selection Program” 12(4), pp. 211-229 (2002).;;George Odian, “Principles of Polymerization”, III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for EP 09251035.3 dated Jun. 3, 2009.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;Lendlein, et al., “Shape-memory polymers as stimuli-sensitive implant materials”, Clinical Hemorheology and Microcirculation 2005, 32:105-116.;;Lendlein, et al., “Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications”, Science 2002, 296:1673-1676.;;Lendlein, “Solving a knotty problem—surgical sutures from shape memorypolymers”, Materials World 2002, 10 (7):29-30.;;Small, et al., “Laser-activated shape memory polymer intravascular thrombectomy device”, Optics Express 2005, 13 (20):8204-8213.;;Fare, et al., “In vitro interaction of human fibroblasts and platelets with a shape-memory polyurethane”, Fibroblast/Platelet Interaction With SMPu Wiley Periodicals, Inc. (2005), pp. 1-11.;;Tim Thompson, “Polyurethanes as Specialty Chemicals Principles and Applications”, 2005 CRC Press, Chapter 2: Polyurethane Chemistry in Brief.;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;Japanese Final Official Action with English translation mailed Apr. 9, 2015 from Application No. JP 2011-061379.;;First Office Action, and English Translation, from Chinese Applicaiton No. 201410073521X issued Jun. 23, 2015.;;Austalian Examination Report from Appl. No. 2015200379 issued Feb. 4, 2016.;;Australian Examination Report from Appl. No. AU 2015200379 issued Apr. 8, 2016.;;Canadian Office Action from Appl. No. 2,654,655 dated Mar. 23, 2016.;;Australian Examination Report issued May 15, 2015 in Application No. AU 2011201185.",ACTIVE
403,US,A1,US 2018/0121524 A1,023-071-552-027-045,2018-05-03,2018,US 201715859167 A,2017-12-29,US 201715859167 A;;US 201615253676 A,2016-08-31,"SYSTEMS, METHODS, USER INTERFACES AND ALGORITHMS FOR PERFORMING DATABASE ANALYSIS AND SEARCH OF INFORMATION INVOLVING STRUCTURED AND/OR SEMI-STRUCTURED DATA","Implementations for searching and analyzing large, object-oriented data sets in an efficient manner involving innovative user interface features and/or search algorithm functionality are disclosed. In one exemplary embodiment, a system may search for information and/or relationships based on specified search criteria and return results that may be displayed dynamically and further filtered or analyzed. Systems may involve object oriented database(s) and a software layer including a specialized user interface between the user and the database(s). The user interface may comprise various tools as well as predefined and configurable features that enable effective search of the data as well as display of search results that are configurable and readily managed to provide immediate and useful search results. The user interface may display the search results and various associated graphical representations and models, and/or provide tools enabling dynamic manipulation and display of search results or underlying object models, among other things.",PALANTIR TECHNOLOGIES INC,YOUSAF TIMOTHY;;MARK ALEXANDER;;HAO SHARON;;COHEN DAVID;;ELDER ANDREW;;LIDOR DANIEL;;OSSHER JOEL;;RICHBOURG CHRISTOPHER;;ZAVILLA JOSHUA;;ZHANG KEVIN,PALANTIR TECHNOLOGIES INC (2017-06-06),https://lens.org/023-071-552-027-045,Patent Application,yes,3,3,4,4,0,G06F16/248;;G06F16/2428;;G06F3/0482;;G06F16/248,G06F17/30;;G06F3/0482,,0,0,,,,ACTIVE
404,US,B2,US 8454653 B2,057-314-398-327-02X,2013-06-04,2013,US 72747510 A,2010-03-19,US 72747510 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/057-314-398-327-02X,Granted Patent,yes,103,22,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/04,606/228,28,6,038-883-790-728-523;;078-408-284-487-032;;056-637-733-372-822;;017-262-666-726-279;;040-259-248-838-936;;017-497-355-401-844,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784;;15764819;;10.1126/science.1066102;;11976407;;19498850;;10.1364/opex.13.008204;;15704114;;10.1002/jbm.a.30193;;10.1201/9781420039665.ch2,"European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;JLT1204-211-229 (175) : R. R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle Evaluation and Selection Program"" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization"", III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for EP 09251035.3 dated Jun. 3, 2009.;;Lendlein, et al., ""Shape-memory polymers as stimuli-sensitive implant materials"", Clinical Hemorheology and Microcirculation 2005, 32:105-116.;;Lendlein, et al., ""Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications"", Science 2002, 296:1673-1676.;;Lendlein, ""Solving a knotty problem-surgical sutures from shape memorypolymers"", Materials World 2002, 10(7):29-30.;;Small, et al., ""Laser-activated shape memory polymer intravascular thrombectomy device"", Optics Express 2005, 13(20):8204-8213.;;Faré, et al., ""In vitro interaction of human fibroblasts and platelets with a shape-memory polyurethane"", Fibroblast/Platelet Interaction With SMPu Wiley Periodicals, Inc. (2005), pp. 1-11.;;Tim Thompson, ""Polyurethanes as Specialty Chemicals Principles and Applications"", 2005 CRC Press, Chapter 2: Polyurethane Chemistry in Brief.;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.",ACTIVE
405,US,B2,US 8932329 B2,120-443-956-578-469,2015-01-13,2015,US 201313870235 A,2013-04-25,US 201313870235 A;;US 72747510 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.,COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/120-443-956-578-469,Granted Patent,yes,101,3,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/04;;A61B17/00;;A61B17/06;;A61B17/064,606/228,28,6,038-883-790-728-523;;078-408-284-487-032;;056-637-733-372-822;;017-262-666-726-279;;040-259-248-838-936;;017-497-355-401-844,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784;;15764819;;10.1126/science.1066102;;11976407;;19498850;;10.1364/opex.13.008204;;15704114;;10.1002/jbm.a.30193;;10.1201/9781420039665.ch2,"U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;JLT1204-211-229 (175): R. R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle Evaluation and Selection Program"" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization"", III Edition, pp. 569-573 (1991).;;Lendlein, et al., ""Shape-memory polymers as stimuli-sensitive implant materials"", Clinical Hemorheology and Microcirculation 2005, 32:105-116.;;Lendlein, et al., ""Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications"", Science 2002, 296:1673-1676.;;Lendlein, ""Solving a knotty problem-surgical sutures from shape memorypolymers"", Materials World 2002, 10(7):29-30.;;Small, et al., ""Laser-activated shape memory polymer intravascular thrombectomy device"", Optics Express 2005, 13(20):8204-8213.;;Fare, et al., ""In vitro interaction of human fibroblasts and platelets with a shape-memory polyurethane"", Fibroblast/Platelet Interaction With SMPu Wiley Periodicals, Inc. (2005), pp. 1-11.;;Tim Thompson, ""Polyurethanes as Specialty Chemicals Principles and Applications"", 2005 CRC Press, Chapter 2: Polyurethane Chemistry in Brief.;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for EP 09251035.3 dated Jun. 3, 2009.;;European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;European Search Report for EP 12151535.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).;;European Search Report EP 12 16 5912 dated Jul. 18, 2012.;;European Search Report EP 12 16 9370 dated Sep. 12, 2012.",ACTIVE
406,US,B2,US 8888810 B2,097-005-569-864-535,2014-11-18,2014,US 72681510 A,2010-03-18,US 72681510 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.",HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/097-005-569-864-535,Granted Patent,yes,104,19,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/08;;A61B17/00;;A61B17/06;;A61B17/064,606/213,26,6,038-883-790-728-523;;078-408-284-487-032;;056-637-733-372-822;;017-262-666-726-279;;040-259-248-838-936;;017-497-355-401-844,10.1615/jlongtermeffmedimplants.v12.i4.10;;12627784;;15764819;;10.1126/science.1066102;;11976407;;19498850;;10.1364/opex.13.008204;;15704114;;10.1002/jbm.a.30193;;10.1201/9781420039665.ch2,"European Search Report for Application No. EP 08 25 3618 dated Jul. 25, 2011.;;U.S. Appl. No. 60/994,173, filed Sep. 17, 2007, Maiorino et al.;;European Search Report for EP 09250460.4-2310 date of completion is Jun. 2, 2009 (3 pages).;;JLT1204-211-229 (175) : R. R. Szarmach et al., Journal of Long-Term Effects of Medical Implants, ""An Innovative Surgical Suture and Needle Evaluation and Selection Program"" 12(4), pp. 211-229 (2002).;;George Odian, ""Principles of Polymerization"", III Edition, pp. 569-573 (1991).;;International Search Report from Appln. No. EP 06 012688 dated Aug. 1, 2007.;;European Search Report from Appln. No. EP 07 253438 dated Feb. 1, 2008.;;European Search Report from application No. 07 25 4703 dated Feb. 10, 2009.;;European Search Report from application No. 07 25 4341 dated Apr. 20, 2009.;;European Search Report for EP 09251035.3 dated Jun. 3, 2009.;;European Search Report for EP 10177651.6-1526 date of completion is Dec. 14, 2010 (3 pages).;;Lendlein, et al., ""Shape-memory polymers as stimuli-sensitive implant materials"", Clinical Hemorheology and Microcirculation 2005, 32:105-116.;;Lendlein, et al., ""Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications"", Science 2002, 296:1673-1676.;;Lendlein, ""Solving a knotty problem-surgical sutures from shape memorypolymers"", Materials World 2002, 10(7):29-30.;;Small, et al., ""Laser-activated shape memory polymer intravascular thrombectomy device"", Optics Express 2005, 13(20):8204-8213.;;Faré, et al., ""In vitro interaction of human fibroblasts and platelets with a shape-memory polyurethane"", Fibroblast/Platelet Interaction With SMPu Wiley Periodicals, Inc. (2005), pp. 1-11.;;Tim Thompson, ""Polyurethanes as Specialty Chemicals Principles and Applications"", 2005 CRC Press, Chapter 2: Polyurethane Chemistry in Brief.;;European Search Report for European Application No. 10250002.2 dated Mar. 24, 2010. (9 pages).;;European Search Report for EP 12151535.7-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151526.6-2310 date of completion is Mar. 23, 2012 (6 pages).;;European Search Report for EP 12151532.4-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151531.6-2310 date of completion is Mar. 27, 2012 (6 pages).;;European Search Report for EP 12151525.8-2310 date of completion is Mar. 27, 2012 (5 pages).;;European Search Report for EP 12151530.8-2310 date of completion is Mar. 16, 2012 (6 pages).;;European Search Report for EP 12151537.3-2310 date of completion is Mar. 19, 2012 (6 pages).;;European Search Report for EP 11250537.1269 date of completion Aug. 8, 2011 (3 pages).",ACTIVE
407,WO,A1,WO 2016/054067 A1,181-926-589-426-672,2016-04-07,2016,US 2015/0052984 W,2015-09-29,US 201462056773 P,2014-09-29,NON-DESTRUCTIVE ACOUSTIC METROLOGY FOR VOID DETECTION,"Advanced interconnect technologies such as Through Silicon Vias (TSVs) have become an integral part of 3-D integration. Methods and systems and provided for laser-based acoustic techniques in which a short laser pulse generates broadband acoustic waves that propagate in the TSV structure. An optical interferometer detects the surface displacement caused by the acoustic waves reflecting within the structure as well as other acoustic waves traveling near the surface that has information about the structure dimensions and irregularities, such as voids. Features of voids, such as their location, are also identified based on the characteristics of the acoustic wave as it propagates through the via. Measurements typically take few seconds per site and can be easily adopted for in-line process monitoring.",MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,,https://lens.org/181-926-589-426-672,Patent Application,yes,5,3,6,6,0,G01N29/04;;G01N29/06;;G01N29/0681;;G01N29/069;;G01N29/07;;G01N29/2418;;G01N29/2418;;G01N29/46;;G01N2291/0289;;G01N2291/0289;;H01L22/12;;H01L22/12;;H01L21/76898;;H01L22/20,H01L21/66;;H01L21/268,,0,0,,,,PENDING
408,US,B1,US 9881066 B1,001-876-362-816-254,2018-01-30,2018,US 201615253676 A,2016-08-31,US 201615253676 A,2016-08-31,"Systems, methods, user interfaces and algorithms for performing database analysis and search of information involving structured and/or semi-structured data","Implementations for searching and analyzing large, object-oriented data sets in an efficient manner involving innovative user interface features and/or search algorithm functionality are disclosed. In one exemplary embodiment, a system may search for information and/or relationships based on specified search criteria and return results that may be displayed dynamically and further filtered or analyzed. Systems may involve object oriented database(s) and a software layer including a specialized user interface between the user and the database(s). The user interface may comprise various tools as well as predefined and configurable features that enable effective search of the data as well as display of search results that are configurable and readily managed to provide immediate and useful search results. The user interface may display the search results and various associated graphical representations and models, and/or provide tools enabling dynamic manipulation and display of search results or underlying object models, among other things.",PALANTIR TECHNOLOGIES INC;;PALANTIR TECHNOLOGIES INC,YOUSAF TIMOTHY;;MARK ALEXANDER;;HAO SHARON;;COHEN DAVID;;ELDER ANDREW;;LIDOR DANIEL;;OSSHER JOEL;;RICHBOURG CHRISTOPHER;;ZAVILLA JOSHUA;;ZHANG KEVIN,PALANTIR TECHNOLOGIES INC (2017-06-06),https://lens.org/001-876-362-816-254,Granted Patent,yes,125,47,4,4,0,G06F16/248;;G06F16/2428;;G06F3/0482;;G06F16/248,G06F17/30;;G06F3/0482,,64,2,076-694-841-541-52X;;096-285-615-897-438,10.1145/76372.76377;;10.1109/pacificvis.2014.40,"About 80 Minutes, “Palantir in a Number of Parts—Part 6—Graph,” Mar. 21, 2013, pp. 1-6, retrieved from the internet http://about80minutes.blogspot.nl/2013/03/palantir-in-number-of-parts-part-6-graph.html retrieved on Aug. 18, 2015.;;Bluttman et al., “Excel Formulas and Functions for Dummies,” 2005, Wiley Publishing, Inc., pp. 280, 284-286.;;Chung, Chin-Wan, “Dataplex: An Access to Heterogeneous Distributed Databases,” Communications of the ACM, Association for Computing Machinery, Inc., vol. 33, No. 1, Jan. 1, 1990, pp. 70-80.;;Gesher, Ari, “Palantir Screenshots in the Wild: Swing Sightings,” The Palantir Blog, Sep. 11, 2007, pp. 1-12, retrieved from the internet https://www.palantir.com/2007/09/palantir-screenshots/ retrieved on Aug. 18, 2015.;;Hardesty, “Privacy Challenges: Analysis: It's Surprisingly Easy to Identify Individuals from Credit-Card Metadata,” MIT News on Campus and Around the World, MIT News Office, Jan. 29, 2015, 3 pages.;;Jelen, Bill, “Excell 2013 in Depth, Video Enhanced Edition,” Jan. 25, 2013.;;Keylines.com, “An Introduction to KeyLines and Network Visualization,” Mar. 2014, http://keylines.com/wp-content/uploads/2014/03/KeyLines-White-Paper.pdf downloaded May 12, 2014 in 8 pages.;;Keylines.com, “KeyLines Datasheet,” Mar. 2014, http//keylines.com/wp-content/uploads/2014/03/KeyLines-datasheet.pdf downloaded May 12, 2014 in 2 pages.;;Keylines.com, “Visualizing Threats: Improved Cyber Security Through Network Visualization,” Apr. 2014, http//keylines.com/wp-content/uploads/2014/04/Visualizing-Threats1.pdf downloaded May 12, 2014 in 10 pages.;;Palantir Technolgies, “Palantir Labs—Timeline,” Oct. 1, 2010, retrieved from the internet https://www.youtube.com/watch?v=JCgDW5bru9M retrieved on Aug. 19, 2015.;;Palmas et al., “An Edge-Bunding Layout for Interactive Parallel Coordinates” 2014 IEEE Pacific Visualization Symposium, pp. 57-64.;;Vose et al., “Help File for ModelRisk Version 5,” 2007, Vose Software, pp. 349-353. [Uploaded in 2 Parts].;;Wikipedia, “Federated Database System,” Sep. 7, 2013, retrieved from the internet on Jan. 27, 2015 http://en.wikipedia.org/w/index.php?title=Federated—database—system&oldid-571954221.;;Wikipedia, “Mobile Web,” Jan. 23, 2015, retrieved from the internet on Mar. 15, 2016 https://en.wikipedia.org/w/index.php?title=Mobile—Web&oldid=643800164.;;Wright et al., “Palantir Technologies VAST 2010 Challenge Text Records—Investigations into Arms Dealing,” Oct. 29, 2010, pp. 1-10, retrieved from the internet http://hcil2.cs.umd.edu/newvarepository/VAST%20Challenge%202010/challenges/MC1%20%20Investigations%20into%20Arms%20Dealing/entries/Palantir%20Technologies/ retrieved on Aug. 20, 2015.;;Notice of Allowance for U.S. Appl. No. 13/247,987 dated Mar. 17, 2016.;;Notice of Allowance for U.S. Appl. No. 14/320,236 dated Jun. 29, 2016.;;Notice of Allowance for U.S. Appl. No. 14/326,738 dated Nov. 18, 2015.;;Notice of Allowance for U.S. Appl. No. 14/504,103 dated May 18, 2015.;;Notice of Allowance for U.S. Appl. No. 14/923,364 dated May 6, 2016.;;Notice of Allowance for U.S. Appl. No. 14/948,009 dated May 6, 2016.;;Official Communication for European Patent Application No. 14189344.6 dated Feb. 20, 2015.;;Official Communication for European Patent Application No. 14197879.1 dated Apr. 28, 2015.;;Official Communication for European Patent Application No. 14197895.7 dated Apr. 28, 2015.;;Official Communication for European Patent Application No. 14197938.5 dated Apr. 28, 2015.;;Official Communication for European Patent Application No. 15165244.3 dated Aug. 27, 2015.;;Official Communication for European Patent Application No. 15166137.8 dated Sep. 14, 2015.;;Official Communication for European Patent Application No. 16152984.7 dated Mar. 24, 2016.;;Official Communication for New Zealand Patent Application No. 622513 dated Apr. 3, 2014.;;Official Communication for U.S. Appl. No. 14/306,138 dated Sep. 14, 2015.;;Official Communication for U.S. Appl. No. 14/306,138 dated Mar. 17, 2016.;;Official Communication for U.S. Appl. No. 14/306,138 dated Sep. 23, 2014.;;Official Communication for U.S. Appl. No. 14/306,138 dated Dec. 24, 2015.;;Official Communication for U.S. Appl. No. 14/306,138 dated May 26, 2015.;;Official Communication for U.S. Appl. No. 14/306,138 dated Dec. 3, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Feb. 19, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Dec. 24, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Jun. 3, 2016.;;Official Communication for U.S. Appl. No. 14/306,147 dated Aug. 7, 2015.;;Official Communication for U.S. Appl. No. 14/306,147 dated Sep. 9, 2014.;;Official Communication for U.S. Appl. No. 14/306,154 dated Feb. 1, 2016.;;Official Communication for U.S. Appl. No. 14/306,154 dated Mar. 11, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated May 15, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated Nov. 16, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated Mar. 17, 2016.;;Official Communication for U.S. Appl. No. 14/306,154 dated Jul. 6, 2015.;;Official Communication for U.S. Appl. No. 14/306,154 dated Sep. 9, 2014.;;Official Communication for U.S. Appl. No. 14/319,765 dated Feb. 1, 2016.;;Official Communication for U.S. Appl. No. 14/319,765 dated Sep. 10, 2015.;;Official Communication for U.S. Appl. No. 14/319,765 dated Jun. 16, 2015.;;Official Communication for U.S. Appl. No. 14/319,765 dated Nov. 25, 2014.;;Official Communication for U.S. Appl. No. 14/319,765 dated Feb. 4, 2015.;;Official Communication for U.S. Appl. No. 14/323,935 dated Jun. 22, 2015.;;Official Communication for U.S. Appl. No. 14/323,935 dated Nov. 28, 2014.;;Official Communication for U.S. Appl. No. 14/323,935 dated Mar. 31, 2015.;;Official Communication for U.S. Appl. No. 14/326,738 dated Dec. 2, 2014.;;Official Communication for U.S. Appl. No. 14/326,738 dated Jul. 31, 2015.;;Official Communication for U.S. Appl. No. 14/326,738 dated Mar. 31, 2015.;;Official Communication for U.S. Appl. No. 14/504,103 dated Mar. 31, 2015.;;Official Communication for U.S. Appl. No. 14/504,103 dated Feb. 5, 2015.;;Official Communication for U.S. Appl. No. 14/645,304 dated Jan. 25, 2016.;;Official Communication for U.S. Appl. No. 14/874,690 dated Jun. 1, 2016.;;Official Communication for U.S. Appl. No. 14/874,690 dated Dec. 21, 2015.;;Official Communication for U.S. Appl. No. 14/948,009 dated Feb. 25, 2016.",ACTIVE
409,EP,B1,EP 2384705 B1,028-111-314-069-691,2017-05-03,2017,EP 11250340 A,2011-03-18,US 72747510 A,2010-03-19,Compound barb medical device,,COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/028-111-314-069-691,Granted Patent,yes,4,0,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/06,,0,0,,,,ACTIVE
410,TW,A,TW 201618208 A,043-247-005-604-669,2016-05-16,2016,TW 104132117 A,2015-09-30,US 201462056773 P,2014-09-29,Non destructive acoustic metrology for void detection,"Advanced interconnect technologies such as Through Silicon Vias (TSVs) have become an integral part of 3-D integration. Methods and systems and provided for laser-based acoustic techniques in which a short laser pulse generates broadband acoustic waves that propagate in the TSV structure. An optical interferometer detects the surface displacement caused by the acoustic waves reflecting within the structure as well as other acoustic waves traveling near the surface that has information about the structure dimensions and irregularities, such as voids. Features of voids, such as their location, are also identified based on the characteristics of the acoustic wave as it propagates through the via. Measurements typically take few seconds per site and can be easily adopted for in-line process monitoring.",RUDOLPH TECHNOLOGIES INC;;UNIV COLORADO,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,,https://lens.org/043-247-005-604-669,Patent of Addition,no,0,1,6,6,0,G01N29/04;;G01N29/06;;G01N29/0681;;G01N29/069;;G01N29/07;;G01N29/2418;;G01N29/2418;;G01N29/46;;G01N2291/0289;;G01N2291/0289;;H01L22/12;;H01L22/12;;H01L21/76898;;H01L22/20,H01L21/66;;G01N21/17;;G01N21/95;;G01N29/04,,0,0,,,,ACTIVE
411,CA,A1,CA 2733805 A1,107-116-924-852-188,2011-09-18,2011,CA 2733805 A,2011-03-10,US 72681510 A,2010-03-18,COMPOUND BARB MEDICAL DEVICE AND METHOD,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.",TYCO HEALTHCARE,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/107-116-924-852-188,Patent Application,no,0,0,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/064;;A61B17/04;;A61L17/04;;A61L17/06;;A61L17/10;;B21G3/00;;F16B15/06,,0,0,,,,INACTIVE
412,US,A1,US 2017/0221778 A1,166-126-130-103-651,2017-08-03,2017,US 201515515126 A,2015-09-29,US 201515515126 A;;US 201462056773 P;;US 2015/0052984 W,2014-09-29,NON-DESTRUCTIVE ACOUSTIC METROLOGY FOR VOID DETECTION,"Advanced interconnect technologies such as Through Silicon Vias (TSVs) have become an integral part of 3-D integration. Methods and systems and provided for laser-based acoustic techniques in which a short laser pulse generates broadband acoustic waves that propagate in the TSV structure. An optical interferometer detects the surface displacement caused by the acoustic waves reflecting within the structure as well as other acoustic waves traveling near the surface that has information about the structure dimensions and irregularities, such as voids. Features of voids, such as their location, are also identified based on the characteristics of the acoustic wave as it propagates through the via. Measurements typically take few seconds per site and can be easily adopted for in-line process monitoring.",UNIV COLORADO REGENTS,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,THE REGENTS OF THE UNIVERSITY OF COLORADO (2015-10-29);;RUDOLPH TECHNOLOGIES INC (2018-04-30);;ONTO INNOVATION INC (2020-04-30),https://lens.org/166-126-130-103-651,Patent Application,yes,3,8,6,6,0,G01N29/04;;G01N29/06;;G01N29/0681;;G01N29/069;;G01N29/07;;G01N29/2418;;G01N29/2418;;G01N29/46;;G01N2291/0289;;G01N2291/0289;;H01L22/12;;H01L22/12;;H01L21/76898;;H01L22/20,H01L21/66;;G01N29/04;;G01N29/24;;G01N29/46;;H01L21/768,,0,0,,,,ACTIVE
413,EP,A3,EP 2384705 A3,187-572-883-515-636,2015-03-11,2015,EP 11250340 A,2011-03-18,US 72747510 A,2010-03-19,Compound barb medical device and method,"A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.
",COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/187-572-883-515-636,Search Report,yes,4,0,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/06,,0,0,,,,ACTIVE
414,EP,A2,EP 2384705 A2,071-933-498-246-219,2011-11-09,2011,EP 11250340 A,2011-03-18,US 72747510 A,2010-03-19,Compound barb medical device,"A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.
",TYCO HEALTHCARE,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/071-933-498-246-219,Patent Application,yes,18,1,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/06,,5,4,078-408-284-487-032;;056-637-733-372-822;;078-704-694-741-917;;014-816-904-459-077,15764819;;10.1126/science.1066102;;11976407;;19746597;;10.1002/1521-3773(20020617)41:12<2034::aid-anie2034>3.0.co;2-m;;10.1016/j.biomaterials.2006.03.043;;16675009,"LENDLEIN: ""Shape Memory Polymers-Biodegradable Sutures"", MATERIALS WORLD, vol. 10, no. 7, July 2002 (2002-07-01), pages 29 - 30, XP008049264;;LENDLEIN ET AL.: ""Shape memory polymers as stimuli-sensitive implant materials"", CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, vol. 32, 2005, pages 105 - 116;;LENDLEIN ET AL.: ""Biodegradable, Elastic Shape memory Polymers for Potential Biomedical Applications"", SCIENCE, vol. 269, 2002, pages 1673 - 1676, XP002516073, DOI: doi:10.1126/science.1066102;;LENDLEIN ET AL.: ""Shape-Memory Polymers"", ANGEW. CHEM. INT. ED., vol. 41, 2002, pages 2035 - 2057, XP055071565;;ZHENG ET AL.: ""Shape memory properties of poly (DL-actde/hydroxyapatte composites"", BIOMATERIALS, vol. 27, 2006, pages 4288 - 4295",ACTIVE
415,AU,A1,AU 2011/201185 A1,090-537-940-515-00X,2011-10-06,2011,AU 2011/201185 A,2011-03-16,US 72681510 A,2010-03-18,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD Barbed medical devices (100) include a crown interconnecting a pair of legs and at least one barb (12) extending from each of the legs. The at least one barb may define an inner surface with a first portion (12a) disposed at a first orientation relative to a longitudinal axis of the leg, a second portion (1 2b) disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion (12c) disposed at a third orientation relative to the longitudinal axis of the leg. 12c 12b 12a",TYCO HEALTHCARE,ROBERT HADBA AHMAD;;GERALD HODGKINSON;;SETH GLEIMAN;;COHEN MATTHER D;;NICHOLAS MAIORINO;;KOSA TIMOTHY D;;BUCHTER MARK S;;MICHAEL PRIMAVERA,,https://lens.org/090-537-940-515-00X,Patent Application,no,0,0,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/04;;A61B17/064,,0,0,,,,INACTIVE
416,CN,A,CN 114303002 A,158-793-631-590-231,2022-04-08,2022,CN 202080027340 A,2020-04-03,US 201962830104 P;;US 201916460467 A;;US 2020/0026638 W,2019-04-05,Tool replacement control for diving remote control vehicle,"A system receives data from a submersible remote control vehicle (ROV), the data relating to operation of an arm of the ROV. Upon docking the arm to the tool holder, the system automatically controls movement of the arm based on the data. In some cases, the system implements image-based control. In some cases, the system implements force regulation control. In some cases, the system implements both.",FMC TECH SHARE LIMITED COMPANY,LEONHARDT MATTHIAS;;ABRAHAM BIJU;;BOISSIERE PIERRE;;COHEN SHMUEL;;HERDEN KARIN;;MAYNE DAVID;;LANSTROM TIMOTHY;;S ROGERS;;KJELL KARLHEINZ;;SRAM SIDDHARTH,,https://lens.org/158-793-631-590-231,Patent Application,no,14,0,9,9,0,B25J9/1633;;B25J9/1689;;B25J13/085;;B25J15/0491;;B63C11/52;;B63G2008/007;;E21B41/04;;G05B2219/40184;;G05B2219/40271;;B63G2008/005;;B63G8/001;;B63C11/52;;B63G2008/002;;G05B2219/40271;;B25J15/0491;;B25J9/1633;;B25J13/085;;B25J9/1664,E21B41/04;;B25J9/16;;B25J13/08;;B25J15/04;;B63C11/52,,1,0,,,"张铁栋 等: ""《潜水器设计原理》"", 哈尔滨工程大学出版社, pages: 228 - 229",PENDING
417,US,B1,US 6657305 B1,146-057-754-263-010,2003-12-02,2003,US 70373400 A,2000-11-01,US 70373400 A,2000-11-01,Semiconductor recessed mask interconnect technology,"
    A metal plus low dielectric constant (low-k) interconnect structure is provided for a semiconductor device wherein adjacent regions in a surface separated by a dielectric have dimensions in width and spacing in the sub 250 nanometer range, and in which reduced lateral leakage current between adjacent metal lines, and a lower effective dielectric constant than a conventional structure, is achieved by the positioning of a differentiating or mask member that is applied for the protection of the dielectric in subsequent processing operations, at a position about 2-5 nanometers below a, to be planarized, surface where there will be a lower electric field. The invention is particularly useful in the damascene type device structure in the art wherein adjacent conductors extend from a substrate through an interlevel dielectric material, connections are made in a trench, a diffusion barrier liner is provided in the interlevel dielectric material and masking is employed to protect the dielectric material between conductors during processing operations. 
",IBM,COHEN STEPHEN ALAN;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;GATES STEPHEN MCCONNELL;;HERBST BRIAN WAYNE;;PURUSHOTHAMAN SAMPATH;;WHITEHAIR STANLEY JOSEPH,GOOGLE LLC (2011-08-17);;IBM CORPORATION (2000-10-12),https://lens.org/146-057-754-263-010,Granted Patent,yes,6,7,2,2,0,H01L21/76804;;H01L21/76829;;H01L21/76834;;H01L21/76885;;H01L23/5222;;H01L23/5283;;H01L2924/0002;;H01L21/76829;;H01L21/76834;;H01L21/76804;;H01L23/5222;;H01L21/76885;;H01L23/5283;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/528,257/773,1,0,,,"""Pursuing the Perfect Low-K Dielectric"", Laura Peters, Semiconductor International Magazine, Sep. 1, 1998 7 pages.",EXPIRED
418,CA,A1,CA 2733835 A1,150-521-253-061-470,2011-09-19,2011,CA 2733835 A,2011-03-11,US 72747510 A,2010-03-19,COMPOUND BARB MEDICAL DEVICE AND METHOD,A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.,TYCO HEALTHCARE,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/150-521-253-061-470,Patent Application,no,0,0,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/064;;A61B17/04;;A61F2/06;;A61F2/82;;A61L17/00;;A61L17/10;;A61L17/12,,0,0,,,,DISCONTINUED
419,EP,A3,EP 2366339 A3,073-139-422-661-525,2015-03-11,2015,EP 11250329 A,2011-03-17,US 72681510 A,2010-03-18,Compound barb medical device and method,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.
",COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NOCHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/073-139-422-661-525,Search Report,yes,4,0,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/064;;A61B17/00;;A61B17/06,,0,0,,,,ACTIVE
420,AU,B8,AU 2011/201185 B8,105-011-143-744-797,2015-09-24,2015,AU 2011/201185 A,2011-03-16,US 72681510 A,2010-03-18,Compound barb medical device and method,,COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHER D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/105-011-143-744-797,Amended Patent,no,0,0,14,14,0,A61B2017/00004;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B2017/00867;;A61B17/06166;;A61B17/064;;A61B2017/00004;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B2017/00867;;A61B17/06166;;A61B17/064;;B21G7/02,,,0,0,,,,INACTIVE
421,AU,B2,AU 2011/201185 B2,137-545-094-880-801,2015-09-17,2015,AU 2011/201185 A,2011-03-16,US 72681510 A,2010-03-18,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD Barbed medical devices (100) include a crown interconnecting a pair of legs and at least one barb (12) extending from each of the legs. The at least one barb may define an inner surface with a first portion (12a) disposed at a first orientation relative to a longitudinal axis of the leg, a second portion (1 2b) disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion (12c) disposed at a third orientation relative to the longitudinal axis of the leg. 12c 12b 12a",COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHER D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/137-545-094-880-801,Granted Patent,no,4,0,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/04;;A61B17/064,,0,0,,,,INACTIVE
422,US,A1,US 2010/0211097 A1,094-903-043-485-309,2010-08-19,2010,US 72681510 A,2010-03-18,US 72681510 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.",HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/094-903-043-485-309,Patent Application,yes,102,51,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/04;;B21G7/02,606/232;;59/77,0,0,,,,ACTIVE
423,US,B2,US 9991176 B2,195-856-512-917-825,2018-06-05,2018,US 201515515126 A,2015-09-29,US 201515515126 A;;US 201462056773 P;;US 2015/0052984 W,2014-09-29,Non-destructive acoustic metrology for void detection,"Advanced interconnect technologies such as Through Silicon Vias (TSVs) have become an integral part of 3-D integration. Methods and systems and provided for laser-based acoustic techniques in which a short laser pulse generates broadband acoustic waves that propagate in the TSV structure. An optical interferometer detects the surface displacement caused by the acoustic waves reflecting within the structure as well as other acoustic waves traveling near the surface that has information about the structure dimensions and irregularities, such as voids. Features of voids, such as their location, are also identified based on the characteristics of the acoustic wave as it propagates through the via. Measurements typically take few seconds per site and can be easily adopted for in-line process monitoring.",MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY;;RUDOLPH TECH INC;;UNIV COLORADO REGENTS,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,THE REGENTS OF THE UNIVERSITY OF COLORADO (2015-10-29);;RUDOLPH TECHNOLOGIES INC (2018-04-30);;ONTO INNOVATION INC (2020-04-30),https://lens.org/195-856-512-917-825,Granted Patent,yes,8,2,6,6,0,G01N29/04;;G01N29/06;;G01N29/0681;;G01N29/069;;G01N29/07;;G01N29/2418;;G01N29/2418;;G01N29/46;;G01N2291/0289;;G01N2291/0289;;H01L22/12;;H01L22/12;;H01L21/76898;;H01L22/20,H01L21/66;;G01N29/04;;G01N29/06;;G01N29/07;;G01N29/24;;G01N29/46;;H01L21/768,,1,0,,,"International Search Report and Written Opinion from corresponding International Patent Application No. PCT/US2015/052984, dated Dec. 28, 2015, 9 pages.",ACTIVE
424,JP,A,JP 2011194236 A,042-249-464-474-907,2011-10-06,2011,JP 2011063408 A,2011-03-22,US 72747510 A,2010-03-19,COMPOUND BARB MEDICAL DEVICE AND METHOD,"PROBLEM TO BE SOLVED: To improve a barbed suture thread or a barbed staple, and also to improve a method for producing the same.SOLUTION: A compound barb medical device is provided which includes a main part 14 and at least one barb 12 extending from the main part. At least the one barb defines an inner surface. The inner surface of at least the one barb 12 includes a first section 12a disposed at a first orientation relative to a longitudinal axis of the main part and a second section 12b disposed at a second orientation relative to the longitudinal axis. At least the one barb 12 is made of a shape memory material. The shape memory material changes its shape from a permanent shape to a temporary shape. When the shape memory material is in the temporary shape, the barb projects from a first position with respect to the main part. When the shape memory material is in the permanent shape, the barb projects from a second position different from the first position.",TYCO HEALTHCARE,HADBA AHMAD R;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/042-249-464-474-907,Patent Application,no,0,5,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/08;;A61L31/00,,0,0,,,,DISCONTINUED
425,JP,A,JP 2011194233 A,100-360-696-996-605,2011-10-06,2011,JP 2011061379 A,2011-03-18,US 72681510 A,2010-03-18,COMPOUND BARB MEDICAL DEVICE AND METHOD,"PROBLEM TO BE SOLVED: To improve a barbed suture thread or a barbed staple, and also to improve the method for manufacturing the same.SOLUTION: A compound barb medical device 100 is provided which includes a crown for interconnecting a pair of legs and at least one barb 12 extending from each of the legs. At least the one barb 12 defines an inner surface. The inner surface of the one barb 12 includes a first section disposed at a first orientation relative to a longitudinal axis of the legs and a second section disposed at a second orientation relative to the longitudinal axis.",TYCO HEALTHCARE,HADBA AHMAD R;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/100-360-696-996-605,Patent Application,no,7,3,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/08;;A61L31/00,,0,0,,,,DISCONTINUED
426,CN,A,CN 114428882 A,116-403-857-720-705,2022-05-03,2022,CN 202111266934 A,2021-10-28,US 202017083357 A,2020-10-29,Measurement of data quality of data in graphical database,"A method, computer program product and/or system is provided that performs obtaining a first graph comprising a first node representing a first entity and a first edge representing a relationship between the first entities, the first node being associated with a first entity attribute describing the first entity represented by the first node, the first edge is associated with a first edge attribute describing a relationship represented by the first edge; determining a first subgraph for a specific node in the first nodes of the first graph, wherein the first subgraph comprises the specific node and at least one adjacent node of the specific node; and determining a data quality problem with respect to the particular node based at least in part on applying one or more applicable rules in the set of data quality rules to the first entity attribute value and the first edge attribute value of the first sub-graph.",INT COMMERCIAL MACHINE COMPANY,SAILLET YANNICK;;FANCONE CHRISTOPHER A;;OBERHOFER MARTIN;;BABU HARISH KUMAR;;ELASSIRDI BAHMAN;;GRASSELT MICHAEL W;;COHEN RON;;STEWART TIMOTHY K,,https://lens.org/116-403-857-720-705,Patent Application,no,0,1,7,7,0,G06F16/9024;;G06N5/022;;G06N5/025;;G06F16/9024;;G06F16/215;;G06N5/025;;G06F18/24147;;G06F18/22;;G06F18/24765,G06F16/901,,0,0,,,,PENDING
427,SG,A,SG 11201702573V A,134-972-881-787-734,2017-04-27,2017,SG 11201702573V A,2015-09-29,US 201462056773 P;;US 2015/0052984 W,2014-09-29,NON-DESTRUCTIVE ACOUSTIC METROLOGY FOR VOID DETECTION,,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,MEHENDALE MANJUSHA;;KOTELYANSKII MICHAEL;;MURRAY TODD W;;MAIR ROBIN;;MUKUNDHAN PRIYA;;DOVE JACOB D;;RU XUEPING;;COHEN JONATHAN;;KRYMAN TIMOTHY,,https://lens.org/134-972-881-787-734,Unknown,no,0,0,6,6,0,G01N29/04;;G01N29/06;;G01N29/0681;;G01N29/069;;G01N29/07;;G01N29/2418;;G01N29/2418;;G01N29/46;;G01N2291/0289;;G01N2291/0289;;H01L22/12;;H01L22/12;;H01L21/76898;;H01L22/20,H01L21/66;;H01L21/268,,0,0,,,,PENDING
428,EP,A2,EP 2366339 A2,189-358-272-043-292,2011-09-21,2011,EP 11250329 A,2011-03-17,US 72681510 A,2010-03-18,Compound barb medical device,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.
",TYCO HEALTHCARE,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/189-358-272-043-292,Patent Application,yes,20,1,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/064;;A61B17/00;;A61B17/06,,5,4,078-408-284-487-032;;056-637-733-372-822;;078-704-694-741-917;;014-816-904-459-077,15764819;;10.1126/science.1066102;;11976407;;19746597;;10.1002/1521-3773(20020617)41:12<2034::aid-anie2034>3.0.co;2-m;;10.1016/j.biomaterials.2006.03.043;;16675009,"LENDLEIN: ""Shape Memory Polymers-Biodegradable Sutures"", MATERIALS WORLD, vol. 10, no. 7, July 2002 (2002-07-01), pages 29 - 30, XP008049264;;LENDLEIN ET AL.: ""Shape memory polymers as stimuli-sensitive implant materials"", CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, vol. 32, 2005, pages 105 - 116;;LENDLEIN ET AL.: ""Biodegradable, Elastic Shape memory Polymers for Potential Biomedical Applications"", SCIENCE, vol. 269, 2002, pages 1673 - 1676, XP002516073, DOI: doi:10.1126/science.1066102;;LENDLEIN ET AL.: ""Shape-Memory Polymers"", ANGEW. CHEM. INT. ED., vol. 41, 2002, pages 2035 - 2057, XP055071565;;ZHENG ET AL.: ""Shape memory properties of poly (DL-actde/hydroxyapatte composites"", BIOMATERIALS, vol. 27, 2006, pages 4288 - 4295",ACTIVE
429,US,A1,US 2020/0334237 A1,187-116-400-208-246,2020-10-22,2020,US 202016921127 A,2020-07-06,US 202016921127 A;;US 201715859167 A;;US 201615253676 A,2016-08-31,"SYSTEMS, METHODS, USER INTERFACES AND ALGORITHMS FOR PERFORMING DATABASE ANALYSIS AND SEARCH OF INFORMATION INVOLVING STRUCTURED AND/OR SEMI-STRUCTURED DATA","Implementations for searching and analyzing large, object-oriented data sets in an efficient manner involving innovative user interface features and/or search algorithm functionality are disclosed. In one exemplary embodiment, a system may search for information and/or relationships based on specified search criteria and return results that may be displayed dynamically and further filtered or analyzed. Systems may involve object oriented database(s) and a software layer including a specialized user interface between the user and the database(s). The user interface may comprise various tools as well as predefined and configurable features that enable effective search of the data as well as display of search results that are configurable and readily managed to provide immediate and useful search results. The user interface may display the search results and various associated graphical representations and models, and/or provide tools enabling dynamic manipulation and display of search results or underlying object models, among other things.",PALANTIR TECHNOLOGIES INC,YOUSAF TIMOTHY;;MARK ALEXANDER;;HAO SHARON;;COHEN DAVID;;ELDER ANDREW;;LIDOR DANIEL;;OSSHER JOEL;;RICHBOURG CHRISTOPHER;;ZAVILLA JOSHUA;;ZHANG KEVIN,PALANTIR TECHNOLOGIES INC (2017-06-06),https://lens.org/187-116-400-208-246,Patent Application,yes,2,0,4,4,0,G06F16/248;;G06F16/2428;;G06F3/0482;;G06F16/248,G06F16/248;;G06F3/0482,,0,0,,,,PENDING
430,AU,A1,AU 2011/201072 A1,055-492-926-133-405,2011-10-06,2011,AU 2011/201072 A,2011-03-11,US 72747510 A,2010-03-19,Compound barb medical device and method,COMPOUND BARB MEDICAL DEVICE AND METHOD A compound barb medical device (100) includes a body portion (14) and at least one barb (12) extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion (12a) disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion (126) disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape. 12c 12b 12a,COVIDIEN LP,ROBERT HADBA AHMAD;;GERALD HODGKINSON;;SETH GLEIMAN;;COHEN MATTHER D;;NICHOLAS MAIORINO;;KOSA TIMOTHY D;;BUCHTER MARK S;;MICHAEL PRIMAVERA,,https://lens.org/055-492-926-133-405,Patent Application,no,0,0,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/064;;A61B17/04,,0,0,,,,DISCONTINUED
431,EP,B1,EP 2366339 B1,118-151-983-745-270,2017-10-04,2017,EP 11250329 A,2011-03-17,US 72681510 A,2010-03-18,Compound barb medical device,,COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2012-12-26),https://lens.org/118-151-983-745-270,Granted Patent,yes,4,0,14,14,0,A61B2017/00004;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B2017/00867;;A61B17/06166;;A61B17/064;;A61B2017/00004;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B2017/00867;;A61B17/06166;;A61B17/064;;B21G7/02,A61B17/064;;A61B17/00;;A61B17/06,,0,0,,,,ACTIVE
432,US,A1,US 2010/0211098 A1,196-525-759-228-132,2010-08-19,2010,US 72747510 A,2010-03-19,US 72747510 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound Barb Medical Device and Method,A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/196-525-759-228-132,Patent Application,yes,103,45,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/04,606/232,0,0,,,,ACTIVE
433,US,A1,US 2013/0231702 A1,112-355-320-018-140,2013-09-05,2013,US 201313870235 A,2013-04-25,US 201313870235 A;;US 72747510 A;;US 36196209 A;;US 2996408 P,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,A compound barb medical device includes a body portion and at least one barb extending therefrom. The at least one barb defines an inner surface. The inner surface includes a first portion disposed at a first orientation relative to a longitudinal axis of the body portion and a second portion disposed at a second orientation relative to the longitudinal axis. The at least one barb is made from a shape memory material which can be deformed into a temporary shape from a permanent shape. The barb projects from the body portion in a first position relative to the body portion when in the permanent shape and in a second position when in the temporary shape.,COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/112-355-320-018-140,Patent Application,yes,2,2,10,10,0,A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;A61B17/064;;A61B2017/00526;;A61B2017/00871;;A61B2017/00893;;A61B2017/06176;;A61B17/0401,A61B17/04,606/232,0,0,,,,ACTIVE
434,US,A1,US 2015/0040534 A1,173-976-641-248-101,2015-02-12,2015,US 201414514818 A,2014-10-15,US 201414514818 A;;US 72681510 A;;US 36196209 A;;US 2996408 P,2008-02-20,COMPOUND BARB MEDICAL DEVICE AND METHOD,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.",COVIDIEN LP,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,COVIDIEN LP (2010-04-23),https://lens.org/173-976-641-248-101,Patent Application,yes,2,3,14,14,0,A61B17/064;;A61B17/064;;A61B17/06166;;A61B17/06166;;A61B2017/00004;;A61B2017/00004;;A61B2017/00526;;A61B2017/00526;;A61B2017/00867;;A61B2017/00867;;A61B2017/00893;;A61B2017/00893;;A61B2017/06176;;A61B2017/06176;;B21G7/02,A61B17/064;;B21G7/02,59/77,0,0,,,,ACTIVE
435,CA,C,CA 2733805 C,186-547-609-068-772,2017-12-12,2017,CA 2733805 A,2011-03-10,US 72681510 A,2010-03-18,COMPOUND BARB MEDICAL DEVICE AND METHOD,"Barbed medical devices include a crown interconnecting a pair of legs and at least one barb extending from each of the legs. The at least one barb may define an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the leg, a second portion disposed at a second orientation relative to the longitudinal axis, and optionally, a third portion disposed at a third orientation relative to the longitudinal axis of the leg.",TYCO HEALTHCARE,HADBA AHMAD ROBERT;;HODGKINSON GERALD;;GLEIMAN SETH;;COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL,,https://lens.org/186-547-609-068-772,Granted Patent,no,0,0,14,14,0,A61B2017/00004;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B2017/00867;;A61B17/06166;;A61B17/064;;A61B2017/00004;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B2017/00867;;A61B17/06166;;A61B17/064;;B21G7/02,A61B17/064;;A61B17/04;;A61L17/04;;A61L17/06;;A61L17/10;;B21G3/00;;F16B15/06,,0,0,,,,INACTIVE
436,WO,A1,WO 2019/194858 A1,126-734-740-241-515,2019-10-10,2019,US 2018/0047993 W,2018-08-24,US 201862652169 P,2018-04-03,MODULAR SYNTHESIS OF AMINOGLYCOSIDES,The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.,ACHAOGEN INC,CALABRESE ANDREW;;KANE TIMOTHY ROBERT;;HILDEBRANDT DARIN;;LOPEZ MICHAEL;;EVDOKIMOV NIKOLAI;;COHEN FREDERICK;;BAYRAKDARIAN MALKEN;;XU SANJIA;;DESJARDINS SAMUEL;;SOUEIDAN OLIVIER,,https://lens.org/126-734-740-241-515,Patent Application,yes,3,3,4,4,0,C07H15/224;;C07H15/232;;C07H15/23;;C07H17/00;;C07H1/00;;A61P31/04;;C07H5/06;;C07H7/04;;C07H17/02,A61K31/70;;A61K31/7034;;A61K31/7036;;C07H15/224;;C07H15/228;;C07H15/232,,2,2,113-402-046-959-858;;028-644-852-991-263,29091410;;pmc5831329;;10.1021/jacs.7b09890;;28343384;;10.1021/acsinfecdis.6b00214.s001;;pmc5526222;;10.1021/acsinfecdis.6b00214,"KIM ET AL.: ""Reaction Catalyzed by GenK, a Cobalamin-Dependent Radical S-Adenosyl-l-methionine Methyltransferase in the Biosynthetic Pathway of Gentamicin, Proceeds with Retention of Configuration"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 139, no. 45, 1 March 2018 (2018-03-01), pages 16084 - 16087, XP055640907;;SATI ET AL: ""N6′, N6′′′, and O4′ Modifications to Neomycin Affect Ribosomal Selectivity without Compromising Antibacterial Activity"", ACS INFECTIOUS DISEASES, vol. 3, no. 5, 27 March 2017 (2017-03-27), pages 368 - 377, XP055550824",PENDING
437,US,A1,US 2022/0411456 A1,187-220-150-778-712,2022-12-29,2022,US 201817044960 A,2018-08-24,US 201817044960 A;;US 201862652169 P;;US 2018/0047993 W,2018-04-03,MODULAR SYNTHESIS OF AMINOGLYCOSIDES,The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.,REVAGENIX INC,CALABRESE ANDREW;;KANE TIMOTHY ROBORT;;HILDEBRANDT DARIN;;LOPEZ MICHAEL;;EVDOKIMOV NIKOLAI;;COHEN FREDERICK;;BAYRAKDARIAN MALKEN;;XU SANIJIA;;DESJARDINS SAMUEL;;SOUEIDAN OLIVIER,ACHAOGEN INC (2018-08-10);;INTELLISYN R&D (2018-08-03);;REVAGENIX INC (2019-12-19),https://lens.org/187-220-150-778-712,Patent Application,yes,0,0,4,4,0,C07H15/224;;C07H15/232;;C07H15/23;;C07H17/00;;C07H1/00;;A61P31/04;;C07H5/06;;C07H7/04;;C07H17/02,C07H7/04;;C07H5/06;;C07H17/02,,1,1,113-402-046-959-858,29091410;;pmc5831329;;10.1021/jacs.7b09890,"Kim et al., Journal of the American Chemical Society, 11/15/2017, 139(45), pp 16084-87 and Suppl. Material pp S1-S52 . (Year: 2017)",ACTIVE
438,US,B2,US 11673907 B2,104-842-236-254-130,2023-06-13,2023,US 201817044960 A,2018-08-24,US 201817044960 A;;US 201862652169 P;;US 2018/0047993 W,2018-04-03,Modular synthesis of aminoglycosides,The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.,REVAGENIX INC,CALABRESE ANDREW;;KANE TIMOTHY ROBERT;;HILDEBRANDT DARIN;;LOPEZ MICHAEL;;EVDOKIMOV NIKOLAI;;COHEN FREDERICK;;BAYRAKDARIAN MALKEN;;XU SANJIA;;DESJARDINS SAMUEL;;SOUEIDAN OLIVIER,ACHAOGEN INC (2018-08-10);;INTELLISYN R&D (2018-08-03);;REVAGENIX INC (2019-12-19),https://lens.org/104-842-236-254-130,Granted Patent,yes,48,0,4,4,0,C07H15/224;;C07H15/232;;C07H15/23;;C07H17/00;;C07H1/00;;A61P31/04;;C07H5/06;;C07H7/04;;C07H17/02,C07H5/06;;C07H7/04;;C07H17/02,,15,12,113-402-046-959-858;;044-078-920-759-658;;004-374-923-989-083;;057-153-200-948-898;;060-549-679-397-360;;057-663-865-680-03X;;113-402-046-959-858;;002-840-751-610-104;;001-798-919-451-934;;006-573-393-244-088;;028-644-852-991-263;;013-622-237-638-087,29091410;;pmc5831329;;10.1021/jacs.7b09890;;10.1021/jm00385a015;;3543366;;10.1021/ja972599h;;24439205;;10.1016/j.chembiol.2014.01.002;;29296992;;pmc5818290;;10.1039/c7cs00407a;;10.1086/315124;;10558951;;29091410;;pmc5831329;;10.1021/jacs.7b09890;;10.1021/cb5003416;;25019242;;2953976;;10.1038/327389a0;;10.1021/jacs.8b00148;;10.1021/jacs.8b00148.s001;;29377682;;28343384;;10.1021/acsinfecdis.6b00214.s001;;pmc5526222;;10.1021/acsinfecdis.6b00214;;17456024;;10.2174/092986707780362817,"Kim et al., Journal of the American Chemical Society, Nov. 15, 2017, 139(45), p. 16084-87 and Suppl. Material pp. S1-S52 . (Year: 2017).;;Allen et al. Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. J Med Chem. Feb. 1987;30(2):333-40.;;Alper et al. Probing the Specificity of Aminoglycoside-Ribosomal RNA Interactions with Designed Synthetic Analogs. J Am Chem Soc 120(9):1965-1978 (Feb. 24, 1998). DOI: https://doi.org/10.1021/ja972599h.;;Anish et al. Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol. Jan. 16, 2014;21(1):38-50.doi: 10.1016/j.chembiol.2014.01.002.;;Chandrika et al. Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities. Chem Soc Rev. Feb. 19, 2018;47(4):1189-1249.doi: 10.1039/c7cs00407a.;;Co-pending U.S. Appl. No. 16/642,879, inventors Andrews; Logan et al., filed Feb. 27, 2020.;;Hamouda et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis. Dec. 1999;180(6):1939-49.doi: 10.1086/315124.;;Kim et al. Reaction Catalyzed by GenK, a Cobalamin-Dependent Radical S-Adenosyl-l-methionine Methyltransferase in the Biosynthetic Pathway of Gentamicin, Proceeds with Retention of Configuration. J Am Chem Soc. Nov. 15, 2017;139(45):16084-16087 and Supplementary Material, pp. S1-S52.doi: 10.1021/jacs.7b09890. Epub Nov. 7, 2017.;;Maianti et al. Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial neomycin analogs. ACS Chem Biol. Sep. 19, 2014;9(9):2067-73.doi: 10.1021/cb5003416. Epub Jul. 14, 2014.;;Moazed et al. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature. Jun. 4-10, 1987;327(6121):389-94.doi: 10.1038/327389a0.;;PCT/US2018/047969 International Search Report and Written Opinion dated Dec. 4, 2018.;;PCT/US2018/047993 International Search Report and Written Opinion dated Dec. 6, 2018.;;Qin et al. Total Synthesis of a Densely Functionalized Plesiomonas shigelloides Serotype 51 Aminoglycoside Trisaccharide Antigen. J. Am. Chem. Soc. 140(8):3120-3127 (Jan. 29, 2018). DOI: https://doi.org/10.1021/jacs.8b00148.;;Sati et al. N6′, N6″, and O4′ Modifications to Neomycin Affect Ribosomal Selectivity without Compromising Antibacterial Activity. ACS Infect. Dis. 2017, 3, 5, 368-377 with Supporting Information, pp. S1-S71 (Mar. 27, 2017). DOI: https://doi.org/10.1021/acsinfecdis.6b00214.;;Silva et al. New insights into aminoglycoside antibiotics and derivatives. Curr Med Chem. 2007;14(10):1101-19.doi: 10.2174/092986707780362817.",ACTIVE
439,AU,B2,AU 2015/200379 B2,046-920-685-389-558,2017-02-02,2017,AU 2015/200379 A,2015-01-28,AU 2015/200379 A;;AU 2009/200521 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD A compound barb (620) medical device comprising: an elongate body (610) wherein the elongate body (610) is a monofilament suture including an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body (610) and defining an inner surface, the inner surface including: a first portion (620a) disposed at a first orientation relative to a first longitudinal axis of the elongate body (610), wherein the first portion (620a) is disposed at a first angle from about 0 degrees to 90 degrees relative to the first longitudinal axis of the elongate body (610); and a second portion (620b) disposed at a second orientation relative to a second longitudinal axis of the elongate body (610), wherein the second portion (620b) is disposed at a second angle from about 0 degrees to 90 degrees relative to the second longitudinal axis of the elongate body (610).",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;STELLON GENE A;;CARTER SALLY;;ROCKROHR BRIAN;;HARTOUMBEKIS ELIAS,,https://lens.org/046-920-685-389-558,Granted Patent,no,3,0,4,49,0,,A61B17/04,,0,0,,,,INACTIVE
440,US,A1,US 2017/0044136 A1,017-165-501-871-713,2017-02-16,2017,US 201615091776 A,2016-04-06,US 201615091776 A;;US 201414296911 A;;US 201213363895 A;;US 22191908 A;;US 50977004 A;;US 0308455 W;;US 36908802 P,2002-03-29,Pyridinoylpiperidines As 5-HT1F Agonists,"The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl;R 4 is hydrogen, halo, or C 1 -C 3 alkyl;R 5 is hydrogen or C 1 -C 3 alkyl;R 6 is hydrogen or C 1 -C 6 alkyl; andn is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/017-165-501-871-713,Patent Application,yes,0,1,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;C07D401/06;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,DISCONTINUED
441,US,A1,US 2023/0167148 A1,040-686-892-048-819,2023-06-01,2023,US 202218085645 A,2022-12-21,US 202218085645 A;;US 202017044960 A;;US 2018/0047993 W;;US 201862652169 P,2018-04-03,MODULAR SYNTHESIS OF AMINOGLYCOSIDES,The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.,REVAGENIX INC,CALABRESE ANDREW ANTONY;;KANE TIMOTHY ROBERT;;HILDEBRANDT DARIN;;LOPEZ MICHAEL;;EVDOKIMOV NIKOLAI;;COHEN FREDERICK;;BAYRAKDARIAN MALKEN;;XU SANIJIA;;DESJARDINS SAMUEL;;SOUEIDAN OLIVIER,,https://lens.org/040-686-892-048-819,Patent Application,yes,0,0,4,4,0,C07H15/224;;C07H15/232;;C07H15/23;;C07H17/00;;C07H1/00;;A61P31/04;;C07H5/06;;C07H7/04;;C07H17/02,C07H7/04;;C07H5/06;;C07H17/02,,0,0,,,,PENDING
442,CA,C,CA 2478229 C,127-195-528-330-445,2011-03-22,2011,CA 2478229 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/127-195-528-330-445,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
443,AU,A1,AU 2009/200521 A1,127-036-204-518-566,2009-09-03,2009,AU 2009/200521 A,2009-02-11,US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,,TYCO HEALTHCARE,PRIMAVERA MICHAEL;;STELLON GENE A;;COHEN MATTHEW D;;KOSA TIMOTHY D;;HARTOUMBEKIS ELIAS;;MAIORINO NICHOLAS;;CARTER SALLY;;ROCKROHR BRIAN;;BUCHTER MARK S,,https://lens.org/127-036-204-518-566,Patent Application,no,0,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,,0,0,,,,INACTIVE
444,AU,A1,AU 2015/200379 A1,113-074-998-975-572,2015-02-19,2015,AU 2015/200379 A,2015-01-28,AU 2015/200379 A;;AU 2009/200521 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD A compound barb (620) medical device comprising: an elongate body (610) wherein the elongate body (610) is a monofilament suture including an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body (610) and defining an inner surface, the inner surface including: a first portion (620a) disposed at a first orientation relative to a first longitudinal axis of the elongate body (610), wherein the first portion (620a) is disposed at a first angle from about 0 degrees to 90 degrees relative to the first longitudinal axis of the elongate body (610); and a second portion (620b) disposed at a second orientation relative to a second longitudinal axis of the elongate body (610), wherein the second portion (620b) is disposed at a second angle from about 0 degrees to 90 degrees relative to the second longitudinal axis of the elongate body (610).",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;STELLON GENE A;;CARTER SALLY;;ROCKROHR BRIAN;;HARTOUMBEKIS ELIAS,,https://lens.org/113-074-998-975-572,Patent Application,no,0,0,4,49,0,,A61B17/04,,0,0,,,,INACTIVE
445,US,B2,US 7342065 B2,096-904-617-793-19X,2008-03-11,2008,US 93253404 A,2004-09-02,US 93253404 A;;US 50442403 P,2003-09-18,"Preparation of nanocomposite of elastomer and exfoliated clay platelets, rubber compositions comprised of said nanocomposite and articles of manufacture, including tires",This invention relates to preparation of nanocomposites comprised of elastomer and a dispersion of an at least partially exfoliated water swellable clay and to rubber compositions containing such nanocomposite and articles of manufacture which contain at least one component thereof. The nanocomposite is prepared by addition of a water suspension of water swellable clay particles to an anionic aqueous emulsion of elastomer particles to form a mixture to which an amine having at least two amine centers is added to intercalate and at least partially exfoliate the water swelled clay particles by an ion exchange within the galleries of the multilayered clay with cation exchangeable ion(s) and to aid in coagulating the elastomer and resultant clay particles to form said nanocomposite.,GOODYEAR TIRE & RUBBER,YANG XIAOPING;;COHEN MARTIN PAUL;;SENYEK MICHAEL LESLIE;;PARKER DANE KENTON;;CRONIN STEVEN WAYNE;;LUKICH LEWIS TIMOTHY;;FRANCIK WILLIAM PAUL;;GURER CIGDEM,GOODYEAR TIRE & RUBBER COMPANY THE (2004-08-26),https://lens.org/096-904-617-793-19X,Granted Patent,yes,11,12,5,5,0,B60C1/00;;B60C1/0008;;B60C1/0016;;B60C1/0025;;B60C2200/02;;C08J3/215;;C08J2321/00;;C08K3/346;;C08L21/00;;B60C17/0009;;C08K9/04;;C08J3/215;;C08L21/00;;B60C1/0008;;B60C2200/02;;B60C1/0016;;B60C1/0025;;C08J2321/00;;B60C1/00;;C08K3/346;;B60C17/0009;;C08K9/04,C08K3/34;;B60C1/00;;B60C19/00;;C08J3/215;;C08L9/04;;C08L21/00;;C08L79/02,524/445;;524/492;;524/493;;524/495,1,0,,,European Search Report.,INACTIVE
446,US,A1,US 2005/0065266 A1,124-369-940-208-239,2005-03-24,2005,US 93253404 A,2004-09-02,US 93253404 A;;US 50442403 P,2003-09-18,"Preparation of nanocomposite of elastomer and exfoliated clay platelets, rubber compositions comprised of said nanocomposite and articles of manufacture, including tires","This invention relates to preparation of nanocomposites comprised of elastomer and a dispersion therein of an at least partially exfoliated, intercalated, multilayered, water swellable clay (e.g. smectite clay). The invention further relates to rubber compositions comprised of such nanocomposite, articles of manufacture, such as for example tires and industrial products such as, for example conveyor belts, power transmission belts and hoses, which contain at least one component comprised of said nanocomposite or said rubber composition. A particular adaptation for such rubber composition is contemplated for rubber tire components, such as for example treads, where significant replacement of carbon black reinforcement may be desired to reduce heat buildup for tire durability and reduction in tire weight for vehicular fuel economy such as, for example, aircraft tire treads. The nanocomposite is prepared by addition of a water suspension of water swellable clay particles to an aqueous emulsion of anionic (negatively charged) elastomer particles to form a mixture thereof to which an amine having at least two amine centers in a form of a cationic (positively charged) polymeric quaternary amine or ethylene polyamine is subsequently added to both intercalate and at least partially exfoliate the water swelled clay particles by an ion exchange within the galleries of the multilayered clay with cation exchangeable ion(s) and to aid in promoting the elastomer and resultant clay particles to coagulate and form a nanocomposite thereof. The coagulation may be aided by addition of an acid or salt/acid to reduce the pH and thereby destabilize the aqueous emulsion. The aqueous emulsion may be of, for example, synthetic anionic styrene/butadiene copolymer particles, or natural anionic cis 1,4-polyisoprene rubber particles (e.g. natural rubber latex).",YANG XIAOPING;;COHEN MARTIN PAUL;;SENYEK MICHAEL LESLIE;;PARKER DANE KENTON;;CRONIN STEVEN WAYNE;;LUKICH LEWIS TIMOTHY;;FRANCIK WILLIAM PAUL;;GURER CIGDEM,YANG XIAOPING;;COHEN MARTIN PAUL;;SENYEK MICHAEL LESLIE;;PARKER DANE KENTON;;CRONIN STEVEN WAYNE;;LUKICH LEWIS TIMOTHY;;FRANCIK WILLIAM PAUL;;GURER CIGDEM,GOODYEAR TIRE & RUBBER COMPANY THE (2004-08-26),https://lens.org/124-369-940-208-239,Patent Application,yes,8,27,5,5,0,B60C1/00;;B60C1/0008;;B60C1/0016;;B60C1/0025;;B60C2200/02;;C08J3/215;;C08J2321/00;;C08K3/346;;C08L21/00;;B60C17/0009;;C08K9/04;;C08J3/215;;C08L21/00;;B60C1/0008;;B60C2200/02;;B60C1/0016;;B60C1/0025;;C08J2321/00;;B60C1/00;;C08K3/346;;B60C17/0009;;C08K9/04,B60C1/00;;B60C19/00;;C08J3/215;;C08K3/34;;C08L9/04;;C08L21/00;;C08L79/02,524/445,0,0,,,,INACTIVE
447,JP,A,JP 2005089758 A,092-805-059-791-675,2005-04-07,2005,JP 2004271744 A,2004-09-17,US 50442403 P,2003-09-18,"METHOD FOR PRODUCING NANOCOMPOSITE COMPRISING ELASTOMER AND FLAKED CLAY PLATELET, RUBBER COMPOSITION COMPRISING THE NANOCOMPOSITE AND PRODUCT ARTICLE INCLUDING TIRE","<P>PROBLEM TO BE SOLVED: To provide a rubber composition for increasing durability of rubber products such as tire and decreasing heat accumulation or weight. <P>SOLUTION: The production method comprises the production of nanocomposite comprising elastomer and at least partially flaked inserted multilayered water-swelling clay and of a suspension system thereof. The nanocomposite is produced by forming a mixture by adding a water-suspension of water-swelling clay particles into an aqueous emulsion of an anionic elastomer particles, adding an amine having two amine centers to the mixture as a cationic polymer quaternary amine or an ethylene polyamine and, by ion-exchange using cation-changeable ion and in galleries of the multilayered clay, inserting the mixture in water-swelled clay particles to partially flake and to coagulate the elastomer and the obtained clay particles so as to promote formation of the nanocomposite. <P>COPYRIGHT: (C)2005,JPO&NCIPI",GOODYEAR TIRE & RUBBER,YANG XIAOPING;;COHEN MARTIN P;;SENYEK MICHAEL LESLIE;;PARKER DANE KENTON;;CRONIN STEVEN WAYNE;;LUKICH LEWIS TIMOTHY;;FRANCIK WILLIAM PAUL;;GURER CIGDEM,,https://lens.org/092-805-059-791-675,Patent Application,no,7,10,5,5,0,B60C1/00;;B60C1/0008;;B60C1/0016;;B60C1/0025;;B60C2200/02;;C08J3/215;;C08J2321/00;;C08K3/346;;C08L21/00;;B60C17/0009;;C08K9/04;;C08J3/215;;C08L21/00;;B60C1/0008;;B60C2200/02;;B60C1/0016;;B60C1/0025;;C08J2321/00;;B60C1/00;;C08K3/346;;B60C17/0009;;C08K9/04,B60C1/00;;B60C19/00;;C08J3/215;;C08K3/34;;C08L9/04;;C08L21/00;;C08L79/02,,0,0,,,,PENDING
448,BR,A,BR PI0403820 A,012-528-095-553-899,2005-05-24,2005,BR PI0403820 A,2004-09-10,US 50442403 P,2003-09-18,"Preparação de nanocompósito de elastÈmero e plaquetas de argila exfoliadas, composições de borracha compostas por esse nanocompósito e artigos de fabricação, incluindo pneus","""PREPARAçãO DE NANOCOMPóSITO DE ELASTÈMERO E PLAQUETAS DE ARGILA EXFOLIADAS, COMPOSIçõES DE BORRACHA COMPOSTAS POR ESSE NANOCOMPóSITO E ARTIGOS DE FABRICAçãO, INCLUINDO PNEUS"". Esta invenção se refere à preparação de nanocompósitos compostos por elastómero e uma dispersão de uma argila inchável com água, em múltiplas camadas, intercalada e pelo menos parcialmente exfoliada (por exemplo, argila esmectita) . A invenção também se refere a composições de borracha compostas por esse nanocompósito, artigos de fabricação, por exemplo, pneus e produtos industriais como, por exemplo, correias transportadoras, correias de transmissão de potência e mangueiras, que contenham pelo menos um componente composto pelo nanocompósito ou a composição de borracha. Uma adaptação particular para essa composição de borracha é considerada para componentes de pneu de borracha, por exemplo, bandas de rodagem, em que uma substituição significativa do reforço de negro-de-fumo possa ser desejável para reduzir o acúmulo de calor para durabilidade do pneu e redução do peso do pneu para economia de combustível do veículo, por exemplo, bandas de rodagem de pneus de aviões. O nanocompósito é preparado pela adição de uma suspensão em água de partículas de argila incháveis em agua a uma emulsão aquosa de partículas elastomericas aniónicas (negativamente carregadas), para formar uma mistura à qual uma amina com pelo menos dois centros amina na forma de uma amina quaternária polimérica catiónica (positivamente carregada) ou etileno poliamina é subseq³entemente adicionada tanto para intercalar, quanto para exfoliar pelo menos parcialmente as partículas de argila inchadas com água por uma troca iónica dentro das galerias da argila em múltiplas camadas com íons trocáveis por cátions e para auxiliar na promoção da coagulação do elastómero e partículas de argila resultantes e formação de seu nanocompósito. A coagulação pode ser auxiliada pela adição de um ácido ou sal/ácido para reduzir o pH e, dessa forma, estabilizar a emulsão aquosa. A emulsão aquosa pode ser, por exemplo, de partículas de copolímero de estireno/butadieno aniónico sintético ou de partículas de borracha de cis 1,4-poliisopreno aniónica natural (por exemplo, látex de borracha natural).",GOODYEAR TIRE & RUBBER,YANG XIAOPING;;COHEN MARTIN PAUL;;SENYEK MICHAEL LESLIE;;PARKER DANE KENTON;;CRONIN STEVEN WAYNE;;LUKICH LEWIS TIMOTHY;;FRANCIK WILLIAM PAUL;;GURER CIGDEM,,https://lens.org/012-528-095-553-899,Patent Application,no,0,0,5,5,0,B60C1/00;;B60C1/0008;;B60C1/0016;;B60C1/0025;;B60C2200/02;;C08J3/215;;C08J2321/00;;C08K3/346;;C08L21/00;;B60C17/0009;;C08K9/04;;C08J3/215;;C08L21/00;;B60C1/0008;;B60C2200/02;;B60C1/0016;;B60C1/0025;;C08J2321/00;;B60C1/00;;C08K3/346;;B60C17/0009;;C08K9/04,B60C1/00;;B60C19/00;;C08J3/215;;C08K3/34;;C08L9/04;;C08L21/00;;C08L79/02,,0,0,,,,DISCONTINUED
449,AU,B2,AU 2009/200521 B2,063-416-835-899-363,2014-10-30,2014,AU 2009/200521 A,2009-02-11,US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD A compound barb medical device is provided which includes an elongated body (14) having at least one barb formed along the length of the body, the barb (12) defining s an inner surface with a first portion (12a) disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion (12b) disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion (12c) disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided. 12c 12b 12a 12b12",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;STELLON GENE A;;CARTER SALLY;;ROCKROHR BRIAN;;HARTOUMBEKIS ELIAS,,https://lens.org/063-416-835-899-363,Granted Patent,no,3,0,43,49,0,A61B17/06166;;A61B2017/06176;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166;;Y10T29/49996;;Y10T83/0341;;Y10T29/49996;;Y10T83/0341;;A61B2017/00526;;A61B2017/00893;;A61B2017/06176;;A61B17/06166,A61B17/04,,0,0,,,,INACTIVE
450,EP,A1,EP 1518893 A1,065-388-286-197-840,2005-03-30,2005,EP 04104242 A,2004-09-03,US 50442403 P,2003-09-18,"Preparation of a composite of elastomer and exfoliated clay platelets, rubber compositions comprised of said composite and articles of manufacture, including tires","This invention relates to the preparation of nanocomposites comprised of an elastomer and a dispersion therein of an at least partially exfoliated, intercalated, multilayered, water swellable clay (e.g. smectite clay). The invention further relates to rubber compositions comprised of such nanocomposites and tires and industrial products such as, for example conveyor belts, power transmission belts and hoses, which contain at least one component comprised of said nanocomposite or said rubber composition. A particular adaptation for such rubber composition is contemplated for rubber tire components, such as for example treads, where significant replacement of carbon black reinforcement may be desired to reduce heat buildup for tire durability and reduction in tire weight for vehicular fuel economy such as, for example, aircraft tire treads. The nanocomposite is prepared by addition of a water suspension of water swellable clay particles to an aqueous emulsion of anionic (negatively charged) elastomer particles to form a mixture thereof to which an amine having at least two amine centers in a form of a cationic (positively charged) polymeric quaternary amine or ethylene polyamine is subsequently added to both intercalate and at least partially exfoliate the water swelled clay particles by an ion exchange within the galleries of the multilayered clay with cation exchangeable ion(s) and to aid in promoting the elastomer and resultant clay particles to coagulate and form a nanocomposite thereof.",GOODYEAR TIRE & RUBBER,YANG XIAOPING;;COHEN MARTIN PAUL;;SENYEK MICHAEL LESLIE;;PARKER DANE KENTON;;CRONIN STEVEN WAYNE;;LUKICH LEWIS TIMOTHY;;FRANCIK WILLIAM PAUL;;GURER CIGDEM,,https://lens.org/065-388-286-197-840,Patent Application,yes,3,6,5,5,0,B60C1/00;;B60C1/0008;;B60C1/0016;;B60C1/0025;;B60C2200/02;;C08J3/215;;C08J2321/00;;C08K3/346;;C08L21/00;;B60C17/0009;;C08K9/04;;C08J3/215;;C08L21/00;;B60C1/0008;;B60C2200/02;;B60C1/0016;;B60C1/0025;;C08J2321/00;;B60C1/00;;C08K3/346;;B60C17/0009;;C08K9/04,B60C1/00;;B60C19/00;;C08J3/215;;C08K3/34;;C08L9/04;;C08L21/00;;C08L79/02,,0,0,,,,DISCONTINUED
451,AU,A1,AU 2017/202006 A1,013-539-869-896-909,2017-04-13,2017,AU 2017/202006 A,2017-03-24,AU 2017/202006 A;;AU 2015/200379 A;;AU 2009/200521 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD A compound barb (620) medical device comprising: an elongate body (610) wherein the elongate body (610) is a monofilament suture including an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body (610) and defining an inner surface, the inner surface including: a first portion (620a) disposed at a first orientation relative to a first longitudinal axis of the elongate body (610), wherein the first portion (620a) is disposed at a first angle from about 0 degrees to 90 degrees relative to the first longitudinal axis of the elongate body (610); and a second portion (620b) disposed at a second orientation relative to a second longitudinal axis of the elongate body (610), wherein the second portion (620b) is disposed at a second angle from about 0 degrees to 90 degrees relative to the second longitudinal axis of the elongate body (610).",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;STELLON GENE A;;CARTER SALLY;;ROCKROHR BRIAN;;HARTOUMBEKIS ELIAS,,https://lens.org/013-539-869-896-909,Patent Application,no,0,0,4,49,0,,A61B17/04,,0,0,,,,INACTIVE
452,AU,B2,AU 2017/202006 B2,057-883-806-703-515,2018-02-01,2018,AU 2017/202006 A,2017-03-24,AU 2017/202006 A;;AU 2015/200379 A;;AU 2009/200521 A;;US 36196209 A;;US 2996408 P,2008-02-20,Compound barb medical device and method,"COMPOUND BARB MEDICAL DEVICE AND METHOD A compound barb (620) medical device comprising: an elongate body (610) wherein the elongate body (610) is a monofilament suture including an outer surface, and the outer surface is in direct contact with tissue; at least one barb extending from the elongated body (610) and defining an inner surface, the inner surface including: a first portion (620a) disposed at a first orientation relative to a first longitudinal axis of the elongate body (610), wherein the first portion (620a) is disposed at a first angle from about 0 degrees to 90 degrees relative to the first longitudinal axis of the elongate body (610); and a second portion (620b) disposed at a second orientation relative to a second longitudinal axis of the elongate body (610), wherein the second portion (620b) is disposed at a second angle from about 0 degrees to 90 degrees relative to the second longitudinal axis of the elongate body (610).",COVIDIEN LP,COHEN MATTHEW D;;MAIORINO NICHOLAS;;KOSA TIMOTHY D;;BUCHTER MARK S;;PRIMAVERA MICHAEL;;STELLON GENE A;;CARTER SALLY;;ROCKROHR BRIAN;;HARTOUMBEKIS ELIAS,,https://lens.org/057-883-806-703-515,Granted Patent,no,3,0,4,49,0,,A61B17/04,,0,0,,,,INACTIVE
453,US,A1,US 2015/0376178 A1,019-289-191-907-908,2015-12-31,2015,US 201414296911 A,2014-06-05,US 201414296911 A;;US 201213363895 A;;US 22191908 A;;US 50977004 A;;US 0308455 W;;US 36908802 P,2002-03-29,Pyridinoylpiperidines As 5-HT1F Agonists,"The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl;R 4 is hydrogen, halo, or C 1 -C 3 alkyl;R 5 is hydrogen or C 1 -C 3 alkyl;R 6 is hydrogen or C 1 -C 6 alkyl; andn is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,ELI LILLY AND COMPANY (2009-03-10),https://lens.org/019-289-191-907-908,Patent Application,yes,0,2,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;C07D417/14;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14,,0,0,,,,DISCONTINUED
454,US,B2,US 8748459 B2,061-447-181-983-417,2014-06-10,2014,US 201213363895 A,2012-02-01,US 201213363895 A;;US 22191908 A;;US 50977004 A;;US 0308455 W;;US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,"The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl;R 4 is hydrogen, halo, or C 1 -C 3 alkyl;R 5 is hydrogen or C 1 -C 3 alkyl;R 6 is hydrogen or C 1 -C 6 alkyl; andn is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT lF receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,ELI LILLY AND COMPANY (2009-03-10),https://lens.org/061-447-181-983-417,Granted Patent,yes,59,2,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/445;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,514/318;;546/193,31,26,048-876-758-350-978;;027-278-035-303-236;;065-063-131-125-53X;;019-627-386-067-151;;007-364-858-655-289;;013-597-873-563-117;;045-703-328-642-685;;071-512-616-217-270;;004-545-024-528-332;;102-727-957-145-819;;053-561-554-765-682;;040-682-865-651-788;;079-965-527-840-59X;;074-303-768-545-546;;080-073-336-592-230;;060-970-497-336-355;;058-891-300-348-778;;050-722-468-239-809;;016-901-772-944-853;;095-899-905-718-899;;025-984-532-372-449;;023-803-857-779-302;;060-179-119-642-043;;007-090-443-628-857;;099-773-360-998-131;;010-425-342-754-264,10.1503/cmaj.081657;;20159899;;pmc2855933;;8380639;;10.1073/pnas.90.2.408;;pmc45671;;9395253;;10.1016/s0024-3205(97)00885-0;;10.1135/cccc19990377;;10.1002/jps.2600660104;;833720;;18727647;;10.1111/j.1468-2982.2008.01660.x;;10.1016/s0140-6736(01)06711-3;;11728541;;11807151;;10.1056/nejmra010917;;11675061;;10.1016/s0140-6736(01)06347-4;;10.1001/archneurpsyc.1938.02270040093005;;10.1002/chin.199818154;;10.1016/j.cct.2005.02.001;;15911469;;29368949;;10.1177/0333102417738202;;10.1111/j.1471-4159.1988.tb03052.x;;3361315;;19036425;;10.1016/s0140-6736(08)61626-8;;10.1111/j.1749-6632.1990.tb16912.x;;2252337;;10.1046/j.1468-2982.2000.00117.x;;11167908;;9665056;;10.1161/01.cir.98.1.25;;1559258;;10.1046/j.1468-2982.1992.1201005.x;;8389008;;15014183;;10.1056/nejmoa030505;;18502781;;10.1093/brain/awn094;;10.1111/j.1468-2982.2007.01288.x;;17381554;;8980858;;10.1046/j.1468-2982.1996.1608554.x;;10.1073/pnas.89.8.3630;;pmc48922;;1565658;;10.1111/j.1468-2982.2000.00116.x;;11167896;;10.1046/j.1468-2982.2000.00116.x,"Streitwieser et al. ""Metallation."" Introduction to Organic Chemistry. eds. Upper Saddie River, NJ: Prentice Hall. (1992):1011-1012.;;Pringsheim et al. ""Prophylaxis of Migraine Headache"". CMAJ. 182.7(2010):E269-276.;;""A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine."" Study 2 of 2 for search of: CoLucid, Clinical Trials, Oct. 4, 2006.;;King, F. D. ""Bioisosteres, Conformational Restriction, and Pro-drugs-Case History: An Example of a Conformational Restriction Approach."" Medicinal Chemistry: Principles and Practice, Royal Society of Chemistry, Cambridge, England, Ch. 14 (1994) : 206-209.;;Adham et al. ""Cloning of another human serotonin receptor (5-HT1F): A fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase."" Proc. Natl. Acad. Sci. USA 90 (1993) : 408-412.;;Phebus et al. ""Characterization of LY344864 as a Pharmacological Tool to Study 5-HT1F Receptors: Binding Affinities, Brain Penetration and Activity in the Neurogenic Dural Inflammational Model of Migraine."" CA 128:18603, Life Sciences 61.21 (1997) : 2117-2126.;;Radl et al. ""Synthesis and Antinociceptive Activity of Some 3-Chlorophenyl- and 6-Chloro-2-Pyridinyl Derivatives."" CA 130:352171, Collection of Czechoslovak Chemical Communications 64.2 (1999) : 377-388.;;""Dose-ranging Study of Oral COL-144 in Acute Migraine Treatmen-Study 1 of 2 for search of: Colucid"", Clinical Trials, Apr. 16, 2009 (5 pages).;;Berge et al. ""Pharmaceutical Salts."" J. Pharm. Sci. 66.1(1977):1-19.;;Diener et al. ""The Importance of Placebo in Headache Research."" Cephalalgia. 28.10(2008):1003-1011.;;Ferrari et al. ""Oral Triptans (Serotonin 5-HT1B/1D Agonists) in Acute Migraine Treatment: A Meta-Analysis of 53 Trials."" Lancet. 358(2001):1668-1675.;;Goadsby et al. ""Migraine-Current Understanding and Treatment."" N. Engl. J. Med. 346.4(2002):257-270.;;Goldstein et al. ""Selective Seratonin 1F (5-HT1F) Receptor Agonist LY334370 for Acute Migraine: A Randomised Controlled Trial."" Lancet. 358.9289(2001):1230-1234.;;Graham et al. ""Mechanism of Migraine Headache and Action of Ergotamine Tartrate."" Arch. Neurol. Psychaitry. 39.4(1938):737-763.;;Gros et al. ""Aggregative Activation in Heterocyclic Chemistry. Part 5. Lithiation of Pyridine and Quinoline with the Complex Base BuLi-Me2N(CH2)2OLi (BuLi-LiDMAE)."" J. Chem. Soc., Perkin Trans. 1. 24(1997):3597-3600.;;Hall et al. ""A Group Sequential Adaptive Treatment Assignment Design for Proof of Concept and Dose Selection in Headache Trials."" Contemp. Clin. Trials. 26.3(2005):349-364.;;Headache Classification Subcommittee of the International Headache Society. ""The International Classification of Headache Disorders: Second Edition."" Cephalalgia. 24.S11(2004):1-160.;;Herrick-Davis et al. ""Detection and Characterization of the Serotonin 5-HT 1D Receptor in Rat and Human Brain."" J. Neurochem. 50.5(1988):1624-1631.;;Ho et al. ""Efficacy and Tolerability of MK-0974 (telcagepant), a New Oral Antagonist of Calcitonin Gene-Related Peptide Receptor, Compared with Zolmitriptan for Acute Migraine: A Randomised, Placebo-Controlled, Parallel-Treatment Trial."" Lancet. 372.9656(2008):2115-2123.;;Humphrey et al. ""Serotonin and Migraine."" Ann. N.Y. Acad. Sci. 600(1990):587-598.;;International Headache Society Clinical Trials Subcommittee. ""Guidelines for Controlled Trials of Drugs in Migraine: Second Edition."" Cephalalgia. 20.9(2000):765-786.;;MaassenVanDenBrink et al. ""Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs."" Circulation. 98.1(1998):25-30.;;Moskowitz. ""Interpreting Vessel Diameter Changes in Vascular Headaches."" Cephalalgia. 12.1(1992):5-7.;;Moskowitz. ""Neurogenic Inflammation in the Pathophysiology and Treatment of Migraine."" Neurol. 43.S3(1993):S16-S20.;;Nelson et al. COL-144: Preclinical Profile of a Selective 5-HT1F Receptor Agonist for Migraine. Cephalalgia. 29(2009):122-123. (Abstract # PC.12).;;Olesen et al. ""Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine."" N. Engl. J. Med. 350.11(2004):1104-1110.;;Schoonman et al. ""Migraine Headache is not Associated with Cerebral of Meningeal Vasodilation-a 3 T Magnetic Resonance Angiography Study."" Brain. 131.Pt8(2008):2192-2200.;;Stovner et al. ""The Global Burden of Headache: A Documentation of Headache Prevalence and Disablity Worldwide."" Cephalalgia. 27.3(2007):193-210.;;Visser et al. ""Chest Symptoms After Sumatriptan: A Two-Year Clinical Practice Review in 735 Consecutive Migraine Patients."" Cephalalgia. 16.8(1996):554-559.;;Weinshank et al. ""Human Serotonin 1D Receptor is Encoded by a Subfamily of Two Distinct Genes: 5-HT1Dalpha and 5-HT1Dbeta."" PNAS. 89.8(1992):3630-3634.;;Welch et al. ""Tolerability of Sumatriptan: Clinical Trials and Post-Marketing Experience."" Cephalalgia. 20.8(2000):687-695.",EXPIRED
455,US,A1,US 2022/0257266 A1,034-178-279-631-127,2022-08-18,2022,US 202017627567 A,2020-07-16,US 202017627567 A;;US 201962874823 P;;US 2020/0042370 W,2019-07-16,AUTOMATED CRANIAL BURR HOLE DEVICE AND METHOD,An intracranial access device includes a housing having an operator-facing side and a patient-facing side and an opening therethrough extending from the operator-facing side to the patient-facing side. The device further includes at least one fastener configured to secure the device to a cranium of a patient. The device further includes a drill mounted to a surface of the housing and a cauterizer. The device may further include a number of sensors arranged on the patient-facing side of the housing and configured to identify a hemorrhage location.,HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC;;UNIV JOHNS HOPKINS,BRODY DAVID L;;BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M,THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC (2022-08-02);;UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (2022-02-10),https://lens.org/034-178-279-631-127,Patent Application,yes,0,0,4,4,0,A61B17/1695;;A61B17/1739;;A61B2090/103;;A61B90/10;;A61B2090/033;;A61B2018/00595;;A61B2090/374;;A61B2090/3762;;A61B2018/00791;;A61B2218/007;;A61B2217/005;;A61B2090/064;;A61B18/1402;;A61B2018/00565;;A61B2018/00321;;A61B2090/033;;A61B2090/064;;A61B2090/103;;A61B90/11;;A61B2090/374;;A61B2090/3762;;A61B5/031;;A61B17/1695;;A61B17/1739;;A61B18/1402;;A61B2018/00321;;A61B2018/00565;;A61B2018/00595;;A61B2018/00791;;A61B2217/005;;A61B2218/007;;A61N1/0539,A61B17/16;;A61B5/03;;A61B17/17;;A61B18/14;;A61B90/11;;A61N1/05,,0,0,,,,PENDING
456,US,A1,US 2014/0093192 A1,062-722-693-138-41X,2014-04-03,2014,US 201213631549 A,2012-09-28,US 201213631549 A,2012-09-28,Storage Bag With Textured Area On Lips To Facilitate Closing Process,A storage bag has first and second closure profiles that include interlocking members configured to seal an opening of the bag. A textured area is provided on the first closure profile adjacent to the interlocking member and adjacent to an end of the first closure profile. The textured area provides a visual cue to indicate that the process of sealing the interlocking members should begin at the end of the first closure profile and move towards a center of the bag.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;STARK TIMOTHY D;;ALTHOFF CHARLES P;;EDEN COHEN ERICA,S.C. JOHNSON & SON INC (2012-10-24);;SMART DESIGN LLC (2012-10-25),https://lens.org/062-722-693-138-41X,Patent Application,yes,4,10,2,33,0,B65D33/007;;B65D33/2508;;B65D33/28;;B65B7/06;;B65D33/007;;B65D33/2508,B65B7/06;;B65D33/28,383/65;;53/481,0,0,,,,ACTIVE
457,WO,A1,WO 2021/011795 A1,064-998-230-353-041,2021-01-21,2021,US 2020/0042370 W,2020-07-16,US 201962874823 P,2019-07-16,AUTOMATED CRANIAL BURR HOLE DEVICE AND METHOD,An intracranial access device includes a housing having an operator-facing side and a patient-facing side and an opening therethrough extending from the operator-facing side to the patient-facing side. The device further includes at least one fastener configured to secure the device to a cranium of a patient. The device further includes a drill mounted to a surface of the housing and a cauterizer. The device may further include a number of sensors arranged on the patient-facing side of the housing and configured to identify a hemorrhage location.,HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC;;UNIV JOHNS HOPKINS;;BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M,BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M;;BRODY DAVID L,,https://lens.org/064-998-230-353-041,Patent Application,yes,14,8,4,4,0,A61B17/1695;;A61B17/1739;;A61B2090/103;;A61B90/10;;A61B2090/033;;A61B2018/00595;;A61B2090/374;;A61B2090/3762;;A61B2018/00791;;A61B2218/007;;A61B2217/005;;A61B2090/064;;A61B18/1402;;A61B2018/00565;;A61B2018/00321;;A61B2090/033;;A61B2090/064;;A61B2090/103;;A61B90/11;;A61B2090/374;;A61B2090/3762;;A61B5/031;;A61B17/1695;;A61B17/1739;;A61B18/1402;;A61B2018/00321;;A61B2018/00565;;A61B2018/00595;;A61B2018/00791;;A61B2217/005;;A61B2218/007;;A61N1/0539,A61B17/16;;A61B50/20,,1,0,,,See also references of EP 3998965A4,PENDING
458,DE,D1,DE 60308850 D1,198-092-050-503-573,2006-11-16,2006,DE 60308850 T,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINE ALS 5-HT1F AGONISTEN,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL PIATT;;ZHANG DEYI,,https://lens.org/198-092-050-503-573,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
459,CA,C,CA 3041612 C,143-422-252-497-638,2022-04-05,2022,CA 3041612 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CA 2993710 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/143-422-252-497-638,Granted Patent,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/08;;B65D30/10,,0,0,,,,PENDING
460,EP,A1,EP 3998965 A1,034-340-141-740-171,2022-05-25,2022,EP 20841620 A,2020-07-16,US 201962874823 P;;US 2020/0042370 W,2019-07-16,AUTOMATED CRANIAL BURR HOLE DEVICE AND METHOD,,HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC;;UNIV JOHNS HOPKINS;;BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M,BRODY DAVID L;;BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M,,https://lens.org/034-340-141-740-171,Patent Application,yes,0,0,4,4,0,A61B17/1695;;A61B17/1739;;A61B2090/103;;A61B90/10;;A61B2090/033;;A61B2018/00595;;A61B2090/374;;A61B2090/3762;;A61B2018/00791;;A61B2218/007;;A61B2217/005;;A61B2090/064;;A61B18/1402;;A61B2018/00565;;A61B2018/00321;;A61B2090/033;;A61B2090/064;;A61B2090/103;;A61B90/11;;A61B2090/374;;A61B2090/3762;;A61B5/031;;A61B17/1695;;A61B17/1739;;A61B18/1402;;A61B2018/00321;;A61B2018/00565;;A61B2018/00595;;A61B2018/00791;;A61B2217/005;;A61B2218/007;;A61N1/0539,A61B17/16;;A61B50/20,,0,0,,,,PENDING
461,DE,T2,DE 60308850 T2,188-466-283-316-702,2007-05-24,2007,DE 60308850 T,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINE ALS 5-HT1F AGONISTEN,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL PIATT;;ZHANG DEYI,,https://lens.org/188-466-283-316-702,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
462,EP,A4,EP 3998965 A4,001-982-013-370-118,2023-08-09,2023,EP 20841620 A,2020-07-16,US 201962874823 P;;US 2020/0042370 W,2019-07-16,AUTOMATED CRANIAL BURR HOLE DEVICE AND METHOD,,HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC;;UNIV JOHNS HOPKINS;;BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M,BRODY DAVID L;;BLODGETT DAVID;;RODRIGUEZ CARISSA;;SLEASMAN TIMOTHY;;FITCH MICHAEL J;;COHEN ADAM;;BASESCU MAX R;;WOLFE KEVIN C;;WORMLEY JARED M,,https://lens.org/001-982-013-370-118,Search Report,no,2,0,4,4,0,A61B17/1695;;A61B17/1739;;A61B2090/103;;A61B90/10;;A61B2090/033;;A61B2018/00595;;A61B2090/374;;A61B2090/3762;;A61B2018/00791;;A61B2218/007;;A61B2217/005;;A61B2090/064;;A61B18/1402;;A61B2018/00565;;A61B2018/00321;;A61B2090/033;;A61B2090/064;;A61B2090/103;;A61B90/11;;A61B2090/374;;A61B2090/3762;;A61B5/031;;A61B17/1695;;A61B17/1739;;A61B18/1402;;A61B2018/00321;;A61B2018/00565;;A61B2018/00595;;A61B2018/00791;;A61B2217/005;;A61B2218/007;;A61N1/0539,A61B17/16;;A61B50/20,,1,0,,,See also references of WO 2021011795A1,PENDING
463,US,B2,US 9114914 B2,113-392-516-942-596,2015-08-25,2015,US 201213631549 A,2012-09-28,US 201213631549 A,2012-09-28,Storage bag with textured area on lips to facilitate closing process,A storage bag has first and second closure profiles that include interlocking members configured to seal an opening of the bag. A textured area is provided on the first closure profile adjacent to the interlocking member and adjacent to an end of the first closure profile. The textured area provides a visual cue to indicate that the process of sealing the interlocking members should begin at the end of the first closure profile and move towards a center of the bag.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;STARK TIMOTHY D;;ALTHOFF CHARLES P;;EDEN COHEN ERICA,S.C. JOHNSON & SON INC (2012-10-24);;SMART DESIGN LLC (2012-10-25),https://lens.org/113-392-516-942-596,Granted Patent,yes,114,14,2,33,0,B65D33/007;;B65D33/2508;;B65D33/28;;B65B7/06;;B65D33/007;;B65D33/2508,B65D33/16;;B65B7/06;;B65D33/00;;B65D33/25;;B65D33/28,,2,0,,,"Picture of Ziploc� Brand Bag-Quart Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.;;Picture of Ziploc� Brand Bag-Sandwich Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.",ACTIVE
464,AU,A1,AU 2003/224719 A1,023-002-421-339-39X,2003-10-20,2003,AU 2003/224719 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/023-002-421-339-39X,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
465,EG,A,EG 25226 A,089-368-021-167-286,2011-11-17,2011,EG 2003030289 A,2003-03-26,US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HT1F agon.,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/089-368-021-167-286,Patent of Addition,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,PENDING
466,WO,A1,WO 2003/084949 A1,004-553-346-455-068,2003-10-16,2003,US 0308455 W,2003-03-27,US 36908802 P,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI;;COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/004-553-346-455-068,Patent Application,yes,1,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,PATENTED
467,NO,B1,NO 330394 B1,037-879-257-623-178,2011-04-04,2011,NO 20044654 A,2004-10-28,US 36908802 P;;US 0308455 W,2002-03-29,Piperidinoylpiperidiner som 5-HTIF-agonister,"Det er beskrevet forbindelser av formel I: eller farmasøytisk akseptable syreaddisjonssalter derav, hvor R1 er C1-C6-alkyl, substituert C1-C6-alkyl, C3-C7-sykloalkyl, substituert C3-C7-sykloalkyl, C3-C7-sykloalkyl-C1-C3-alkyl, substituert C3-C7-sykloalkyl-C1-C3-alkyl, fenyl, substituert fenyl, heterosyklus eller substituert heterosyklus; R2 er hydrogen, C1-C3-alkyl, C3-C6-sykloalkyl-C1-C3-alkyl eller en gruppe av formel hvor R3 er hydrogen eller C1-C3-alkyl; R4 er hydrogen, halogen eller C1-C3-alkyl; R5 er hydrogen eller C1-C3-alkyl; R6 er hydrogen eller C1-C6-alkyl; og n er et heltall fra og med 1 til og med 6. Forbindelsene er nyttige for aktivering av 5-HT1F-reseptorer, for inhibering av neuronal proteinekstravasasjon og for behandling eller forebyggelse av migrene i et pattedyr. Det er også beskrevet en fremgangsmåte for syntese av mellomprodukter ved syntesen av forbindelser av formel I..",LILLY CO ELI,MANCUSO VINCENT;;KOHLMAN DANIEL TIMOTHY;;XU YAO-CHANG;;VICTOR FRANTZ;;COHEN MICHAEL PHILIP;;LIANG SIDNEY X;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/037-879-257-623-178,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
468,PT,E,PT 1492786 E,071-584-168-550-506,2007-01-31,2007,PT 03721402 T,2003-03-27,US 36908802 P,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,VICTOR FRANTZ;;XU YAO-CHANG;;COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/071-584-168-550-506,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
469,HR,B1,HR P20040883 B1,123-931-396-705-029,2012-11-30,2012,HR P20040883 A,2004-09-24,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/123-931-396-705-029,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
470,HR,A2,HR P20040883 A2,062-075-695-127-935,2004-12-31,2004,HR P20040883 A,2004-09-24,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/062-075-695-127-935,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
471,PL,B1,PL 210019 B1,054-987-045-645-863,2011-11-30,2011,PL 37284503 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/054-987-045-645-863,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
472,CA,A1,CA 2694410 A1,069-484-733-750-181,2003-10-16,2003,CA 2694410 A,2003-03-27,US 36908802 P;;CA 2478229 A,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILLIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERI DEANNE PIATT;;ZHANG DEYI,,https://lens.org/069-484-733-750-181,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
473,CA,A1,CA 2478229 A1,118-538-815-617-903,2003-10-16,2003,CA 2478229 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl- C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1- C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,LIANG SIDNEY XI;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;KOHLMAN DANIEL TIMOTHY;;VICTOR FRANTZ;;XU YAO-CHANG;;MANCUSO VINCENT;;COHEN MICHAEL PHILIP;;YING BAI-PING,,https://lens.org/118-538-815-617-903,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
474,HK,A1,HK 1073464 A1,114-527-148-417-123,2005-10-07,2005,HK 05104936 A,2005-06-13,US 36908802 P;;US 0308455 W,2002-03-29,Pyridinoylpiperidines as 5-ht1f agonists,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/114-527-148-417-123,Patent Application,no,0,1,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D/;;A61K/;;A61K31/4545;;A61K31/506;;A61P/;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,DISCONTINUED
475,AT,T1,AT E341543 T1,046-429-083-539-491,2006-10-15,2006,AT 03721402 T,2003-03-27,US 36908802 P,2002-03-29,PYRIDINOYLPIPERIDINE ALS 5-HT1F AGONISTEN,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/046-429-083-539-491,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
476,EP,B1,EP 1492786 B1,136-267-891-209-857,2006-10-04,2006,EP 03721402 A,2003-03-27,US 0308455 W;;US 36908802 P,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,ELI LILLY AND COMPANY (2008-06-25),https://lens.org/136-267-891-209-857,Granted Patent,yes,1,5,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
477,DK,T3,DK 1492786 T3,038-117-476-581-604,2007-02-12,2007,DK 03721402 T,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,Pyridinoylpiperidiner som 5-HT1F-agonister,,LILLY CO ELI,VICTOR FRANTZ;;ZACHERL DEANNA PIATT;;COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;XU YAO-CHANG;;YING BAI-PING;;ZHANG DEYI,,https://lens.org/038-117-476-581-604,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
478,EP,A1,EP 1492786 A1,068-545-283-860-526,2005-01-05,2005,EP 03721402 A,2003-03-27,US 0308455 W;;US 36908802 P,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,ELI LILLY AND COMPANY (2008-06-25),https://lens.org/068-545-283-860-526,Patent Application,yes,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
479,US,A1,US 2008/0300407 A1,114-320-625-625-69X,2008-12-04,2008,US 22022508 A,2008-07-22,US 22022508 A;;US 50977004 A;;US 0308455 W;;US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,"The invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II; R 3 is hydrogen or C 1 -C 3 alkyl;R 4 is hydrogen, halo, or C 1 -C 3 alkyl;R 5 is hydrogen or C 1 -C 3 alkyl;R 6 is hydrogen or C 1 -C 6 alkyl; andn is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,ELI LILLY AND COMPANY (2002-11-26),https://lens.org/114-320-625-625-69X,Patent Application,yes,12,13,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/14;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D405/14;;C07D409/14;;C07D417/14,544/300;;546/194,0,0,,,,EXPIRED
480,BR,B1,BR PI0308495 B1,145-496-564-704-610,2015-07-07,2015,BR 0308495 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,"Composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto",,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/145-496-564-704-610,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
481,NZ,A,NZ 534952 A,134-303-092-379-932,2005-11-25,2005,NZ 53495203 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,"Pyridinoylpiperidines as serotonin agonists and the use as medicaments for inhibition of neuronal protein extravasation, disorders due to dysfunction of the serotonin receptors and migraines","5-HT1F receptor agonists of formula I are described wherein: R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, heterocycle or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl or a group of formula II; R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C3 alkyl; and n is an integer from 1-6. Pharmaceutical compositions comprising the compounds are useful for activating 5-HT1F receptors, the inhibition of neuronal protein extravasation and for the treatment or prevention of migraines. Also described is a process for the production of the compounds.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/134-303-092-379-932,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,DISCONTINUED
482,PL,A1,PL 372845 A1,034-946-153-849-058,2005-08-08,2005,PL 37284503 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,,LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/034-946-153-849-058,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
483,BR,B8,BR PI0308495 B8,074-758-440-912-50X,2021-05-25,2021,BR 0308495 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,"composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto","""composto, formulação farmacêutica, métodos para ativar receptores de 5-ht~ 1f~, para inibir o extravasamento de proteína neuronal, para tratar ou prevenir enxaqueca em um mamífero e papa preparar um composto, uso de um composto, e, processo para preparar um composto"". a presente invenção refere-se aos compostos de fórmula i ou sais de adição de ácido farmaceuticamente aceitáveis dos mesmos, na qual r^ 1^ é c~ 1~-c~ 6~-alquila, c~ 1~-c~ 6~-alquila substituída, c~ 3~-c~ 7~ ciclo-alquila, c~ 3~-c~ 7~ cicloalquila substituída, c~ 3~-c~ 7~ ciclo-alquil-c~ 1~-c~ 3~-alquila, c~ 3~-c~ 7~ ciclo-alquil-c~ 1~-c~ 3~alquila substituída, fenila, fenila substituída, heterociclo, ou heterociclo substituído; r^ 2^ é hidrogênio, c~ 1~-c~ 3~-alquila, c~ 3~-c~ 6~ ciclo-alquil-c~ 1~-c~ 3~-alquila, ou um grupo de fórmula ii; r^ 3^ é hidrogênio ou c~ 1~-c~ 3~-alquila; r^ 4^ é hidrogênio, halo, ou c~ 1~c~ 3~-alquila; r^ 5^ é hidrogênio ou c~ 1~-c~ 3~-alquila, r^ 6^ é hidrogênio ou c~ 1~-c~ 6~-alquila; e n é um número inteiro de 1 a 6 inclusive. os compostos da presente invenção são úteis para a ativação de receptores de 5-htif, inibição de extravasamento de proteína neuronal, e para o tratamento ou a prevenção de enxaqueca em um mamífero. a presente invenção também se refere a um processo para a síntese de intermediários na sintese de compostos de fórmula i.",LILLY CO ELI,BAI-PING YING;;DANIEL TIMOTHY KOHLMAN;;DEANNA PIATT ZACHERL;;DEYI ZHANG;;FRANTZ VICTOR;;MICHAEL PHILIP COHEN;;SIDNEY XI LIANG;;VINCENT MANCUSO;;YAO-CHANG XU,,https://lens.org/074-758-440-912-50X,Amended Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
484,NO,L,NO 20044654 L,176-864-681-490-544,2004-10-28,2004,NO 20044654 A,2004-10-28,US 36908802 P;;US 0308455 W,2002-03-29,Piperidinoylpiperidiner som 5-HTIF-agonister,,LILLY CO ELI,MANCUSO VINCENT;;KOHLMAN DANIEL TIMOTHY;;XU YAO-CHANG;;VICTOR FRANTZ;;COHEN MICHAEL PHILIP;;LIANG SIDNEY X;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/176-864-681-490-544,Abstract,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
485,BR,A,BR 0308495 A,024-476-380-700-791,2005-02-01,2005,BR 0308495 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,"Composto, formulação farmacêutica, métodos para ativar receptores de 5-ht1f, para inibir o extravasamento de proteìna neuronal, para tratar ou prevenir enxaqueca em um mamìfero e para preparar um composto, uso de um composto, e, processo para preparar um composto","""COMPOSTO, FORMULAçãO FARMACêUTICA, MéTODOS PARA ATIVAR RECEPTORES DE 5-HT~ 1F~, PARA INIBIR O EXTRAVASAMENTO DE PROTEìNA NEURONAL, PARA TRATAR OU PREVENIR ENXAQUECA EM UM MAMìFERO E PAPA PREPARAR UM COMPOSTO, USO DE UM COMPOSTO, E, PROCESSO PARA PREPARAR UM COMPOSTO"". A presente invenção refere-se aos compostos de fórmula I ou sais de adição de ácido farmaceuticamente aceitáveis dos mesmos, na qual R^ 1^ é C~ 1~-C~ 6~-alquila, C~ 1~-C~ 6~-alquila substituída, C~ 3~-C~ 7~ ciclo-alquila, C~ 3~-C~ 7~ cicloalquila substituída, C~ 3~-C~ 7~ ciclo-alquil-C~ 1~-C~ 3~-alquila, C~ 3~-C~ 7~ ciclo-alquil-C~ 1~-C~ 3~alquila substituída, fenila, fenila substituída, heterociclo, ou heterociclo substituído; R^ 2^ é hidrogênio, C~ 1~-C~ 3~-alquila, C~ 3~-C~ 6~ ciclo-alquil-C~ 1~-C~ 3~-alquila, ou um grupo de fórmula II; R^ 3^ é hidrogênio ou C~ 1~-C~ 3~-alquila; R^ 4^ é hidrogênio, halo, ou C~ 1~C~ 3~-alquila; R^ 5^ é hidrogênio ou C~ 1~-C~ 3~-alquila, R^ 6^ é hidrogênio ou C~ 1~-C~ 6~-alquila; e n é um número inteiro de 1 a 6 inclusive. Os compostos da presente invenção são úteis para a ativação de receptores de 5-HTIF, inibição de extravasamento de proteína neuronal, e para o tratamento ou a prevenção de enxaqueca em um mamífero. A presente invenção também se refere a um processo para a síntese de intermediários na sintese de compostos de fórmula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/024-476-380-700-791,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
486,US,B2,US 7423050 B2,126-054-159-519-078,2008-09-09,2008,US 50977004 A,2004-09-28,US 50977004 A;;US 36908802 P;;US 0308455 W,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,"The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl; R 4 is hydrogen, halo, or C 1 -C 3 alkyl; R 5 is hydrogen or C 1 -C 3 alkyl; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;VICTOR FRANTZ,ELI LILLY AND COMPANY (2002-11-26),https://lens.org/126-054-159-519-078,Granted Patent,yes,24,19,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/445;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,514/318;;546/193,5,0,,,"Phebus et al. ""Characterization of LY344864 . . . "" CA 128:18603 (1997).;;Radl et al. ""Synthesis and antinociceptive . . . "" CA 130:352171 (1999).;;King ""Medicinal chemistry: proinceples and practice"" p. 206-209 (1994).;;Nika Adham, et al, Proc. Natl. Acad. Sci. USA, vol. 9, pp. 408-412, Jan. 1993 Neurobiology.;;Japanese Abstract for JP 03255426 (Nov. 14, 1991), Toshiba Corp., Japan.",ACTIVE
487,MY,A,MY 134666 A,176-291-835-077-029,2007-12-31,2007,MY PI20031097 A,2003-03-26,US 36908802 P,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS,"THE PRESENT INVENTION RELATES TO COMPOUNDS OF FORMULA I: OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, WHERE; R1 IS C1-C6 ALKYL, SUBSTITUTED C1-C6 ALKYL, C3-C7 CYCLOALKYL, SUBSTITUTED C3-C7 CYCLOALKYL, C3-C7 CYCLOALKYL-C1-C3 ALKYL, SUBSTITUTED C3-C7 CYCLOALKYL-C1-C3 ALKYL, PHENYL,SUBSTITUTED PHENYL, HETEROCYCLE, OR SUBSTITUTED HETEROCYCLE; R2 IS HYDROGEN, C1-C3 ALKYL, C3-C6 CYCLOALKYL-C1-C3 ALKYL, OR A GROUP OF FORMULA R3 IS HYDROGEN OR C1-C3 ALKYL; R4 IS HYDROGEN, HALO, OR C1-C3 ALKYL; R5 IS HYDROGEN OR C1-C3 ALKYL; R6 IS HYDROGEN OR C1-C6 ALKYL; AND N IS AN INTEGER FROM 1 TO 6 INCLUSIVELY.THE COMPOUNDS OF THE PRESENT INVENTION ARE USEFUL FOR ACTIVATING 5-HT1F RECEPTORS, INHIBITING NEURONAL PROTEIN EXTRAVASATION, AND FOR THE TREATMENT OR PREVENTION OF MIGRAINE IN A MAMMAL. THE PRESENT INVENTION ALSO RELATES TO A PROCESS FOR THE SYNTHESIS OF INTERMEDIATES IN THE SYNTHESIS OF COMPOUNDS OF FORMULA I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/176-291-835-077-029,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
488,JP,A,JP 2010159272 A,075-381-945-611-031,2010-07-22,2010,JP 2010044032 A,2010-03-01,US 36908802 P,2002-03-29,PYRIDINOYL-PIPERIDINE AS 5-HT1F AGONIST,"<P>PROBLEM TO BE SOLVED: To provide a method for producing a pyridinoyl-piperidine. <P>SOLUTION: The method for producing a compound represented by formula (III) or formula (V) is provided. <P>COPYRIGHT: (C)2010,JPO&INPIT",LILLY CO ELI,COHEN MICHAEL PHILIP;;DANIEL TIMOTHY KOHLMAN;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/075-381-945-611-031,Patent Application,no,1,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/4545;;A61K31/506;;A61P9/08;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,2,0,,,"JPN7012003335; ＲＡＤＬ，Ｓ． ｅｔ ａｌ: 'Ｓｙｎｔｈｅｓｉｓ ａｎｄ ａｎｔｉｎｏｃｉｃｅｐｔｉｖｅ ａｃｔｉｖｉｔｙ ｏｆ ｓｏｍｅ ３-ｃｈｌｏｒｏｐｈｅｎｙｌ- ａｎｄ ６-ｃｈｌｏｒｏｐｙｒｉｄｉｎ-２-ｙｌ ｄｅｒｉｖａｔｉｖｅｓ' Ｃｏｌｌｅｃｔｉｏｎ ｏｆ Ｃｚｅｃｈｏｓｌｏｖａｋ Ｃｈｅｍｉｃａｌ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．６４， Ｎｏ．２, 1999, ｐ．３７７-３８８;;JPN7012003336; ＩＮＴＲＯＤＵＣＴＩＯＮ ＴＯ ＯＲＧＡＮＩＣ ＣＨＥＭＩＳＴＲＹ Ｒｅｖｉｓｅｄ ｐｒｉｎｔｉｎｇ, 1998, ｐ．１０１１-１０１２, Ｐｒｅｎｔｉｃｅ-Ｈａｌｌ，Ｉｎｃ．",PENDING
489,AU,B2,AU 2003/224719 B2,044-304-182-280-874,2008-08-14,2008,AU 2003/224719 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,,LILLY CO ELI,VICTOR FRANTZ;;YING BAI-PING;;COHEN MICHAEL PHILIP;;LIANG SIDNEY XI;;ZACHERL DEANNA PIATT;;XU YAO-CHANG;;MANCUSO VINCENT;;ZHANG DEYI;;KOHLMAN DANIEL TIMOTHY,,https://lens.org/044-304-182-280-874,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
490,EA,B1,EA 007966 B1,084-886-219-964-211,2007-02-27,2007,EA 200401282 A,2003-03-27,US 36908802 P;;US 0308455 W,2002-03-29,PYRIDINOYLPIPERIDINES AS 5-HTAGONISTS,"The present invention relates to compounds of formula I; or pharmaceutically acceptable acid addition salts thereof, where; Ris C-Calkyl, substituted C-Calkyl, C-Ccycloalkyl, substituted C-Ccycloalkyl, C-Ccycloalkyl-C-Calkyl, substituted C-Ccycloalkyl- C-Calkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C-Calkyl, C-Ccycloalkyl- C-Calkyl, or a group of formula II; Ris hydrogen or C-Calkyl; Ris hydrogen, halo, or C-Calkyl; Ris hydrogen or C-Calkyl; Ris hydrogen or C-Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VICENT;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/084-886-219-964-211,Granted Patent,no,1,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,C07D401/06;;A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
491,TW,A,TW 200306186 A,027-104-198-551-170,2003-11-16,2003,TW 92106334 A,2003-03-21,US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HT1F agonists,"The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula, R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.",LILLY CO ELI,COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;LIANG SIDNEY XI;;MANCUSO VINCENT;;VICTOR FRANTZ;;YAO-CHANG XU;;BAI-PING YING;;DEANNA PIATT ZACHERL;;DEYI ZHANG,,https://lens.org/027-104-198-551-170,Patent of Addition,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
492,US,B2,US 11697526 B2,029-887-811-519-440,2023-07-11,2023,US 202117329407 A,2021-05-25,US 202117329407 A;;US 201715424928 A;;US 201213631636 A,2012-09-28,Storage bag with features that facilitate sealing and unsealing of the bag,"A storage bag includes first and second side surfaces that form an interior of the bag with an opening to the interior. A first closure profile connected to the first side surface and positioned adjacent to the opening has a top edge and includes an interlocking member that extends between first and second sides of the first closure profile forms a lip between the interlocking member and the top edge. A second closure profile connected to the second side surface and positioned adjacent to the opening of the bag has a top edge and includes an interlocking member. A first portion of the lip of the second closure profile smoothly transitions into a third portion of the lip of the second closure profile, and the third portion of the lip of the second closure profile smoothly transitions into a second portion of the lip of the second closure profile.",JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;PORCHIA JOSE;;ALTHOFF CHARLES P;;EDEN COHEN ERICA;;STARK TIMOTHY D,,https://lens.org/029-887-811-519-440,Granted Patent,yes,181,0,8,8,0,B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/28;;B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/004,B65D33/28;;B65D33/00;;B65D33/25,,19,0,,,"Picture of Ziploc® Brand Bag—Quart Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.;;Picture of Ziploc® Brand Bag—Sandwich Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.;;Office Action dated May 22, 2018, issued in corresponding Japanese Patent Application No. 2017-133100.;;Office Action (with English translation) dated Jul. 30, 2018, issued in corresponding Chinese Patent Application No. 201610921899.X.;;Office Action dated Aug. 14, 2018, issued in corresponding Mexican Patent Application No. MX/a/2018/002289.;;Office Action dated Aug. 22, 2018, issued in corresponding Mexican Patent Application No. MX/a/2015/004033.;;Office Action dated May 15, 2018, issued in corresponding Japanese Patent Application No. 2017-157711.;;Office Action (with English translation) dated Jan. 30, 2019, issued in corresponding Chinese Patent Application No. 201610921899.X.;;Office Action (with English translation) dated Jan. 4, 2019, issued in corresponding Chinese Patent Application No. 201810023069.4.;;Office Action (with English translation) dated Feb. 5, 2019, issued in corresponding Japanese Patent Application No. 2017-13310.;;Office Action (with English translation) dated Mar. 11, 2019, issued in corresponding Chinese Patent Application No. 201610616406.1.;;Office Action (with English translation) dated Apr. 10, 2019, issued in corresponding Chinese Patent Application No. 201710617576.6.;;Office Action (with English translation) dated Feb. 26, 2019, issued in corresponding Mexican Patent Application No. MX/a/2018/002289.;;Office Action dated Feb. 27, 2019 (and dated May 7, 2019), issued in corresponding Mexican Patent Application No. MX/a/2015/004033.;;Office Action dated Mar. 5, 2019, issued in corresponding Chinese Patent Application No. 201810045452.X.;;Office Action (with English translation) dated May 27, 2019, issued in corresponding Japanese Patent Application No. 2017-254201.;;Office Action (with English translation) dated Jun. 20, 2019, issued in corresponding Chinese Patent Application No. 201810023069.4.;;Office Action (with English translation) dated Aug. 21, 2019, issued in corresponding Chinese Patent Application No. 201710617576.6.;;Office Action dated Oct. 13, 2020, issued in corresponding Mexican Application No. MX/a/2016/017401.",ACTIVE
493,CA,A1,CA 2886031 A1,055-074-891-031-617,2014-04-03,2014,CA 2886031 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;US 2013/0061910 W,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/055-074-891-031-617,Patent Application,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
494,WO,A1,WO 2014/165075 A1,082-760-164-344-296,2014-10-09,2014,US 2014/0024304 W,2014-03-12,US 201361777547 P,2013-03-12,ANTIBACTERIAL AGENTS,"Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts and esters thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.",ACHAOGEN INC,LINSELL MARTIN SHERINGHAM;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;HILDEBRANDT DARIN JAMES;;COHEN FREDERICK;;KASAR RAMESH ANNASAHEB;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;MCENROE GLENN A,,https://lens.org/082-760-164-344-296,Patent Application,yes,19,27,1,1,0,A61P31/04;;C07D205/04;;C07D205/08;;C07D207/10;;C07D207/12;;C07D403/06;;C07D405/04;;C07D413/04,C07D403/06;;A61K31/166;;A61P31/04;;C07D205/04;;C07D205/08;;C07D207/10;;C07D207/12;;C07D405/04;;C07D413/04,,21,19,052-786-510-319-542;;063-057-186-495-585;;033-869-942-034-174;;084-631-016-055-064;;097-301-404-322-646;;096-566-626-532-419;;103-691-137-905-071;;012-149-576-277-557;;075-732-623-743-359;;099-806-085-859-345;;170-420-271-401-873;;112-084-571-476-777;;032-636-211-896-252;;060-090-115-312-556;;057-256-465-069-25X;;027-054-162-158-905;;023-875-030-580-082;;125-989-746-564-938;;038-070-261-669-988,10.1074/jbc.275.15.11002;;10753902;;10.1016/s0966-842x(98)01230-x;;9587193;;10.1021/jm010579r;;12086497;;10.1021/jo00129a059;;10.1021/jo971274g;;11671806;;10.1016/s0040-4039(97)00594-7;;10.1016/s0040-4039(98)01794-8;;10.1016/s0960-894x(99)00498-9;;10522699;;10.1021/ja00794a065;;10.1080/00397917408063498;;10.1002/jlac.197419740615;;10.1039/p19930001629;;10.1016/0040-4020(95)00356-d;;10.1016/s0040-4039(97)00383-3;;10.1021/jo971883o;;10395484;;10.1021/jm990058s;;11029192;;10.1021/ol000178q;;10.1016/0040-4039(95)01322-9;;10.1055/s-2003-44346,"JACKMAN ET AL., J. BIOL. CHEM., vol. 275, no. 15, 2000, pages 11002 - 11009;;WYCKOFF ET AL., TRENDS IN MICROBIOLOGY, vol. 6, no. 4, 1998, pages 154 - 159;;KLINE, T. ET AL.: ""Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC"", J. MED CHEM., vol. 45, no. 14, 2002, pages 3112 - 29, XP008045411, DOI: doi:10.1021/jm010579r;;PIRRUNG, M. C. ET AL.: ""A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters"", J. ORG. CHEM., vol. 60, 1995, pages 8084 - 8085;;NHU, K. ET AL.: ""A New and Efficient Solid Phase Synthesis of Hydroxamic Acids"", J. ORG. CHEM., vol. 62, 1997, pages 7088 - 7089;;MELLOR, S. L. ET AL.: ""N-Fmoc-aminoxy-2-chlortrityl Polystyrene Resin: A Facile Solid-phase Methodology for the Synthesis of Hydroxamic Acids"", TETRAHEDRON LETT., vol. 38, 1997, pages 3311 - 3314;;KHAN, S. I. ET AL.: ""A Facile and Convenient Solid-phase Procedure for Synthesizing Nucleoside Hydroxamic Acids"", TERAHEDRON. LETT., vol. 39, 1998, pages 8031 - 8034, XP004138853, DOI: doi:10.1016/S0040-4039(98)01794-8;;ZHANG, Y. ET AL.: ""Design, Combinatorial Chemical Synthesis, and in vitro Characterization of Novel Urea Based Gelatinase Inhibitors"", BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2823 - 2826, XP004179171, DOI: doi:10.1016/S0960-894X(99)00498-9;;ITO, Y. ET AL.: ""Synthetic Reactions by Complex Catalysts. XXXI, A Novel and Versatile Method of Heterocycle Synthesis"", J. AM CHEM. SOC., vol. 95, 1973, pages 4447 - 4448;;ITO, Y. ET AL.: ""Synthetic Reactions by Complex Catalysts XXXV"", SYN. COMMUN., vol. 4, 1974, pages 97 - 103;;WITTE, H. ET AL.: ""Cyclische Imidsaurester aus Nitrilen und Aminoalkoholen"", LIEBIGS ANN. CHEM., 1974, pages 996 - 1009;;PATTENDEN, G. ET AL.: ""Naturally Occurring Linear Fused Thiazoline-Thiazole Containing Metabolites: Total Synthesis of (-) Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae"", J. CHEM. SOC. PERKIN TRANS, vol. 1, 1993, pages 1629 - 1636, XP009071913;;BOYCE, R. J. ET AL.: ""Total Synthesis of Thiangazole, A Novel Naturally Occurring HIV-1 Inhibitor from Polyangium sp"", TEFRAHEDRON, vol. 51, 1995, pages 7321 - 7330, XP002128001, DOI: doi:10.1016/0040-4020(95)00356-D;;GALEOTTI, N. ET AL.: ""Synthesis of Peptidyl Aldehydes from Thiazolines"", TETRAHEDRON. LETT., vol. 38, 1997, pages 2459 - 2462, XP004056732, DOI: doi:10.1016/S0040-4039(97)00383-3;;CHARETTE, A. B. ET AL.: ""Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amides"", J. ORG. CHEM., vol. 63, 1998, pages 908 - 909;;BERGERON, R. J. ET AL.: ""Effects of C-4 Stereochemistry and C-4' Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues"", J. MED. CHEM., vol. 42, 1999, pages 2432 - 2440, XP002182656, DOI: doi:10.1021/jm990058s;;RAMAN, P. ET AL.: ""Titanium (IV)-mediated Tandem Deprotection-cyclodehydration of Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline- and Thiazole-containing Heterocycles"", ORG. LETT., vol. 2, 2000, pages 3289 - 3292;;FEMANDEZ, X. ET AL.: ""Novel Synthesis of 2-Thioazolines"", TETRAHEDRON LETT., vol. 41, 2000, pages 3381 - 3384;;WIPF, P. ET AL.: ""C. Thiolysis of Oxazolinenes: A New, Selective Method for the Direct Conversion of Peptide Oxazolines into Thiazolines"", TETRAHEDRON LETT., vol. 36, 1995, pages 6395 - 6398, XP004027240, DOI: doi:10.1016/0040-4039(95)01322-9;;""Remington: The Science and Practice of Pharmacy ., 19th Edition"", 1995, MACK PUBLISHING COMPANY;;G. ROTH, B. LIEPOLD; S. MÜLLER; H. J. BESTMANN, SYNTHESIS, vol. 1, 2004, pages 59 - 62",PENDING
495,US,B2,US 9604761 B2,018-850-884-895-668,2017-03-28,2017,US 201213631636 A,2012-09-28,US 201213631636 A,2012-09-28,Storage bag with features that facilitate sealing and unsealing of the bag,"A storage bag is provide with features that facilitate unsealing an opening of the bag, including shaped lips and visual cues for areas that the lips that should be grasped during the unsealing process. The visual cue may include relative coloring of portions of the lips of the bag. The storage bag also includes features that facilitate sealing the opening of the bag, including textured areas and dimples. Such features may provide visual cues, tactile feedback and/or audio feedback in order to facilitate the sealing process.",JOHNSON & SON INC S C;;JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;PORCHIA JOSE;;ALTHOFF CHARLES P;;EDEN COHEN ERICA;;STARK TIMOTHY D,S.C. JOHNSON & SON INC (2012-10-24);;SMART DESIGN LLC (2012-10-25),https://lens.org/018-850-884-895-668,Granted Patent,yes,141,4,8,8,0,B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/28;;B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/004,B65D33/00;;B65D33/16;;B65D33/24;;B65D33/25;;B65D33/28,,2,0,,,"Picture of Ziploc® Brand Bag—Quart Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.;;Picture of Ziploc® Brand Bag—Sandwich Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.",ACTIVE
496,JP,A,JP 2017214155 A,121-923-685-462-294,2017-12-07,2017,JP 2017133100 A,2017-07-06,US 201213631549 A;;US 201213631513 A,2012-09-28,STORAGE BAG HAVING DIMPLE CHARACTERISTIC,"PROBLEM TO BE SOLVED: To provide storage bags which have characteristics for more easily encapsulation and opening thereof, and further, which can be easily distinguished from each other.SOLUTION: A storage bag 100 has first and second closure profiles 107, 109 adjacent to an opening in the bag. The first and second closure profiles comprise dimples which are so aligned as to face each other. The dimple of the first closure profile is formed as a concave surface on the first closure profile side which is oriented to the interior of the bag and a convex surface on the first closure profile side which is oriented to an outer side of the bag. The dimple of the second closure profile is formed as a convex surface on the second closure profile side which is oriented to the interior of the bag and a concave surface of the second closure profile side which is oriented to the outer side of the bag. The dimple of the first closure profile is present at least partially in the dimple of the second closure profile when encapsulating the bag.SELECTED DRAWING: Figure 1",JOHNSON & SON INC S C,DAIS BRIAN C;;IMTIAZ A MUSALIAR;;BONLIM LY;;JOSE PORCHIA;;TIMOTHY D STARK;;JONATHAN DAVID HORN;;PAMELA J WEISENBERGER;;CHARLES P ALTHOFF;;ERICA EDEN COHEN,,https://lens.org/121-923-685-462-294,Patent Application,no,11,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25,,0,0,,,,ACTIVE
497,CN,A,CN 106945926 A,041-199-532-841-571,2017-07-14,2017,CN 201610921899 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CN 201380062343 A,2012-09-28,Storage bag with dimple features,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/041-199-532-841-571,Patent Application,no,7,2,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
498,US,B2,US 7037112 B2,076-789-211-681-466,2006-05-02,2006,US 32436502 A,2002-12-20,US 32436502 A,2002-12-20,"Virtual arm for measurement of humidity, temperature, and water vapor transmission rate in materials","A device is provided for simulating a human skin microclimate and for measuring conditions such as temperature and humidity in the simulated microclimate. The microclimate is formed, for example, with fluids, gases and/or heat in a chamber of the device or between a surface of the device and a material disposed about the surface. In one aspect, a sensor is placed in the chamber to sense the microclimate. Methods of using the device and measuring microclimate conditions are also provided.",KIMBERLY CLARK CO,LORD PATRICK R;;SCHMITZ TIMOTHY;;SINGH KAINTH ARVINDER PAL;;KROMENAKER FRANK F;;BEAL RICHARD B;;COHEN JASON;;TATE MARTHA L;;WRIGHT AUDRA S;;PUCKETT NANCY,KIMBERLY-CLARK WORLDWIDE INC (2003-07-17),https://lens.org/076-789-211-681-466,Granted Patent,yes,41,9,3,3,0,G09B23/28;;G09B23/28,G09B23/28,434/262;;434/268;;434/272,0,0,,,,EXPIRED
499,CA,A1,CA 3041612 A1,109-330-148-895-782,2014-04-03,2014,CA 3041612 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CA 2993710 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/109-330-148-895-782,Patent Application,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/08;;B65D30/10,,0,0,,,,PENDING
500,MX,A,MX 2015004029 A,102-247-452-356-992,2015-10-29,2015,MX 2015004029 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;US 2013/0061910 W,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES.,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,PORCHIA JOSE;;STARK TIMOTHY D;;DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/102-247-452-356-992,Patent Application,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
501,US,A1,US 2021/0276765 A1,043-597-732-372-892,2021-09-09,2021,US 202117329407 A,2021-05-25,US 202117329407 A;;US 201715424928 A;;US 201213631636 A,2012-09-28,STORAGE BAG WITH FEATURES THAT FACILITATE SEALING AND UNSEALING OF THE BAG,"A storage bag includes first and second side surfaces that form an interior of the bag with an opening to the interior. A first closure profile connected to the first side surface and positioned adjacent to the opening has a top edge and includes an interlocking member that extends between first and second sides of the first closure profile forms a lip between the interlocking member and the top edge. A second closure profile connected to the second side surface and positioned adjacent to the opening of the bag has a top edge and includes an interlocking member. A first portion of the lip of the second closure profile smoothly transitions into a third portion of the lip of the second closure profile, and the third portion of the lip of the second closure profile smoothly transitions into a second portion of the lip of the second closure profile.",JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;PORCHIA JOSE;;ALTHOFF CHARLES P;;EDEN COHEN ERICA;;STARK TIMOTHY D,,https://lens.org/043-597-732-372-892,Patent Application,yes,6,0,8,8,0,B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/28;;B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/004,B65D33/28;;B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
502,ZA,B,ZA 200407666 B,194-193-398-610-748,2006-02-22,2006,ZA 200407666 A,2004-09-22,US 36908802 P,2002-03-29,Pyridinoylpiperidines as 5-HTif agonists.,,LILLY CO ELI,COHEN MICHAEL PHILIP;;LIANG SIDNEY XI;;FRANTZ VICTOR;;YING BAI-PING;;DEYI ZHAN G;;KOHLMAN DANIEL TIMOTHY;;MANCUSO VINCENT;;XU YAO-CHANG;;PIATT ZACHERL DEANNA,,https://lens.org/194-193-398-610-748,Granted Patent,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,ACTIVE
503,CA,A1,CA 2993710 A1,067-614-793-052-078,2014-04-03,2014,CA 2993710 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CA 2980778 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUMLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/067-614-793-052-078,Patent Application,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/08;;B65D30/10,,0,0,,,,ACTIVE
504,CN,A,CN 108408223 A,062-582-932-825-611,2018-08-17,2018,CN 201810045452 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CN 201380062343 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to eachother. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profilewhen the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/062-582-932-825-611,Patent Application,no,6,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/16,,0,0,,,,ACTIVE
505,CA,A1,CA 2980778 A1,029-789-902-402-628,2014-04-03,2014,CA 2980778 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CA 2886031 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/029-789-902-402-628,Patent Application,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/10,,0,0,,,,ACTIVE
506,WO,A3,WO 2014/052582 A3,050-404-999-456-198,2014-05-30,2014,US 2013/0061910 W,2013-09-26,US 201213631513 A;;US 201213631549 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C;;DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/050-404-999-456-198,Search Report,yes,4,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D33/00,,0,0,,,,PENDING
507,WO,A2,WO 2014/052582 A2,105-440-680-456-956,2014-04-03,2014,US 2013/0061910 W,2013-09-26,US 201213631513 A;;US 201213631549 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C;;DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/105-440-680-456-956,Patent Application,yes,12,3,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00,,0,0,,,,PENDING
508,US,A1,US 2017/0144801 A1,005-632-467-103-036,2017-05-25,2017,US 201715424928 A,2017-02-06,US 201715424928 A;;US 201213631636 A,2012-09-28,STORAGE BAG WITH FEATURES TO FACILITATE SEALING AND UNSEALING OF THE BAG,"A storage bag includes first and second side surfaces that form an interior of the bag with an opening to the interior. A first closure profile connected to the first side surface and positioned adjacent to the opening has a top edge and includes an interlocking member that extends between first and second sides of the first closure profile forms a lip between the interlocking member and the top edge. A second closure profile connected to the second side surface and positioned adjacent to the opening of the bag has a top edge and includes an interlocking member. A first portion of the lip of the second closure profile smoothly transitions into a third portion of the lip of the second closure profile, and the third portion of the lip of the second closure profile smoothly transitions into a second portion of the lip of the second closure profile.",JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;PORCHIA JOSE;;ALTHOFF CHARLES P;;EDEN COHEN ERICA;;STARK TIMOTHY D,,https://lens.org/005-632-467-103-036,Patent Application,yes,21,1,8,8,0,B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/28;;B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/004,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
509,US,B2,US 11046485 B2,184-454-344-414-952,2021-06-29,2021,US 201715424928 A,2017-02-06,US 201715424928 A;;US 201213631636 A,2012-09-28,Storage bag with features to facilitate sealing and unsealing of the bag,"A storage bag includes first and second side surfaces that form an interior of the bag with an opening to the interior. A first closure profile connected to the first side surface and positioned adjacent to the opening has a top edge and includes an interlocking member that extends between first and second sides of the first closure profile forms a lip between the interlocking member and the top edge. A second closure profile connected to the second side surface and positioned adjacent to the opening of the bag has a top edge and includes an interlocking member. A first portion of the lip of the second closure profile smoothly transitions into a third portion of the lip of the second closure profile, and the third portion of the lip of the second closure profile smoothly transitions into a second portion of the lip of the second closure profile.",JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;PORCHIA JOSE;;ALTHOFF CHARLES P;;EDEN COHEN ERICA;;STARK TIMOTHY D,,https://lens.org/184-454-344-414-952,Granted Patent,yes,188,0,8,8,0,B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/28;;B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/004,B65D33/28;;B65D33/00;;B65D33/25,,23,0,,,"Picture of Ziploc® Brand Bag—Quart Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.;;Picture of Ziploc® Brand Bag—Sandwich Size Storage Bag. Two (2) pictures taken Mar. 15, 2013.;;Office Action (with English translation) dated Jul. 30, 2018, issued in corresponding Chinese Patent Application No. 201610921899.X.;;Office Action dated May 15, 2018, issued in corresponding Japanese Patent Application No. 2017-157711.;;Office Action dated May 22, 2018, issued in corresponding Japanese Patent Application No. 2017-133100.;;Office Action dated Aug. 14, 2018, issued in corresponding Mexican Patent Application No. MX/a/2018/002289.;;Office Action dated Aug. 22, 2018, issued in corresponding Mexican Patent Application No. MX/a/2015/004033.;;Office Action (with English translation) dated Sep. 10, 2018, issued in corresponding Chinese Patent Application No. 201610616406.1.;;Office Action (with English translation) dated Sep. 12, 2018, issued in corresponding Japanese Patent Application No. 2017-157711.;;Office Action (with English translation) dated Aug. 22, 2018, issued in corresponding Chinese Patent Application No. 201710617576.6.;;Office Action (with English translation) dated Jan. 4, 2019, issued in corresponding Chinese Patent Application No. 201810023069.4.;;Office Action (with English translation) dated Jan. 30, 2019, issued in corresponding Chinese Patent Application No. 201610921899.X.;;Office Action (with English translation) dated Feb. 5, 2019, issued in corresponding Japanese Patent Application No. 2017-13310.;;Office Action (with English translation) dated Oct. 23, 2018, issued in corresponding Japanese Patent Application No. 2017-254201.;;Office Action (with English translation) dated Mar. 11, 2019, issued in corresponding Chinese Patent Application No. 201610616406.1.;;Office Action dated Feb. 27, 2019 (and dated May 7, 2019), issued in corresponding Mexican Patent Application No. MX/a/2015/004033.;;Office Action (with English translation) dated May 27, 2019, issued in corresponding Japanese Patent Application No. 2017-254201.;;Office Action (with English translation) dated Jun. 20, 2019, issued in corresponding Chinese Patent Application No. 201810023069.4.;;Office Action (with English translation) dated Feb. 26, 2019, issued in corresponding Mexican Patent Application No. MX/a/2018/002289.;;Office Action (with English translation) dated Apr. 10, 2019, issued in corresponding Chinese Patent Application No. 201710617576.6.;;Office Action (with English translation) dated Aug. 21, 2019, issued in corresponding Chinese Patent Application No. 201710617576.6.;;Office Action dated Mar. 5, 2019, issued in corresponding Chinese Patent Application No. 201810045452.X.;;Office Action dated Oct. 13, 2020, issued in corresponding Mexican Application No. MX/a/2016/017401.",ACTIVE
510,CA,C,CA 2993710 C,196-747-502-075-12X,2019-06-18,2019,CA 2993710 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CA 2980778 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUMLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/196-747-502-075-12X,Granted Patent,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/08;;B65D30/10,,0,0,,,,ACTIVE
511,PE,A1,PE 20030976 A1,110-597-934-621-576,2003-11-12,2003,PE 2003000301 A,2003-03-25,US 36908802 P,2002-03-29,PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5-HT1F,"DE FORMULA (I) O UNA SAL DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLE DEL MISMO, DONDE R1 ES ALQUILO C1-C6, ALQUILO C1-C6 SUSTITUIDO, CICLOALQUILO C3-C7, CICLOALQUILO C3-C7 SUSTITUIDO, CICLOALQUIL (C3-C7) ALQUILO (C1-C3), CICLOALQUIL (C3-C7)ALQUILO (C1-C3) SUSTITUIDO, FENILO, FENILO SUSTITUIDO, HETEROCICLO O HETEROCICLO SUSTITUIDO; R2 ES H, ALQUILO C1-C3, CICLOALQUIL (C3-C6)ALQUILO (C1-C3), O UN GRUPO DE FORMULA (II), DONDE, R3 ES H O ALQUILO C1-C3, R4 ES H, HALO O ALQUILO C1-C3, R5 ES H O ALQUILO C1-C3, R6 ES H O ALQUILO C1-C6 Y n ES UN NUMERO ENTRE 1 Y 6. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA QUE COMPRENDE EL COMPUESTO DESCRITO, EL CUAL ES UN AGONISTA SELECTIVO DE 5-HT1F CON PROPIEDADES QUIMICAS Y DE UNION A RECEPTORES DISTINTOS, QUE INHIBEN LA EXTRAVASACION DE PEPTIDOS EVITANDO UNA ACTIVIDAD VASOCONSTRICTORA SIGNIFICATIVA, UTIL EN EL TRATAMIENTO DE LA MIGRANA Y OTROS TRANSTORNOS ASOCIADOS A 5-HT1F",LILLY CO ELI,YING BAI-PING;;KOHLMAN DANIEL TIMOTHY;;XU YAO-CHANG;;MANCUSO VINCENT;;VICTOR FRANTZ;;ZHANG DEYI;;LIANG SIDNEY XI;;ZACHERL DE ANNA PIATT;;COHEN MICHAEL PHILIP,,https://lens.org/110-597-934-621-576,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,EXPIRED
512,CN,A,CN 109911389 A,161-500-287-990-661,2019-06-21,2019,CN 201910016208 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CN 201380062343 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to eachother. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profilewhen the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/161-500-287-990-661,Patent Application,no,2,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/02;;B65D33/00,,0,0,,,,ACTIVE
513,CN,A,CN 104936863 A,197-627-697-196-49X,2015-09-23,2015,CN 201380062343 A,2013-09-26,US 2013/0061910 W;;US 201213631549 A;;US 201213631513 A,2012-09-28,Storage bag with dimple features,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;B LI;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/197-627-697-196-49X,Patent Application,no,7,3,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
514,CN,A,CN 107098050 A,083-672-028-949-035,2017-08-29,2017,CN 201610922057 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CN 201380062343 A,2012-09-28,Storage bag with dimple features,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/083-672-028-949-035,Patent Application,no,6,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
515,CA,C,CA 2886031 C,101-968-375-549-590,2017-11-14,2017,CA 2886031 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;US 2013/0061910 W,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag The first and second closure profiles are provided with dimples that are aligned opposite to each other The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/101-968-375-549-590,Granted Patent,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/00;;B65D33/25,,0,0,,,,ACTIVE
516,CR,A,CR 7496 A,148-061-417-280-631,2004-11-27,2004,CR 7496 A,2004-09-24,US 36908802 P,2002-03-29,PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5- HT1F,"Se refiere a compuestos de formula I. o sales de adicion de acidos farmaceuticamente aceptables de los mismos. Donde R1 es alquilo C1-C6 alquilo C1-C6 sustituido, cicloalquiloC3-C7, cicloalquilo C3-C7sustituido, cicloalquil-C3-C7-alquiloC1-C3, cicloalquilC3-C7 sustituido-alquilo C1-C3, fenilo, fenilo sustituido, heterociclo, o heterociclo sustituido Los compuestos de la presente invencion son utiles para activar los receptores 5-HT 1f inhibir extravasacion neuronal de proteinas y para el tratamiento o prevencion de migrana en un mamifero. Tambien se refiere a un procedimiento para la sintesis de intermedios en la sintesis de compuesos de formula I",LILLY CO ELI,MICHAEL PHILIP COHEN;;DANIEL TIMOTHY KOHLMAN;;SYDNEY XI LIANG;;VINCENT MANCUSO;;FRANTZ VICTOR;;YAO-CHANG XU;;BAI-PING YING;;DE ANNA PIATT ZACHERL;;DEYI ZHANG,,https://lens.org/148-061-417-280-631,Patent Application,no,0,0,56,56,0,C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/00;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;A61P9/08;;Y02P20/55;;C07D401/06;;C07D409/14;;C07D401/14;;C07D405/14;;C07D409/14;;C07D401/06;;C07D417/14,A61K31/44;;A61K31/4545;;A61K31/506;;A61P15/00;;A61P15/10;;A61P17/14;;A61P25/06;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P43/00;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D417/14,,0,0,,,,PENDING
517,MX,B,MX 354342 B,049-400-585-103-487,2018-02-27,2018,MX 2015004029 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;US 2013/0061910 W,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES.,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,JOSE PORCHIA;;TIMOTHY D STARK;;BRIAN C DAIS;;IMTIAZ A MUSALIAR;;BUNLIM LY;;JONATHAN DAVID HORN;;PAMELA J WEISENBERGER;;CHARLES P ALTHOFF;;ERICA EDEN COHEN,,https://lens.org/049-400-585-103-487,Granted Patent,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/16;;B65D33/25,,0,0,,,,ACTIVE
518,US,A1,US 2014/0093195 A1,195-644-160-470-606,2014-04-03,2014,US 201213631636 A,2012-09-28,US 201213631636 A,2012-09-28,Storage Bag With Features That Facilitate Sealing And Unsealing Of The Bag,"A storage bag is provide with features that facilitate unsealing an opening of the bag, including shaped lips and visual cues for areas that the lips that should be grasped during the unsealing process. The visual cue may include relative coloring of portions of the lips of the bag. The storage bag also includes features that facilitate sealing the opening of the bag, including textured areas and dimples. Such features may provide visual cues, tactile feedback and/or audio feedback in order to facilitate the sealing process.",JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;PORCHIA JOSE;;ALTHOFF CHARLES P;;EDEN COHEN ERICA;;STARK TIMOTHY D,S.C. JOHNSON & SON INC (2012-10-24);;SMART DESIGN LLC (2012-10-25),https://lens.org/195-644-160-470-606,Patent Application,yes,12,12,8,8,0,B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/28;;B65D33/255;;B65D33/2566;;B65D33/007;;B65D33/004,B65D33/28,383/65,0,0,,,,ACTIVE
519,CA,C,CA 2980778 C,007-325-399-781-793,2018-05-22,2018,CA 2980778 A,2013-09-26,US 201213631549 A;;US 201213631513 A;;CA 2886031 A,2012-09-28,STORAGE BAG WITH DIMPLE FEATURES,A storage bag has first and second closure profiles adjacent to an opening to the interior of the bag. The first and second closure profiles are provided with dimples that are aligned opposite to each other. The dimples of the first closure profile are formed as a concave surface on the side of the first closure profile facing the interior of the bag and a convex surface on the side of the first closure profile facing the outside of the bag. The dimples of the second closure profile are formed as a convex surface on the side of the second closure profile facing the interior of the bag and a concave surface on the side of the second closure profile facing the outside of the bag. The dimples of the first closure profile are at least partially within the dimples of the second closure profile when the bag is being sealed.,JOHNSON & SON INC S C,DAIS BRIAN C;;MUSALIAR IMTIAZ A;;LY BUNLIM;;PORCHIA JOSE;;STARK TIMOTHY D;;HORN JONATHAN DAVID;;WEISENBERGER PAMELA J;;ALTHOFF CHARLES P;;COHEN ERICA EDEN,,https://lens.org/007-325-399-781-793,Granted Patent,no,0,0,26,33,0,B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255;;B65D33/00;;B65D33/2508;;B65D33/2541;;B65D33/255,B65D33/25;;B65D30/10,,0,0,,,,ACTIVE
520,US,A1,US 2004/0121294 A1,053-198-793-742-935,2004-06-24,2004,US 32436502 A,2002-12-20,US 32436502 A,2002-12-20,"Virtual arm for measurement of humidity, temperature, and water vapor transmission rate in materials","
   A device is provided for simulating a human skin microclimate and for measuring conditions such as temperature and humidity in the simulated microclimate. The microclimate is formed, for example, with fluids, gases and/or heat in a chamber of the device or between a surface of the device and a material disposed about the surface. In one aspect, a sensor is placed in the chamber to sense the microclimate. Methods of using the device and measuring microclimate conditions are also provided. 
",LORD PATRICK R.;;SCHMITZ TIMOTHY L.;;KAINTH ARVINDER PAL SINGH;;KROMENAKER FRANK F.;;BEAL RICHARD B.;;COHEN JASON C.;;TATE MARTHA L.;;WRIGHT AUDRA S.;;PUCKETT NANCY,LORD PATRICK R;;SCHMITZ TIMOTHY L;;SINGH KAINTH ARVINDER PAL;;KROMENAKER FRANK F;;BEAL RICHARD B;;COHEN JASON C;;TATE MARTHA L;;WRIGHT AUDRA S;;PUCKETT NANCY,KIMBERLY-CLARK WORLDWIDE INC (2003-07-17),https://lens.org/053-198-793-742-935,Patent Application,yes,39,13,3,3,0,G09B23/28;;G09B23/28,G09B23/28,434/262,0,0,,,,EXPIRED
521,AU,A,AU 1999/055726 A,099-657-806-176-741,2000-03-14,2000,AU 1999/055726 A,1999-08-18,US 9722898 P;;US 9918908 W,1998-08-20,Ring modified cyclic peptide analogs,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON,,https://lens.org/099-657-806-176-741,Patent Application,no,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,EXPIRED
522,US,A1,US 2004/0068094 A1,048-560-557-381-830,2004-04-08,2004,US 67657503 A,2003-09-30,US 67657503 A;;US 76311401 A;;US 9722898 P;;US 9918908 W,1998-08-20,Ring modified cyclic peptide analogs,"
   A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents. 
",BORROMEO PETER S.;;COHEN JEFFREY D.;;GREGORY GEORGE S.;;HENLE STACY K.;;HITCHCOCK STEPHEN A.;;JUNGHEIM LOUIS N.;;MAYHUGH DANIEL R.;;SHEPHERED TIMOTHY A.;;TURNER WILLIAM W.,BORROMEO PETER S;;COHEN JEFFREY D;;GREGORY GEORGE S;;HENLE STACY K;;HITCHCOCK STEPHEN A;;JUNGHEIM LOUIS N;;MAYHUGH DANIEL R;;SHEPHERED TIMOTHY A;;TURNER WILLIAM W,ELI LILLY AND COMPANY (2003-10-09),https://lens.org/048-560-557-381-830,Patent Application,yes,1,3,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/72;;A61K38/00;;A61P31/10;;A61K9/08;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,530/317,0,0,,,,EXPIRED
523,EP,A2,EP 1107981 A2,151-860-788-973-751,2001-06-20,2001,EP 99942321 A,1999-08-18,US 9918908 W;;US 9722898 P,1998-08-20,SYNTHESIS OF RING-MODIFIED CYCLIC PEPTIDE ANALOGS,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/151-860-788-973-751,Patent Application,yes,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,EXPIRED
524,WO,A2,WO 2000/011023 A2,103-702-264-877-510,2000-03-02,2000,US 9918908 W,1999-08-18,US 9722898 P,1998-08-20,RING MODIFIED CYCLIC PEPTIDE ANALOGS,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI;;BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/103-702-264-877-510,Patent Application,yes,0,9,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/72;;A61K38/00;;A61K9/08;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,PATENTED
525,PT,E,PT 1107981 E,099-723-750-549-643,2005-05-31,2005,PT 99942321 T,1999-08-18,US 9722898 P,1998-08-20,SINTESE DE ANALOGOS PEPTIDICOS CICLICOS DE ANEL MODIFICADO,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,TURNER WILLIAM WILSON JR;;SHEPHERD TIMOTHY ALAN;;JUNGHEIM LOUIS NICKOLAUS;;HENLE STACY K;;BORROMEO PETER STANLEY;;DANIEL COHEN JEFFREY;;STUART GREGORY GEORGE;;ANDREW HITCHCOCK STEPHEN;;RAY MAYHUGH DANIEL,,https://lens.org/099-723-750-549-643,Granted Patent,no,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/72;;A61K38/00;;A61P31/10;;A61K9/08;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,EXPIRED
526,EP,B1,EP 1107981 B1,052-929-172-975-648,2005-01-26,2005,EP 99942321 A,1999-08-18,US 9918908 W;;US 9722898 P,1998-08-20,SYNTHESIS OF RING-MODIFIED CYCLIC PEPTIDE ANALOGS,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/052-929-172-975-648,Granted Patent,yes,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,4,0,,,"NATSUKO KUROKAWA ET AL: ""SYNTHETIC STUDIES ON ANTIFUNGAL CYCLIC PEPTIDES, ECHINOCANDINS. STEREOSELECTIVE TOTAL SYNTHESIS OF ECHINOCANDIN D VIA A NOVAL PEPTIDE COUPLING"" TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 49, no. 28, page 6195-7022 XP000571478 ISSN: 0040-4020 cited in the application;;HENSENS E.A.: ""Pneumocandins from Zalerion arboricola"" JOURNAL OF ANTIBIOTICS., vol. 45, no. 12, XP002126647 JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO., JP ISSN: 0021-8820;;JAMISON E.A.: ""The synthesis and antifungal activity of nitrogen containing hemiaminal ethers of LY303366"" JOURNAL OF ANTIBIOTICS., vol. 51, no. 2, February 1998 (1998-02), pages 239-242, XP002126600 JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO., JP ISSN: 0021-8820;;ZAMBIAS E.A.: ""Preparation and structure-activity ewlationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach"" JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 15, 1992, pages 2843-2855, XP002126648 WASHINGTON US cited in the application",EXPIRED
527,AU,B2,AU 765660 B2,155-826-560-095-389,2003-09-25,2003,AU 1999/055726 A,1999-08-18,US 9722898 P;;US 9918908 W,1998-08-20,Ring modified cyclic peptide analogs,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/155-826-560-095-389,Granted Patent,no,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,EXPIRED
528,DK,T3,DK 1107981 T3,046-179-226-710-526,2005-05-30,2005,DK 99942321 T,1999-08-18,US 9918908 W;;US 9722898 P,1998-08-20,"Syntese af ringmodificerede, cykliske peptidanaloger","A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/046-179-226-710-526,Granted Patent,no,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,EXPIRED
529,US,A1,US 2022/0228956 A1,144-198-708-512-334,2022-07-21,2022,US 202217576969 A,2022-01-16,US 202217576969 A;;US 202163138310 P;;US 202163138312 P;;US 202163138314 P;;US 202163138316 P;;US 202163138318 P;;US 202163138320 P;;US 202163138321 P;;US 202163138323 P;;US 202163138337 P;;US 202163138341 P;;US 202163148527 P,2021-01-15,Heating Device for Testing a Biological Sample,"A heating device for testing a biological sample is disclosed. The heating device can include a heat source operable to generate heat. In addition, the heating device can include a controller in communication with the heat source and operable to control heat generation by the heat source to heat a biological sample at less than or equal to about 2 degrees C./s. Furthermore, a heating device for testing a biological sample is disclosed that can include a heat source operable to generate heat to heat a biological sample. The biological sample can be at least partially contained within a removable enclosure distinct from the heating device. Additionally, the heating device can include an enclosure interface associated with the heat source. The enclosure interface can be configured to interface with the enclosure such that heat is transferred from the heat source to the enclosure by conduction.",RAYTHEON BBN TECHNOLOGIES CORP;;PURDUE RESEARCH FOUNDATION,HORVATH DYLAN;;MAN CHARLIE;;LOWE ANDREW;;DEMPSTER DAVID;;JAIN PARTH;;ADLER AARON;;BARTLEY BRYAN;;DRYER PAUL;;QUINN TIMOTHY;;BAR-COHEN AVRAM;;GAVIN MIKE;;LADUCA FRANK M;;VERMA MOHIT,,https://lens.org/144-198-708-512-334,Patent Application,yes,0,0,8,61,0,B01L3/5023;;B01L2300/0681;;B01L2200/10;;B01L2300/0832;;C12Q1/6806;;C12Q1/6844;;G01N1/44;;G01K7/02;;G01K7/22;;C12Q1/6806;;C12Q1/6888;;C12Q1/701;;B01L3/5023;;B01L7/00;;B01L2200/04;;B01L2200/0689;;B01L2300/069;;B01L2300/0809;;C12Q1/6844;;G01J3/524;;G01J2003/467;;G01N21/78;;G01N33/526;;B01L2200/16;;B01L2300/0825;;C12Q1/6848;;C12Q2600/112;;C12Q1/70,G01N1/44;;G01K7/02;;G01K7/22,,0,0,,,,PENDING
530,US,B2,US 6939946 B2,174-980-871-059-064,2005-09-06,2005,US 67657503 A,2003-09-30,US 67657503 A;;US 76311401 A;;US 9722898 P;;US 9918908 W,1998-08-20,Ring modified cyclic peptide analogs,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER JR WILLIAM WILSON,ELI LILLY AND COMPANY (2003-10-09),https://lens.org/174-980-871-059-064,Granted Patent,yes,33,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/72;;A61K9/08;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,530/317;;530/338;;530/339;;530/343,16,12,033-174-478-156-432;;000-251-364-021-766;;003-546-984-502-816;;023-536-067-391-692;;031-803-770-910-400;;012-100-213-163-334;;130-589-465-154-789;;101-178-598-441-281;;026-693-133-110-667;;068-133-574-280-272;;067-425-820-717-678;;011-098-930-627-430,10.1246/cl.1989.889;;10.1016/s0040-4039(00)95547-3;;10.1021/jo01329a049;;10.1021/ja00257a041;;1490878;;10.7164/antibiotics.45.1875;;9544949;;10.7164/antibiotics.51.239;;10.1021/ja00279a064;;22175372;;10.1016/s0040-4020(01)87959-x;;10.1016/s0040-4039(00)96866-7;;10.1016/s0040-4039(00)94887-1;;10.1021/jo00003a038;;10.1021/jm00093a018;;1495015,"U.S. Appl. No. 07/992,390, filed Dec. 16, 1992, Burkhardt et al.;;U.S. Appl. No. 08/032,228, filed Mar. 17, 1993, Burkhardt et al.;;Baba, N., et al. (1989). ""Intramolecular Asymmetric Lactonization Using Optically Active 1,2-Diphenylethylenediamine as a Chiral Auxiliary,"" Chemistry Letters 5: 889-892.;;Baldwin, J.E. and Finn, A., (1987). ""Use of L-Aspartic Acid beta-Semialdehyde in the Synthesis of More Complex Non-Protein Amino Acids,"" Tetrahedron Letters 28(31): 3605-3608.;;Curphey, et al. (1979). ""Trifluoroacetylation of Amino Acids and Peptides by Ethyl Trifluoroacetate,"" J. Org. Chem. 44(15): 2805-2807.;;Evans, D.A., and Weber, A.E., (1987). ""Synthesis of Cyclic Hexapeptide Echinocandin D. New Approaches to the Asymmetric Synthesis of beta-Hydroxy alpha-Amino Acids,"" J. Am. Chem. Soc. 109: 7151-7157.;;Hensens, D.O. et al. (1992) ""Pneumocandins from Zalerion arboricola"" Journal of Antibiotics 45(12):1875-1885.;;Jamison, J.A. et al. (1998) ""The synthesis and antifungal activity of nitrogen containing hemiaminal ethers of LY303366"" Journal of Antibiotics 51(2):239-242.;;Kurokawa, N. and Ohfune, Y., (1986). ""Total Synthesis of Echinocandins 1. Stereocontrolled Synthesis of the Constituent Amino Acids,"" J. Am. Chem. Soc108: 6041-6043.;;Kurokawa, N.and Ohfune, Y., (1993). ""Synthetic Studies on Antifungal Cyclic Peptides Echinocandins. Stereoselective Total Synthesis of Echinocandin D via a Novel Peptide Coupling,"" Tetrahedron 49(28): 6195-6222.;;Sasaki, N.A., et al. (1987). ""A Novel Approach to the Synthesis of Optically Pure Non Protein alphaAmino Acids in Both L and D Configuration from L-Serine,"" Tetrahedron Letters 28(48): 6069-6072.;;Tanaka, K., et al. (1985). ""Asymmetric Synthesis of gamma-Alkyl-alpha-Methylene-gamma-Butyrolactone Via 1,6-Remore Induciton Using 2-[Tributylstannyl)Methyl]Propenamides,"" Tetrahedron Letters 26(10): 1337-1340.;;Turner, W.W. and Rodriguez, M.J. (1996). ""Recent Advances in the Medicinal Chemistry of Antifungal Agents,"" Current Pharmaceutical Design 2: 209-224.;;Yamamoto, Y., et al. (1991). ""Asymmetric Synthesis of 5- and 6-Membered Lactones from Cyclic Substrates Bearing a C<SUB>2</SUB>-Chiral Auxiliary,"" J. Org Chem 56(3): 1112-1119.;;Yoda, H., et al. (1989). ""New Synthetic Method of gamma- and delta- Lactones via Successive Alkylation and Reduction of Cyclic Imides,"" Chemistry Express 4(8): 515-518.;;Zambias, R.A. et al., (1992). ""Preparation and Structure- Activity Relationships of Simplified Analogues of Antifungal Agent Cilofungin: A Total Synthesis Approach,"" J. Med. Chem. 35: 2843-2855.",EXPIRED
531,US,B1,US 6653281 B1,046-767-172-131-828,2003-11-25,2003,US 76311401 A,2001-05-24,US 76311401 A;;US 9722898 P;;US 9918908 W,1998-08-20,Ring modified cyclic peptide analogs,"
    A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal omithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents. 
",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER JR WILLIAM WILSON,ELI LILLY AND COMPANY (2003-01-13),https://lens.org/046-767-172-131-828,Granted Patent,yes,32,16,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/72;;A61K38/00;;A61K9/08;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,514/11;;530/317;;530/338,16,11,033-174-478-156-432;;000-251-364-021-766;;003-546-984-502-816;;023-536-067-391-692;;031-803-770-910-400;;012-100-213-163-334;;130-589-465-154-789;;101-178-598-441-281;;026-693-133-110-667;;068-133-574-280-272;;067-425-820-717-678,10.1246/cl.1989.889;;10.1016/s0040-4039(00)95547-3;;10.1021/jo01329a049;;10.1021/ja00257a041;;1490878;;10.7164/antibiotics.45.1875;;9544949;;10.7164/antibiotics.51.239;;10.1021/ja00279a064;;22175372;;10.1016/s0040-4020(01)87959-x;;10.1016/s0040-4039(00)96866-7;;10.1016/s0040-4039(00)94887-1;;10.1021/jo00003a038,"U.S. patent application Ser. No. 07/992,390, Burkhardt et al., Filed Dec. 16, 1992.;;U.S. patent application Ser. No. 08/032,228, Burkhardt et al., filed Mar. 17, 1993.;;Baba, N., et al. (1989). ""Intramolecular Asymmetric Lactonization Using Optically Active, 1,2-Diphenylethylenediamine as a Chiral Auxiliary,"" Chemistry Letters 5: 889-892.;;Baldwin, J.E. and Finn, A., (1987). ""Use of L-Aspartic Acid beta-Semialdehyde in the Synthesis of More Complex Non-Protein Amino Acids,"" Tetrahedron Letters 28(31): 3605-3608.;;Curphey, et al. (1979). ""Trifluoroacetylation of Amino Acids and Peptides by Ethyl Trifluoroacetate,"" J. Org. Chem. 44(15): 2805-2807.;;Evans, D.A., and Weber, A.E., (1987). ""Synthesis of Cyclic Hexapeptide Echinocandin D. New Approaches to the Asymmetric Synthesis of beta-Hydroxy alpha-Amino Acids,"" J. Am. Chem. Soc. 109: 7151-7157.;;Hensens, D.O. et al. (1992) ""Pneumocandins from Zalerion arboricola"" Journal of Antibiotics 45(12):1875-1885.;;Jamison, J.A. et al. (1998) ""The synthesis and antifungal activity of nitrogen containing hemiaminal ethers of LY303366"" Journal of Antibiotics 51(2):239-242.;;Kurokawa, N. and Ohfune, Y., (1986). ""Total Synthesis of Echinocandins 1. Stereocontrolled Syntheses of the Constituent Amino Acids,"" J. Am. Chem. Soc 108: 6041-6043.;;Kurokawa, N.and Ohfune, Y., (1993). ""Synthetic Studies on Antifungal Cyclic Peptides Echinocandins. Stereoselective Total Synthesis of Echinocandin D via a Novel Peptide Coupling,"" Tetrahedron 49(28): 6195-6222.;;Sasaki, N.A., et al. (1987). ""A Novel Approach to the Synthesis of Optically Pure Non Protein alpha-Amino Acids in both L and D Configuration from L-Serine,"" Tetrahedron Letters 28(48): 6069-6072.;;Amino Acids in both L and D Configuration from L-Sering, Tetrahedron Letters 28(48): 6069-6072.;;Tanaka, K., et al. (1985). ""Asymmetric Synthesis of gamma-Alkyl-alpha-Methylene-gamma-Butyrolactone Via 1,6-Remore Induciton Using 2-[(Tributylstannyl)Methyl]Propenamides,"" Tetrahedron Letters 26(10); 1337-1340.;;Turner, W.W. and Rodriguez, M.J. (1996). ""Recent advances in the Medicinal Chemistry of Antifungal Agents,"" Current Pharmaceutical Design 2: 209-224.;;Yamamoto, Y., et al. (1991). ""Asymmetric Synthesis of 5- and 6-Membered Lactones from Cyclic Substrates Bearing a C2-Chiral Auxiliary,"" J. Org Chem 56(3): 1112-1119.;;Yoda, H., et al. (1989). ""New Synthetic Method of gamma- and delta- Lactones via Successive Alkylation and Reduction of Cyclic Imides,"" Chemistry Express 4(8): 515-518.",EXPIRED
532,WO,A3,WO 2000/011023 A3,113-276-636-775-616,2000-06-15,2000,US 9918908 W,1999-08-18,US 9722898 P,1998-08-20,RING MODIFIED CYCLIC PEPTIDE ANALOGS,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI;;BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/113-276-636-775-616,Search Report,yes,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/72;;A61K38/00;;A61K9/08;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,4,4,101-178-598-441-281;;031-803-770-910-400;;012-100-213-163-334;;011-098-930-627-430,10.1016/s0040-4020(01)87959-x;;1490878;;10.7164/antibiotics.45.1875;;9544949;;10.7164/antibiotics.51.239;;10.1021/jm00093a018;;1495015,"NATSUKO KUROKAWA ET AL: ""SYNTHETIC STUDIES ON ANTIFUNGAL CYCLIC PEPTIDES, ECHINOCANDINS. STEREOSELECTIVE TOTAL SYNTHESIS OF ECHINOCANDIN D VIA A NOVAL PEPTIDE COUPLING"", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 49, no. 28, pages 6195-7022, XP000571478, ISSN: 0040-4020;;HENSENS E.A.: ""Pneumocandins from Zalerion arboricola"", JOURNAL OF ANTIBIOTICS., vol. 45, no. 12, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO., JP, XP002126647, ISSN: 0021-8820;;JAMISON E.A.: ""The synthesis and antifungal activity of nitrogen containing hemiaminal ethers of LY303366"", JOURNAL OF ANTIBIOTICS., vol. 51, no. 2, February 1998 (1998-02-01), JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO., JP, pages 239 - 242, XP002126600, ISSN: 0021-8820;;ZAMBIAS E.A.: ""Preparation and structure-activity ewlationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 15, 1992, WASHINGTON US, pages 2843 - 2855, XP002126648",PATENTED
533,AT,T1,AT E287899 T1,159-659-382-359-125,2005-02-15,2005,AT 99942321 T,1999-08-18,US 9722898 P;;US 9918908 W,1998-08-20,VERFAHREN ZUR HERSTELLUNG VON RING-MODIFIZIERTEN ZYKLISCHEN PEPTIDANALOGEN,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;GREGORY GEORGE STUART;;HENLE STACY KAY;;HITCHCOCK STEPHEN ANDREW;;JUNGHEIM LOUIS NICKOLAUS;;MAYHUGH DANIEL RAY;;SHEPHERD TIMOTHY ALAN;;TURNER WILLIAM WILSON JR,,https://lens.org/159-659-382-359-125,Granted Patent,no,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,DISCONTINUED
534,CA,A1,CA 2340676 A1,176-685-478-860-980,2000-03-02,2000,CA 2340676 A,1999-08-18,US 9722898 P;;US 9918908 W,1998-08-20,RING MODIFIED CYCLIC PEPTIDE ANALOGS,"A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water- solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of member s within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.",LILLY CO ELI,BORROMEO PETER STANLEY;;COHEN JEFFREY DANIEL;;HITCHCOCK STEPHEN ANDREW;;SHEPHERD TIMOTHY ALAN;;MAYHUGH DANIEL RAY;;TURNER WILLIAM WILSON JR;;GREGORY GEORGE STUART;;HENLE STACY KAY;;JUNGHEIM LOUIS NICKOLAUS,,https://lens.org/176-685-478-860-980,Patent Application,no,0,0,17,17,0,A61K38/00;;C07K7/50;;C07K7/56;;A61P31/10;;A61P33/00;;Y02A50/30;;C07K7/50;;A61K38/00;;C07K7/56;;Y02A50/30,A61K9/08;;A61K9/72;;A61K38/00;;A61P31/10;;A61P33/00;;C07K1/06;;C07K7/50;;C07K7/54;;C07K7/56;;C07K7/64,,0,0,,,,DISCONTINUED
535,WO,A1,WO 2013/170030 A1,072-069-241-506-65X,2013-11-14,2013,US 2013/0040350 W,2013-05-09,US 201261644659 P;;US 201361777540 P,2012-05-09,ANTIBACTERIAL AGENTS,"Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.",ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,,https://lens.org/072-069-241-506-65X,Patent Application,yes,2,21,3,3,0,C07C259/06;;C07D233/64;;C07D261/08;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;C07D233/64;;C07D261/08;;C07C259/06;;C07C2601/16;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/02;;C07C235/66,A61K31/16;;C07C259/06;;C07D233/64;;C07D261/08,,0,0,,,,PENDING
536,US,B2,US 9701622 B2,100-862-618-116-895,2017-07-11,2017,US 201615179751 A,2016-06-10,US 201615179751 A;;US 201414537048 A;;US 2013/0040571 W;;US 201261645439 P,2012-05-10,Antibacterial agents,Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,ACHAOGEN INC (2015-01-14),https://lens.org/100-862-618-116-895,Granted Patent,yes,77,0,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07D213/64;;C07C259/06;;C07C313/04;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/50;;C07C323/42;;C07C323/60;;C07D213/79;;C07D213/81;;C07D333/70;;C07D471/04,,102,83,032-939-390-423-183;;037-284-547-589-286;;116-172-603-719-223;;085-866-024-606-009;;019-202-223-773-381;;020-850-449-729-958;;027-054-162-158-905;;032-636-211-896-252;;058-285-411-828-58X;;006-284-396-402-001;;107-882-302-465-493;;057-256-465-069-25X;;055-642-299-685-702;;023-247-521-718-210;;050-080-148-632-79X;;088-668-631-297-633;;004-866-827-865-540;;048-279-158-487-158;;193-110-735-220-423;;130-620-184-256-992;;053-081-445-266-590;;060-090-115-312-556;;017-742-847-973-597;;015-018-021-624-948;;143-501-107-115-352;;013-920-314-832-04X;;043-466-176-044-504;;099-806-085-859-345;;099-806-085-859-345;;052-786-510-319-542;;000-237-983-616-83X;;079-991-507-348-660;;056-591-131-567-824;;103-691-137-905-071;;033-869-942-034-174;;033-869-942-034-174;;010-776-269-665-066;;170-181-253-510-309;;061-655-093-633-173;;011-338-514-035-778;;138-270-463-142-369;;031-183-600-780-071;;039-540-522-976-143;;096-566-626-532-419;;017-722-106-597-75X;;006-453-596-091-820;;110-538-496-197-583;;009-628-770-391-986;;032-102-292-842-195;;016-670-276-058-267;;097-301-404-322-646;;052-950-406-858-222;;047-955-037-980-602;;083-092-215-272-057;;014-103-933-147-70X;;029-095-358-395-56X;;035-230-547-171-641;;112-084-571-476-777;;084-631-016-055-064;;014-586-270-826-582;;072-132-898-605-088;;147-518-077-164-036;;023-875-030-580-082;;080-925-708-804-167;;024-064-471-145-999;;141-855-688-720-74X;;011-770-604-574-09X;;022-826-785-597-432;;005-816-364-769-544;;073-155-911-616-610;;055-942-557-128-939;;056-391-790-700-135;;078-996-988-201-876;;040-706-196-113-731;;039-215-529-314-522;;016-103-803-403-333;;125-989-746-564-938;;170-420-271-401-873;;063-057-186-495-585;;022-420-632-844-770;;065-556-326-486-808;;012-149-576-277-557;;040-259-782-407-765,10.1016/j.chembiol.2003.09.002;;14522049;;6803666;;pmc181877;;10.1128/aac.21.2.299;;10.1055/s-2006-942434;;10.1002/cber.19220550504;;10.1021/jo01135a015;;pmc2709454;;17335290;;10.1021/bi6025165;;10395484;;10.1021/jm990058s;;10.1016/0040-4020(95)00356-d;;8709092;;10.1021/jm960088k;;10.2210/pdb3u1y/pdb;;10.1021/jm2014748;;22175825;;10.1128/aac.42.3.675;;pmc105516;;9517950;;10.1021/jo971883o;;10.1016/s0960-894x(98)00749-5;;10091675;;10.1128/aac.46.6.1793-1799.2002;;pmc127247;;12019092;;10.1039/a906223h;;19473108;;10.1517/13543770902766829;;10.1016/s0040-4039(03)01128-6;;10.1021/jo0256078;;12098286;;10.1021/jo00804a019;;10.1016/s0040-4039(00)00419-6;;10.1021/jm00397a037;;2892937;;10.1016/s0040-4039(97)00383-3;;14552786;;10.1016/s0960-894x(03)00794-7;;7568331;;10.1152/ajplegacy.1947.150.1.70;;20252828;;14670693;;10.1016/j.vascn.2003.07.001;;pmc178929;;9068651;;10.1128/jb.179.6.2029-2037.1997;;10.1080/00397917408063498;;10.1080/00397917408063498;;10.1074/jbc.275.15.11002;;10753902;;10.1378/chest.119.2_suppl.397s;;11171776;;10.1016/0040-4020(89)80091-2;;10.1081/scc-120024003;;10.1016/s0040-4039(98)01794-8;;10.1021/jm010579r;;12086497;;10.1021/jm010579r;;12086497;;10.1007/bf00471192;;21167751;;10.1016/j.chembiol.2010.11.011;;pmc3149848;;pmc3035996;;21194954;;10.1016/j.bmc.2010.12.017;;4745833;;10.1021/jm00266a008;;2002478;;10.1021/jm00107a018;;10.1016/0021-8502(73)90006-2;;16342948;;pmc2742919;;10.1021/bi0518186;;10.1016/s0040-4039(97)00594-7;;10.1021/ja00476a050;;10.1021/jm2014875;;22257165;;10.1246/cl.2002.756;;10.1016/j.bmc.2006.03.032;;16621578;;10.3891/acta.chem.scand.47-1141;;10.1021/jm00299a056;;5458406;;10.1021/jo971274g;;11671806;;9710669;;10.1086/514920;;10.1055/s-1999-3379;;10.1126/science.274.5289.980;;8875939;;10.1021/jm700967e;;18260614;;10.1021/jo00366a009;;10.1021/cr950066q;;11848856;;10.1039/p19930001629;;10.1021/jo00129a059;;10.1021/jm020183v;;12213077;;12568618;;10.1021/ja0209114;;15496101;;10.1021/ol048235t;;11029192;;10.1021/ol000178q;;10.1021/ol0170152;;11843575;;10.1128/aac.45.1.267-274.2001;;11120976;;pmc90271;;14193890;;10.1002/jps.2600530518;;10964383;;10.1021/ol006282p;;11674792;;10.1021/jo991116k;;10.1021/j100166a022;;14579524;;10.1002/cber.19220550803;;10.1002/hlca.19850680410;;15122286;;10.1038/nbt0504-513;;8285603;;pmc192375;;10.1128/aac.37.11.2255;;10.1016/j.tetlet.2004.07.132;;10.1021/jo00323a031;;10.1016/0040-4039(95)01322-9;;10.1002/jlac.197419740615;;10.1016/s0966-842x(98)01230-x;;9587193;;10.1021/ol0483192;;15496093;;10.1128/jb.173.12.3609-3614.1991;;1904854;;pmc207986;;10.1016/s0960-894x(99)00498-9;;10522699;;10.1016/j.bmcl.2006.03.041;;16603355,"Almstead et al., Database CAPLUS on STN, Acc. No. 1999:113626, WO 9906340 (Feb. 11, 1999) (Abstract 2 pages).;;Anderson, “The Process of Structure-Based Drug Design”, Chemistry & Biology, 10:787-797 (2003).;;Angus et al., “Outer Membrane Permeability in Pseudomonas aeruginosa: Comparison of Wild-type with an Antibiotic-Supersusceptible Mutant”, Antimicrob. Agents Chemother., 21(2):299-309 (1982).;;Arcadi et al., “Synthesis of New Cardanol Derivatives through Combined Iodination/Palladium-Catalysed Cross-Coupling Reactions”, Synthesis, 15:2523-2530 (2006).;;Auwers et al., “Uber halogenierte Indazole and Raumisomerie bei freien Indazolen”, Berichte der Deutschen Chemischen Gesellschaft, 55(3):1139-1173 (1922). (and English Abstract).;;Baker et al., “An Antimalarial Alkaloid from Hydrangea. XV. Synthesis of 5-, 6-, 7-, and 8-Derivatives with Two Identical Substituents”, J. Org. Chem., 17(1):149-156, 1952.;;Barb et al. , “Inhibition of Lipid A Biosynthesis as the Primary Mechanism of CHIR-090 Antibiotic Activity in Escherichia coli”, Biochemistry, 46(12):3793-3802 (2007).;;Bergeron et al., “Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues”, J. Med. Chem., 42(13):2432-2440 (1999).;;Boyce et al., “Total Synthesis of Thiangazole, A Novel Naturally Occurring HIV-1 Inhibitor from Polyangium sp.”, Tetrahedron, 51:7321-7330 (1995).;;Brooks et al., “Modulators of Leukotriene Biosynthesis and Receptor Activation”, J. Med. Chem., 39(14):2629-2654 (1996).;;Brown et al., “Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections”, J. Med. Chem., 55(2):914-923 (2012).;;Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., vol. 1, Manfred E. Wolff ed., John Wiley & Sons, NY, pp. 975-977 (1995).;;Byrne et al., “Antibiotic Treatment of Experimental Pneumonic Plague in Mice”, Antimicrob. Agents Chemother., 42(3):675-678 (1998).;;CAS Registry Database, CAS Registry 71972-38-8 (1984).;;CAS Registry Database, CAS Registry 202273-66-3 (1998).;;Charette et al., “Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amines”, J. Org. Chem., 63(4):908-909 (1998).;;Chen et al., “Carbohydroxamido-Oxazolidines: Antibacterial Agents to Target Lipid A Biosynthesis”, Bioorg. Med. Chem. Lett., 9:313-318 (1999).;;Clements et al., “Antibacterial Activities and Characterization of Novel Inhibitors of LpxC”, Antibacterial Agents and Chemotherapy, 46(6):1793-1799 (2002).;;Coghlan et al., “A one-pot three-component synthesis of b-nitro-a-amino acids and their N-alkyl derivatives”, J. Chem. Soc., Perkin Trans., 1:2659-2660 (1999).;;Cuny, G. D., “A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466”, Exp. Opin. Ther. Pat., 19(6):893-899 (2009).;;Daku et al, “Suzuki cross-coupling reactions using reverse-phase glass beads in aqueous media”, Tetrahedron Lett., 44(27):5095-5098 (2003).;;Dong et al., “Total Synthesis of Exochelin MN and Analogues”, J. Org. Chem., 67(14):4759-4770 (2002).;;Farnum et al., “The Nuclear Magnetic Resonance Spectra of Cyclic 1,3-Diphenylallyl Cations. Some Observations on 1,3-Orbital Interaction”, J. Org. Chem., 36(5):698-702 (1971).;;Fernandez et al., “Novel Synthesis of 2-Thioazolines”, Tetrahedron Lett., 41:3381-3384 (2000).;;Fourneau, E., “Amino Alcohols and Derivatives with Therapeutic Properties. II”, Database CAPLUS on STN, Acc. No. 1911:22205.;;Fushiya et al., “4-N-Hydroxy-L-2,4-diaminobutyric Acid. A Strong Inhibitor of Glutamine Synthetase”, J. Med. Chem., 31(2):480-483 (1988).;;Galéotti et al., “Synthesis of Peptidyl Aldehydes from Thiazolines”, Tetrahedron Lett., 38(14):2459-2462 (1997).;;Gallant et al., “Structure-Activity Relationship of Triaryl Propionic Acid Analogues on the Human EP3 Prostanoid Receptor”, Bioorg. Med. Chem. Lett., 13(21):3813-3816 (2003).;;Goodman & Gilman, “The Pharmacological Basis of Therapeutics”, Sixth Edition, pp. 1097-1098 (1980).;;Greco et al., “The Search for Synergy: A Critical Review from a Response Surface Perspective”, Pharmacol. Rev., 47(2):331-385 (1995).;;Guyton, A.C., “Measurement of the Respiratory Volumes of Laboratory Animals”, Am. J. Physiol., 150:70-77 (1947).;;Hartings et al., “The automated bioaerosol exposure system: Preclinical platform development and a respiratory dosimetry application with nonhyman primates”, J. Pharmacol. Toxicol. Methods, 49:39-55 (2004).;;Hyland et al., “Cloning, Expression, and Purification of UDP-3-O-Acyl-GlcNAc Deacetylase from Pseudomon as a Metalloamidase of the Lipid a Biosynthesis Pathway”, J. Bacteriol., 179(6):2029-2037 (1997).;;Ito et al., “Synthetic Reactions by Complex Catalysts. XXXI, A Novel and Versatile Method of Cyclic Imino Ethers and Imino Thioethers”, J. Am. Chem. Soc., 95(13):4447-4448 (1973).;;Ito et al., “Synthetic Reactions by Complex Catalysts. XXXV. A Facile Synthetic Method of Cyclic Imino Ethers and Imino Thioethers”, Synthetic Comm., 4(2):97-103 (1974).;;Jackman et al., “Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs”, J. Biol. Chem., 275(15):11002-11009 (2000).;;Jeng et al., “Endothelin Converting Enzyme Inhibitors”, Curr. Pharm. Des., 3(6):597-614 (1997).;;Jones, R. N., “Resistance Patterns Among Nosocomial Pathogens: Trends Over the Past Few Years”, Chest, 119(Supp 2):397S-404S (2001).;;Juaristi et al., “Use of Hexamethylphosphoramide (HMPA) in the Alkylation of Aromatic Amines: Synthesis of Azetidines, Pyrrolidines, Piperidines and Hexahydroazephines”, Tetrahedron, 45(3):629-636 (1989).;;Khan et al., “An Alternative Method for the Synthesis of g-Lactones by Using Cesium Fluoride-Celite/Acetonitrile Combination”, Synthetic Comm., 33(19)3:435-3453 (2003).;;Khan et al., “A Facile and Convenient Solid-phase Procedure for Synthesizing Nucleoside Hydroxam+A92ic Acids”, Tetrahedron Lett., 39:8031-8034 (1998).;;Kline et al., “Potent, Novel in Vitro Inhibitors of the Pseudomonas aeruginosa Deacetylase LpxC”, J. Med. Chem., 45(14):3112-3129 (2002).;;Kline et al., Database CAPLUS on STN, Acc. No. 2002:429779, J. Med. Chem., 45(14):3112-3129 (2002). (Abstract 1 page).;;Kleinman, Database CAPLUS on STN, Acc. No. 1997:224101, WO 9705105 (Feb. 13, 1997) (Abstract 1 page).;;Krasovitskii et al., “4-(5-aryl-2-oxazolyl)phthalic anhydrides”, Chem. Het. Compounds, 15(1): 28-31 (1979).;;Lee et al., “Species-Specific and Inhibitor-Dependent Conformations of LpxC: Implications for Antibiotic Design”, Chem. Biol., 18:38-47 (2011).;;Liang et al., “Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold”, Bioorg. Med. Chem. 19:852-860 (2011).;;Lopez et al., “Potency and Efficacy of Small Molecule Inhibitors of the Gram-Negative Bacterial Enzyme LpxC Against Yersinia Pestis and Other Enterobacteriaceae”, Poster W032, Poster presentation, the Chemical and Biological Defense Science and Technology (CBD S&T) Conference, Dallas, Texas, Nov. 2009 (1 pages).;;Lopez et al., “Small Molecule LpxC Inhibitors of Burkholderia Mallei and Burkholderia Psuedomallei: In Vitro and In Vivo Potency and Efficacy”, Poster WO33, Poster presentation, the Chemical and Biological Defense Science and Technology (CBD S&T) Conference, Dallas, Texas, Nov. 2009 (1 page).;;Matier et al., “Antihypertensive Agents. Synthesis and Biological Properties of 2-Amino-4-aryl-2imidazolines”, J. Med. Chem. 16(8):901-908 (1973).;;Matsuda et al., “Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro”, J. Med. Chem., 34(3):999-1002 (1991).;;May, K. R., “The Collison Nebulizer: Description, Performance and Application”, Aerosol Science, 4:235-243 (1973).;;MCCLERREN AMANDA L., ET AL.: ""A Slow, Tight-Binding Inhibitor of the Zinc-Dependent Deacetylase LpxC of Lipid A Biosynthesis with Anitbiotic Activity Comparable to Ciprofloxacin"", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 44, no. 50, 1 January 2005 (2005-01-01), US, pages 16574 - 16583, XP002499759, ISSN: 0006-2960, DOI: 10.1021/BI0518186;;Mellor et al., “N-Fmoc-Aminoxy-2-Chlortrityl Polystyrene Resin: A Facile Solid-Phase Methodology for the synthesis of hydroxyamic acids”, Tetrahedron Lett., 38(18):3311-3314 (1997).;;Metcalf et al., “Catalytic Irreversible Inhibition of Mammalian Ornithine Decarboxylase (E. C. 4.1.1.17) by Substrate and Product Analogues”, J. Am. Chem. Soc., 100(8):2551-2553 (1978).;;“Modern Pharmaceutics”, 3rd ed., Gilbert S. Banker et al., ed., Marcel Dekker, Inc., NY, p. 596 (1996).;;Montgomery et al., “Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections”, J. Med. Chem., 44(4):1662-70 (2012).;;Mori et al., “Sonogashira Coupling with Aqueous Ammonia”, Chem. Lett., 31(7):756-757 (2002).;;Nakatani, S. et al., “Design and synthesis of novel metalloproteinase inhibitors”, Bioorg. Med. Chem. 14: 5402-5422 (2006).;;Neset et al., “Synthesis of Cyclic Hydroxamic Acids by Oxidation of Secondary Amines with Dimethyldioxirane”, Acta Chemica Scandinavica, 47:1141-1143 (1993).;;Neumeyer et al., “Isoquinolines. 2. 3-(Dialkylaminoalkylamino)isoquinolines as Potential Antimalarial Drugs”, J. Med. Chem., 13(5):999-1002 (1970).;;Ngu and Patel, “A New and Efficient Solid Phase Synthesis of Hydroxamic Acids”, J. Org. Chem., 62(21):7088-7089 (1997).;;Nicolaus, “Symbiotic Approach to Drug Design”, in Decision Making in Drug Research, 173-186, Franz Gross ed. (1983).;;Nikaido, H., “Antibacterial Resistance Caused by Gram-negative Multidrug Efflux Pumps”, Clin. Infect. Dis., 27(Supp 1):S32-S41 (1998).;;Numata et al., “General Synthetic Method for Naphthyridines and Their N-Oxides Containing Isoquinolinic Nitrogen”, Synthesis, 2:306-3011 (1999).;;Onishi et al., “Antibacterial Agents that Inhibit Lipid A Biosynthesis”, Science, 274:980-982 (1996).;;O'Shea et al., “Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery”, J. Med. Chem., 51(10):2871-2878 (2008).;;Oslo (editor), Remington's Pharmaceutical Sciences, Philadelphia College of Pharmaceutical Science, Chapter 27: Structure-Activity Relationship and Drug Design, pp. 420-435 (1990).;;Padwa et al., “1,3-Dipolar Cycloadditions of Nitrones Derived from the Reaction of Acetylenes with Hydroxylamines”, J. Org. Chem, 51(16):3125-3133 (1986).;;Patani et al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev., 96:3147-3176 (1996).;;Patchett et al., Database CAPLUS on STN, Acc. No. 1997:746038, WO 9742179 (Nov. 13, 1997) (Abstract, 2 pages).;;Pattenden et al., “Naturally Occurring Linear Fused Thiazoline-Thiazole Containing Metabolites: Total Synthesis of (−) Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae”, J.Chem. Soc. Perkin Trans., 1:1629-1636 (1993).;;Pirrung et al., “A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters”, J. Org. Chem., 60(24):8084-8085 (1995).;;Pirrung et al., “Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups”, J. Med. Chem., 45(19):4359-4370 (2002).;;Pirrung et al., “High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-Activity Relationships in Novel Inhibitors of Escherichia coli LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties”, J. Am. Chem. Soc., 125(6):1575-1586 (2003).;;Powell et al., “Practical Synthesis of 1-Aryl-6-(hydroxymethyl)-2-ketopiperazines via a 6-exo Amide-Epoxide Cyclization”, Org. Lett., 6(22):4069-4072 (2004).;;Raman et al., “Titanium (IV)-mediated Tandem Deprotection-cyclodehydration of Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline- and Thiazole-containing Heterocycles”, Org. Lett., 2(21):3289-3292 (2000).;;Righi et al., “Solution- and Solid-Phase Synthesis of 4-Hydroxy-4,5-dihydroisoxazole Derivatives from Enantiomerically Pure N-Tosyl-2,3-aziridine Alcohols”, Org. Lett., 4(4):497-500 (2002).;;Sahm et al., “Evaluation of Current Activities of Fluoroquinolones Against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance”, Antimicrob. Agents Chemother., 45(1):267-274, (2001).;;Sam et al., “Benzoxazoles: Potent Skeletal Muscle Relaxants”, J. Pharm. Sciences, 53(5):538-544 (1964).;;Scribner et al., “Activities of Various βLactams and Aminoglycosides Along and in Combination, Against Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis”, Antimicrob. Agents Chemother., 21(6):939-943 (1982).;;Shen et al., “Synthesis of 1,3-Diynes via Palladium-catalyzed Reaction of 1,1-Dibromo-1-alkenes”, Org. Lett., 2(18):2857-2860 (2000).;;Shen et al., “The Stille Reaction of 1,1-Dibromo-1-alkenes: Preparation of Trisubstituted Alkenes and Internal Alkynes”, J. Org. Chem., 64(24):8873-8879 (1999).;;Sigman et al., “Free Energy and Structure Dependence of Intramolecular Triplet Energy Transfer in Organic Model Compounds”, J. Phys. Chem., 95(13):5012-5017 (1991).;;Skotnicki et al., “Design Strategies for the Identification of MMP-13 and TACE Inhibitors”, Curr. Opin. Drug Disc. Devel., 6(5):742-759 (2003).;;Stella et al., “Biotechnology: Pharmaceutical Aspects”, Prodrugs: Challenges and Rewards, Part 1 (2007) (3 pages).;;Stobbe et al., “Lichtreaktionen der trans- und cis-Zimtsauren”, Berichte der Deutschen Chemischen Gesellschaft, 55(8):2225-2245 (1922).;;Susse et al., “Chinazolincarbonsauren. VII. Mitteilung. Ein enfacher Zugang zu(4-Oxo-3,4-dihydrochinazolin-3-yl)-alkansauren, (4-Oxo-3,4-dihydro-1,2,3-benzotriazin-3-yl)-alkansauren und deren estern”, Helv. Chim. Acta, 68:892-899 (1985). (and English Abstract).;;Thiel, “Structure-aided drug design's next generation”, Nature Biotechnol., 22(5):513-519 (2004).;;Vaara et al., “Antibiotic-Supersusceptible Mutants of Escherichia coli and Salmonella typhimurium”, Antimicrob. Agents Chemother., 37(11):2255-2260 (1993).;;Vachal et al., “General facile synthesis of 2,5-diarylheteropentalenes”, Tetrahedron Lett., 45:7157-7161 (2004).;;Van Den Haak et al., “Chichibabin Amination of 1,X-Napthyridines. Nuclear magnetic Resonance Studies on the s Adducts of Heterocyclic Systems with Nucleophiles”, J. Org. Chem., 46(10):2134-2137 (1981).;;Williams et al., “Drug Design and Relationship of Functional Groups to Pharmacological Activity”, Foye's Principles of Medicinal Chemistry, Fifth Edition, Lippincott Williams & Wilkins, 2:59-63 (2002).;;Wipf et al., “Thiolysis of Oxazolines: A New, Selective Method for the Direct Conversion of Peptide Oxazolines into Thiazolines”, Tetrahedron Lett., 36(36):6395-6398 (1995).;;Witte et al., “Cyclische Imidsäureester aus Nitrilen und Aminoalkoholen”, Liebigs Ann. Chem., 996-1009 (1974). (and English Abstract).;;Wyckoff et al., “Antibacterial and Anti-inflammatory Agents That Target Endotoxin”, Trends Microbiol., 6(4):154-159 (1998).;;Yoon et al., “Oxygen-Promoted Palladium (II) Catalysis: Facile C(sp2)-C(sp2) Bond Formation via Cross Coupling of Alkenylboronic Compounds and Olefins”, Org. Lett., 6(22):4037-4039 (2004).;;Young et al., “Leakage of Periplasmic Enzymes from envA1 Strains of Escherichia coli ”, J. Bacteriol., 173(12):3609-3614 (1991).;;Youngman et al., “The Synthesis of Novel cis- α-Substituted-β-aminotetralins”, Synth. Comm. 33(13):2215-2227 (2003).;;Zask et al., “Inhibition of Matrix Metalloproteinases: Structure Based Design”, Curr. Pharm. Des., 2(6):624-661 (1996).;;Zhang et al., “Design, Combinatorial Chemical Synthesis, and in vitro Characterization of Novel Urea Based Gelatinase Inhibitors”, Bioorg. Med. Chem. Lett. 9:2823-2826 (1999).;;Zhu et al., “Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity”, Bioorg. Med. Chem. Lett., 16(12):3150-3155 (2006).",INACTIVE
537,US,A1,US 2016/0016895 A1,112-820-063-149-991,2016-01-21,2016,US 201414537048 A,2014-11-10,US 201414537048 A;;US 2013/0040571 W;;US 201261645439 P,2012-05-10,ANTIBACTERIAL AGENTS,Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,ACHAOGEN INC (2015-01-14),https://lens.org/112-820-063-149-991,Patent Application,yes,1,3,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07C259/06;;C07C313/12;;C07C317/28;;C07C323/42;;C07D213/64;;C07D213/81;;C07D333/70;;C07D471/04,,0,0,,,,INACTIVE
538,US,A1,US 2016/0280639 A1,114-996-929-899-905,2016-09-29,2016,US 201615179751 A,2016-06-10,US 201615179751 A;;US 201414537048 A;;US 2013/0040571 W;;US 201261645439 P,2012-05-10,ANTIBACTERIAL AGENTS,Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,ACHAOGEN INC (2015-01-14),https://lens.org/114-996-929-899-905,Patent Application,yes,1,0,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07C259/06;;C07C313/04;;C07C317/28;;C07C323/42;;C07D213/64;;C07D213/81;;C07D333/70;;C07D471/04,,0,0,,,,INACTIVE
539,WO,A1,WO 2013/170165 A1,079-097-911-804-203,2013-11-14,2013,US 2013/0040571 W,2013-05-10,US 201261645439 P,2012-05-10,ANTIBACTERIAL AGENTS,"Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.",ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,,https://lens.org/079-097-911-804-203,Patent Application,yes,2,41,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07D213/78;;A61K31/38;;A61K31/4375;;A61K31/44;;A61K31/4412;;A61P31/04;;C07C235/00;;C07D213/64;;C07D333/70;;C07D471/04,,0,0,,,,PENDING
540,EP,A1,EP 2847168 A1,165-477-751-414-258,2015-03-18,2015,EP 13725017 A,2013-05-10,US 201261645439 P;;US 2013/0040571 W,2012-05-10,ANTIBACTERIAL AGENTS,,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,,https://lens.org/165-477-751-414-258,Patent Application,yes,0,0,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07D213/78;;A61K31/38;;A61K31/4375;;A61K31/44;;A61K31/4412;;A61P31/04;;C07C235/00;;C07D213/64;;C07D333/70;;C07D471/04,,1,0,,,See references of WO 2013170165A1,DISCONTINUED
541,US,B2,US 9403758 B2,076-583-737-351-812,2016-08-02,2016,US 201414537048 A,2014-11-10,US 201414537048 A;;US 2013/0040571 W;;US 201261645439 P,2012-05-10,Antibacterial agents,Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,ACHAOGEN INC (2015-01-14),https://lens.org/076-583-737-351-812,Granted Patent,yes,76,8,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07D213/81;;C07C259/06;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/50;;C07C323/42;;C07C323/60;;C07D213/64;;C07D213/79;;C07D333/70;;C07D471/04,,99,83,032-939-390-423-183;;037-284-547-589-286;;116-172-603-719-223;;085-866-024-606-009;;019-202-223-773-381;;020-850-449-729-958;;027-054-162-158-905;;032-636-211-896-252;;058-285-411-828-58X;;006-284-396-402-001;;107-882-302-465-493;;057-256-465-069-25X;;055-642-299-685-702;;023-247-521-718-210;;050-080-148-632-79X;;088-668-631-297-633;;004-866-827-865-540;;048-279-158-487-158;;193-110-735-220-423;;130-620-184-256-992;;053-081-445-266-590;;060-090-115-312-556;;017-742-847-973-597;;015-018-021-624-948;;143-501-107-115-352;;013-920-314-832-04X;;043-466-176-044-504;;099-806-085-859-345;;099-806-085-859-345;;052-786-510-319-542;;000-237-983-616-83X;;079-991-507-348-660;;056-591-131-567-824;;103-691-137-905-071;;033-869-942-034-174;;033-869-942-034-174;;010-776-269-665-066;;170-181-253-510-309;;061-655-093-633-173;;011-338-514-035-778;;138-270-463-142-369;;031-183-600-780-071;;039-540-522-976-143;;096-566-626-532-419;;017-722-106-597-75X;;006-453-596-091-820;;110-538-496-197-583;;032-102-292-842-195;;016-670-276-058-267;;097-301-404-322-646;;052-950-406-858-222;;047-955-037-980-602;;083-092-215-272-057;;014-103-933-147-70X;;029-095-358-395-56X;;035-230-547-171-641;;112-084-571-476-777;;084-631-016-055-064;;014-586-270-826-582;;072-132-898-605-088;;147-518-077-164-036;;023-875-030-580-082;;080-925-708-804-167;;024-064-471-145-999;;141-855-688-720-74X;;014-462-696-036-962;;011-770-604-574-09X;;022-826-785-597-432;;005-816-364-769-544;;073-155-911-616-610;;055-942-557-128-939;;056-391-790-700-135;;078-996-988-201-876;;040-706-196-113-731;;039-215-529-314-522;;016-103-803-403-333;;125-989-746-564-938;;170-420-271-401-873;;063-057-186-495-585;;022-420-632-844-770;;065-556-326-486-808;;051-797-597-980-954;;012-149-576-277-557,10.1016/j.chembiol.2003.09.002;;14522049;;6803666;;pmc181877;;10.1128/aac.21.2.299;;10.1055/s-2006-942434;;10.1002/cber.19220550504;;10.1021/jo01135a015;;pmc2709454;;17335290;;10.1021/bi6025165;;10395484;;10.1021/jm990058s;;10.1016/0040-4020(95)00356-d;;8709092;;10.1021/jm960088k;;10.2210/pdb3u1y/pdb;;10.1021/jm2014748;;22175825;;10.1128/aac.42.3.675;;pmc105516;;9517950;;10.1021/jo971883o;;10.1016/s0960-894x(98)00749-5;;10091675;;10.1128/aac.46.6.1793-1799.2002;;pmc127247;;12019092;;10.1039/a906223h;;19473108;;10.1517/13543770902766829;;10.1016/s0040-4039(03)01128-6;;10.1021/jo0256078;;12098286;;10.1021/jo00804a019;;10.1016/s0040-4039(00)00419-6;;10.1021/jm00397a037;;2892937;;10.1016/s0040-4039(97)00383-3;;14552786;;10.1016/s0960-894x(03)00794-7;;7568331;;10.1152/ajplegacy.1947.150.1.70;;20252828;;14670693;;10.1016/j.vascn.2003.07.001;;pmc178929;;9068651;;10.1128/jb.179.6.2029-2037.1997;;10.1080/00397917408063498;;10.1080/00397917408063498;;10.1074/jbc.275.15.11002;;10753902;;10.1378/chest.119.2_suppl.397s;;11171776;;10.1016/0040-4020(89)80091-2;;10.1081/scc-120024003;;10.1016/s0040-4039(98)01794-8;;10.1021/jm010579r;;12086497;;10.1021/jm010579r;;12086497;;10.1007/bf00471192;;21167751;;10.1016/j.chembiol.2010.11.011;;pmc3149848;;pmc3035996;;21194954;;10.1016/j.bmc.2010.12.017;;4745833;;10.1021/jm00266a008;;2002478;;10.1021/jm00107a018;;10.1016/0021-8502(73)90006-2;;16342948;;pmc2742919;;10.1021/bi0518186;;10.1016/s0040-4039(97)00594-7;;10.1021/ja00476a050;;10.1021/jm2014875;;22257165;;10.1246/cl.2002.756;;10.3891/acta.chem.scand.47-1141;;10.1021/jm00299a056;;5458406;;10.1021/jo971274g;;11671806;;9710669;;10.1086/514920;;10.1055/s-1999-3379;;10.1126/science.274.5289.980;;8875939;;10.1021/jm700967e;;18260614;;10.1021/jo00366a009;;10.1021/cr950066q;;11848856;;10.1039/p19930001629;;10.1021/jo00129a059;;10.1021/jm020183v;;12213077;;12568618;;10.1021/ja0209114;;15496101;;10.1021/ol048235t;;11029192;;10.1021/ol000178q;;10.1021/ol0170152;;11843575;;10.1128/aac.45.1.267-274.2001;;11120976;;pmc90271;;14193890;;10.1002/jps.2600530518;;6810757;;pmc182049;;10.1128/aac.21.6.939;;10964383;;10.1021/ol006282p;;11674792;;10.1021/jo991116k;;10.1021/j100166a022;;14579524;;10.1002/cber.19220550803;;10.1002/hlca.19850680410;;15122286;;10.1038/nbt0504-513;;8285603;;pmc192375;;10.1128/aac.37.11.2255;;10.1016/j.tetlet.2004.07.132;;10.1021/jo00323a031;;10.1016/0040-4039(95)01322-9;;10.1002/jlac.197419740615;;10.1016/s0966-842x(98)01230-x;;9587193;;10.1021/ol0483192;;15496093;;10.1128/jb.173.12.3609-3614.1991;;1904854;;pmc207986;;10.1081/scc-120021500;;10.1016/s0960-894x(99)00498-9;;10522699,"Almstead et al., Database CAPLUS on STN, Acc. No. 1999:113626, WO 9906340 (Feb. 11, 1999) (Abstract 2 pages).;;Anderson, ""The Process of Structure-Based Drug Design"", Chemistry & Biology, 10:787-797 (2003).;;Angus et al., ""Outer Membrane Permeability in Pseudomonas aeruginosa: Comparison of Wild-type with an Antibiotic-Supersusceptible Mutant"", Antimicrob. Agents Chemother., 21(2):299-309 (1982).;;Arcadi et al., ""Synthesis of New Cardanol Derivatives through Combined Iodination/Palladium-Catalysed Cross-Coupling Reactions"", Synthesis, 15:2523-2530 (2006).;;Auwers et al., ""Uber halogenierte Indazole und Raumisomerie bei freien Indazolen"", Berichte der Deutschen Chemischen Gesellschaft, 55(3):1139-1173 (1922). (and English Abstract).;;Baker et al., ""An Antimalarial Alkaloid from Hydrangea. XV. Synthesis of 5-, 6-, 7-, and 8-Derivatives with Two Identical Substitutents"", J. Org. Chem., 17(1):149-156, 1952.;;Barb et al., ""Inhibition of Lipid A Biosynthesis as the Primary Mechanism of CHIR-090 Antibiotic Activity in Escherichia coli"", Biochemistry, 46(12):3793-3802 (2007).;;Bergeron et al., ""Effects of C-4 Stereochemistry and C-4' Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues"", J. Med. Chem., 42(13):2432-2440 (1999).;;Boyce et al., ""Total Synthesis of Thiangazole, A Novel Naturally Occurring HIV-1 Inhibitor from Polyangium sp."", Tetrahedron, 51:7321-7330 (1995).;;Brooks et al., ""Modulators of Leukotriene Biosynthesis and Receptor Activation"", J. Med. Chem., 39(14):2629-2654 (1996).;;Brown et al., ""Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections"", J. Med. Chem., 55(2):914-923 (2012).;;Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., vol. 1, Manfred E. Wolff ed., John Wiley & Sons, NY, pp. 975-977 (1995).;;Byrne et al., ""Antibiotic Treatment of Experimental Pneumonic Plague in Mice"", Antimicrobial Agents Chemotherapy, 42(3):675-678 (1998).;;CAS Registry Database, CAS Registry 71972-38-8 (1984).;;CAS Registry Database, CAS Registry 202273-66-3 (1998).;;Charette et al., ""Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amines"", J. Org. Chem., 63(4):908-909 (1998).;;Chen et al., ""Carbohydroxamido-Oxazolidines: Antibacterial Agents to Target Lipid a Biosynthesis"", Bioorganic & Medicinal Chemistry Letters, 9:313-318 (1999).;;Clements et al., ""Antibacterial Activities and Characterization of Novel Inhibitors of LpxC"", Antibacterial Agents and Chemotherapy, 46(6):1793-1799 (2002).;;Coghlan et al., ""A one-pot three-component synthesis of b-nitro-a-amino acids and their N-alkyl derivatives"", J. Chem. Soc., Perkin Trans., 1:2659-2660 (1999).;;Cuny, G. D., ""A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466"", Expert Opin. Ther. Patents, 19(6):893-899 (2009).;;Daku et al, ""Suzuki cross-coupling reactions using reverse-phase glass beads in aqueous media"", Tetrahedron Letters, 44(27):5095-5098 (2003).;;Dong et al., ""Total Synthesis of Exochelin MN and Analogues"", J. Org. Chem., 67(14):4759-4770 (2002).;;Farnum et al., ""The Nuclear Magnetic Resonance Spectra of Cyclic 1,3-Diphenylallyl Cations. Some Observations on 1,3-Orbital Interaction"", J. Org. Chem., 36(5):698-702 (1971).;;Fernandez et al., ""Novel Synthesis of 2-Thioazolines"", Tetrahedron Lett., 41:3381-3384 (2000).;;Fourneau, E., ""Amino Alcohols and Derivatives with Therapeutic Properties. II"", Database CAPLUS on STN, Acc. No. 1911:22205.;;Fushiya et al., ""4-N-Hydroxy-L-2,4-diaminobutyric Acid. A Strong Inhibitor of Glutamine Synthetase"", J. Med. Chem., 31(2):480-483 (1988).;;Galéotti et al., ""Synthesis of Peptidyl Aldehydes from Thiazolines"", Tetrahedron Lett., 38(14):2459-2462 (1997).;;Gallant et al., ""Structure-Activity Relationship of Triaryl Propionic Acid Analogues on the Human EP3 Prostanoid Receptor"", Bioorganic & Medicinal Chemistry Letters, 13(21):3813-3816 (2003).;;Goodman & Gilman, ""The Pharmacological Basis of Therapeutics"", Sixth Edition, pp. 1097-1098 (1980).;;Greco et al., ""The Search for Synergy: A Critical Review from a Response Surface Perspective"", Pharmacological Reviews, 47(2):331-385 (1995).;;Guyton, A.C., ""Measurement of the Respiratory Volumes of Laboratory Animals"", Am. J. Physiol., 150:70-77 (1947).;;Hartings et al., ""The automated bioaerosol exposure system: Preclinical platform development and a respiratory dosimetry application with nonhyman primates"", Journal of Pharmacological and Toxicological Methods, 49:39-55 (2004).;;Hyland et al., ""Cloning, Expression, and Purification of UDP-3-O-Acyl-GlcNAc Deacetylase from Pseudomon as a Metalloamidase of the Lipid a Biosynthesis Pathway"", J. Bacteriol., 179(6):2029-2037 (1997).;;Ito et al., ""Synthetic Reactions by Complex Catalysts. XXXI, A Novel and Versatile Method of Cyclic Imino Ethers and Imino Thioethers"", J. Am. Chem. Soc., 95(13):4447-4448 (1973).;;Ito et al., ""Synthetic Reactions by Complex Catalysts. XXXV. A Facile Synthetic Method of Cyclic Imino Ethers and Imino Thioethers"", Synthetic Communications, 4(2):97-103 (1974).;;Jackman et al., ""Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs"", J. Biol. Chem., 275(15):11002-11009 (2000).;;Jeng et al., ""Endothelin Converting Enzyme Inhibitors"", Current Pharmaceutical Design, 3(6):597-614 (1997).;;Jones, R. N., ""Resistance Patterns Among Nosocomial Pathogens: Trends Over the Past Few Years"", Chest, 119(Supp 2):397S-404S (2001).;;Juaristi et al., ""Use of Hexamethylphosphoramide (HMPA) in the Alkylation of Aromatic Amines: Synthesis of Azetidines, Pyrrolidines, Piperidines and Hexahydroazephines"", Tetrahedron, 45(3):629-636 (1989).;;Khan et al., ""An Alternative Method for the Synthesis of g-Lactones by Using Cesium Fluoride-Celite/Acetonitrile Combination"", Synthetic Communications, 33(19)3:435-3453 (2003).;;Khan et al., ""A Facile and Convenient Solid-phase Procedure for Synthesizing Nucleoside Hydroxam+A92ic Acids"", Tetrahedron Lett., 39:8031-8034 (1998).;;Kline et al., ""Potent, Novel in Vitro Inhibitors of the Pseudomonas aeruginosa Deacetylase LpxC"", J. Med. Chem., 45(14):3112-3129 (2002).;;Kline et al., Database CAPLUS on STN, Acc. No. 2002:429779, Journal of Medicinal Chemistry, 45(14):3112-3129 (2002). (Abstract 1 page).;;Kleinman, Database CAPLUS on STN, Acc. No. 1997:224101, WO 9705105 (Feb. 13, 1997) (Abstract 1 page).;;Krasovitskii et al., ""4-(5-Aryl-2-Oxazolyl)Phthalic Anhydrides"", Chemistry of Heterocyclic Compounds, 15(1): 28-31 (1979).;;Lee et al., ""Species-Specific and Inhibitor-Dependent Conformations of LpxC: Implications for Antibiotic Design"", Chemistry & Biology, 18:38-47 (2011).;;Liang et al., ""Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold"", Bioorganic & Medicinal Chemistry, 19:852-860 (2011).;;Lopez et al., ""Potency and Efficacy of Small Molecule Inhibitors of the Gram-Negative Bacterial Enzyme LpxC Against Yersinia ersinia Pestis and Other Enterobacteriaceae"", Poster W032, Poster presentation, the Chemical and Biological Defense Science and Technology (CBD S&T) Conference, Dallas, Texas, Nov. 2009 (1 page).;;Lopez et al., ""Small Molecule LpxC Inhibitors of Burkholderia Mallei and Burkholderia Psuedomallei: In Vitro and In Vivo Potency and Efficacy"", Poster WO33, Poster presentation, the Chemical and Biological Defense Science and Technology (CBD S&T) Conference, Dallas, Texas, Nov. 2009 (1 page).;;Matier et al., ""Antihypertensive Agents. Synthesis and Biological Properties of 2-Amino-4-aryl-2imidazolines"", Journal of Medicinal Chemistry, 16(8):901-908 (1973).;;Matsuda et al., ""Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-beta-D-arabinofuranosyl)cytosine (cytarazid) and -thymine. Inhibitory spectrum of cytarazid on the growth of various human tumor cells in vitro"", J. Med. Chem., 34(3):999-1002 (1991).;;May, K. R., ""The Collison Nebulizer: Description, Performance and Application"", Aerosol Science, 4:235-243 (1973).;;McClerren et al., ""A Slow Tight-Binding Inhibitor of the Zinc-Dependent Deacetylase LpxC of Lipid A Biosynthesis with Antibiotic Activity Comparable to Ciprofloxacin"", Biochemistry, 44(50):167574-16583 (XP002499759) (2005).;;Mellor et al., ""N-Fmoc-Aminoxy-2-Chlortrityl Polystyrene Resin: A Facile Solid-Phase Methodology for the synthesis of hydroxyamic acids"", Tetrahedron Letters, 38(18):3311-3314 (1997).;;Metcalf et al., ""Catalytic Irreversible Inhibition of Mammalian Ornithine Decarboxylase (E. C. 4.1.1.17) by Substrate and Product Analogues"", Journal of the American Chemical Society, 100(8):2551-2553 (1978).;;""Modern Pharmaceutics"", 3rd ed., Gilbert S. Banker et al., ed., Marcel Dekker, Inc., NY, p. 596 (1996).;;Montgomery et al., ""Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections"", J. Med. Chem., 44(4):1662-70 (2012).;;Mori et al., ""Sonogashira Coupling with Aqueous Ammonia"", Chemistry Letters, 31(7):756-757 (2002).;;Neset et al., ""Synthesis of Cyclic Hydroxamic Acids by Oxidation of Secondary Amines with Dimethyldioxirane"", Acta Chemica Scandinavica, 47:1141-1143 (1993).;;Neumeyer et al., ""Isoquinolines. 2. 3-(Dialkylaminoalkylamino)isoquinolines as Potential Antimalarial Drugs"", Journal of Medicinal Chemistry, 13(5):999-1002 (1970).;;Ngu and Patel, ""A New and Efficient Solid Phase Synthesis of Hydroxamic Acids"", J. Org. Chem., 62(21):7088-7089 (1997).;;Nicolaus, ""Symbiotic Approach to Drug Design"", in Decision Making in Drug Research, 173-186, Franz Gross ed. (1983).;;Nikaido, H., ""Antibacterial Resistance Caused by Gram-negative Multidrug Efflux Pumps"", Clin. Infect. Dis., 27(Supp 1):S32-S41 (1998).;;Numata et al., ""General Synthetic Method for Naphthyridines and Their N-Oxides Containing Isoquinolinic Nitrogen"", Synthesis, 2:306-3011 (1999).;;Onishi et al., ""Antibacterial Agents that Inhibit Lipid a Biosynthesis"", Science, 274:980-982 (1996).;;O'Shea et al., ""Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery"", Journal of Medicinal Chemistry, 51(10):2871-2878 (2008).;;Padwa et al., ""1,3-Dipolar Cycloadditions of Nitrones Derived from the Reaction of Acetylenes with Hydroxylamines"", J. Org. Chem, 51(16):3125-3133 (1986).;;Patani et al., ""Bioisosterism: A Rational Approach in Drug Design"", Chem. Rev., 96:3147-3176 (1996).;;Patchett et al., Database CAPLUS on STN, Acc. No. 1997:746038, WO 9742179 (Nov. 13, 1997) (Abstract, 2 pages).;;Pattenden et al., ""Naturally Occurring Linear Fused Thiazoline-Thiazole Containing Metabolites: Total Synthesis of (-) Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae"", J. Chem. Soc. Perkin Trans., 1:1629-1636 (1993).;;Pirrung et al., ""A Convenient Procedure for the Preparation of Amino Acid Hydrokamates from Esters"", J. Org. Chem., 60(24):8084-8085 (1995).;;Pirrung et al., ""Inhibition of the antibacterial target UDP-(3-O-acyl)N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups"", J. Med. Chem., 45(19):4359-4370 (2002).;;Pirrung et al., ""High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-Activity Relationships in Novel Inhibitors of Escherichia coli LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties"", J. Am. Chem. Soc., 125(6):1575-1586 (2003).;;Powell et al., ""Practical Synthesis of 1-Aryl-6-(hydroxymethyl)-2-ketopiperazines via a 6-exo Amide-Epoxide Cyclization"", Org. Lett., 6(22):4069-4072 (2004).;;Raman et al., ""Titanium (IV)-mediated Tandem Deprotection-cyclodehydration of Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline- and Thiazole-containing Heterocycles"", Org. Lett., 2(21):3289-3292 (2000).;;Righi et al., ""Solution- and Solid-Phase Synthesis of 4-Hydroxy-4,5-dihyddroisoxazole Derivatives from Enantiomerically Pure N-Tosyl-2,3-aziridine Alcohols"", Org. Lett., 4(4):497-500 (2002).;;Sahm et al., ""Evaluation of Current Activities of Fluoroquinolones Against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance"", Antimicrobial Agents and Chemotherapy, 45(1):267-274, (2001).;;Sam et al., ""Benzoxazoles: Potent Skeletal Muscle Relaxants"", Journal of Pharmaceutical Sciences, 53(5):538-544 (1964).;;Scribner et al., ""Activities of Venous b-Lactams and Aminoglycosides Along and in Combination, Against Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis"", Antimicrobial Agents and Chemotherapy, 21(6):939-943 (1982).;;Shen et al., ""Synthesis of 1,3-Diynes via Palladium-catalyzed Reaction of 1,1-Dibromo-1-alkenes"", Org. Lett., 2(18):2857-2860 (2000).;;Shen et al., ""The Stille Reaction of 1,1-Dibromo-1-alkenes: Preparation of Trisubstituted Alkenes and Internal Alkynes"", J. Org. Chem., 64(24):8873-8879 (1999).;;Sigman et al., ""Free Energy and Structure Dependence of Intramolecular Triplet Energy Transfer in Organic Model Compounds"", J. Phys. Chem., 95(13):5012-5017 (1991).;;Skotnicki et al., ""Design Strategies for the Identification of MMP-13 and TACE Inhibitors"", Current Opinion in Drug Discovery & Development, 6(5):742-759 (2003).;;Stella et al., ""Biotechnology: Pharmaceutical Aspects"", Prodrugs: Challenges and Rewards, Part 1 (2007) (3 pages).;;Stobbe et al., ""Lichtreaktionen der trans- und cis-Zimtsauren"", Berichte der Deutschen Chemischen Gesellschaft, 55(8):2225-2245 (1922).;;Susse et al., ""Chinazolincarbonsauren. VII. Mitteilung. Ein enfacher Zugang zu(4-Oxo-3,4-dihydrochinazolin-3-yl)-alkansauren, (4-Oxo-3,4-dihydro-1,2,3-benzotriazin-3-yl)-alkansauren und deren estern"", Helvetica Chimica Acta, 68:892-899 (1985). (and English Abstract).;;Thiel, ""Structure-aided drug design's next generation"", Nature Biotechnology, 22(5):513-519 (2004).;;Vaara et al., ""Antibiotic-Supersusceptible Mutants of Escherichia coli and Salmonella typhimurium"", Antimicrobial Agents and Chemotherapy, 37(11):2255-2260 (1993).;;Vachal et al., ""General facile synthesis of 2,5-diarylheteropentalenes"", Tetrahedron Letters, 45:7157-7161 (2004).;;Van Den Haak et al., ""Chichibabin Amination of 1,X-Napthyridines. Nuclear magnetic Resonance Studies on the s Adducts of Heterocyclic Systems with Nucleophiles"", J. Org. Chem., 46(10):2134-2137 (1981).;;Williams et al., ""Drug Design and Relationship of Functional Groups to Pharmacological Activity"", Foye's Principles of Medicinal Chemistry, Fifth Edition, Lippincott Williams & Wilkins, 2:59-63 (2002).;;Wipf et al., ""Thiolysis of Oxazolines: A New, Selective Method for the Direct Conversion of Peptide Oxazolines into Thiazolines"", Tetrahedron Letters, 36(36):6395-6398 (1995).;;Witte et al., ""Cyclische Imidsäureester aus Nitrilen und Aminoalkoholen"", Liebigs Ann. Chem., 996-1009 (1974). (and English Abstract).;;Wyckoff et al., ""Antibacterial and Anti-inflammatory Agents That Target Endotoxin"", Trends in Microbiology, 6(4):154-159 (1998).;;Yoon et al., ""Oxygen-Promoted Palladium(II) Catalysis: Facile C(sp2)-C(sp2) Bond Formation via Cross Coupling of Alkenylboronic Compounds and Olefins"", Org. Lett., 6(22):4037-4039 (2004).;;Young et al., ""Leakage of Periplasmic Enzymes from envA1 Strains of Escherichia coli"", Journal of Bacteriology, 173(12):3609-3614 (1991).;;Youngman et al., ""The Synthesis of Novel cis-a-Substituted-b-aminotetralins"", Synthetic Communications, 33(13):2215-2227 (2003).;;Zask et al., ""Inhibition of Matrix Metalloproteinases: Structure Based Design"", Current Pharmaceutical Design, 2(6):624-661 (1996).;;Zhang et al., ""Design, Combinatorial Chemical Synthesis, and in vitro Characterization of Novel Urea Based Gelatinase Inhibitors"", Bioorganic & Medicinal Chemistry Letters, 9:2823-2826 (1999).",INACTIVE
542,US,A1,US 2017/0369426 A1,061-453-091-927-201,2017-12-28,2017,US 201715615276 A,2017-06-06,US 201715615276 A;;US 201615179751 A;;US 201414537048 A;;US 2013/0040571 W;;US 201261645439 P,2012-05-10,ANTIBACTERIAL AGENTS,Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK,ACHAOGEN INC (2015-01-14),https://lens.org/061-453-091-927-201,Patent Application,yes,0,0,7,7,0,A61P31/04;;C07C259/06;;C07C259/06;;C07C313/04;;C07C313/12;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/46;;C07C317/50;;C07C317/50;;C07C323/42;;C07C323/60;;C07C323/60;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07D213/64;;C07D213/64;;C07D213/79;;C07D213/79;;C07D213/81;;C07D213/81;;C07D333/70;;C07D333/70;;C07D471/04;;C07D471/04,C07C259/06;;C07C313/04;;C07C313/12;;C07C317/28;;C07C317/46;;C07C317/50;;C07C323/42;;C07C323/60;;C07D213/64;;C07D213/79;;C07D213/81;;C07D333/70;;C07D471/04,,0,0,,,,DISCONTINUED
543,SG,A1,SG 101955 A1,114-903-707-870-650,2004-02-27,2004,SG 200100551 A,2001-02-03,US 50272900 A,2000-02-11,DIFFUSION BARRIER LAYER AND SEMICONDUCTOR DEVICE CONTAINING SAME,,IBM,STEPHAN ALAN COHEN;;TIMOTHY JOSEPH DALTON;;JOHN ANTHONY FITZSIMMONS;;STEPHEN MCCONNELL GATES;;LYNNE M GIGNAC;;PAUL CHARLES JAMISON;;KANG-WOOK LEE;;SAMPATH PURUSHOTHAMAN;;DARRYL D RESTAINO;;EVA SIMONYI;;HORATIO SEYMOUR WILDMAN,,https://lens.org/114-903-707-870-650,Patent Application,no,3,0,13,13,0,H01L21/76826;;H01L21/76832;;H01L21/76834;;H01L23/53228;;H01L2924/0002;;H01L21/0217;;H01L21/28;;H01L21/3185;;H01L21/76834;;H01L21/76832;;H01L23/53228;;H01L21/76826;;H01L2924/0002,H01L21/28;;H01L21/31;;H01L21/316;;H01L21/318;;H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,PENDING
544,US,B1,US 6784485 B1,020-878-764-655-439,2004-08-31,2004,US 50272900 A,2000-02-11,US 50272900 A,2000-02-11,Diffusion barrier layer and semiconductor device containing same,"
    A semiconductor device containing a diffusion barrier layer is provided. The semiconductor device includes at least a semiconductor substrate containing conductive metal elements; and, a diffusion barrier layer applied to at least a portion of the substrate in contact with the conductive metal elements, the diffusion barrier layer having an upper surface and a lower surface and a central portion, and being formed from silicon, carbon, nitrogen and hydrogen with the nitrogen being non-uniformly distributed throughout the diffusion barrier layer. Thus, the nitrogen is more concentrated near the lower and upper surfaces of the diffusion barrier layer as compared to the central portion of the diffusion barrier layer. Methods for making the semiconductor devices are also provided. 
",IBM,COHEN STEPHAN ALAN;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;GATES STEPHEN MCCONNELL;;GIGNAC LYNNE M;;JAMISON PAUL CHARLES;;LEE KANG-WOOK;;PURUSHOTHAMAN SAMPATH;;RESTAINO DARRYL D;;SIMONYI EVA;;WILDMAN HORATIO SEYMOUR,ALSEPHINA INNOVATIONS INC (2018-11-26);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2000-01-27);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/020-878-764-655-439,Granted Patent,yes,12,25,13,13,0,H01L21/76826;;H01L21/76832;;H01L21/76834;;H01L23/53228;;H01L2924/0002;;H01L21/0217;;H01L21/28;;H01L21/3185;;H01L21/76834;;H01L21/76832;;H01L23/53228;;H01L21/76826;;H01L2924/0002,H01L21/28;;H01L21/31;;H01L21/316;;H01L21/318;;H01L21/768;;H01L23/522;;H01L23/532,257/325;;257/288;;257/296;;257/321;;257/374;;257/411;;257/501;;257/506;;257/508;;257/635;;257/639,0,0,,,,EXPIRED
545,IE,A1,IE 20010123 A1,028-038-681-305-256,2001-09-19,2001,IE 20010123 A,2001-02-09,US 50272900 A,2000-02-11,Diffusion barrier layer and semiconductor device containing same,"A semiconductor device containing a diffusion barrier layer is provided. The semiconductor device includes at least a semiconductor substrate containing conductive metal elements; and, a diffusion layer applied to at least a portion of the substrate in contact with the conductive metal elements, the diffusion barrier layer having an upper surface and a lower surface and a central portion, and being formed from silicon, carbon, nitrogen and hydrogen with the nitrogen being non-uniformly distributed throughout the diffusion barrier layer. Thus, the nitrogen is more concentrated near the lower and upper surfaces of the diffusion barrier layer as compared to the central portion of the diffusion barrier layer. Methods for making the semiconductor devices are also provided.",IBM,COHEN STEPHEN ALAN;;PURUSHOTHAMAN SAMPATH;;GIGNAC LYNNE M;;GATES STEPHEN MCCONNELL;;SIMONYI EVA;;WILDMAN HORATIO SEYMOUR;;RESTAINO DARRYL D;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;JAMISON PAUL CHARLES;;LEE KANG-WOOK,,https://lens.org/028-038-681-305-256,Patent Application,no,0,0,13,13,0,H01L21/76826;;H01L21/76832;;H01L21/76834;;H01L23/53228;;H01L2924/0002;;H01L21/0217;;H01L21/28;;H01L21/3185;;H01L21/76834;;H01L21/76832;;H01L23/53228;;H01L21/76826;;H01L2924/0002,H01L21/28;;H01L21/31;;H01L21/316;;H01L21/318;;H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,DISCONTINUED
546,GB,B,GB 2365216 B,112-700-137-559-461,2004-10-13,2004,GB 0102506 A,2001-02-01,US 50272900 A,2000-02-11,Diffusion barrier layer for a semiconductor device,,IBM,COHEN STEPHEN ALAN;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;GATES STEPHEN MCCONNELL;;GIGNAC LYNNE M;;JAMISON PAUL CHARLES;;LEE KANG-WOOK;;PURUSHOTHAMAN SAMPATH;;RESTAINO DARRYL D;;SIMONYI EVA;;WILDMAN HORATIO SEYMOUR,,https://lens.org/112-700-137-559-461,Granted Patent,no,3,0,13,13,0,H01L21/76826;;H01L21/76832;;H01L21/76834;;H01L23/53228;;H01L2924/0002;;H01L21/0217;;H01L21/28;;H01L21/3185;;H01L21/76834;;H01L21/76832;;H01L23/53228;;H01L21/76826;;H01L2924/0002,H01L21/28;;H01L21/31;;H01L21/316;;H01L21/318;;H01L21/768;;H01L23/522;;H01L23/532,H1K KJAB          JAB;;H1K K5BX          JAB;;H1K K5B2          JAB;;H1K K5B5          JAB;;H1K K5B9          JAB;;H1K K5C3C         JAB;;H1K K5C3G         JAB;;H1K K5C3X         JAB;;H1K K5L           JAB,1,0,,,"Conf. Rec. 1988 IEEE Int. Symp. Electrical Insulation, pages 141-144",EXPIRED
547,GB,A,GB 2365216 A,135-165-633-418-61X,2002-02-13,2002,GB 0102506 A,2001-02-01,US 50272900 A,2000-02-11,Diffusion barrier layer for a semiconductor device,"A semiconductor device contains a diffusion barrier layer 14a, 14b, 14c. The semiconductor device preferably includes a semiconductor substrate 8 and a dielectric layer 10 containing conductive metal elements 12; and the diffusion barrier layer 14 is applied to at least a portion of the substrate in contact with the conductive metal elements, the diffusion barrier layer being formed from silicon, carbon, nitrogen and hydrogen with the nitrogen being non-uniformly distributed throughout the diffusion barrier layer. Thus, the nitrogen is typically more concentrated near the lower and upper surfaces 14a, 14b of the diffusion barrier layer as compared to the central portion 14c of the diffusion barrier layer. It is found that this process leads to improved adhesion of the diffusion barrier layer, but without raising the dielectric constant too much. The diffusion barrier layer may also include oxygen. The diffusion barrier layer may be formed by atomic layer deposition or by PECVD.",IBM,COHEN STEPHEN ALAN;;DALTON TIMOTHY JOSEPH;;FITZSIMMONS JOHN ANTHONY;;GATES STEPHEN MCCONNELL;;GIGNAC LYNNE M;;JAMISON PAUL CHARLES;;LEE KANG-WOOK;;PURUSHOTHAMAN SAMPATH;;RESTAINO DARRYL D;;SIMONYI EVA;;WILDMAN HORATIO SEYMOUR,,https://lens.org/135-165-633-418-61X,Patent Application,no,3,2,13,13,0,H01L21/76826;;H01L21/76832;;H01L21/76834;;H01L23/53228;;H01L2924/0002;;H01L21/0217;;H01L21/28;;H01L21/3185;;H01L21/76834;;H01L21/76832;;H01L23/53228;;H01L21/76826;;H01L2924/0002,H01L21/28;;H01L21/31;;H01L21/316;;H01L21/318;;H01L21/768;;H01L23/522;;H01L23/532,H1K KJAB          JAB;;H1K K5BX          JAB;;H1K K5B2          JAB;;H1K K5B5          JAB;;H1K K5B9          JAB;;H1K K5C3C         JAB;;H1K K5C3G         JAB;;H1K K5C3X         JAB;;H1K K5L           JAB,1,0,,,"Conf. Rec. 1988 IEEE Int. Symp. Electrical Insulation, pages 141-144",EXPIRED
548,US,A,US 5239627 A,068-855-095-623-13X,1993-08-24,1993,US 67892991 A,1991-03-26,US 67892991 A,1991-03-26,BI-DIRECTIONAL PARALLEL PRINTER INTERFACE,A parallel interface connects a data processor and a printer so that each may transmit information to the other or receive information from the other. The transmitted information from the data processor can be data or status signals. The data or status signals are transmitted over the same eight information lines between the data processor and the printer with a predetermined signal being sent over another line from the data processor to the printer prior to transmission over the eight lines to identify whether the transmitted information is data or status signals. The printer sends status signals to the data processor over the same eight information lines after sending a predetermined signal to the data processor over a further line that it is going to transmit.,IBM;;LEXMARK INT INC,BECK JAMES L;;BOOTH JAMES R;;BUCHANAN JAMES C;;CLAFFEY-COHEN MARGARET E;;COLE CARL P;;LOUIE TIMOTHY J;;NEEL II ALAN F;;OLIVER LYNN M;;WARD JAMES P;;WEBB JAMES F,INTERNATIONAL BUSINESS MACHINES CORPORATION A CORPORATION OF NY (1991-06-18);;LEXMARK INTERNATIONAL INC (1991-06-18),https://lens.org/068-855-095-623-13X,Granted Patent,yes,3,21,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,G06F3/12;;G06F13/42;;B41J29/38,395/275,0,0,,,,EXPIRED
549,EP,A3,EP 0506594 A3,071-494-325-089-161,1993-11-24,1993,EP 92480031 A,1992-02-26,US 67892991 A,1991-03-26,BI-DIRECTIONAL PARALLEL PRINTER INTERFACE,A parallel interface connects a data processor and a printer so that each may transmit information to the other or receive information from the other. The transmitted information from the data processor can be data or status signals. The data or status signals are transmitted over the same eight information lines between the data processor and the printer with a predetermined signal being sent over another line from the data processor to the printer prior to transmission over the eight lines to identify whether the transmitted information is data or status signals. The printer sends status signals to the data processor over the same eight information lines after sending a predetermined signal to the data processor over a further line that it is going to transmit.,IBM,BECK JAMES L;;BOOTH JAMES R;;BUCHANAN JAMES C;;CLAFFEY-COHEN MARGARET E;;COLE CARL P;;LOUIE TIMOTHY J;;NEEL II ALAN F;;OLIVER LYNN M;;WARD JAMES P;;WEBB JAMES F,,https://lens.org/071-494-325-089-161,Search Report,yes,3,0,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,G06F3/12;;G06F13/42;;B41J29/38,,1,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN. vol. 25, no. 10, March 1983, NEW YORK US pages 5230 - 5235 FREEMAN ET AL. 'Microprocessor-to-microprocessor communications via an 8-bit data bus'",EXPIRED
550,US,A1,US 2022/0226817 A1,073-862-187-331-464,2022-07-21,2022,US 202217576968 A,2022-01-16,US 202217576968 A;;US 202163138310 P;;US 202163138312 P;;US 202163138314 P;;US 202163138316 P;;US 202163138318 P;;US 202163138320 P;;US 202163138321 P;;US 202163138323 P;;US 202163138337 P;;US 202163138341 P;;US 202163148527 P,2021-01-15,Liquid Biological Sample Test Cartridge,"A liquid biological sample test cartridge is disclosed. The cartridge can include a tray. The cartridge can also include a chemical reaction pad supported by the tray. The cartridge can further include a chemical reaction pad cover disposed over the chemical reaction pad and coupled to the tray. The chemical reaction pad cover can have a sample opening to facilitate depositing a liquid biological sample at a predetermined location on the chemical reaction pad. In addition, the cartridge can include an outer cover operable to at least partially form an enclosure about the chemical reaction pad.",RAYTHEON BBN TECHNOLOGIES CORP;;PURDUE RESEARCH FOUNDATION,HORVATH DYLAN;;MAN CHARLIE;;LOWE ANDREW;;DEMPSTER DAVID;;JAIN PARTH;;ADLER AARON;;BARTLEY BRYAN;;DRYER PAUL;;QUINN TIMOTHY;;BAR-COHEN AVRAM;;GAVIN MIKE;;SEVILLE JORDAN;;MCCHESNEY DARBY;;LADUCA FRANK M;;VERMA MOHIT,,https://lens.org/073-862-187-331-464,Patent Application,yes,0,0,8,61,0,B01L3/5023;;B01L2300/0681;;B01L2200/10;;B01L2300/0832;;C12Q1/6806;;C12Q1/6844;;G01N1/44;;G01K7/02;;G01K7/22;;C12Q1/6806;;C12Q1/6888;;C12Q1/701;;B01L3/5023;;B01L7/00;;B01L2200/04;;B01L2200/0689;;B01L2300/069;;B01L2300/0809;;C12Q1/6844;;G01J3/524;;G01J2003/467;;G01N21/78;;G01N33/526;;B01L2200/16;;B01L2300/0825;;C12Q1/6848;;C12Q2600/112;;C12Q1/70,B01L3/00;;B01L7/00;;C12Q1/6806,,0,0,,,,PENDING
551,DE,D1,DE 69229079 D1,157-006-178-576-498,1999-06-10,1999,DE 69229079 T,1992-02-26,US 67892991 A,1991-03-26,Bidirektionale parallele Drucker-Schnittstelle,,IBM,BECK JAMES L;;BOOTH JAMES R;;BUCHANAN JAMES C;;CLAFFEY-COHEN MARGARET E;;COLE CARL P;;LOUIE TIMOTHY J;;NEEL II ALAN F;;OLIVER LYNN M;;WARD JAMES P;;WEBB JAMES F,,https://lens.org/157-006-178-576-498,Granted Patent,no,0,0,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,G06F3/12;;G06F13/42;;B41J29/38,,0,0,,,,EXPIRED
552,EP,A2,EP 0506594 A2,150-242-968-271-39X,1992-09-30,1992,EP 92480031 A,1992-02-26,US 67892991 A,1991-03-26,Bi-directional parallel printer interface.,A parallel interface connects a data processor and a printer so that each may transmit information to the other or receive information from the other. The transmitted information from the data processor can be data or status signals. The data or status signals are transmitted over the same eight information lines between the data processor and the printer with a predetermined signal being sent over another line from the data processor to the printer prior to transmission over the eight lines to identify whether the transmitted information is data or status signals. The printer sends status signals to the data processor over the same eight information lines after sending a predetermined signal to the data processor over a further line that it is going to transmit.,IBM,BECK JAMES L;;BOOTH JAMES R;;BUCHANAN JAMES C;;CLAFFEY-COHEN MARGARET E;;COLE CARL P;;LOUIE TIMOTHY J;;NEEL II ALAN F;;OLIVER LYNN M;;WARD JAMES P;;WEBB JAMES F,,https://lens.org/150-242-968-271-39X,Patent Application,yes,0,14,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,G06F3/12;;G06F13/42;;B41J29/38,,0,0,,,,EXPIRED
553,AU,A1,AU 2004/280320 A1,190-245-349-147-191,2005-04-21,2005,AU 2004/280320 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists,,LILLY CO ELI,ZACHERL DEANNA PIATT;;KOHLMAN DANIEL TIMOTHY;;FILLA SANDRA ANN;;XU YAO-CHANG;;COHEN MICHAEL PHILIP;;ZHANG DEYI;;BENESH DANA RAE;;HUDZIAK KEVIN JOHN;;BLANCO-PILLADO MARIA-JESUS;;VICTOR FRANTZ;;YING BAI-PING,,https://lens.org/190-245-349-147-191,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
554,EP,B1,EP 0506594 B1,145-500-384-282-042,1999-05-06,1999,EP 92480031 A,1992-02-26,US 67892991 A,1991-03-26,Bi-directional parallel printer interface,,IBM,BECK JAMES L;;BOOTH JAMES R;;BUCHANAN JAMES C;;CLAFFEY-COHEN MARGARET E;;COLE CARL P;;LOUIE TIMOTHY J;;NEEL II ALAN F;;OLIVER LYNN M;;WARD JAMES P;;WEBB JAMES F,,https://lens.org/145-500-384-282-042,Granted Patent,yes,1,0,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,G06F3/12;;G06F13/42;;B41J29/38,,0,0,,,,EXPIRED
555,WO,A3,WO 2022/155552 A3,146-782-804-787-202,2022-08-25,2022,US 2022/0012642 W,2022-01-15,US 202163138337 P;;US 202163138341 P,2021-01-15,LIQUID BIOLOGICAL SAMPLE TEST CARTRIDGE AND HEATING DEVICE,"A liquid biological sample test cartridge is disclosed. The cartridge can include a tray. The cartridge can also include a chemical reaction pad supported by the tray. The cartridge can further include a chemical reaction pad cover disposed over the chemical reaction pad and coupled to the tray. The chemical reaction pad cover can have a sample opening to facilitate depositing a liquid biological sample at a predetermined location on the chemical reaction pad. In addition, the cartridge can include an outer cover operable to at least partially form an enclosure about the chemical reaction pad.",RAYTHEON BBN TECHNOLOGIES CORP;;PURDUE RESEARCH FOUNDATION,HORVATH DYLAN;;MAN CHARLIE;;LOWE ANDREW;;DEMPSTER DAVID;;JAIN PARTH;;ADLER AARON;;BARTLEY BRYAN;;DRYER PAUL;;QUINN TIMOTHY;;BAR-COHEN AVRAM;;GAVIN MIKE;;SEVILLE JORDAN;;MCCHESNEY DARBY;;LADUCA FRANK M;;VERMA MOHIT,,https://lens.org/146-782-804-787-202,Search Report,yes,3,0,3,61,0,B01L2300/043;;B01L2200/16;;B01L2200/147;;B01L3/5023;;B01L2300/1805;;B01L7/52;;B01L9/527;;B01L2300/0825,B01L3/00;;B01L7/00;;B01L9/00,,0,0,,,,PENDING
556,TW,A,TW 202235874 A,180-430-624-984-27X,2022-09-16,2022,TW 111101759 A,2022-01-14,US 202163138337 P;;US 202163138341 P,2021-01-15,Liquid biological sample test cartridge and heating device,"A liquid biological sample test cartridge is disclosed. The cartridge can include a tray. The cartridge can also include a chemical reaction pad supported by the tray. The cartridge can further include a chemical reaction pad cover disposed over the chemical reaction pad and coupled to the tray. The chemical reaction pad cover can have a sample opening to facilitate depositing a liquid biological sample at a predetermined location on the chemical reaction pad. In addition, the cartridge can include an outer cover operable to at least partially form an enclosure about the chemical reaction pad.",PURDUE RESEARCH FOUNDATION;;RAYTHEON BBN TECHNOLOGIES CORP,HORVATH DYLAN;;MAN CHARLIE;;LOWE ANDREW;;DEMPSTER DAVID;;JAIN PARTH;;ADLER AARON;;BARTLEY BRYAN;;DRYER PAUL;;QUINN TIMOTHY;;BAR-COHEN AVRAM;;GAVIN MIKE;;SEVILLE JORDAN;;MCCHESNEY DARBY;;LADUCA FRANK M;;VERMA MOHIT,,https://lens.org/180-430-624-984-27X,Patent of Addition,no,0,0,3,61,0,B01L2300/043;;B01L2200/16;;B01L2200/147;;B01L3/5023;;B01L2300/1805;;B01L7/52;;B01L9/527;;B01L2300/0825,G01N33/487;;B01L3/00;;B01L9/00,,0,0,,,,PENDING
557,CA,A1,CA 3175289 A1,081-505-563-688-446,2021-11-25,2021,CA 3175289 A,2021-05-12,US 202063027329 P;;US 202063067805 P;;IB 2021054039 W,2020-05-19,STEERABLE CATHETER,"A delivery system (e.g., 200, 300, 1100, 1200, 1300, 1500, 1700, 1800, 1900, 2000, 2100) includes a handle (e.g., 900, 1502, 1702, 2002), a catheter shaft (e.g., 211, 301, 912, 1004, 1402, 1404, 1504, 1704), and a steering mechanism (e.g., 400, 500, 600, 700, 800, 910, 1000, 1600, 1706, 1901, 2020, 2030). The catheter shaft extends from the handle to a flexible distal end portion. The steering mechanism is configured to steer the flexible distal end portion. The steering mechanism can include a steering element (e.g., 403, 505, 805, 905, 1304, 1610, 1708, 2026, 3026) a control member (e.g., 804, 907, 1008, 1506, 1508, 1604, 2008, 2010), and one or more actuation elements (e.g., 203, 303, 402, 501, 601, 701, 801, 901, 1001, 1101, 1601, 1802, 1910, 2120). Actuating the control member can move the steering element to increase and/or decrease tension in one or more actuation elements.",EDWARDS LIFESCIENCES INNOVATION ISRAEL LTD,BRAUON HAIM;;COHEN OR;;MURPHY BRIAN PATRICK;;AZANKI OMAR FAWZI;;HEFLIN ERNEST WILLIAM;;DECKER STEVEN ERIC;;DALTON TIMOTHY ALLEN;;AVIV EHUD;;HALL LINDSAY MARIE;;KAZALBASH MURRAD MIRZA;;ROCHE JULIA AKIKO;;BALDO JR,,https://lens.org/081-505-563-688-446,Patent Application,no,0,0,5,5,0,A61M25/0133;;A61M25/0136;;A61M25/0147;;A61M2025/015;;A61B2017/00243;;A61B2017/00314;;A61M25/0136;;A61M25/0138,A61M25/01,,0,0,,,,PENDING
558,WO,A1,WO 2005/035499 A1,051-233-701-207-109,2005-04-21,2005,US 2004/0025607 W,2004-09-03,US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"ABSTRACT The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c= or N=; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II (II) provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R3c)=, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI;;BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI,,https://lens.org/051-233-701-207-109,Patent Application,yes,3,3,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
559,JP,A,JP H07168678 A,104-605-182-875-687,1995-07-04,1995,JP 5939592 A,1992-02-13,US 67892991 A,1991-03-26,BIDIRECTIONAL PARALLEL PRINTER INTERFACE,"PURPOSE: To make an operator confirm the state of a printer without going to the place of the printer by making a data processor report whether information transmitted to the printer is data signals or state signals. CONSTITUTION: A computer 40 which is the data processor is connected to the printer 41 by a cable 42. When the power of the computer 40 and the printer 41 is turned ON, it is assumed that they are operated in a mode where the printer 41 is placed in a single direction. In order to activate a bidirectional mode so as to make the printer 41 able to transmit and receive the information, the computer 41 sets-INIT to low and the printer 41 sets +BUSY to high in response to it. When the printer 41 is prepared to receive a state command, +BUSY is turned low. In the case that the printer 41 does not set +BUSY, it is assumed that the computer 40 can not respond whether the printer 41 is unidiretional or bidirectional due to the fault of a hardware.",IBM,BECK JAMES L;;BOOTH JAMES R;;BUCHANAN JAMES C;;CLAFFEY-COHEN MARGARET E;;COLE CARL P;;LOUIE TIMOTHY J;;NEEL II ALAN F;;OLIVER LYNN M;;WARD JAMES P;;WEBB JAMES F,,https://lens.org/104-605-182-875-687,Patent Application,no,2,0,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,B41J29/38;;G06F3/12;;G06F13/42,,0,0,,,,EXPIRED
560,WO,A2,WO 2022/155552 A2,012-855-509-752-90X,2022-07-21,2022,US 2022/0012642 W,2022-01-15,US 202163138337 P;;US 202163138341 P,2021-01-15,LIQUID BIOLOGICAL SAMPLE TEST CARTRIDGE AND HEATING DEVICE,"A liquid biological sample test cartridge is disclosed. The cartridge can include a tray. The cartridge can also include a chemical reaction pad supported by the tray. The cartridge can further include a chemical reaction pad cover disposed over the chemical reaction pad and coupled to the tray. The chemical reaction pad cover can have a sample opening to facilitate depositing a liquid biological sample at a predetermined location on the chemical reaction pad. In addition, the cartridge can include an outer cover operable to at least partially form an enclosure about the chemical reaction pad.",RAYTHEON BBN TECHNOLOGIES CORP;;PURDUE RESEARCH FOUNDATION,HORVATH DYLAN;;MAN CHARLIE;;LOWE ANDREW;;DEMPSTER DAVID;;JAIN PARTH;;ADLER AARON;;BARTLEY BRYAN;;DRYER PAUL;;QUINN TIMOTHY;;BAR-COHEN AVRAM;;GAVIN MIKE;;SEVILLE JORDAN;;MCCHESNEY DARBY;;LADUCA FRANK M;;VERMA MOHIT,,https://lens.org/012-855-509-752-90X,Patent Application,yes,0,0,3,61,0,B01L2300/043;;B01L2200/16;;B01L2200/147;;B01L3/5023;;B01L2300/1805;;B01L7/52;;B01L9/527;;B01L2300/0825,B01L3/00;;B01L7/00;;B01L9/00,,0,0,,,,PENDING
561,WO,A1,WO 2021/234510 A1,198-062-651-421-023,2021-11-25,2021,IB 2021054039 W,2021-05-12,US 202063027329 P;;US 202063067805 P,2020-05-19,STEERABLE CATHETER,"A delivery system (e.g., 200, 300, 1100, 1200, 1300, 1500, 1700, 1800, 1900, 2000, 2100) includes a handle (e.g., 900, 1502, 1702, 2002), a catheter shaft (e.g., 211, 301, 912, 1004, 1402, 1404, 1504, 1704), and a steering mechanism (e.g., 400, 500, 600, 700, 800, 910, 1000, 1600, 1706, 1901, 2020, 2030). The catheter shaft extends from the handle to a flexible distal end portion. The steering mechanism is configured to steer the flexible distal end portion. The steering mechanism can include a steering element (e.g., 403, 505, 805, 905, 1304, 1610, 1708, 2026, 3026) a control member (e.g., 804, 907, 1008, 1506, 1508, 1604, 2008, 2010), and one or more actuation elements (e.g., 203, 303, 402, 501, 601, 701, 801, 901, 1001, 1101, 1601, 1802, 1910, 2120). Actuating the control member can move the steering element to increase and/or decrease tension in one or more actuation elements.",VALTECH CARDIO LTD,BRAUON HAIM;;COHEN OR;;MURPHY BRIAN PATRICK;;AZANKI OMAR FAWZI;;HEFLIN ERNEST WILLIAM;;DECKER STEVEN ERIC;;DALTON TIMOTHY ALLEN;;AVIV EHUD;;HALL LINDSAY MARIE;;KAZALBASH MURRAD MIRZA;;ROCHE JULIA AKIKO;;BALDO JR,,https://lens.org/198-062-651-421-023,Patent Application,yes,4,2,5,5,0,A61M25/0133;;A61M25/0136;;A61M25/0147;;A61M2025/015;;A61B2017/00243;;A61B2017/00314;;A61M25/0136;;A61M25/0138,A61M25/01,,0,0,,,,PENDING
562,US,B2,US 9691431 B2,004-962-782-386-609,2017-06-27,2017,US 201514885285 A,2015-10-16,US 201514885285 A,2015-10-16,Generating videos of media items associated with a user,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items. The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item. The method also includes generating a video that includes the target media for each of the segments by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video.",GOOGLE INC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,GOOGLE LLC (2015-10-14),https://lens.org/004-962-782-386-609,Granted Patent,yes,3,0,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,H04N9/80;;G11B27/034;;G11B27/10;;G11B27/34;;H04N5/76;;H04N5/93,,5,2,170-666-634-134-031;;038-631-887-000-183,10.1109/tcsvt.2006.877394;;10.1109/icics.2003.1292724,"“Active Sideshow—Pro”, http://www.dmxzone.com/Downloads/Tutorial—ActSlideShowPro.zip/Active—Slideshow—PRO.pdf, Dec. 31, 2005, 20 pages.;;European Patent Office, International Search Report for International Patent Application No. PCT/US2016/056313, Mar. 10, 2017, 10 pages.;;European Patent Office, Written Opinion for International Patent Application No. PCT/US2016/056313, Mar. 10, 2017, 13 pages.;;Hua, et al., “Photo2Video—A System for Automatically Converting Photographic Series Into Video”, IEEE Transactions on Circuits and Systems for Video Technology, IEEE Service Center, Piscataway, NJ, vol. 16, No. 7, Jul. 1, 2006, pp. 803-819.;;Li, et al., “Automatic Summarization for Personal Digital Photos”, Information, Communications and Signal Processing, 2003 and Fourth Pacific Rim Conference on Multimedia; Proceedings from the 2003 Joint Conference of the Fourth International Conference in Singapore; Dec. 15-18, 2003; Piscataway, NJ, US, IEEE vol. 3, Dec. 15, 2003, pp. 1536-1540.",ACTIVE
563,US,A1,US 2017/0309311 A1,107-308-429-959-128,2017-10-26,2017,US 201715633011 A,2017-06-26,US 201715633011 A;;US 201514885285 A,2015-10-16,GENERATING VIDEOS OF MEDIA ITEMS ASSOCIATED WITH A USER,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items. The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item. The method also includes generating a video that includes the target media for each of the segments by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video.",GOOGLE INC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,GOOGLE LLC (2015-10-14),https://lens.org/107-308-429-959-128,Patent Application,yes,0,1,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,G11B27/036;;G11B27/28;;G11B27/34;;H04N5/262,,0,0,,,,ACTIVE
564,GB,B,GB 2527817 B,165-115-431-121-247,2016-06-22,2016,GB 201411872 A,2014-07-02,GB 201411872 A,2014-07-02,Tidal energy converter system,,ENERGY TECH INST LLP,ANDY BALDOCK;;ROBERT RANKIN;;ANDY JONES;;IAN WILSON;;HOLLY BOWER;;TIMOTHY WILLIAM BAKER;;DANIEL MATSON;;CLAIRE LEGRAND;;ARUNA SENEVIRATNE;;JOE FISON;;DAVE RIGG;;SIMON CHAPMAN;;RICHARD CLARK;;NANCY WASSON;;RICHARD PARKINSON;;CLAIRE COHEN,,https://lens.org/165-115-431-121-247,Granted Patent,no,4,0,9,9,0,F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B13/264;;F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B17/061;;F03B17/061;;F03B17/061;;F03B17/061;;F05B2240/95;;F05B2240/95;;F05B2240/97;;F05B2240/97;;F05B2240/97;;F05B2240/97;;Y02E10/20;;Y02E10/20;;Y02E10/30,F03B13/26,,0,0,,,,INACTIVE
565,EP,A1,EP 3164594 A1,002-310-608-694-394,2017-05-10,2017,EP 15738411 A,2015-06-11,GB 201411872 A;;GB 2015051717 W,2014-07-02,SUPPORT STRUCTURE FOR TIDAL ENERGY CONVERTER SYSTEM,,ENERGY TECH INST LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,,https://lens.org/002-310-608-694-394,Patent Application,yes,0,0,9,9,0,F03B13/10;;F03B13/264;;F03B17/061;;F05B2240/97;;F03B13/10;;F03B17/061;;F05B2240/97;;F03B13/264;;F05B2240/95;;Y02E10/30;;F03B13/264;;F03B13/10;;F03B13/264;;F03B17/061;;F05B2240/97;;Y02E10/20;;F03B13/10;;F03B17/061;;F05B2240/97;;Y02E10/20;;F03B13/264;;F05B2240/95,F03B13/10;;F03B13/26;;F03B17/06,,0,0,,,,DISCONTINUED
566,CN,A,CN 106574598 A,017-486-482-098-610,2017-04-19,2017,CN 201580036065 A,2015-06-11,GB 201411872 A;;GB 2015051717 W,2014-07-02,Tidal energy converter system,"The present invention generally relates to a support structure for Tidal Energy Converters (TECs), the support structure being for completely submerged deployment. A preferred support structure includes a single stanchion (4), extending in a first direction, and a cross arm (5), extending in a second direction perpendicular or substantially perpendicular to the first direction. The cross arm (5) is statically attached to the stanchion (4), and can support a plurality of TECs (3). A support structure also includes a support frame (7), which extends further in a third direction, perpendicular or substantially perpendicular to the first and second directions, than in the second direction. The support frame (7) is operable to anchor the support structure to a seabed.",ENERGY TECH INST LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,,https://lens.org/017-486-482-098-610,Patent Application,no,9,7,9,9,0,F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B13/264;;F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B17/061;;F03B17/061;;F03B17/061;;F03B17/061;;F05B2240/95;;F05B2240/95;;F05B2240/97;;F05B2240/97;;F05B2240/97;;F05B2240/97;;Y02E10/20;;Y02E10/20;;Y02E10/30,F03B13/10;;F03B13/26;;F03B17/06,,0,0,,,,DISCONTINUED
567,US,B2,US 10242711 B2,040-595-982-661-891,2019-03-26,2019,US 201715633011 A,2017-06-26,US 201715633011 A;;US 201514885285 A,2015-10-16,Generating videos of media items associated with a user,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items. The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item. The method also includes generating a video that includes the target media for each of the segments by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video.",GOOGLE INC;;GOOGLE LLC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,GOOGLE LLC (2015-10-14),https://lens.org/040-595-982-661-891,Granted Patent,yes,5,0,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,H04N9/80;;G11B27/034;;G11B27/036;;G11B27/10;;G11B27/28;;G11B27/34;;H04N5/262;;H04N5/76;;H04N5/93,,7,2,170-666-634-134-031;;038-631-887-000-183,10.1109/tcsvt.2006.877394;;10.1109/icics.2003.1292724,"International Bureau of WIPO, International Preliminary Report on Patentability for International Patent Application No. PCT/US2016/056313, dated Apr. 17, 2018, 14 pages.;;“Active_Sideshow_Pro”, http://www.dmxzone.com/Downloads/Tutorial_ActSlideShowPro.zip/Active_Slideshow_PRO.pdf, Dec. 31, 2005, 20 pages.;;European Patent Office, International Search Report for International Patent Application No. PCT/US2016/056313, dated Mar. 10, 2017, 10 pages.;;European Patent Office, Written Opinion for International Patent Application No. PCT/US2016/056313, dated Mar. 10, 2017, 13 pages.;;Hua, et al., “Photo2Video—A System for Automatically Converting Photographic Series Into Video”, IEEE Transactions on Circuits and.Systems for Video Technology, IEEE Service Center, Piscataway, NJ, vol. 16, No. 7, Jul. 1, 2006, pp. 803-819.;;Li, et al., “Automatic Summarization for Personal Digital Photos”, Information, Communications and Signal Processing, 2003 and Fourth Pacific Rim Conference on Multimedia; Proceedings from the 2003 Joint Conference of the Fourth International Conference in Singapore; Dec. 15-18, 2003; Piscataway, NJ, US, IEEE vol. 3, Dec. 15, 2003, pp. 1536-1540.;;USPTO, Notice of Allowance for U.S. Appl. No. 14/885,285, dated Feb. 23, 2017, 9 pages.",ACTIVE
568,US,A1,US 2024/0058129 A1,053-978-118-768-40X,2024-02-22,2024,US 202318112455 A,2023-02-21,US 202318112455 A;;US 2021/0047443 W;;US 202163165294 P;;US 202063069842 P,2020-08-25,MEDICAL BALLOON SENSING ASSEMBLY AND METHOD,"A medical balloon sensing assembly constituted of: a handle; a first catheter extending distally from the handle; an inflatable medical balloon, the inflatable medical balloon secured by the first catheter; at least one sensor position member; and at least one sensor secured to the at least one sensor position member, wherein the at least one sensor position member is arranged to contact an outer face of the inflatable medical balloon.",EDWARDS LIFESCIENCES CORP,FETHERSTON SHAUN;;SIEMONS ALEXANDER H;;AXELROD BLAKE W;;SENESH GIL;;SAAR TOMER;;COHEN OREN;;SCHWARCZ ELAZAR LEVI;;LEVI TAMIR S;;BUKIN MICHAEL;;BIALAS MICHAEL R;;GEISER TIMOTHY A;;PRANATHARTHIKARAN SUDARSAN;;CERQUEIRA CARLA SUSANA,EDWARDS LIFESCIENCES CORPORATION (2021-04-06),https://lens.org/053-978-118-768-40X,Patent Application,yes,0,0,3,3,0,A61M25/10187;;A61M25/10188;;A61F2/2433;;A61F2/2496;;A61B5/6853;;A61B5/6885;;A61B2562/12;;A61B5/1076;;A61B2562/04;;A61B5/1077;;A61B8/12;;A61M25/10188;;A61B2090/064;;A61B8/0883;;A61B8/445;;A61F2/2433;;A61F2/2496;;A61F2250/0093;;A61M25/1011,A61F2/24;;A61B8/00;;A61B8/08,,0,0,,,,PENDING
569,US,A1,US 2017/0110154 A1,168-721-403-603-272,2017-04-20,2017,US 201514885285 A,2015-10-16,US 201514885285 A,2015-10-16,GENERATING VIDEOS OF MEDIA ITEMS ASSOCIATED WITH A USER,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items. The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item. The method also includes generating a video that includes the target media for each of the segments by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video.",GOOGLE INC;;GOOGLE INC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,GOOGLE LLC (2015-10-14),https://lens.org/168-721-403-603-272,Patent Application,yes,2,5,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,G11B27/034;;G11B27/10;;G11B27/34;;H04N5/76,,0,0,,,,ACTIVE
570,US,B1,US 6965012 B1,047-967-621-797-40X,2005-11-15,2005,US 93602401 A,2001-09-07,US 93602401 A;;US 18339800 P;;US 16056699 P;;US 14015699 P;;US 14007799 P;;US 12683999 P;;US 0006417 W,1999-03-30,Flint polypeptide analogs,"Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.",LILLY CO ELI,BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ-DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHNACHALAM RADHAKRISHNAN;;TSCHANG SHENG-HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,ELI LILLY AND COMPANY (2001-08-16),https://lens.org/047-967-621-797-40X,Granted Patent,yes,9,2,1,28,4,C07K14/70578;;C07K14/70578;;C07H21/04;;C07H21/04;;C07K2319/30;;C07K2319/30,C07H21/04;;C07K14/705,530/350;;536/23.5,3,3,002-950-706-878-117;;113-845-674-479-495;;113-845-674-479-495,pmc38588;;8799147;;10.1073/pnas.93.17.9021;;9872321;;10.1038/25387;;9872321;;10.1038/25387,"Vukicevic et al., 1996, PNAS USA 93:9021-9026.;;Pitti et al., Nature, vol. 396, pp. 699-703, Dec., 1998.;;Pitti et al., Nature, vol. 396, pp. 699-703, Dec., 1998.",EXPIRED
571,EP,A1,EP 2847162 A1,035-738-952-356-372,2015-03-18,2015,EP 13724478 A,2013-05-09,US 201261644659 P;;US 201361777540 P;;US 2013/0040350 W,2012-05-09,ANTIBACTERIAL AGENTS,,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK;;MOSER HEINZ E,,https://lens.org/035-738-952-356-372,Patent Application,yes,0,0,3,3,0,C07C259/06;;C07D233/64;;C07D261/08;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;C07D233/64;;C07D261/08;;C07C259/06;;C07C2601/16;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/02;;C07C235/66,C07C259/06;;A61K31/16;;C07D233/64;;C07D261/08,,0,0,,,,DISCONTINUED
572,US,B2,US 10685680 B2,069-692-228-139-791,2020-06-16,2020,US 201916359928 A,2019-03-20,US 201916359928 A;;US 201715633011 A;;US 201514885285 A,2015-10-16,Generating videos of media items associated with a user,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items. The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item. The method also includes generating a video that includes the target media for each of the segments by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video.",GOOGLE LLC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,GOOGLE LLC (2015-10-14),https://lens.org/069-692-228-139-791,Granted Patent,yes,6,0,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,H04N5/93;;G11B27/034;;G11B27/036;;G11B27/10;;G11B27/28;;G11B27/34;;H04N5/262;;H04N5/76,,9,2,170-666-634-134-031;;038-631-887-000-183,10.1109/tcsvt.2006.877394;;10.1109/icics.2003.1292724,"“Active_Sideshow_Pro”, http://www.dmxzone.com/Downloads/Tutorial_ActSlideShowPro.zip/Active_Slideshow_PRO.pdf, Dec. 31, 2005, 20 pages.;;European Patent Office, International Search Report for International Patent Application No. PCT/US2016/056313, dated Mar. 10, 2017, 10 pages.;;European Patent Office, Written Opinion for International Patent Application No. PCT/US2016/056313, dated Mar. 10, 2017, 13 pages.;;Hua, et al., “Photo2Video—A System for Automatically Converting Photographic Series Into Video”, IEEE Transactions on Circuits and Systems for Video Technology, IEEE Service Center, Piscataway, NJ, vol. 16, No. 7, Jul. 1, 2006, pp. 803-819.;;International Bureau of WIPO, International Preliminary Report on Patentability for International Patent Application No. PCT/US2016/056313, dated Apr. 17, 2018, 14 pages.;;Li, et al., “Automatic Summarization for Personal Digital Photos”, Information, Communications and Signal Processing, 2003 and Fourth Pacific Rim Conference on Multimedia; Proceedings from the 2003 Joint Conference of the Fourth International Conference in Singapore; Dec. 15-18, 2003; Piscataway, NJ, US, IEEE vol. 3, Dec. 15, 2003, pp. 1536-1540.;;USPTO, Notice of Allowance for U.S. Appl. No. 14/885,285, dated Feb. 23, 2017, 9 pages.;;USPTO, Non-final Office Action for U.S. Appl. No. 15/633,011, dated Jul. 23, 2018, 8 pages.;;USPTO, Notice of Allowance for U.S. Appl. No. 15/633,011, dated Nov. 15, 2018, 8 pages",ACTIVE
573,AU,A,AU 2000/037394 A,171-669-511-106-786,2000-10-16,2000,AU 2000/037394 A,2000-03-20,US 12683999 P;;US 14007799 P;;US 14015699 P;;US 16056699 P;;US 18339800 P;;US 0006417 W,1999-03-30,Flint polypeptide analogs,,LILLY CO ELI,BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ-DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHMACHALAM RADHAKRISHNAN;;TSCHANG SHENG-HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,,https://lens.org/171-669-511-106-786,Patent Application,no,0,0,6,28,0,A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/70578;;C07K2319/00;;C07K2319/30,C12N15/09;;A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/47;;C07K14/705;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/12;;C12P21/02,,0,0,,,,DISCONTINUED
574,WO,A1,WO 2016/001623 A1,130-972-177-825-578,2016-01-07,2016,GB 2015051717 W,2015-06-11,GB 201411872 A,2014-07-02,SUPPORT STRUCTURE FOR TIDAL ENERGY CONVERTER SYSTEM,"The present invention generally relates to a support structure for Tidal Energy Converters (TECs), the support structure being for completely submerged deployment. A preferred support structure includes a single stanchion (4), extending in a first direction, and a cross arm (5), extending in a second direction perpendicular or substantially perpendicular to the first direction. The cross arm (5) is statically attached to the stanchion (4), and can support a plurality of TECs (3). A support structure also includes a support frame (7), which extends further in a third direction, perpendicular or substantially perpendicular to the first and second directions, than in the second direction. The support frame (7) is operable to anchor the support structure to a seabed.",ENERGY TECHNOLOGIES INST LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,,https://lens.org/130-972-177-825-578,Patent Application,yes,4,0,9,9,0,F03B13/10;;F03B13/264;;F03B17/061;;F05B2240/97;;F03B13/10;;F03B17/061;;F05B2240/97;;F03B13/264;;F05B2240/95;;Y02E10/30;;F03B13/264;;F03B13/10;;F03B13/264;;F03B17/061;;F05B2240/97;;Y02E10/20;;F03B13/10;;F03B17/061;;F05B2240/97;;Y02E10/20;;F03B13/264;;F05B2240/95,F03B13/10;;F03B13/26;;F03B17/06,,0,0,,,,PENDING
575,EP,A2,EP 1165780 A2,128-435-873-824-178,2002-01-02,2002,EP 00916263 A,2000-03-20,US 0006417 W;;US 12683999 P;;US 14007799 P;;US 14015699 P;;US 16056699 P;;US 18339800 P,1999-03-30,FLINT POLYPEPTIDE ANALOGS,,LILLY CO ELI,BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ-DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHMACHALAM RADHAKRISHNAN;;TSCHANG SHENG-HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,,https://lens.org/128-435-873-824-178,Patent Application,yes,1,0,6,28,0,A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/70578;;C07K2319/00;;C07K2319/30,C12N15/09;;A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/47;;C07K14/705;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/12;;C12P21/02,,1,0,,,See also references of WO 0058465A3,DISCONTINUED
576,DE,T2,DE 69229079 T2,071-505-797-834-28X,1999-12-16,1999,DE 69229079 T,1992-02-26,US 67892991 A,1991-03-26,Bidirektionale parallele Drucker-Schnittstelle,,IBM,BECK JAMES LEE;;BOOTH JAMES RONALD;;BUCHANAN JAMES CLOYD;;CLAFFEY-COHEN MARGARET ELIZABE;;COLE CARL PRICE;;LOUIE TIMOTHY JUNG-MING;;NEEL II ALAN FOBES;;OLIVER LYNN MARVIN;;WARD JAMES PETER;;WEBB JAMES FRANCIS,,https://lens.org/071-505-797-834-28X,Granted Patent,no,0,0,8,8,0,G06F13/4226;;G06F2213/0004;;G06F3/1203;;G06F3/1229;;G06F3/1236;;G06F3/1284;;G06F13/4226;;G06F2213/0004;;G06F3/1284;;G06F3/1236;;G06F3/1229;;G06F3/1203,G06F3/12;;G06F13/42;;B41J29/38,,0,0,,,,EXPIRED
577,KR,A,KR 20170028329 A,138-034-862-383-528,2017-03-13,2017,KR 20167036928 A,2015-06-11,GB 201411872 A;;GB 2015051717 W,2014-07-02,TIDAL ENERGY CONVERTER SYSTEM,"본 발명은 일반적으로 조석 에너지 변환기(TEC:Tidal Energy Converter)들에 대한 지지 구조에 관한 것이며, 상기 지지 구조는 완전히 잠수되는 배치를 위한 것이다. 바람직한 지지 구조는 제 1 방향으로 연장되는 단일 기둥부(4), 및 제 1 방향과 수직하거나 또는 실질적으로 수직한 제 2 방향으로 연장되는 교차 암(5)을 포함한다. 교차 암(5)은 기둥부(4)에 정적으로 부착되며 그리고 복수의 TEC들(3)을 지지할 수 있다. 지지 구조는 또한 지지 프레임(7)을 포함하며, 이는 제 1 방향 및 제 2 방향과 수직하거나 또는 실질적으로 수직한 제 3 방향으로 제 2 방향의 경우 보다 더 연장된다. 지지 프레임(7)은 지지 구조를 해저에 앵커링하도록 동작가능하다.",ENERGY TECH INST LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,,https://lens.org/138-034-862-383-528,Patent Application,no,0,0,9,9,0,F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B13/264;;F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B17/061;;F03B17/061;;F03B17/061;;F03B17/061;;F05B2240/95;;F05B2240/95;;F05B2240/97;;F05B2240/97;;F05B2240/97;;F05B2240/97;;Y02E10/20;;Y02E10/20;;Y02E10/30,F03B13/10;;F03B13/26;;F03B17/06,,0,0,,,,PENDING
578,WO,A2,WO 2000/058465 A2,031-720-015-957-164,2000-10-05,2000,US 0006417 W,2000-03-20,US 12683999 P;;US 14007799 P;;US 14015699 P;;US 16056699 P;;US 18339800 P,1999-03-30,FLINT POLYPEPTIDE ANALOGS,"Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.",LILLY CO ELI;;BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHMACHALAM RADHAKRISHNAN;;TSCHANG SHENG HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ-DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHMACHALAM RADHAKRISHNAN;;TSCHANG SHENG-HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,,https://lens.org/031-720-015-957-164,Patent Application,yes,0,11,6,28,4,A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/70578;;C07K2319/00;;C07K2319/30,C12N15/09;;A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/47;;C07K14/705;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/12;;C12P21/02,,0,0,,,,PENDING
579,US,A1,US 2017/0342957 A1,081-505-852-989-763,2017-11-30,2017,US 201515318657 A,2015-06-11,GB 201411872 A;;GB 2015051717 W,2014-07-02,SUPPORT STRUCTURE FOR TIDAL ENERGY CONVERTER SYSTEM,"The present invention generally relates to a support structure for Tidal Energy Converters (TECs), the support structure being for completely submerged deployment. A preferred support structure includes a single stanchion 4 , extending in a first direction, and a cross arm 5 , extending in a second direction perpendicular or substantially perpendicular to the first direction. The cross arm 5 is statically attached to the stanchion 4 , and can support a plurality of TECs 3 . A support structure also includes a support frame 7 , which extends further in a third direction, perpendicular or substantially perpendicular to the first and second directions, than in the second direction. The support frame 7 is operable to anchor the support structure to a seabed.",ENERGY TECH INSTITUTE LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,ENERGY TECHNOLOGIES INSTITUTE LLP (2017-01-06),https://lens.org/081-505-852-989-763,Patent Application,yes,102,3,9,9,0,F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B13/264;;F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B17/061;;F03B17/061;;F03B17/061;;F03B17/061;;F05B2240/95;;F05B2240/95;;F05B2240/97;;F05B2240/97;;F05B2240/97;;F05B2240/97;;Y02E10/20;;Y02E10/20;;Y02E10/30,F03B13/26;;F03B13/10;;F03B17/06,,0,0,,,,DISCONTINUED
580,CA,A1,CA 2368760 A1,145-687-271-003-708,2000-10-05,2000,CA 2368760 A,2000-03-20,US 12683999 P;;US 14007799 P;;US 14015699 P;;US 16056699 P;;US 18339800 P;;US 0006417 W,1999-03-30,FLINT POLYPEPTIDE ANALOGS,"Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino aci d sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprisi ng FLINT and FLINT analogs.",LILLY CO ELI,WROBLEWSKI VICTOR JOHN;;NOBLITT TIMOTHY WAYNE;;WITCHER DERRICK RYAN;;TSCHANG SHENG-HUNG RAINBOW;;RATHMACHALAM RADHAKRISHNAN;;BECKER GERALD WAYNE;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;COHEN FREDRIC JAY;;GONZALEZ-DEWHITT PATRICIA ANN,,https://lens.org/145-687-271-003-708,Patent Application,no,0,0,6,28,4,A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/70578;;C07K2319/00;;C07K2319/30,C12N15/09;;A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/47;;C07K14/705;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/12;;C12P21/02,,0,0,,,,DISCONTINUED
581,GB,A,GB 2527817 A,045-510-970-241-618,2016-01-06,2016,GB 201411872 A,2014-07-02,GB 201411872 A,2014-07-02,Tidal energy converter system,"A submerged support structure for Tidal Energy Converters (TECs), comprises a single column or stanchion 4 and a cross arm 5, statically attached to the stanchion and extending substantially perpendicular to the stanchion axis. A support frame 7 extends from the stanchion in a plane substantially perpendicular to the cross arm and is attachable to the sea bed. The support frame may include struts 10 connecting between the stanchion 4 and sleeves 9 which are attachable to piles 11 in the seabed. This may produce a bi-pod arrangement, which is able to efficiently resist the main forces due to hydrodynamic loading. The cross arm and other components may be streamlined to minimise loading and turbulence.",ENERGY TECHNOLOGIES INST LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,,https://lens.org/045-510-970-241-618,Patent Application,no,4,0,9,9,0,F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B13/264;;F03B13/10;;F03B13/10;;F03B13/264;;F03B13/264;;F03B17/061;;F03B17/061;;F03B17/061;;F03B17/061;;F05B2240/95;;F05B2240/95;;F05B2240/97;;F05B2240/97;;F05B2240/97;;F05B2240/97;;Y02E10/20;;Y02E10/20;;Y02E10/30,F03B13/26,,0,0,,,,INACTIVE
582,WO,A3,WO 2000/058465 A3,112-892-072-864-48X,2001-01-25,2001,US 0006417 W,2000-03-20,US 12683999 P;;US 14007799 P;;US 14015699 P;;US 16056699 P;;US 18339800 P,1999-03-30,FLINT POLYPEPTIDE ANALOGS,"Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.",LILLY CO ELI;;BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHMACHALAM RADHAKRISHNAN;;TSCHANG SHENG HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,BECKER GERALD WAYNE;;COHEN FREDRIC JAY;;GONZALEZ-DEWHITT PATRICIA ANN;;HALE JOHN EDWARD;;MICANOVIC RADMILA;;NEWTON CHRISTY MICHELLE;;NOBLITT TIMOTHY WAYNE;;RATHMACHALAM RADHAKRISHNAN;;TSCHANG SHENG-HUNG RAINBOW;;WITCHER DERRICK RYAN;;WROBLEWSKI VICTOR JOHN,,https://lens.org/112-892-072-864-48X,Search Report,yes,4,0,6,28,0,A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/70578;;C07K2319/00;;C07K2319/30,C12N15/09;;A61K38/00;;A61P1/04;;A61P11/00;;A61P43/00;;C07K14/47;;C07K14/705;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/12;;C12P21/02,,3,2,113-845-674-479-495;;006-660-850-977-371,9872321;;10.1038/25387;;10942251;;10.1038/sj.leu.2401865,"PITTI ET AL: ""Genomic amplification of a decoy receptor for FAS ligand in lung and colon cancer"", NATURE, vol. 396, 17 December 1998 (1998-12-17), pages 699 - 703, XP002139977;;SHEIKH M S ET AL.: ""Death and decoy receptors and p53-mediated apoptosis"", LEUKEMIA, vol. 14, no. 8, August 2000 (2000-08-01), pages 1509 - 1513, XP000946082;;See also references of EP 1165780A2",PENDING
583,WO,A1,WO 2017/066131 A1,045-261-464-650-414,2017-04-20,2017,US 2016/0056313 W,2016-10-10,US 201514885285 A,2015-10-16,GENERATING VIDEOS OF MEDIA ITEMS ASSOCIATED WITH A USER,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items (402). The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item (404). The method also includes generating a video that includes the target media for each of the segments (406) by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video (408).",GOOGLE INC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,,https://lens.org/045-261-464-650-414,Patent Application,yes,1,0,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,G06F17/30;;G11B27/28,,3,2,038-631-887-000-183;;170-666-634-134-031,10.1109/icics.2003.1292724;;10.1109/tcsvt.2006.877394,"JUN LI ET AL: ""Automatic summarization for personal digital photos"", INFORMATION, COMMUNICATIONS AND SIGNAL PROCESSING, 2003 AND FOURTH PAC IFIC RIM CONFERENCE ON MULTIMEDIA. PROCEEDINGS OF THE 2003 JOINT CONFE RENCE OF THE FOURTH INTERNATIONAL CONFERENCE ON SINGAPORE 15-18 DEC. 2003, PISCATAWAY, NJ, USA,IEEE, vol. 3, 15 December 2003 (2003-12-15), pages 1536 - 1540, XP010701781, ISBN: 978-0-7803-8185-8, DOI: 10.1109/ICICS.2003.1292724;;""Active_Slideshow_PRO"", 31 December 2005 (2005-12-31), pages 1 - 20, XP007913028, Retrieved from the Internet <URL:http://www.dmxzone.com/Downloads/Tutorial_ActSlideShowPro.zip/Active_Slideshow_PRO.pdf> [retrieved on 20150314];;HUA X-S ET AL: ""Photo2Video - A System for Automatically Converting Photographic Series Into video"", IEEE TRANSACTIONS ON CIRCUITS AND SYSTEMS FOR VIDEO TECHNOLOGY, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 16, no. 7, 1 July 2006 (2006-07-01), pages 803 - 819, XP001548833, ISSN: 1051-8215, DOI: 10.1109/TCSVT.2006.877394",PENDING
584,US,A1,US 2019/0252001 A1,148-497-384-399-579,2019-08-15,2019,US 201916359928 A,2019-03-20,US 201916359928 A;;US 201715633011 A;;US 201514885285 A,2015-10-16,GENERATING VIDEOS OF MEDIA ITEMS ASSOCIATED WITH A USER,"A method includes grouping media items associated with a user into segments based on a timestamp associated with each media item and a total number of media items. The method also includes selecting target media from the media items for each of the segments based on media attributes associated with the media item. The method also includes generating a video that includes the target media for each of the segments by generating a first animation that illustrates a first transition from a first item from the target media to a second item from the target media with movement of the first item from an onscreen location to an offscreen location, wherein the first item is adjacent to the second item in the first animation and determining whether the target media includes one or more additional items. The method also includes adding a song to the video.",GOOGLE LLC,DAI SHENGYANG;;ST CLAIR TIMOTHY SEPKOSKI;;ASHIDA KOJI;;CUI JINGYU;;STEELE JAY;;GU QI;;MURPHY-CHUTORIAN ERIK;;NEULANDER IVAN;;LERDA FLAVIO;;HENRY ERIC CHARLES;;CHENG SHINKO YUANHSIEN;;KRISHNASWAMY ARAVIND;;COHEN DAVID;;BEIKZADEH PARDIS,GOOGLE LLC (2015-10-14),https://lens.org/148-497-384-399-579,Patent Application,yes,1,0,7,7,0,G11B27/28;;G11B27/10;;G11B27/034;;G11B27/105;;G11B27/34;;G11B27/034;;G11B27/105;;H04N5/7605;;G11B27/34;;G11B27/28;;G11B27/10;;G11B27/036;;H04N5/2628,G11B27/036;;G11B27/034;;G11B27/10;;G11B27/28;;G11B27/34;;H04N5/262;;H04N5/76,,0,0,,,,ACTIVE
585,AR,A1,AR 124667 A1,161-964-915-497-372,2023-04-19,2023,AR P220100092 A,2022-01-17,US 202163138337 P,2021-01-15,CARTUCHO DE PRUEBA DE MUESTRAS BIOLÓGICAS LÍQUIDAS Y DISPOSITIVO DE CALENTAMIENTO,"Se divulga un cartucho de prueba de muestras biológicas líquidas. El cartucho puede incluir una bandeja. El cartucho también puede incluir una almohadilla de reacción química soportada por la bandeja. El cartucho puede incluir además una cubierta de la almohadilla de reacción química dispuesta sobre la almohadilla de reacción química y acoplada a la bandeja. La cubierta de la almohadilla de reacción química puede tener una abertura de muestra para facilitar el depósito de una muestra biológica líquida en un lugar predeterminado de la almohadilla de reacción química. Además, el cartucho puede incluir una cubierta exterior operativa para formar, al menos parcialmente, una carcasa sobre la almohadilla de reacción química.",PURDUE RESEARCH FOUNDATION;;RAYTHEON BBN TECHNOLOGIES CORP,HORVATH DYLAN;;MAN CHARLIE;;LOWE ANDREW;;DEMPSTER DAVID;;JAIN PARTH;;ADLER AARON;;BARTLEY BRYAN;;DRYER PAUL;;QUINN TIMOTHY;;DR BAR-COHEN AVRAM;;GAVIN MIKE;;SEVILLE JORDAN;;MCHESNEY DARBY;;LDUCA FRANK M;;VERMA MOHIT,,https://lens.org/161-964-915-497-372,Patent Application,no,0,0,1,61,0,,G01N1/00;;B01L3/00;;B01L7/00;;B01L9/00,,0,0,,,,PENDING
586,US,A1,US 2015/0175530 A1,084-709-954-979-690,2015-06-25,2015,US 201414536286 A,2014-11-07,US 201414536286 A;;US 2013/0040350 W;;US 201261644659 P;;US 201361777540 P,2012-05-09,ANTIBACTERIAL AGENTS,Antibacterial compounds of formula (I) are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.,ACHAOGEN INC,PATTERSON BRIAN D;;LU QING;;AGGEN JAMES BRADLEY;;DOZZO PAOLA;;KASAR RAMESH ANNASAHEB;;LINSELL MARTIN SHERINGHAM;;KANE TIMOTHY ROBERT;;GLIEDT MICAH JAMES;;HILDEBRANDT DARIN JAMES;;MCENROE GLENN A;;COHEN FREDERICK;;MOSER HEINZ E,ACHAOGEN INC (2015-01-14),https://lens.org/084-709-954-979-690,Patent Application,yes,0,3,3,3,0,C07C259/06;;C07D233/64;;C07D261/08;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;C07D233/64;;C07D261/08;;C07C259/06;;C07C2601/16;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/02;;C07C235/66,C07C235/66;;C07D233/64;;C07D261/08,,0,0,,,,DISCONTINUED
587,CA,A1,CA 2953882 A1,174-697-360-809-907,2016-01-07,2016,CA 2953882 A,2015-06-11,GB 201411872 A;;GB 2015051717 W,2014-07-02,SUPPORT STRUCTURE FOR TIDAL ENERGY CONVERTER SYSTEM,"The present invention generally relates to a support structure for Tidal Energy Converters (TECs), the support structure being for completely submerged deployment. A preferred support structure includes a single stanchion (4), extending in a first direction, and a cross arm (5), extending in a second direction perpendicular or substantially perpendicular to the first direction. The cross arm (5) is statically attached to the stanchion (4), and can support a plurality of TECs (3). A support structure also includes a support frame (7), which extends further in a third direction, perpendicular or substantially perpendicular to the first and second directions, than in the second direction. The support frame (7) is operable to anchor the support structure to a seabed.",ENERGY TECH INST LLP,BALDOCK ANDY;;RANKIN ROBERT;;JONES ANDY;;WILSON IAN;;BOWER HOLLY;;BAKER TIMOTHY WILLIAM;;MATSON DANIEL;;LEGRAND CLAIRE;;SENEVIRATNE ARUNA;;FISON JOE;;RIGG DAVE;;CHAPMAN SIMON;;CLARK RICHARD;;WASSON NANCY;;PARKINSON RICHARD;;COHEN CLAIRE,,https://lens.org/174-697-360-809-907,Patent Application,no,0,0,9,9,0,F03B13/10;;F03B13/264;;F03B17/061;;F05B2240/97;;F03B13/10;;F03B17/061;;F05B2240/97;;F03B13/264;;F05B2240/95;;Y02E10/30;;F03B13/264;;F03B13/10;;F03B13/264;;F03B17/061;;F05B2240/97;;Y02E10/20;;F03B13/10;;F03B17/061;;F05B2240/97;;Y02E10/20;;F03B13/264;;F05B2240/95,E02D29/02;;E02B9/06;;E02B9/08;;F03B13/10;;F03B13/26;;F03B17/06,,0,0,,,,DISCONTINUED
588,US,A1,US 2023/0078736 A1,194-097-469-657-659,2023-03-16,2023,US 202217990570 A,2022-11-18,US 202217990570 A;;IB 2021054039 W;;US 202063067805 P;;US 202063027329 P,2020-05-19,STEERABLE CATHETER,"A delivery system includes a handle, a catheter shaft, and a steering mechanism. The catheter shaft extends from the handle to a flexible distal end portion. The steering mechanism is configured to steer the flexible distal end portion. The steering mechanism can include a steering element a control member, and one or more actuation elements. Actuating the control member can move the steering element to increase and/or decrease tension in one or more actuation elements.",LIFESCIENCES INNOVATION ISRAEL LTD,BRAUON HAIM;;COHEN OR;;MURPHY BRIAN PATRICK;;AZANKI OMAR FAWZI;;HEFLIN ERNEST WILLIAM;;DECKER STEVEN ERIC;;DALTON TIMOTHY ALLEN;;AVIV EHUD;;HALL LINDSAY MARIE;;KAZALBASH MURRAD MIRZA;;ROCHE JULIA AKIKO;;BALDO DANNY BARRIENTOS,,https://lens.org/194-097-469-657-659,Patent Application,yes,0,0,5,5,0,A61M25/0133;;A61M25/0136;;A61M25/0147;;A61M2025/015;;A61B2017/00243;;A61B2017/00314;;A61M25/0136;;A61M25/0138,A61M25/01,,0,0,,,,PENDING
589,CN,A,CN 115551582 A,015-002-731-894-911,2022-12-30,2022,CN 202180035039 A,2021-05-12,US 202063027329 P;;US 202063067805 P;;IB 2021054039 W,2020-05-19,Steerable catheter,"A delivery system (e.g., 200, 300, 110, 1200, 1300, 1500, 1700, 1800, 190, 200, 210) includes a handle (e.g., 900, 150, 1702, 2002), a catheter shaft (e.g., 211, 301, 912, 100, 1402, 1404, 1504, 1704), and a steering mechanism (e.g., 400, 500, 600, 700, 800, 910, 100, 1600, 1706, 190, 202, 2000). The catheter shaft extends from the handle to the flexible distal end portion. The steering mechanism is configured to steer the flexible distal portion. The steering mechanism may include a steering element (e.g., 403, 505, 805, 905, 1304, 1610, 1708, 202, 302 6), a control member (e.g., 804, 907, 1008, 1506, 1508, 1604, 2008, 201), and one or more actuation elements (e.g., 203, 303, 402, 501, 601, 701, 801, 901, 1001, 1101, 1601, 1802, 1910, 2200). The actuation control member may move the steering element to increase and/or decrease tension in the one or more actuation elements.",EDWARDS LIFESCIENCES INNOVATIONS ISRAEL LTD,BRAUN HEIKO;;COHEN OFIR;;MURPHY BRYAN PATRICK;;AZANKI OMAR FAWZI;;HEFLIN ERIK WILLIAM;;DECKER STEVEN E;;DALTON TIMOTHY ALLEN;;AVIV EYAL;;HALL LEE M;;KAZARBASH MICHAEL M;;ROCHE JEFFREY A;;BALDO DAVID B JR,,https://lens.org/015-002-731-894-911,Patent Application,no,0,0,5,5,0,A61M25/0133;;A61M25/0136;;A61M25/0147;;A61M2025/015;;A61B2017/00243;;A61B2017/00314;;A61M25/0136;;A61M25/0138,A61M25/01,,0,0,,,,PENDING
590,CR,A,CR 8275 A,006-232-716-571-484,2006-06-06,2006,CR 8275 A,2006-03-03,US 50278003 P,2003-09-12,2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3- PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1f AGONISTAS,"La presente invencion se relaciona a compuestos de la formula I: o una adicion de sal de acido farmaceuticamente aceptable de la misma, donde; X es -C(R3c)=-N=.",LILLY CO ELI,MARIA JESUS BLANCO PILLADO;;MICHAEL PHILIP COHEN;;SANDRA ANN FILLA;;KEVIN JOHN HUDZIAK;;DANIEL TIMOTHY COLMAN;;DANA RAE BENESH;;FRANTZ VICTOR;;YAO-CHANG XU;;BAI PING YING;;DEANNA PIATTZACHERL;;DEYI ZHANG;;BRIAN MICHAEL MATHES,,https://lens.org/006-232-716-571-484,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
591,EP,A1,EP 4096760 A1,103-401-429-671-037,2022-12-07,2022,EP 21728296 A,2021-05-12,US 202063027329 P;;US 202063067805 P;;IB 2021054039 W,2020-05-19,STEERABLE CATHETER,,EDWARDS LIFESCIENCES INNOVATION ISRAEL LTD,BRAUON HAIM;;COHEN OR;;MURPHY BRIAN PATRICK;;AZANKI OMAR FAWZI;;HEFLIN ERNEST WILLIAM;;DECKER STEVEN ERIC;;DALTON TIMOTHY ALLEN;;AVIV EHUD;;HALL LINDSAY MARIE;;KAZALBASH MURRAD MIRZA;;ROCHE JULIA AKIKO;;BALDO JR DANNY BARRIENTOS,,https://lens.org/103-401-429-671-037,Patent Application,yes,0,0,5,5,0,A61M25/0133;;A61M25/0136;;A61M25/0147;;A61M2025/015;;A61B2017/00243;;A61B2017/00314;;A61M25/0136;;A61M25/0138,A61M25/01,,0,0,,,,PENDING
592,DK,T3,DK 1663971 T3,007-493-507-417-298,2012-03-19,2012,DK 04780442 T,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,"Substituerede 2-carbonylamino-6-piperidinaminopyridiner og substituerede 1-carbonylamino-3-piperidinamino-,benzener som 5-HT1F agonister",,LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/007-493-507-417-298,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
593,NZ,A,NZ 545049 A,063-246-008-434-643,2009-06-26,2009,NZ 54504904 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists,"Disclosed are substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes of formula I or a pharmaceutically acceptable acid addition salt thereof, where the substituents are as disclosed herein. The use of a compound of formula I in the manufacture of a medicament for the treatment or prevention of migraine in a mammal is further disclosed.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,"ELI LILLY AND COMPANY, US (2007-02-23)",https://lens.org/063-246-008-434-643,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
594,MA,A1,MA 28212 A1,109-645-749-504-616,2006-10-02,2006,MA 28928 A,2006-04-10,US 50278003 P,2003-09-12,2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES SUBSTITUES ET 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES SUBSTITUES UTILISES EN TANT QU'AGONISTES DE 5-HT1F,"La présente invention concerne des composés de formule ou un sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, où X représente -C(R3c)= ou ~N=; R1 représente alkyle en C2-C6, alkyle en C2-C6 substitué, cycloalkyle en C3-C7, cycloalkyle en C3-C7 substitué, phényle, phényle substitué, hétérocycle ou hétérocycle substitué; R2 représente hydrogène, n-alkyle en C1-C3, (cycloalkyle en C3-C6)-(alkyle en d- C3) ou un groupe de formule II à condition que lorsque R1 représente alkyle en C2-C6 ou alkyle en C2-C6 substitué, R2 représente hydrogène ou méthyle; R3a R3b et |orSqUe x représente -C(R3c)=, R3c, représentent, indépendamment l'un de l'autre hydrogène, fluoro ou méthyle, à condition que pas plus d'un radical parmi R3a, R3b et R3c puisse être différent d'hydrogène; R4 représente hydrogène ou alkyle en C1-C3; R5 représente hydrogène, alkyle en C1-C3 ou cycloalkylcarbonyle en C3-C6, à condition que lorsque R3a est différent d'hydrogène, R5 représente hydrogène; R6 représente hydrogène ou alkyle en C-i-Ce; et n représente un entier de 1 à 6 compris. Les composés de la présente invention sont utiles pour activer les récepteurs 5- HTIF, inhiber l'extravasation de protéines neuronales et pour le traitement ou la prévention de la migraine chez un mammifère.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/109-645-749-504-616,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
595,EP,A1,EP 1663971 A1,076-286-983-218-493,2006-06-07,2006,EP 04780442 A,2004-09-03,US 2004/0025607 W;;US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,,LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/076-286-983-218-493,Patent Application,yes,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
596,US,B2,US 7291632 B2,157-279-192-414-86X,2007-11-06,2007,US 56910904 A,2004-09-03,US 56910904 A;;US 50278003 P;;US 2004/0025607 W,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists,"The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R 3c ═ or N═; R 1 is C 2 –C 6 alkyl, substituted C 2 –C 6 alkyl, C 3 –C 7 cycloalkyl, substituted C 3 –C 7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 –C 3 n-alkyl, C 3 –C 6 cycloalkyl-C 1 –C 3 alkyl, or a group of formula II (II) provided that when R 1 is C 2 –C 6 alkyl or substituted C 2 –C 6 alkyl, R 2 is hydrogen or methyl; R 3a , R 3b , and, when X is C(R 3c )═, R 3c , are each independently hydrogen, fluoro, or methyl, provided that no more than one of R 3a , R 3b , and R 3c may be other than hydrogen; R 4 is hydrogen or C 1 –C 3 alkyl; R 5 is hydrogen, C 1 –C 3 alkyl, or C 3 –C 6 cycloalkylcarbonyl, provided that when R 3a is other than hydrogen, R 5 is hydrogen; R 6 is hydrogen or C 1 –C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,ELI LILLY AND COMPANY (2005-04-11),https://lens.org/157-279-192-414-86X,Granted Patent,yes,21,8,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K31/445;;C07D211/32;;C07D211/58;;C07D211/72;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;C07D421/00,514/318;;546/211;;546/233;;546/309,1,0,,,Hcaplus 122:105695.,INACTIVE
597,CY,T1,CY 1112475 T1,022-183-565-294-812,2015-12-09,2015,CY 121100254 T,2012-03-12,EP 04780442 A;;US 50278003 P,2003-09-12,ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ 2-ΚΑΡΒΟΝΥΛΑΜΙΝΟ-6-ΠΙΠΕΡΙΔΙΝΑΜΙΝΟ ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ 1-ΚΑΡΒΟΝΥΛΑΜΙΝΟ-3-ΠΙΠΕΡΙΔΙΝΑΜΙΝΟΒΕΝΖΟΛΙΑ ΩΣ ΑΓΩΝΙΣΤΕΣ 5-ΗΤ1F,"Η παρούσα εφεύρεση αφορά ενώσεις του τύπου Ι: (Ι) ένα φαρμακευτικά αποδεκτό άλας δια προσθήκης οξέος αυτής όπου· το Χ είναι C(R<3c>= ή Ν=· το R<1> είναι C2-C6 αλκύλιο, υποκατεστημένο C2-C6 αλκύλιο, C3-C7 κυκλοαλκύλιο, υποκατεστημένο C3-C7 κυκλοαλκύλιο, φαινύλιο, υποκατεστημένο φαινύλιο, ετερόκυκλος, ή υποκατεστημένος ετερόκυκλος· το R<2> είναι υδρογόνο, C1-C3 n-αλκύλιο, C3-C6 κυκλοαλκύλιο-C1-C3 αλκύλιο, ή μία ομάδα του τύπου II (II) δεδομένου ότι όταν το R<1> είναι C2-C6 αλκύλιο ή υποκατεστημένο C2-C6 αλκύλιο, το R<2> είναι υδρογόνο ή μεθύλιο· τα R<3a>, R3b, και, όταν το Χ είναι C(R<3c>)=, R<3c>, είναι έκαστο ανεξάρτητα υδρογόνο, φθορουπόλοιπο, ή μεθύλιο, δεδομένου ότι κανένα περισσότερο από ένα από τα R<3a>, R<3b> και R<3c> είναι δυνατόν να είναι διαφορετικά από υδρογόνο· το R<4> είναι υδρογόνο ή C1-C3 αλκύλιο· το R<5> είναι υδρογόνο, C1-C3 αλκύλιο, ή C3-C6 κυκλοαλκυλοκαρβονύλιο, δεδομένου ότι όταν το R<3a> είναι διαφορετικό από υδρογόνο, το R<5> είναι υδρογόνο· το R<6> είναι υδρογόνο ή C1-C6 αλκύλιο· και το n είναι ένας ακέραιος από 1 έως 6 συμπεριλαμβανομένου. Οι ενώσεις της παρούσας εφεύρεσης είναι χρήσιμες για την ενεργοποίηση υποδοχέων 5-ΗΤ1F, αναστέλλοντας νευρονική εξίδρωση πρωτεΐνης και για την θεραπευτική αγωγή ή πρόληψη ημικρανίας σε ένα θηλαστικό.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/022-183-565-294-812,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
598,TW,B,TW I340740 B,138-900-703-086-866,2011-04-21,2011,TW 93124248 A,2004-08-12,US 50278003 P,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists,,LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/138-900-703-086-866,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
599,SI,T1,SI 1663971 T1,181-155-016-904-822,2012-05-31,2012,SI 200431842 T,2004-09-03,US 50278003 P;;US 2004/0025607 W;;EP 04780442 A,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,,LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/181-155-016-904-822,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/00;;A61K31/00;;C07D211/58;;C07D401/00;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
600,PT,E,PT 1663971 E,014-282-896-851-111,2012-03-21,2012,PT 04780442 T,2004-09-03,US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,,LILLY CO ELI,VICTOR FRANTZ;;XU YAO-CHANG;;COHEN MICHAEL PHILIP;;KOHLMAN DANIEL TIMOTHY;;YING BAI-PING;;ZHANG DEYI;;BLANCO-PILLADO MARIA-JESUS;;FILLA SANDRA ANN;;KEVIN JOHN HUDZIAK;;DANA RAE BENESH;;ZACHERL DEANNA PIATT;;MATHES BRIAN MICHAEL,,https://lens.org/014-282-896-851-111,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
601,UA,C2,UA 82711 C2,021-561-798-173-148,2008-05-12,2008,UA A200602613 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R= or N=; Ris C-Calkyl, substituted C-Calkyl, С-Сcycloalkyl, substituted C-Ccycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, С-Сn-alkyl, C-Ccycloalkyl -С-Сalkyl, or a group of formula II (II) provided that when Ris C-Calkyl or substituted C-Calkyl, Ris hydrogen or methyl; R, R, and, when X is C(R)=, R, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R, R, and Rmay be other than hydrogen; Ris hydrogen or С-Сalkyl; Ris hydrogen, С-Сalkyl, or C-Ccycloalkylcarbonyl, provided that when Ris other than hydrogen, Ris hydrogen; Ris hydrogen or С-Сalkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.I,II.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/021-561-798-173-148,Limited Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,EXPIRED
602,CN,B,CN 1849307 B,056-448-813-535-158,2011-08-03,2011,CN 200480026400 A,2004-09-03,US 2004/0025607 W;;US 50278003 P,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists,"The present invention relates to compounds of formula I or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R<3c>= or N=; R<1> is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R<2> is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II provided that when R<1> is C2-C6 alkyl or substituted C2-C6 alkyl, R<2> is hydrogen or methyl; R<3a>, R3b, and, when X is C(R<3c>)=, R<3c>, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R<3a>, R<3b>, and R<3c> may be other than hydrogen; R<4> is hydrogen or C1-C3 alkyl; R<5> is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R<3a> is other than hydrogen, R<5> is hydrogen; R<6> is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,MARIS-JESUS BLANCO-PILLADO;;ANN FILLA SANDRA;;PIATT ZACHERL DEANNA;;MICHAEL MATHES BRIAN;;RAE BENESH DANA;;JOHN HUDZIAK KEVIN;;BAI-PING YING;;TIMOTHY KOHLMAN DANIEL;;PHILIP COHEN MICHAEL;;YAO-CHANG XU;;DEYI ZHANG;;FRANTZ VICTOR,,https://lens.org/056-448-813-535-158,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
603,EA,B1,EA 011274 B1,068-896-820-284-726,2009-02-27,2009,EA 200600570 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,SUBSTITUTED 20CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I:(I) or a pharmaceutically acceptable acid addition salt thereof, where values of X, R, R, R, R, R, R, and Rare defined in the invention claims. The present invention also relates to pharmaceutical compositions based on compounds of formula I for the treatment of a disorder associated with dysfunction of the 5-HTreceptors, in particular, migraine in a mammal. Further, the present invention relates to a method for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal, especially humans, comprising administering mammal in need of such treatment or prevention an effective amount of compound of formula I or the pharmaceutically acceptable acid addition salt thereof. Another embodiment of the invention relates to the use of compound of formula I in the manufacture of a medicament for the activation of 5-hip receptors in a mammal in the manufacture of a medicament for activating 5-HTreceptors, inhibiting neuronal protein extravasation and/or for the treatment of a disorder associated with dysfunction of the 5-HTreceptors, in particular, migraine in a mammal.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESIS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PLATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/068-896-820-284-726,Granted Patent,no,3,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;A61P25/06;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
604,PE,A1,PE 20050350 A1,045-003-048-521-988,2005-05-17,2005,PE 2004000870 A,2004-09-08,US 50278003 P,2003-09-12,2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3-PIPERIDINAMINOBENCENOS SUSTITUIDOS COMO AGONISTAS DE 5-HT1F,"SE REFIERE A 2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3-PIPERIDINAMINOBENCENOS SUSTITUIDOS DE FORMULA I DONDE X ES C(R3c)= o N=; R1 ES ALQUILO C2-C6, CICLOALQUILO C3-C7, FENILO, ENTRE OTROS; R2 ES H, n-ALQUILO C1-C3, CICLOALQUILO C3-C6-ALQUILO C1-C3, ENTRE OTROS; CON LA CONDICION DE QUE CUANDO R1 ES ALQUILO C2-C6 SUSTITUIDO O NO SUSTITUIDO, R2 ES H o METILO; R3a, R3b, Y CUANDO X ES C(R3c)=, R3c SON H, F o METILO, CON LA CONDICION DE QUE NO MAS DE UNO DE R3a, R3b Y R3c PUEDE SER DIFERENTE DE H; R4 ES H o ALQUILO C1-C3; R5 ES H, ALQUILO C1-C3 o CICLOALQUILCARBONILO C3-C6. SON COMPUESTOS PREFERIDOS: DICLORHIDRATO DE 2-CLORO-4-FLUORO-N-(3-(1-METILPIPERIDIN-4-ILAMINO)FENIL)BENZAMIDA; CLORHIDRATO DE 2-CLORO-4-FLUOR-N-(3-(N-CICLOPROPILCARBONIL-N-(1-METILPIPERIDIN-4-IL)AMINO)FENIL)BENZAMIDA; CLORHIDRATO DE 2-CLORO-4-FLUOR-N-(3-(N-CICLOBUTANOCARBONIL-N-(1-METILPIPERIDIN-4-IL))AMINO)FENIL)BENZAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS ACTIVAN RECEPTORES 5-HT1F E INHIBEN LA EXTRAVASACION DE PROTEINAS NEURONALES, Y SON UTILES PARA EL TRATAMIENTO O PREVENCION DE LA MIGRANA",LILLY CO ELI,BENESH DANA RAE;;VICTOR FRANTZ;;ZACHERL DEANNA PIATT;;HUDZIAK KEVIN JOHN;;BLANCO-PILLADO MARIA-JESUS;;YING BAI-PING;;FILLA SANDRA ANN;;COHEN MICHAEL PHILIP;;ZHANG DEYI;;XU YAO-CHANG;;KOHLMAN DANIEL TIMOTHY;;MATHES BRIAN MICHAEL,,https://lens.org/045-003-048-521-988,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K31/4436;;A61K31/444;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
605,AU,B2,AU 2004/280320 B2,047-761-927-847-146,2010-02-18,2010,AU 2004/280320 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists,,LILLY CO ELI,KOHLMAN DANIEL TIMOTHY;;HUDZIAK KEVIN JOHN;;BLANCO-PILLADO MARIA-JESUS;;YING BAI-PING;;VICTOR FRANTZ;;ZACHERL DEANNA PIATT;;FILLA SANDRA ANN;;COHEN MICHAEL PHILIP;;XU YAO-CHANG;;ZHANG DEYI;;MATHES BRIAN MICHAEL;;BENESH DANA RAE,,https://lens.org/047-761-927-847-146,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/167;;A61P25/00;;A61P25/06;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
606,CA,A1,CA 2537936 A1,062-275-250-296-003,2005-04-21,2005,CA 2537936 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c= o r N=; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substitute d C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II (II) provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R3c)=, R3c , are each independently hydrogen, fluoro, or methyl, provided that no more th an one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided th at when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,ZACHERL DEANNA PIATT;;VICTOR FRANTZ;;KOHLMAN DANIEL TIMOTHY;;ZHANG DEYI;;YING BAI-PING;;FILLA SANDRA ANN;;XU YAO-CHANG;;HUDZIAK KEVIN JOHN;;BENESH DANA RAE;;BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;MATHES BRIAN MICHAEL,,https://lens.org/062-275-250-296-003,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
607,US,A1,US 2011/0034511 A1,072-580-375-192-201,2011-02-10,2011,US 89243310 A,2010-09-28,US 89243310 A;;US 81038807 A;;US 56910904 A;;US 2004/0025607 W;;US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R3 c )═ or N═; R 1 is C 2 -C 6 alkyl, substituted C 2 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 n-alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II provided that when R 1 is C 2 -C 6 alkyl or substituted C 2 -C 6 alkyl, R 2 is hydrogen or methyl; R 3a , R 3b and, when X is —C(R 3c )═, R 3c , are each independently hydrogen, fluoro, or methyl, provided that no more than one of R 3a , R 3b , and R 3c may be other than hydrogen; R 4 is hydrogen or C 1 -C 3 alkyl; R 5 is hydrogen, C 1 -C 3 alkyl, or C 3 -C 6 cycloalkylcarbonyl, provided that when R 3a is other than hydrogen, R 5 is hydrogen; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,ELI LILLY AND COMPANY (2005-04-11),https://lens.org/072-580-375-192-201,Patent Application,yes,7,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K31/4468;;A61K31/454;;A61K31/4545;;A61P25/06;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,514/318;;546/224;;546/211;;546/213;;546/194;;546/193;;514/329;;514/326,0,0,,,,DISCONTINUED
608,CA,C,CA 2537936 C,173-520-543-535-697,2013-03-12,2013,CA 2537936 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"ABSTRACT The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c= or N=; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II (II) provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R3c)=, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/173-520-543-535-697,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
609,PL,T3,PL 1663971 T3,059-367-825-140-553,2012-05-31,2012,PL 04780442 T,2004-09-03,US 50278003 P;;EP 04780442 A;;US 2004/0025607 W,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,,LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/059-367-825-140-553,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
610,EC,A,EC SP066415 A,132-612-149-013-816,2006-09-18,2006,EC SP066415 A,2006-03-07,US 50278003 P,2003-09-12,2-CARBONILAMINO-6-PIPERIDINAMINOPIRIDINAS SUSTITUIDAS Y 1-CARBONILAMINO-3-PIPERIDINAMINOBENZENOS SUSTITUIDOS COMO 5-HT1F AGONISTAS,"La presente invención se relaciona a compuestos de la fórmula I: o una adición de sal de ácido farmacéuticamente aceptable de la misma, donde; X es -C(R3c)= o -N=.R1 es C2-C6 alquilo, C2-C6 alquilo sustituido, C3-C7 cicloalquilo, C3-C7 cicloalquilo sustituido, fenil, fenil sustituido, heterociclo o heterociclo sustituido. R2 es hidrógeno, C1-C3 n-alquilo, C3-C6 cicloalquilo-C1-C3 alquilo, o un grupo de fórmula II II provisto que cuando R1 es C2-C6 alquilo o C2-C6 alquilo sustituido, R2 es hidrógeno o metilo.R3a, R3b, y, cuando X es -C(R3c)=, R3c, son cada uno independientemente hidrógeno, flúor, o metilo, provisto que no más de uno de R3a, R3b, y R3c pueda ser otro que hidrógeno; R4 es hidrógeno o C1-C3 alquilo.R5 es hidrógeno, C1-C3 alquilo, o C3-C6 cicloalquilocarbonil, provisto que cuando R3a es otro que hidrógeno, R5 es hidrógeno. R6 es hidrógeno o C1-C6 alquilo. Y. n es un íntegro de 1 a 6 inclusive. Los compuestos de la presente invención son útiles para activar receptores 5-HT1F, inhibiendo extravasión neuronal proteínica, y para el tratamiento o prevención de migraña en un mamífero.",LILLY CO ELI,BLANCO PILLADO MARIA JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/132-612-149-013-816,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,PENDING
611,NO,L,NO 20061584 L,180-808-449-451-821,2006-06-06,2006,NO 20061584 A,2006-04-07,US 50278003 P;;US 2004/0025607 W,2003-09-12,Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister,"Foreliggende oppfinnelse angår forbindelser med formel I eller et farmasøytisk akseptabelt syreaddisjonssalt derav, hvorr X er -C(R3c)= eller -N=, R1 er C2-C6 alkyl, substituert C2-C6 alkyl, C3-C7 sykloalkyl, substituert C3-C7 sykloalkyl, fenyl, substituert fenyl, heterosykel eller substituert heterosykel, R2 er hydrogen, Ci-Cj-n-alkyl, Cj-C6-sykloalkyl-Ci-C3-alkyl eller en gruppe med formel II forutsatt at når R C2-C6 alkyl eller susbtituert C2-C6 alkyl er R2 hydrogen eller metyl; R3a, R3b og, når X er -C(R3c)=, er R3c hver uavhengig hydrogen, fluor eller metyl, forutsatt at ikke mer enn en av R3a, R3b og R3c kan være forskjellig fra hydrogen, R4 er hydrogen eller C1-C3 alkyl, R5 er hydrogen, CrC3 alkyl eller C3-C6 sykloalkylkarbonyl, forutsatt at når R3a er forskjellig fra hydrogen er R5 hydrogen; R6 er hydrogen eller C|-C6 alkyl, og n er et heltall på fra 1 til 6 inklusive Forbindelsene ifølge oppfinnelsen er anvendelige for aktivering av 5-HTiF-reseptorer, inhibering av neuronal proteinekstravasasjon og for behandling eller hindring av migrene hos et pattedyr.",LILLY CO ELI,MATHES BRIAN MICHAEL;;KOHLMAN DANIEL TIMOTHY;;XU YAO-CHANG;;COHEN MICHAEL PHILIP;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;BLANCO-PILLADO MARIA-JESUS;;BENESH DANA RAE;;VICTOR FRANTZ,,https://lens.org/180-808-449-451-821,Abstract,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
612,MY,A,MY 144623 A,121-666-022-977-532,2011-10-14,2011,MY PI20043665 A,2004-09-09,US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT 1F AGONISTS,"THE PRESENT INVENTION RELATES TO COMPOUNDS OF FORMULA I :OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF, WHERE; X IS -C(R³C)= OR-N=;R¹ IS C2-C6 ALKYL, SUBSTITUTED C2-C6 ALKYL, C3-C7 CYCLOALKYL, SUBSTITUTED C3-C7 CYCLOALKYL, PHENYL, SUBSTITUTED PHENYL, HETEROCYCLE, OR SUBSTITUTED HETEROCYCLE; R² IS HYDROGEN, C1-C₃n-ALKYL, C3-C6 CYCLOALKYL-C1-C3 ALKYL, OR A GROUP OF FORMULA II PROVIDED THAT WHEN R¹ IS C2-C6 ALKYL OR SUBSTITUTED C2-C6 ALKYL, R² IS HYDROGEN OR MEHTYL; R³a, R³b, AND, WHEN X IS -C(R³C)=, R³C, ARE EACH INDEPENDENTLY HYDROGEN, FLUORO, OR METHYL, PROVIDED THAT NO MORE THAN ONE OF R³a, R³b, AND R³C MAY BE OTHER THAN HYDROGEN; R⁴IS HYDROGEN OR C1-C3 ALKYL; R5 IS HYDROGEN, C1-C3 ALKYL, OR C3-C6 CYCLOALKYLCARBONYL, PROVIDED THAT WHEN R³a IS OTHER THAN HYDROGEN, R5 IS HYDROGEN; R6 IS HYDROGEN OR C1-C6 ALKYL; AND N IS AN INTEGER FROM 1 TO 6 INCLUSIVELY. THE COMPOUNDS OF THE PRESENT INVENTION ARE USEFUL FOR ACTIVATING 5HT1F RECEPTORS, INHIBITING NEURONAL PROTEIN EXTRAVASATION, AND FOR THE TREATMENT OR PREVENTION OF MIGRAINE IN A MAMMAL.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING,,https://lens.org/121-666-022-977-532,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K31/445;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
613,EP,B1,EP 1663971 B1,160-955-704-332-331,2011-12-21,2011,EP 04780442 A,2004-09-03,US 2004/0025607 W;;US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,,LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/160-955-704-332-331,Granted Patent,yes,3,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;A61K31/4409;;A61K31/4436;;A61K31/4439;;A61K31/444;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
614,TW,A,TW 200521113 A,109-616-896-517-107,2005-07-01,2005,TW 93124248 A,2004-08-12,US 50278003 P,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists,"The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, where; X is -C(R3c)=or-N=; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II, provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is -C(R3c)=, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,BLANCO-PILLADO MARIA-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/109-616-896-517-107,Patent of Addition,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
615,BR,A,BR PI0414241 A,158-544-676-094-066,2006-11-07,2006,BR PI0414241 A,2004-09-03,US 50278003 P;;US 2004/0025607 W,2003-09-12,"composto, composição farmacêutica, métodos para ativar receptores 5-ht1f em um mamìfero, para inibir o extravasamento de proteìna neuronal em um mamìfero e para tratar ou prevenir enxaqueca em um mamìfero, e, uso de um composto","""COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA ATIVAR RECEPTORES 5-HT~ 1F~ EM UM MAMìFERO, PARA INIBIR O EXTRAVASAMENTO DE PROTEìNA NEURONAL EM UM MAMìFERO E PARA TRATAR OU PREVENIR ENXAQUECA EM UM MAMìFERO, E, USO DE UM COMPOSTO"". A presente invenção diz respeito a compostos da fórmula I: ou um sal de adição de ácido farmaceuticamente aceitável destes, onde; X é C(R¬ 3c¬= ou N=; R¬ 1¬ é alquila C~ 2~-C~ 6~, alquila C~ 2~-C~ 6~ substituído, cicloalquila C~ 3~-C~ 7~, cicloalquila C~ 3~-C~ 7~ substituído, fenila, fenila substituído, heterociclo, ou heterociclo substituído; R¬ 2¬ é hidrogênio, n-alquila C~ 1~-C~ 3~, cicloaquila C~ 3~-C~ 6~-alquila C~ 1~-C~ 3~, ou um grupo da fórmula II contanto que quando R¬ 1¬ é alquila C~ 2~-C~6~ ou alquila C~ 2~-C~ 6~ substituída, R¬ 2¬ é hidrogênio ou metila; R¬ 3a¬, R¬ 3b¬ , e, quando X é C(R¬ 3c¬)=, R¬ 3c¬, são cada um independentemente hidrogênio, flúor, ou metila, contanto que não mais do que um de R¬ 3a¬ , R¬ 3b¬ , e R¬ 3c¬ possa ser outro além de hidrogênio; R¬ 4¬ é hidrogênio ou alquila C~ 1~-C~ 3~; R¬ 5¬ é hidrogênio, alquila C~ 1~-C~ 3~, ou cicloalquilcarbonila C~ 3~-C~ 6~, contanto que quando R¬ 3a¬ for outro que não hidrogênio, R¬ 5¬ é hidrogênio; R¬ 6¬ é hidrogênio ou alquila C~ 1~-C~ 6~; e n é um número inteiro de 1 a 6 inclusive. Os compostos da presente invenção são úteis para ativar os receptores 5-HT~ 1F~, inibir extravasamento de proteína neuronal, e para o tratamento ou prevenção de enxaqueca em um mamífero.",LILLY CO ELI,BLANCO-PILLADO MARIS-JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO-CHANG;;YING BAI-PING;;ZACHERL DEANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/158-544-676-094-066,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,DISCONTINUED
616,ZA,B,ZA 200602072 B,081-755-336-085-938,2007-09-26,2007,ZA 200602072 A,2006-03-10,US 50278003 P,2003-09-12,Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists,,LILLY CO ELI,JESUS BLANCO-PILLADO MARIA;;ANN FILLA SANDRA;;TIMOTHY KOHLMAN DANIEL;;FRANTZ VICTOR;;BAI-PING YING;;DEYI ZHANG;;PHILIP COHEN MICHAEL;;JOHN HUDZIAK KEVIN;;RAE BENESH DANA;;YAO-CHANG XU;;PIATT ZACHERL DE ANNA;;MICHAEL MATHES BRIAN,,https://lens.org/081-755-336-085-938,Granted Patent,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,A61K/;;C07D/;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,ACTIVE
617,KR,A,KR 20060087554 A,105-805-869-510-599,2006-08-02,2006,KR 20067004982 A,2006-03-10,US 50278003 P,2003-09-12,SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS,"ABSTRACT The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c= or N=; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C 7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3n-alkyl, C3-C 6 cycloalkyl-C1-C3 alkyl, or a group of formula II (II) provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R 3c)=, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C 1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3ais other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.",LILLY CO ELI,BLANCO PILLADO MARIA JESUS;;COHEN MICHAEL PHILIP;;FILLA SANDRA ANN;;HUDZIAK KEVIN JOHN;;KOHLMAN DANIEL TIMOTHY;;BENESH DANA RAE;;VICTOR FRANTZ;;XU YAO CHANG;;YING BAI PING;;ZACHERL DE ANNA PIATT;;ZHANG DEYI;;MATHES BRIAN MICHAEL,,https://lens.org/105-805-869-510-599,Patent Application,no,0,0,43,43,0,A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61P1/02;;A61P1/14;;A61P15/00;;A61P15/10;;A61P25/00;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/32;;A61P25/34;;A61P3/02;;A61P3/04;;A61P43/00;;C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14;;A61K31/4468;;A61K31/4523;;C04B35/632;;C07D211/58;;C04B35/632;;C07D405/12;;C07D401/14;;C07D409/14;;C07D401/12;;A61K31/4523;;C07D401/06;;A61K31/4468;;C07D409/12,C07D211/58;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/12;;C07D409/12;;C07D409/14,,0,0,,,,INACTIVE
618,WO,A1,WO 2022/093955 A1,149-893-059-764-174,2022-05-05,2022,US 2021/0056846 W,2021-10-27,US 202063107680 P,2020-10-30,"SYSTEMS AND METHODS FOR SKU INDUCTION, DECANTING AND AUTOMATED- ELIGIBILITY ESTIMATION","An object induction system is disclosed for assigning handling parameters to an object. The system includes an analysis system, an association system, and an assignment system. The analysis system includes at least one characteristic perception system for providing perception data regarding an object to be processed. The association system includes an object information database and assigns association data to the object responsive to commonality with of any of the characteristic perception data with any of the characteristic recorded data. The assignment system is for assigning programmable motion device handling parameters to the indicia perception data based on the association data, and includes a workflow management system as well as a separate operational controller.",BERKSHIRE GREY INC,AMEND JOHN;;BARBER TIMOTHY;;COHEN BENJAMIN;;GEYER CHRISTOPHER;;GLASGOW EVAN;;GUILLOCHON JAMES;;HERCHENRODER KIRSTEN;;HINCHEY VICTORIA;;KING JENNIFER;;LONG GUOMING;;KOLETSCHKA THOMAS;;MARONEY KYLE;;MASON MATTHEW;;MCMAHAN WILLIAM;;NASEFF SAMUEL;;O'BRIEN KEVIN;;PECHYONI DIMITRY;;ROMANO JOSEPH;;SACCOCCIO MAX;;SCOLNIC JESSICA;;VELAGAPUDI PRASANNA,,https://lens.org/149-893-059-764-174,Patent Application,yes,6,0,6,6,0,G05B19/4182;;G05B19/4183;;B25J9/1697;;G05B2219/39106;;G05B2219/39107;;G05B2219/40542;;G05B2219/40554;;G05B2219/31304;;G05B2219/31305;;G05B2219/39543;;G05B2219/40543;;G05B2219/40053;;B65G1/1378;;B65G47/905;;Y02P90/02;;B25J9/12;;B25J9/1602;;B25J9/1653;;B25J9/1664,B65G47/12;;B65G1/137;;B65G47/90,,0,0,,,,PENDING
619,WO,A9,WO 2022/093955 A9,139-639-339-071-464,2022-07-14,2022,US 2021/0056846 W,2021-10-27,US 202063107680 P,2020-10-30,"SYSTEMS AND METHODS FOR SKU INDUCTION, DECANTING AND AUTOMATED- ELIGIBILITY ESTIMATION","An object induction system is disclosed for assigning handling parameters to an object. The system includes an analysis system, an association system, and an assignment system. The analysis system includes at least one characteristic perception system for providing perception data regarding an object to be processed. The association system includes an object information database and assigns association data to the object responsive to commonality with of any of the characteristic perception data with any of the characteristic recorded data. The assignment system is for assigning programmable motion device handling parameters to the indicia perception data based on the association data, and includes a workflow management system as well as a separate operational controller.",BERKSHIRE GREY INC,AMEND JOHN;;BARBER TIMOTHY;;COHEN BENJAMIN;;GEYER CHRISTOPHER;;GLASGOW EVAN;;GUILLOCHON JAMES;;HERCHENRODER KIRSTEN;;HINCHEY VICTORIA;;KING JENNIFER;;KOLETSCHKA THOMAS;;LONG GUOMING;;MARONEY KYLE;;MASON MATTHEW;;MCMAHAN WILLIAM;;NASEFF SAMUEL;;O'BRIEN KEVIN;;PECHYONI DIMITRY;;ROMANO JOSEPH;;SACCOCCIO MAX;;SCOLNIC JESSICA;;VELAGAPUDI PRASANNA,,https://lens.org/139-639-339-071-464,Search Report,yes,0,0,6,6,0,G05B19/4182;;G05B19/4183;;B25J9/1697;;G05B2219/39106;;G05B2219/39107;;G05B2219/40542;;G05B2219/40554;;G05B2219/31304;;G05B2219/31305;;G05B2219/39543;;G05B2219/40543;;G05B2219/40053;;B65G1/1378;;B65G47/905;;Y02P90/02;;B25J9/12;;B25J9/1602;;B25J9/1653;;B25J9/1664,B65G47/12;;B65G1/137;;B65G47/90,,0,0,,,,PENDING
620,US,A1,US 2022/0134543 A1,077-491-575-008-39X,2022-05-05,2022,US 202117512234 A,2021-10-27,US 202117512234 A;;US 202063107680 P,2020-10-30,"SYSTEMS AND METHODS FOR SKU INDUCTION, DECANTING AND AUTOMATED-ELIGIBILITY ESTIMATION","An object induction system is disclosed for assigning handling parameters to an object. The system includes an analysis system, an association system, and an assignment system. The analysis system includes at least one characteristic perception system for providing perception data regarding an object to be processed. The association system includes an object information database and assigns association data to the object responsive to commonality with of any of the characteristic perception data with any of the characteristic recorded data. The assignment system is for assigning programmable motion device handling parameters to the indicia perception data based on the association data, and includes a workflow management system as well as a separate operational controller.",BERKSHIRE GREY INC,AMEND JR JOHN RICHARD;;BARBER TIMOTHY;;COHEN BENJAMIN;;GEYER CHRISTOPHER;;GLASGOW EVAN;;GUILLOCHON JAMES;;WANG KIRSTEN;;HINCHEY VICTORIA;;KING JENNIFER EILEEN;;KOLETSCHKA THOMAS;;LONG GUOMING ALEX;;MARONEY KYLE;;MASON MATTHEW T;;MCMAHAN WILLIAM CHU-HYON;;NASEEF SAMUEL;;O'BRIEN KEVIN;;PECHYONI DIMITRY;;ROMANO JOSEPH;;SACCOCCIO MAX;;SCOLNIC JESSICA;;VELAGAPUDI PRASANNA,BERKSHIRE GREY INC (2021-10-28);;BERKSHIRE GREY OPERATING COMPANY INC (2021-07-21),https://lens.org/077-491-575-008-39X,Patent Application,yes,11,0,6,6,0,G05B19/4182;;G05B19/4183;;B25J9/1697;;G05B2219/39106;;G05B2219/39107;;G05B2219/40542;;G05B2219/40554;;G05B2219/31304;;G05B2219/31305;;G05B2219/39543;;G05B2219/40543;;G05B2219/40053;;B65G1/1378;;B65G47/905;;Y02P90/02;;B25J9/12;;B25J9/1602;;B25J9/1653;;B25J9/1664,B25J9/12;;B25J9/16,,0,0,,,,PENDING
621,CA,A1,CA 3199782 A1,050-937-707-626-215,2022-05-05,2022,CA 3199782 A,2021-10-27,US 202063107680 P;;US 2021/0056846 W,2020-10-30,"SYSTEMS AND METHODS FOR SKU INDUCTION, DECANTING AND AUTOMATED- ELIGIBILITY ESTIMATION","An object induction system is disclosed for assigning handling parameters to an object. The system includes an analysis system, an association system, and an assignment system. The analysis system includes at least one characteristic perception system for providing perception data regarding an object to be processed. The association system includes an object information database and assigns association data to the object responsive to commonality with of any of the characteristic perception data with any of the characteristic recorded data. The assignment system is for assigning programmable motion device handling parameters to the indicia perception data based on the association data, and includes a workflow management system as well as a separate operational controller.",BERKSHIRE GREY OPERATING COMPANY INC,AMEND JOHN RICHARD;;BARBER TIMOTHY;;COHEN BENJAMIN;;GEYER CHRISTOPHER;;GLASGOW EVAN;;GUILLOCHON JAMES;;WANG KIRSTEN;;HINCHEY VICTORIA;;KING JENNIFER EILEEN;;KOLETSCHKA THOMAS;;LONG GUOMING ALEX;;MARONEY KYLE;;MASON MATTHEW T;;MCMAHAN WILLIAM CHU-HYON;;NASEFF SAMUEL;;O'BRIEN KEVIN;;PECHYONI DIMITRY;;ROMANO JOSEPH;;SACCOCCIO MAX;;SCOLNIC JESSICA;;VELAGAPUDI PRASANNA,,https://lens.org/050-937-707-626-215,Patent Application,no,0,0,6,6,0,G05B19/4182;;G05B19/4183;;B25J9/1697;;G05B2219/39106;;G05B2219/39107;;G05B2219/40542;;G05B2219/40554;;G05B2219/31304;;G05B2219/31305;;G05B2219/39543;;G05B2219/40543;;G05B2219/40053;;B65G1/1378;;B65G47/905;;Y02P90/02;;B25J9/12;;B25J9/1602;;B25J9/1653;;B25J9/1664,B65G1/137;;B65G47/12;;B65G47/90,,0,0,,,,PENDING
622,EP,A1,EP 4237356 A1,092-292-734-511-673,2023-09-06,2023,EP 21820357 A,2021-10-27,US 202063107680 P;;US 2021/0056846 W,2020-10-30,"SYSTEMS AND METHODS FOR SKU INDUCTION, DECANTING AND AUTOMATED- ELIGIBILITY ESTIMATION",,BERKSHIRE GREY OPERATING COMPANY INC,AMEND JOHN RICHARD;;BARBER TIMOTHY;;COHEN BENJAMIN;;GEYER CHRISTOPHER;;GLASGOW EVAN;;GUILLOCHON JAMES;;WANG KIRSTEN;;HINCHEY VICTORIA;;KING JENNIFER EILEEN;;KOLETSCHKA THOMAS;;LONG GUOMING ALEX;;MARONEY KYLE;;MASON MATTHEW T;;MCMAHAN WILLIAM CHU-HYON;;NASEFF SAMUEL;;O'BRIEN KEVIN;;PECHYONI DIMITRY;;ROMANO JOSEPH;;SACCOCCIO MAX;;SCOLNIC JESSICA;;VELAGAPUDI PRASANNA,,https://lens.org/092-292-734-511-673,Patent Application,yes,0,0,6,6,0,G05B19/4182;;G05B19/4183;;B25J9/1697;;G05B2219/39106;;G05B2219/39107;;G05B2219/40542;;G05B2219/40554;;G05B2219/31304;;G05B2219/31305;;G05B2219/39543;;G05B2219/40543;;G05B2219/40053;;B65G1/1378;;B65G47/905;;Y02P90/02;;B25J9/12;;B25J9/1602;;B25J9/1653;;B25J9/1664,B65G47/12;;B65G1/137;;B65G47/90,,0,0,,,,PENDING
623,BR,A,BR 9811948 A,035-631-362-189-826,2000-08-22,2000,BR 9811948 A,1998-08-19,US 5614297 P;;US 9817229 W,1997-08-19,Secretores de hormÈnio do crescimento,"Patente de Invenção: <B>""SECRETORES DE HORMÈNIO DO CRESCIMENTO""<D>. Esta invenção refere-se a novos compostos que são úteis na modulação dos níveis de hormónio do crescimento endógeno em um mamífero. A invenção refere-se a novos intermediários para uso na síntese dos ditos compostos, bem como a novos processos empregando essas sínteses. Também estão incluídos métodos de tratamento de um mamífero que incluem a administração dos ditos compostos.",LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;JUNGHEIM LOUIS NICKLAUS;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/035-631-362-189-826,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,A61K38/00;;C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,DISCONTINUED
624,TR,T2,TR 200000930 T2,082-980-857-456-447,2000-11-21,2000,TR 200000930 T,1998-08-19,US 5614297 P,1997-08-19,Büyüme hormonu sekretagogları.,Bulus memelilerde endojen büyüme hormonu düzeylerinin degistirilmesinde kullanilan yeni bilesiklerle ilgilidir. Bulus ayrica bu bilesiklerin sentezinde kullanilan yeni ara ürünlerle ve bu sentezlerde kullanilan yeni islemlerle ilgilidir. Ayrica sözü geçen bilesikler kullanilarak memelilerin tedavisi için yöntemler açiklanmaktadir.,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;III CHARLES WILLIS LUGAR;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/082-980-857-456-447,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;A61K38/00;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,PENDING
625,CZ,A3,CZ 2000596 A3,054-836-514-207-594,2000-12-13,2000,CZ 2000596 A,1998-08-19,CZ 2000596 A,1998-08-19,"Growth hormone secretagogues, process of their preparation and pharmaceutical preparation in which they are comprised",,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILIAM GEORGE,,https://lens.org/054-836-514-207-594,Patent Application,no,0,0,1,1,0,,A61K38/05;;A61P5/06;;C07K7/06,,0,0,,,,PENDING
626,CA,A1,CA 2340344 A1,059-114-721-408-193,2000-03-02,2000,CA 2340344 A,1999-02-19,EP 98306622 A;;EP 98306621 A;;US 9817229 W;;US 9903525 W,1998-08-18,GROWTH HORMONE SECRETAGOGUES,"This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relat es to novel intermediates for use in the synthesis of said compounds, as well a s novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.</SDOAB >",LILLY CO ELI,GRITTON WILLIAM HARLAN;;LUGAR CHARLES WILLIS III;;DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;RHODES GARY ANTHONY;;ALT CHARLES ARTHUR;;JONES SCOTT ALAN;;JUNGHEIM LOUIS NICKOLAUS;;TRANKLE WILLIAM GEORGE;;THRASHER KENNETH JEFF;;ROBEY ROGER LEWIS;;RATZ ANDREW MICHAEL;;PALKOWITZ ALAN DAVID;;MUEHL BRIAN STEPHEN;;COPP JAMES DENSMORE;;BRYANT HENRY UHLMAN;;SHEPHERD TIMOTHY ALAN;;COHEN JEFFREY DANIEL,,https://lens.org/059-114-721-408-193,Patent Application,no,0,0,1,8,0,,A61K31/415,,0,0,,,,DISCONTINUED
627,NZ,A,NZ 502947 A,104-901-251-082-514,2001-11-30,2001,NZ 50294798 A,1998-08-19,US 5614297 P;;US 9817229 W,1997-08-19,Compounds for modulating endogenous growth hormone,"Compounds of formula I wherein: A is C1-C6alkyl, aryl, C1-C6alkylaryl, C1-C6alkyl(O)C1-C6alkylaryl, C1-C6alkyl(S)C1-C6alkylaryl, indolyl, indolinyl, thienyl, (C1-C6alkyl)thienyl, benzothienyl, benzofuranyl, naphthanyl, cyclohexyl, (C1-C6alkyl)indolyl, (C1-C6alkyl)benzothienyl, (C1-C6alkyl)naphthanyl, (C1-C6alkyl)benzofuranyl, and (C1-C6alkyl)cyclohexyl; B is NH2, NHR1, C1-C6alkylNH2, C1-C6alkylNHR1, C1-C6alkylarylNH2, C1-C6alkylarylNHR1, C1-C6alkylcyclohexylNH2, C1-C6alkylcyclohexyl- NHR1, R1-piperidin-3-yl(C1-C6alkyl), R1-piperidin-2-yl(C1-C6alkyl), R1-piperidin-4-yl(C1-C6alkyl), R1-quinolin-2-yl(C1-C6alkyl), R1-(2,4-dihydroquinolin-2-yl(C1-C6alkyl), R1-isoquinolin-2-yl(C1-C6alkyl), and R1-(2,4-dihydroisoquinolin-2-yl(C1-C6alkyl); R1 is hydrogen, C1-C6alkyl, C1-C6alkyl(OH), or C1-C6 alkylidenyl(OH)R2; R2 is C1-C6alkyl, C1-C6alkenyl, C1-C6alkyl(O)C1-C6 alkyl, C(O)O-C1-C6 alkyl, aryl, or C1-C6alkylaryl; X is C1-C6alkylidenyl, O, S, NH, or N(C1-C6alkyl); V is selected from the group of formula listed; W is S, O, NH, or CH2; Y, Z, Y' and Z' are N or CH; E is hydrogen, C1-C6alkyl, C(O)C1-C6alkyl, aryl, (aryl)C(O)NR6, (aryl)(C1-C6alkylC(O)R6, C1-C6alkylaryl, C(O)aryl, C1-C6 alkylC(O)aryl, naphthyl, C1-C6alkylnaphthyl, C(O)naphthyl, C1-C6alkylC(O)naphthyl, heteroaryl, C1-C6alkylheteroaryl, C(O)heteroaryl, and C1-C6 alkylC(O)heteroaryl, indanyl, C1-C6alkylindanyl, C(O)indanyl, C1-C6alkylC(O)indanyl, cycloalkyl; G is hydrogen, C1-C6alkyl, aryl, C1-C6 alkylaryl, and C1-C6alkenyl; J is hydrogen, C1-C6alkyl, aryl, and C1-C6 alkylaryl; L is hydrogen, C1-C6alkyl, C(O)OC1-C6alkyl, aryl, C1-C6 alkylaryl, C(O)OC1-C6alkylaryl, C1-C6alkenyl, -F, and -CN, C1-C6alkyl-OH, C1-C6alkyl-O-C1-C6alkyl, C1-C6alkyl-C(O)R6; R4, R5, R6, R7 and D are defined in the specification; or a pharmaceutically acceptable salt or solvate thereof. The compounds are act to increase the level of endogenous growth hormone in a human or animal and are useful in treating or preventing a physiological condition which may be modulated by an increase in endogenous growth hormone.",LILLY CO ELI,TRANKLE WILLIAM GEORGE;;THRASHER KENNETH JEFF;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;LUGAR CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SHEPHERD TIMOTHY ALAN;;ALT CHARLES ARTHUR;;DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN,,https://lens.org/104-901-251-082-514,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;A61K38/00;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,PENDING
628,CA,A1,CA 2302467 A1,131-698-960-296-775,1999-02-25,1999,CA 2302467 A,1998-08-19,US 5614297 P;;US 9817229 W,1997-08-19,GROWTH HORMONE SECRETAGOGUES,"This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.",LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;COHEN JEFFREY DANIEL;;ROBEY ROGER LEWIS;;RHODES GARY ANTHONY;;GRITTON WILLIAM HARLAN;;TRANKLE WILLIAM GEORGE;;COPP JAMES DENSMORE;;RATZ ANDREW MICHAEL;;MUEHL BRIAN STEPHEN;;LUGAR CHARLES WILLIS III;;HEIMAN MARK LOUIS;;JUNGHEIM LOUIS NICKOLAUS;;PALKOWITZ ALAN DAVID;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN,,https://lens.org/131-698-960-296-775,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,A61K38/00;;C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,DISCONTINUED
629,EP,A4,EP 1112071 A4,041-923-748-230-600,2003-03-19,2003,EP 99907136 A,1999-02-19,EP 98306622 A;;EP 98306621 A;;US 9903525 W;;US 9817229 W,1998-08-18,GROWTH HORMONE SECRETAGOGUES,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALANDAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/041-923-748-230-600,Search Report,no,7,0,4,8,0,A61K45/06;;C07D207/416;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,A61K45/06;;C07D207/16;;C07D207/40;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,,1,0,,,See also references of WO 0010565A1,DISCONTINUED
630,EA,B1,EA 002746 B1,150-350-602-277-12X,2002-08-29,2002,EA 200000239 A,1998-08-19,US 5614297 P;;US 9817229 W,1997-08-19,GROWTH HORMONE SECRETAGOGUES,"1. A compound of formula I wherein: A is C1-C6alkyl, aryl, C1-C6alkylaryl, C1-C6alkyl (O)C1-C6alkylaryl, C1-C6alkyl (S)C1-C6alkylaryl, indolyl, indolinyl, thienyl, (C1-C6alkyl)thienyl, benzothienyl, benzofuranyl, naphthanyl, cyclohexyl, (C1-C6alkyl)indolyl, (C1-C6alkyl)benzothienyl, (C1-C6alkyl)naphthanyl, (C1-C6alkyl)benzofuranyl, and (C1-C6alkyl)cyclohexyl; B is NH2, NHR1, C1-C6alkyl NH2, C1-C6alkyl NHR1, C1-C6alkylaryl NH2, C1-C6alkylaryl NHR1, C1-C6a1kylcyclohexyl NH2, C1-C6alkylcyclohexyl NHR1, R1-piperidin-3-yl(C1-C6alkyl), R1-piperidin-2-yl(C1-C6alkyl), R1-piperidin-4-yl(C1-C6alkyl), R1-quinolin-2-yl(C1-C6alkyl), R1-(2,4-dihydroquinolin-2-yl(C1-C6alkyl), R1-isoquinolin-2-yl(C1-C6alkyl), and R1-(2,4-dihydroisoquinolin-2-yl(C1-C6alkyl); R1 is hydrogen, C1-C6alkyl, C1-C6alkyl(OH), or C1-C6alkylidenyl(OH)R2; R2 is C1-C6alkyl, C1-C6alkenyl, C1-C6alkyl(O)C1-C6 alkyl, C(O)O-C1-C6 alkyl, aryl, or C1-C6alkylaryl; X is C1-C6alkylidenyl, O, S, NH, or N(C1-C6alkyl); V is selected from the group consisting of W is S, O, NH, or CH2; Y is N or CH; Z is N or CH; Y' is N or CH; Z' is N or CH; R4 and R5 are independently hydrogen, C1-C6alkyl, aryl, C1-C6alkylaryl, C(O)O(C1-C6alkyl), C(O)N(C1-C6alkyl)2, or C1-C6alkylCOR7; R7 is hydrogen, C1-C6alkyl, pyrrolidinyl, piperidinyl, homoproline, or proline; D is hydrogen, C1-C6alkyl, C1-C6alkyl(O)(CO)C1-C6alkyl, C1-C6alkyl(O)(CO)N(C1-C6alkyl)2, C1-C6alkylaryl, C(O)R6, C1-C6alkyl(O)R6, C1-C6alkyl(OH), C1-C6 alkylC(O)R6, C1-C6alkylR6, aryl, (C1-C6alkyl)NHSO2(C1-C6alkyl), (C1-C6alkyl)NHSO2(aryl); R6 is H, C1-C6alkyl, aryl, naphthyl, C1-C6alkylaryl, acetyl, NH2, NH (C1-C6alkyl), NH(C1-C6alkyl)O(C1-C6alkyl), NH(C1-C6alkyl)S(C1-C6alkyl), NH(C1-C6alkylidenyl)OCH3, NH(C1-C6alkyl)aryl, NH(C3-C6cycloalkyl), NH(C1-C6alkyl)C(O)(C1-C6alkyl), NH(C1-C6alkyl)NH(C1-C6alkyl), NH(C1-C6alkyl)NH(C1-C6alkylaryl), NHSO2(C1-C6alkylaryl), NH(C1-C6alkyl)C(O)O(C1-C6alkyl), NH(naphthyl), N(C1-C6alkyl)2, N(C1-C6alkyl)(aryl), N(C1-C6alkyl)(C1-C6alkylaryl), O(C1-C6alkyl), O(aryl), O(C1-C6alkylaryl), piperidinyl, piperidinyl-C(O)NH(C1-C6alkyl), piperidinyl-C(O)NH(C1-C6alkylaryl), piperidinyl-C(O)N(C1-C6alkyl)2, piperidinyl-C(O)N(C1-C6alkyl)(aryl), pyrrolidinyl, pyrrolidinyl C(O)NH(aryl), pyrrolidinyl C(O)NH(C1-C6alkyl), pyrrolidinyl C(O)N(C1-C6alkyl)2, pyrrolidinyl C(O)NH(C1-C6alkylaryl), pyrrolidinyl C(O)NH(C1-C6alkyl)(aryl), pyrrolinyl, morpholino, hexamethyleneimino, heptamethyleneimino, quinolinyl, 2,4-dihydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, 2,4-dihydroisoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, indolinyl, an amino acid selected from the group consisting of proline, homoproline, glycine, alanine, valine, leucine, isoleucine, tyrosine, tryptophan, phenylalanine, serine, threonine, asparagine, glutamic acid, aspartic acid, lysine, arginine, glutamine, histidine, cysteine, and methionine, or a nitrogen-containing heterocycle selected from the group consisting of E is hydrogen, C1-C6alkyl, C(O)C1-C6alkyl, aryl, (aryl)C(O)NR6, (aryl) (C1-C6alkyl)C(O)R6, C1-C6alkylaryl, C(O) aryl, C1-C6 alkylC(O)aryl, naphthyl, C1-C6alkylnaphthyl, C(O)naphthyl, C1-C6alkylC(O)naphthyl, heteroaryl, C1-C6alkylheteroaryl, C(O)heteroaryl, C1-C6alkylC(O)heteroaryl, indanyl, C1-C6alkylindanyl, C(O)indanyl, C1-C6alkylC(O)indanyl, cycloalkyl; or D and E combine to form indanyl, fluorenyl, or cycloalkyl; G is hydrogen, C1-C6alkyl, aryl, C1-C6alkylaryl, and C1-C6alkenyl; J is hydrogen, C1-C6alkyl, aryl, and C1-C6alkylaryl; L is hydrogen, C1-C6alkyl, C(O)OC1-C6alkyl, aryl, C1-C6alkylaryl, C(O)OC1-C6alkylaryl, C1-C6alkenyl, -F, and -CN, C1-C6alkyl-OH, C1-C6alkyl-O-C1-C6alkyl, C1-C6alkyl-C(O)R6; or a pharmaceutically acceptable salt or solvate thereof. 2. A compound according to Claim 1 wherein A is selected from the group consisting of 3. A compound according to Claim 1 wherein B is 4. A compound according to Claim 1 wherein X is NH. 5. A compound according to Claim 1 wherein V is selected from the group consisting of 6. A compound according to Claim 1 wherein D is -C(O)R6, and R6 is 1-pyrrolidinyl, 1-piperidinyl, 4-methyl-1-piperidinyl, 7. A compound according to Claim 1 wherein E is 8. A compound according to Claim 1 wherein G is H. 9. A compound according to Claim 1 wherein J is H. 10. A compound according to Claim 1 wherein L is H or CH3. 11. A compound of formula IA: or a pharmaceutically acceptable salt or solvate thereof. 12. A compound of formula IB: or a pharmaceutically acceptable salt or solvate thereof. 13. A compound of formula Ia': wherein E is selected from the group consisting of hydrogen, C1-C6alkyl, C(O)C1-C6alkyl, aryl, (aryl)C(O)NR6, (aryl) (C1-C6alkyl)C(O)R6, C1-C6alkylaxyl, C(O)aryl, C1-C6 alkylC(O)aryl, naphthyl, C1-C6alkylnaphthyl, C(O)naphthyl, C1-C6alkylC(O)naphthyl, heteroaryl, C1-C6alkylheteroaryl, C(O)heteroaryl, C1-C6 alkylC(O)heteroaryl, indanyl, C1-C6alkylindanyl, C(O)indanyl, C1-C6alkylC(O)indanyl, cycloalkyl; or a pharmaceutically acceptable salt or solvate thereof. 14. A compound of formula ZZ: wherein E is selected from the group consisting of hydrogen, C1-C6alkyl, C(O)C1-C6alkyl, aryl, C1-C6alkylaryl, C(O)aryl, C1-C6 alkylC(O)aryl, naphthyl, C1-C6alkylnaphthyl, C(O)naphthyl, C1-C6alkylC(O)naphthyl, heteroaryl, C1-C6alkylheteroaryl, C(O)heteroaryl, C1-C6alkylC(O)heteroaryl, indanyl, C1-C6alkylindanyl, C(O)indanyl, C1-C6alkylC(O)indanyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. 15. A compound of formula ZZZ: wherein E is selected from the group consisting of hydrogen, C1-C6alkyl, C(O)C1-C6alkyl, aryl, C1-C6alkylaryl, C(O)aryl, C1-C6alkylC(O)aryl, naphthyl, C1-C6alkylnaphthyl, C(O)naphthyl, C1-C6alkylC(O)naphthyl, heteroaryl, C1-C6alkylheteroaryl, C(O)heteroaryl, C1-C6 alkylC(O)heteroazyl, indanyl, C1-C6alkylindanyl, C(O)indanyl, C1-C6alkylC(O)indanyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. 16. A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or animal an effective amount of a compound of formula Id: or a pharmaceutically acceptable salt or solvate thereof. 17. A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients. 18. A compound according to Claim 1 wherein A is selected from the group consisting of B is J is H; G is H; X is NH; V is E is D is -C(O)R6, and R6 is 1-pyrrolidinyl, 1-piperidinyl, 4-methyl-1-piperidinyl, L is H or CH3; or a pharmaceutically acceptable salt or solvate thereof. 19. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 20. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 21. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 22. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 23. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 24. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 25. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 26. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 27. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 28. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 29. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 30. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 31. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof. 32. A compound according to claim 1, which is a compound of formula or a pharmaceutically acceptable salt or solvate thereof.",LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN GEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICCKOLAUS;;LUGAR CHARES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/150-350-602-277-12X,Granted Patent,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062;;A61K38/00,,0,0,,,,EXPIRED
631,ZA,B,ZA 987385 B,147-469-387-018-060,2000-04-18,2000,ZA 987385 A,1998-08-17,US 5614297 P,1997-08-19,Growth hormone secretagogues.,,LILLY CO ELI,LODGE JEFFREY ALAN;;JONES SCOTT ALAN;;BRYANT HENRY UHLMAN;;JUNGHEIM LOUIS NICKOLAUS;;MUEHL BRIAN STEPHEN;;RHODES GARY ANTHONY;;SHEPHERD TIMOTHY ALAN;;HAUSER KENNETH LEE;;ALT CHARLES ARTHUR;;COHEN JEFFREY DANIEL;;GRITTON WILLIAM HARLAN;;PALKOWITZ ALAN DAVID;;ROBEY ROGER LEWIS;;THRASHER KENNETH JEFF;;HEIMAN MARK LOUIS;;COPP JAMES DENSMORE;;LUGAR CHARLES WILLIS III;;RATZ ANDREW MICHAEL;;TRANKLE WILLIAM GEORGE,,https://lens.org/147-469-387-018-060,Granted Patent,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;C07K5/06;;A61K38/00;;C07K5/062,,0,0,,,,EXPIRED
632,AU,B2,AU 738204 B2,067-837-111-057-815,2001-09-13,2001,AU 1998/090256 A,1998-08-19,US 5614297 P;;US 9817229 W,1997-08-19,Growth hormone secretagogues,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/067-837-111-057-815,Granted Patent,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,A61K38/00;;C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,EXPIRED
633,HR,A2,HR P20000090 A2,028-673-432-438-122,2001-04-30,2001,HR P20000090 A,2000-02-17,US 5614297 P;;US 9817229 W,1997-08-19,GROWTH HORMONE SECRETAGOGUES,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETHLEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/028-673-432-438-122,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;A61K38/00;;C07K5/06;;C07K5/062,,0,0,,,,DISCONTINUED
634,EP,A1,EP 1112071 A1,045-721-891-457-015,2001-07-04,2001,EP 99907136 A,1999-02-19,EP 98306622 A;;EP 98306621 A;;US 9903525 W;;US 9817229 W,1998-08-18,GROWTH HORMONE SECRETAGOGUES,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALANDAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/045-721-891-457-015,Patent Application,yes,0,0,4,8,0,A61K45/06;;C07D207/416;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,A61K45/06;;C07D207/16;;C07D207/40;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,,0,0,,,,DISCONTINUED
635,HU,A2,HU P0002392 A2,019-387-332-074-33X,2000-10-28,2000,HU P0002392 A,1998-08-19,US 5614297 P;;US 9817229 W,1997-08-19,"DIAZOLE AND OXAZOLE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES, PROCESS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","A találmány tárgyát az (I) általános képletű vegyületek, e vegyületekgyógyászatilag megfelelő sói vagy szolvátjai, valamint ezekettartalmazó gyógyászati készítmények képezik. A találmány tárgyáhoztartozik ezen kívül az (I) általános képletű vegyületek előállításáraszolgáló eljárás is. A találmány szerinti vegyületek kedvezőenbefolyásolják a növekedési hormonszintet. Az (I) általános képletben aszubsztituensek jelentése igen sokféle, többek között A jelentése alkil-, aril-, alkil-aril-, alkil-(O)-alkil-aril-, alkil-(S)-alkil-aril-, indolil-, indolinil-, tienil-, alkil-tienil-,benzotienil-, benzofuranil-, naftil-, ciklohexil-, alkil-indolil-,alkil-benzotienil-, alkil-naftil-, alkil-benzofuranil- vagy alkil-ciklohexil-csoport; B jelentése -NH2, -NHR1, alkil-NH2, alkil-NHR1, alkil-aril-NH2, alkil-aril-NHR1, alkil-ciklohexil-NH2, alkil-ciklohexil-NH-R1, R1-piperidin-3-il-alkil-, R1-piperidin-2-il-alkil-, R1-piperidin-4-il-alkil-, R1-kinolin-2-il-alkil-, R1-(2,4-dihidrokinolin-2-il-alkil-, R1-izokinolin-2-il-alkil- vagy R1-(2,4-dihidroizokinolin-2-il)-alkil-csoport; X jelentése alkilidenil-, O, S, NH- vagy N-alkil-csoport; V jelentése heterociklusos csoport, D jelentése hidrogénatom, alkil-, alkil-(O)(CO)-alkil-, alkil-(O)(CO)N-(alkil)2-, alkil-aril-, C(O)R6, alkil-(O)-R6, alkil-(OH)-,alkil-C(O)-R6, alkil-R6, aril-, alkil-NHSO2-alkil-, alkil)-NHSO2-arilcsoport; E jelentése hidrogénatom, alkil-, C(O)-alkil-, aril-, (aril)-C(O)NR6,aril-alkil-C(O)R6, alkil-aril-, C(O)-aril-, alkil-C(O)-aril-, naftil-,alkil-naftil, C(O)-naftil-, alkil-C(O)-naftil-, heteroaril-, alkil-heteroaril-, C(O)-heteroaril-, alkil-C(O)-heteroaril-, indanil-,alkil-indanil-, C(O)-indanil-, -C(O)-indanil- vagy cikloalkilcsoort; G jelentése hidrogénatom, alkil-, aril-, alkil-aril- vagyalkenilcsoport; J jelentése hidrogénatom, alkil-, aril- vagy alkil-aril-csoport; L jelentése hidrogénatom, alkil-, C(O)O-alkil-, aril-, alkil-aril-,C(O)O-alkil-aril-, alkenil-, -F vagy -CN, alkil-OH, alkil-O-alkil-,alkil-C(O)R6 képletű csoport. Ó",Eli Lilly and Co.,"Alt, Charles Arthur;;Bryant, Henry Uhlman;;Cohen, Jeffrey Daniel;;Copp, James Densmore;;Dodge, Jeffrey Alan;;Fahey, Kennan Joseph;;Gritton, William Harlan;;Hauser, Kenneth Lee;;Heiman, Mark Louis;;Jones, Scott Alan;;Jungheim, Louis Nickolaus;;Kennedy, Joseph Henry;;Lugar, Charles Willis III.;;Muehl, Brian Stephen;;Palkowitz, Alan David;;Ratz, Andrew Michael;;Rhodes, Gary Anthony;;Robey, Robert Lewis;;Seyler, David Edward;;Shepherd, Timothy Alan;;Thrasher, Kenneth Jeff;;Trankle, William George",,https://lens.org/019-387-332-074-33X,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062;;A61K38/00,,0,0,,,,PENDING
636,AU,A,AU 1999/026868 A,168-099-532-900-153,2000-03-14,2000,AU 1999/026868 A,1999-02-19,EP 98306622 A;;EP 98306621 A;;US 9817229 W;;US 9903525 W,1998-08-18,Growth hormone secretagogues,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/168-099-532-900-153,Patent Application,no,0,0,4,8,0,A61K45/06;;C07D207/416;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,A61K45/06;;C07D207/16;;C07D207/40;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,,0,0,,,,DISCONTINUED
637,EC,A,EC SP982630 A,035-519-328-972-323,1999-02-22,1999,EC SP982630 A,1998-08-18,EC SP982630 A,1998-08-18,SECRETAGOGOS DE LA HORMONA DEL CRECIMIENTO,"Esta invención se refiere a nuevos compuestos que son útiles para modular los niveles endógenos de hormona del crecimiento de un mamífero. La invención se refiere además a nuevos intermedios para usar en la sintesis de dichos compuestos, asi como a nuevos procedimientos empleados en estas sintesis. También se incluyen procedimientos para tratar a un mamífero que incluyen la administración de dichos compuestos.",,DODGE JEFFREY ALAN;;LUGAR CHARLES WILLIS III;;JONES SCOTT ALAN;;SHEPHERD TIMOTHY ALAN;;HEIMAN MARK LOUIS;;FAHEY KENNAN JOSEPH;;MUEHL BRIAN STEPHEN;;ALT CHARLES ARTHUR;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;PALKOWITZ ALAN DAVID;;THRASHER KENNETH JEFF;;BRYANT HENRY UHLMAN;;HAUSER KENNETH LEE;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;RATZ ANDREW MICHAEL;;SEYLER DAVID EDWARD;;TRANKLE WILLIAM GEORGE,,https://lens.org/035-519-328-972-323,Patent Application,no,0,0,1,1,0,,A61K31/16;;C07C233/00,,0,0,,,,PENDING
638,NO,L,NO 20000823 L,145-909-795-625-795,2000-04-12,2000,NO 20000823 A,2000-02-18,US 5614297 P;;US 9817229 W,1997-08-19,Et middel for Õ fremme sekresjon av veksthormon,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR III CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/145-909-795-625-795,Abstract,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062;;A61K38/00,,0,0,,,,DISCONTINUED
639,CO,A1,CO 5121066 A1,005-842-824-642-990,2002-01-30,2002,CO 98047011 A,1998-08-18,US 5614297 P,1997-08-19,SECRETAGOGOS DE LA HORMONA DEL CRECIMIENTO Y DERIVADOS DE CARBODIAMIDAS,"Un compuesto de fórmula I<EMI FILE=""98047011_1"" ID=""1"" IMF=JPEG >en la que: A es un alquilo C1-C6, arilo, (alquil C1-C6)arilo, (alquil C1-C6) (O) (alquil C1-C6) arilo, -SH, -OH, indolilo, indolinilo, tienilo, benzotienilo, benzofuranilo, naftanilo, ciclohexilo, (alquil C1-C6)indol-3-ilo, (alquil C1-C6)benzotien-3-ilo), (alquil C1-C6)naftan-2-ilo, (alquil C1-C6)benzofuran-3-ilo y (alquil C1-C6) ciclohexilo;B es NH2 NHR1 (alquil C1-C6)NH2, (alquil C1-C6)NHR1, (alquil C1-C6)aril-NH2, (alquil C1-C6)aril-NHR1, (alquil C1-C6)ciclohexil-NH2, (alquil C1-C6)ciclohexil-NHR1, R1-piperidin-3-il(alquilo C1-C6), R1-piperidin-2-il (alquilo C1-C6), R1-piperidin-4-il(alquilo C1-C6), R1-quinolin-2-il(alquilo C1-C6), R1-(2,4-dihidroquinolin-2-il)alquilo C1-C6), R1-isoquinolin-2-il(alquilo C1-C6) y R1-(2,4-dihidroisoquinolin-2-il) (alquilo C1-C6);R1 es hidrógeno, alquilo C1-C6, (alquil C1-C6) OH o (alquilidenil C1-C6) (OH)R2;R2 es alquilo C1-C6, alquenilo C1-C6, (alquil C1-C6) (O) (alquilo C1-C6), C(0)-O-alquilo C1-C6, arilo o (alquil C1-C6)arilo;X es un enlace, alquilidenilo C1-C6, O, S, HN o N(alquiloC1-C6);V se selecciona entre el grupo formado por<EMI FILE=""98047011_2"" ID=""2"" IMF=JPEG >- 2 -W es S, O, NH ó CH2;Y es N ó CH;Z es N ó CH;Y´ es N, S, CH2, O;Z' es N, CH2;R4 y R5 son, de forma independiente, hidrógeno, alquilo C1-C6, arilo, (alquil C1-C6)arilo, C(O)O(alquilo C1-C6), C(O)ON(alquilo C1-C6)2 o (alquil C1-C6)COR7;R7 es hidrógeno, alquilo C1-C6, pirrolidinilo, piperidinilo, homoprolina o prolina;D es C(O)R6, (alquil C1-C6)OH, (alquil C1-C6)C(0)R6, (alquil C1-C6)R6, arilo, CH2NHSO2(alquilo C1-C6),R6 es H, alquilo C1-C6, arilo, (alquil C1-C6) arilo, acetilo, NH2, NH(alquilo C1-C6), NH(alquilidenil C1-C6)OCH3,NH(alquil C1-C6)arilo, N(alquilo C1-C6)2, N(alquil C1-C6)arilo,N(alquil C1-C6) (alquil C1-C6) )arilo, O(alquilo C1-C6), piperidinilo o piperidinilo opcionalmente sustituido, pirrolidinilo o pirrolidinilo opcionalmente sustituido, pirrolinilo o pirrolinilo opcionalmente sustituido, morfolino, hexametilenimino, heptametilenimino, quinolinilo, 2,4-dihidroquinolinilo, isoquinolinilo, 2,4-dihidroisoquinolinilo, un aminoácido seleccionado entre el grupo de prolina, homoprolina, glicina, alanina, valina, leucina, isoleucina, tirosina, triptófano, fenilalanina, serina, treonina, asparragina, ácido glutámico, ácido aspártico, lisina, arginina, glutamina, histidina, cisteína y metionina o un heterociclo que contiene un nitrógeno seleccionado entre el grupo formado por<EMI FILE=""98047011_3"" ID=""3"" IMF=JPEG >E es hidrógeno, alquilo C1-C6, C(O)alquilo C1-C6, arilo (alquil C1-C6) arilo, C(0)arilo, (alquil C1-C6)(O)arilo, naftilo, (alquil C1-C6)naftilo, C(0)naftilo, (alquil C1-C6)C(O)naftilo, heteroarilo, (alquil C1-C6)heteroarilo, C(O)heteroarilo y (alquil C1-C6)C(0)heteroarilo;G es hidrógeno, alquilo C1-C6, arilo, (alquil C1-C6)arilo y alquenilo C1-C6;J es hidrógeno, alquilo, arilo y (alquil C1-C6) arilo;L es hidrógeno, alquilo C1-C6, arilo, (alquil C1-C6) arilo, alquenilo C1-C6, -F y -CN;o una sal farmacéuticamente aceptable o un solvato delmismo.",LILLY CO ELI,DODGE JEFFREY ALAN;;JONES SCOTT ALAN;;UHLMAN BRYANT HENRY;;ALT CHARLES ARTHUR;;BARNETT CHARLES JACKSON;;COHEN JEFFREY DANIEL;;DENSMORE COPP JAMES;;KENNAN JOSEPH FAHEY;;GRITTON WILLIAM HARLAN;;RUI LIN GU;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR III CHARLES WILLS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;TOBEY ROGER LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANIDE WILLIAM GEORGE,,https://lens.org/005-842-824-642-990,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,A61K38/00;;A61K31/445;;C07D233/54;;C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,PENDING
640,US,B2,US 6992097 B2,055-230-627-079-605,2006-01-31,2006,US 45383303 A,2003-06-03,US 45383303 A;;EP 98306622 A;;EP 98306621 A;;US 76252901 A;;US 9903525 W,1998-08-18,Growth hormone secretagogues,"This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.",LILLY CO ELI,HAUSER KENNETH LEE;;DODGE JEFFREY ALAN;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR III CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/055-230-627-079-605,Granted Patent,yes,46,1,3,8,0,A61K45/06;;C07D207/16;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08;;C07D207/416;;C07D417/06;;C07D487/08;;C07D409/12;;C07D401/06;;C07D207/16;;A61K45/06;;C07D233/88;;C07D207/42;;C07D403/12;;C07D231/40;;C07D403/06,A61K31/415;;A61K45/06;;C07D207/16;;C07D207/40;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/44;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,514/398;;548/326.5,8,3,023-117-697-418-750;;162-175-081-480-252;;076-174-979-408-52X,1444756;;10.1002/ardp.19923250602;;10.1016/s0040-4039(00)91958-0;;10.1016/0021-9673(93)83382-3,"Skamrov et al. ""Specific protection . . ."" CA 103:215 (1985).;;Kim et al. ""synthesis and antiinflammatory-analgesic . . ."" CA 138:221510 (2002).;;U.S. Appl. No. 09/486,019, filed Aug. 19, 1998, Arthur et al.;;Synthesis of 4-Nitroimidazoles with 1-Substituents Containing Acid, Ester or Phenol Functions, and Radiosensitizing Efficiency of Some of These Compounds, Suwinski, et al., Arch. Pharm., vol. 325, pp. 317-324 (1992).;;Synthetic Approaches to the 'Azole' Peptide Mimetics, Gordon, et al., Tetrahedron Letters, vol. 34, No. 12, pp. 1901-1904 (1993).;;Chem. Abst. No. 130:209977, Kaufffman, et al., ""Treatment of Congestive Heart Failure with Growth Hormone Secretagogues"", Kauffman, et al. application of WO 99/08697, Aug. 19, 1998.;;Chem. Abst. No. 130:182769, Dodge, et al;, Preparation of Heterocyclic Peptide Derivatives as Growth Hormone Secretagogues, application of WO 9908699, Aug. 19, 1998.;;Chem. Abst. No. 119:261758, Uzunov, et al., Some Aspects of the Enantiorecognition of Derivatized Primary Amines on a Pirkle-Type Chiral Stationary Phase Utilizing Tocainide and Mexiletine as Model Compounds, (1993).",EXPIRED
641,US,A1,US 2004/0122234 A1,135-238-437-316-362,2004-06-24,2004,US 45383303 A,2003-06-03,US 45383303 A;;EP 98306622 A;;EP 98306621 A;;US 76252901 A;;US 9903525 W,1998-08-18,Growth Hormone secretagogues,"
   This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds. 
",HAUSER KENNETH LEE;;DODGE JEFFREY ALAN;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,HAUSER KENNETH LEE;;DODGE JEFFREY ALAN;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROGER LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/135-238-437-316-362,Patent Application,yes,21,20,3,8,0,A61K45/06;;C07D207/16;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08;;C07D207/416;;C07D417/06;;C07D487/08;;C07D409/12;;C07D401/06;;C07D207/16;;A61K45/06;;C07D233/88;;C07D207/42;;C07D403/12;;C07D231/40;;C07D403/06,A61K45/06;;C07D207/16;;C07D207/40;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,546/147;;546/168;;546/201;;546/202;;546/212;;546/205;;546/196,0,0,,,,EXPIRED
642,PE,A1,PE 115999 A1,095-980-655-797-472,1999-11-26,1999,PE 00074898 A,1998-08-19,US 5614297 P,1997-08-19,SECRETAGOGOS DE LA HORMONA DEL CRECIMIENTO,"SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES ALQUILO C1-C6, ARILO, (ALQUIL C1-C6)ARILO, ENTRE OTROS; B ES NH2, NHR1, (ALQUIL C1-C6)NH2, ENTRE OTROS; R1 ES H, ALQUILO C1-C6, (ALQUIL C1-C6)OH o ALQUILIDENIL C1-C6)(OH)R2; R2 ES ALQUILO C1-C6, ALQUENILO C1-C6, (ALQUIL C1-C6)(O)(ALQUILO C1-C6), CO-O-ALQUILO C1-C6, ARILO o (ALQUIL C1-C6)ARILO; X ES UN ENLACE, ALQUILIDENILO C1-C6, O, S, NH o N(ALQUILO C1-C6); V ES UN GRUPO DE FORMULA (a, b, c, d); W ES S, O, NH, o CH2; ""Y"" Y Z SON N o CH; Y` ES N, S, CH2, O; Z' ES N, CH2; R4 Y R5 SON H, ALQUILO C1-C6, ARILO, (ALQUIL C1-C6)COR7, ENTRE OTROS; R7 ES H, ALQUILO C1-C6, PIRROLIDINILO, PIPERIDINILO, HOMOPROLINA O PROLINA; D ES C(O)R6, (ALQUIL C1-C6)OH, (ALQUIL C1-C6)C(O)R6, ENTRE OTROS; R6 ES H, ALQUILO C1-C6, ARILO, ENTRE OTROS; E ES H, ALQUILO C1-C6, C(O)ALQUILO C1-C6, ENTRE OTROS; G ES H, ALQUILO C1-C6, ARILO, (ALQUIL C1-C6)ARILO, ALQUENILO C1-C6; J ES H, ALQUILO, ARILO o (ALQUIL C1-C6)ARILO; L ES H, ALQUILO C1-C6, ARILO, ENTRE OTROS. TAMBIEN SE REFIERE A COMPUESTOS DE FORMULA IA, IB. EL COMPUESTO I ES UN SECRETAGOGO DE LA HORMONA DE CRECIMIENTO",LILLY CO ELI,ALT CHARLES ARTHUR;;ROBEY ROGER LEWIS;;FAHEY KENNAN JOSEPH;;PALKOWITZ ALAN DAVID;;HAUSER KENNETH LEE;;COHEN JEFFREY DANIEL;;GRITTON WILLIAM HARLAN;;KENNEDY JOSEPH HENRY;;SEYLER DAVID EDWARD;;LUGAR III CHARLES WILLIS;;DODGE JEFFREY ALAN;;BRYANT HENRY UHLMAN;;MUEHL BRIAN STEPHEN;;HEIMAN MARK LOUIS;;TRANKLE WILLIAM GEORGE;;SHEPHERD TIMOTHY ALAN;;RATZ ANDREW MICHAEL;;JUNGHEIM LOUIS NICKOLAUS;;COPP JAMES DENSMORE;;JONES SCOTT ALAN;;THRASHER KENNETH JEFF;;RHODES GARY ANTHONY,,https://lens.org/095-980-655-797-472,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,A61K38/00;;A61K31/195;;C07D401/06;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/435;;A61K31/445;;C07D233/88;;C07D403/06;;C07D413/06;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,EXPIRED
643,WO,A1,WO 2000/010565 A1,074-892-549-019-771,2000-03-02,2000,US 9903525 W,1999-02-19,EP 98306622 A;;EP 98306621 A;;US 9817229 W,1998-08-18,GROWTH HORMONE SECRETAGOGUES,"This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.",LILLY CO ELI;;DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/074-892-549-019-771,Patent Application,yes,2,2,4,8,0,A61K45/06;;C07D207/416;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,A61K45/06;;C07D207/16;;C07D207/40;;C07D207/416;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12;;C07D417/06;;C07D487/08,,3,0,,,"CHEMICAL ABSTRACTS, vol. 130, no. 16, 1999, Columbus, Ohio, US; abstract no. 130:209977W, KAUFFMAN ET AL.: ""Treatment of congestive heart failure with growth hormone secretagogues"" XP002932087;;CHEMICAL ABSTRACTS, vol. 130, no. 14, Columbus, Ohio, US; abstract no. 130:182769R, DODGE ET AL.: ""Preparation of heterocyclic peptide derivatives as growth hormone secretagogues"" XP002932088;;See also references of EP 1112071A4",PENDING
644,NO,D0,NO 20000823 D0,088-788-969-260-957,2000-02-18,2000,NO 20000823 A,2000-02-18,US 5614297 P;;US 9817229 W,1997-08-19,Et middel for å fremme sekresjon av veksthormon,,LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR III CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/088-788-969-260-957,Patent Application,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;A61K38/00;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,DISCONTINUED
645,WO,A1,WO 1999/008699 A1,182-782-475-027-178,1999-02-25,1999,US 9817229 W,1998-08-19,US 5614297 P,1997-08-19,GROWTH HORMONE SECRETAGOGUES,"This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.",LILLY CO ELI;;DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;ROBEY ROBERT LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/182-782-475-027-178,Patent Application,yes,1,32,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;A61K38/00;;C07K5/06;;C07K5/062,,0,0,,,,PATENTED
646,EP,A2,EP 0933365 A2,137-878-076-157-885,1999-08-04,1999,EP 98306622 A,1998-08-18,US 5614297 P,1997-08-19,Growth hormone secretagogues,"This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.",LILLY CO ELI,DODGE JEFFREY ALAN;;HAUSER KENNETH LEE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BARNETT CHARLES JACKSON;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE;;FAHEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;GU RUI LIN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTONY;;ROBEY ROGER LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE,,https://lens.org/137-878-076-157-885,Patent Application,yes,0,4,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062;;A61K38/00,,0,0,,,,DISCONTINUED
647,MY,A,MY 138258 A,136-275-558-411-963,2009-05-29,2009,MY PI9803772 A,1998-08-18,US 5614297 P,1997-08-19,GROWTH HORMONE SECRETAGOGUES,"THIS INVENTION RELATES TO NOVEL COMPOUNDS WHICH ARE USEFUL IN THE MODULATION OF ENDOGENOUS GROWTH HORMONE LEVELS IN A MAMMAL. THE INVENTION FURTHER RELATES TO NOVEL INTERMEDIATES FOR USE IN THE SYNTHESIS OF SAID COMPOUNDS, AS WELL AS NOVEL PROCESSES EMPLOYED IN THESE SYNTHESES. ALSO INCLUDED ARE METHOD OF TREATING A MAMMAL WHICH INCLUDE THE ADMINISTRATION OF SAID COMPOUNDS.",LILLY CO ELI,DODGE JEFFREY ALAN;;FAHNEY KENNAN JOSEPH;;GRITTON WILLIAM HARLAN;;GU RUI LIN;;JUNGHEIM LOUIS NICKOLAUS;;KENNEDY JOSEPH HENRY;;LUGAR CHARLES WILLIS III;;MUEHL BRIAN STEPHEN;;PALKOWITZ ALAN DAVID;;RATZ ANDREW MICHAEL;;RHODES GARY ANTHONY;;HAUSER KENNETH LEE;;ROBEY ROGER LEWIS;;SEYLER DAVID EDWARD;;SHEPHERD TIMOTHY ALAN;;THRASHER KENNETH JEFF;;TRANKLE WILLIAM GEORGE;;HEIMAN MARK LOUIS;;JONES SCOTT ALAN;;ALT CHARLES ARTHUR;;BARNETT CHARLES JACKSON;;BRYANT HENRY UHLMAN;;COHEN JEFFREY DANIEL;;COPP JAMES DENSMORE,,https://lens.org/136-275-558-411-963,Granted Patent,no,0,0,30,30,0,C07K5/06026;;C07K5/0606;;A61P43/00;;A61P5/00;;A61P5/02;;A61P5/04;;C07D207/416;;A61K45/06;;C07D207/16;;C07D207/42;;C07D231/40;;C07D233/88;;C07D401/06;;C07D403/06;;C07D403/12;;C07D409/12,A61K38/00;;C07D233/88;;C07K1/10;;C07K5/06;;C07K5/062,,0,0,,,,EXPIRED
